ID	Species	ncRNA	ncRNA type	Environmental factor (EF)	Phenotype	Sample	Condition of EF	Evidence	PubMed ID
1	Human	hsa-let-2b-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
2	Human	hsa-let-7	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
3	Human	hsa-let-7	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
4	Human	hsa-let-7	miRNA	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	colorectal cancer (CRC)	HCT116 cells£»HT29 cells£»SW480 cells£» SW620 cells	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	upregulated	22983985
5	Human	hsa-let-7	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	downregulated	30692507
6	Human	hsa-let-7	miRNA	epstein-barr virus EBNA1 protein	EBV infection	nasopharyngeal carcinoma cell lines	EBNA1 treatment	downregulated	25031339
7	Human	hsa-let-7	miRNA	HT-3O sulfate (HT-3Os)	epithelial-mesenchymal transition (EMT)	IL-1¦Â-treated human umbilical endothelial cells (HUVEC) and human retinal endothelial cells (HREC)	HT-3O sulfate (HT-3Os) treatmment	upregulated	30725211
8	Human	hsa-let-7	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	human umbilical endothelial cells (HUVEC) and human retinal endothelial cells (HREC)	interleukin-1¦Â (IL-1¦Â) treatment	downregulated	30725211
9	Human	hsa-let-7	miRNA	HT-3O sulfate (HT-3Os)	epithelial-mesenchymal transition (EMT)	human umbilical EC (HUVEC); human retinal EC (HREC)	HT-3O sulfate (HT-3Os) treatment	Exposure of HUVEC and HREC to IL-1¦Â alone led to a sig- nificant reduction of let-7 miRNA levels which were restored in the presence of HT-3Os.	30725211
10	Human	hsa-let-7	miRNA	H2O2	gastric cancer (GC)	GC cells	H2O2 treatment	Hsa-let-7 g miRNA increased the sensitivity of GC to oxidative stress by repression activation of DDR indirectly. Let-7 g improved the effects of X-rays on GC cells involving in DDR regulation as well.	25972194
11	Human	hsa-let-7	miRNA	phenformin	glioblastoma multiforme (GBM)	glioma stem cells (GSCs)	Phenformin treatment	upregulated	27486821
12	Human	hsa-let-7	miRNA	secretin	human primary sclerosing cholangitis (PSC)	"PSC liver tissue biopsies, serum, and bile"	secretin? treatment	downregulated	27115285
13	Human	hsa-let-7	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?9 cells	heme treatment	upregulated	23538684
14	Human	hsa-let-7	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
15	Human	hsa-let-7	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
16	Human	hsa-let-7	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	human non-small cell lung cancer cells A549	cisplatin treatment	downregulated	28235063
17	Human	hsa-let-7	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	human non-small cell lung cancer cells A549	2 Gy of irradiation once a week	downregulated	28235063
18	Human	hsa-let-7	miRNA	tankyrase inhibitor JW74	osteosarcoma (OS)	"OS cell lines (KPD, U2OS, and SaOS-2)"	JW74 treatment	upregulated	24403055
19	Human	hsa-let-7	miRNA	metformin (Met)	ovarian cancer (OC)	ovarian cancer cells	metformin treatment	upregulated	27775072
20	Human	hsa-let-7	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human endometrial cell-lines	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	28499250
21	Human	hsa-let-7	miRNA	fractionated radiation	prostate cancer	Human Prostate Cancer Cells	radiation treatment	Tumor suppressor miR-34a and let-7 miRNAs were upregulated by fractionated radiation in radiosensitive LNCaP (p53 positive) and PC3 (p53-null) cells indicating	22827214
22	Human	hsa-let-7	miRNA	simvastatin	prostate cancer	human castration-resistant prostate cancer (CRPC) cells	simvastatin treatment	upregulated	28910332
23	Human	hsa-let-7	miRNA	TGF-¦Â1	Pancreatic ductal adenocarcinoma (PDAC)	Panc1 cells	?TGF-¦Â1 treatment	downregulated	21057545
24	Human	hsa-let-7	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	ARK2 and MCF-7 cells	metformin treatment	upregulated	27775072
25	Human	hsa-let-7	miRNA	cryptosporidium parvum	cryptosporidium parvum infection	"C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)"	cryptosporidium parvum? infection	downregulated	20486857
26	Human	hsa-let-7	miRNA	cryptosporidium parvum	cryptosporidium parvum infection	"C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)"	cryptosporidium parvum? infection	downregulated	20486857
27	Human	hsa-let-7	miRNA	sorafenib (SOR)	human immunodeficiency virus (HIV)-1 infection	Huh7 hepatoma cells	sorafenib treatment	downregulated	20347499
28	Human	hsa-let-7a	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
29	Human	hsa-let-7a	miRNA	"sulforaphane, quercetin and GTC"	pancreatic ductal adenocarcinoma (PDAC)	BxPc-3 and MIA-PaCa2 and human hTERT-HPNE	"sulforaphane, quercetin and GTC complement treatment"	upregulated	25017900
30	Human	hsa-let-7a	miRNA	antidiabetic	glycemic control	ment-na?ve diabetic patients with poor metabolic control	12 months of antidiabetic treatment	upregulated	24937531
31	Human	hsa-let-7a	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	acute myeloid leukemia (AML)	"human myeloid leukemic cell line, AML-193"	GM-CSF treatment	downregulated	22015065
32	Human	hsa-let-7a	miRNA	lipopolysaccharide (LPS) and TGF-¦Â	alcoholic liver disease (ALD)	human hepatic stellate cells (HSCs)	lipopolysaccharide (LPS) and TGF-¦Â treatment	downregulated	28536261
33	Human	hsa-let-7a	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
34	Human	hsa-let-7a	miRNA	high glucose-induced endothelial microparticles (EMPs)	apoptosis	human umbilical vein endothelial cells (HUVECs)	high glucose EMPs	downregulated	28942148
35	Human	hsa-let-7a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"let-7a, which directly targets the 3'-UTR of periostin mRNA. In addition, periostin overexpression partly reversed the biological effects of H19 knockdown in ox-LDL-treated HUVECs, which were almost recapitulated by let-7 overexpression."	31054453
36	Human	hsa-let-7a	miRNA	androgen	breast cancer	"MCF-7, MDA-MB-453 , MDA-MB-231"	androgen treatment	upregulated	24172884
37	Human	hsa-let-7a	miRNA	arsenic trioxide (ATO)	breast cancer	MCF-7 and SK-BR-3 cell lines	arsenic trioxide (ATO) treatment	upregulated	28980872
38	Human	hsa-let-7a	miRNA	benzo(a)pyrene (BaP)	breast cancer	MDA-MB-231 cells	benzo(a)pyrene (BaP) exposure	downregulated	30155724
39	Human	hsa-let-7a	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
40	Human	hsa-let-7a	miRNA	metformin (Met)	breast cancer	MCF-7 cells	metformin?treatment	upregulated	21368581
41	Human	hsa-let-7a	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells; MDA-MB-231 cells	paclitaxel treatment	downregulated	30019863
42	Human	hsa-let-7a	miRNA	paclitaxel (PTX)	breast cancer	BT-474 cells	paclitaxel treatment	upregulated	30019863
43	Human	hsa-let-7a	miRNA	nanoparticle (NP)	colorectal cancer (CRC)	Human colon cancer HCT-116 cells	Nanoparticle (NP) technology	"Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulated of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms,"	21929751
44	Human	hsa-let-7a	miRNA	honeysuckle aqueous extract	dengue virus (DENV) infection	human blood	aqueous extract treatment	upregulated	28052239
45	Human	hsa-let-7a	miRNA	honeysuckle aqueous extract	dengue virus (DENV) infection	mouse blood	aqueous extract treatment	upregulated	28052239
46	Human	hsa-let-7a	miRNA	Rhein-8-O-¦Â-D-glucopyranoside (Rg)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	Rhein-8-O-¦Â-D-glucopyranoside (Rg) treatment	Rg attenuated HG-induced apoptosis of HMCs by regulating the lincRNA ANRIL/let-7a/TGF-¦Â1/Smad signaling pathway	32256771
47	Human	hsa-let-7a	miRNA	acrolein	environmental pollutants	human umbilical vein endothelial cells	acrolein treatment	upregulated	24812010
48	Human	hsa-let-7a	miRNA	curcumin (Cur)	fat	esophageal cancer cell lines	curcumin treatment	downregulated	22363450
49	Human	hsa-let-7a	miRNA	urolithin A (UA)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	urolithin A treatment	upregulated	29742265
50	Human	hsa-let-7a	miRNA	honeysuckle (HS)	enterovirus 71 (EV71) infection	human muscle rhabdomyosarcoma RD cells	Honeysuckle treatment	"Moreover, honeysuckle-induced?let-7a?suppression of EV71 RNA and protein expression as well as viral replication were investigated both in vitro and in vivo."	33669264
51	Human	hsa-let-7a	miRNA	estradiol-17¦Â (E2)	inflammation	human macrophages	estradiol-17¦Â (E2) treatment	"LPS induces let-7a and inhibits miR-125b expression in human macrophages, and pretreatment with estradiol abrogates these effects"	20351193
52	Human	hsa-let-7a	miRNA	sepsis	liver damage	liver tissues	sepsis induce treatment	The expression of let-7a in liver tissue of patients with sepsis-induced liver injury was clearly decreased	31344555
53	Human	hsa-let-7a	miRNA	particulate matter (PM2.5)	lung cancer	human non-small cell lung cancer cell line A549	chronic (five passages) PM2.5 exposure treatment	downregulated	28846189
54	Human	hsa-let-7a	miRNA	ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE)	metastasized melanoma	A375 melanoma cells	SLE treatment	upregulated	31514083
55	Human	hsa-let-7a	miRNA	"pan-JAK inhibitor, INC424"	myeloproliferative neoplasms	Ton.JAK2.V617F cells	"pan-JAK inhibitor, INC424 treatment"	upregulated	28057739
56	Human	hsa-let-7a	miRNA	pan-HDAC inhibitor ITF2357	non-Hodgkin lymphoma (NHL)	human B-cell non-Hodgkin lymphomas (B-NHLs)	pan-HDAC inhibitor ITF2357 treatment	upregulated	24648290
57	Human	hsa-let-7a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells	cisplatin treatment	downregulated	31189742
58	Human	hsa-let-7a	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
59	Human	hsa-let-7a	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
60	Human	hsa-let-7a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	preeclampsia (PE)	JEG-3 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	Let-7a inhibits Bcl-xl and YAP1 expression to induce apoptosis of trophoblast cells in early-onset severe preeclampsia	32721616
61	Human	hsa-let-7a	miRNA	CXCR4	pregnancy disease	AML cells	CXCR4 treatment	downregulated	23676502
62	Human	hsa-let-7a	miRNA	Yangzheng Sanjie decoction (YZSJD)	gastric cancer (GC)	AGS and HS-746T GC cells	YZSJD treatment	downregulated	28852313
63	Human	hsa-let-7a	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (PASMCs)	hypoxia exposure	miR-let-7a was downregulated in hypoxic PASMCs.	32803651
64	Human	hsa-let-7a	miRNA	arsenite	lung fibrosis	THP-1 cells	arsenic (As) exposure	downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages.	33162208
65	Human	hsa-let-7a	miRNA	arsenite	lung fibrosis	lung tissues; bone marrow-derived macrophages (BMDMs)	arsenite exposure	downregulated	33162208
66	Human	hsa-let-7a	miRNA	anti-citrullinated protein antibodies (ACPAs)	rheumatoid arthritis (RA)	macrophages isolated from patients with RA	ACPAs treatment (160IU/mL)	downregulated	28802150
67	Human	hsa-let-7a	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	upregulated	30182520
68	Human	hsa-let-7a	miRNA	melatonin	subarachnoid hemorrhage (SAH)	U87 cells; U251 cells	melatonin (MT) treatment	downregulated	29367587
69	Human	hsa-let-7a	miRNA	IL-22	systemic sclerosis (SSc)	normal human dermal fibroblast	IL-22	downregulated	29336866
70	Human	hsa-let-7a	miRNA	IL-22	systemic sclerosis (SSc)	Human dermal fibroblasts	IL-22 treatment	downregulated	29336866
71	Human	hsa-let-7a	miRNA	arsenite	tumorigenesis of arsenite	human keratinocyte HaCaT cells	arsenic exposure	downregulated	24704393
72	Human	hsa-let-7a1	miRNA	listeria monocytogenes (L. monocytogenes)	Listeria infection	Human epithelial cells (Caco-2)	Listeria infection	downregulated	22312311
73	Human	hsa-let-7a-2	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	muscarinic M(1) receptor dysfunction	A549 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	23469214
74	Human	hsa-let-7a-3	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
75	Human	hsa-let-7a-5p	miRNA	paclitaxel (PTX)	breast cancer	BC tissues; MCF-7 cells MDA-MB-231	Paclitaxel (PTX) treatment	downregulated	32273769
76	Human	hsa-let-7a-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	downregulated	30503955
77	Human	hsa-let-7a-5p	miRNA	silica	pneumoconiosis	THP-1 cells	silica treatment	downregulated	29516679
78	Human	hsa-let-7a-5p	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	human lens epithelial cells (LECs)	TGF-¦Â2 treatment	TGF-¦Â2 upregulated Smad2 expression and reduced let-7a-5p expression in LECs	32345785
79	Human	hsa-let-7a-5p	miRNA	doxorubicin (DOX)	prostate cancer	prostate cancer DU-145 cells	doxorubicin (DOX) treatment	upregulated	31188543
80	Human	hsa-let-7a-5p	miRNA	radiation	prostate cancer	serum	curative radiotherapy (RT) treatment	upregulated	30103771
81	Human	hsa-let-7b	miRNA	hypoxia	acute myocardial infarction (AMI)	AC16	hypoxia treatment	downregulated	32922590
82	Human	hsa-let-7b	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	Cryopreserved primary human hepatocytes (cPHH)	ethanol (EtOH) exposure	upregulated	30103265
83	Human	hsa-let-7b	miRNA	lipopolysaccharide (LPS) and TGF-¦Â	alcoholic liver disease (ALD)	human hepatic stellate cells (HSCs)	lipopolysaccharide (LPS) and TGF-¦Â treatment	downregulated	28536261
84	Human	hsa-let-7b	miRNA	curcumin (Cur)	breast cancer	MCF-10F cells	curcumin (Cur) treatment	upregulated	31894298
85	Human	hsa-let-7b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
86	Human	hsa-let-7b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
87	Human	hsa-let-7b	miRNA	electrode	cervical cancer (CC)	HeLa cells	electric treatment	upregulated	16503596
88	Human	hsa-let-7b	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	colonic epithelial cells	adherent invasive escherichia coli (AIEC) treatment	AIEC elicits/exacerbate gut inflammation in WT/IL-10 KO mice that correlates with increased expression of TLR4 and decreased level of let-7b in IECs.	30142321
89	Human	hsa-let-7b	miRNA	mycolactone	expression regulation	human primary T cells	Mycolactone treatment	mycolactone-induced suppression of CD62-L expression by human primary T cells was induced rapidly at both the mRNA and protein levels and correlated with the reduced expression of one miRNA: let-7b.	21768364
90	Human	hsa-let-7b	miRNA	preoperative radiotherapy	esophageal squamous cell carcinoma (ESCC)	ESCC tissues	preoperative radiotherapy treatment	dysregulated	24576011
91	Human	hsa-let-7b	miRNA	helicobacter pylori (H. pylori)	hepatitis B virus (HBV) infection	gastric mucosa specimens and two gastric epithelial cell lines	Helicobacter pylori infection	downregulated	23437218
92	Human	hsa-let-7b	miRNA	oleic acid (OA)	inflammation	LPS-activated human acute monocytic leukemia cells (THP-1)	oleic acid (OA) treatment	upregulated	29790117
93	Human	hsa-let-7b	miRNA	palmitic acid (PA)	inflammation	LPS-activated human acute monocytic leukemia cells (THP-1)	palmitic acid (PA) treatment	upregulated	29790117
94	Human	hsa-let-7b	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
95	Human	hsa-let-7b	miRNA	"RESMENA (reduction of metabolic syndrome in Navarra, Spain)"	metabolic syndrome	MetS patients white blood cells (WBC)	RESMENA treatment	"miR-155-3p was decreased ,miR-Let-7b was strongly upregulated in white blood cells (WBC)"	26421388
96	Human	hsa-let-7b	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
97	Human	hsa-let-7b	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
98	Human	hsa-let-7b	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
99	Human	hsa-let-7b	miRNA	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á)	renal fibrosis	HK-2 cell lines	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) overexpression treatment	upregulated	31614978
100	Human	hsa-let-7b	miRNA	arsenite	tumorigenesis of arsenite	human keratinocyte HaCaT cells	arsenic exposure	downregulated	24704393
101	Human	hsa-let-7b*	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
102	Human	hsa-let-7b-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
103	Human	hsa-let-7b-5p	miRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"LINC00987 Ameliorates COPD by Regulating LPS-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Autophagy Through Let-7b-5p/SIRT1 Axis."	33311978
104	Human	hsa-let-7b-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC 7901cells; AGC cells	cisplatin treatment	downregulated	33009035
105	Human	hsa-let-7b-5p	miRNA	fibroblast growth factor receptor (FGFR) 1	mitochondrial dynamics	normal human dermal microvascular endothelial cells (HMVECs)	Fibroblast growth factor receptor (FGFR) 1 treatment	downregulated	29269295
106	Human	hsa-let-7b-5p	miRNA	N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP)	mitochondrial dynamics	normal human dermal microvascular endothelial cells (HMVECs)	N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) treatment	upregulated	29269295
107	Human	hsa-let-7b-5p	miRNA	"triple cytokines (TGF-¦Â2, interleukin-1¦Â, tumor necrosis factor-¦Á)"	mitochondrial dynamics	normal human dermal microvascular endothelial cells (HMVECs)	"triple cytokines (TGF-¦Â2, interleukin-1¦Â, tumor necrosis factor-¦Á) treatment"	downregulated	29269295
108	Human	hsa-let-7b-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
109	Human	hsa-let-7b-5p	miRNA	trichloroethylene (TCE)	non-Hodgkin lymphoma (NHL)	serum	trichloroethylene (TCE) exposure treatment	downregulated	31161417
110	Human	hsa-let-7b-5p	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	"NEAT1 regulated TRAF6 expression by sponging let-7b-5p in HK-2 cells, which promotes LPS-induced injury and inflammation in HK-2 cells."	32724027
111	Human	hsa-let-7b-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 human macrophages	?Mycobacterium tuberculosis (Mtb) infection	upregulated	29471394
112	Human	hsa-let-7c	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
113	Human	hsa-let-7c	miRNA	androgen	prostate cancer	prostate cancer cells	androgen treatment	downregulated	23503464
114	Human	hsa-let-7c	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
115	Human	hsa-let-7c	miRNA	all-trans retinoic acid (ATRA)	acute myeloid leukemia (AML)	"human leukemic cell lines NB4, HEL, HL-60, KG1, K562, SKNO-1, THP-1, and UF-1"	all-trans retinoic acid (ATRA) treatment	upregulated	24637061
116	Human	hsa-let-7c	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
117	Human	hsa-let-7c	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
118	Human	hsa-let-7c	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	human umbilical cord vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	22917031
119	Human	hsa-let-7c	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	ARPE-19 cells	TGF-¦Â2 treatment	The expression of miR-let7c was dramatically reduced after induction by TGF-¦Â2	32420214
120	Human	hsa-let-7c	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
121	Human	hsa-let-7c	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
122	Human	hsa-let-7c	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cell	cigarette smoke extract (CSE) treatment	downregulated	28184029
123	Human	hsa-let-7c	miRNA	fulvestrant	non-small cell lung cancer (NSCLC)	H1975 NSCLC cells	fulvestrant treatment	upregulated	24268810
124	Human	hsa-let-7c	miRNA	H2O2	osteoporosis	Adipose-derived mesenchymal stem cells (ADMSCs)	H2O2 treatment	upregulated	30379578
125	Human	hsa-let-7c	miRNA	H2O2	osteoporosis	human adipose-derived mesenchymal stem cells (hADMSCs)	H2O2 treatment	upregulated	30379578
126	Human	hsa-let-7c	miRNA	N-acetyl-L-cysteine (NAC)	osteoporosis	H2O2-treated human adipose-derived mesenchymal stem cells (hADMSCs)	N-acetyl-L-cysteine (NAC) treatment	downregulated	30379578
127	Human	hsa-let-7c	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
128	Human	hsa-let-7c	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
129	Human	hsa-let-7c	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
130	Human	hsa-let-7c	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
131	Human	hsa-let-7c	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
132	Human	hsa-let-7c	miRNA	quercetin	pancreatic ductal adenocarcinoma (PDAC)	PDA cells	quercetin treatment	upregulated	27521217
133	Human	hsa-let-7c	miRNA	lipoxins	premature ovarian failure (POF)	HK-2 cells	Lipoxins?treatment	upregulated	23520204
134	Human	hsa-let-7c	miRNA	fulvestrant	progesterone production in rat granulosa cells	H1975 NSCLC cells	Fulvestrant treatment	let-7c plays an important role in fulvestrant-induced upregulation of gefitinib sensitivity in H1975 cells	24268810
135	Human	hsa-let-7c	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
136	Human	hsa-let-7c	miRNA	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á)	renal fibrosis	HK-2 cell lines	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) overexpression treatment	upregulated	31614978
137	Human	hsa-let-7c	miRNA	arsenite	tumorigenesis of arsenite	human keratinocyte HaCaT cells	arsenic exposure	downregulated	24704393
138	Human	hsa-let-7c-3p	miRNA	H2O2	age-related cataract (ARC)	Human lens epithelial cells (LECs)	H2O2 treatment	the expression of let-7c-3p was also lower under oxidative stress.	32258130
139	Human	hsa-let-7c-3p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
140	Human	hsa-let-7c-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
141	Human	hsa-let-7c-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
142	Human	hsa-let-7c-5p	miRNA	olive oil polyphenol hydroxytyrosol (HT)	inflammation	TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	olive oil polyphenol hydroxytyrosol (HT) treatment	upregulated	31627295
143	Human	hsa-let-7c-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31627295
144	Human	hsa-let-7c-5p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	upregulated	31176168
145	Human	hsa-let-7c-5p	miRNA	oleacein (OA)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleacein (OA) treatment	upregulated	31766503
146	Human	hsa-let-7c-5p	miRNA	oleocanthal (OC)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleocanthal (OC) treatment	upregulated	31766503
147	Human	hsa-let-7c-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31766503
148	Human	hsa-let-7c-5p	miRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp cells (HDPCs)	lipopolysaccharide (LPS) treatment	LPS exposure upregulated the expression of NUTM2A-AS1 and High-Mobility Group Box 1 (HMGB1) and downregulated the level of let-7c-5p.	33831808
149	Human	hsa-let-7d	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
150	Human	hsa-let-7d	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
151	Human	hsa-let-7d	miRNA	platelet-derived growth factor (PDGF)	glioblastoma and ovarian cancer	U118-MG cells£»U87-MG glioblastoma cells£» human WI-38 fibroblasts?£» ovarian cells C272/hTert/E7	Platelet derived growth factor (PDGF)? treatment	downregulated	21266476
152	Human	hsa-let-7d	miRNA	ficus carica	glioblastoma multiforme (GBM)	"T98G, U-138 MG, and U-87 MG human GBM cell lines"	ficus carica treatment	upregulated	25212824
153	Human	hsa-let-7d	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
154	Human	hsa-let-7d	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
155	Human	hsa-let-7d	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
156	Human	hsa-let-7d	miRNA	diesel exhaust particle (DEP)	pulmonary inflammatory response	16HBE and Beas-2B cells	diesel exhaust particle (DEP) exposure	downregulated	30172002
157	Human	hsa-let-7d	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
158	Human	hsa-let-7d-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
159	Human	hsa-let-7d-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
160	Human	hsa-let-7d-5p	miRNA	house dust mite (HDM)	lung fibrosis	serum	dust exposure	upregulated	30090591
161	Human	hsa-let-7e	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
162	Human	hsa-let-7e	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
163	Human	hsa-let-7e	miRNA	olive leaf extract (OLE)	atherosclerosis (AS)	Serum amyloid A (SAA)-induced human coronary artery endothelial cells (HCAEC)	Olive leaf extract (OLE) treatment	downregulated	31157238
164	Human	hsa-let-7e	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28195197
165	Human	hsa-let-7e	miRNA	serum amyloid A (SAA)	atherosclerosis (AS)	human coronary artery endothelial cells (HCAEC)	Serum amyloid A (SAA) treatment	upregulated	31157238
166	Human	hsa-let-7e	miRNA	cisplatin (DDP)	breast cancer	Human umbilical vein endothelial cells (HUVECs)	cisplatin (DPP) treatment	downregulated	30670152
167	Human	hsa-let-7e	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
168	Human	hsa-let-7e	miRNA	D-glucose	epithelial-mesenchymal transition (EMT)	peritoneal mesothelial cells (PMCs)	D-glucose treatment	downregulated	25683944
169	Human	hsa-let-7e	miRNA	IL-1¦Â	inflammatory response	monocytes	IL-1¦Â treatment	upregulated	30245693
170	Human	hsa-let-7e	miRNA	lipopolysaccharide (LPS)	inflammatory response	monocytes	lipopolysaccharide (LPS) treatment	upregulated	30245693
171	Human	hsa-let-7e	miRNA	TLR2 agonist pam3CSK4	inflammatory response	monocytes	TLR2 agonist pam3CSK4 treatment	upregulated	30245693
172	Human	hsa-let-7e	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
173	Human	hsa-let-7e	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
174	Human	hsa-let-7e	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
175	Human	hsa-let-7e	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
176	Human	hsa-let-7e	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
177	Human	hsa-let-7e-5p	miRNA	insulin and high glucose (HG)	insulin resistance (IR)	HepG2 cells	insulin and high glucose treatment	upregulated	32710190
178	Human	hsa-let-7f	miRNA	antidiabetic	glycemic control	ment-na?ve diabetic patients with poor metabolic control	12 months of antidiabetic treatment	upregulated	24937531
179	Human	hsa-let-7f	miRNA	¦Â 2-Adrenergic receptors (¦Â 2ARs)	asthma	human airway smooth muscle (HASM) cells	¦Â 2-Adrenergic receptors (¦Â 2ARs) treatment	"In cultured HASM cells from nonasthmatic and asthmatic lungs, 18 h of ¦Â-agonist exposure increased let-7f by 2-3-fold"	29455573
180	Human	hsa-let-7f	miRNA	aromatase inhibitors (AIs)	breast cancer	MCF-7; SK-BR-3 cells	Aromatase inhibitors (AIs) treatment	upregulated	22407818
181	Human	hsa-let-7f	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
182	Human	hsa-let-7f	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
183	Human	hsa-let-7f	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
184	Human	hsa-let-7f	miRNA	TLR9 and RIG-I	immune tolerance	Endocervical cells (End1/E6E7)	ligands of TLR9 and RIG-I once or after pre-stimulation with same ligand treatment	"Stimulation with TLR9 downregulated let-7f , RIG-I stimulation upregulated let-7f"	24405266
185	Human	hsa-let-7f	miRNA	ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE)	metastasized melanoma	A376 melanoma cells	SLE treatment	upregulated	31514083
186	Human	hsa-let-7f	miRNA	cigarette smoke extract (CSE)	neovascularization	HUVECs	cigarette smoke extracts (CSE) exposure	downregulated	28345812
187	Human	hsa-let-7f	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	downregulated	20110569
188	Human	hsa-let-7f-1	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
189	Human	hsa-let-7f-1	miRNA	lycopene	prostate cancer	Human prostate carcinoma cells PC3	lycopene treatment	upregulated	26847233
190	Human	hsa-let-7f-1-3p	miRNA	smoking	smoke-induced lung injury (SILI)	Human small airway epithelial cells (HSAEC) and human pulmonary alveolar epithelial cells (HPAEpiC)	Smoke was generated by heating 500 mg of degreasing cotton at about 400 ¡ãC for 15 min in a tube furnace with air stream of 1L/min for combustion in a non-flaming fashion and 10 L/min for dilution treatment	downregulated	31301310
191	Human	hsa-let-7f-2	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
192	Human	hsa-let-7f-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	downregulated	30503955
193	Human	hsa-let-7f-5p	miRNA	adriamycin (ADR)	leukemia	K562 cells	adriamycin (ADR) treatment	downregulated	31793054
194	Human	hsa-let-7f-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
195	Human	hsa-let-7f-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells; WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	33300070
196	Human	hsa-let-7f-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells; WI-38 cells	lipopolysaccharide (LPS) treatment	let-7f-5p expression levels was significantly decreased in lipopolysaccharide (LPS) induced A549 and WI-38 cells.	33300070
197	Human	hsa-let-7g	miRNA	disulfiram (DSF)	atypical teratoid/rhabdoid tumors (AT/RT)	human ALDH(+) AT/RT cells	DSF treatment	upregulated	25378634
198	Human	hsa-let-7g	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
199	Human	hsa-let-7g	miRNA	hepatitis B X-interacting protein (HBXIP)	breast cancer	MCF-7 cells	hepatitis B X-interacting protein (HBXIP) treatment	downregulated	29174803
200	Human	hsa-let-7g	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
201	Human	hsa-let-7g	miRNA	angiotensin II (Ang II)	endothelial senescence	Human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	downregulated	29393358
202	Human	hsa-let-7g	miRNA	aspirin	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 cell lines	aspirin treatment	upregulated	31278071
203	Human	hsa-let-7g	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
204	Human	hsa-let-7g	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
205	Human	hsa-let-7g	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
206	Human	hsa-let-7g	miRNA	kallistatin	oxidative stress	human umbilical vein endothelial cells (HUVECs)	Kallistatin treatment	upregulated	29992759
207	Human	hsa-let-7g	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
208	Human	hsa-let-7g	miRNA	diesel exhaust particle (DEP)	pulmonary inflammatory response	16HBE and Beas-2B cells	diesel exhaust particle (DEP) exposure	downregulated	30172002
209	Human	hsa-let-7g	miRNA	IFN-¦Á	cell senescence	HeLa cells	24-h of IFN¦Á treatment	downregulated	24942926
210	Human	hsa-let-7g	miRNA	lipopolysaccharide (LPS)	sepsis	Neonatal Polymorphonuclear Leukocytes	lipopolysaccharide (LPS) treatment	dysregulated	28655995
211	Human	hsa-let-7g-5p	miRNA	mitogen activated-protein kinase pathway inhibitors (MAPKis)	cutaneous malignant melanoma (CMM)	extracellular microvesicle in matched plasma	Mitogen activated-protein kinase pathway inhibitors (MAPKis) treatment	upregulated	30399176
212	Human	hsa-let-7g-5p	miRNA	verbascoside (VB)	glioblastoma multiforme (GBM)	A172 cells; SHG139 cells; SHG-44 cells; U87 cells; U251 cells	verbascoside (VB) treatment	let-7g-5p expression was upregulated upon VB treatment	32000296
213	Human	hsa-let-7g-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
214	Human	hsa-let-7i	miRNA	recombinant tissue plasminogen activator (rt-PA)	acute ischemic stroke (AIS)	AIS patients blood samples	rt-PA treatment	upregulation of let-7i and downregulated of miR-15a	28892656
215	Human	hsa-let-7i	miRNA	propofol (PPF)	anti-cancer therapy	human EOC cells	expression in OVCAR-3 with or without propofol treatment	upregulated	25556276
216	Human	hsa-let-7i	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
217	Human	hsa-let-7i	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
218	Human	hsa-let-7i	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-let-7i was downregulated in resistant patients when compared with sensitive patients	33072545
219	Human	hsa-let-7i	miRNA	propofol (PPF)	colorectal cancer (CRC)	Colo205; SW620 cells	"Propofol (2,6-diisopropylphenol) treatment"	Propofol suppresses colorectal cancer tumorigenesis by modulating the HOXA11-AS-let-7i-ABCC10 regulatory network	31013434
220	Human	hsa-let-7i	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
221	Human	hsa-let-7i	miRNA	oxygen glucose deprivation (OGD)	inflammation	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation (OGD) treatment	downregulated	28844675
222	Human	hsa-let-7i	miRNA	cryptosporidium parvum	innate immune response	H69 cells	cryptosporidium parvum? infection	downregulated	24862934
223	Human	hsa-let-7i	miRNA	oxygen glucose deprivation (OGD)	post-stroke cognitive impairment (PSCI)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	MicroRNA Let-7i Is a Promising Serum Biomarker for Post-stroke Cognitive Impairment and Alleviated OGD-Induced Cell Damage in vitro by Regulating Bcl-2	32265630
224	Human	hsa-let-7i	miRNA	IFN-¦Á	cell senescence	HeLa cells	24-h of IFN¦Á treatment	downregulated	24942926
225	Human	hsa-let-7i-3p	miRNA	melatonin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	melatonin treatment	melatonin treatment markedly induced the expression of the miRNA let7i-3p in cells.	30201903
226	Human	hsa-let-7i-3p	miRNA	cyclic mechanical stretch (CMS)	osteogenesis	human adipose-derived stem cells (hASCs)	cyclic strain induce	downregulated	31753039
227	Human	hsa-let-7i-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
228	Human	hsa-let-7i-5p	miRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	downregulated	32926961
229	Human	hsa-let-7i-5p	miRNA	silica	pneumoconiosis	THP-1 cells	silica treatment	downregulated	29516679
230	Human	hsa-let-7i-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
231	Human	hsa-miR-1	miRNA	coronary artery bypass graft (CABG)	acute coronary syndrome (ACS)	acute coronary syndrome patients heart	CABG treatment	upregulated	29506853
232	Human	hsa-miR-1	miRNA	myocardin	andes hantavirus (ANDV) infection	human smooth muscle cells (SMCs)	myocardin treatment	myocardin was reported to induce the expression of microRNA-1 (miR-1) in cardiomyocytes.miR-1 participates in myocardin-dependent of SMC proliferation inhibition.	21051663
233	Human	hsa-miR-1	miRNA	IL-13	asthma	human lung endothelium	IL-13 treatment	IL-13 stimulation decreased miR-1 levels in human lung endothelium.	32035607
234	Human	hsa-miR-1	miRNA	IFN-¦Â	autophagy	HeLa cells	IFN-¦Â treatment	upregulated	31799933
235	Human	hsa-miR-1	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
236	Human	hsa-miR-1	miRNA	angiotensin-converting enzyme 2 (ACE2) inhibitor	cardiovascular disease (CVD)	H9c2 cardiac myoblast cells	ACE2 (angiotensin-converting enzyme 2) treatment	upregulated	26400542
237	Human	hsa-miR-1	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
238	Human	hsa-miR-1	miRNA	bortezomib	congenital muscular dystrophy	congenital muscular dystrophy type 1A muscle cells	bortezomib? treatment	downregulated	24631023
239	Human	hsa-miR-1	miRNA	myocardin	contractility of  vascular smooth muscle cells	human aortic SMCs	myocardin treatment	upregulated	20458751
240	Human	hsa-miR-1	miRNA	glucose	diabetes mellitus (DM)	human retinal microvascular endothelial cells	25mM glucose treatment	downregulated	24394957
241	Human	hsa-miR-1	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	"LN15, LN18, LN229, U138, U87, U251 cell lines"	TGF-¦Â treatment	downregulated	25256711
242	Human	hsa-miR-1	miRNA	carvedilol	heart failure (HF)	serum	carvedilol treatment	upregulated	32943906
243	Human	hsa-miR-1	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells	sorafenib treatment	downregulated	32560747
244	Human	hsa-miR-1	miRNA	oxidized low density lipoprotein (ox-LDL)	hyperlipidemia	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	24792518
245	Human	hsa-miR-1	miRNA	multiwalled carbon nanotubes (MWCNT)	liver fibrosis	A549 cells	MWCNT (20 or 50 ?g/mL) for 6 or 24 h	downregulated after 6 or 24 h of treatment regardless of the dose	28128526
246	Human	hsa-miR-1	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	upregulated	29899866
247	Human	hsa-miR-1	miRNA	active pterocarpanquinone LQB-118 	active pterocarpanquinone LQB-118 cytotoxicity	"PC3, LNCaP, and LAPC4 PCa cells"	LQB-118	downregulated	29105806
248	Human	hsa-miR-1	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	downregulated	19748927
249	Human	hsa-miR-1	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
250	Human	hsa-miR-1	miRNA	(-)-epigallocatechin gallate (EGCG)	osteosarcoma (OS)	MG-63 and U-2OS	(-)-Epigallocatechin gallate (EGCG) treatment	upregulated	26499783
251	Human	hsa-miR-1	miRNA	prednisolone	polymyositis (PM)	serum	prednisolone (PSL) treatment	the serum miR-1 level is significantly reduced by treatment	31483179
252	Human	hsa-miR-1	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	29167124
253	Human	hsa-miR-1	miRNA	H2O2	sepsis	A549 cell line and HKC cell line	H2O2 treatment	upregulated	28673002
254	Human	hsa-miR-1	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
255	Human	hsa-miR-1	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
256	Human	hsa-miR-100	miRNA	"androgen receptor (AR) agonist, CI-4AS-1"	breast cancer	luminal MCF-7 and T47D cells and the molecular apocrine MDA-MB-453 cells.	CI-4AS-1 treatment	downregulated	28816390
257	Human	hsa-miR-100	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
258	Human	hsa-miR-100	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-100 was upregulated in resistant patients when compared with sensitive patients	33072545
259	Human	hsa-miR-100	miRNA	arsenic trioxide (ATO)	epithelial-mesenchymal transition (EMT)	BEAS-2B cells	arsenic trioxide (As2O3) treatment	downregulated	28956730
260	Human	hsa-miR-100	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
261	Human	hsa-miR-100	miRNA	docetaxel (DTX)	head and neck squamous cell carcinoma (HNSCC)	UMSCC-1 cells;SQ20B cells	docetaxel (DTX) treatment	downregulated	21560177
262	Human	hsa-miR-100	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
263	Human	hsa-miR-100	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG-63 cells	cisplatin (DPP) treatment	downregulated	30280766
264	Human	hsa-miR-100	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
265	Human	hsa-miR-100	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cell	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	31298038
266	Human	hsa-miR-100	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38?cells	lipopolysaccharide (LPS) treatment	downregulated	29673591
267	Human	hsa-miR-100	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	prostate cancer	?primary prostatic epithelial cells (PrE)	"?1,25-dihydroxyvitamin D"	downregulated	23503652
268	Human	hsa-miR-100	miRNA	mifepristone (MIF)	prostate cancer	prostate cells	Mifepristone treatment	upregulated	27340920
269	Human	hsa-miR-100	miRNA	iodine-131 (131I)	thyroid cancer (TC)	A follicular thyroid carcinoma cell line (FTC-133)	I131 treatment	downregulated	24785011
270	Human	hsa-miR-100*	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
271	Human	hsa-miR-100-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
272	Human	hsa-miR-100-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	downregulated	33194074
273	Human	hsa-miR-100-5p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells; Hep3B cells; HepG2 cells	hypoxia treatment	The expression of miR-100-5p expression was significantly suppressed in HCC cell lines under 1% O2-induced hypoxia.	32152275
274	Human	hsa-miR-100-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
275	Human	hsa-miR-100-5p	miRNA	rapamycin	osteoarthritis (OA)	Chondrocytes	Rapamycin treatment	upregulated	31358056
276	Human	hsa-miR-101	miRNA	hypoxia	angiogenesis	HUVECs	2¡À1% O2 treatment	upregulated	24844779
277	Human	hsa-miR-101	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	apoptosis 	breast cancer cells	HIF1¦Á treatment	upregulated	26841847
278	Human	hsa-miR-101	miRNA	H2O2	apoptosis	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	upregulated	33226571
279	Human	hsa-miR-101	miRNA	melatonin	apoptosis	H2O2 treated human umbilical vein endothelial cells (HUVECs)	melatonin treatment	downregulated	33226571
280	Human	hsa-miR-101	miRNA	lipopolysaccharide (LPS)	autophagy	intestinal epithelial cell line Caco-2	lipopolysaccharide (LPS) treatment	downregulated	31185236
281	Human	hsa-miR-101	miRNA	octreotide (OCT)	autophagy	LPS-treated Caco-2 cells	Octreotide (OCT) treatment	upregulated	31185236
282	Human	hsa-miR-101	miRNA	gambogic acid (GA) and methyl jasmonate (MJ)	bladder cancer	human bladder cancer cells	GA and MJ treatment	upregulated	24490857
283	Human	hsa-miR-101	miRNA	histone deacetylase inhibitor (HDACi)	burkitt lymphoma (BL)	Raji B-cell lymphoma	HDACi treatment	upregulated	24577510
284	Human	hsa-miR-101	miRNA	cadmium (Cd)	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	cadmium (Cd) treatment	CdCl2-induced abnormal angiogenesis is mediated by miR-101/COX-2/VEGF-axis-dependent ER stress.	32783891
285	Human	hsa-miR-101	miRNA	Sphingosine-1-phosphate (S1P)	chondrosarcoma	human chondrosarcoma cells	S1P treatment	downregulated	28672103
286	Human	hsa-miR-101	miRNA	hypoxia	clear cell renal cell carcinoma (ccRCC)	ACHN and HK-2 cells	hypoxia treatment	upregulated	28138701
287	Human	hsa-miR-101	miRNA	jasmonate	colorectal cancer (CRC)	SW620 human colorectal cancer cells	jasmonate treatment	"Compared with control, the anticancer effect of methyl jasmonate inhibited Enhancer of zeste homolog 2 (EZH2) protein expression and activated microRNA (miR)-101 expression in SW620 cells."	28000868
288	Human	hsa-miR-101	miRNA	methyl jasmonate (MeJA)	colorectal cancer (CRC)	SW620 human colorectal cancer cells	"were treated with 0, 0.5, 0.75, 1.5 and 2.0 mM methyl jasmonate for 12, 24 and 48 h"	upregulated	28000868
289	Human	hsa-miR-101	miRNA	etoposide (VP-16)	DNA damage	MCF7 cells	1 ?M/5 ?M etoposide treatment	upregulated	25353636
290	Human	hsa-miR-101	miRNA	melatonin	apoptosis	human umbilical vein endothelial cells (HUVECs)	Melatonin treatment	Melatonin upregulates DNA-PKcs to suppress apoptosis of human umbilical vein endothelial cells via inhibiting miR-101 under H 2 O 2-induced oxidative stress	33226571
291	Human	hsa-miR-101	miRNA	nicotine	epithelial-mesenchymal transition (EMT)	"head and neck squamous cell carcinoma cell lines, UMSCC-10B and HN-1"	nicotine treatment	downregulated	23300583
292	Human	hsa-miR-101	miRNA	cyclooxygenase-2 (COX-2)	gastric cancer (GC)	Human gastric cancer cell lines SGC-7901; BGC-823;matched normal tissue	Cyclooxygenase-2 (COX-2)? treatment	downregulated	23013439
293	Human	hsa-miR-101	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	Expression of miR-101 largely decreased in U-251/ TMZ compared with the parental cell	29479863
294	Human	hsa-miR-101	miRNA	Sinomenine (SIN)	glucocorticoids dermatitis	HaCaT cells	Sinomenine (SIN) treatment	downregulated	29501764
295	Human	hsa-miR-101	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	downregulated	28797462
296	Human	hsa-miR-101	miRNA	apigenin	hepatocellular carcinoma (HCC)	doxorubicin-resistant hepatocellular carcinoma cell line BEL-7402/ADM	apicidin treatment	upregulated	29137246
297	Human	hsa-miR-101	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	human liver cancer cells (HepG2)	cisplatin (DDP) treatment	"Cell proliferation, apoptosis, intracellular reactive oxygen species and comet assay results indicated that the upregulation of miR-101 sensitized HepG2 cells to CDDP, and downregulated of miR-101 reduced chemosensitivity."	31516578
298	Human	hsa-miR-101	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
299	Human	hsa-miR-101	miRNA	lipopolysaccharide (LPS)	inflammation	pancreatic ¦Â cell Min6	lipopolysaccharide (LPS) treatment	upregulated	31213095
300	Human	hsa-miR-101	miRNA	tetramethylpyrazine (TMP)	inflammation	LPS-treated pancreatic ¦Â cell Min6	Tetramethylpyrazine (TMP) treatment	downregulated	31213095
301	Human	hsa-miR-101	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
302	Human	hsa-miR-101	miRNA	octreotide (OCT)	intestinal mucositis	Caco-2 cells	octreotide (OCT) treatment	OCT affected autophagy through up-regulating miR-101 in LPS-treated cells.	30205395
303	Human	hsa-miR-101	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	HSCs	carbon tetrachloride (CCl4) treatment	downregulated	24817606
304	Human	hsa-miR-101	miRNA	active pterocarpanquinone LQB-118 	active pterocarpanquinone LQB-118 cytotoxicity	"PC3, LNCaP, and LAPC4 PCa cells"	LQB-118	downregulated	29105806
305	Human	hsa-miR-101	miRNA	IL-1¦Â	lung cancer	lung	IL-1¦Â treatment	the interleukin 1 receptor antagonist and interleukin-1¦Â antibody can reduce silica particle-induced downregulated of mir-101	25428391
306	Human	hsa-miR-101	miRNA	silica particle	lung cancer	Xuan Wei lung cancer cell line	silica particle treatment	downregulated	25428391
307	Human	hsa-miR-101	miRNA	curcumin (Cur)	multiple myeloma (MM)	MM cell lines RPMI8226 and U266	curcumin treatment	upregulated	28322158
308	Human	hsa-miR-101	miRNA	IL-1¦Â	osteoarthritis (OA)	primary OA chondrocytes	IL-1¦Â treatment	"LINC00623/miR-101/HRAS axis modulates OA chondrocyte apoptosis, senescence and ECM degradation through MAPK signaling"	32062610
309	Human	hsa-miR-101	miRNA	zoledronic acid (ZA)	osteoporosis	serum	ZOL treatment	"?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment"	33637048
310	Human	hsa-miR-101	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
311	Human	hsa-miR-101	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
312	Human	hsa-miR-101	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
313	Human	hsa-miR-101	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	parkinson's disease (PD)	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
314	Human	hsa-miR-101	miRNA	sunitinib (SU)	renal cell carcinoma (RCC)	RCC cells	sunitinib treatment	downregulated	27487138
315	Human	hsa-miR-101	miRNA	ultraviolet (UV) irradiation	skin senescence	skin fibroblasts	UVB treatment	microRNA-mRNA functional interactions in UVB-induced senescence of human diploid fibroblasts	23557329
316	Human	hsa-miR-101	miRNA	TPA (12-O-tetradecanoylphorbol 13-acetate)	hepatocellular carcinoma (HCC)	HepG2 cells	TPA (12-O-tetradecanoylphorbol 13-acetate) treatment	"TPA not only upregulated miR-101 expression, but also reduced protein level of EZH2, EED and H3K27me3 in HepG2 cells"	20444294
317	Human	hsa-miR-101-3p	miRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	thyroid papillary cell line TPC-1 (BNCC337912) and B-CPAP (BNCC338685)	131I treatment	NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo.	30596336
318	Human	hsa-miR-101-3p	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	autophagy	human HTR-8/SVneo (HTR) cells	Titanium dioxide nanoparticles (TiO2 NPs) treatment	upregulated	30345998
319	Human	hsa-miR-101-3p	miRNA	cisplatin (DDP)	bladder cancer	The 5637 and EJ-M3 cells	cisplatin treatment	MALAT1 affected the cisplatin resistance of the BC cells via regulating the miR-101-3p/VEGF-C pathway.	31650173
320	Human	hsa-miR-101-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
321	Human	hsa-miR-101-3p	miRNA	serum deprivation	endothelial cell death associated with vascular disorders	HUVECs	serum deprivation treatment	downregulated	28518140
322	Human	hsa-miR-101-3p	miRNA	cigarette smoke extract (CSE)	esophageal squamous cell carcinoma (ESCC)	human immortalized non-tumorigenic esophageal epithelial cell line (Het-1A)	cigarette smoking extract (CSE) treatment	downregulated	26530100
323	Human	hsa-miR-101-3p	miRNA	cigarette smoke extract (CSE)	esophageal squamous cell carcinoma (ESCC)	Eca109 cancer cells	cigarette smoking extract (CSE) treatment	downregulated	26530100
324	Human	hsa-miR-101-3p	miRNA	bupivacaine	neurotoxicity	Primary dorsal root ganglion (DRG) neurons	bupivacaine treatment	miR-101-3p was decreased with increasing concentrations of bupivacaine exposure.	31254586
325	Human	hsa-miR-101-3p	miRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	SH-SY5Y cells	abnormal accumulation of ¦Á-Syn treatment	Overexpressed lncRNA-T199678 significantly downregulated the expression in SH-SY5Y cells	33328976
326	Human	hsa-miR-101-3p	miRNA	docetaxel (DTX)	prostate cancer	LNCaP and CWR22Rv1 cells	docetaxel (DTX) treatment	downregulated	30621625
327	Human	hsa-miR-101-3p	miRNA	Treponema pallidum (Tp)	treponema pallidum (Tp) infection	THP-1 cells	Treponema pallidum (Tp) infection treatment	Stimulation of THP-1 cells with Tp increased miR-101-3p expression	31930972
328	Human	hsa-miR-101a	miRNA	cyclooxygenase-2 (COX-2)	bladder cancer	human bladder cancer cells	COX-2 treatment	downregulated	25109742
329	Human	hsa-miR-101a-3p	miRNA	osthole	Alzheimer's disease (AD)	SH-SY5Y cells	osthole treatment	"osthole had a protective effect on APP-SH-SY5Y cells, and it could raise miRNA-101a-3p expression and inhibit APP mRNA/protein expression, the formation of A¦Â protein was inhibited too."	30951743
330	Human	hsa-miR-101a-3p	miRNA	osthole	Alzheimer's disease (AD)	SH-SY5Y cells	osthole treatment	Osthole inhibits the expression of APP by up-regulating miR-101a-3p in AD cell model.	30693688
331	Human	hsa-miR-103	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
332	Human	hsa-miR-103	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	K562 cells	adriamycin (ADR) treatment	upregulated	29058777
333	Human	hsa-miR-103	miRNA	tetrabromobisphenol-A (TBBPA)	adipogenesis	human adipose-derived primary MSCs	TBBPA treatment	upregulated	28329833
334	Human	hsa-miR-103	miRNA	human immunodeficiency virus (HIV)-1	antiviral immune response	monocyte-derived macrophage (MDM)	human immunodeficiency virus type 1 (HIV-1) treatment	upregulated	32994328
335	Human	hsa-miR-103	miRNA	IL-1¦Â	antiviral immune response	monocyte-derived macrophage (MDM)	IL-1¦Â treatment	Treatment of MDMs with interleukin-1¦Â (IL-1¦Â) enhanced microRNA 103 expression.	32994328
336	Human	hsa-miR-103	miRNA	glucocorticoid (GC)	apoptosis	"CEM-C7H2 , CUTLL, MOLT-4, Loucy, BJAB, SUD-H6 , DAUDI cell lines"	GC	upregulated	27888798
337	Human	hsa-miR-103	miRNA	H2O2	atherosclerosis (AS)	human coronary artery endothelial cells	H2O2 treatment	"Under the stimulation of H 2O 2, the expression of miR-103 decreased."	32190178
338	Human	hsa-miR-103	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31232476
339	Human	hsa-miR-103	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 6¡ã HDT bed rest experiment	downregulated	28261104
340	Human	hsa-miR-103	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
341	Human	hsa-miR-103	miRNA	H2O2	cardiovascular disease (CVD)	HUVEC	H2O2 treatment	downregulated	26000071
342	Human	hsa-miR-103	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	The cisplatin-resistant Hep3B (Hep3B-R) and Huh7 (Huh7-R) cells	cisplatin treatment	"circRNA_101505 could sensitize HCC cells to cisplatin by sponging miR-103, and thereby promoting oxidored-nitro domain-containing protein 1 (NOR1) expression."	31372241
343	Human	hsa-miR-103	miRNA	lipopolysaccharide (LPS)	inflammation	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31284776
344	Human	hsa-miR-103	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	human umbilical vein endothelial cells (HUVECs)	oxygen-glucose deprivation (OGD) treatment	downregulated	29511499
345	Human	hsa-miR-103	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30007440
346	Human	hsa-miR-103	miRNA	morphine	morphine tolerance	"human embryonic kidney 293 (HEK293) cells, Be(3)C cells"	chronic morphine men treatment	upregulated	24302561
347	Human	hsa-miR-103	miRNA	retinoic acid (RA)	nervous system cancers	SK-N-BE(2)-C £»SH SY5Y??cells?;SH-EP cells£» HEK 293T cells	retinoic acid treatment	upregulated	22848373
348	Human	hsa-miR-103	miRNA	IL-1¦Â	osteoarthritis (OA)	Human primary chondrocyte	IL-1¦Â treatment	upregulated	31302420
349	Human	hsa-miR-103	miRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	CD4 + cells from PTC patients	131?I treatment	downregulated	30267584
350	Human	hsa-miR-103	miRNA	Shenmai injection (SMI)	papillary thyroid cancer (PTC)	CD4 + cells from PTC patients	131?I and Shenmai injection (SMI) dual treatment	upregulated	30267584
351	Human	hsa-miR-103	miRNA	hypoxia	prostate cancer	colorectal cancer (CRC) cells	Hypoxia treatment	upregulated	22593189
352	Human	hsa-miR-103	miRNA	hypoxia	retinal pigment epithelium (RPE) cells injuries	ARPE-19 human RPE cells	hypoxia treatment	hypoxia downregulated microRNA-103 (miR-103).	30144973
353	Human	hsa-miR-103	miRNA	lipopolysaccharide (LPS)	sepsis	Monocytes	lipopolysaccharide (LPS) treatment	downregulated	32455124
354	Human	hsa-miR-103-3p	miRNA	lipopolysaccharide (LPS)	liver fibrosis	THP-1 cells	lipopolysaccharide (LPS)	Exosomal miR-103-3p from LPS-activated THP-1 macrophage contributes to the activation of hepatic stellate cells.	32061112
355	Human	hsa-miR-103-3p	miRNA	salidroside (SAL)	non small cell lung cancer (NSCLC)	A549 cells; H460 cells	salidroside (SAL) treatment	"Salidroside could inhibit the proliferation of nonsmall cell lung cancer (NSCLC) cells, and elevated the level of miR-103-3p"	32304408
356	Human	hsa-miR-103a-2-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SKhep1 cells; Huh7 cells; LM3 cells	sorafenib treatment	downregulated	33222692
357	Human	hsa-miR-103a-3p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
358	Human	hsa-miR-103a-3p	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	gastric cancer (GC)	MGC-803 and MKN-45 cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	downregulated	31606381
359	Human	hsa-miR-103a-3p	miRNA	hyperbaric oxygen (HBO)	hepatocellular carcinoma (HCC)	Hepatoma cell lines (BEL-7402 and SK-Hep1)	HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment	downregulated	24956259
360	Human	hsa-miR-103a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
361	Human	hsa-miR-103a-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
362	Human	hsa-miR-103a-3p	miRNA	L-dopa	parkinson's disease (PD)	peripheral blood	L-dopa-treated treatment	the results suggest a role of L-dopa treatment in miR-103a-3p expression only	25596505
363	Human	hsa-miR-103b	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
364	Human	hsa-miR-103b	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
365	Human	hsa-miR-103b	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
366	Human	hsa-miR-103b	miRNA	fibroblast growth factor 2 (FGF2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fibroblast growth factor 2 (FGF2) treatment	downregulated	30414893
367	Human	hsa-miR-103b	miRNA	TGF-¦Â	angiogenesis	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â treatment	downregulated	30414893
368	Human	hsa-miR-103b	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	vascular endothelial cell growth factor (VEGF) treatment	downregulated	30414893
369	Human	hsa-miR-105	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	"human colon epithelial cell line FHC and CRC cell lines including LS174T, LoVo, HT29, SW620, SW480, HCT116"	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29238068
370	Human	hsa-miR-105	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	upregulated	32807750
371	Human	hsa-miR-105	miRNA	fibroblast growth factor 2 (FGF2)	osteoarthritis (OA)	chondrocytes	Fibroblast growth factor 2 (FGF2) treatment	downregulated	27998273
372	Human	hsa-miR-106	miRNA	baicalin (BAI)	bladder cancer	T24 cells	baicalin (BAI) treatment	downregulated	30257376
373	Human	hsa-miR-106	miRNA	diet	obesity	Plasma	diet treatment	"Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss."	32439373
374	Human	hsa-miR-106	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
375	Human	hsa-miR-106	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	K562 cells	cisplatin (DPP) treatment	miR-106 and miR-150 were downregulated	20428827
376	Human	hsa-miR-106	miRNA	high glucose (HG)	vascular endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	downregulated	30055307
377	Human	hsa-miR-106?b-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
378	Human	hsa-miR-106-5p	miRNA	H2O2	cell senescence	multipotent stromal cells	H2O2 treatment	downregulated	32174776
379	Human	hsa-miR-106a	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
380	Human	hsa-miR-106a	miRNA	lipopolysaccharide (LPS)	breast cancer	HeLa cells	lipopolysaccharide (LPS) treatment	the expression of miR-17-3p and miR-106a is regulated by  LPS in HeLa cells	21370248
381	Human	hsa-miR-106a	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	malignant human bronchial epithelial cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide treatment"	upregulated	20889678
382	Human	hsa-miR-106a	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells; HT-29 cells	oxaliplatin (OXA) treatment	upregulated	31897182
383	Human	hsa-miR-106a	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 and HT-29 CELLS	oxaliplatin treatment	"Elevation of miR-106a and a decrease of FOXQ1 expression levels were detected in tumor tissues from patients with oxaliplatin-sensitive colorectal cancer, compared with patients with oxaliplatin-resistant colorectal cancer"	31897182
384	Human	hsa-miR-106a	miRNA	5-fluorouracil (5-Fu)	diabetic nephropathy (DN)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
385	Human	hsa-miR-106a	miRNA	platelet-derived growth factor-D (PDGF-D)	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 cells	platelet-derived growth factor-D (PDGF-D) treatment	downregulated	25760076
386	Human	hsa-miR-106a	miRNA	TGF-¦Â	inflammatory bowel disease (IBD)	Jurkat T cells	TGF-¦Â treatment	downregulated	30327532
387	Human	hsa-miR-106a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Jurkat T cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30327532
388	Human	hsa-miR-106a	miRNA	Src-TKIs (saracatinib or dasatinib)	lung cancer	"A549, H460, and H1299 NSCLC cells"	Src-TKIs treatment	downregulated	27372519
389	Human	hsa-miR-106a	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
390	Human	hsa-miR-106a	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells	lipopolysaccharide (LPS) treatment	upregulated	23562609
391	Human	hsa-miR-106a	miRNA	5-fluorouracil (5-Fu)	metastatic colorectal cancer (mCRC)	mCRC patients	5-fluorouracil (5-FU) treatment	upregulated	24119443
392	Human	hsa-miR-106a	miRNA	IL-6	ovarian cancer (OC)	SKOV3 and OVCAR3 cell lines	IL-6 treatment	downregulated	275100942
393	Human	hsa-miR-106a	miRNA	radiation	prostate cancer	PC3 cells; DU145 cells	radiation treatment	upregulated	29191361
394	Human	hsa-miR-106a	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
395	Human	hsa-miR-106a-363	miRNA	estrogen receptor-¦Á	breast cancer	breast cancer cells	The estrogen receptor-¦Á treatment	upregulated	19706389
396	Human	hsa-miR-106a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	miR-106a-3p was increased in exosomes from ox-LDL induced THP-1.	32633398
397	Human	hsa-miR-106a-5p	miRNA	melatonin	intervertebral disc degeneration (IDD)	human annulus fibrosus (AF)	melatonin treatment	downregulated	30992660
398	Human	hsa-miR-106a-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
399	Human	hsa-miR-106a-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	MGC-803 cells	5-fluorouracil (5-FU) treatment	upregulated	31115533
400	Human	hsa-miR-106a-5p	miRNA	cryptotanshinone	osteoarthritis (OA)	priamry cultured chondrocytes	Cryptotanshinone (CTS) treatment	upregulated	29858052
401	Human	hsa-miR-106a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	31894109
402	Human	hsa-miR-106b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32130290
403	Human	hsa-miR-106b	miRNA	prolactin and estradiol	breast cancer	"human breast cancer cell lines, T47D and MCF-7, the human prostate cancer cell line, PC3, and human ovarian cancer cell lines, TOV-112D, OV-90 and TOV-21G"	prolactin and estradiol treatment	upregulated	28422740
404	Human	hsa-miR-106b	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells	docosahexaenoic acid (DHA) fatty acids treatment	MDA-MB-231 cells with DHA caused a decrease in the miR-106b expression.	31713924
405	Human	hsa-miR-106b	miRNA	TGF-¦Â	breast cancer	"MDA-MB-231, MCF-7 and MCF-10A cell lines"	TGF-¦Â treatment	upregulated	24292682
406	Human	hsa-miR-106b	miRNA	radiation	cervical cancer (CC)	SiHa cells	radiation treatment	miR-106b expression was highly expressed in the radio-resistant SiHa cells	30579899
407	Human	hsa-miR-106b	miRNA	X-rays	cervical cancer (CC)	CC tissues and cell lines (SiHa and ME180)	6 MV X-ray irradiation	upregulated	30579899
408	Human	hsa-miR-106b	miRNA	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC)	chronic inflammatory diseases	human umbilical vein endothelial cells (HUVECs) exosomes	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment	upregulated	29161413
409	Human	hsa-miR-106b	miRNA	butyrate	colorectal cancer (CRC)	HCT-116 cells	butyrate treatment	"Butyrate decreased HCT-116 proliferation, an effect reversed with the addition of the miR-106b mimic"	21283757
410	Human	hsa-miR-106b	miRNA	shikonin	endometrial cancer (EC)	Ishikawa cells	Shikonin treatment	downregulated	29449346
411	Human	hsa-miR-106b	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
412	Human	hsa-miR-106b	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	gastric epithelial cells	lipopolysaccharide (LPS) treatment	downregulated	25307786
413	Human	hsa-miR-106b	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	"human gastric epithelial cell lines, AGS and MKN45"	LPS from H. pylori 26695 treatment	downregulated	25307786
414	Human	hsa-miR-106b	miRNA	shikonin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	Shikonin treatment	Shikonin suppresses cell progression and EMT and accelerates cell death of HCC cells via modulating miR-106b/SMAD7/TGF-¦Â signaling pathway	31617643
415	Human	hsa-miR-106b	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
416	Human	hsa-miR-106b	miRNA	TGF-¦Â	innate immune response	MDA-MB-231 cells; MCF-7 cells; MCF-10A cells	TGF-¦Â treatment	upregulated	24292682
417	Human	hsa-miR-106b	miRNA	grape seed proanthocyanidins (GSPs)	lung cancer	"human NSCLC lines, A549 (Adenocarcinoma), H520 (squamous cell carcinoma), H1299 (Metastatic NSCLC), DMS114 (small cell lung cancer), H23 (adenocarcinoma)"	grape seed procyanidin extract (GSE) treatment	downregulated	29643994
418	Human	hsa-miR-106b	miRNA	leucoselect phytosome (LP)	lung cancer	human lung tumor xenografts	leucoselect phytosome (LP) treatment	downregulated	29643994
419	Human	hsa-miR-106b	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
420	Human	hsa-miR-106b	miRNA	grape seed proanthocyanidins (GSPs)	melanoma	A375 and Hs294t cells	with GSPs treatment	downregulated	25361006
421	Human	hsa-miR-106b	miRNA	H2O2	mitophagy	HeLa and HEK 293T cells	H2O2 treatment	"We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions."	33627622
422	Human	hsa-miR-106b	miRNA	berberine (BBR)	multiple myeloma (MM)	"human multiple myeloma cell, RPMI-8266 and U266"	berberine (BBR) treatment	downregulated	27647143
423	Human	hsa-miR-106b	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	cancer-associated fibroblasts (CAFs) and the exosomes derived from CAFs	Gemcitabine (GEM) treatment	upregulated	31374207
424	Human	hsa-miR-106b	miRNA	hypoxia	prostate cancer	PCa cell lines (LNCaP£» PC3)£»neural crest (NC) cells	hypoxia treatment	downregulated	24135225
425	Human	hsa-miR-106b	miRNA	hypoxia	prostate cancer	LNCaP cells	5% O2 treatment	upregulated	24135225
426	Human	hsa-miR-106b	miRNA	salvianolic acid B (Sal B)	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	Sal B treatment	upregulated	25094038
427	Human	hsa-miR-106b	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	TGF-¦Â1 treatment	downregulated	25094038
428	Human	hsa-miR-106b	miRNA	toxoplasma gondii (T. gondii)	toxoplasma gondii infection	primary human foreskin fibroblasts (HFFs)	toxoplasma gondii (T. gondii) infection treatment	upregulated	20090903
429	Human	hsa-miR-106b	miRNA	docosahexaenoic acid (DHA)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	Docosahexaenoic acid (DHA) treatment	downregulated	31713924
430	Human	hsa-miR-106b	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
431	Human	hsa-miR-106b-25	miRNA	natalizumab	B lymphocytic leukemia	whole blood  lymphocytes	natalizumab treatment	downregulated	22659298
432	Human	hsa-miR-106b-25	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
433	Human	hsa-miR-106b-3p	miRNA	matrine	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	matrine treatment	downregulated	29045804
434	Human	hsa-miR-106b-3p	miRNA	BIX01294	lung cancer	human NSCLC cells	BIX01294 treatment	downregulated	24932239
435	Human	hsa-miR-106b-5p	miRNA	TGF-¦Â1	asthma	human bronchial epithelial cells BEAS-2B	TGF-¦Â1 treatment	The present study revealed downregulated miR-106b-5p expression and upregulated SIX1 expression in asthmatic mice and TGF-¦Â1-induced BEAS-2B cells	33495833
436	Human	hsa-miR-106b-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
437	Human	hsa-miR-106b-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
438	Human	hsa-miR-106b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	cardiac dysfunction	SH-SY5Y cells; HCN-2 cells	MPP+ (1-methyl-4-phenylpyridinium) treatment	Inhibition of miR-6862 induces SphK1 elevation and protects neuronal cells from MPP+-induced cell death.	33414358
439	Human	hsa-miR-106b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-106b-5p expression was increased in OGD/R induced SH-SY5Y cells	32407850
440	Human	hsa-miR-106b-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
441	Human	hsa-miR-106b-5p	miRNA	magnesium-free extracellular fluid	temporal lobe epilepsy (TLE)	SK-N-SH cells; IMR-32 cells	magnesium-free extracellular solution	upregulated	33370579
442	Human	hsa-miR-106b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
443	Human	hsa-miR-106b-93-25	miRNA	trichostatin A (TSA)	inflammation	human endometrial cancer (EMC) cells	trichostatin (TSA)? treatment	downregulated	23028803
444	Human	hsa-miR-107	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2£» PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
445	Human	hsa-miR-107	miRNA	hyperbaric oxygen (HBO)	intervertebral disc degeneration (IDD)	nucleus pulposus cells (NPCs)	Hyperbaric oxygen (HBO) treatment	upregulated	30704538
446	Human	hsa-miR-107	miRNA	tetrabromobisphenol-A (TBBPA)	adipogenesis	human adipose-derived primary MSCs	TBBPA treatment	upregulated	28329833
447	Human	hsa-miR-107	miRNA	6-hydroxydopamine (6-OHDA)	Alzheimer's disease (AD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	31778666
448	Human	hsa-miR-107	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y; SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	"NEAT1 expression was enhanced in A¦Â-treated SH-SY5Y and SK-N-SH cells, miR-107 abundance was reduced in A¦Â-treated cells, and its overexpression reversed A¦Â-induced injury. Moreover, interference of miR-107 abated silencing of NEAT1-mediated inhibition of neuronal damage in A¦Â-treated SH-SY5Y and SK-N-SH cells."	31250578
449	Human	hsa-miR-107	miRNA	6-hydroxydopamine (6-OHDA)	Alzheimer's disease (AD)	SH-SY5Y Cells	6-hydroxydopamine (6-OHDA) treatment	6-OHDA suppressed miR-107 expression.	31778666
450	Human	hsa-miR-107	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y; SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	SOX21-AS1 silencing could attenuate A¦Â1-42-induced neuronal damage by sponging miR-107	32124921
451	Human	hsa-miR-107	miRNA	metformin (Met)	anti-cancer therapy	CD8 + T cells	Metformin treatment	downregulated	32221038
452	Human	hsa-miR-107	miRNA	human immunodeficiency virus (HIV)-1	antiviral immune response	monocyte-derived macrophage (MDM)	human immunodeficiency virus type 1 (HIV-1) treatment	upregulated	32994328
453	Human	hsa-miR-107	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs) and human umbilical vein smooth muscle cells (HUVSMCs)	lipopolysaccharide (LPS) treatment	"The expression of miR-107 was significantly decreased in the blood cells of patients with atherosclerosis compared with the controls. In addition, miR-107 mimics significantly inhibited the proliferation of HUVECs and HUVSMCs, compared with the control groups, at 48 and 72 h, which was in contrast to the observed effects of circRNA-0044073."	30864721
454	Human	hsa-miR-107	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
455	Human	hsa-miR-107	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
456	Human	hsa-miR-107	miRNA	hypoxia	colorectal cancer (CRC)	Bone marrow mononuclear cells (BMMCs)	hypoxia treatment	MiR-107 expression were increased in EPCs under hypoxic conditions	22792280
457	Human	hsa-miR-107	miRNA	dichloroacetate (DCA) and oxaliplatin (L-OHP)	colorectal cancer (CRC)	HCT-116 cells	dichloroacetate (DCA) and oxaliplatin (L-OHP) treatment	upregulated	31919406
458	Human	hsa-miR-107	miRNA	Skullcapflavone I (SF I)	colorectal cancer (CRC)	HCT116 cells	Skullcapflavone I treatment	downregulated	30509103
459	Human	hsa-miR-107	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma extracellular vesicle (EV)	doxorubicin (Dox) treatment	downregulated	32255536
460	Human	hsa-miR-107	miRNA	rapamycin	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	downregulated	29579170
461	Human	hsa-miR-107	miRNA	extract of Stellerachamaejasme L(ESC)	hepatocellular carcinoma (HCC)	HepG2 and MHCC97H cells	extract of Stellerachamaejasme L(ESC) treatment	upregulated	29554896
462	Human	hsa-miR-107	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
463	Human	hsa-miR-107	miRNA	ischemia/reperfusion (I/R) 	ischemic stroke (IS)	brain tissues	ischemia/reperfusion (I/R) treatment	upregulated in rat hippocampal cultures	24943094
464	Human	hsa-miR-107	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30007440
465	Human	hsa-miR-107	miRNA	cisplatin (DDP)	laryngeal squamous cell carcinoma (LSCC)	TU-177 cells; AMC-HN-8 cells	cisplatin treatment	H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo.	33314408
466	Human	hsa-miR-107	miRNA	morphine	morphine tolerance	"human embryonic kidney 293 (HEK293) cells, Be(2)C cells"	chronic morphine men treatment	upregulated	24302561
467	Human	hsa-miR-107	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
468	Human	hsa-miR-107	miRNA	hyperbaric oxygen (HBO)	osteoarthritis (OA)	osteoarthritic (OA) chondrocytes	Hyperbaric oxygen (HBO) treatment	upregulated	31146014
469	Human	hsa-miR-107	miRNA	dexamethasone (DEX)	oxidative stress	OB-6 human osteoblastic cells	dexamethasone (DEX) treatment	miR-107 inhibition upregulates CAB39 and activates AMPK-Nrf2 signaling to protect osteoblasts from dexamethasone-induced oxidative injury and cytotoxicity	32527986
470	Human	hsa-miR-107	miRNA	hypoxia	prostate cancer	colorectal cancer (CRC) cells	Hypoxia treatment	upregulated	22593189
471	Human	hsa-miR-107	miRNA	hypoxia	tumor angiogenesis	HCT116 cells	Hypoxia treatment	upregulated	20308559
472	Human	hsa-miR-10a	miRNA	alcohol	alcohol stress	alcohol consumption in heavy drinkers	were allowed to drink up to 750 cc of beer? treatment	upregulated	25421511
473	Human	hsa-miR-10a	miRNA	tamoxifen (TAM)	breast cancer	tumour samples of breast cancer	tamoxifen treatment	upregulated	23968733
474	Human	hsa-miR-10a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	?SH-SY5Y cell	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30798122
475	Human	hsa-miR-10a	miRNA	trametenolic acid B (TAB)	cerebral ischemia/reperfusion (I/R) injury	oxygen glucose deprivation/reoxygenation (OGD/R) induced?SH-SY5Y cell	Trametenolic acid B (TAB) treatment	downregulated	30798122
476	Human	hsa-miR-10a	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
477	Human	hsa-miR-10a	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-10a was upregulated in resistant patients when compared with sensitive patients	33072545
478	Human	hsa-miR-10a	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma-derived exosomes (GDEs)	hypoxia treatment	The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN).	29713056
479	Human	hsa-miR-10a	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	human glioma cell	transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	24100613
480	Human	hsa-miR-10a	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
481	Human	hsa-miR-10a	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
482	Human	hsa-miR-10a	miRNA	infliximab	inflammatory bowel disease (IBD)	IBD patients	infliximab treatment	downregulated	25281418
483	Human	hsa-miR-10a	miRNA	cisplatin (DDP)	lung cancer	A549 cells; H1299 cells	cisplatin treatment	CTCs treated with cisplatin demonstrated higher miR-10a expression and lower PIK3CA expression than that in A549 and H1299 cells.	32186774
484	Human	hsa-miR-10a	miRNA	icariin (ICA)	lung cancer	A549 cells	Icaritin treatment	downregulated	31829310
485	Human	hsa-miR-10a	miRNA	retinoic acid (RA)	neuroblastoma (NB)	SH-SY5Y (ATCC CRL-2266); HeLa (ATCC CCL-2) cells	Retinoic acid treatment	upregulated	21118818
486	Human	hsa-miR-10a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
487	Human	hsa-miR-10a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid treatment	downregulated	32143184
488	Human	hsa-miR-10a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
489	Human	hsa-miR-10a	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	peripheral blood	methotrexate treatment	circulating miR-10a was upregulated in RA patients treated with MTX.	29667551
490	Human	hsa-miR-10a-3p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
491	Human	hsa-miR-10a-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human articular chondrocyte	?IL-6?treatment treatment	"?IL-6 downregulated miR-10a-5p, which subsequently derepressed IL-6R expression"	33166496
492	Human	hsa-miR-10a-5p	miRNA	lipopolysaccharide (LPS)	apical periodontitis (AP)	K-562 cells	lipopolysaccharide (LPS) treatment	upregulated	33245973
493	Human	hsa-miR-10a-5p	miRNA	S-equol	breast cancer	MCF-7?cells	S-equol treatment	upregulated	31390527
494	Human	hsa-miR-10a-5p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
495	Human	hsa-miR-10a-5p	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
496	Human	hsa-miR-10a-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
497	Human	hsa-miR-10a-5p	miRNA	heparin-binding EGF-like growth factor (HB-EGF)	keratinocytes (KCs) diferentiation	human primary KCs	heparin-binding EGF-like growth factor (HB-EGF) treatment	upregulated	31049964
498	Human	hsa-miR-10a-5p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
499	Human	hsa-miR-10a-5p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
500	Human	hsa-miR-10a-5p	miRNA	cyclosporine A (CsA)	nephrotoxicity	human proximal tubule cells	cyclosporine A treatment	dysregulated	28925592
501	Human	hsa-miR-10a-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	downregulated	26298803
502	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	interleukin-1¦Â treatment	upregulated	30731321
503	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	upregulated	30731321
504	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	LncRNA SNHG5 promotes chondrocyte proliferation and inhibits apoptosis in osteoarthritis by regulating miR-10a-5p/H3F3B axis	32967481
505	Human	hsa-miR-10a-5p	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	downregulated	32028542
506	Human	hsa-miR-10a-5p	miRNA	tyrosine kinase inhibitors (TKI)	renal cell carcinoma (RCC)	patients with advanced renal cell carcinoma (RCC)	tyrosine kinase inhibitors (TKI) treatment	downregulated	28746769
507	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	SW982 cells	IL-5¦Â treatment	downregulated	28782180
508	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	human synovial sarcoma cell line SW982	IL-1¦Â treatment	downregulated	28782180
509	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	SW982 cells	IL-1¦Â treatment	downregulated	29545315
510	Human	hsa-miR-10b	miRNA	fenretinide	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fenretinide treatment	downregulated	31925643
511	Human	hsa-miR-10b	miRNA	propofol (PPF)	bladder cancer	T24 cells	"2,6-diisopropylphenol (propofol) treatment"	downregulated	31788099
512	Human	hsa-miR-10b	miRNA	hyperthermia	breast cancer	BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231	Hyperthermia treatment	downregulated	27380148
513	Human	hsa-miR-10b	miRNA	linifanib	breast cancer	"MCF-7, MM231, MM468, T47D cells"	Linifanib treatment	downregulated	30166612
514	Human	hsa-miR-10b	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
515	Human	hsa-miR-10b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	chondrosarcoma	JJ012 and SW1353 chondrosarcoma cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	26549320
516	Human	hsa-miR-10b	miRNA	acidic microenvironment	early-stage hepatocellular carcinoma (E-HCC)	The human HCC cell lines SMMC-7721 and Hep3B	acidic microenvironment treatment	upregulated	31037150
517	Human	hsa-miR-10b	miRNA	TGF-¦Â	esophageal squamous cell carcinoma (ESCC)	"Esophageal cancer cells, TE-1 and EC9706"	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	31602239
518	Human	hsa-miR-10b	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	downregulated	33285269
519	Human	hsa-miR-10b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	GC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24481854
520	Human	hsa-miR-10b	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
521	Human	hsa-miR-10b	miRNA	lidocaine	gastric cancer (GC)	MGC-803 cells	lidocaine (Lido) treatment	Lido declined cisplatin resistance by down-regulating miR-10b.	32892697
522	Human	hsa-miR-10b	miRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	human glioma cell lines U87 and U251	5 ng/ml of TGF-¦Â treatment	upregulated	28393237
523	Human	hsa-miR-10b	miRNA	neferine (NEF)	glioblastoma multiforme (GBM)	human glioma cell line U251	neferine (NEF) treatment	downregulated	30551353
524	Human	hsa-miR-10b	miRNA	neferine (NEF)	glioblastoma multiforme (GBM)	human glioma cell line U251	neferine (NEF) treatment	downregulated	30551353
525	Human	hsa-miR-10b	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	human glioma cell	transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	24100613
526	Human	hsa-miR-10b	miRNA	heparin	angiogenesis	human microvascular endothelial cells (HMEC-1)	Heparin treatment	downregulated	21642433
527	Human	hsa-miR-10b	miRNA	B cell lymphoma/lewkmia-2 (Bcl2)	medulloblastoma	medulloblastoma cell	B cell lymphoma/lewkmia-2 (Bcl2) treatment	high expression of miRNA-10b in medulloblastoma cell lines compared to a normal cerebellar control	26394044
528	Human	hsa-miR-10b	miRNA	retinoic acid (RA)	neuroblastoma (NB)	SH-SY5Y (ATCC CRL-2266); HeLa (ATCC CCL-2) cells	Retinoic acid treatment	upregulated	21118818
529	Human	hsa-miR-10b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
530	Human	hsa-miR-10b	miRNA	hyaluronan-CD44	thymic atrophy and alterations in T cell differentiation	breast tumor cells (MDA-MB-231 cells)	Hyaluronan-CD44? treatment	upregulated	20843787
531	Human	hsa-miR-10b	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
532	Human	hsa-miR-10b	miRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	human nasopharyngeal carcinoma cells	Epstein-Barr virus (EBV) infection	upregulated	20732742
533	Human	hsa-miR-10b-3p	miRNA	hypoxia	esophageal squamous cell carcinoma (ESCC)	ECA109 cells; KYSE410 cells	hypoxia induce	upregulated	31772141
534	Human	hsa-miR-10b-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
535	Human	hsa-miR-10b-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
536	Human	hsa-miR-10b-3p	miRNA	hypoxia	preeclampsia (PE)	human trophoblast HTR-8/SVneo cells	hypoxia induce	downregulated	30552989
537	Human	hsa-miR-10b-3p	miRNA	hypoxia	preeclampsia (PE)	HTR-8/SVneo cells	hypoxia treatment	Lower levels of miR-10b-3p but higher expression of WDR86-AS1 and LITAF were observed in PE-affected placentas and trophoblast cells under hypoxia.	30552989
538	Human	hsa-miR-10b-5p	miRNA	Kv channel blocker 4-aminopyridine (4-AP)	cell proliferation and apoptosis	U87-MG cells; U251 cells	Kv channel blocker 4-aminopyridine (4-AP) treatment	"4-AP altered the miRNA expression in glioma cells, and the downregulated of miR-10b-5p induced by 4-AP was verified by real-time PCR."	29514931
539	Human	hsa-miR-10b-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
540	Human	hsa-miR-10b-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
541	Human	hsa-miR-10b-5p	miRNA	hypoxia	ischemic injury	endothelial colony-forming cells (ECFCs) exosomes	hypoxia induce	downregulated	30183690
542	Human	hsa-miR-10b-5p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
543	Human	hsa-miR-1178	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human macrophages (HTP-1 and U937 cells)	Mycobacterium tuberculosis (M.tb) infection	upregulated	29781535
544	Human	hsa-miR-1179	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
545	Human	hsa-miR-1180	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
546	Human	hsa-miR-1180	miRNA	paclitaxel (PTX)	triple negative breast cancer (TNBC)	HCC38 (paclitaxel-sensitive) and MDA-MB436 (paclitaxel-resistant) TNBC cells	paclitaxel treatment	downregulated	29416635
547	Human	hsa-miR-1181	miRNA	platelet derived growth factor-BB (PDGF-BB)	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	Platelet-derived growth factor BB (PDGFBB) treatment	downregulated	30211651
548	Human	hsa-miR-1181	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
549	Human	hsa-miR-1182	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
550	Human	hsa-miR-1182	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
551	Human	hsa-miR-1182	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	H522; H1975; BEAS-2B	hypoxia treatment	Circ_0000376 promoted NSCLC progression by regulating the miR-1182/NOVA2 axis	32922073
552	Human	hsa-miR-1183	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
553	Human	hsa-miR-1183	miRNA	radiation	glioblastoma multiforme (GBM)	U87 cells; U251 cells	radiation treatment	miR-1183 expression was significantly upregulated in U87 and U251 cells following irradiation	32080097
554	Human	hsa-miR-1183	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
555	Human	hsa-miR-1184	miRNA	lipopolysaccharide (LPS)	neonatal sepsis (NS)	serum	lipopolysaccharide (LPS) treatment	The results indicated that the serum levels of miR-1184 in neonates with sepsis were decreased	33732323
556	Human	hsa-miR-1193	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	MH7A cells	IL-1¦Â treatment	downregulated	32597556
557	Human	hsa-miR-12	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
558	Human	hsa-miR-1202	miRNA	antidepressant	major depressive disorder (MDD)	cohorts of depressed patients	received 8 weeks of antidepressant therapy	upregulated	28520926
559	Human	hsa-miR-1202	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuroinflammation	human microglial cells (HM cells)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated of miR-1202 and upregulated of Rab1a were found in OGD/R induced HM cells.	32124161
560	Human	hsa-miR-1203	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	T-HESC and primary human endometrial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-1203 targets and silences CypD to protect human endometrial cells from OGDR	32041924
561	Human	hsa-miR-1205	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
562	Human	hsa-miR-1207-3p	miRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells; PANC-1 cells	Gemcitabine treatment	"Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)."	30341811
563	Human	hsa-miR-1207-5p	miRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells; PANC-1 cells	Gemcitabine treatment	"Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)."	30341811
564	Human	hsa-miR-1207-5p	miRNA	lucidum	breast cancer	MCF-7 breast cancer cells	lucidum treatment	upregulated	25954907
565	Human	hsa-miR-1207-5p	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
566	Human	hsa-miR-1207-5p	miRNA	tanshinol (TAN)	melanoma	"Human melanoma cell lines (M14, A375)"	Tanshinol treatment	upregulated	31828417
567	Human	hsa-miR-1207-5p	miRNA	tanshinol (TAN)	melanoma	A375 cells; M14 cells	Tanshinol treatment	Tanshinol induced miR-1207-5p expression and suppressed cell growth and mobility of melanoma cells	31828417
568	Human	hsa-miR-122	miRNA	N-3 polyunsaturated fatty acids (PUFA)	nonalcoholic fatty liver disease (NAFLD)	blood	n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) treatment	 n-3 PUFA were effective in reducing ALP and liver fibrosis without altering the expression of circulating miR-122 in individuals with NAFLD.	33147705
569	Human	hsa-miR-122	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	primary human hepatocytes (PHH)	acetaminophen (APAP) treatment	upregulated	32379794
570	Human	hsa-miR-122	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
571	Human	hsa-miR-122	miRNA	coptisine (COP)	acute liver failure (ALF)	HepG2 cells and LO2 cells	COP treatment for 7d	upregulated	29253766
572	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	acute lymphoblastic leukemia (ALL)	liver and serum	hepatitis C virus (HCV) infection	downregulated	23085648
573	Human	hsa-miR-122	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19 cells	H2O2 treatment	downregulated	31784665
574	Human	hsa-miR-122	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	Both lncRNA Rpph1 and miR-122 were upregulated in AD mouse and Rpph1 activated Wnt/¦Â-catenin signaling to ameliorate amyloid-¦Â induced neuronal apoptosis in SK-N-SH cells via direct targeting miR-122.	31718352
575	Human	hsa-miR-122	miRNA	amoxicillin or clavulanate	amoxicillin/clavulanate-induced liver injury (AC-DILI)	healthy subjects liver	administered amoxicillin/clavulanate for 14 days	upregulated	27785887
576	Human	hsa-miR-122	miRNA	PAX8/PPAR¦Ã fusion protein (PPFP)	anaplastic thyroid carcinoma (ATC)	"ATC cell lines: BHT-101; FRO, C-643; KTC-2;KTC-3"	PAX8/PPAR¦Ã fusion protein (PPFP) treatment	upregulated	23598436
577	Human	hsa-miR-122	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
578	Human	hsa-miR-122	miRNA	rhinoviruses (RVs)	asthma	human airway epithelial cells	rhinoviruses (RVs) infection treatment	"Here, we found that RV infection induced the expression of miRNA 122 (miR-122) in mouse lungs and in human airway epithelial cells"	33830082
579	Human	hsa-miR-122	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic Endothelial cell (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31228514
580	Human	hsa-miR-122	miRNA	benzimidazotriazin	breast cancer	breast cancer (BC) tissues	benzimidazotriazin treatment	miR-122 was significantly higher in both groups treated with benzimidazotriazine compared to the cisplatin group.	33232730
581	Human	hsa-miR-122	miRNA	bile duct ligation (BDL)	breast cancer	serum	bile-duct ligation (BDL) treatment	Serum miR-122 increased significantly after BDL-induced cholestatic injury	24086271
582	Human	hsa-miR-122	miRNA	trichostatin A (TSA)	cell differentiation	hepatocyte-like cells (HLCs) generated from human adipose tissue-derived mesenchymal stem cells (hAT-MSCs)	hepatocyte-like cells (HLCs) generated from human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) treatment	upregulation	26360933
583	Human	hsa-miR-122	miRNA	hepatitis B virus (HBV)	cell-intrinsic angiogenic activity of ECs	liver tissue	hepatitis B virus (HBV) infection	downregulated	22105316
584	Human	hsa-miR-122	miRNA	leptin	cholangiocarcinoma (CCA)	The human cholangiocarcinoma cell lines SK-ChA-1 and TFK-1	Leptin treatment	downregulated	31115511
585	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV) direct-acting antiviral agents (DAAs)	chronic hepatitis C virus (HCV) infection	Plasma HCV RNA	DAAs treatment	downregulated	26436610
586	Human	hsa-miR-122	miRNA	IFN-¦Ã	chronic hepatitis C virus (HCV) infection	HCV-infected hepatocytes	IFN-¦Ë treatment	downregulated	24385435
587	Human	hsa-miR-122	miRNA	transarterial chemoembolization (TACE)	chronic hepatitis and hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	upregulated in plasma	27194671
588	Human	hsa-miR-122	miRNA	PEG-interferon plus ribavirin therapy	chronic hepatitis C virus (HCV) infection	Blood and plasma	PEG-interferon plus ribavirin therapy treatment	upregulated	27054010
589	Human	hsa-miR-122	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells	oxaliplatin treatment	downregulated	31901148
590	Human	hsa-miR-122	miRNA	H2O2	crohn disease (CD)	HT-29 cells	H2O2 treatment	downregulated	31019652
591	Human	hsa-miR-122	miRNA	ionic liquids (ILs) 1-decyl-3-methylimidazolium bromide	cytotoxicity	HepG2 cells	Ionic liquids (ILs) 1-decyl-3-methylimidazolium bromide treatment	upregulated	31702098
592	Human	hsa-miR-122	miRNA	H2O2	deep vein thrombosis (DVT)	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	downregulated	33195700
593	Human	hsa-miR-122	miRNA	trichostatin A (TSA)	differentiated phenotype in hepatocytes	hepatocyte-like cells (HLCs)	trichostatin A (TSA) treatment	upregulated	26360933
594	Human	hsa-miR-122	miRNA	acetaminophen (APAP)	drug hepatotoxicity	healthy men and women	acetaminophen (APAP) treatment	upregulated	24118944
595	Human	hsa-miR-122	miRNA	grape pomace extract (GPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape pomace extract (GPE) treatment	GPE reduced miR-122 but increased miR-33a expression.	24165878
596	Human	hsa-miR-122	miRNA	grape seed proanthocyandin extract (GSPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape seed proanthocyandin extract (GSPE) treatment	GSPE reduced both miR-122 and miR-33a levels.	24165878
597	Human	hsa-miR-122	miRNA	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P)	early non-genotoxic events	HepaRG cells	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) treatment	downregulated	26609139
598	Human	hsa-miR-122	miRNA	2-octynoic acid	endometrial cancer (EC)	human hepatocytes HepG2.2.15	2-octynoic acid treatment	over expression	23741428
599	Human	hsa-miR-122	miRNA	H2O2	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs); human aortic endothelial cells (HAECs)	H2O2 treatment	miR-122 was markedly upregulated after treatment with H2O2 for 48 h.	33278397
600	Human	hsa-miR-122	miRNA	cisplatin (DDP)	gastric cancer (GC)	MKN74 cells	cisplatin treatment	downregulated	31152437
601	Human	hsa-miR-122	miRNA	aflatoxin B1 (AFB1)	genotoxicity	HepaRG cells	aflatoxin B1 (AFB1) treatment	downregulated	26609139
602	Human	hsa-miR-122	miRNA	peginterferon alfa-2a (PEG-IFN)	HBV/HCV dually infection	HBV/HCV patients serum	PEG-IFN treatment	upregulated	25788377
603	Human	hsa-miR-122	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	upregulated	27874954
604	Human	hsa-miR-122	miRNA	FeSO4	hepatic inflammation	Huh7 cells	100 ?¦¬ FeSO4 treatment	downregulated	29176318
605	Human	hsa-miR-122	miRNA	holo-transferrin (holo-Tf)	hepatic inflammation	Huh7 cells	holo-transferrin (holo-Tf) treatment	downregulated	29176318
606	Human	hsa-miR-122	miRNA	alcohol	liver damage	Huh-7.5 cells; Huh-7.5 cells;CYP2E1 expressing cells	alcohol exposure	upregulated	23126531
607	Human	hsa-miR-122	miRNA	miravirsen?(SPC3649)	hepatitis C virus (HCV) infection	HeLa cells; Huh-7 cells	Miravirsen (SPC3649) treatment	downregulated	24068553
608	Human	hsa-miR-122	miRNA	miravirsen?(SPC3649)	hepatitis C virus (HCV) infection	HeLa cells;Huh-7 cells	miravircsen?(SPC3649) treatment	upregulated	24068553
609	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	ML-1 human thyroid cells	hepatitis C virus (HCV) infection	upregulated	31784757
610	Human	hsa-miR-122	miRNA	ribavirin and interferon ¦Â	hepatitis C virus (HCV) infection	The human hepatoma cell line Huh7	ribavirin and interferon ¦Â treatment	downregulated	20428788
611	Human	hsa-miR-122	miRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	HepG2 cells	astragaloside IV (AS-IV) treatment	upregulated	28179291
612	Human	hsa-miR-122	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	HepG2 cells	curcumin treatment	upregulated	28179291
613	Human	hsa-miR-122	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
614	Human	hsa-miR-122	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	hepatitis B virus (HBV) infection	downregulated	31485598
615	Human	hsa-miR-122	miRNA	radiofrequency ablation (RFA)	hepatocellular carcinoma (HCC)	plasma	radiofrequency ablation (RFA) treatment	upregulated	26129878
616	Human	hsa-miR-122	miRNA	TP-1	hepatocellular carcinoma (HCC)	SMMC-7721 cells	TP-1 treatment	upregulated	25787750
617	Human	hsa-miR-122	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
618	Human	hsa-miR-122	miRNA	ochratoxin A (OTA)	hepatocyte apoptosis	"human hepatoblastoma cell line, HepG2"	ochratoxin A treatment	inhibited	30090334
619	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	liver damage	monocytes	hepatitis C virus (HCV) infection	Serum levels of miR-122 were elevated in cHCV patients and correlated with increased ALT and AST levels and serum miR-155 levels	22846613
620	Human	hsa-miR-122	miRNA	tolvaptan	idiosyncratic drug-induced liver injury (IDILI)	primary hepatocytes	tolvaptan treatment	upregulated	29029277
621	Human	hsa-miR-122	miRNA	pginterferon (PEG IFN)	hepatitis C virus (HCV) infection	patients liver	IFN treatment	upregulated	24612050
622	Human	hsa-miR-122	miRNA	lipopolysaccharide (LPS)	inflammation	HaCaT cells	lipopolysaccharide (LPS) treatment	upregulated	30632205
623	Human	hsa-miR-122	miRNA	tanshinol (TAN)	inflammation	LPS-treated HaCaT cells	tanshinol (TAN) treatment	downregulated	30632205
624	Human	hsa-miR-122	miRNA	ionic liquids (ILs)	Ionic liquids (ILs)-related human health risks	HepG2 cells	Ionic liquids (ILs) treatment	ILs increased the expression of miR-122.	31702098
625	Human	hsa-miR-122	miRNA	anoxia/reoxygenation (A/R)	ischemia/reperfusion (I/R) injury	LO2 cell	anoxia/reoxygenation (A/R) treatment	downregulated	28093198
626	Human	hsa-miR-122	miRNA	citrus peel flavonoid extracts (CPFE)	lipid metabolism	HepG2 cells	citrus peel flavonoid extracts (CPFE) treatment	downregulated	31017523
627	Human	hsa-miR-122	miRNA	daphnane diterpenoid genkwanine M (GENK)	hepatocellular carcinoma (HCC)	Huh-7 cells	daphnane diterpenoid genkwanine M (GENK) treatment	downregulated	22761847
628	Human	hsa-miR-122	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?13 cells	heme treatment	upregulated	23538684
629	Human	hsa-miR-122	miRNA	IFN-¦Á	hepatocellular carcinoma (HCC)	;Huh-7 ; HepG2	Alpha Interferon (IFN-¦Á) treatment	downregulated	23055569
630	Human	hsa-miR-122	miRNA	microcystin-leucine arginine (MC-LR)	hepatocellular carcinoma (HCC)	WRL-70 cells	microcystin-LR treatment	downregulated	22265967
631	Human	hsa-miR-122	miRNA	P body protein LSm1	hepatocellular carcinoma (HCC)	Huh7 cells; Huh7.5 cells	P body protein LSm1 treatment	The P body protein LSm1 contributes to stimulation of hepatitis C virus translation by microRNA-122	24141094
632	Human	hsa-miR-122	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	upregulated	32656599
633	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	liver cirrhosis and hepatocellular carcinoma	human hepatocellular carcinoma-derived Huh7; Hep3B; HepG2; embryonic kidney-derived HEK293 ; 293T; lung-derived RERF-LC-AI;NCI-H-2030; A-427; kidney-derived Caki-2 and 769-P; neuron-derived MC-IXC ;SK-PN-DW; uterus-derived Hec1B; ovary-derived SK-OV3; colon-derived SW620; urinary bladder-derived SW780 cells	hepatitis C virus (HCV) infection	Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus	22593164
634	Human	hsa-miR-122	miRNA	coptisine (COP)	liver damage	HepG2 cells; L02 cells	coptisine (COP) treatment	COP increased the miR-122 level in LPS-treated HepG2 and L02 cells.	29253766
635	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	liver fibrosis	hepatoma cells	hepatitis C virus (HCV) infection	upregulated	26157120
636	Human	hsa-miR-122	miRNA	amoxicillin/clavulanate-induced liver injury (AC-DILI)	liver damage	Blood and urine	amoxicillin/clavulanate-induced liver injury (AC-DILI) treatment	upregulated	27785887
637	Human	hsa-miR-122	miRNA	IFN and ribavirin	liver damage	HIV-HCV co-infected patients	interferon and ribavirin treatment	downregulated	24895202
638	Human	hsa-miR-122	miRNA	paraquat (PQ)	liver damage	paraquat-exposed individuals liver tissue	paraquat (PQ) treatment	downregulated	22427142
639	Human	hsa-miR-122	miRNA	oleanolic acid (OLA)	lung cancer	"human lung cancer cell lines, A549, NCI-H460, and NCI_x0002_H1299"	oleanolic acid (OLA) treatment	upregulated	25472877
640	Human	hsa-miR-122	miRNA	oleanolic acid (OLA)	lung cancer	lung carcinoma cell lines	Oleanolic acid treatment	upregulated	25472877
641	Human	hsa-miR-122	miRNA	ethanol (EtOH)	mitochondrial dysfunction	human hepatoma cells	Ethanol?treatment	downregulated	22898980
642	Human	hsa-miR-122	miRNA	amyloid-¦Â (A¦Â)	neuronal cell injury	SK-N-SH cells	amyloid-¦Â (A¦Â) treatment	LncRNA Rpph1 protects amyloid-¦Â induced neuronal injury in SK-N-SH cells via miR-122/Wnt1 axis	31718352
643	Human	hsa-miR-122	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
644	Human	hsa-miR-122	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
645	Human	hsa-miR-122	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	human liver cell line (L02)	free fatty acid (FFA) treatment	upregulated	31126802
646	Human	hsa-miR-122	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 and Huh-7 cells	free fatty acids (FFA) treatment	upregulated	31195981
647	Human	hsa-miR-122	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Huh7 cells exosomes	palmitic acid (PA) treatment	upregulated in exosomes	28623272
648	Human	hsa-miR-122	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	downregulated	32143184
649	Human	hsa-miR-122	miRNA	post-bariatric surgery	obesity	obesity patients serum	a 3 months post-bariatric surgery treatment	upregulated in serum	29103239
650	Human	hsa-miR-122	miRNA	propofol (PPF)	papillary thyroid cancer (PTC)	TPC-1 cells; IHH-4 cells	propofol treatment	Propofol promoted the expression of miR-122	32432774
651	Human	hsa-miR-122	miRNA	acetaminophen (APAP)	prostate cancer	serum	acetaminophen (APAP) treatment	?Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients	22045675
652	Human	hsa-miR-122	miRNA	docetaxel (DTX)	prostate cancer	LNCaP cells	docetaxel (DTX) treatment	downregulated	33178345
653	Human	hsa-miR-122	miRNA	silica	lung fibrosis	HBE cells	silica treatment	downregulated	33297121
654	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	short bowel syndrome (SBS)	human liver	hepatitis C virus (HCV) infection	downregulated	20625373
655	Human	hsa-miR-122	miRNA	noncanonical polymerase Gld2	stabilizes specific miRNA populations in human fibroblasts	Human primary fibroblasts	The noncanonical polymerase Gld2 treatment	The noncanonical polymerase Gld2 has been implicated in the stabilization of miR-122	23200856
656	Human	hsa-miR-122	miRNA	free fatty acids (FFA)	steatotic hepatocytes	human HCC cell lines HepG2 and Huh7	free fatty acid treatment	downregulated	29216638
657	Human	hsa-miR-122	miRNA	lipopolysaccharide (LPS)	triple negative breast cancer (TNBC)	HT-29 cells	lipopolysaccharide (LPS) treatment	downregulated	23872065
658	Human	hsa-miR-122	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
659	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	downregulated	23537271
660	Human	hsa-miR-122*	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
661	Human	hsa-miR-1222-5p	miRNA	M¦ÂCD-cholesterol	nonalcoholic steatohepatitis (NASH)	Huh7 cells secreted exosomes	M¦ÂCD-cholesterol treatment	upregulated	31759057
662	Human	hsa-miR-122-3p	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	downregulated	29590087
663	Human	hsa-miR-1224	miRNA	H2O2	acute liver injury (ALI)	L02 cells	H2O2 treatment	upregulated	30848506
664	Human	hsa-miR-1224-3p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	upregulated	32438192
665	Human	hsa-miR-1224-3p	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
666	Human	hsa-miR-1224-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
667	Human	hsa-miR-1224-3p	miRNA	proanthocyanidin extract (GSPE)	hepatocellular carcinoma (HCC)	HepG2 cells	proanthocyanidin extract (GSPE) treatment	upregulated	21998738
668	Human	hsa-miR-1224-5p	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	upregulated	32362797
669	Human	hsa-miR-1224-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
670	Human	hsa-miR-1225-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
671	Human	hsa-miR-1225-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
672	Human	hsa-miR-122-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
673	Human	hsa-miR-122-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen (APAP) treatment	upregulated	32779042
674	Human	hsa-miR-122-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	upregulated	33782973
675	Human	hsa-miR-122-5p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
676	Human	hsa-miR-122-5p	miRNA	resveratrol	breast cancer	adriamycin-resistant breast cancer cells MCF-7 cells	resveratrol (RSV) treatment	upregulated	31155753
677	Human	hsa-miR-122-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	downregulated	31198949
678	Human	hsa-miR-122-5p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	cyclosporine A (CYCA) treatment	downregulated	31198949
679	Human	hsa-miR-122-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
680	Human	hsa-miR-122-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
681	Human	hsa-miR-122-5p	miRNA	glucosamine	insulin resistance (IR)	HepG2 hepatic cells	glucosamine treatment	upregulated	30958584
682	Human	hsa-miR-122-5p	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	downregulated	29899866
683	Human	hsa-miR-122-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
684	Human	hsa-miR-122-5p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
685	Human	hsa-miR-122-5p	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	pancreatic cancer (PC)	THP-1 cells	lipopolysaccharide; interferon-¦Ã treatment	"lncRNA SBF2-AS1 in M2 macrophage-derived exosomes increases miR-122-5p expression to restrain XIAP expression, which further inhibits PC progression."	32301277
686	Human	hsa-miR-122-5p	miRNA	IL-22	psoriatic lesions	HaCaT cells	IL-22	upregulated	27943426
687	Human	hsa-miR-122-5p	miRNA	radiation	rectal injury	human intestinal epithelial crypt (HIEC) cells	radiation treatment	miR-122-5p aggravates radiation-induced rectal injury through targeting CCAR1	32422326
688	Human	hsa-miR-122-5p	miRNA	cadmium (Cd)	renal toxic	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
689	Human	hsa-miR-122-5p	miRNA	curcumin (Cur)	schwannoma	RT4 schwannoma cells	curcumin treatment	upregulated	30534000
690	Human	hsa-miR-122-5p	miRNA	coal-burning type fluoride	skeletal fluorosis	plasma	coal-burning type fluoride exposure	"In human populations with coal-burning type fluoride exposure, the results showed that miR-122-5p was downregulated"	32572801
691	Human	hsa-miR-122-5p	miRNA	cadmium (Cd)	toxic effects of cadmium	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
692	Human	hsa-miR-122-5p	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
693	Human	hsa-miR-122-5p	miRNA	ursolic acid (UA)	uric acid nephropathy (UAN)	HK-2?cells	uric acid treatment	miR-122-5p was reduced uric acid-treated HK-2 cells	30347231
694	Human	hsa-miR-1228-3p	miRNA	TGF-¦Â1	chronic kidney disease (CKD)	HK-2 cells	TGF-¦Â1 treatment	Upregulation of miRNA-1228-3p markedly inhibited the progression of renal fibrosis in vitro	32720699
695	Human	hsa-miR-1228-5p	miRNA	particulate matter (PM2.5)	non-small cell lung cancer (NSCLC)	human A549 cells	particulate matter (PM2.5) treatment	downregulated	26867688
696	Human	hsa-miR-1229	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
697	Human	hsa-miR-1229	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
698	Human	hsa-miR-1229-5p	miRNA	occupational noise	occupational noise-induced hearing loss (ONIHL)	serum	occupational noise exposure	upregulated	29340520
699	Human	hsa-miR-1229-5p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
700	Human	hsa-miR-122a	miRNA	"chenodeoxycholic acid, GW4064"	bile acid synthesis	human primary hepatocytes	"chenodeoxycholic acid, GW4064 treatment"	upregulated	20351063
701	Human	hsa-miR-122a	miRNA	fibroblast growth factor ( FGF)19	bile acid synthesis	human primary hepatocytes	fibroblast growth factor ( FGF)19 treatment	upregulated	20351063
702	Human	hsa-miR-122a	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	upregulated	24396484
703	Human	hsa-miR-122a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intestinal inflammation	Caco-2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	21763238
704	Human	hsa-miR-122a	miRNA	adenovirus (ADV)	hepatocellular carcinoma (HCC)	Huh7.5 cells; N52.E6 cell line48; CCL-185 cells; CCL 243 cells; CRL 1772	adenovirus vectors treatment	miRNA-mediated regulation of antigen expression in the context of adenovirus vectors can significantly improve transgene product-directed immune responses	21556053
705	Human	hsa-miR-122a	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
706	Human	hsa-miR-1231	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
707	Human	hsa-miR-1234	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 8¡ã HDT bed rest experiment	downregulated	28261104
708	Human	hsa-miR-1234	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
709	Human	hsa-miR-1236	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
710	Human	hsa-miR-1236	miRNA	hypoxia	epithelial-mesenchymal transition (EMT)	"Human breast cancer (MCF7), lung cancer (H1299), head and neck cancer (SAS) and embryonic kidney (293T) cell lines"	hypoxia treatment	downregulated	27177472
711	Human	hsa-miR-1236-3p	miRNA	cisplatin (DDP)	lung cancer	lung cancer tissues and A549 cell line	cisplatin treatment	downregulated	30805558
712	Human	hsa-miR-1237	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
713	Human	hsa-miR-1237-3p	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-1237-3p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
714	Human	hsa-miR-1237-3p	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-1237-3p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
715	Human	hsa-miR-1238	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
716	Human	hsa-miR-1238	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human thyroid	infect with HHV-6A	upregulated	28081700
717	Human	hsa-miR-1238-2	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
718	Human	hsa-miR-1238-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
719	Human	hsa-miR-124	miRNA	H2O2	acute lung injury (ALI)	Beas2B cells	H2O2 treatment	downregulated	31938089
720	Human	hsa-miR-124	miRNA	hyperoxia	acute lung injury (ALI)	Beas2B cells	hyperoxia treatment	downregulated	31938089
721	Human	hsa-miR-124	miRNA	Mito-TEMPO	acute lung injury (ALI)	hyperoxia-/H2O2-treated Beas2B cells	Mito-TEMPO treatment	upregulated	31938089
722	Human	hsa-miR-124	miRNA	N-acetyl-L-cysteine (NAC)	acute lung injury (ALI)	hyperoxia-/H2O2-treated Beas2B cells	N-acetyl-L-cysteine (NAC) treatment	upregulated	31938089
723	Human	hsa-miR-124	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
724	Human	hsa-miR-124	miRNA	estradiol	breast cancer	BC cell lines MCF7 and MDA-MB-231	estradiol treatment	downregulated	27175587
725	Human	hsa-miR-124	miRNA	paclitaxel (PTX)	breast cancer	"Human breast cancer cells, BT474, SKBR3 and MCF7"	paclitaxel (PTX) treatment	"The miR-124, a tumor suppressive miRNA, was significantly downregulated in Taxol resistant cells."	31367191
726	Human	hsa-miR-124	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Myeloid-derived suppressor cells (MDSCs)	chronic hepatitis C virus (HCV) infection	downregulated	27753084
727	Human	hsa-miR-124	miRNA	quercetin	chronic kidney disease (CKD)	HK-2 cells	quercetin (QUE) treatment	MyD88 and miR-124 expression was elevated by LPS and alleviated by Quercetin	31804760
728	Human	hsa-miR-124	miRNA	lipopolysaccharide (LPS)	chronic kidney disease (CKD)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31804760
729	Human	hsa-miR-124	miRNA	quercetin	chronic kidney disease (CKD)	LPS-treated HK-2 cells	quercetin treatment	downregulated	31804760
730	Human	hsa-miR-124	miRNA	IFN-¦Ã and TNF-¦Á	chronic skin inflammation in atopic eczema	human keratinocyte	IFN-¦Ã and TNF-¦Á	downregulated	28847568
731	Human	hsa-miR-124	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	Caco-2 cells and HT-29 cells	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	"downregulated or upregulation of miR-124 in TNBS-induced colitic colon alleviated or aggravated experimental colitis, respectively."	26802080
732	Human	hsa-miR-124	miRNA	5-aza-2'-deoxycytidine and trichostatin A	colonic inflammation	Squamous cell carcinoma (SCC) cell line	5-aza-deoxycytidine and trichostatin A treatment	downregulated	22828925
733	Human	hsa-miR-124	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	colorectal cancer (CRC)	Hct-116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-124 expression was upregulated after 5-AZA-CdR treatment in the Hct-116 cells.	32552060
734	Human	hsa-miR-124	miRNA	high-intensity focused ultrasound (HIFU)	colorectal cancer (CRC)	HCT-116 cells	High-intensity focused ultrasound (HIFU) induce	upregulated	30980700
735	Human	hsa-miR-124	miRNA	H2O2	cytotoxicity	OB-6 cells	Hydrogen peroxide (H2O2) treatment	upregulated	31955154
736	Human	hsa-miR-124	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
737	Human	hsa-miR-124	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
738	Human	hsa-miR-124	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human RPE cells	TGF-¦Â1 treatment	downregulated	26746014
739	Human	hsa-miR-124	miRNA	fluoride	fluorosis	sodium fluoride (NaF) treated human osteosarcoma (HOS) cells	fluoride treatment	miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor ¦Ê-B ligand (RANKL) genes	26339601
740	Human	hsa-miR-124	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	AGS human gastric cancer cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27041578
741	Human	hsa-miR-124	miRNA	pemetrexed	gastric cancer (GC)	Human gastric cancer MGC-803 cells	pemetrexed (MTA) treatment	"In MGC-803/MTA cells, miR-124 could remarkably increase the resistance of MGC-803/MTA cells to MTA"	31841184
742	Human	hsa-miR-124	miRNA	phenformin	glioblastoma multiforme (GBM)	glioma stem cells (GSCs)	Phenformin treatment	upregulated	27486821
743	Human	hsa-miR-124	miRNA	H2O2	H2O2-induced apoptosis and oxidative stress	human lens epithelial cells (hLEC)	H2O2 treatment	The H2O2-induced hLEC showed reductions in cell viability with decreased miRNA-124 but increased p-p65 in a dose-/time-dependent manner.	30099456
744	Human	hsa-miR-124	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	"Hela,HEK293FT,SK-N-SH,SHSY5Y"	infect with EV71	upregulated	29120300
745	Human	hsa-miR-124	miRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2 cells	Hepatitis B virus X protein (HBx) infection	HBx upregulated lncRNA-MALAT1 expression while downregulating miR-124 expression in HepG2-X cells.	30500989
746	Human	hsa-miR-124	miRNA	glucocorticoid (GC)	hematological malignancies	human embryonic kidney (HEK) 293 and DLBCL cell lines	Glucocorticoids (GCs) treatment	Our study supports the notion that miR-124 could be an attractive therapeutic target for overcoming GC resistance in DLBCL	25576220
747	Human	hsa-miR-124	miRNA	citalopram	major depressive disorder (MDD)	plasma	citalopram treatment	Plasma miR-124 in the treatment-free MDD and citalopram-treated MDD groups was 1.8-fold and 4-fold that in the control group.	29689690
748	Human	hsa-miR-124	miRNA	alpinumisoflavone (AIF)	melanoma	A375 and SK-MEL-1 human melanoma cells	alpinumisoflavone (AIF) treatment	upregulated	28386327
749	Human	hsa-miR-124	miRNA	high glucose (HG)	diabetes mellitus (DM)	human vascular smooth muscle cells (VSMCs)		downregulated	29042195
750	Human	hsa-miR-124	miRNA	mycobacterium bovis bacille Calmette-Gu¨¦rin (BCG)	mycobacterium tuberculosis (Mtb) infection	A549 alveolar epithelial cells	infect with Mycobacterium bovis BCG treatment	upregulated	24705038
751	Human	hsa-miR-124	miRNA	TGF-¦Â	nasopharyngeal carcinoma (NPC)	6-10B cells	TGF-¦Â treatment	TGF-¦Â-induced the suppression of miR-124 in NPC cells	29710466
752	Human	hsa-miR-124	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	SH-SY5Y Cells	oxygen glucose deprivation (OGD) treatment	downregulated	31916069
753	Human	hsa-miR-124	miRNA	niclosamide	oral cancer	HN6 cells	niclosamide treatment	upregulated	29251334
754	Human	hsa-miR-124	miRNA	niclosamide	oral cancer	WSU-HN6 cells	5 ?M niclosamide	upregulated	29251334
755	Human	hsa-miR-124	miRNA	icariin (ICA)	oral squamous cell carcinoma (OSCC)	human oral squamous cell carcinoma cells	Icaritin?treatment	upregulated	27889233
756	Human	hsa-miR-124	miRNA	dexamethasone (DEX)	osteoblast injury	OB-6 osteoblastic cells and primary human osteoblasts	dexamethasone (DEX) treatment	miR-124 accumulated following DEX treatment in OB-6?cells and primary osteoblasts. miR-124 inhibitor attenuated cell death in human osteoblasts.	31242973
757	Human	hsa-miR-124	miRNA	dihydroartemisinin (DHA) and curcumin (Cur)	ovarian cancer (OC)	human ovarian cancer SKOV3 cells	dihydroartemisinin (DHA) and curcumin (Cur)	upregulated	28934730
758	Human	hsa-miR-124	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	1-methyl-4-phenylpyridinium (MPP+) treatment	miR-124 was a target of NEAT1. Anti-miR-124 could reverse the effects caused by NEAT1 knockdown in MPP+ treated SH-SY5Y cells.	31228597
759	Human	hsa-miR-124	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	human neuroblastoma cell lines SH-SY5Y (SH-SY5Y) cells	lipopolysaccharide (LPS) treatment	downregulated	30995872
760	Human	hsa-miR-124	miRNA	hypoxia	prostate cancer	prostate cancer cell lines (DU145 and PC3)	hypoxia treatment	downregulated	26990493
761	Human	hsa-miR-124	miRNA	TGF-¦Â	prostate cancer	"MKN-45, MDA-MB-231, HCT15 and PA1 cell lines"	TGF-¦Á treatment	downregulated	24969691
762	Human	hsa-miR-124	miRNA	baicalin (BAI)	renal fibrosis	HK-2 cells	baicalin (BAI) treatment	Baicalin prevented renal fibrosis by increasing miR-124 and inactivating downstream TLR4/NF-¦ÊB pathway in DN.	32500512
763	Human	hsa-miR-124	miRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	downregulated	29717517
764	Human	hsa-miR-124	miRNA	ultraviolet (UV) irradiation	Skin senescence	human epidermal keratinocytes (NHEKs)	UVB treatment	upregulated	27818465
765	Human	hsa-miR-124	miRNA	ultraviolet (UV) irradiation	skin senescence	normal human epidermal keratinocytes (NHEKs)	UVB-irradiated treatment	upregulated	27818465
766	Human	hsa-miR-124	miRNA	acute stress	stress response	mice amygdala	acute Stress treatment	downregulated	24023867
767	Human	hsa-miR-124	miRNA	TGF-¦Â1	tongue squamous cell carcinoma (TSCC)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
768	Human	hsa-miR-124	miRNA	nicotine	ulcerative colitis (UC)	human ulcerative colonic mucosa	Nicotine treatment	upregulated	27709266
769	Human	hsa-miR-124	miRNA	high glucose (HG)	vascular injury	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	30454897
770	Human	hsa-miR-124	miRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2-X cell line was induced by transfect HBx into HepG2 cells.	HBx-induce	HBx downregulating miR-124 expression in HepG2-X cells.	30500989
771	Human	hsa-miR-124-2	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
772	Human	hsa-miR-1243	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose treatment	circ_0002570 could upregulate angiomotin by targeting miR-1243 to mediate the dysfunction of hRMECs induced by high glucose.	32319024
773	Human	hsa-miR-124-3	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
774	Human	hsa-miR-124-3	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	28958159
775	Human	hsa-miR-124-3p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	"SNHG14 was boosted in renal tissues of I/R-stimulated rats and H/R-induced HK-2 cells, while miR-124-3p was diminished in H/R-stimulated HK-2 cells."	33490282
776	Human	hsa-miR-124-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	"LPS induced A549 cells apoptosis and inflammation, wherein SNHG14 was upregulated and miR-124-3p was downregulated."	33652176
777	Human	hsa-miR-124-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	"VSMCs were treated with different doses of ox-LDL (0, 25, 50, and 100 mg/L) and for different time points (0, 12, 24, and 48 h) to mimic an in vitro environment of hyperlipidemia."	miRNA-124-3p was gradually upregulated in ox-LDL-treated VSMCs.	31696492
778	Human	hsa-miR-124-3p	miRNA	calcium oxalate (CaOx)	calcium oxalate (CaOx) nephrolithiasis	HK-2 cell	calcium oxalate (CaOx) treatment	HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis.	31878844
779	Human	hsa-miR-124-3p	miRNA	calcium oxalate monohydrate (COM)	calcium oxalate (CaOx) nephrolithiasis	calcium oxalate monohydrate (COM)-treated HK-2 cells	calcium oxalate monohydrate (COM)-treatment	miR©\124©\3p was down©\regulated in calcium oxalate monohydrate (COM)-treated HK-2 cells.	31680444
780	Human	hsa-miR-124-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
781	Human	hsa-miR-124-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	MGC803 cells	cisplatin treatment	upregulated	33337849
782	Human	hsa-miR-124-3p	miRNA	hydrogen gas (H2)	gastric cancer (GC)	MGC-803 cells;and BGC-823 cells	?hydrogen treatment	"H2?gas significantly inhibited gastric tumor growth in vivo and the proliferation, migration, and lncRNA MALAT1 and EZH2 expression of gastric cancer cells while upregulated miR-124-3p expression"	33482814
783	Human	hsa-miR-124-3p	miRNA	paclitaxel (PTX)	gastric cancer (GC)	"Human GC tissues and tumor cell lines (MKN-45, HGC-27, MGC-803, and AGS)"	paclitaxel (PTX) treatment	circ-PVT1 expression was upregulated in PTX-resistant GC tissues and cells. Circ-PVT1 downregulated enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p.	31793989
784	Human	hsa-miR-124-3p	miRNA	amentoflavone (AF)	glioblastoma multiforme (GBM)	"The glioma cell lines U87, LV229, U251, LN18 and U373"	amentoflavone (AF) treatment	upregulated	30153494
785	Human	hsa-miR-124-3p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	human glioma cell lines U251 and U87	sevoflurane (SEVO) treatment	upregulated	30915607
786	Human	hsa-miR-124-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U251 cells; U87MG cells; A172 cells	hypoxia treatment	Hypoxia-induced lncRNA PDIA3P1 promotes mesenchymal transition via sponging of miR-124-3p in glioma.	32127518
787	Human	hsa-miR-124-3p	miRNA	midazolam (MDZ)	hepatocellular carcinoma (HCC)	HepG2 human HCC cells	midazolam (MDZ) treatment	upregulated	31651086
788	Human	hsa-miR-124-3p	miRNA	suberoylanilide hydroxamic acid (SAHA)	hepatocellular carcinoma (HCC)	Hep3B and Huh7 HCC cell lines	suberanilohydroxamic acid (SAHA) treatment	upregulated	31092334
789	Human	hsa-miR-124-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
790	Human	hsa-miR-124-3p	miRNA	sevoflurane (SEV)	malignant glioma	U251 cells; U87 cells	sevoflurane treatment	Sevoflurane Inhibits Glioma Cells Proliferation and Metastasis through miRNA-124-3p/ROCK1 Axis	30915607
791	Human	hsa-miR-124-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Human-derived cardiomyocytes HCM	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	circHIPK3 overexpression reversed the protective effects of miRNA-124-3p on myocardial I/R and cardiomyocyte apoptosis	31799682
792	Human	hsa-miR-124-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	The human cardiac myocyte (HCM) cell line	HCMs were exposed to hypoxic conditions for 2?h followed by re-oxygenation (H/R) treatment.	"miR-124-3p was significantly downregulated in both MIRI rat model and H/R treated HCMs.?Overexpression of miR-124-3p reversed the H/R-induced cell apoptosis and upregulation of TNF-¦Á, IL-6, and IL-1¦Â."	31768721
793	Human	hsa-miR-124-3p	miRNA	¦Ã- Mangostin (¦Ã-MS)	osteoarthritis (OA)	SW984 cells	¦Ã- Mangostin (¦Ã-MS) treatment	upregulated	32302289
794	Human	hsa-miR-124-3p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28543594
795	Human	hsa-miR-124-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"We demonstrated that, in SH-SY5Y cells treated with MPP+, NEAT1 and PDE4B expression levels were raised, while miR-124-3p expression was repressed"	33522352
796	Human	hsa-miR-124-3p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28543594
797	Human	hsa-miR-124-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
798	Human	hsa-miR-124-3p	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
799	Human	hsa-miR-124-3p.1	miRNA	propofol (PPF)	colorectal cancer (CRC)	RKO cell; HCT116 cells	Propofol treatment	Propofol treatment evidently enhanced the expression of miR- 124-3p1	31894425
800	Human	hsa-miR-1244	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
801	Human	hsa-miR-1244	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	downregulated	29510375
802	Human	hsa-miR-1244	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
803	Human	hsa-miR-1244	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC patients NSCLC tissue	cisplatin treatment	downregulated	28498474
804	Human	hsa-miR-124-5p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
805	Human	hsa-miR-124-5p	miRNA	5-fluorouracil (5-Fu)	non-small cell lung cancer (NSCLC)	A549 cells	5-fluorouracil (5-FU) treatment	A decrease in miR-124-5p expression level was observed in A549/5-FU cells compared with the parental A549 cells.	33240411
806	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	30253370
807	Human	hsa-miR-1246	miRNA	ultraviolet (UV) irradiation	apoptosis	HaCaT cells	UV irradiation treatment	upregulated	24880483
808	Human	hsa-miR-1246	miRNA	curcumin (Cur)	bladder cancer	"T24 cells, SV-HUC-1 cells, HT-1376 cells"	curcumin treatment	downregulated	31236854
809	Human	hsa-miR-1246	miRNA	curcumin (Cur)	corneal neovascularization (CNV)	HUVECs	curcumin treatment	upregulated	27625050
810	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	corneal neovascularization (CNV)	human corneal fibroblasts (HCFs)	lipopolysaccharide (LPS) treatment	downregulated	30328354
811	Human	hsa-miR-1246	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	U87 cells; U118 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-1246 was increased in the glioma cell lines treated with 5-Aza.	33153768
812	Human	hsa-miR-1246	miRNA	hypoxia	glioblastoma multiforme (GBM)	The human GBM cell lines U87MG and U251 exosomes	hypoxia induce	upregulated	31485019
813	Human	hsa-miR-1246	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87 cells; U251 cells	hypoxia treatment	upregulated	31485019
814	Human	hsa-miR-1246	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO2 cells	hypoxia induce	downregulated	31709894
815	Human	hsa-miR-1246	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
816	Human	hsa-miR-1246	miRNA	tetrandrine	hypertrophic scars (HS)	human hypertrophic scar fibroblasts (HSFs)	tetrandrine treatment	downregulated	26909951
817	Human	hsa-miR-1246	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
818	Human	hsa-miR-1246	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
819	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	lung injury	human PMVECs	lipopolysaccharide (LPS) treatment	upregulated	28386354
820	Human	hsa-miR-1246	miRNA	metformin (Met)	melanoma	"The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951"	Metformin treatment	upregulated	30754729
821	Human	hsa-miR-1246	miRNA	radiation	non-small cell lung cancer (NSCLC)	A549 cells; PC9 cells	radiation treatment	Both intracellular and extracellular miR-1246 was found to be upregulated after irradiation in a time-dependent pattern	32064170
822	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human CHON-001 cells	lipopolysaccharide (LPS) treatment	"CAIF overexpression inhibited the apoptosis of CHON-001 cells under LPS treatment, while miR-1246 overexpression attenuated the effects of CAIF overexpression."	31653823
823	Human	hsa-miR-1246	miRNA	hypoxia	preeclampsia (PE)	primary human cytotrophoblasts	hypoxia induce	downregulated	29546425
824	Human	hsa-miR-1246	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
825	Human	hsa-miR-1246	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
826	Human	hsa-miR-1246	miRNA	enterovirus 71 (EV71)	viral encephalitis in children	human neuroblastoma SH-SY5Y cells	HEV71-infected treatment	upregulated	24739954
827	Human	hsa-miR-1247	miRNA	lipopolysaccharide (LPS)	acute pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	miR-1247 was decreased expression after LPS treatment.	30378300
828	Human	hsa-miR-1247	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	upregulated	29172709
829	Human	hsa-miR-1247	miRNA	curcumin (Cur)	prostate cancer	HuPCaSC lines DU145 and 22Rv1	curcumin treatment	dysregulated	29172709
830	Human	hsa-miR-1247-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HepG2 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28586038
831	Human	hsa-miR-1247-5p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
832	Human	hsa-miR-1247-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
833	Human	hsa-miR-1248	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
834	Human	hsa-miR-1249	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
835	Human	hsa-miR-124a	miRNA	lipopolysaccharide (LPS)	acute-on-chronic liver failure (ACLF)	U937 and HepG2 cells	lipopolysaccharide (LPS) treatment	upregulated	31628069
836	Human	hsa-miR-124a	miRNA	lipopolysaccharide (LPS)	acute-on-chronic liver failure (ACLF)	U937 cells; HepG2 cells	lipopolysaccharide (LPS) treatment	upregulated	31628069
837	Human	hsa-miR-124a	miRNA	atorvastatin	hypercholesterolemia	HepG2 cells	atorvastatin treatment	downregulated	25926069
838	Human	hsa-miR-124a	miRNA	laquinimod	multiple sclerosis (MS)	human microglia	laquinimod treatment	upregulated	25356411
839	Human	hsa-miR-124a	miRNA	glucocorticoid (GC)	neuronal development	NS1 cells;A549 cells;COS-1cells	Glucocorticoids (GCs) treatment	upregulated	19131573
840	Human	hsa-miR-124a	miRNA	CoCl2	neuronal differentiation	human mesenchymal stem cells	CoCl2 treatment	upregulated	24491559
841	Human	hsa-miR-124a	miRNA	liraglutide	nonalcoholic fatty liver disease (NAFLD)	palmitate-treated normal human liver cell line (HL-7702)	liraglutide treatment	downregulated	30861258
842	Human	hsa-miR-124a	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	normal human liver cell line (HL-7702)	palmitate treatment	upregulated	30861258
843	Human	hsa-miR-124a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLS)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27824863
844	Human	hsa-miR-124a	miRNA	geniposide (GEN)	rheumatoid arthritis (RA)	MH7A cells	geniposide (GE) treatment	GE upregulated the expression of miRNA-124a and decreased the expression of Itg¦Â1 at the mRNA and protein levels.	30342345
845	Human	hsa-miR-125	miRNA	"androgen receptor (AR) agonist, CI-4AS-1"	breast cancer	luminal MCF-7 and T47D cells and the molecular apocrine MDA-MB-453 cells.	CI-4AS-1 treatment	downregulated	28816390
846	Human	hsa-miR-125	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U-87 cells; A172 cells	temozolomide (TMZ) treatment	downregulated	32279420
847	Human	hsa-miR-1252	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells; HeyA-8 cells	paclitaxel (PTX) treatment	downregulated	31945729
848	Human	hsa-miR-1252	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	ovarian cancer cells (SKOV3/PTX and HeyA-8/PTX)	paclitaxel (PTX) treatment	circCELSR1 acts as a sponge for miR-1252 and verified that forkhead box 2 (FOXR2) is a novel target of miR-1252	31945729
849	Human	hsa-miR-125-3p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
850	Human	hsa-miR-125-3p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
851	Human	hsa-miR-1255a	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
852	Human	hsa-miR-1255b-5p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
853	Human	hsa-miR-1256	miRNA	isoflavone	apoptosis	PCa cells	isoflavone? treatment	downregulated	22805767
854	Human	hsa-miR-1257	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
855	Human	hsa-miR-1257	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-miR-1257 was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
856	Human	hsa-miR-125a	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
857	Human	hsa-miR-125a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	miR-125a expression was markedly lower in HL60/ADR cells than HL60 cells.	29663500
858	Human	hsa-miR-125a	miRNA	macrophage colony stimulating factor (M-CSF)	bone formation	CD14+ peripheral blood mononuclear cells (PBMCs)	macrophage colony stimulating factor (M-CSF) treatment	downregulated	24360988
859	Human	hsa-miR-125a	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	bone formation	CD14+ peripheral blood mononuclear cells (PBMCs)	receptor activator of nuclear factor-¦ÊB ligand (RANKL) treatment	downregulated	24360988
860	Human	hsa-miR-125a	miRNA	cisplatin (DDP)	breast cancer	Human umbilical vein endothelial cells (HUVECs)	cisplatin (DPP) treatment	downregulated	30670152
861	Human	hsa-miR-125a	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
862	Human	hsa-miR-125a	miRNA	entinostat	breast cancer	MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells	entinostat treatment	downregulated	23519125
863	Human	hsa-miR-125a	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
864	Human	hsa-miR-125a	miRNA	paclitaxel (PTX)	cervical cancer (CC)	CC cell lines	paclitaxel treatment	downregulated	26878391
865	Human	hsa-miR-125a	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	"LN15, LN18, LN229, U138, U87, U251 cell lines"	TGF-¦Â treatment	downregulated	25256711
866	Human	hsa-miR-125a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HuH-7 and HepG2 HCC cells	sorafenib treatment	upregulated	27982429
867	Human	hsa-miR-125a	miRNA	hepatitis B virus X protein (HBx)	hepatocyte death and liver damage	immortalized liver (L-O2) and HepG2 cell lines	Hepatitis B virus X protein (HBx) treatment	upregulated	25993287
868	Human	hsa-miR-125a	miRNA	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2)"	angiogenesis	human umbilical vein endothelial cells	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2) treatment"	upregulated	27836539
869	Human	hsa-miR-125a	miRNA	IL-1¦Â	inflammatory response	monocytes	IL-1¦Â treatment	upregulated	30245693
870	Human	hsa-miR-125a	miRNA	lipopolysaccharide (LPS)	inflammatory response	monocytes	lipopolysaccharide (LPS) treatment	upregulated	30245693
871	Human	hsa-miR-125a	miRNA	TLR2 agonist pam3CSK4	inflammatory response	monocytes	TLR2 agonist pam3CSK4 treatment	upregulated	30245693
872	Human	hsa-miR-125a	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
873	Human	hsa-miR-125a	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	nasopharyngeal tissues and matched adjacent nasopharyngeal tissues	cisplatin treatment	upregulated	26017674
874	Human	hsa-miR-125a	miRNA	radiation	non-small cell lung cancer (NSCLC)	A549; LTEP-a2 cells	radiation exposure treatment	MicroRNA-125a-5p modulates radioresistance in LTEP-a2 non-small cell lung cancer cells by targeting SIRT7	31683458
875	Human	hsa-miR-125a	miRNA	curcumin (Cur)	osteosarcoma (OS)	osteosarcoma cell lines U2OS and MG63	curcumin in indicated concentrations	upregulated	27231954
876	Human	hsa-miR-125a	miRNA	curcumin (Cur)	osteosarcoma (OS)	U2OS cells	curcumin treatment	upregulated	27231954
877	Human	hsa-miR-125a	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	H2O2 induced TrxR1 expression partly through downregulated of miR-125a.	30225271
878	Human	hsa-miR-125a-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
879	Human	hsa-miR-125a-3p	miRNA	nonylphenol (NP)	tumorigenesis	Sertoli TM4 cells	nonylphenol (NP) treatment	upregulated	21914226
880	Human	hsa-miR-125a-3p	miRNA	LukS-PV	cell differentiation and apoptosis	human monocytic leukaemia cell line THP-1	LukS-PV	upregulated	29179212
881	Human	hsa-miR-125a-3p	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	NCI-H460 cells and another kind of NSCLC cells	EGCG treatment	upregulated	24712372
882	Human	hsa-miR-125a-3p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
883	Human	hsa-miR-125a-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
884	Human	hsa-miR-125a-3p	miRNA	hypoxia	pancreatic cancer (PC)	"pancreatic cancer cell lines SW1990, Capan-1, PANC-1, AsPC-1, CFPAC-1, MIAPaCa-2, and BxPC-3"	1% O2	downregulated	29121972
885	Human	hsa-miR-125a-3p	miRNA	TGF-¦Â1	lung fibrosis	MRC-5 cells	TGF-¦Â1 treatment	downregulated	30658076
886	Human	hsa-miR-125a-5p	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
887	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (oxLDL) treatment	upregulated	30370524
888	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30370524
889	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human vascular smooth muscle cells (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31410121
890	Human	hsa-miR-125a-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
891	Human	hsa-miR-125a-5p	miRNA	histone deacetylase inhibitor (HDACi)	breast cancer	human breast cancer cells	Histone deacetylase inhibitors (HDACi) treatment	downregulated	25531695
892	Human	hsa-miR-125a-5p	miRNA	histone deacetylase inhibitor (HDACi)	breast cancer	MDA-MB-231 human breast cancer cell line	HDACi treatment	downregulated	25531695
893	Human	hsa-miR-125a-5p	miRNA	tamoxifen (TAM)	breast cancer	tamoxifen resistant MCF7 cell lines (MCF7/TAM1 and MCF7/TAM2)	tamoxifen treatment	downregulated	31894257
894	Human	hsa-miR-125a-5p	miRNA	tamoxifen (TAM)	breast cancer	MCF7 / TAM2; MCF7 / TAM1	tamoxifen treatment	downregulated	31894257
895	Human	hsa-miR-125a-5p	miRNA	propofol (PPF)	cervical cancer (CC)	A2780 cells; SKOV3 cells	propofol treatment	Propofol significantly upregulated miR-125a-5p to exert its antitumor activity	32627014
896	Human	hsa-miR-125a-5p	miRNA	schisandrin B (Sch B)	glioblastoma multiforme (GBM)	U251 and U87 cells	Sch B treatment	upregulated	27977512
897	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	Marek's disease (MD)	primary peripheral blood monocytes	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	19377067
898	Human	hsa-miR-125a-5p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
899	Human	hsa-miR-125a-5p	miRNA	IFNs	monocytic differentiation	monocyte	IFNs treatment	dysregulated	25148686
900	Human	hsa-miR-125a-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
901	Human	hsa-miR-125a-5p	miRNA	gefitinib	nasopharyngeal carcinoma (NPC)	"HNE-1 cells,HK-1 cells"	geftinib treatment	upregulated	24602316
902	Human	hsa-miR-125a-5p	miRNA	cisplatin (DDP)	osteosarcoma (OS)	U2-OS and Saos-2 osteosarcoma cell lines	cisplatin (DPP) treatment	MiR-125a-5p inhibitor attenuated ANRIL knockdown-induced chemosensitivity to cisplatin.	30777616
903	Human	hsa-miR-125a-5p	miRNA	imiquimod (IMQ)	psoriasis	HaCaT cells	?imiquimod treatment	downregulated	33948156
904	Human	hsa-miR-125a-5p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-125a-5p was upregulated in treated patients when compared with untreated patients.	29523324
905	Human	hsa-miR-125a-5p	miRNA	cisplatin (DDP) and?thiosemicarbazone compound 4	triple negative breast cancer (TNBC)	MDA-MB 231 breast cancer cell line	Cisplatin?+?thiosemicarbazone compound 4 treatment	upregulated	31541355
906	Human	hsa-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	insulin-treated HepG2 cells	dioscin treatment	upregulated	31881477
907	Human	hsa-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	palmitic acid-treated AML12 cells	dioscin treatment	upregulated	31881477
908	Human	hsa-miR-125a-5p	miRNA	insulin	type 2 diabetes mellitus (T2DM)	HepG2 cells	insulin treatment	downregulated	31881477
909	Human	hsa-miR-125a-5p	miRNA	palmitic acid (PA)	type 2 diabetes mellitus (T2DM)	AML12 cells	palmitic acid treatment	downregulated	31881477
910	Human	hsa-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	HepG2 cells	dioscin treatment	Dioscin was found to markedly elevate miR-125a-5p level and decrease STAT3 expression.	31881477
911	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular disease	human brain microvessel endothelial cells (HBMEC)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	27903586
912	Human	hsa-miR-125b	miRNA	"1,24-dihydroxyvitamin D 3 (tacalcitol)"	breast cancer	MCF-7 cells	"1,24-dihydroxyvitamin D3 (tacalcitol) treatment"	downregulated	30503385
913	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	breast cancer	MCF-7 cells	"1,25-dihydroxyvitamin D3 (calcitriol) treatment"	downregulated	30503385
914	Human	hsa-miR-125B	miRNA	transcription factor NRF2	acute myeloid leukemia (AML)	peripheral blood	Transcription factor NRF2 treatment	upregulated	25323587
915	Human	hsa-miR-125b	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
916	Human	hsa-miR-125b	miRNA	H2O2	age-related macular degeneration (AMD)	human retinal pigment epithelial (RPE) cell	H2O2 treatment	miR-125b is induced by H2O2 treatments in RPE cells.	29631677
917	Human	hsa-miR-125b	miRNA	lipopolysaccharide (LPS)	allergic airway inflammation	normal human tracheal epithelial (HTEpC) and A549 cells	lipopolysaccharide (LPS) treatment	downregulated	27112664
918	Human	hsa-miR-125b	miRNA	epigallocatechin-3-gallate (EGCG)	Alzheimer's disease (AD)	SH-SY5Y cells	32mol/L EGCG	downregulated	28731435
919	Human	hsa-miR-125b	miRNA	metal	Alzheimer's disease (AD)	human astroglial (HAG)	metal sulfate treatment	upregulated	22099153
920	Human	hsa-miR-125b	miRNA	metal	Alzheimer's disease (AD)	human astroglial (HAG)	metal sulfate treatment	upregulated	22099153
921	Human	hsa-miR-125b	miRNA	platelet derived growth factor-BB (PDGF-BB)	arteriosclerosis obliterans (ASO)	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	29689557
922	Human	hsa-miR-125b	miRNA	dexamethasone (DEX)	B-cell malignant multiple myeloma£¨MM£©	MM cells	dexamethasone (DEX) treatment	upregulated	23759586
923	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	breast cancer	MCF-7 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	30503385
924	Human	hsa-miR-125b	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
925	Human	hsa-miR-125b	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
926	Human	hsa-miR-125b	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
927	Human	hsa-miR-125b	miRNA	entinostat	breast cancer	MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells	entinostat treatment	downregulated	23519125
928	Human	hsa-miR-125b	miRNA	trastuzumab	breast cancer	SKBR-3-TR and BT474-TR cell lines	Trastuzumab treatment	downregulated	30621694
929	Human	hsa-miR-125b	miRNA	proteinase activated receptor 2 (PAR2)	tumorigenesis	human colorectal carcinoma	Proteinase activated-receptor 2 (PAR2) treatment	downregulated	26354435
930	Human	hsa-miR-125b	miRNA	camptothecin	cancer cell apoptosis	PC3 cells; K562 cells; CCRF-CEM cells; NCI-H1299 cells; HCT-15 cells;HBE cells; RBE cells	camptothecin treatment	downregulated	22252650
931	Human	hsa-miR-125b	miRNA	ultraviolet (UV) irradiation	cataract	SRA01/04 cell	15W UVB lamps treatment	downregulated	25312242
932	Human	hsa-miR-125b	miRNA	ultraviolet (UV) irradiation	cell cycle arrest	"Human embryonic kidney cell line HEK293, human colon cancer cell line HCT116,human osteosarcoma cell line U2OS and Human keratinocyte cell line HaCaT"	ultraviolet radiation (UV) treatment	UV radiation induces upregulated of miR-125b	22854965
933	Human	hsa-miR-125b	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	upregulated	24178909
934	Human	hsa-miR-125b	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	HCV replicon cells Con1 (type 1b) and Huh7/Ava5 (type 1b) and sera from HCV-infected patients	hepatitis C virus (HCV) infection	upregulated	29541414
935	Human	hsa-miR-125b	miRNA	rituximab (RTX)	chronic lymphocytic leukemia (CLL)	CD19 cells of CML patients	rituximab treatment	downregulated	28126961
936	Human	hsa-miR-125b	miRNA	granulocyte-colony stimulating factor (G-CSF)	colorectal cancer (CRC)	"human CRC cell line HCT-8, SW480, SW620, HCT-116, LOVO"	Granulocyte colony-stimulating factor?treatment	upregulated	28881590
937	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 renal tubular epithelial cells	high glucose treatment	upregulated	27775793
938	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
939	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retina microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	downregulated	30988072
940	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial (RPE) cells	high glucose (HG) treatment	miR-125b expressions were significantly downregulated by the high glucose treatments.	31938439
941	Human	hsa-miR-125b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	encephalitis	SH-SY5Y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	Overexpression of circARF3 mitigates TNF-¦Á-induced inflammatory damage by up-regulating miR-125b.	32329660
942	Human	hsa-miR-125b	miRNA	cocaine	viral replication	CD4+ T cells	Cocaine treatment	downregulated	23251514
943	Human	hsa-miR-125b	miRNA	reactive oxygen species (ROS)	Epstein-Barr virus (EBV) infection	ovarian cancer cells	reactive oxygen species (ROS) treatment	downregulated	23146892
944	Human	hsa-miR-125b	miRNA	phorbol-12-myristate-13-acetate(PMA)	functions of human macrophages	U937 cells	phorbol 12-myristate 13-acetate (PMA) treatment	upregulated	33268675
945	Human	hsa-miR-125b	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
946	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	MCF-7 cells	"1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))?treatment"	upregulated	19437538
947	Human	hsa-miR-125b	miRNA	arsenic trioxide (ATO)	glioblastoma multiforme (GBM)	human glioma U251 cells	arsenic trioxide (As2O3) treatment	downregulated	24479808
948	Human	hsa-miR-125b	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
949	Human	hsa-miR-125b	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
950	Human	hsa-miR-125b	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
951	Human	hsa-miR-125b	miRNA	propranolol (PRO)	infantile hemangioma (IH)	hemangioma endothelial cells	propranolol treatment	upregulated	30986805
952	Human	hsa-miR-125b	miRNA	estradiol-17¦Â (E2)	inflammation	human macrophages	estradiol-17¦Â (E2) treatment	"LPS induces let-7a and inhibits miR-125b expression in human macrophages, and pretreatment with estradiol abrogates these effects"	20351193
953	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	leukemia	U937 and HL60 cells2	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	28389358
954	Human	hsa-miR-125b	miRNA	daunorubicin	leukemia	leukemia cell lines	on the resistance to the chemotherapeutic agent treatment	upregulated	24604579
955	Human	hsa-miR-125b	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
956	Human	hsa-miR-125b	miRNA	TGF-¦Â	liver fibrosis	LX2 cells	TGF-¦Â treatment	downregulated	31548167
957	Human	hsa-miR-125b	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
958	Human	hsa-miR-125b	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
959	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	macrophage polarization	LPS-treated THP-1 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	30540970
960	Human	hsa-miR-125b	miRNA	lipopolysaccharide (LPS)	macrophage polarization	THP-1 cells	lipopolysaccharide (LPS) treatment	upregulated	30540970
961	Human	hsa-miR-125b	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	nasopharyngeal tissues and matched adjacent nasopharyngeal tissues	cisplatin treatment	upregulated	26017674
962	Human	hsa-miR-125b	miRNA	tanshinone IIA (Tan IIA)	nasopharyngeal carcinoma (NPC)	HK1 cells	tanshinone IIA treatment	the present study demonstrates that tanshinone IIA enhances pyroptosis and inhibits the proliferation of HK1 cells by modulating miR-125b/foxp3/caspase-1/GSDMD signaling	33760137
963	Human	hsa-miR-125b	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
964	Human	hsa-miR-125b	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
965	Human	hsa-miR-125b	miRNA	osimertinib	non-small cell lung cancer (NSCLC)	H1975 cells	osimertinib treatment	The relative expression levels of miR-125b was significantly upregulated after treated with 100 nM osimertinib for 24 h.	32375124
966	Human	hsa-miR-125b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
967	Human	hsa-miR-125b	miRNA	"dexamethasone (DEX), ascorbic acid, and ¦Â-glycerol phosphate"	PDLCs osteoblastic differentiation	periodontal ligament cells (PDLCS)	"dexamethasone, ¦Â-glycerol phosphate and ¦Á-ascorbic acid treatment"	miR-125b was downregulated during the process of ostoblast differentiation of PDLCs.	30078007
968	Human	hsa-miR-125b	miRNA	decitabine	precursor B-cell acute lymphoblastic leukemia (B-ALL)	Nalm6 cell line	decitabine treatment	downregulated	30912184
969	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	prostate cancer	?primary prostatic epithelial cells (PrE)	"?1,25-dihydroxyvitamin D"	downregulated	23503652
970	Human	hsa-miR-125b	miRNA	capecitabine	rectal cancer	rectal cancer tissue	capecitabine treatment	upregulated	18695884
971	Human	hsa-miR-125b	miRNA	trichostatin A (TSA)	systemic sclerosis (SSc)	primary dermal fibroblasts	trichostatin A treatment	downregulated	31309742
972	Human	hsa-miR-125b	miRNA	tubastatin A	systemic sclerosis (SSc)	primary dermal fibroblasts	tubastatin A treatment	downregulated	31309742
973	Human	hsa-miR-125b	miRNA	glucosamine	type 2 diabetes mellitus (T2DM)	HepG2 cells	glucosamine treatment	upregulated	29319168
974	Human	hsa-miR-125b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	type 2 diabetes mellitus (T2DM)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29319168
975	Human	hsa-miR-125b	miRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells	high levels of phosphate treatment	downregulated	28522697
976	Human	hsa-miR-125b	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	keratinocytes HaCaT	lipopolysaccharide (LPS) treatment	downregulated	27133077
977	Human	hsa-miR-125b	miRNA	homocysteine (Hcy)	vascular smooth muscle cell proliferation	vascular smooth muscle cells	homocysteine treatment	downregulated	27426728
978	Human	hsa-miR-125b-1*	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
979	Human	hsa-miR-125b-1-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
980	Human	hsa-miR-125b-1-3p	miRNA	cortisol	schizophrenia (SZ)	"The immortalized multipotent, human hippocampal progenitor cell line, HPC0A07/03C (propriety of ReNeuron)"	HPC0A07/03C cells were treated with the stress hormone cortisol (100 ¦ÌM) or vehicle for 3 days during the proliferation stage (to mimic the early stress exposure)	downregulated	30057098
981	Human	hsa-miR-125b-2	miRNA	androgen	prostate cancer	prostate cancer cells	androgen treatment	downregulated	23503464
982	Human	hsa-miR-125b-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
983	Human	hsa-miR-125b-5p	miRNA	IL-1¦Â	arthritis	human osteoarthritic (OA) chondrocytes	IL-1¦Â treatment	downregulated	31053727
984	Human	hsa-miR-125b-5p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
985	Human	hsa-miR-125b-5p	miRNA	brucella.suis	brucellosis	HEK293T cell lines	Brucella infection treatment	downregulated	27473222
986	Human	hsa-miR-125b-5p	miRNA	sevoflurane (SEV)	cognitive impairment	SH-SY5Y cells	Sevoflurane treatment	upregulated	31490755
987	Human	hsa-miR-125b-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells; HCT8 cells; HT29 cells	5-fluorouracil (5-FU) treatment	downregulated	31746054
988	Human	hsa-miR-125b-5p	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cells	cisplatin treatment	downregulated	32766131
989	Human	hsa-miR-125b-5p	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells; HCT8 cells; HT29 cells	oxaliplatin treatment	downregulated	31746054
990	Human	hsa-miR-125b-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE©\19 cells	high glucose treatment	downregulated	31094072
991	Human	hsa-miR-125b-5p	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
992	Human	hsa-miR-125b-5p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
993	Human	hsa-miR-125b-5p	miRNA	IL-1¦Â	lumbar disc degeneration (LDD)	human lumbar degenerative NP specimens and IL-1¦Â-treated NP cells	IL-1¦Â? treatment	miR-125b-5p was markedly upregulated in both human lumbar degenerative NP specimens and IL-1¦Â-treated NP cells.	33123835
994	Human	hsa-miR-125b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY6Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	32057951
995	Human	hsa-miR-125b-5p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
996	Human	hsa-miR-125b-5p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
997	Human	hsa-miR-125b-5p	miRNA	bortezomib	cutaneous T-cell lymphoma (CTCL)	MyLa2000 and SeAx	?bortezomib treatment	upregulated	23527180
998	Human	hsa-miR-126	miRNA	arsenic trioxide (ATO)	acute promyelocytic leukemia (APL)	HUVECs	arsenic trioxide (ATO) treatment	upregulated	26274316
999	Human	hsa-miR-126	miRNA	cysteine-rich 61 (CCN1)	angiogenesis	"human osteoblast-like cell line MG-63, human fetal osteoblastic cell line hFOB"	cysteine-rich 61 (CCN1) treatment	downregulated	27465842
1000	Human	hsa-miR-126	miRNA	fenretinide	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fenretinide treatment	upregulated	31925643
1001	Human	hsa-miR-126	miRNA	palmitic acid (PA)	antiapoptotic	HUVECs	palmitic acid (PA) treatment	downregulated	25318608
1002	Human	hsa-miR-126	miRNA	actinomycin X2 (AX2)	apoptosis	human prostate cancer cells (PC-3)	actinomycin X2 (AX2) treatment	miR-144 was decreased ; smiR-126 was increased	26645890
1003	Human	hsa-miR-126	miRNA	palmitate	apoptosis	HUVECs	palmitate treatment	downregulated	25318608
1004	Human	hsa-miR-126	miRNA	resveratrol	apoptosis	CRL-1730 cells	resveratrol (RS) treatment	upregulated	24107596
1005	Human	hsa-miR-126	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
1006	Human	hsa-miR-126	miRNA	curcumin (Cur)	arteriosclerosis (AS)	Human microvascular endothelial HMEC-1 cells	curcumin treatment	upregulated	31016760
1007	Human	hsa-miR-126	miRNA	asbestos	asbestos-related malignancies	serum	asbestos treatment	upregulated	30257964
1008	Human	hsa-miR-126	miRNA	inhaled corticosteroids	asthma	bronchial epidermal cells from asthma patients	inhaled corticosteroids treatment	downregulated	24995087
1009	Human	hsa-miR-126	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-126 level was significantly reduced in ox-LDL-treated HUVECs.	29203244
1010	Human	hsa-miR-126	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29203244
1011	Human	hsa-miR-126	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	HUVEC	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	24870014
1012	Human	hsa-miR-126	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
1013	Human	hsa-miR-126	miRNA	arachidonic acid (AA)	breast cancer	platelet microvesicle (MV)	arachidonic acid (AA) treatment	upregulated	31665654
1014	Human	hsa-miR-126	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
1015	Human	hsa-miR-126	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
1016	Human	hsa-miR-126	miRNA	tamoxifen (TAM)	breast cancer	tumour samples of breast cancer	tamoxifen treatment	upregulated	23968733
1017	Human	hsa-miR-126	miRNA	hypoxia	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	22282338
1018	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	cell damage	HK-2 cells	lipopolysaccharide (LPS) treatment	LncRNA?Mirt2 prohibits lipopolysaccharide-evoked HK-2 cell injury via modulation of?microRNA-126.	31889348
1019	Human	hsa-miR-126	miRNA	benzo(a)pyrene (BaP)	cell proliferation	primary cell cultures from normal and malignant endometrial tissue	benzo(a)pyrene (BaP) exposure	downregulated	30811740
1020	Human	hsa-miR-126	miRNA	high glucose (HG)	cell senescence	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	downregulated	30717558
1021	Human	hsa-miR-126	miRNA	tea polyphenols (TP)	cell senescence	high glucose (HG)-treated human glomerular mesangial cells (HGMCs)	tea polyphenols (TP) treatment	upregulated	30717558
1022	Human	hsa-miR-126	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell-to-cell communication	human aortic endothelial cells (ECs) and their transfer to recipient cells	tumor necrosis factor alpha (TNF-¦Á) treatment	differently regulation	25315114
1023	Human	hsa-miR-126	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	human umbilical vein endothelial cells (HUVECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-126 expression was markedly reduced in HUVECs subjected to OGD/R treatment	33355373
1024	Human	hsa-miR-126	miRNA	naringin	chondrosarcoma	human chondrosarcoma cell line JJ012	naringin treatment	upregulated	24975661
1025	Human	hsa-miR-126	miRNA	HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA)	chronic heart failure (CHF)	human aortic endothelial cells	HDLNYHA treatment	downregulated	24958738
1026	Human	hsa-miR-126	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patient cells	ibrutinib treatment	upregulated	28299881
1027	Human	hsa-miR-126	miRNA	capecitabine	colorectal cancer (CRC)	colon cancer cells	capecitabine treatment	upregulated	22397399
1028	Human	hsa-miR-126	miRNA	oxaliplatin	colorectal cancer (CRC)	colon cancer cells	oxaliplatin treatment	upregulated	22397399
1029	Human	hsa-miR-126	miRNA	docosahexaenoic acid (DHA)	colorectal cancer (CRC)	HCT116 and Caco2 cell lines	Docosahexaenoic acid (DHA) treatment	upregulated	30598703
1030	Human	hsa-miR-126	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
1031	Human	hsa-miR-126	miRNA	IL-1¦Â and TNF-¦Á	cystic fibrosis (CF)	cystic fibrosis airway epithelial cells	IL-1¦Â and TNF-¦Á treatment	downregulated	20083669
1032	Human	hsa-miR-126	miRNA	glucose plus advanced glycation end product-BSA	diabetes mellitus (DM)	human cavernous endothelial cells (hCECs)	glucose plus advanced glycation end product-BSA treatment	downregulated	29942117
1033	Human	hsa-miR-126	miRNA	icariside II (ICA II)	diabetes mellitus (DM)	glucose plus advanced glycation end product-BSA-treated human cavernous endothelial cells (hCECs)	icariside II (ICA II) treatment	upregulated	29942117
1034	Human	hsa-miR-126	miRNA	hyperglycemia and advanced glycation end products (AGE)	diabetic vasculopathy	Endothelial Progenitor Cells	Hyperglycemia and Advanced Glycation End Products treatment	downregulated	27673690
1035	Human	hsa-miR-126	miRNA	maggot debridement therapy (MDT)	diabetic foot ulcer (DFU)	patients with DFUs	maggot debridement therapy (MDT) treatment	upregulated	27623390
1036	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose treatment	downregulated	30341510
1037	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose treatment	downregulated	31608649
1038	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	miR-126 was downregulated in high-glucose-induced HRECs.	31608649
1039	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal capillary endothelial cells (HRCECs)	high glucose (HG) treatment	downregulated	33416109
1040	Human	hsa-miR-126	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	serum	streptozotocin (STZ) treatment	downregulated	33416109
1041	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal capillary endothelial cells (HRCECs)	high glucose (HG) treatment	The diabetic rats were found to exhibit downregulated serum and retinal miR-126 levels compared with the non-diabetic rats.	33416109
1042	Human	hsa-miR-126	miRNA	palmitate	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	palmitate treatment	MicroRNA-126 Modulates Palmitate-Induced Migration in HUVECs by Downregulating Myosin Light Chain Kinase via the ERK/MAPK Pathway	32850751
1043	Human	hsa-miR-126	miRNA	aspirin	fetal neural stem cells (NSCs)maturation	?plasma	aspirin treatment	downregulated	23386708
1044	Human	hsa-miR-126	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
1045	Human	hsa-miR-126	miRNA	Cl-amidine	glioblastoma multiforme (GBM)	LN18 and LN229 cells	Cl-amidine treatment	upregulated	30597867
1046	Human	hsa-miR-126	miRNA	high glucose (HG)	hyperglycemia-induced senescence	human glomerular mesangial cells (HGMCs)	high glucose treatment	downregulated	31089945
1047	Human	hsa-miR-126	miRNA	tea polyphenols (TP)	hyperglycemia-induced senescence	High glucose-treated human glomerular mesangial cells (HGMCs)	tea polyphenols (TPs) treatment	upregulated	31089945
1048	Human	hsa-miR-126	miRNA	training	hypertension and skeletal muscle microcirculation rarefaction	heart tissues	training treatment	upregulated	33105326
1049	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	IgA nephropathy (IgAN)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31889348
1050	Human	hsa-miR-126	miRNA	polychlorinated biphenyls (PCBs)	inflammation	HUVECs	polychlorinated biphenyls (PCBs) treatment	upregulated	27288564
1051	Human	hsa-miR-126	miRNA	angiopoietin-1 (Ang-1)	inflammatory injury	HPDE6-C7 treated with LPS (10 ?g/mL)	angiopoietin-1 (Ang-1) treatment	upregulated	31966500
1052	Human	hsa-miR-126	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	OGD induced downregulated of miR-126 in HBMECs.	32591985
1053	Human	hsa-miR-126	miRNA	a?a¨ª (Ac) and red muscadine grape (Gp)	lipid accumulation and inflammatory response	human vascular endothelial cells (HUVEC)	a?a¨ª (Ac) and red muscadine grape (Gp)treatment	?microRNA-126 expression was found to be modulated by Ac and Gp	21682256
1054	Human	hsa-miR-126	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
1055	Human	hsa-miR-126	miRNA	exercise and diet	microvascular endothelial dysfunction	serum	exercise and diet treatment	"After 6-weeks intervention, microRNA-126 was significantly decreased."	30472037
1056	Human	hsa-miR-126	miRNA	exercise and diet	microvascular endothelial dysfunction	serum from obese adolescents	food and exercise treatment	downregulated	30472037
1057	Human	hsa-miR-126	miRNA	natalizumab	multiple sclerosis (MS)	CD4+T lymphocytes	natalizumab treatment	downregulated	24598267
1058	Human	hsa-miR-126	miRNA	dimethyloxalylglycine (DMOG)	myocardial angiogenesis	human umbilical vein endothelial cells (HUVECs)	dimethyloxalylglycine (DMOG) treatment	DMOG significantly increased the expression level of HIF-1¦Á and miR-126 in a concentration-dependent manner in normoxia.	32939968
1059	Human	hsa-miR-126	miRNA	danhong injection (DHI)	myocardial infarction (MI)	hypoxia-induced human umbilical vein endothelial cells (HUVECs)	danhong injection (DHI) treatment	upregulated	31629250
1060	Human	hsa-miR-126	miRNA	hypoxia	myocardial infarction (MI)	human cardiosphere-derived cells (CDCs) exosomes	hypoxia induce	upregulated	29243842
1061	Human	hsa-miR-126	miRNA	hypoxia	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	31629250
1062	Human	hsa-miR-126	miRNA	"TNF¦Á , IFN¦Ã"	neuroinflammation	human brain endothelial cell line	"TNF¦Á , IFN¦Ã treatment"	downregulated	28358058
1063	Human	hsa-miR-126	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
1064	Human	hsa-miR-126	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
1065	Human	hsa-miR-126	miRNA	matrine	non-small cell lung cancer (NSCLC)	A549 NSCLC cell line	matrine treatment	"matrine induced cell cycle arrest and apoptosis, and recovered the expression of miR-126 in the A549 NSCLC cell line."	27665734
1066	Human	hsa-miR-126	miRNA	radiation	non-small cell lung cancer (NSCLC)	non-small cell lung cancer tissue	radiation treatment	upregulated	20728239
1067	Human	hsa-miR-126	miRNA	total flavonoids (TFs)	non-small cell lung cancer (NSCLC)	human lung cancer cell line A549	TFS treatment	downregulated	28404902
1068	Human	hsa-miR-126	miRNA	high glucose (HG)	obesity	obesity subjects' adipose tissue-derived stem cells (ASCs)	high glucose (HG) treatment	downregulated in cell-derived extracellular vesicles (EVs)	26122028
1069	Human	hsa-miR-126	miRNA	palmitic acid (PA)	obesity	obesity subjects' adipose tissue-derived stem cells (ASCs)	palmitic acid (PA) treatment	downregulated in cell-derived extracellular vesicles (EVs)	26122028
1070	Human	hsa-miR-126	miRNA	baicalin (BAI)	osteoarthritis (OA)	IL-1¦Â-treated CHON-001 cells	baicalin (BAI) treatment	downregulated	29331857
1071	Human	hsa-miR-126	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	upregulated	29331857
1072	Human	hsa-miR-126	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocyte cell line CHON-001	IL-1¦Â treatment	upregulated	30034795
1073	Human	hsa-miR-126	miRNA	ailanthone (AIL)	osteosarcoma (OS)	MG63 cells	ailanthone (AIL) treatment	upregulated	31571500
1074	Human	hsa-miR-126	miRNA	angelica polysaccharide (AP)	oxidative stress	H2O2-treated HaCaT cells	angelica polysaccharide (AP) treatment	upregulated	31288012
1075	Human	hsa-miR-126	miRNA	H2O2	oxidative stress	HaCaT cells	H2O2 treatment	downregulated	31288012
1076	Human	hsa-miR-126	miRNA	high glucose (HG)	periodontitis with diabetes	THP-1 cells	high glucose (HG) treatment	High glucose condition can inhibit the proliferation of THP-1-derived macrophages and increase the expression of miR-126.	33280362
1077	Human	hsa-miR-126	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
1078	Human	hsa-miR-126	miRNA	carbon black (CB) particles	lung fibrosis	human bronchial epithelial cell line (16HBE)	carbon black (CB) particles treatment	downregulated	31502903
1079	Human	hsa-miR-126	miRNA	carbon black (CB) particles	lung fibrosis	16HBE cells	carbon black (CB) particles treatment	miR-126 in 16HBE cells after treatment with different concentration of CB was statistically decreased.	31502903
1080	Human	hsa-mir-126	miRNA	carbon black (CB) particles	lung fibrosis	16HBE cells	carbon black (CB) particles treatment	pri-miR-126 in 16HBE cells after treatment with different concentration of CB was statistically increased.	31502903
1081	Human	hsa-miR-126	miRNA	oxygen glucose deprivation (OGD)	remote ischemic preconditioning (RIPC)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	upregulated	32380415
1082	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	sepsis-induced severe cardiomyopathy	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharides (LPS) treatment	upregulated	32411123
1083	Human	hsa-miR-126	miRNA	naringin	small-cell lung cancer (SCLC)	human small cell lung cancer H69AR cells	naringin treatment	upregulated	30197681
1084	Human	hsa-miR-126	miRNA	Buyang Huanwu decoction (BYHWD)	stroke	mesenchymal stem cell (MSC)	Buyang Huanwu decoction (BYHWD) treatment	upregulated	25796380
1085	Human	hsa-miR-126	miRNA	"diet control and exercise in IGT/IFG subjects, insulin plus diet control and exercise"	type 2 diabetes mellitus (T2DM)	type 2 diabetes mellitus (T2DM) patients	six months of treatment	upregulated	24927146
1086	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	CCD-18Co cells	lipopolysaccharide (LPS) treatment	downregulated	27061150
1087	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	CCD-18Co cells	lipopolysaccharide (LPS) treatment	downregulated	27061150
1088	Human	hsa-miR-126	miRNA	mango extract	ulcerative colitis (UC)	CCD-18Co cells	mango extract treatment	upregulated	27061150
1089	Human	hsa-miR-126	miRNA	polyphenolics extracted from mango (var. Keitt)	ulcerative colitis (UC)	LPS-treated CCD-18Co cells	polyphenolics extracted from mango (var. Keitt) treatment	upregulated	27061150
1090	Human	hsa-miR-126	miRNA	asbestos	asbestos toxicity	BEAS-2B cells	asbestos exposure	upregulated	32006662
1091	Human	hsa-miR-126	miRNA	red wine polyphenolics	chronic intestinal inflammation and colon cancer	CCD-18Co myofibroblast cells	red wine polyphenolics treatment	downregulated	22572890
1092	Human	hsa-miR-126*	miRNA	"TNF¦Á , IFN¦Ã"	neuroinflammation	human brain endothelial cell line	"TNF¦Á , IFN¦Ã treatment"	downregulated	28358058
1093	Human	hsa-miR-1260	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
1094	Human	hsa-miR-1260	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
1095	Human	hsa-miR-1260b	miRNA	hypoxia	pathological proliferation of VSMCs	human primary pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	Hypoxia-induced miR-1260b promotes VSMC proliferation.	31818357
1096	Human	hsa-miR-1261	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
1097	Human	hsa-miR-126-3p	miRNA	etanercept	ankylosing spondylitis (AS)	Blood	etanercept treatment	upregulated	26273623
1098	Human	hsa-miR-126-3p	miRNA	high-intensity interval training (HIIT)	atherosclerosis (AS)	individuals	three exercise sessions/week of 4 ¡Á 30 s at maximum speed (all-out) with one extra session every week (up to 7 ¡Á 30 s)	upregulated	28611681
1099	Human	hsa-miR-126-3p	miRNA	low-intensity training	atherosclerosis (AS)	individuals	three exercise sessions/week for 25 min <75% of maximum heart rate	upregulated	28611681
1100	Human	hsa-miR-126-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	downregulated	31722571
1101	Human	hsa-miR-126-3p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
1102	Human	hsa-miR-126-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
1103	Human	hsa-miR-126-3p	miRNA	high-intensity interval training (HIIT)	endothelial dysfunction	blood	high-intensity interval (HII) cycling exercise bouts treatment	upregulated	31487226
1104	Human	hsa-miR-126-3p	miRNA	hydroquinone (HQ)	erythroid cell differentiation	CD34 + hematopoietic progenitor cells	hydroquinone (HQ) treatment	downregulated	28733890
1105	Human	hsa-miR-126-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
1106	Human	hsa-miR-126-3p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
1107	Human	hsa-miR-126-3p	miRNA	hydroquinone (HQ)	hematotoxicity	CD34 hematopoietic progenitor cells	treat with HQ	downregulated	28733890
1108	Human	hsa-miR-126-3p	miRNA	Traumatic brain injury (TBI)	hypopituitarism	blood	Traumatic brain injury (TBI) treatment	downregulated	27027233
1109	Human	hsa-miR-126-3p	miRNA	dabrafenib	melanoma	The BRAF-mutant human melanoma cell lines A375 and SK-Mel28	?dabrafenib treatment	downregulated	31227006
1110	Human	hsa-miR-126-3p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
1111	Human	hsa-miR-126-3p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oxidative stress	HTR-8/SVneo cell line	mono-(2-ethylhexyl) phthalate (MEHP) treatment	upregulation	26871967
1112	Human	hsa-miR-126-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	preeclampsia (PE)	HUVECs	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	31323164
1113	Human	hsa-miR-126-3p	miRNA	adalimumab(ADA)	psoriasis	circulating angiogenic cells (CACs)	adalimumab treatment	upregulated	26943583
1114	Human	hsa-miR-126-3p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
1115	Human	hsa-miR-126-3p	miRNA	high glucose (HG)	wound healing defects and vascular dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	"High glucose decreased the endogenous H2S and miR-126-3p levels and increased the DNMT1 expression, thus inducing the migration dysfunction of HUVECs."	32186933
1116	Human	hsa-miR-126-3p	miRNA	hydrogen sulfide (H2S)	wound healing defects and vascular dysfunction	human umbilical vein endothelial cells (HUVECs)	hydrogen sulfide (H2S) treatment	upregulated	32186933
1117	Human	hsa-miR-1264	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
1118	Human	hsa-miR-126-5p	miRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	human aortic smooth muscle cells (hAoSMCs)	angiotensin II (Ang II) treatment	miR-126-5p expression significantly decreased in primary hAoSMCs stimulated with Ang II.	32612287
1119	Human	hsa-miR-126-5p	miRNA	bone morphogenetic protein 4 (BMP4)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	bone morphogenetic protein 4 (BMP4) treatment	upregulated(miR-126-5p) ;downregulated (miR-494 )	28124060
1120	Human	hsa-miR-126-5p	miRNA	baicalin (BAI)	atherosclerosis (AS)	ox-LDL-treated HA-VSMCs	baicalin (BAI) treatment	upregulated	31204352
1121	Human	hsa-miR-126-5p	miRNA	high-intensity interval training (HIIT)	atherosclerosis (AS)	individuals	three exercise sessions/week of 4 ¡Á 30 s at maximum speed (all-out) with one extra session every week (up to 7 ¡Á 30 s)	upregulated	28611681
1122	Human	hsa-miR-126-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HA-VSMCs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31204352
1123	Human	hsa-miR-126-5p	miRNA	IL-1¦Â	chondrocyte inflammation	cartilage cells	IL-1¦Â treatment	upregulated	33098220
1124	Human	hsa-miR-126-5p	miRNA	paclitaxel (PTX)	colorectal cancer (CRC)	SW480 cells; SW620 cells	Paclitaxel (PTX) treatment	?CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis	32581554
1125	Human	hsa-miR-126-5p	miRNA	high-intensity interval training (HIIT)	endothelial dysfunction	blood	high-intensity interval (HII) cycling exercise bouts treatment	upregulated	31487226
1126	Human	hsa-miR-126-5p	miRNA	proresolution lipid mediator lipoxin (LX)A4	inflammation	HUVECs and EMVs	LXA4 treatment	upregulated in HUVECs and in EMVs	28100645
1127	Human	hsa-miR-126-5p	miRNA	lipopolysaccharide (LPS)	liver damage	L02 cells	lipopolysaccharide (LPS) treatment	LPS significantly elevated the expression of miR-126-5p in L02 cells.	32031750
1128	Human	hsa-miR-126-5p	miRNA	Tubeimoside-1 (TBMS1)	non-small cell lung cancer (NSCLC)	NCI-H1299 cells	Tubeimoside-1 (TBMS1) treatment	upregulated	29363720
1129	Human	hsa-miR-126-5p	miRNA	Tubeimoside-1 (TBMS1)	non-small cell lung cancer (NSCLC)	NCI-H1299 cells	Tubeimoside-1 (TBMS1) treatment	upregulated	30127904
1130	Human	hsa-miR-1268a	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
1131	Human	hsa-miR-1268a	miRNA	hypoxia	cell proliferation	human primary pulmonary artery smooth muscle cells	hypoxia induce	upregulated	31370272
1132	Human	hsa-miR-1268a	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
1133	Human	hsa-miR-1268b	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
1134	Human	hsa-miR-1268b	miRNA	steviol	gastrointestinal cancer	MKN-45 cells	steviol treatment	upregulated	29899860
1135	Human	hsa-miR-1269b	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	miR-1269b expression was upregulated in cisplatin-resistant NSCLC specimens and NSCLC cell lines.	32021259
1136	Human	hsa-miR-1269b	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV)? treatment	upregulated	27349221
1137	Human	hsa-miR-126a-5p	miRNA	H2O2 and hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	H9C2 cells	myocardial ischemia-reperfusion (M-I/R)	upregulated	29212219
1138	Human	hsa-miR-127	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	"Human bladder carcinoma cell line,T24 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	16766263
1139	Human	hsa-miR-127	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
1140	Human	hsa-miR-127	miRNA	schizandrin A (SchA)	inflammatory skin diseases	HaCaT cells	schizandrin A (SchA) treatment	miR-127 expression was upregulated in LPS-treated HaCaT cells but downregulated after SchA treatment.	30257250
1141	Human	hsa-miR-127	miRNA	TGF-¦Â	lung cancer	HCC cell	TGF-¦Â? treatment	TGF¦Â decreases miR-127 expression by enhancing c-Jun-mediated inhibition of miR-127 promoter activity	23762330
1142	Human	hsa-miR-127	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
1143	Human	hsa-miR-127	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	"miR-127 was repressed by overexpressed TUG1, meanwhile the protective impacts of TUG1 against LPS-evoked inflammatory injury in MRC-5 cells were overturned by overexpressed miR-127."	31017717
1144	Human	hsa-miR-127	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
1145	Human	hsa-miR-1270	miRNA	cisplatin (DDP)	ovarian cancer (OC)	Human ovarian cancer cell lines (A2780 and SKOV-3)	cisplatin treatment	miR-1270 Plays an Oncogenic Role in Ovarian Cancer Cells and Reduces Their Cisplatin Chemosensitivity.	31479922
1146	Human	hsa-miR-1271	miRNA	huaier extract	acute kidney injury (AKI)	HK-2 cells	Huaier extract (HE) treatment	HE Downregulates CHOP and GRP78 and Upregulates miR-1271 in HK-2 Cells.	33457422
1147	Human	hsa-miR-1271	miRNA	hepatitis B virus (HBV)	HBV-associated hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues and cells	hepatitis B virus (HBV) infection	downregulated	30565670
1148	Human	hsa-miR-1271	miRNA	dietary saturated fatty acids (SFA)	insulin resistance (IR)	HepG2 cells	Dietary saturated fatty acids (SFA) treatment	upregulated	27613089
1149	Human	hsa-miR-1271-5p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
1150	Human	hsa-miR-1273c	miRNA	XAV939	non-small cell lung cancer (NSCLC)	"The NSCLC cell line, NCI-H1299"	10 ?M XAV939 for 12 h treatment	The downregulated of lncRNA?MIR503HG?induced by XAV939 may serve an important role in NSCLC suppression via sponging?miR-1273c?and regulating?SOX4?expression	31186710
1151	Human	hsa-miR-1273d	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
1152	Human	hsa-miR-1273d	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
1153	Human	hsa-miR-1273f	miRNA	hypoxia	hepatocellular carcinoma (HCC)	exosomes from Huh7 cells	hypoxia induce	upregulated	31562861
1154	Human	hsa-miR-127-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
1155	Human	hsa-miR-127-3p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	downregulated	32742197
1156	Human	hsa-miR-1274a	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
1157	Human	hsa-miR-1274a	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	upregulated	23159985
1158	Human	hsa-miR-1274b	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	upregulated	23159985
1159	Human	hsa-miR-1275	miRNA	curcumin (Cur)	corneal neovascularization (CNV)	HUVECs	curcumin treatment	upregulated	27625050
1160	Human	hsa-miR-1275	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
1161	Human	hsa-miR-1275	miRNA	"tamarix articulata, quercetin , epigallocatechin gallate (EGCG)"	hepatocellular carcinoma (HCC)	Huh-7 cells	"T. articulata, quercetin and EGCG treatment"	downregulated	28817968
1162	Human	hsa-miR-1275	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
1163	Human	hsa-miR-127-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
1164	Human	hsa-miR-127-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteonecrosis of femoral head (GIONFH)	human Bone mesenchymal stem cells (BMSCs)	glucocorticoids (GCs) treatment	upregulated	30579595
1165	Human	hsa-miR-127-5p	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
1166	Human	hsa-miR-1276	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
1167	Human	hsa-miR-1276	miRNA	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL)	osteoclast differentiation	THP-1 cells	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL) treatment	NF-¦ÊB promotes osteoclast differentiation by overexpressing MITF via down regulating microRNA-1276 expression	32673666
1168	Human	hsa-miR-1277-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	articular chondrocytes (ACs)	IL-1¦Â treatment	downregulated	31198977
1169	Human	hsa-miR-1277-5p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	CHON-001 chondrocytes	lipopolysaccharide (LPS) treatment	"HOTAIR and SGTB were upregulated, while miR-1277-5p was downregulated in OA cartilages and LPS-stimulated CHON-001 chondrocytes."	33721916
1170	Human	hsa-miR-1277-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30671473
1171	Human	hsa-miR-1277-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	30671473
1172	Human	hsa-miR-1277-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MMP+) treatment	downregulated	33069733
1173	Human	hsa-miR-128	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
1174	Human	hsa-miR-128	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	particulate matter (PM)treatment treatment	upregulated	24515752
1175	Human	hsa-miR-128	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	PM-ed A549 pulmonary cell lines in v treatment	upregulated	24515752
1176	Human	hsa-miR-128	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
1177	Human	hsa-miR-128	miRNA	TGF-¦Â1	cell differentiation	human hair follicle mesenchymal stem cells (hHFMSCs)	human hair follicle mesenchymal stem cells (hHFMSCs) treatment	downregulated	27087048
1178	Human	hsa-miR-128	miRNA	H2O2	extracellular matrices (ECMs) homeostasis	"human prostate cancer epithelial cell lines, LNCaP, C4-2, PC3, PC3M, and DU145"	hydrogen peroxide	upregulated	28831065
1179	Human	hsa-miR-128	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	SGC-7901 cells	Helicobacter pylori £¨H. pylori£©infection	downregulated	29604247
1180	Human	hsa-miR-128	miRNA	radiation	glioblastoma multiforme (GBM)	U87 cells	radiation treatment	MicroRNA-128 increases glioma cell radio-sensitivity by suppressing senescent evasion through oncogene Bmi-1	31938239
1181	Human	hsa-miR-128	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
1182	Human	hsa-miR-128	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	human glioma-derived cell lines U251 and U87	TMZ treatment	downregulated	25017996
1183	Human	hsa-miR-128	miRNA	ginsenoside Rh2	glioblastoma multiforme (GBM)	U251 cells	ginsenoside Rh2 (Rh2) treatment	The anti-proliferative effect of Rh2 in human glioma cells was mediated in part through upregulated of miRNA-128 expression	21372826
1184	Human	hsa-miR-128	miRNA	insulin	glycolysis	human HepG2 hepatocellular carcinoma cells	insulin treatment	dysregulated	24895527
1185	Human	hsa-miR-128	miRNA	NPV-LDE-225 (Erismodegib)	human immunodeficiency virus (HIV)-1 infection	Glioblastoma initiating cells (GICs)	NPV-LDE-225 (Erismodegib) treatment	downregulated	23482671
1186	Human	hsa-miR-128	miRNA	opiate	neuroblastoma (NB)	neuroblastoma SH-SY5Y cell line	chronic opiate administration treatment	"low doses of morphine (10nM) reduced the expression levels of miR133b, higher doses (1¦ÌM) downregulated levels of miR133b and miR128"	24440526
1187	Human	hsa-miR-128	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG5 cells	high glucose (HG) treatment	downregulated	31889412
1188	Human	hsa-miR-128	miRNA	adipogenesis medium	osteogenesis	human mesenchymal stem cells	adipogenic	upregulated	27485180
1189	Human	hsa-miR-128	miRNA	P. gingivalis	periodontitis	THP-1 cells and CA9-22 cells	P. gingivalis treatment	upregulated	27240473
1190	Human	hsa-miR-1281	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
1191	Human	hsa-miR-1281	miRNA	high glucose (HG)	diabetes microvascular complications	ARPE-19 cells	high glucose (HG) treatment	upregulated	32849308
1192	Human	hsa-miR-1281	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
1193	Human	hsa-miR-1281	miRNA	asbestos fibers	malignant pleural mesothelioma (MPM)	serum	ex-exposed to asbestos fibers (WEA)	upregulated	27716620
1194	Human	hsa-miR-1281	miRNA	radiation	nasopharyngeal carcinoma (NPC)	serum	radiation treatment	downregulated	32198434
1195	Human	hsa-miR-1281	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	primary human macrophages differentiated from PBMCs	Mycobacterium tuberculosis (MTB) infection	"microRNA-1281 inhibition in human macrophages, by the anti-sense sequence, increased CypD expression and potentiated MTB-induced cytotoxicity."	31884421
1196	Human	hsa-miR-128-1-5P	miRNA	liraglutide	atherosclerosis (AS)	human vascular smooth muscle cells	liraglutide treatment	Liraglutide could curb the expression of inflammatory cytokines and apoptosis related protein in coronary atherosclerosis by regulating RMRP/miR-128-1-5P/Gadd45g signaling pathway	32196624
1197	Human	hsa-miR-128-1-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
1198	Human	hsa-miR-1282	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
1199	Human	hsa-miR-1282	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	downregulated	31359311
1200	Human	hsa-miR-1283	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	Human embryonic cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	"GADD45A and miR-1283 were upregulated or downregulated in myocardial infarction, respectively"	33293495
1201	Human	hsa-miR-1283	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	human embryonic cardiomyocytes	hypoxia /reoxygenation (H/R) treatment	The miR-1283-GADD45A axis may protect against H/R -induced cardiomyocyte injury by suppressing the JNK and p38 MAPK pathways.	33293495
1202	Human	hsa-miR-128-3p	miRNA	laminar shear stress	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	Laminar shear stress induce	downregulated	30905197
1203	Human	hsa-miR-128-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30905197
1204	Human	hsa-miR-128-3p	miRNA	angiotensin II (Ang II)	atrial fibrosis	human atrial fibroblasts	angiotensin II (Ang II) treatment	LncRNA PVT1 promotes atrial fibrosis via miR-128-3p-SP1-TGF-¦Â1-Smad axis in atrial fibrillation.	30894138
1205	Human	hsa-miR-128-3p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
1206	Human	hsa-miR-128-3p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
1207	Human	hsa-miR-128-3p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
1208	Human	hsa-miR-128-3p	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells; colorectal cancer (CRC) tissues	oxaliplatin treatment	miR-18b-5p was increased in oxaliplatin-resistant CRC cells and tissues	33147048
1209	Human	hsa-miR-128-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	High-level glucose (HG) treatment significantly upregulated miRNA-128- 3p expression in HRECs.	32572899
1210	Human	hsa-miR-128-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Seven HCC cell lines PLC/PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC©\7721, and HCCLM3"	sorafenib treatment	downregulated	30132868
1211	Human	hsa-miR-128-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human bone marrow mesenchymal stem cells (BMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31635801
1212	Human	hsa-miR-128-3p	miRNA	gypenoside LI	melanoma	A375 cells; SK-MEL-28 cells	gypenoside LI treatment	Gypenoside LI can induce the upregulation of the tumor suppressor miR-128-3p during melanoma apoptosis.	32022984
1213	Human	hsa-miR-128-3p	miRNA	all-trans retinoic acid (ATRA)	neurogenesis	amniotic epithelial cells (AECs)	all-trans retinoic acid (ATRA) treatment	"lncRNA MEG3 is upregulated by the ATRA/cAMP/CREB pathway, and it, in turn, is directly downregulated by miR-128-3p to increase the amount of neuron differentiation."	31921854
1214	Human	hsa-miR-128-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	C28/I2 cells	IL-1¦Â treatment	miR-128-3p was downregulated in chondrocytes stimulated with interleukin (IL)-1¦Â.	32830547
1215	Human	hsa-miR-128-3p	miRNA	hydrochloric acid	reflux esophagitis	Het-1A cells	hydrochloric acid (HCl) treatment	miR-128-3p was upregulated in Het-1A cells after HCl treatment.	30223934
1216	Human	hsa-miR-128-3p	miRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMEC-1)	lipopolysaccharide (LPS) treatment	HULC knockdown partially reversed LPS-induced sepsis via the regulation of miR-128-3p/RAC1 axis.	33174038
1217	Human	hsa-miR-1284	miRNA	propofol (PPF)	lung cancer	A549 cells	propofol treatment	upregulated	29402342
1218	Human	hsa-miR-1284	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
1219	Human	hsa-miR-1285	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
1220	Human	hsa-miR-1285	miRNA	methylmercury (MeHg)	neurotoxicity	human neural progenitor cells (ihNPCs)	methylmercury (MeHg) treatment	downregulated	27941687
1221	Human	hsa-miR-1285-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cervical cancer (CC)	HeLa cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"TNF-¦Á-induced lncRNA LOC105374902 may function as a ceRNA for miR-1285-3p to promote the expression of RPL14, promoting the migration, invasion and EMT of CC cells."	30935691
1222	Human	hsa-miR-1285-3p	miRNA	herapy with transarterial chemoembolisation (TACE)	hepatocellular carcinoma (HCC)	HCC patients	TACE treatment	dysregulated	25230788
1223	Human	hsa-miR-1285-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
1224	Human	hsa-miR-1286	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
1225	Human	hsa-miR-1286	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
1226	Human	hsa-miR-1286	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
1227	Human	hsa-miR-1287	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
1228	Human	hsa-miR-1287-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
1229	Human	hsa-miR-1287-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
1230	Human	hsa-miR-1287-5p	miRNA	TGF-¦Â	angiogenesis	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â treatment	downregulated	30414893
1231	Human	hsa-miR-1287-5p	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	vascular endothelial cell growth factor (VEGF) treatment	downregulated	30414893
1232	Human	hsa-miR-1287-5p	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	Huh7 cells; HepG2 cells	pHBV1.3 infection	The expression of miR-1287-5p was significantly decreased in the circ_0004812 overexpressing cells.	32188476
1233	Human	hsa-miR-1287-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
1234	Human	hsa-miR-1287-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
1235	Human	hsa-miR-128a	miRNA	X-rays	glioblastoma multiforme (GBM)	U-87 MG glioblastoma cells	X-ray radiation treatment	"High doses of X-ray radiation increased the expression levels of Bmi-1, which may be associated with the evasion of cellular senescence miRNA-128a and its downstream target gene Bmi-1 may have an important role in the radioresistance of U-87 MG glioma cells"	26238021
1236	Human	hsa-miR-128a	miRNA	"haloperidol, clozapine and olanzapine"	schizophrenia (SZ)	"HepG2 (ATCC,CRL-1573)"	"haloperidol, clozapine , olanzapine treatment"	downregulated	28429622
1237	Human	hsa-miR-129	miRNA	piceatannol (PIC)	colorectal cancer (CRC)	HCT116 and HT29 cells	piceatannol treatment	upregulated	25218158
1238	Human	hsa-miR-129	miRNA	gefitinib	esophageal squamous cell carcinoma (ESCC)	TE1 cells; KYSE-450 cells	gefitinib treatment	miR-129 is downregulated in both gefitinib-resistant cell lines in contrast with their respective parental cell lines.	30049286
1239	Human	hsa-miR-129	miRNA	cisplatin (DDP)	gastric cancer (GC)	MGC-803 cells	cisplatin treatment	downregulated	31378887
1240	Human	hsa-miR-129	miRNA	histone deacetylase (HDAC)	histone deacetylase resistance in nasopharyngeal cancer (NPC)	CNE1; CNE2; C666¨C1	Histone deacetylase treatment	downregulated	32692721
1241	Human	hsa-miR-129	miRNA	magnolol	multiple myeloma (MM)	MM cells U266 and LP1	Magnolol treatment	And magnolol increased the miR-129 expression in MM cells.	33440989
1242	Human	hsa-miR-129	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	A549 cells	TGF-¦Â treatment	TGF-¦Â induced EMT accompanied by the reduction of miR-129 and elevating of SOX4	30475081
1243	Human	hsa-miR-129	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Human neuroblastoma cell line SH©\SY5Y	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30260025
1244	Human	hsa-miR-129	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
1245	Human	hsa-miR-129	miRNA	resveratrol	parkinson's disease (PD)	MPTP-treated human neuroblastoma cell line SH©\SY5Y	resveratrol (RS) treatment	upregulated	30260025
1246	Human	hsa-miR-129	miRNA	resveratrol	parkinson's disease (PD)	SH©\SY5Y cells	resveratrol (RS) treatment	upregulated	30260025
1247	Human	hsa-miR-129	miRNA	perioglas (PG) and P-15	promote bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
1248	Human	hsa-miR-129	miRNA	TGF-¦Â1	renal fibrosis	HK-3 cells	TGF-¦Â1 treatment	downregulated	32475133
1249	Human	hsa-miR-1290	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
1250	Human	hsa-miR-1290	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 9¡ã HDT bed rest experiment	downregulated	28261104
1251	Human	hsa-miR-1290	miRNA	asiatic acid (AA)	cardiomyocyte apoptosis	human AC16 cardiomyocytes under hypoxia	treat with various doses of AA for 24 h	upregulated	28686797
1252	Human	hsa-miR-1290	miRNA	polygonatum odoratum lectin (POL)	cell apoptosis and autophagy	A549 cells	Polygonatum odoratum lectin (POL) treatment	downregulated	26562549
1253	Human	hsa-miR-1290	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
1254	Human	hsa-miR-1290	miRNA	polygonatum odoratum lectin (POL)	lung adenocarcinoma (LUAD)	A549 cells	Polygonatum odoratum lectin (POL) treatment	downregulated	26562549
1255	Human	hsa-miR-1290	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	31173947
1256	Human	hsa-miR-1290	miRNA	platinum	lung adenocarcinoma (LUAD)	LADC tissues	platinum-based doublet chemotherapy treatment	dysregulated	25142144
1257	Human	hsa-miR-1290	miRNA	asiatic acid (AA)	non-small cell lung cancer (NSCLC)	A549 NSCLC cells	asiatic acid treatment	upregulated	25016979
1258	Human	hsa-miR-1290	miRNA	TGF-¦Â1	lung fibrosis	A549 cells	TGF-¦Â1 treatment	upregulated	32319530
1259	Human	hsa-miR-1290	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
1260	Human	hsa-miR-1290	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
1261	Human	hsa-miR-1291	miRNA	¦Á-melanocyte-stimulating hormone (¦Á-MSH)	skin pigmentation disorders	human skin primary melanocytes (MCs)	¦Á-MSH treatment	downregulated	33318297
1262	Human	hsa-miR-129-2	miRNA	progesterone (P4)	breast cancer	"T47D, BT474, MDA-MB-231 and MCF7 breast cancer cell lines"	2.5 mg/ml Amphotericin-B (Abbott) and 1.25 ?l/ml Gentamycin (Abbott) treatment	upregulated	28876975
1263	Human	hsa-miR-129-2	miRNA	neuron-glial antigen 2 (NG2) protein	diffuse intrinsic pontine gliomas (DIPGs)	Human DIPG cells	neuron-glial antigen 2 (NG2) protein treatment	downregulated	25987129
1264	Human	hsa-miR-129-2	miRNA	trichostatin A (TSA)	glioblastoma multiforme (GBM)	GBM patient specimens and cultured cell lines	trichostatin A treatment	miR-129-2 expression could be restored upon treatment with a histone deadetylase inhibitor (trichostatin A) but not a DNA methylation inhibitor (5-Aza-2'-deoxycytidine)	26320507
1265	Human	hsa-miR-129-3p	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
1266	Human	hsa-miR-129-3p	miRNA	histone deacetylase inhibitor (HDACi)	cell death	"Huh7 cells, MGC-803 cells"	Histone deacetylase inhibitors (HDACis) treatment	upregulated	30852137
1267	Human	hsa-miR-129-3p	miRNA	avenanthramide A (AVN A)	colorectal cancer (CRC)	"human colon carcinoma cell lines HCT-8, HCT-116"	avenanthramide A (AVN A) treatment	upregulated	30888162
1268	Human	hsa-miR-129-3p	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
1269	Human	hsa-miR-129-3p	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
1270	Human	hsa-miR-129-3p	miRNA	chidamide	non-small cell lung cancer (NSCLC)	H1355 and A549 cells	chidamide treatment	Chidamide repressed telomerase activity through ROS accumulation and cell cycle arrest by miR-129-3p upregulation in both H1355 and A549 cells.	30668358
1271	Human	hsa-miR-129-3p	miRNA	chidamide	non-small cell lung cancer (NSCLC)	H1355 cells; A549 cells	Chidamide treatment	Chidamide upregulates miR-129-3p expression in lung cancer cells.	30668358
1272	Human	hsa-miR-1294	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	SMMC7721 cells; HepG2 cells	arsenic trioxide (ATO) treatment	miR-1294 was found to be significantly upregulated in ATO-treated HCC cells.	32280078
1273	Human	hsa-miR-1294	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
1274	Human	hsa-miR-129-5p	miRNA	CoCl2	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	CoCl2 treatment	downregulated	33175458
1275	Human	hsa-miR-129-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	33175458
1276	Human	hsa-miR-129-5p	miRNA	alcohol	alcoholic liver disease (ALD)	differentiated Caco-2 cells	alcohol treatment	upregulated	31814565
1277	Human	hsa-miR-129-5p	miRNA	physical exercise	Alzheimer's disease (AD)	serum	physical exercise treatment	miR-129-5p is significantly upregulated by physical exercise	32434194
1278	Human	hsa-miR-129-5p	miRNA	suberoylanilide hydroxamic acid (SAHA)	apoptosis	"human lung adenocarcinoma (A549 and SL-LU-1), squamous cell carcinoma (HCC-95 and HCC-1588), large cell carcinoma (NCI-H460 and NCI-H1299), and small cell lung cancer (SCLC; HCC-33, NCI-H69, and Calu-6) cells ,human small airway epithelial cells (HSAEC), human bronchial epithelial cells (HBEC), human pulmonary artery endothelial cells (HPEC) and human pulmonary fibroblast (HPF) cells"	SAHA treatment	upregulated	28667779
1279	Human	hsa-miR-129-5p	miRNA	CoCl2	apoptosis	HK-2 cells	CoCl2 treatment	downregulated	33175458
1280	Human	hsa-miR-129-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	Human cardiac myocytes (HCMs)	angiotensin II (Ang II) treatment	downregulated	33569456
1281	Human	hsa-miR-129-5p	miRNA	IFN-¦Â	cervical intraepithelial neoplasia (CIN) and cancer	Hela cells;HPV 16-negative Siha cells;HPV-negative C33A cells; HCC94 cells	Interferon-¦Â treatment	Interferon-b Induced microRNA-129-5p Down-Regulates HPV-18 E6 and E7 Viral Gene Expression by Targeting SP1 in Cervical Cancer Cells	24358111
1282	Human	hsa-miR-129-5p	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	MCF-7 and MDA-MB-231 cells	cisplatin treatment	lncRNA ZEB1-AS1 silencing protects against drug resistance in breast cancer by promoting miR-129-5p-dependent ZEB1 downregulated.	33430826
1283	Human	hsa-miR-129-5p	miRNA	toxic acetaminophen (APAP)	drug metabolizing enzymes (DMEs) expression	HepaRG cells	toxic acetaminophen (APAP) treatment	APAP treatment increased the level of hsa-miR-129-5p	32273307
1284	Human	hsa-miR-129-5p	miRNA	cisplatin (DDP)	gastric adenocarcinoma (GAC)	HGC27; AGS	cisplatin treatment	Circ_0000260 Regulates the Development and Deterioration of Gastric Adenocarcinoma with Cisplatin Resistance by Upregulating MMP11 via Targeting MiR-129-5p.	33122949
1285	Human	hsa-miR-129-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	SGC7901/VCR gastric cancer multi-drug resistant cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25344911
1286	Human	hsa-miR-129-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	Pri GBM; Rec GBM; N3S; N3T3rd; U251; U251T3rd; glioblastoma (GBM) tissues	temozolomide (TMZ) treatment	downregulated	32039732
1287	Human	hsa-miR-129-5p	miRNA	osteopontin (OPN)	liver fibrosis	human hepatic stellate cells (HSCs) LX-2 cells	Osteopontin (OPN) treatment	downregulated	29196165
1288	Human	hsa-miR-129-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
1289	Human	hsa-miR-129-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteosarcoma (OS)	OS tissues with pulmonary metastasis	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25566966
1290	Human	hsa-miR-129-5p	miRNA	lipopolysaccharide (LPS)	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	lipopolysaccharide (LPS) treatment	downregulated	30855347
1291	Human	hsa-miR-129-5p	miRNA	matrine	peritoneal fibrosis	LPS-treated human peritoneal mesothelial cells (HPMCs)	matrine treatment	upregulated	30855347
1292	Human	hsa-miR-129-5p	miRNA	docetaxel (DTX)	prostate cancer	PC-3 cells	docetaxel (DTX) treatment	upregulated	31876385
1293	Human	hsa-miR-129-5p	miRNA	royal jelly	skin senescence	human dermal microvascular endothelial cells (HDMEC)	royal jelly treatment	downregulated	31723098
1294	Human	hsa-miR-129-5p	miRNA	ultraviolet (UV) irradiation	skin senescence	human dermal microvascular endothelial cells (HDMEC)	UVB radiation treatment	upregulated	31723098
1295	Human	hsa-miR-129-5p	miRNA	histone deacetylase inhibitor (HDACi)	thyroid cancer (TC)	TPC-1 cells;BCPAP cells;8505C clls;CAL62 cells	histone deacetylase inhibitors (HDACi) treatment	miR-129-5p is involved in the antitumor activity of HDACi and highlight a miRNA-driven cell death mechanism.	21946411
1296	Human	hsa-miR-1296	miRNA	genistein	renal fibrosis	PC3 cells	Genistein treatment	downregulated	29967188
1297	Human	hsa-miR-1296	miRNA	trichostatin A (TSA)	renal fibrosis	PC3 cells	TSA treatment	downregulated	29967188
1298	Human	hsa-miR-1297	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"We predicted and verified miR-1297 as the regulatory miRNA of COL1A2, and the expression of miR-1297 was decreased in DN tissues and HG-stimulated HK-2 cells."	33811432
1299	Human	hsa-miR-1297	miRNA	propofol (PPF)	oral squamous cell carcinoma (OSCC)	UM-SCC6 and SCC090 cells	Propofol treatment	downregulated	31583913
1300	Human	hsa-miR-130	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
1301	Human	hsa-miR-1301	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	upregulated	28797462
1302	Human	hsa-miR-1301-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated of NEAT1 repressed ¦Á-syn-induced activation of NLRP3 inflammasome via inhibiting the expression of GJB1 by targeting miR-1301-3p.	32712773
1303	Human	hsa-miR-1301-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	32712773
1304	Human	hsa-miR-1303	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-1303 was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
1305	Human	hsa-miR-1303	miRNA	coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human umbilical vein endothelial cell (HUVECs)	Coxsackievirus A16 (CA16) infection	downregulated	30228270
1306	Human	hsa-miR-1305	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HCC tissues	hepatitis B virus (HBV) infection	downregulated	33372396
1307	Human	hsa-miR-1305	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
1308	Human	hsa-miR-1305	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
1309	Human	hsa-miR-1306	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	upregulated	33197057
1310	Human	hsa-miR-1306-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	"SNHG7-003 may inhibit the proliferation, migration and invasion of VSMCs via the miR-1306-5p/SIRT7 signaling pathway."	33416100
1311	Human	hsa-miR-1306-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	31460837
1312	Human	hsa-miR-1307	miRNA	cisplatin (DDP)	breast cancer	MCF-7 cells; MDA-MB-468 cells	cisplatin treatment	MiR-1307 was downregulated while MDM4 was upregulated in MCF-7/cisplatin (CDDP) and MDA-MB-468/CDDP cells compared with parental MCF-7 and MDA-MB-468 cells.	29697201
1313	Human	hsa-miR-1308	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
1314	Human	hsa-miR-130a	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	downregulated	33716779
1315	Human	hsa-miR-130a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	miR-130a expression was decreased in increasing Adr concentrations.	32945422
1316	Human	hsa-miR-130a	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	U251 cells	amyloid-¦Â (A¦Â) treatment	upregulated	29238290
1317	Human	hsa-miR-130a	miRNA	hypoxia	angiogenesis	human primary endothelial colony-forming cells (ECFCs)	hypoxia induce	"Here, we identify miR-130a as a mediator of the hypoxic response in human primary endothelial colony-forming cells (ECFCs)."	33614244
1318	Human	hsa-miR-130a	miRNA	high glucose (HG)	cell damage	ARPE-19 cells	high glucose (HG) treatment	high-glucose (50 mM) significantly decreased the levels of miR-130a.	32018221
1319	Human	hsa-miR-130a	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 7¡ã HDT bed rest experiment	downregulated	28261104
1320	Human	hsa-miR-130a	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
1321	Human	hsa-miR-130a	miRNA	imatinib	chronic myeloid leukemia (CML)	CML patients	imatinib (IM) treatment	differently regulated	24629639
1322	Human	hsa-miR-130a	miRNA	nilotinib	chronic myeloid leukemia (CML)	HL-60.BCR-ABL cells	nilotinib (NIL) treatment	differently regulated	24629639
1323	Human	hsa-miR-130a	miRNA	curcumin (Cur)	colorectal cancer (CRC)	SW480 cells	curcumin treatment	downregulated	29225578
1324	Human	hsa-miR-130a	miRNA	mesalazine (MSLZ)	colorectal cancer (CRC)	CaCo2 cell line	Mesalazine (5-ASA) treatment	downregulated	29794245
1325	Human	hsa-miR-130a	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	intestinal epithelial cells T84 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	24148619
1326	Human	hsa-miR-130a	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	T85 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	32583714
1327	Human	hsa-miR-130a	miRNA	docetaxel (DTX)	head and neck squamous cell carcinoma (HNSCC)	UMSCC-1 cells;SQ20B cells	docetaxel (DTX) treatment	downregulated	21560177
1328	Human	hsa-miR-130a	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cells	cisplatin treatment	upregulated	22846564
1329	Human	hsa-miR-130a	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	Blood samples	cisplatin treatment	upregulated	22846564
1330	Human	hsa-miR-130a	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
1331	Human	hsa-miR-130a	miRNA	IL-2	immunotherapy	NK-92 cells	IL-2 treatment	upregulated	31883616
1332	Human	hsa-miR-130a	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
1333	Human	hsa-miR-130a	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
1334	Human	hsa-miR-130a	miRNA	radiation	lung cancer	A549 cells	radiation treatment	upregulated	32968458
1335	Human	hsa-miR-130a	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
1336	Human	hsa-miR-130a	miRNA	apicidin	myocardial infarction (MI)	human bone marrow-derived MSC	apicidin treatment	downregulated	28498815
1337	Human	hsa-miR-130a	miRNA	hypoxia	myocardial infarction (MI)	human cardiosphere-derived cells (CDCs) exosomes	hypoxia induce	upregulated	29243842
1338	Human	hsa-miR-130a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
1339	Human	hsa-miR-130a	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	hypoxia treatment	downregulated	32450163
1340	Human	hsa-miR-130a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	H19 negatively regulated the expression of miR-130a via acting as a molecular sponge for miR-130a. The stimulatory effects of H19 on cell damage were abolished following the restoration of miR-130a.	30900425
1341	Human	hsa-miR-130a	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
1342	Human	hsa-miR-130a	miRNA	human immunodeficiency virus (HIV)-1 and cocaine	pulmonary vascular remodeling	human monocyte derived macrophages	HIV-infected and cocaine treatment	upregulated	29672222
1343	Human	hsa-miR-130a	miRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	HK-2 cells (human renal proximal tubule cells)	lipopolysaccharide (LPS) treatment	upregulated	29441906
1344	Human	hsa-miR-130a	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	serum	liraglutide treatment	upregulated	33008044
1345	Human	hsa-miR-130a*	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
1346	Human	hsa-miR-130a-3p	miRNA	indoxyl sulfate (IS)	chronic kidney disease (CKD)	human coronary artery endothelial cells (HCAECs)	indoxyl sulfate (IS) treatment	"Consistent with the clinical data, treatment with the uremia toxin indoxyl sulfate (IS) reduced miR-130a-3p levels in HCAEC-derived EVs."	33135066
1347	Human	hsa-miR-130a-3p	miRNA	TGF-¦Â1	crohn disease (CD)	human intestinal epithelial cells (HIECs); normal-derived colon mucosa cell line 460 (NCM460) cells	TGF-¦Â1 treatment	Hsa_circRNA_102610 upregulation in CD patients could promote the proliferation and EMT of intestinal epithelial cells via sponging of hsa-miR-130a-3p	32587447
1348	Human	hsa-miR-130a-3p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2; Huh7	hypoxia treatment	knockdown of HOTAIR suppressed glycolysis by regulating miR-130a-3p and HIF1A in HCC cells treated by hypoxia	32062551
1349	Human	hsa-miR-130a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	26669941
1350	Human	hsa-miR-130a-3p	miRNA	tobacco smoke	lung cancer	"bronchial epithelial BEAS-2B cells that were malignantly transformed into S30 cells, human lung cancer cell lines A549 and H1299"	tobacco smoke exposure	downregulated	31526129
1351	Human	hsa-miR-130a-3p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
1352	Human	hsa-miR-130a-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	downregulated	31678554
1353	Human	hsa-miR-130a-3p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	downregulated	27018851
1354	Human	hsa-miR-130a-3p	miRNA	TGF-¦Â1	renal fibrosis	"human renal proximal tubular epithelial cells (HRPTEpiCs, HK-2 and primary HRPTEpiCs)"	TGF-¦Â1 treatment	upregulated	31836508
1355	Human	hsa-miR-130a-3p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells; HRPTEpiCs	TGF-¦Â1 treatment	"After TGF-¦Â1 treatment, miR-130a-3p was highly expressed in renal tubular epithelial cells"	31836508
1356	Human	hsa-miR-130a-3p	miRNA	metformin (Met)	cell senescence	HK-2 cells	Metformin treatment	Metformin Increased the Stability of miR-130a-3p by Upregulating MBNL1 and Thus Reduced the High-Glucose- Induced Senescence of Renal Tubular Epithelial Cells.	32104542
1357	Human	hsa-miR-130a-5p	miRNA	tamoxifen (TAM)	breast cancer	Human MCF-7 cells	Tamoxifen (TAM) treatment	Low expression of ADAMTS9-AS2 inhibits PTEN expression and enhances tamoxifen resistance through targeting microRNA-130a-5p	30840279
1358	Human	hsa-miR-130a-5p	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	podocyte cell line AB8/13	angiotensin II (Ang II) treatment	downregulated	30394845
1359	Human	hsa-miR-130a-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
1360	Human	hsa-miR-130b	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	THP-1 cells	Tanshinone IIA (Tan) treatment	upregulated	31512787
1361	Human	hsa-miR-130b	miRNA	5-fluorouracil (5-Fu)	diabetic nephropathy (DN)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
1362	Human	hsa-miR-130b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HMCs)	high glucose treatment	upregulated	30260005
1363	Human	hsa-miR-130b	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
1364	Human	hsa-miR-130b	miRNA	lipopolysaccharide (LPS)	hepatolithiasis	Human intrahepatic biliary epithelial cells (HIBEpiCs)	lipopolysaccharide (LPS) treatment	Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium	33300069
1365	Human	hsa-miR-130b	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	downregulated	28347920
1366	Human	hsa-miR-130b	miRNA	5-fluorouracil (5-Fu)	metastatic colorectal cancer (mCRC)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
1367	Human	hsa-miR-130b	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx7 treatment"	downregulated	21572246
1368	Human	hsa-miR-130b	miRNA	lipopolysaccharide (LPS)	vascular injury	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharides (LPS) treatment	downregulated	28759810
1369	Human	hsa-miR-130b-3p	miRNA	high glucose (HG)	diabetic pregnancy	BeWo cells	high glucose	upregulated	28433632
1370	Human	hsa-miR-130b-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
1371	Human	hsa-miR-132	miRNA	aspergillus fumigatus (A. fumigatus)	Aspergillus fumigatus infection	human monocytes and dendritic cells (DCs)	infect with A. fumigatus	upregulated	24841251
1372	Human	hsa-miR-132	miRNA	notoginsenoside R1 (NGR1)	atherosclerosis (AS)	Human umbilical vascular endothelial cells (HUVECs)	Notoginsenoside R1 (NGR1) treatment	downregulated	30504696
1373	Human	hsa-miR-132	miRNA	hypoxia	blood-brain barrier (BBB) dysfunction	human brain microvascular endothelial cells (BMEC)	hypoxia induce	upregulated	30617994
1374	Human	hsa-miR-132	miRNA	co-nanoencapsulated curcumin (Cur) and chrysin (Chr)	breast cancer	MDA-MB-231 breast cancer cells	co-nanoencapsulated Curcumin (Cur) and Chrysin (Chr) treatment	upregulated	30955355
1375	Human	hsa-miR-132	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
1376	Human	hsa-miR-132	miRNA	luteolin	bronchopneumonia	BEAS-2B cells	Luteolin treatment	luteolin alleviated the LPS-induced miR-132 expression increase in BEAS-2B cells.	30119240
1377	Human	hsa-miR-132	miRNA	doxorubicin (DOX)	cardiotoxicity	human iPSC-derived cardiomyocytes	doxorubicin treatment	"In vitro, overexpression of the pro-hypertrophic miR-212/132 cluster in primary rodent and human iPSC-derived cardiomyocytes inhibited doxorubicin-induced toxicity."	30527757
1378	Human	hsa-miR-132	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
1379	Human	hsa-miR-132	miRNA	recombinant human thymic stromal lymphopoietin (rhTSLP)	cervical cancer (CC)	HeLa and SiHa cells	rhTSLP were significantly impaired inwith treatment	upregulated	29250181
1380	Human	hsa-miR-132	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	THP-1 cells	cigarette smoke extract (CSE) treatment	upregulated	30292646
1381	Human	hsa-miR-132	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	LncRNA SNHG5 regulates cell apoptosis and inflammation by miR-132/PTEN axis in COPD	32145584
1382	Human	hsa-miR-132	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	We revealed that HG-treated ARPE-19 cells exhibited significantly increased miR-132 expression	33563844
1383	Human	hsa-miR-132	miRNA	fluid shear stress (FSS)	epairing the oral cavity	human periodontal ligament (PDL) cells	fluid shear stress? treatment	dysregulated	24556727
1384	Human	hsa-miR-132	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8/SVneo cell	high glucose (HG) treatment	downregulated	31653266
1385	Human	hsa-miR-132	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	LN229 cells; U251 cells	temozolomide (TMZ) treatment	exosome-mediated transfer of CircNFIX enhances TMZ resistance in glioma at least partially through sponging miR-132	32194140
1386	Human	hsa-miR-132	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	Human glioma cell lines U87MG	TGF treatment	upregulated	25983322
1387	Human	hsa-miR-132	miRNA	TGF-¦Â1	hard-to-heal skin wounds	human dermal fibroblasts (HDFs)	TGF-¦Â1 treatment	upregulated	28798331
1388	Human	hsa-miR-132	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	HCC cells	hepatitis C virus (HCV) infection	downregulated	23376496
1389	Human	hsa-miR-132	miRNA	angiotensin II (Ang II)	hypertension	human breast artery tissues	angiotensin II (Ang II) treatment	upregulated	23712358
1390	Human	hsa-miR-132	miRNA	notoginsenoside R1 (NGR1)	inflammation	human lung fibroblast MRC-5 cell	Notoginsenoside R1 (NGR1) treatment	upregulated	30622031
1391	Human	hsa-miR-132	miRNA	palmitate	inflammation	THP-1 cells	PA treatment	upregulated	29258239
1392	Human	hsa-miR-132	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Colon mucosa	dextran sulfate sodium treatment	upregulated	26878986
1393	Human	hsa-miR-132	miRNA	oxygen glucose deprivation (OGD)	hepatocellular carcinoma (HCC)	HepG2 cells	OGD treatment	downregulated	24661879
1394	Human	hsa-miR-132	miRNA	citalopram	major depressive disorder (MDD)	plasma	citalopram treatment	Plasma miR-132 in the treatment-free MDD group was 2.4-fold that in the control group and significantly higher than that in the citalopram-treated MDD group.	29689690
1395	Human	hsa-miR-132	miRNA	nanocurcumin	multiple sclerosis (MS)	blood	nanocurcumin treatment	downregulated	30340096
1396	Human	hsa-miR-132	miRNA	basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF)	neurogenesis	periodontal ligament-derived neural crest stem cells (NCSCs)	basic fibroblast growth factor and epidermal growth factor treatment	upregulated	30352481
1397	Human	hsa-miR-132	miRNA	Toll-like receptor (TLR)	neurological diseases	U251 human astrocytoma cell line	Toll-like receptor (TLR) treatment	upregulated	25957996
1398	Human	hsa-miR-132	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
1399	Human	hsa-miR-132	miRNA	bupivacaine	neurotoxicity	SH-SY5Y cells	bupivacaine treatment	upregulated	30850243
1400	Human	hsa-miR-132	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
1401	Human	hsa-miR-132	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
1402	Human	hsa-miR-132	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	CAL-27cells	cisplatin treatment	miR-132 expression was significantly decreased in the OSCC tissues and CDDP resistant OSCC cell line (CAL-27/CDDP).	31906769
1403	Human	hsa-miR-132	miRNA	dexamethasone (DEX)	pancreatic cancer (PC)	AsPC-1 CELLS; PANC-1 cells; ASAN-PaCa cells	dexamethasone (Dex) treatment	DEX inhibits miR-132 expression by promoter hypermethylation.	30387838
1404	Human	hsa-miR-132	miRNA	dexamethasone (DEX)	pancreatic ductal adenocarcinoma (PDAC)	"human primary pancreatic cancer cell line ASAN-PaCa, AsPC-1 and PANC-1 pancreatic cancer cell lines"	dexamethasone (DEX) treatment	downregulated	30387838
1405	Human	hsa-miR-132	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
1406	Human	hsa-miR-132	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	"TUG1 had a decreased expression in both periodontal ligament (PDL) tissues with periodontitis and PDLCs under a LPS-induced inflammatory condition, and TUG1 expression was negatively correlated with miR-132 expression in periodontitis-affected PDL tissues."	31735958
1407	Human	hsa-miR-132	miRNA	melatonin	primary biliary cholangitis (PBC)	H69 cells	melatonin treatment	downregulated	33352965
1408	Human	hsa-miR-132	miRNA	platelet-derived growth factor (PDGF)	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	platelet-derived growth factor treatment	upregulated	30896881
1409	Human	hsa-miR-132	miRNA	sevoflurane (SEV)	sevoflurane-induced neuronal apoptosis	human H4 neuroglioma cell line	sevoflurane treatment	downregulated	30272258
1410	Human	hsa-miR-132*	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
1411	Human	hsa-miR-132*	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
1412	Human	hsa-miR-1323	miRNA	¦Â-elemene	gastric cancer (GC)	SGC7901 cells	¦Â-Elemene treatment	downregulated	32199253
1413	Human	hsa-miR-1323	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8/SVneo cells; BeWo cells	high-glucose (HG) treatment	HG upregulated the miR-1323 expression and inhibited trophoblast cell viability.	33603839
1414	Human	hsa-miR-132-3p	miRNA	5-fluorouracil (5-Fu)	advanced colorectal cancer (CRC)	HCT-15 cells	5-fluorouracil (5-FU) treatment	"HF inhibited the proliferation, invasion and migration of HCT-15/FU cells by upregulating the expression levels of miR-132-3p."	33154782
1415	Human	hsa-miR-132-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	HPN; SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31898085
1416	Human	hsa-miR-132-3p	miRNA	berberine (BBR)	Alzheimer's disease (AD)	HPN; SK-N-SH cells	berberine (BBR) treatment	upregulated	31898085
1417	Human	hsa-miR-132-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
1418	Human	hsa-miR-132-3p	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
1419	Human	hsa-miR-132-3p	miRNA	influenza A virus (IAV)	innate immune response	peripheral blood samples from IAV patients and A549 cells	H1N1 influenza A virus (IAV) infection	upregulated	31746331
1420	Human	hsa-miR-132-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
1421	Human	hsa-miR-132-3p	miRNA	nephrotoxicants	kidney injury and fibrosis	Primary human proximal tubular epithelial cells (HPTECs)	nephrotoxicants treatment	upregulated	26707937
1422	Human	hsa-miR-132-3p	miRNA	liposomal bupivacaine (BUP)	neurotoxicity	SH-SY5Y cells	liposomal bupivacaine (BUP) treatment	upregulated	32335807
1423	Human	hsa-miR-132-3p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	whole-blood	methotrexate (MTX) treatment	downregulated	30511295
1424	Human	hsa-miR-132-3p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	RA patients whole-blood	methotrexate (MTX) treatment	upregulated	30511295
1425	Human	hsa-miR-132-5p	miRNA	candida albicans (C. albicans) and aspergillus fumigatus (A. fumigatus)	fungal infection	human monocyte-derived dendritic cells	6 and 12 h of infection with C. albicans and A. fumigatus as well as treatment with lipopolysaccharides (LPS)	dysregulated	28280489
1426	Human	hsa-miR-133	miRNA	hypoxia	cardiac fibrosis	human endothelial progenitor cell (EPC) and EPCs-derived exosomes	hypoxia induce	upregulated	31443679
1427	Human	hsa-miR-133	miRNA	nicotine	cardiomyocyte apoptosis	Human embryonic kidney cell line (HEK293)	nicotine treatment	downregulated	24190542
1428	Human	hsa-miR-133	miRNA	nicotine	cardiomyocyte apoptosis	human embryonic kidney cell line	nicotine treatment	downregulated	24190542
1429	Human	hsa-miR-133	miRNA	angiotensin-converting enzyme 2 (ACE2) inhibitor	cardiovascular disease (CVD)	H9c2 cardiac myoblast cells	ACE2 (angiotensin-converting enzyme 2) treatment	upregulated	26400542
1430	Human	hsa-miR-133	miRNA	neurotensin (NT)	colonic inflammation	HCT-116 cells	Neurotensin (NT) treatment	upregulated	25112884
1431	Human	hsa-miR-133	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human renal proximal tubular epithelial cell line human kidney-2 (HK-2)	high glucose (HG) treatment	upregulated	31858564
1432	Human	hsa-miR-133a	miRNA	brazilein	acoustic neuroma	The vestibular schwannoma (VS) cells	brazilein treatment	upregulated	30610843
1433	Human	hsa-miR-133a	miRNA	coronary artery bypass graft (CABG)	acute coronary syndrome (ACS)	acute coronary syndrome patients heart	CABG treatment	upregulated	29506853
1434	Human	hsa-miR-133a	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
1435	Human	hsa-miR-133a	miRNA	IL-13	asthma	human BSM cells (hBSMCs)	interleukin-13 (IL-13) treatment	the level of miR-133a was significantly decreased in BSMs of the diseased animals.	33132251
1436	Human	hsa-miR-133a	miRNA	high glucose (HG)	hyperglycemia-induced beta-cell dysfunction	human islet	?high glucose exposure	Prolonged high-glucose exposure down-regulates PTB levels and insulin biosynthesis rates in human islets by increasing miR-133a levels	20520763
1437	Human	hsa-miR-133a	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	airway epithelial cells of smokers	cigarette smoke (CS) exposure	upregulated	30341388
1438	Human	hsa-miR-133a	miRNA	bortezomib	congenital muscular dystrophy	congenital muscular dystrophy type 1A muscle cells	bortezomib? treatment	downregulated	24631023
1439	Human	hsa-miR-133a	miRNA	aortic valve replacement (AVR)	aortic stenosis	plasma	aortic valve replacement (AVR) treatmenr	upregulated	23948643
1440	Human	hsa-miR-133a	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
1441	Human	hsa-miR-133a	miRNA	paclitaxel (PTX)	esophageal squamous cell carcinoma (ESCC)	esophageal squamous cell carcinoma (ESCC) tissues	the patients received four cycles of paclitaxel-based chemotherapy treatment	downregulated	25280517
1442	Human	hsa-miR-133a	miRNA	ursolic acid (UA)	gastric cancer (GC)	BGC-823 cells	UA treatment	upregulated	26629938
1443	Human	hsa-miR-133a	miRNA	benzene	hematotoxicity	workers	benzene treatment	downregulated	26435271
1444	Human	hsa-miR-133a	miRNA	homocysteine (Hcy)	hyperhomocysteinemia (HHcy)	HL-1 cardiomyocytes	100 ¦ÌM homocysteine treatment	downregulated	24495916
1445	Human	hsa-miR-133a	miRNA	angiotensin II (Ang II)	hypertension	Human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	downregulated	31524252
1446	Human	hsa-miR-133a	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	downregulated	31926162
1447	Human	hsa-miR-133a	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	human lung fibroblasts (HFL)	transforming growth factor (TGF)-¦Â1 treatment	upregulated	31511493
1448	Human	hsa-miR-133a	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
1449	Human	hsa-miR-133a	miRNA	TGF-¦Â	liver fibrosis	hepatic stellate cells(HSC)	TGF-¦Â treatment	Treatment of primary murine and human HSC with transforming growth factor (TGF)-¦Â resulted in a significant downregulated of miR-133a in these cells	23183523
1450	Human	hsa-miR-133a	miRNA	matrine	lung cancer	NCI-H1299 cells	Matrine treatment	upregulated	26379863
1451	Human	hsa-miR-133a	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
1452	Human	hsa-miR-133a	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
1453	Human	hsa-miR-133a	miRNA	Vitamin K2	osteogenesis	human bone marrow stromal cells (hBMSCs)	Vitamin K2 treatment	downregulated	28447758
1454	Human	hsa-miR-133a	miRNA	astragalus polysaccharide (APS)	osteosarcoma (OS)	MG63 cells	astragalus polysaccharide (APS) treatment	APS enhanced the expression of miR-133a in MG63 cells.	30462772
1455	Human	hsa-miR-133a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
1456	Human	hsa-miR-133a	miRNA	normoxia	pancreatic cancer (PC)	"human PC cell lines PANC©\1, SW1990"	normoxia condition induce	downregulated	30693518
1457	Human	hsa-miR-133a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
1458	Human	hsa-miR-133a	miRNA	propofol (PPF)	pancreatic cancer (PC)	peripheral blood	Propofol treatment	upregulated	26214431
1459	Human	hsa-miR-133a	miRNA	lactoferrin (LF)	prostate cancer	DU-145 cells	lactoferrin (LF) treatment	upregulated	30285009
1460	Human	hsa-miR-133a	miRNA	¦Â-glycerophosphate (¦Â-GP)	prostate cancer	vascular smooth muscle cells (VSMCs)	?¦Â-glycerophosphate treatment	downregulated	23798596
1461	Human	hsa-miR-133a	miRNA	estrogen (ES)	pulmonary arterial hypertension (PAH)	human pulmonary smooth muscle cell (HPASMC)	estrogen (ES) treatment	upregulated	31562386
1462	Human	hsa-miR-133a	miRNA	20-hydroxyeicosatetraeonic acid (20-HETE)	pulmonary hypertension (PH)	vascular smooth muscle cell	20-Hydroxyeicosatetraeonic acid (20-HETE) treatment	downregulated	26921441
1463	Human	hsa-miR-133a	miRNA	endothelin-1 (ET-1)	renal cytotoxicity	human renal proximal tubule cells (RPTECs)	endothelin-1 (ET-1) treatment	upregulated	25871823
1464	Human	hsa-miR-133a	miRNA	artesunate (ART)	rhabdomyosarcoma (RMS)	ERMS cell lines	artesunate (ARS) treatment	downregulated	26153023
1465	Human	hsa-miR-133a	miRNA	high-intensity interval training (HIIT)	skeletal muscle adaptation	human	human treatment	downregulated	27101297
1466	Human	hsa-miR-133a	miRNA	nuclear factor 90 (NF90)-NF45 complex	skeletal muscle atrophy	Mouse myoblast C2C12 cells	nuclear factor 90 (NF90)-NF45 complex treatment	downregulated	25918244
1467	Human	hsa-miR-133a	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
1468	Human	hsa-miR-133a	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	human dermal fibroblasts (HDFs)	ultraviolet radiation (UVA) treatment	downregulated	30378537
1469	Human	hsa-miR-133a	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HAVSMC)	inorganic phosphate (Pi) treatment	downregulated	27419135
1470	Human	hsa-miR-133a-3p	miRNA	puerarin	breast cancer	HCC38 cells	Puerarin treatment	upregulated	30483784
1471	Human	hsa-miR-133a-3p	miRNA	IL-17A	asthma	human BSM cells (hBSMCs)	IL-17A treatment	upregulated	28267638
1472	Human	hsa-miR-133a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human VSMCs (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ_0010283 participated in ox-LDL-induced dysfunctions of HVSMCs by modulating the miR-133a-3p/PAPPA pathway.	33162460
1473	Human	hsa-miR-133a-3p	miRNA	puerarin	breast cancer	HCC38 cells	Puerarin treatment	upregulated	30483784
1474	Human	hsa-miR-133a-3p	miRNA	bufothionine	gastric cancer (GC)	MGC-803 cells; BGC-823 cells	bufothionine treatment	miR-133a-3p was upregulated by Bufothionine.	32758622
1475	Human	hsa-miR-133a-3p	miRNA	cigarette smoke extract (CSE)	oropharyngeal squamous cell carcinoma (OPSCC)	lymph node and serum	cigarette smoke extract (CSE) treatment	HPV(+) smokers exhibit lymph node metastasis and reduced miR-133a-3p in both lymph node and serum.	30289952
1476	Human	hsa-miR-133a-3p	miRNA	warfarin	 anticoagulation	Peripheral Blood Mononuclear Cells (PBMCs)	warfarin treatment	miR-133a-3p is involved in the coagulation pathway	29296264
1477	Human	hsa-miR-133a-5p	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	QSG-7701 cells	hypoxia condition for 15 h and then in reoxygenation condition for 6 h	downregulated	28198596
1478	Human	hsa-miR-133b	miRNA	thyroid hormone	hepatocellular carcinoma (HCC)	skeletal muscle	thyroid hormone (TH) treatment	downregulated	19567520
1479	Human	hsa-miR-133b	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	downregulated	29393545
1480	Human	hsa-miR-133b	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31572518
1481	Human	hsa-miR-133b	miRNA	dihydrotestosterone (DHT)	androgenetic alopecia (AGA)	human hair follicles (HFs)	dihydrotestosterone (DHT) treatment	upregulated	33290799
1482	Human	hsa-miR-133b	miRNA	KHCO3	bone resorption of alkali	human serum	potassium bicarbonate [(KHCO3); 81 mmol/d; n = 12] vs placebo (n = 12) for 84 days	upregulated in serum	29264553
1483	Human	hsa-miR-133b	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
1484	Human	hsa-miR-133b	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	SW 780 cells	cisplatin treatment	MST1P2 serves as a competing endogenous RNA for miR-133b to counteract miR-133b-induced suppression on Sirt1.	32052927
1485	Human	hsa-miR-133b	miRNA	¦Á-mangostin	colorectal cancer (CRC)	human colon cancer DLD-1 cell line	¦Á-mangostin treatment	downregulated	26304927
1486	Human	hsa-miR-133b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	"CASC2 upregulation suppressed HG-induced proliferation, ECM accumulation and oxidative stress of HMCs through miR-133b /FOXP1 regulatory axis."	32016985
1487	Human	hsa-miR-133b	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	miR-133b was highly expressed in TGF-¦Â1-treated HK-2 cells	30125566
1488	Human	hsa-miR-133b	miRNA	paclitaxel (PTX)	esophageal squamous cell carcinoma (ESCC)	esophageal squamous cell carcinoma (ESCC) tissues	the patients received four cycles of paclitaxel-based chemotherapy treatment	downregulated	25280517
1489	Human	hsa-miR-133b	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
1490	Human	hsa-miR-133b	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) tissues	criplatin (DPP) treatment	downregulated	29344640
1491	Human	hsa-miR-133b	miRNA	insulin-like growth factor 1 (IGF-1)	infertility	oocytes at MI stage were obtained from patients who received intra-cytoplasmic sperm injection (ICSI) ments	IGF-1 treatment	upregulated	24959893
1492	Human	hsa-miR-133b	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	upregulated	29899866
1493	Human	hsa-miR-133b	miRNA	opiate	neuroblastoma (NB)	neuroblastoma SH-SY5Y cell line	chronic opiate administration treatment	"low doses of morphine (10nM) reduced the expression levels of miR133b, higher doses (1¦ÌM) downregulated levels of miR133b and miR128"	24440526
1494	Human	hsa-miR-133b	miRNA	methadone	opioid use disorder (OUD)	blood	methadone treatment	downregulated	31349687
1495	Human	hsa-miR-133b	miRNA	hydrostatic pressure (HP)	osteogenesis	adipose-derived mesenchymal stem cells (AMSCs)	hydrostatic pressure (HP) treatment	miR-133b was downregulated during osteogenic differentiation of AMSCs.	32661199
1496	Human	hsa-miR-133b	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cell line	cisplatin treatment	upregulated	29399170
1497	Human	hsa-miR-133b	miRNA	procaine (PCA)	osteosarcoma (OS)	osteosarcoma MG63 cells	2 ¦ÌM PCA treatment	upregulated	28251881
1498	Human	hsa-miR-133b	miRNA	NaHS and l-cysteine	preeclampsia (PE)	human placenta	NaHS and l-cysteine treatment	upregulated	28454695
1499	Human	hsa-miR-133b	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
1500	Human	hsa-miR-133b	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
1501	Human	hsa-miR-133¦Á	miRNA	neurotensin (NT)	colonic inflammation	NCM-460	neurotensin (NT) treatment	upregulated	25112884
1502	Human	hsa-miR-133¦Á	miRNA	neurotensin (NT)	inflammatory bowel disease (IBD)	human colonocytes NCM460 cells	Neurotensin (NT) treatment	upregulated	26005712
1503	Human	hsa-miR-133¦Á	miRNA	neurotensin (NT)	neurotensin receptor 1 recycling	human NCM460 colonocytes	neurotensin (NT) treatment	upregulation	26902265
1504	Human	hsa-miR-134	miRNA	penicillin-binding protein?1A (PBP1A) mutation-positive H.?pylori (H.?pyloriCagA+/P+)	gastric cancer (GC)	SGC-7901 cells	penicillin-binding protein?1A (PBP1A) mutation-positive H.?pylori (H.?pyloriCagA+/P+)?infection treatment	downregulated	30569124
1505	Human	hsa-miR-134	miRNA	lambertianic acid (LA)	apoptosis	MCF-7 cells	lambertianic acid (LA) treatment	upregulated	31248140
1506	Human	hsa-miR-134	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
1507	Human	hsa-miR-134	miRNA	astragaloside IV (AS-IV)	colorectal cancer (CRC)	colorectal cancer cell line SW-480	astragaloside (AS-IV) treatment	upregulated	29041002
1508	Human	hsa-miR-134	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells	TGF-¦Â1 treatment	"the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2,"	24258346
1509	Human	hsa-miR-134	miRNA	propofol (PPF)	glioblastoma multiforme (GBM)	glioma U87 cells	?propofol treatment	"Compared with the blank group, the proliferation, invasion and migration capacity of U87 cells were reduced in the positive control group and the propofol groups after 48 hours (all?P<005), along with the decreased expression of Ki-67, MMP-2 and MMP-9 and the ratio of p-PI3K/PI3K and p-Akt/Akt (all?P<005), while the level of miR-134 was increased significantly"	33678632
1510	Human	hsa-miR-134	miRNA	pyrogallol	hepatocellular carcinoma (HCC)	Hep3B and Huh7 hepatocellular carcinoma cells	pyrogallol treatment	upregulated	31426282
1511	Human	hsa-miR-134	miRNA	TGF-¦Â1	liver fibrosis	immortalized human hepatic stellate cell line LX-2	TGF-¦Â1 treatment	downregulated	30645141
1512	Human	hsa-miR-134	miRNA	TGF-¦Â1	lung adenocarcinoma (LUAD)	human adenocarcinoma cell lines	transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment	upregulated	24258346
1513	Human	hsa-miR-134	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
1514	Human	hsa-miR-134	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
1515	Human	hsa-miR-134	miRNA	glargine	pancreatic cancer (PC)	pancreatic cancer cells	glargine treatment	upregulated	22690071
1516	Human	hsa-miR-134	miRNA	valproic acid (VPA)	temporal lobe epilepsy (TLE)	epilepsy patients	VPA treatment	downregulated	29069823
1517	Human	hsa-miR-134	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
1518	Human	hsa-miR-134-5p	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	AC16 cells; human cardiomyocytes (HCM)	hypoxia/reoxygenation (H/R) treatment	Expression of miR-134-5p was upregulated in serum of AMI patients and hypoxia/reoxygenation (H/R)-induced cardiomyocytes (AC16 and HCM).	32797709
1519	Human	hsa-miR-134-5p	miRNA	resveratrol	autism spectrum disorder (ASD)	peripheral blood	resveratrol (Res) treatment	downregulated	29510222
1520	Human	hsa-miR-134-5p	miRNA	cisplatin (DDP)	cervical cancer (CC)	Cervical cancer HeLa cells	cisplatin treatment	si-NCK1-AS1 and miR-134-5p mimic both reduced MSH2 activity and increased cisplatin-induced apoptosis in cervical cancer cells.	30221354
1521	Human	hsa-miR-134-5p	miRNA	high glucose (HG)	diabetes mellitus (DM)	Endothelial colony forming cells (ECFCs)	high glucose treatment	upregulated	26799933
1522	Human	hsa-miR-134-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes	high glucose (HG) treatment	miR-134-5p was upregulated in high-glucose (HG)-treated podocytes.	29636888
1523	Human	hsa-miR-134-5p	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	downregulated	29899866
1524	Human	hsa-miR-134-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"circDLGAP4 exerted its functions via regulating miR-134-5p, circDLGAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway both in human and mouse."	31761328
1525	Human	hsa-miR-134-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y Cells	1-methyl-4-phenylpyridinium (MPP+) treatment	miR-134-5p was verified to be increased in PD cell models.	31761328
1526	Human	hsa-miR-135	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	28484287
1527	Human	hsa-miR-135	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	tissue regeneration	Human adult DPSCs	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	26351742
1528	Human	hsa-miR-135a	miRNA	L©\arginine	acute edematous pancreatitis (AEP)	pancreatic acinar cell line (AR43J)	introperitoneal injection of L-arginine (150 mg/kg) treatment	upregulated	24710937
1529	Human	hsa-miR-135a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	25230140
1530	Human	hsa-miR-135a	miRNA	visfatin	acute myeloid leukemia (AML)	HL60 cells	visfatin treatment	downregulated	30876976
1531	Human	hsa-miR-135a	miRNA	prostaglandin E2 (PGE2)	Alzheimer's disease (AD)	human umbilical vein endothelial cells (HUVECs)	PGE2 treatment	upregulated	25554493
1532	Human	hsa-miR-135a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	atherosclerosis (AS)	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 knockdown suppresses inflammation and oxidative stress induced by oxidized low-density lipoprotein in macrophages by sponging miR-135a	33128668
1533	Human	hsa-miR-135a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33128668
1534	Human	hsa-miR-135a	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells; liver tissues	hepatitis C virus (HCV) infection	miR-135a hepatic abundance is upregulated by HCV infection in both cultured hepatocytes and human liver.	30456659
1535	Human	hsa-miR-135a	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Caco-2 and HT-29 cells	dextran sodium sulfate (DSS) treatment	downregulated	30476915
1536	Human	hsa-miR-135a	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
1537	Human	hsa-miR-135a	miRNA	paclitaxel (PTX)	prostate cancer	"Human prostate cancer cells (PC3, C4-2 and DU145)"	Paclitaxel treatment	downregulated of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a	31486484
1538	Human	hsa-miR-135a	miRNA	acute stress	stress response	mice amygdala	acute Stress treatment	downregulated	24023867
1539	Human	hsa-miR-135a*	miRNA	platinum	lung adenocarcinoma (LUAD)	LADC tissues	platinum-based doublet chemotherapy treatment	dysregulated	25142144
1540	Human	hsa-miR-135a*	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
1541	Human	hsa-miR-135a-3p	miRNA	tanshinone I and TRAIL	prostate cancer	"PC-3, M2182 and DU145 cells"	co- of Tanshinone I and TRAIL treatment	upregulated	25015549
1542	Human	hsa-miR-135a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-135a-5p was decreased in oxidized low-density lipoprotein (ox-LDL)-treated HUVECs.	31921409
1543	Human	hsa-miR-135a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (T/G HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	LINC00299 regulated ox-LDL-induced T/G HA-VSMCs injury through the miR-135a-5p/XBP1 axis.	32700888
1544	Human	hsa-miR-135a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33778018
1545	Human	hsa-miR-135a-5p	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	upregulated	32705273
1546	Human	hsa-miR-135b	miRNA	hypoxia	cell proliferation	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	30576641
1547	Human	hsa-miR-135b	miRNA	ligustrazine (Lig)	cell proliferation	hypoxia-induced human umbilical vein endothelial cells (HUVECs)	Ligustrazine (Lig) treatment	upregulated	30576641
1548	Human	hsa-miR-135b	miRNA	mesalazine (MSLZ)	colorectal cancer (CRC)	CaCo2 cell line	Mesalazine (5-ASA) treatment	downregulated	29794245
1549	Human	hsa-miR-135b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
1550	Human	hsa-miR-135b	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
1551	Human	hsa-miR-135b	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	29883713
1552	Human	hsa-miR-135b	miRNA	X-rays	improved radiosensitivity	NSCLC cell lines (A549 and H1975)	X-ray irradiation treatment	downregulated	28117028
1553	Human	hsa-miR-135b	miRNA	5-aza-2'-deoxycytidine and trichostatin A	leukemia	human leukemia cell lines	5-aza-deoxycytidine and trichostatin A treatment	upregulated	27570640
1554	Human	hsa-miR-135b	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
1555	Human	hsa-miR-135b	miRNA	morin	lung cancer	A549 cells	Morin treatment	downregulated	28975847
1556	Human	hsa-miR-135b	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
1557	Human	hsa-miR-135b	miRNA	transcriptional co-activator with PDZ-binding motif (TAZ)	osteosarcoma (OS)	U2OS and HOS cell lines	TAZ treatment	upregulated	28823959
1558	Human	hsa-miR-135b	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	31036506
1559	Human	hsa-miR-135b	miRNA	ligustrazine (Lig)	pressure ulcer (PU)	human umbilical vein endothelial cells (HUVECs)	ligustrazine (Lig) treatment	miR-135b was upregulated by the treatment of Lig.	30576641
1560	Human	hsa-miR-135b	miRNA	E. senticosus extract (ESE)	cell proliferation	normal human keratinocytes	normal human keratinocytes treatment	downregulated	27042261
1561	Human	hsa-miR-135b-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"In this study, ox-LDL inhibited circRSF1 and HDAC1 expression while upregulated miR-135b-5p expression in Human umbilical vein endothelial cells (HUVECs)."	33757583
1562	Human	hsa-miR-135b-5p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	downregulated	30665445
1563	Human	hsa-miR-135b-5p	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	downregulated	32362797
1564	Human	hsa-miR-135b-5p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"Human gastric cancer cell lines (MKN45, SNU601 and SNU1)"	Helicobacter pylori (H. pylori) infection	upregulated	29985646
1565	Human	hsa-miR-135b-5p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"Human gastric cancer cell lines (MKN45, SNU601 and SNU1)"	Helicobacter pylori infection	upregulated	29985646
1566	Human	hsa-miR-135b-5p	miRNA	sulforaphane (SFN)	pancreatic ductal adenocarcinoma (PDAC)	"The established human PDA cell lines AsPC-1, BxPC-3, PANC-1"	sulforaphane treatment	upregulated	31044154
1567	Human	hsa-miR-136	miRNA	platelet-derived growth factor (PDGF)	atherosclerosis (AS)	vascular smooth muscle cells	platelet-derived growth factor (PDGF) treatment	upregulated	25409743
1568	Human	hsa-miR-136	miRNA	TGF-¦Â1	skin wound healing	HaCaT cells	TGF-¦Â1 treatment	downregulated	25654102
1569	Human	hsa-miR-136	miRNA	hypoxia	spinal cord ischemia injury (SCII)	human neuronal cell line AGE1.NH	hypoxia for 3 day supplemented with 1% O2	upregulated	28753453
1570	Human	hsa-miR-136	miRNA	rapamycin complex (mTOR)	tuberous sclerosis complex (TSC)	serum	rapamycin complex (mTOR) treatment	upregulated	27680012
1571	Human	hsa-miR-136*	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
1572	Human	hsa-miR-136-3p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
1573	Human	hsa-miR-136-5p	miRNA	lipopolysaccharide (LPS)	LPS-induced inflammation and damage	ARPE-19 cells	lipopolysaccharide (LPS) treatment	"After the treatment of ripasudil, the expression levels of miR-136-5p was suppressed."	32252692
1574	Human	hsa-miR-136-5p	miRNA	ripasudil	LPS-induced inflammation and damage	ARPE-19 cells	ripasudil treatment	"After the treatment of ripasudil, the expression levels of ROCK1, ROCK2 and miR-136-5p were suppressed"	32252692
1575	Human	hsa-miR-136-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells; CFPAC-1 cells	gemcitabine treatment	"MicroRNA-136-5p can reduce the proliferation rate and metastasis ability of PCa cells via regulating ZNF32, and thus alleviates gemcitabine resistance in PCa cells."	33155203
1576	Human	hsa-miR-136-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
1577	Human	hsa-miR-137	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y and human primary neuron (HPN) cells	amyloid-¦Â (A¦Â) 25-35 treatment	"A¦Â25-35 inhibited cell viability, induced cell apoptosis and increased the expression of SNHG1 in SH-SY5Y and human primary neuron (HPN) cells."	31447119
1578	Human	hsa-miR-137	miRNA	hypoxia	apoptosis	human embryonic kidney 293 (HEK-293) cells	"5% O2, 90% N2 and 5% CO2,"	downregulated	29286063
1579	Human	hsa-miR-137	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
1580	Human	hsa-miR-137	miRNA	osteogenic differentiation medium	calcific aortic valve disease (CAVD)	valve interstitial cells (VICs) isolated from human calcific aortic valves	"a-minimal essential medium (Gibco, Carlsbad, CA, USA) containing 0.1% FBS, bioactive recombinant human bone morphogenetic protein-2 (BMP-2; 50 ng/mL), dexamethasone (100 nmol/L), ascorbic acid (50 mg/mL), and b-glycerophosphate (5 mmol/L) treatment"	upregulated	30846207
1581	Human	hsa-miR-137	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human renal mesangial cells (HRMCs)	high glucose treatment	downregulated	28695984
1582	Human	hsa-miR-137	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	high glucose-treated human renal mesangial cells (HRMCs)	triptolide (TPL) treatment	upregulated	28695984
1583	Human	hsa-miR-137	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HRMCs	high glucose treatment	downregulated	28695984
1584	Human	hsa-miR-137	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	HG-treat HRMCs	high glucose treatment	upregulated	28695984
1585	Human	hsa-miR-137	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
1586	Human	hsa-miR-137	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
1587	Human	hsa-miR-137	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	upregulated	29505767
1588	Human	hsa-miR-137	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8/SVneo cells	high glucose (HG) treatment	upregulated	29786111
1589	Human	hsa-miR-137	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	trophoblast cell line HTR-8/Svneo	high glucose (HG) treatment	upregulated	31109274
1590	Human	hsa-miR-137	miRNA	H2O2	glaucoma	RGCs	H2O2 treatment	We show that miR-137 was downregulated in H2O2-induced human trabecular meshwork cells (HTMCs)	33865939
1591	Human	hsa-miR-137	miRNA	phenformin	glioblastoma multiforme (GBM)	glioma stem cells (GSCs)	Phenformin treatment	upregulated	27486821
1592	Human	hsa-miR-137	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 and A172 cells	temozolomide (TMZ) treatment	downregulated	31750728
1593	Human	hsa-miR-137	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
1594	Human	hsa-miR-137	miRNA	olea europaea leaf extract (OLE)	glioblastoma multiforme (GBM)	GBM cell lines	olea europaea leaf extract (OLE) treatment	upregulation	25232498
1595	Human	hsa-miR-137	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251; A172 cells	temozolomide (TMZ) treatment	NCK1-AS1 could increase drug resistance of glioma cells to TMZ by modulating miR-137/TRIM24 pathway	31750728
1596	Human	hsa-miR-137	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	HEK293 cells	transfection with pHBV1.3	upregulated	29441983
1597	Human	hsa-miR-137	miRNA	aspirin	hepatocellular carcinoma (HCC)	Huh-7 cells	Aspirin treatment	upregulated	32627038
1598	Human	hsa-miR-137	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
1599	Human	hsa-miR-137	miRNA	propofol (PPF)	melanoma	Melanoma cells A2058 and WM793B	Propofol treatment	upregulated	31134615
1600	Human	hsa-miR-137	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC patient tissue samples	criplatin treatment	microRNA-137 in cisplatin-treated NSCLC patient tissue samples was markedly lower than that in healthy tissue samples.	30008879
1601	Human	hsa-miR-137	miRNA	oxaliplatin	oxaliplatin (L-OHP) resistance	HCT116; W480 cells	oxaliplatin (L-OHP) treatment	Silencing OIP5-AS1 reversed the resistance of CC cells to L-OHP by promoting the expression of miR-137	32308348
1602	Human	hsa-miR-137	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	PANC-1 cells; HS766T cells; AsPC-1 cells	cisplatin treatment	downregulated	32280243
1603	Human	hsa-miR-137	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation and migration	VSMCs cell lines (human aortic smooth muscle cells)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	29016699
1604	Human	hsa-miR-137	miRNA	bicalutamide	prostate cancer	human prostate cancer LNCaP cells	bicalutamide treatment	miR-137 modulate the response of human prostate cancer LNCaP cells to the antiandrogen bicalutamide.	31217891
1605	Human	hsa-miR-137	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
1606	Human	hsa-miR-138	miRNA	adipogenesis medium	adipogenesis	adipose tissue-derived mesenchymal stem cells (AMSCs)	adipogenic differentiation medium culture	downregulated	31769250
1607	Human	hsa-miR-138	miRNA	platelet-derived growth factor (PDGF)	bone homeostasis disorders	Multipotent mesenchymal stromal cells	PDGF treatment	upregulated	24792185
1608	Human	hsa-miR-138	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
1609	Human	hsa-miR-138	miRNA	hypoxia	tumorigenesis	EA.hy926 endothelial cells ATCC (CRL-2922)	?hypoxia treatment	upregulated	24244340
1610	Human	hsa-miR-138	miRNA	hypoxia	cardiac dysfunction	human cardiac cells	hypoxia treatment	downregulated	28899927
1611	Human	hsa-miR-138	miRNA	hypoxia	cardiomyocyte apoptosis	Myocardial samples of patients with congenital heart disease (CHD)	hypoxia treatment	upregulated	24211202
1612	Human	hsa-miR-138	miRNA	imatinib	chronic myeloid leukemia (CML)	K562 cells and primary CML samples	1 mmol/l imatinib for 24 or 48 h treatment	downregulated	23208504
1613	Human	hsa-miR-138	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cardiomyocytes	high glucose (HG) treatment	GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model	33682891
1614	Human	hsa-miR-138	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high-glucose (HG) treatment	upregulated	31251107
1615	Human	hsa-miR-138	miRNA	salidroside (SAL)	diabetic retinopathy (DR)	high-glucose (HG)-treated ARPE-19 cells	salidroside (SAL) treatment	downregulated	31251107
1616	Human	hsa-miR-138	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	LC006 cells; LC021 cells	TGF-¦Â1 treatment	"Among those dysregulated miRNAs, the expression of microRNA-138 was time-dependently downregulated by TGF¦Â1 treatment"	29407170
1617	Human	hsa-miR-138	miRNA	¦Á-solanine	esophageal cancer (EC)	human EC cells lines EC9706 and KYSE30	human EC cells lines EC9706 and KYSE30 treatment	upregulation	27536892
1618	Human	hsa-miR-138	miRNA	¦Á-solanine	esophageal squamous cell carcinoma (ESCC)	EC9706 and KYSE30 cells	¦Á-solanine treatment	upregulated	29328459
1619	Human	hsa-miR-138	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	T-cell	hepatitis B virus (HBV)?treatment	"We found that PD-1 was upregulated and miR-138 was downregulated in patients with CHB, LC, and HCC."	33410459
1620	Human	hsa-miR-138	miRNA	hepatitis B virus (HBV)	hepatoblastoma	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	30367502
1621	Human	hsa-miR-138	miRNA	resveratrol	low extremity deep vein thrombosis	Endothelial progenitor cells (EPCs)	resveratrol (Res) treatment	downregulated	29447140
1622	Human	hsa-miR-138	miRNA	"MS-275, a histone deacetylase inhibitor"	lung adenocarcinoma (LUAD)	A549 and HCC827 cell lines	MS-275 treatment	upregulated	31090206
1623	Human	hsa-miR-138	miRNA	¦Á-solanine	lung cancer	human lung adenocarcinoma cell lines (A549 and H1299)	human lung adenocarcinoma cell lines (A549 and H1299) treatment	upregulation	26631041
1624	Human	hsa-miR-138	miRNA	triptolide (TPL)	medulloblastoma	Daoy cells	triptolide (TPL) treatment	upregulated	30156009
1625	Human	hsa-miR-138	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
1626	Human	hsa-miR-138	miRNA	lentivirus	non-small cell lung cancer (NSCLC)	NSCLC cell lines H460 and SPC-A1 cells	Lentivirus treatment	upregulated	26201895
1627	Human	hsa-miR-138	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	human OA chondrocytes	"TNF¦Á for 3, 6, and 12 h treatment"	downregulated	28537665
1628	Human	hsa-miR-138	miRNA	"mechanical tension (10%, 0.5Hz)"	osteogenesis	human BMMSCs (hBMMSCs)	"mechanical tension (10%, 0.5Hz)"	downregulated	29253550
1629	Human	hsa-miR-138	miRNA	tension	osteogenic capability	Bone marrow mesenchymal stem cells (BMMSCs)	tension treatment	mechanical tension could suppress miR-138 expression	29253550
1630	Human	hsa-miR-138	miRNA	oestrogen (E2)	osteoporosis	HFOB and MG63 cells	oestrogen (E2) treatment	a dose-dependent upregulated of HOTAIR was observed in cells treated with oestrogen	33733597
1631	Human	hsa-miR-138	miRNA	curcumin (Cur)	osteosarcoma (OS)	human osteosarcoma cell line MG-63	curcumin treatment	upregulated	26823826
1632	Human	hsa-miR-138	miRNA	desflurane	ovarian cancer (OC)	SKOV3 cells	desflurane treatment	"miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane."	33673181
1633	Human	hsa-miR-138	miRNA	sevoflurane (SEV)	ovarian cancer (OC)	SKOV3 cells	sevoflurane treatment	"miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane"	33673181
1634	Human	hsa-miR-138	miRNA	lipopolysaccharide (LPS)	periodontal disease	periodontal progenitors	lipopolysaccharide (LPS) treatment	upregulated	26518300
1635	Human	hsa-miR-138	miRNA	¦Á-solanine	prostate cancer	human prostate cancer cell PC-3	¦Á-solanine treatment	upregulated	25116803
1636	Human	hsa-miR-138	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLS)	lipopolysaccharides (LPS) treatment	upregulated	31492495
1637	Human	hsa-miR-138	miRNA	cyanidin-3-glucoside (C3G)	triple negative breast cancer (TNBC)	TNBC lines MDA-MB-231 and BT-549	Cyanidin-3-glucoside (C3G) treatment	downregulated	30876970
1638	Human	hsa-miR-138-5p	miRNA	phenytoin	antiepileptic drug (AED) resistance	human brain microvascular endothelial cells (HBMECs)	phenytoin treatment	downregulated	31920517
1639	Human	hsa-miR-138-5p	miRNA	manganese chloride (MnCl2 )	autophagy	SH-SY5Y cells	manganese chloride (MnCl2 ) treatment	MnCl2 could induce autophagic dysregulation and inhibit expression of miR-138-5p.	30672645
1640	Human	hsa-miR-138-5p	miRNA	bruceine D (BD)	gastric cancer (GC)	HGC27 cells; MKN45 cells	bruceine D (BD) treatment	upregulated	33390953
1641	Human	hsa-miR-138-5p	miRNA	hypoxia	gastric cancer (GC)	SGC-7901; BGC-823	hypoxia treatment	downregulated	32425596
1642	Human	hsa-miR-138-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells; U87 cells	temozolomide (TMZ) treatment	LINC00174 downregulated decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis	31713817
1643	Human	hsa-miR-138-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	insulin resistance (IR)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30442237
1644	Human	hsa-miR-138-5p	miRNA	resolvin D1 (RvD1)	non small cell lung cancer (NSCLC)	"A549 cells, H1299 and LLC cells"	resolvin D1 (RvD1) treatment	upregulated	31783879
1645	Human	hsa-miR-138-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	MiR-138-5p was downregulated in CHON-001 cells.	31486753
1646	Human	hsa-miR-138-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells; A2780 cells	cisplatin treatment	miR-138-5p was downregulated in DDP-resistant cells.	32349783
1647	Human	hsa-miR-138-5p	miRNA	hypoxia	pancreatic cancer (PC)	"AsPC-1, BxPC-3, and PANC-1 cell lines"	hypoxia treatment	downregulated	28052003
1648	Human	hsa-miR-138-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31737212
1649	Human	hsa-miR-138-5p	miRNA	lipopolysaccharide (LPS)	preeclampsia (PE)	HTR-8/SVneo cells; JEG-3 cells	lipopolysaccharide (LPS) treatment	downregulated	33550900
1650	Human	hsa-miR-138-5p	miRNA	docetaxel (DTX)	prostate cancer	LNCaP and CWR22Rv1 cells	docetaxel (DTX) treatment	downregulated	30621625
1651	Human	hsa-miR-139	miRNA	hyperthermia	breast cancer	BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231	Hyperthermia treatment	downregulated	27380148
1652	Human	hsa-miR-139	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-139 was significantly downregulated whereas c-Jun was obviously upregulated after OGD/R treatment.	32807449
1653	Human	hsa-miR-139	miRNA	resveratrol	osteosarcoma (OS)	U20S and MG63 cells	resveratrol (RS) treatment	upregulated	31881225
1654	Human	hsa-miR-139	miRNA	a moderate-carbohydrate and high glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and high glycemic index diet	downregulated	29233589
1655	Human	hsa-miR-139	miRNA	low fat diet (LFD)	overweight and obese	plasma	low fat diet (LFD) treatment	downregulated in plasma	29233590
1656	Human	hsa-miR-139	miRNA	TGF-¦Â	scar formation after the glaucoma filtration surgery	human Tenon's fibroblasts (HTFs)	TGF-¦Â treatment	downregulated	30648255
1657	Human	hsa-miR-139-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
1658	Human	hsa-miR-139-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	downregulated	24589211
1659	Human	hsa-miR-139-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
1660	Human	hsa-miR-139-5p	miRNA	sevoflurane (SEV)	breast cancer	MDA-MB-231 and MCF-7 cells	sevoflurane (SEV) treatment	MiR-139-5p was upregulated in BC cells treated with SEV	33317757
1661	Human	hsa-miR-139-5p	miRNA	T-helper type 2 (Th2)-biased cytokine environment 	allergic asthma (AA)	Bronchial epithelial cells	T-helper type 2 (Th2)-biased cytokine environment treatment	downregulated	26289417
1662	Human	hsa-miR-139-5p	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	asthma	human airway smooth muscle cells	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	downregulated	28711603
1663	Human	hsa-miR-139-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human arterial smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33331071
1664	Human	hsa-miR-139-5p	miRNA	sevoflurane (SEV)	breast cancer	MCF-10A cells	Sevoflurane (SEV) treatment	MiR-139-5p was upregulated in BC cells treated with SEV	33317757
1665	Human	hsa-miR-139-5p	miRNA	high glucose (HG)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	miR-139-5p expression was elevated in human umbilical vein endothelial cells (HUVECs) cultured in high glucose media.	33293476
1666	Human	hsa-miR-139-5p	miRNA	ginsenoside Rg3	epithelial-mesenchymal transition (EMT)	iE-DAP-treated human umbilical vein endothelial cells (HUVEC)	Ginsenoside Rg3 (Rg3) treatment	upregulated	32148412
1667	Human	hsa-miR-139-5p	miRNA	¦Ã-d-glutamyl-meso-diaminopimelic acid (iE-DAP)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVEC)	¦Ã-d-glutamyl-meso-diaminopimelic acid (iE-DAP) treatment	downregulated	32148412
1668	Human	hsa-miR-139-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
1669	Human	hsa-miR-139-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
1670	Human	hsa-miR-139-5p	miRNA	particulate matter (PM2.5)	lung cancer	16HBE cells	PM2.5 stimulation treatment	downregulated	32913469
1671	Human	hsa-miR-139-5p	miRNA	ultraviolet (UV) irradiation	lupus erythematosus (LE)	HaCaT cells	30 mJ/cm2 UVB irradiation treatment	upregulated	31966801
1672	Human	hsa-miR-139-5p	miRNA	morphine	morphine addiction	HEK 293 cells	morphine treatment	Chronic morphine pretreatment alone elevated both c-Jun protein and miR-139-5p expression levels.	29916183
1673	Human	hsa-miR-139-5p	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	HNE1 cells	cisplatin (DPP) treatment	downregulated	29337244
1674	Human	hsa-miR-139-5p	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
1675	Human	hsa-miR-139-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
1676	Human	hsa-miR-139-5p	miRNA	hyaluronic acid (HA)	primary ovarian insufficiency (POI)	ovarian granulosa cells (GCs)	HA treatment	downregulated	25232020
1677	Human	hsa-miR-139-5p	miRNA	X-rays	prostate cancer	PC-3 cells; DU145 cells	X-ray radiation treatment	Knockdown of lncRNA TUG1 enhanced radiosensitivity in PCa via the TUG1/miR-139-5p/SMC1A axis	32256083
1678	Human	hsa-miR-1-3p	miRNA	PI3K/mTOR dual inhibitor BEZ235	acute myeloid leukemia (AML)	HL-60/VCR cells	BEZ235 treatment	upregulated	28042875
1679	Human	hsa-miR-1-3p	miRNA	hepatocyte growth factor (HGF)	lung cancer	lung cancer cells PC-9 and HCC-827	Hepatocyte growth factor (HGF) treatment	downregulated	29664235
1680	Human	hsa-miR-1-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
1681	Human	hsa-miR-1-3p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
1682	Human	hsa-miR-140	miRNA	lipopolysaccharide (LPS)	colorectal cancer (CRC)	SW480 cells; HCT116 cells	lipopolysaccharide (LPS) treatment	LPS could increase miR-140 expression in a time- and concentration-dependent manner.	31882548
1683	Human	hsa-miR-140	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	31362245
1684	Human	hsa-miR-140	miRNA	¦Á-Mangostin	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	¦Á-Mangostin treatment	H19 exerted its function via the modulation of H19/miR-140/HE4 in hyperglycemia with ¦Á-Mangostin	31362245
1685	Human	hsa-miR-140	miRNA	Bie Jia Jian Pill (BJJP)	hepatocellular carcinoma (HCC)	cancer stem cells (CSCs)	Bie Jia Jian Pill (BJJP) treatment	?BJJP or BMSCs treatment alone on CSCs lead to increased miR-140 expression and cell apoptosis	33632990
1686	Human	hsa-miR-140	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCC cells	hypoxia treatment	?NR2F1-AS1 level was enhanced in HCC tissues and cells.	33488124
1687	Human	hsa-miR-140	miRNA	lipopolysaccharide (LPS)	inflammation	CD14©\positive cells	lipopolysaccharides (LPS) treatment	downregulated	30321456
1688	Human	hsa-miR-140	miRNA	aucubin	intervertebral disc degeneration (IDD)	IL©\1¦Â or TNF©\¦Á-induced human nucleus pulposus cells (HNPCs)	aucubin treatment	upregulated	30637726
1689	Human	hsa-miR-140	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPCs)	IL-1¦Â treatment	downregulated	30637726
1690	Human	hsa-miR-140	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30637726
1691	Human	hsa-miR-140	miRNA	estradiol-17¦Â (E2)	menopausal arthritis	chondrocytes	estradiol-17¦Â (E2) treatment	upregulated	27165343
1692	Human	hsa-miR-140	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	NEAT1 and miR-140 are upregulated in hepacytes under the NAFLD conditions. The NEAT1-miR-140 axis play a crucial role in modulation of NAFLD via inactivation of AMPK/SREBP1 signaling.	31239155
1693	Human	hsa-miR-140	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	erlotinib-sensitive PC9 cells	TGF¦Â treatment	dysregulated	28646226
1694	Human	hsa-miR-140	miRNA	carnosic acid (CA)	osteoarthritis (OA)	human articular chondrocytes	Carnosic acid (CA) treatment	upregulated	29678719
1695	Human	hsa-miR-140	miRNA	IL-1¦Â	osteoarthritis (OA)	Human Chondrocytes	IL-1¦Â treatment	downregulated	31915516
1696	Human	hsa-miR-140	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	downregulated	32520081
1697	Human	hsa-miR-140	miRNA	IL-1¦Â	osteoarthritis (OA)	human cartilage cells line C28/I2	IL-1¦Â treatment	Expression of miRNA-140 and MMP-13 was elevated in IL-1b-stimulated C28/I2 cells	22273691
1698	Human	hsa-miR-140	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
1699	Human	hsa-miR-140	miRNA	melatonin	osteoarthritis (OA)	Human Chondrocytes	melatonin treatment	upregulated	31915516
1700	Human	hsa-miR-140	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
1701	Human	hsa-miR-140	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
1702	Human	hsa-miR-140	miRNA	insulin	polycystic ovarian syndrome (PCOS)	human granulosa cells (GCs)	insulin treatment	High miR-140 expression was observed in insulin-treated granulosa cells compared to that in unstimulated cells.	32024547
1703	Human	hsa-miR-140	miRNA	TGF-¦Â1	lung fibrosis	HBE and A549 cells	TGF-¦Â1 treatment	H19 knockdown attenuated pulmonary fibrosis via the regulatory network of lncRNA H19-miR-140-TGF-¦Â/Smad3 signaling	30988156
1704	Human	hsa-miR-140-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	"Human retinal vascular endothelial cells (HRVECs), human umbilical vein endothelial cells (HUVECs), human coronary artery endothelial cells (HCAECs) and human coronary artery endothelial cells (EA.hy.926)"	high glucose treatment	downregulated	30862410
1705	Human	hsa-miR-140-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	Loss of circRNA_0084043 depressed HG-induced damage via sponging miR-140-3p and regulating TGFA.	32259630
1706	Human	hsa-miR-140-3p	miRNA	astragaloside IV (AS-IV)	endothelial dysfunction	Oxidized low-density lipoprotein (ox-LDL)-treated human umbilical vein endothelial cells (HUVECs)	astragaloside IV (AS-IV) treatment	upregulated	31257467
1707	Human	hsa-miR-140-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31257467
1708	Human	hsa-miR-140-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (H/R) induce	downregulated	31792649
1709	Human	hsa-miR-140-3p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
1710	Human	hsa-miR-140-3p	miRNA	epigallocatechin-3-gallate (EGCG)	osteoarthritis (OA)	interleukin-1¦Â-stimulated human osteoarthritis chondrocytes	EGCG	downregulated	28110479
1711	Human	hsa-miR-140-3p	miRNA	epigallocatechin-3-gallate (EGCG)	osteoarthritis (OA)	human chondrocytes	Epigallocatechin-3-O-gallate (EGCG) treatment	EGCG inhibited IL-1¦Â-induced ADAMTS5 expression and upregulated the expression of hsa-miR-140-3p.	28110479
1712	Human	hsa-miR-140-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
1713	Human	hsa-miR-140-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-8¦Â treatment	dysregulated	29123165
1714	Human	hsa-miR-140-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 chondrocyte cells	IL-1¦Â treatment	MiR-140-3p Ameliorates the Progression of Osteoarthritis via Targeting CXCR4.	32101839
1715	Human	hsa-miR-140-3p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	downregulated	27018851
1716	Human	hsa-miR-140-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	asthma	human airway smooth muscle cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	22773691
1717	Human	hsa-miR-140-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	30344669
1718	Human	hsa-miR-140-5p	miRNA	particulate matter (PM2.5)	airway inflammation	16HBE cells	fine particulate matter (PM2.5) exposure treatment	MiR-140-5p/TLR4 /NF-¦ÊB signaling pathway: Crucial role in inflammatory response in 16HBE cells induced by dust fall PM 25	33080424
1719	Human	hsa-miR-140-5p	miRNA	particulate matter (PM2.5)	airway inflammation	human bronchial epithelial cells (16HBE)	fine particulate matter (PM2.5) exposure treatment	"In conclusion, this study revealed a new mechanism by which the miR-140-5p/TLR4 signaling pathway mediated the inflammatory response of 16HBE cells induced by PM25"	33080424
1720	Human	hsa-miR-140-5p	miRNA	simvastatin	breast cancer	MDA-MB-231 cells	Simvastatin treatment	upregulated	31138773
1721	Human	hsa-miR-140-5p	miRNA	hypoxia	cerebral ischemia injury (CII)	HUVECs	hypoxia treatment	downregulated	27035554
1722	Human	hsa-miR-140-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	downregulated	32073611
1723	Human	hsa-miR-140-5p	miRNA	high glucose (HG)	diabetic-associated vascular injury	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	High glucose (HG) exposure downregulated the expression of circ_CLASP2 in HUVECs	33776760
1724	Human	hsa-miR-140-5p	miRNA	propofol (PPF)	gastric cancer (GC)	SGC-7901 and MKN45 cells	propofol?treatment treatment	upregulated	31819507
1725	Human	hsa-miR-140-5p	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
1726	Human	hsa-miR-140-5p	miRNA	catalpol	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells	catalpol treatment	Catalpol increased the expression levels of E-cadherin and miR-140-5p.	33179108
1727	Human	hsa-miR-140-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2/SOR cell line	sorafenib treatment	"miR-140-5p overexpression also increases the sensitivity of HepG2/SOR cells to sorafenib, and the effects of SNHG16 knockdown on sorafenib resistance could be blocked by miR-140-5p inhibitor"	30655679
1728	Human	hsa-miR-140-5p	miRNA	TGF-¦Â1	hepatocellular carcinoma (HCC)	MHCC-97H and SMMC-7721 cells	TGF¦Â1 treatment	downregulated	31402791
1729	Human	hsa-miR-140-5p	miRNA	simvastatin	hypercholesterolemia	HepG2 cells; LO2 cells	simvastatin treatment	"Palmitic acid and simvastatin suppressed, whereas LDL-C upregulated the expression of miR-140-5p in HepG2 cells"	32109664
1730	Human	hsa-miR-140-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
1731	Human	hsa-miR-140-5p	miRNA	hypoxia	hypoxic brain injury	SH-SY5Y cells	hypoxia treatment	"LncRNA SNHG1-modulated miR-140-5p inhibition regulates Bcl-XL expression, thereby reducing cell apoptosis and recovering cell viability of SH-SY5Y cells."	32186226
1732	Human	hsa-miR-140-5p	miRNA	oxygen glucose deprivation (OGD)	hypoxic brain injury	SH-SY5Y cells	Oxygen glucose deprivation (OGD) treatment	Oxygen glucose deprivation (OGD) treatment inhibited SNHG1 and Bcl-XL expression and enhanced miR-140-5p expression	32186226
1733	Human	hsa-miR-140-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	lipopolysaccharides (LPS) treatment	downregulated	29901170
1734	Human	hsa-miR-140-5p	miRNA	pioglitazone	metabolic syndrome	endothelial progenitor cells (EPCs)	Pioglitazone treatment	downregulated	26898430
1735	Human	hsa-miR-140-5p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC cell lines (A549 and H1299)	cisplatin treatment	downregulated	31288529
1736	Human	hsa-miR-140-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteoarthritis (OA)	OA chondrocytes and synoviocytes	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31077718
1737	Human	hsa-miR-140-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	The normal human chondrocytes C28/I2	IL-1¦Â treatment	downregulated	31712854
1738	Human	hsa-miR-140-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes C28/I2	IL-1¦Â treatment	upregulated	31712854
1739	Human	hsa-miR-140-5p	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cell lines PANC-1 and BxPC-3	Metformin treatment	dysregulated	28875433
1740	Human	hsa-miR-140-5p	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	The human renal epithelial cells (294T cells)	metformin treatment	differently regulated in circulating	24478399
1741	Human	hsa-miR-141	miRNA	ultraviolet (UV) irradiation	DNA damage	U2OS;EH1; EH2 cell lines	ultraviolet light treatment	upregulated	24163379
1742	Human	hsa-miR-141	miRNA	esomeprazole	adeno and squamous-cell-carcinoma	human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines	esomeprazole treatment	upregulated	25175076
1743	Human	hsa-miR-141	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
1744	Human	hsa-miR-141	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	26823756
1745	Human	hsa-miR-141	miRNA	influenza A virus (IAV)	avian influenza virus (AIV) infection	NCI-H292 cells	avian influenza viruses treatment	the modulation of TGF-¦Â2 expression by different influenza subtypes via miR-141 might be a critical step for determining the outcome of either normal or excessive inflammation progression	23663545
1746	Human	hsa-miR-141	miRNA	arsenic trioxide (ATO)	breast cancer	MDA-MB-231 cells	arsenic trioxide (As2O3) treatment	upregulated	24729530
1747	Human	hsa-miR-141	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 breast cancer cells	Glabridin treatment	upregulated	24754877
1748	Human	hsa-miR-141	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
1749	Human	hsa-miR-141	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
1750	Human	hsa-miR-141	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
1751	Human	hsa-miR-141	miRNA	decabromodiphenyl ether (BDE-209)	cardiovascular disease (CVD)	THP-1 monocytes to human aortic endothelial cells (HAECs)	decabromodiphenyl ether (BDE-209) treatment	downregulated	30419430
1752	Human	hsa-miR-141	miRNA	decabromodiphenyl ether (BDE-209)	cardiovascular disease (CVD)	human aortic endothelial cells (HAECs)	decabromodiphenyl ether (BDE-209) treatment	downregulated	30419430
1753	Human	hsa-miR-141	miRNA	paeonol (PAE)	chondrosarcoma	human chondrosarcoma cell line JJ012	paeonol treatment	upregulated	24992595
1754	Human	hsa-miR-141	miRNA	leukemia inhibitory factor(LIF)	choriocarcinoma	JEG-3 cells	leukemia inhibitory factor(LIF) treatment	downregulated	21726338
1755	Human	hsa-miR-141	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 119 cells	RM (Root methanol) treatment	upregulated	32691634
1756	Human	hsa-miR-141	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	The results showed that SNHG15 was remarkably upregulated in pediatric DN tissues and HG-induced HGMCs.	33506255
1757	Human	hsa-miR-141	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
1758	Human	hsa-miR-141	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-141 towards the control level.	32387379
1759	Human	hsa-miR-141	miRNA	decitabine	gastric cancer (GC)	SGC-7902 cells	decitabine treatment	upregulated	25502084
1760	Human	hsa-miR-141	miRNA	decitabine	gastric cancer (GC)	SGC-7901 cells	the chemotherapeutic agent decitabine treatment	upregulated	25502084
1761	Human	hsa-miR-141	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	people	Helicobacter pylori infected treatment	downregulated	24732377
1762	Human	hsa-miR-141	miRNA	TGF-¦Â	gastric cancer (GC)	SGC-7902 cells	TGF-¦Â treatment	downregulated	25502084
1763	Human	hsa-miR-141	miRNA	high glucose (HG)	hepatic steatosis	HepG2 cells	high glucose (HG) treatment	upregulated	31256424
1764	Human	hsa-miR-141	miRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	5-fluorouracil (5-FU) treatment	miR-141 was sig- nificantly increased in 5-FU-resistant HCC cells.	30119680
1765	Human	hsa-miR-141	miRNA	lipopolysaccharide (LPS)	infantile pneumonia (IP)	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	30500550
1766	Human	hsa-miR-141	miRNA	lipopolysaccharide (LPS)	inflammation	WI-38 fibroblasts	lipopolysaccharides (LPS) treatment	downregulated	30500550
1767	Human	hsa-miR-141	miRNA	TGF-¦Â1	liver fibrosis	LX2 cells	TGF-¦Â1 treatment	downregulated of miR-141 deactivates hepatic stellate cells by targeting the PTEN/AKT/mTOR pathway	32319536
1768	Human	hsa-miR-141	miRNA	arsenite	melanoma	human keratinocyte HaCaT cell line	arsenic (As) exposure	upregulated	27054085
1769	Human	hsa-miR-141	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
1770	Human	hsa-miR-141	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose treatment	upregulated	31256424
1771	Human	hsa-miR-141	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	erlotinib-sensitive PC9 cells	TGF¦Â treatment	dysregulated	28646226
1772	Human	hsa-miR-141	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-19B cells	human papillomaviruses (HPVs) 19 treatment	downregulated	31911577
1773	Human	hsa-miR-141	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	miR-141 expression was low in LPS-induced MRC-5 cells.	32317619
1774	Human	hsa-miR-141	miRNA	hypoxia	preeclampsia (PE)	HTR-8/SVneo cells	hypoxia induce	upregulated	31004838
1775	Human	hsa-miR-141	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (hPASMCs)	hypoxia treatment	The miR-141 expression was decreased under hypoxia culture.	32559140
1776	Human	hsa-miR-141	miRNA	honokiol	renal cell carcinoma (RCC)	A-498 cell line	honokiol treatment	upregulated	24810210
1777	Human	hsa-miR-141	miRNA	ginsenoside Rh3	retinal injury	ARPE-19 cells; retinal ganglion cells (RGCs)	ginsenoside Rh3 treatment	Rh3 dose-dependently increased expression of miR-141.	29427790
1778	Human	hsa-miR-141	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
1779	Human	hsa-miR-141	miRNA	p16 INK4A	cell senescence	human fibroblast and epithelial cells	p16 INK4A treatment	upregulated	27596953
1780	Human	hsa-miR-141-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 enhanced the progression of AS in vitro by regulating the miR-141-3p/ROR2 axis.	32565910
1781	Human	hsa-miR-141-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-141-3p was decreased in oxidized low-density lipoprotein (ox-LDL)-treated human vascular smooth muscle cells (VSMCs)	33818249
1782	Human	hsa-miR-141-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells	high glucose	upregulated	29246323
1783	Human	hsa-miR-141-3p	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	human mesangial cells	triptolide (TPL) treatment	downregulated	29246323
1784	Human	hsa-miR-141-3p	miRNA	trans-nonachlor (TNC)	melanoma	melanoma cell lines	trans-nonachlor (TNC) treatment	downregulated	27616325
1785	Human	hsa-miR-141-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	Long non-coding RNA SNHG15 is a competing endogenous RNA of miR-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression	32247266
1786	Human	hsa-miR-141-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
1787	Human	hsa-miR-141-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	"SNHG16 and sushi domain containing 2 (SUSD2) were upregulated, and miRNA (miR)-141-3p was downregulated in the serum of acute pneumonia patients and lipopolysaccharide (LPS)-challenged human lung fibroblasts WI-38."	33836533
1788	Human	hsa-miR-141-3p	miRNA	hypoxia	preeclampsia (PE)	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	MiR-141-3p expression was upregulated in the HUVECs isolated from PE tissues and hypoxia-induced HUVECs.	33631423
1789	Human	hsa-miR-141-3p	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	transforming growth factor (TGF)-¦Â1 treatment	downregulated	33135476
1790	Human	hsa-miR-141-3p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	synovial fibroblasts (SFs)	lipopolysaccharide (LPS) treatment	miR-141-3p was significantly decreased at the gene level ln LPS induced SFs.	32373221
1791	Human	hsa-miR-141-3p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
1792	Human	hsa-miR-141-5p	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
1793	Human	hsa-miR-141-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	peripheral blood cells	imatinib treatment	miR-141-5p was remarkably elevated in patients after treatment with imatinib.	32038235
1794	Human	hsa-miR-141-5p	miRNA	nilotinib	chronic myeloid leukemia (CML)	peripheral blood cells	nilotinib treatment	miR-141-5p was remarkably elevated in patients after treatment with nilotinib.	32038235
1795	Human	hsa-miR-141-5p	miRNA	lectin	prostate cancer	Prostate cancer (PC) cell lines	lectin treatment	upregulated	26417675
1796	Human	hsa-miR-142	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	chronic periodontitis	human gingival epithelial cells (hGECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28123644
1797	Human	hsa-miR-142	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HCC cell lines HepG2 and SMMC7721	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28963738
1798	Human	hsa-miR-142	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; Hcc827 cells; lung adenocarcinoma (LAD) tissues	cisplatin treatment	downregulated	33416094
1799	Human	hsa-miR-142	miRNA	hypoxia	pancreatic cancer (PC)	human PC cell lines PANC©\1;SW1990	hypoxic condition induce	"In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1¦Á axis under hypoxic condition."	30693518
1800	Human	hsa-miR-142	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	lung fibrosis	"The OHS cell line (IOR/OS14, IOR/OS10, IOR/SARG and IOR/MOS) and cell lines HOS, U-2 OS, MG-63 ;K562 leukemia cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	mir-142 is epigenetically repressed by DNA methylation	24236112
1801	Human	hsa-miR-142-3p	miRNA	respected serum exosomes	acute cellular rejection	human Umbilical Vein Endothelial Cells (HUVECs)	respected serum exosomes treatment	upregulated	28073833
1802	Human	hsa-miR-142-3p	miRNA	bone morphogenetic protein 7 (BMP7)	apoptosis	HA-VSMCs	bone morphogenetic protein 7 (BMP7) treatment	upregulated	29435112
1803	Human	hsa-miR-142-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-142-3p expression was substantially upregulated during the ox-LDL-elicited apoptosis in HAECs.	29949787
1804	Human	hsa-miR-142-3p	miRNA	macrophage migration inhibitory factor (MIF)	cardioprotective therapy	human adipose-derived MSCs (ADMSCs); Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes	macrophage migration inhibitory factor (MIF) treatment	LncRNA-NEAT1/miR-142-3p/FOXO1 at least partially mediates the cardioprotective roles of exosomeMIF in protecting cardiomyocytes from apoptosis.	31964409
1805	Human	hsa-miR-142-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	downregulated	31722571
1806	Human	hsa-miR-142-3p	miRNA	aspergillus fumigatus (A. fumigatus)	cell activation	CD4+?T cells	"CD4+ T cells were activated by co-culturing with dendritic cells (DCs), which were pre-treated with AFE"	"Forced expression of miRNA-142-3P dramatically suppressed RICTOR levels, phosphorylated AKT and IFN-¦Ã in AFE activated T cells."	31930050
1807	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	cell death	The dermal microvascular endothelial cells (HMVEC-D)£» the human skin fibroblasts (ATCC)£»breast cancer cell line MCF7£» prostate cancer cell line PC-3	lipopolysaccharide (LPS) treatment	miR-142-3p in regulating DC responses to LPS	21474672
1808	Human	hsa-miR-142-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	HA-VSMCs	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	29435112
1809	Human	hsa-miR-142-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	neuronal cell line SH-SY5Y	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31863884
1810	Human	hsa-miR-142-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-142-3p expression was decreased after OGD/R induction.	31863884
1811	Human	hsa-miR-142-3p	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	downregulated	20460641
1812	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	downregulated	32269710
1813	Human	hsa-miR-142-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
1814	Human	hsa-miR-142-3p	miRNA	antrodia cinnamomea	colorectal cancer (CRC)	"The human colon cancer cell lines (SW480, SW620 and HCT116)"	antrodia cinnamomea treatment	upregulated	31349708
1815	Human	hsa-miR-142-3p	miRNA	trichosanthes kirilowii extract (TKE)	DNA damage	HaCaT cells	Trichosanthes kirilowii extract (TKE) treatment	"TKE significantly upregulated the expression of the core clock protein, brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein-1 (BMAL1), and downregulated the expression of miRNA (miR)-142-3p"	29115465
1816	Human	hsa-miR-142-3p	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
1817	Human	hsa-miR-142-3p	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
1818	Human	hsa-miR-142-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	Sorafenib treatment	downregulated	29472524
1819	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	hirschsprung's disease (HSCR)	human 293T cells	lipopolysaccharides (LPS) treatment	downregulated	29956457
1820	Human	hsa-miR-142-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
1821	Human	hsa-miR-142-3p	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
1822	Human	hsa-miR-142-3p	miRNA	FTY-720	leukemia	OCI-AML3 cells	FTY-720 treatment	downregulated	24858343
1823	Human	hsa-miR-142-3p	miRNA	licochalcone A (LA)	melanoma	A375 cells	licochalcone A (LCA) treatment	MiR- 142-3p level was significantly upregulated in LCA-treated A375 cells in a time- and dose-dependent manner.	31793097
1824	Human	hsa-miR-142-3p	miRNA	licochalcone A (LA)	melanoma	A375 and B16 melanoma cells	Licochalcone A (LCA) treatment	upregulated	31793097
1825	Human	hsa-miR-142-3p	miRNA	autologous hematopoietic SCT(AHSCT)	multiple sclerosis (MS)	MS patients	AHSCT treatment	upregulated in T- and B-cell	25486582
1826	Human	hsa-miR-142-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
1827	Human	hsa-miR-142-3p	miRNA	high glucose (HG)	cardiac fibrosis	primary human aortic endothelial cells (HAECs)	high glucose (HG) treatment	MiR-142-3p screened by miRNA microarray was significantly downregulated in HAECs under HG stimulation in a dose and time dependent manner.	31938215
1828	Human	hsa-miR-142-3p	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
1829	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human chondrocytes	lipopolysaccharide (LPS) treatment	downregulated	31836002
1830	Human	hsa-miR-142-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	"Pancreatic cancer cell lines including AsPC-1, HPAC, BxPC-3, and PANC-1"	gemcitabine treatment	knock-down of SBF2-AS1 inhibits the expression of TWF1 by competitively binding with miR-142-3p to induce gemcitabine resistance in pancreatic cancer.	31619579
1831	Human	hsa-miR-142-3p	miRNA	triptolide and quercetin	pancreatic ductal adenocarcinoma (PDAC)	MIA PaCa-2; Capan-1; HEK-293 lines ;S2-013 cells	triptolide and quercetin treatment	upregulated	23635652
1832	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	primary human periodontal ligament cells (PDLC	lipopolysaccharide (LPS) treatment	upregulated of lncRNA FGD5-AS1 could protect against periodontitis via regulating the miR-142-3p/SOCS6/NF-¦ÊB signals.	31144533
1833	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	Human rheumatoid fibroblast-like synoviocytes (MH7?A)	lipopolysaccharide (LPS) treatment	downregulated	31022596
1834	Human	hsa-miR-142-3p	miRNA	salvianolic acid B (Sal B)	rheumatoid arthritis (RA)	LPS-treated Human rheumatoid fibroblast-like synoviocytes (MH7?A)	salvianolic acid B (Sal B) treatment	upregulated	31022596
1835	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	sepsis	Neonatal Polymorphonuclear Leukocytes	lipopolysaccharide (LPS) treatment	dysregulated	28655995
1836	Human	hsa-miR-142-3p	miRNA	Trichosanthes kirilowii extract (TKE)	skin diseases	human keratinocytes	TKE treatment	downregulated	29115465
1837	Human	hsa-miR-142-3p	miRNA	mycophenolic acid (MPA)	systemic lupus erythematosus (SLE)	lupus CD4(+)T cells	Mycophenolic acid (MPA) treatment	upregulated	25661834
1838	Human	hsa-miR-142-3p	miRNA	curcumin (Cur)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	curcumin treatment	curcumin suppressed p300/miR-142-3p/PSMB5 axis leading to the inhibition of the CT-l activity of 20S proteasome.	32866906
1839	Human	hsa-miR-142-3p	miRNA	rapamycin complex (mTOR)	tuberous sclerosis complex (TSC)	serum	rapamycin complex (mTOR) treatment	upregulated	27680012
1840	Human	hsa-miR-142-5p	miRNA	CoCl2	acute kidney injury (AKI)	HK-2 cells	CoCl2 treatment	downregulated of XIST ameliorates acute kidney injury by sponging miR-142-5p and targeting PDCD4.	32347551
1841	Human	hsa-miR-142-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	28769761
1842	Human	hsa-miR-142-5p	miRNA	amyloid-¦Â (A¦Â) 42	Alzheimer's disease (AD)	HN cells	amyloid-¦Â (A¦Â) 42 treatment	Berberine attenuates A¦Â42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells	32251633
1843	Human	hsa-miR-142-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	peripheral blood; bone marrow	imatinib treatment	miR-365a-3p showing the most significant downregulated in non-responders treatment by imatinib.	32999756
1844	Human	hsa-miR-142-5p	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	downregulated	31226416
1845	Human	hsa-miR-142-5p	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	upregulated	31226416
1846	Human	hsa-miR-142-5p	miRNA	rotavirus (RV)	colorectal cancer (CRC)	colon cancer cells	rotavirus (SA11 or KU)treatment treatment	upregulated	26572508
1847	Human	hsa-miR-142-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cell (HREC)	high glucose (HG) treatment	miR-142-5p level was downregulated in high glucose (HG)-treated HRECs.	32116075
1848	Human	hsa-miR-142-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec3A cells	Progesterone treatment	upregulated	22543862
1849	Human	hsa-miR-142-5p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
1850	Human	hsa-miR-142-5p	miRNA	triptolide (TPL)	multiple myeloma (MM)	the dexamethasone-sensitive MM.1S human MM cell line	triptolide (TPL)? treatment	downregulated	22260163
1851	Human	hsa-miR-142-5p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
1852	Human	hsa-miR-142-5p	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose (HG) treatment	upregulated	31889412
1853	Human	hsa-miR-142-5p	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG3 cells	high glucose (HG) treatment	upregulated	31889412
1854	Human	hsa-miR-142-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 cells	IL-1¦Â treatment	miR-142-5p was downregulated in IL-1¦Â-treated chondrocytes.	31903636
1855	Human	hsa-miR-142-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	"CircSEC24A and SOX5 expression were enhanced, while miR-142-5p level was reduced in OA cartilage tissues and chondrocytes."	33751650
1856	Human	hsa-miR-142-5p	miRNA	SDF-1	osteoarthritis (OA)	primary human OA chondrocytes	SDF-1 treatment	miR-142-5p as a CXCR4-Targeted MicroRNA Attenuates SDF-1-Induced Chondrocyte Apoptosis and Cartilage Degradation via Inactivating MAPK Signaling Pathway	32047668
1857	Human	hsa-miR-142-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	"OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells"	cisplatin treatment	"in OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells, overexpression or inhibition of miR-142-5p increased or suppressed their sensitivities to cisplatin respectively."	30639456
1858	Human	hsa-miR-142-5p	miRNA	neurofibromatosis type 1 (NF1)	ovarian cancer (OC)	OVCAR3 and SKOV3 cells	Neurofibromatosis type 1 (NF1) deficiency	downregulated	30543142
1859	Human	hsa-miR-142-5p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
1860	Human	hsa-miR-142-5p	miRNA	rotavirus (RV)	rotavirus (RV) infection	blood	rotavirus (SA11 or KU) infection treatment	upregulated	26572508
1861	Human	hsa-miR-142-5p	miRNA	sulforaphane (SFN)	staphylococcus aureus infection	THP-1 cells	sulforaphane (SFN) treatment	SFN pretreatment of the THP-1-derived macrophages significantly attenuated the S aureus-mediated increased expression levels of miR-142-5p	32323751
1862	Human	hsa-miR-142-5p	miRNA	mycophenolic acid (MPA)	systemic lupus erythematosus (SLE)	lupus CD4(+)T cells	Mycophenolic acid (MPA) treatment	upregulated	25661834
1863	Human	hsa-miR-142-5p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
1864	Human	hsa-miR-142-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	HT-29 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TUG1 negatively regulated inflammation in ulcerative colitis through miR-142-5p/SOCS1 axis	32173492
1865	Human	hsa-miR-142-5p	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	Human umbilical cord mesenchymal stem cells (hUCMSCs)	Zika virus (ZIKV) infection treatment	miR-142-5p was significantly downregulated upon ZIKV infection	32902370
1866	Human	hsa-miR-143	miRNA	IFN-¦Â	asthma	airway smooth muscle (ASM)	IFN-beta? treatment	upregulated	20382746
1867	Human	hsa-miR-143	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	Human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	31607223
1868	Human	hsa-miR-143	miRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	U937 cells; HL60 cells	cytarabine treatment	MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.	33077697
1869	Human	hsa-miR-143	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	"miR-143 regulation of IL-13-induced inflammatory cytokine and mucus production in NECs from AR patients probably partly depends on inhibition of IL13R¦Á1. Therefore, the IL13R¦Á1 signaling pathway may be a potential target for the prevention and treatment of AR by miR-143."	25529447
1870	Human	hsa-miR-143	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs) from AR patients	IL-13 treatment	upregulated	25529447
1871	Human	hsa-miR-143	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	vascular smooth muscle cell (VSMC)	homocysteine (Hcy) treatment	downregulated	26573388
1872	Human	hsa-miR-143	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	vascular smooth muscle cell (VSMC)	homocysteine (Hcy) treatment	downregulated	26573388
1873	Human	hsa-miR-143	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
1874	Human	hsa-miR-143	miRNA	estradiol	breast cancer	MCF-7 cells	estradiol (E?) treatment	"E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells"	22260523
1875	Human	hsa-miR-143	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
1876	Human	hsa-miR-143	miRNA	TGF-¦Â1	breast cancer	human coronary artery smooth muscle cells	TGF-¦Â1 treatment	downregulated	21712382
1877	Human	hsa-miR-143	miRNA	histone deacetylase inhibitor (HDACi)	burkitt lymphoma (BL)	Raji B-cell lymphoma	HDACi treatment	upregulated	24577510
1878	Human	hsa-miR-143	miRNA	arsenite	tumorigenesis	derivative normal stem cell (SC) line	arsenite exposure	downregulated	24431212
1879	Human	hsa-miR-143	miRNA	conditioned media (CM)	cardiovascular disease (CVD)	human vascular smooth muscle cells (hVSMC)	exposure to CM from primary human subcutaneous adipocytes treatment	upregulated	24333576
1880	Human	hsa-miR-143	miRNA	taxol	cervical squamous cell carcinoma (SCC)	patients of cervical SCC	taxol treatment	upregulated	24774218
1881	Human	hsa-miR-143	miRNA	epidermal growth factor receptor (EGFR)	colorectal cancer (CRC)	colorectal cancer cells	epidermal growth factor receptor (EGFR) treatment	miRNA-143 expression levels serve as an independent prognostic biomarker for CRC in KRAS wild-type patients. No role for miRNA-143 expression as a predictive biomarker for EGFR-targeted agents could be identified	22549179
1882	Human	hsa-miR-143	miRNA	fluoropyrimidine	colorectal cancer (CRC)	colorectal cancer (CRC) cells	Fluoropyrimidine treatment	upregulated	26392389
1883	Human	hsa-miR-143	miRNA	¦Á-Mangostin	colorectal cancer (CRC)	human colorectal cancer DLD-1 cells	¦Á-Mangostin treatment	?increased miR-143 expression in human colorectal cancer DLD-1 cells	17553685
1884	Human	hsa-miR-143	miRNA	baccharin and drupanin	colorectal cancer (CRC)	human colon cancer DLD-1 cells	baccharin and drupanin treatment	upregulated	24854570
1885	Human	hsa-miR-143	miRNA	hexavalent chromium [Cr(VI)]	Cr(VI)-induced carcinogenesis	blood samples of Cr(VI)-exposing workers and human bronchial epithelial cells (BEAS-2B cells)	Hexavalent chromium [Cr(VI)] exposure	downregulated	31152816
1886	Human	hsa-miR-143	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
1887	Human	hsa-miR-143	miRNA	IL-1¦Â	endothelial activation	human umbilical endothelial cells (HUVECs)	IL-1¦Â treatment	upregulated	28527816
1888	Human	hsa-miR-143	miRNA	endothelial growth medium©\2 (EGM©\2) plus VEGF	endothelial dysfunction	Adipose-derived stem cells (ADSCs)	endothelial growth medium©\2 (EGM©\2) supplemented with 15 ng/mL VEGF innduce	downregulated	31264280
1889	Human	hsa-miR-143	miRNA	shikonin	glioblastoma multiforme (GBM)	glioblastoma stem cells (GSCs)	Shikonin treatment	downregulated	26541455
1890	Human	hsa-miR-143	miRNA	TGF-¦Â	glomerular diseases	human podocytes	TGF-¦Â treatment	"a time dependent, TGF-¦Â inducible expression of miR-143 in human podocytes"	27941332
1891	Human	hsa-miR-143	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	primary liver cells	hepatitis B virus (HBV) infection	upregulated	29236306
1892	Human	hsa-miR-143	miRNA	hexavalent chromium [Cr(VI)]	lung cancer	BEAS-2B cells	Hexavalent chromium [Cr (VI)]?treatment	downregulated	23748240
1893	Human	hsa-miR-143	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	downregulated	19748927
1894	Human	hsa-miR-143	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	downregulated	26356996
1895	Human	hsa-miR-143	miRNA	inorganic phosphate (Pi)	migration of vascular smooth muscle cells	human aortic vascular smooth muscle cells (VSMCs)	inorganic phosphate (Pi) treatment	downregulated	23094093
1896	Human	hsa-miR-143	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	CD34(+) marrow cells	lenalidomide? treatment	upregulated	22929976
1897	Human	hsa-miR-143	miRNA	hypoxia	myocardial infarction (MI)	human cardiac cells	hypoxia induce	upregulated	29728596
1898	Human	hsa-miR-143	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	downregulated	29619741
1899	Human	hsa-miR-143	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
1900	Human	hsa-miR-143	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	The NSCLC cell lines (HCC827 and PC9)	gefitinib treatment	"repressed UCA1 promoted the miR-143 expression, and miR-143 could bind to the predicted binding site of UCA1."	31951852
1901	Human	hsa-miR-143	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC9 cells	gefitinib treatment	lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer.	31951852
1902	Human	hsa-miR-143	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	TGF-¦Â treatment	upregulated	25175415
1903	Human	hsa-miR-143	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
1904	Human	hsa-miR-143	miRNA	cisplatin (DDP)	osteosarcoma (OS)	Sarcoma Osteogenic-2 (Saos-2) cells	cisplatin treatment	upregulated	32508321
1905	Human	hsa-miR-143	miRNA	TGF-¦Â1	osteosarcoma (OS)	osteosarcoma cell	TGF-¦Â1 treatment	downregulated	25562163
1906	Human	hsa-miR-143	miRNA	cisplatin (DDP)	ovarian cancer (OC)	Human ovarian cancer cell lines (A2780 and SKOV-3) and normal ovarian epithelial cell line (IOSE-80)	cisplatin treatment	downregulated	31234009
1907	Human	hsa-miR-143	miRNA	H2O2	oxidative stress	human normal liver cell line L02	H2O2 treatment	upregulated	29258429
1908	Human	hsa-miR-143	miRNA	human mesenchymal stem cell conditioned medium (MSC-CM)	oxidative stress	human normal liver cell line L02	MSC-CM	downregulated	29258429
1909	Human	hsa-miR-143	miRNA	everolimus	pancreatic cancer (PC)	Panc-1 human pancreatic cancer cells	everolimus treatment	upregulated	23251295
1910	Human	hsa-miR-143	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
1911	Human	hsa-miR-143	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
1912	Human	hsa-miR-143	miRNA	curcumin (Cur)	prostate cancer	"DU145, PC3, and RPWE-1 cells"	curcumin treatment	upregulated	28391351
1913	Human	hsa-miR-143	miRNA	curcumin (Cur)	prostate cancer	"PC3, DU145 and LNCaP cells"	curcumin treatment	upregulated	28391715
1914	Human	hsa-miR-143	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	30195228
1915	Human	hsa-miR-143	miRNA	20-hydroxyeicosatetraeonic acid (20-HETE)	pulmonary hypertension (PH)	vascular smooth muscle cell	20-Hydroxyeicosatetraeonic acid (20-HETE) treatment	downregulated	26921441
1916	Human	hsa-miR-143	miRNA	acidic bile salt	reflux esophagitis	Het-1A cells	acidic bile salt treatment	upregulated	24006894
1917	Human	hsa-miR-143	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	sepsis	mesenchymal stem cells (MSCs)	poly(I:C) treatment	downregulated	24105952
1918	Human	hsa-miR-143	miRNA	TGF-¦Â1	subconjunctival fibrosis	Human tenon's capsule fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	31081880
1919	Human	hsa-miR-143	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	tissue regeneration	Human adult DPSCs	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	26351742
1920	Human	hsa-miR-143	miRNA	TGF-¦Â	type 2 diabetes mellitus (T2DM)	Vascular smooth muscle cells (SMC) from T2DM	exposure of ND-SMC to transforming growth factor beta (TGF¦Â) treatment	upregulated	24927876
1921	Human	hsa-miR-143	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HAVSMC)	inorganic phosphate (Pi) treatment	downregulated	27419135
1922	Human	hsa-miR-143-1	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
1923	Human	hsa-miR-143-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	32337953
1924	Human	hsa-miR-143-3p	miRNA	angiotensin II (Ang II)	aortic dissection (AD)	human aortic endothelial cells (HAECs); human aortic smooth muscle cells (HASMCs)	angiotensin II (Ang II) treatment	"We found that lnc-OIP5-AS1 was upregulated, whereas miR-143-3p was downregulated in cells treated with angiotensin II (AngII) and AD tissues."	33577845
1925	Human	hsa-miR-143-3p	miRNA	Resibufogenin (RES)	breast cancer	MDA-MB-453 cells; MCF-7 cells	Resibufogenin (RES) treatment	RES notably enhanced the expression of miR- 143-3p in both MDA-MB-453 and MCF-7 cells compared with the control group	32006291
1926	Human	hsa-miR-143-3p	miRNA	dermatophagoides pteronyssinus peptidase 1 (Der p1)	bronchial asthma	BEAS-2B cells	Dermatophagoides pteronyssinus peptidase 1 (Der p1) treatment	OIP5-AS1 exacerbated Der p1-induced inflammation and apoptosis in BEAS-2B cells by targeting miR-143-3p via HMGB1.	33174035
1927	Human	hsa-miR-143-3p	miRNA	cadmium (Cd)	cadmium-induced toxicity	human bone marrow mesenchymal stem cells (hBMSCs)	cadmium (Cd) treatment	Concentrations of CdCl 2 (2.5 and 5.0 ¦ÌM) increased miR-143-3p levels.	32522577
1928	Human	hsa-miR-143-3p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
1929	Human	hsa-miR-143-3p	miRNA	"hyperglycemia, insulin and lipopolysaccharide (LPS)"	dyslipidemia	HepG2 cells	"hyperglycemia, insulin, and LPS treatment"	"Levels of miR-143-3p increase in response to hyperglycemia, insulin, and LPS treatment."	30261196
1930	Human	hsa-miR-143-3p	miRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	?progesterone (P4) treatment	upregulated	29661100
1931	Human	hsa-miR-143-3p	miRNA	TGF-¦Â1	epithelial ovarian cancer (EOC)	human ovarian tumour cells	TGF-¦Â1 treatment	upregulated	29238081
1932	Human	hsa-miR-143-3p	miRNA	dexamethasone (DEX)	esophageal cancer (EC)	KYSE150 cells	dexamethasone (DEX) treatment	MiR-143-3p could be induced by DEX treatment in esophageal cancer cells.	32701250
1933	Human	hsa-miR-143-3p	miRNA	high glucose (HG)	hyperglycemia	HepG2 cells	high glucose induce	upregulated	30261196
1934	Human	hsa-miR-143-3p	miRNA	insulin	hyperinsulinemic	HepG2 cells	insulin treatment	upregulated	30261196
1935	Human	hsa-miR-143-3p	miRNA	lipopolysaccharide (LPS)	inflammatory response	HepG2 cells	lipopolysaccharide (LPS) treatment	upregulated	30261196
1936	Human	hsa-miR-143-3p	miRNA	TGF-¦Â1	myocardial infarction (MI)	human cardiac fibroblasts (HCFs)	transforming growth ¦Â1 (TGF¦Â1) treatment	upregulated	30878395
1937	Human	hsa-miR-143-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	miR-143-3p level was upregulated in LPS-treated PDLCs.	32520926
1938	Human	hsa-miR-143-3p	miRNA	sulfur mustard (SM)	sulfur mustard induced lung disease	serum	sulfur mustard exposure treatment	upregulated	29566027
1939	Human	hsa-miR-143-3p	miRNA	TGF-¦Â1	asthma	airway smooth muscle cells (ASMCs)	TGF-¦Â1 treatment	over expression	27639060
1940	Human	hsa-miR-143-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
1941	Human	hsa-miR-144	miRNA	actinomycin X2 (AX2)	apoptosis	human prostate cancer cells (PC-3)	actinomycin X2 (AX2) treatment	miR-144 was decreased ; smiR-126 was increased	26645890
1942	Human	hsa-miR-144	miRNA	7-chlorokynurenic acid (7-CTKA)	cardiovascular disease (CVD)	human aortic endothelial cells (HAECs)	7-CTKA intraperitoneal injection	upregulated	24642088
1943	Human	hsa-miR-144	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
1944	Human	hsa-miR-144	miRNA	nanoparticle (NP)	colorectal cancer (CRC)	Human colon cancer HCT-116 cells	Nanoparticle (NP) technology	"Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulated of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms,"	21929751
1945	Human	hsa-miR-144	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	"MiR-144 expression level was enhanced, while CTRP3 expression was reduced in HG-induced AC16 cardiomyocytes."	32211094
1946	Human	hsa-miR-144	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal mesangial cells (HRMCs)	high glucose (HG) treatment	"CASC2 could alleviate the degree and process of apoptosis, inflammation, and fibrosis in diabetic nephropathic models by regulating the miR-144/SOCS2 axis."	33227790
1947	Human	hsa-miR-144	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
1948	Human	hsa-miR-144	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
1949	Human	hsa-miR-144	miRNA	rapamycin	hepatitis	HT29 cells	rapamycin treatment	downregulated	22983984
1950	Human	hsa-miR-144	miRNA	human immunodeficiency virus (HIV)-1	HIV-1 infection-induced pneumonia	human monocyte-derived macrophages (MDMs)	HIV-1 infection	MiR-144 expression was increased in AMs from HIV-1 Tg rats and in HIV-1-infected human MDMs compared to cells from WT rats and non-infected human MDMs.	32773107
1951	Human	hsa-miR-144	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	L. casei LC01 decreased the expression of miR-144 in IECs.	32807750
1952	Human	hsa-miR-144	miRNA	baohuoside-I	melanoma	Human melanoma cell lines M14 and MV3	baohuoside-I treatment	upregulated	29260980
1953	Human	hsa-miR-144	miRNA	triptolide (TPL)	nasopharyngeal carcinoma (NPC)	Epstein-Barr virus-negative human NPC cell lines (NPC-TW 039 and NPC-TW 076)	triptolide (TPL) treatment	downregulated	31059711
1954	Human	hsa-miR-144	miRNA	smoky coal	non-small cell lung cancer (NSCLC)	non-small cell lung cancers (NSCLCs) cells	smoky coal treatment	downregulated	26395400
1955	Human	hsa-miR-144	miRNA	patulin (PAT)	oxidative stress	HEK293 cells	Patulin (PAT)? treatment	PAT significantly decreased miR-144	33403569
1956	Human	hsa-miR-144	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
1957	Human	hsa-miR-144	miRNA	cyclosporine A (CsA)	cell proliferation and invasion	human trophoblast (HT) cells	CsA treatment	downregulated	24453045
1958	Human	hsa-miR-144	miRNA	cisplatin (DDP)	prostate cancer	prostate cancer (PC) cells	cisplatin treatment	downregulated	26566625
1959	Human	hsa-miR-144	miRNA	hypoxia	prostate cancer	prostate cancer cell lines (DU145 and PC3)	hypoxia treatment	downregulated	26990493
1960	Human	hsa-miR-144-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	29492259
1961	Human	hsa-miR-144-3p	miRNA	cisplatin (DDP)	anaplastic thyroid carcinoma (ATC)	TPC1 cells; BHT101 cells	cisplatin (DPP) treatment	downregulated	30540564
1962	Human	hsa-miR-144-3p	miRNA	licochalcone A (LA)	apoptosis	H292 cells	Natural compound licochalcone A (lico A) treatment	lico A significantly promoted the tumor-suppressor miR-144-3p expression.	30709582
1963	Human	hsa-miR-144-3p	miRNA	"oxidized low-density lipoprotein (ox-LDL), IL-6 and TNF-¦Á)"	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	"oxidation Low Lipoprotein (Ox-LDL), interleukin-6 (IL-6) and tumor necrosis factor ¦Á (TNF ¦Á) radiation"	LncRNA HCG11 regulates proliferation and apoptosis of vascular smooth muscle cell through targeting miR-144-3p/FOXF1 axis.	33008472
1964	Human	hsa-miR-144-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	Our data indicated that LOC729178 was underexpressed in COPD tissues and CSE-treated 16HBE cells.	33847879
1965	Human	hsa-miR-144-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Human umbilical vein endothelial cells (HUVEC) and Human Retinal Endothelial Cells (HREC)	high glucose treatment	downregulated	31292167
1966	Human	hsa-miR-144-3p	miRNA	hemin	inflammation	"Neutrophils isolated from human peripheral blood, dHL-60 cells"	hemin treatment	upregulated	30499593
1967	Human	hsa-miR-144-3p	miRNA	licochalcone A (LA)	lung cancer	Human Lung Cancer Cell Line H292	licochalcone A (lico A) treatment	upregulated	30108506
1968	Human	hsa-miR-144-3p	miRNA	TGF-¦Â1	lung cancer	A549 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	31038242
1969	Human	hsa-miR-144-3p	miRNA	hypoxia	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	hypoxia induce	upregulated	31590045
1970	Human	hsa-miR-144-3p	miRNA	tert-butyl hydroperoxide (TBHP)	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
1971	Human	hsa-miR-144-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	27329039
1972	Human	hsa-miR-144-3p	miRNA	hemin	inflammation	Neutrophils isolated from human peripheral blood	hemin treatment	upregulated	30499593
1973	Human	hsa-miR-144-3p	miRNA	tert-butyl hydroperoxide (TBHP)	retinal dysfunction	retinal pigment epithelium (RPE) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
1974	Human	hsa-miR-144-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	abdominal aortic aneurysm (AAA)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32278833
1975	Human	hsa-miR-144-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-144-5p overexpression could inhibit proliferation and induce apoptosis in HUVECs.	31853287
1976	Human	hsa-miR-144-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-144-5p serves an important role in the development of atherosclerosis through regulating the function of HUVECs by targeting SMAD1.	31853287
1977	Human	hsa-miR-144-5p	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-144-5p was downregulated in resistant patients when compared with sensitive patients	33072545
1978	Human	hsa-miR-144-5p	miRNA	hypoxia	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	hypoxia induce	upregulated	31590045
1979	Human	hsa-miR-144-5p	miRNA	tert-butyl hydroperoxide (TBHP)	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
1980	Human	hsa-miR-144-5p	miRNA	tert-butyl hydroperoxide (TBHP)	retinal dysfunction	retinal pigment epithelium (RPE) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
1981	Human	hsa-miR-144-5p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	THP-1 macrophages	lipopolysaccharide (LPS) treatment	downregulated	31853295
1982	Human	hsa-miR-144-5p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	THP-1 cell differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	31853295
1983	Human	hsa-miR-145	miRNA	IFN-¦Â	asthma	airway smooth muscle (ASM)	IFN-beta? treatment	upregulated	20382746
1984	Human	hsa-miR-145	miRNA	basic fibroblast growth factor (bFGF)	adipose-derived stem cells (ASCs) differentiation	Adipose-derived stem cells (ASCs)	ASCs were isolated from clinical lipoaspirates and cultured with DMEM or endothelial cell-conditioned medium. bFGF (basic fibroblast growth factor) released by ECs as inducer of ASCs differentiation.	downregulated	31219744
1985	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	anti-proliferative action	human aortic vascular smooth muscle cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	27412561
1986	Human	hsa-miR-145	miRNA	genistein	apoptosis	human retinoblastoma cell line Y79	genistein treatment	upregulated	28706438
1987	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	apoptosis	GES-1cells	lipopolysaccharides (LPS) treatment	MiR-145 inhibited lipopolysaccharide-induced apoptosis of gastric mucosal via up-regulating JNK-mediated cytoprotective autophagy.	30829205
1988	Human	hsa-miR-145	miRNA	arsenite	arsenic-induced liver injury	L-02 cells	arsenic exposure	upregulated	29705342
1989	Human	hsa-miR-145	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
1990	Human	hsa-miR-145	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
1991	Human	hsa-miR-145	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	upregulated	24396484
1992	Human	hsa-miR-145	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
1993	Human	hsa-miR-145	miRNA	TGF-¦Â1	breast cancer	human coronary artery smooth muscle cells	TGF-¦Â1 treatment	downregulated	21712382
1994	Human	hsa-miR-145	miRNA	histone deacetylase inhibitor (HDACi)	burkitt lymphoma (BL)	Raji B-cell lymphoma	HDACi treatment	upregulated	24577510
1995	Human	hsa-miR-145	miRNA	cortisol	tumorigenesis	cervical cancer cells	Cortisol?treatment	downregulated	22287315
1996	Human	hsa-miR-145	miRNA	TGF-¦Â	cancer-associated fibroblasts (CAFs) activation	primary normal human fibroblasts	TGF-¦Â treatment	upregulated	29506142
1997	Human	hsa-miR-145	miRNA	conditioned media (CM)	cardiovascular disease (CVD)	human vascular smooth muscle cells (hVSMC)	exposure to CM from primary human subcutaneous adipocytes treatment	upregulated	24333576
1998	Human	hsa-miR-145	miRNA	(-)-epigallocatechin gallate (EGCG)	cell proliferation	Ang II-treated human coronary artery smooth muscle cells (HCASMCs)	(-)-epigallocatechin gallate (EGCG) treatment	upregulated	29127880
1999	Human	hsa-miR-145	miRNA	angiotensin II (Ang II)	cell proliferation	Human coronary artery smooth muscle cells (HCASMCs)	angiotensin II (Ang II) treatment	downregulated	29127880
2000	Human	hsa-miR-145	miRNA	homocysteine (Hcy)	cell proliferation	Human aortic vascular smooth muscle cells (HAVSMCs)	homocysteine (HCY) treatment	downregulated	31757424
2001	Human	hsa-miR-145	miRNA	tanshinone IIA (Tan IIA)	cell proliferation	Homocysteine (Hcy)-treated Human aortic vascular smooth muscle cells (HAVSMCs)	Tanshinone IIA (Tan IIA) treatment	upregulated	31757424
2002	Human	hsa-miR-145	miRNA	tanshinone IIA (Tan IIA)	cervical cancer (CC)	HeLa cells	tanshinone II A treatment	Treatment of tanshinone II A significantly upregulated the expression of GSDMD and miR-145	32232409
2003	Human	hsa-miR-145	miRNA	nilotinib	chronic myeloid leukemia (CML)	HL-60.BCR-ABL cells	nilotinib (NIL) treatment	differently regulated	24629639
2004	Human	hsa-miR-145	miRNA	pomegranate beverage (PG)	colitis	CCD-18Co colon-myofibroblastic cells treated with lipopolysaccharide (LPS)	PG treatment	upregulated	28282584
2005	Human	hsa-miR-145	miRNA	troglitazone	collagen synthesis	human dermal fibroblasts	troglitazone treatment	upregulated	25704091
2006	Human	hsa-miR-145	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	parental 5-FU- sensitive DLD-1 cells	5-fluorouracil (5-FU) treatment	upregulated	24447928
2007	Human	hsa-miR-145	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
2008	Human	hsa-miR-145	miRNA	rosiglitazone	colorectal cancer (CRC)	"CaCo2, SW480, HCT116, and HT-29 cell lines"	azone-mediated activation of PPAR¦Ã treatment	upregulated	24631504
2009	Human	hsa-miR-145	miRNA	atorvastatin	cytotoxicity	HepG2 cells	atorvastatin (Ato) treatment	upregulated	29630879
2010	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic atherosclerosis	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	miR-145 was downregulated in cultured human VSMCs exposed to high glucose.	29324316
2011	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human AC16 cardiomyocytes	high glucose (HG) treatment	"the role of MEG3 in HG-treated human cardiomyocytes is to serve as a competing endogenous RNA (ceRNA), which negatively regulates miR-145"	31085717
2012	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	hyperglycemia significantly increased the level of MALAT1 but decreased miR-145 expression in a time-dependent manner in HK-2 cells.	31081103
2013	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells (HMCs)	high glucose treatment	downregulated	31737219
2014	Human	hsa-miR-145	miRNA	baicalin (BAI)	diabetic retinopathy (DR)	ARPE-19 cells and HRMECs	high glucose (HG) and Baicalin (BAI) co-treatment	the expression level of miR-145 was upregulated in HG-and BAI-co-treated cells.	30625293
2015	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
2016	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells (RECs)	high glucose (HG) treatment	miR-145 was significantly downregulated in high glucose (HG)-treated RECs.	29883722
2017	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells and HRMECs	high glucose (HG) and Baicalin (BAI) co-treatment	the expression level of miR-145 was upregulated in HG-and BAI-co-treated cells.	30625293
2018	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high-glucose (HG) treatment	downregulated	31794890
2019	Human	hsa-miR-145	miRNA	schizandrin A (SchA)	diabetic retinopathy (DR)	ARPE-19 cells	schizandrin A (SchA) treatment	upregulated	31794890
2020	Human	hsa-miR-145	miRNA	schizandrin A (SchA)	diabetic retinopathy (DR)	high-glucose (HG)-induced ARPE-19 cells	Schizandrin A (SchA) treatment	upregulated	31794890
2021	Human	hsa-miR-145	miRNA	hypoxia	cell differentiation	umbilical cord mesenchymal stem cells (UCMSCs)	hypoxia treatment	upregulated	28789953
2022	Human	hsa-miR-145	miRNA	TGF-¦Â1 or bone morphogenetic protein-4 (BMP4)	cell differentiation	hASCs to smooth muscle cells (SMCs)	"TGF-¦Â1,BMP4 treatment"	upregulated	28440409
2023	Human	hsa-miR-145	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
2024	Human	hsa-miR-145	miRNA	quercetin	endometrial fibrosis	human endometrial stromal cells (hESCs)	quercetin treatment	The decreased expression of miR-145 induced by TGF-¦Â1 was upregulated with the increase of the concentration of quercetin	33066828
2025	Human	hsa-miR-145	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human renal proximal tubular epithelial (HK-2) cells	TGF-¦Â1 treatment	MIAT served as an endogenous sponge for miR-145 in the TGF-¦Â1-induced-EMT in HK-2 cells	31863776
2026	Human	hsa-miR-145	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	endothelial progenitor cells (EPCs)	treat with TGF-¦Â1 treatment	downregulated	28535533
2027	Human	hsa-miR-145	miRNA	X-rays	esophageal cancer (EC)	TE-3 cells; ECA109 cells	X-ray radiation treatment	lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR-145/p70S6K1 and p53 pathway	31789385
2028	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	facial nerve damage	SH-SY5Y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	miR-145 was revealed to be significantly increased in response to TNF¦Á treatment	30551550
2029	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	facial neuritis	SH-SY5Y cell	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30551550
2030	Human	hsa-miR-145	miRNA	isorhapontigenin (ISO)	glioblastoma multiforme (GBM)	?glioma stem cells (GSCs)	Isorhapontigenin treatment	downregulated	26681767
2031	Human	hsa-miR-145	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
2032	Human	hsa-miR-145	miRNA	dendrosomal curcumin (DNC)	glioblastoma multiforme (GBM)	U87MG cells	dendrosomal curcumin r treatment	downregulated	24531649
2033	Human	hsa-miR-145	miRNA	olea europaea leaf extract (OLE)	glioblastoma multiforme (GBM)	GBM cell lines	olea europaea leaf extract (OLE) treatment	upregulation	25232498
2034	Human	hsa-miR-145	miRNA	insulin	glycolysis	human HepG2 hepatocellular carcinoma cells	insulin treatment	dysregulated	24895527
2035	Human	hsa-miR-145	miRNA	H2O2	granulosa cell (GC) apoptosis	KGN cells	H2O2 treatment	downregulated	28564582
2036	Human	hsa-miR-145	miRNA	carboplatin (CBP)	head and neck squamous cell carcinoma (HNSCC)	Hep-2 cells; FaDu cells	carboplatin treatment	carboplatin induced the expression of miR-145 in a dose-dependent manner.	31886905
2037	Human	hsa-miR-145	miRNA	5-aminolevulinic acid photodynamic therapy(ALA-PDT)	head and neck squamous cell carcinoma (HNSCC)	Two oral cancer cell lines SAS (tongue squamous cell carcinoma) and GNM (neck metastasis of gingival carcinoma)	5-Aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) treatment	upregulated	29936107
2038	Human	hsa-miR-145	miRNA	carboplatin (CBP)	head and neck squamous cell carcinoma (HNSCC)	The human LSCC Hep-2 cell line and the human HSCC FaDu cell line	carboplatin (CBP) treatment	upregulated	31886905
2039	Human	hsa-miR-145	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells £¬ HepG2.2.15 cells.	plasmid transfected treatment	downregulated	25260533
2040	Human	hsa-miR-145	miRNA	emodin	hepatitis	LPS-treated L-02 cell	Emodin treatment	upregulated	31079494
2041	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	hepatitis	L-02 cell	lipopolysaccharide (LPS) treatment	downregulated	31079494
2042	Human	hsa-miR-145	miRNA	compound astragalus and salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	DEN-induced HCC in rats	Compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	upregulated	30412748
2043	Human	hsa-miR-145	miRNA	compound Astragalus and Salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	HepG2 cells	compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	CASE upregulated miR-145 expression in TGF-¦Â 1-stimulated HepG2 cells.	30412748
2044	Human	hsa-miR-145	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells	Hepatitis B virus X protein (HBX)treatment	downregulated	26512974
2045	Human	hsa-miR-145	miRNA	tanshinone IIA (Tan IIA)	human aortic vascular smooth muscle cells (HA-VSMCs) injury	vascular smooth muscle cells (VSMCs)	Tanshinone IIA (Tan IIA) treatment	"The miR-145 expression was downregulated and its targeted gene CD40 was upregulated in Hcy-treating VSMCs, while the Tan IIA reversed the effect of Hcy"	31757424
2046	Human	hsa-miR-145	miRNA	decabromodiphenyl ether (BDE-209)	human embryonic development	human embryonic stem cell lines FY-hES-10 and FY-hES-26	Decabromodiphenyl ether (BDE-209) treatment	upregulated	26206603
2047	Human	hsa-miR-145	miRNA	high glucose (HG)	hyperglycemia	Human coronary artery smooth muscle cells (HCASMCs)	high glucose treatment	downregulated	26181633
2048	Human	hsa-miR-145	miRNA	baicalin (BAI)	hypertension	TNF-¦Á-treated human aortic endothelial cells (HAECs)	baicalin (BAI) treatment	upregulated	31793706
2049	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	hypertension	human aortic endothelial cells (HAECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31793706
2050	Human	hsa-miR-145	miRNA	TGF-¦Â1	hypertrophic scars (HS)	skin myofibroblasts	TGF-¦Â1 treatment	upregulated	25876136
2051	Human	hsa-miR-145	miRNA	IL-1¦Â	osteoarthritis (OA)	OA chondrocytes	IL-1¦Â treatment	upregulated	24873879
2052	Human	hsa-miR-145	miRNA	platelet derived growth factor-BB (PDGF-BB)	juvenile lupus nephritis (JLN)	human vascular smooth muscle cells (HVSMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	31430759
2053	Human	hsa-miR-145	miRNA	TGF-¦Â1	cornea scarring	light-scattering myofibroblasts	TGF-¦Â1 treatment	upregulated	26165705
2054	Human	hsa-miR-145	miRNA	listeria monocytogenes (L. monocytogenes)	Listeria infection	Human epithelial cells (Caco-2)	Listeria infection	downregulated	22312311
2055	Human	hsa-miR-145	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	miR-145 was downregulated in transforming growth factor-¦Â1 induced HSCs	29375381
2056	Human	hsa-miR-145	miRNA	pemetrexed	lung adenocarcinoma (LUAD)	serum	pemetrexed treatment	"Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations"	26687391
2057	Human	hsa-miR-145	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
2058	Human	hsa-miR-145	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
2059	Human	hsa-miR-145	miRNA	inorganic phosphate (Pi)	migration of vascular smooth muscle cells	human aortic vascular smooth muscle cells (VSMCs)	inorganic phosphate (Pi) treatment	downregulated	23094093
2060	Human	hsa-miR-145	miRNA	cerivastatin	mitochondrial dysfunction	RD cells	cerivastatin (1 ¦ÌM for 48 h) treatment	downregulated	28438533
2061	Human	hsa-miR-145	miRNA	TGF-¦Â1	multidrug resistance (MDR)	The HepG2 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30698830
2062	Human	hsa-miR-145	miRNA	IFN-¦Â	multiple sclerosis (MS)	blood	IFN-¦Â treatment	downregulated	27752929
2063	Human	hsa-miR-145	miRNA	nanocurcumin	multiple sclerosis (MS)	blood	nanocurcumin treatment	downregulated	30340096
2064	Human	hsa-miR-145	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	CD34(+) marrow cells	lenalidomide? treatment	upregulated	22929976
2065	Human	hsa-miR-145	miRNA	angiotensin II (Ang II)	neointimal formation	human coronary artery smooth muscle cells (HCASMCs)	angiotensin II (Ang II) treatment	downregulated	29127880
2066	Human	hsa-miR-145	miRNA	epigallocatechin-3-gallate (EGCG)	neointimal formation	human coronary artery smooth muscle cells (HCASMCs)	EGCG	upregulated	29127880
2067	Human	hsa-miR-145	miRNA	flavonoids (TFs)	neointimal formation	human coronary artery smooth muscle cells (HCASMCs)	100 nM flavonoids treatment	upregulated	29127880
2068	Human	hsa-miR-145	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	downregulated	29619741
2069	Human	hsa-miR-145	miRNA	ethanol (EtOH)	neuropsychological disorders	human embryonic stem cells	ethanol treatment	upregulated	28833141
2070	Human	hsa-miR-145	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
2071	Human	hsa-miR-145	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
2072	Human	hsa-miR-145	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	The human NSCLC cell line A549	erlotinib treatment	Pretreatment with miRNA-145 synergistically enhanced the sensitivity of the lung cancer cells to erlotinib. Results of apoptosis assay revealed that miRNA-145 can induce apoptosis and increase the erlotinib-mediated apoptosis.	31554377
2073	Human	hsa-miR-145	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
2074	Human	hsa-miR-145	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
2075	Human	hsa-miR-145	miRNA	CoCl2	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	HK-2 cells	CoCl2 treatment	CoCl2 induced expression of miR-145 while ROR overexpression downregulated expression of miR-145.	31164009
2076	Human	hsa-miR-145	miRNA	cigarette smoke condensate (CSC)	oral cancer	SCC4 cells; H357 cells; primary normal oral fibroblasts (NOF)	Cigarette smoke condensate(CSC) treatment	downregulated	23173553
2077	Human	hsa-miR-145	miRNA	prednisolone	oral submucous fibrosis (OSF)	OSF-fibroblast cells	were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment	upregulated	24921400
2078	Human	hsa-miR-145	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	downregulated	31637891
2079	Human	hsa-miR-145	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	upregulated	32028542
2080	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	human OA cartilage	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29072705
2081	Human	hsa-miR-145	miRNA	osteogenic differentiation medium	osteogenesis	Human jaw bone marrow mesenchymal stem cells (h-JBMMSCs)	osteogenic medium culture	downregulated	31305177
2082	Human	hsa-miR-145	miRNA	ossotide	osteogenesis imperfecta (OI)	osteoblasts	Ossotide treatment	upregulated	27551756
2083	Human	hsa-miR-145	miRNA	zoledronic acid (ZA)	osteoporosis	serum	ZOL treatment	"?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment"	33637048
2084	Human	hsa-miR-145	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	ovarian cancer (OC)	"paclitaxel-resistant cell lines (A2780/PTX, SKOV3/PTX)"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24510775
2085	Human	hsa-miR-145	miRNA	propofol (PPF)	ovarian cancer (OC)	ovarian cancer cell lines (A2780 and SKOV3)	Propofol treatment	Propofol suppressed the progression of ovarian cancer through up-regulating miR-145 via suppressing circVPS13C	33563314
2086	Human	hsa-miR-145	miRNA	quercetin	ovarian cancer (OC)	SKOV-3 and A2780 cells	quercetin treatment	upregulated	25937243
2087	Human	hsa-miR-145	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
2088	Human	hsa-miR-145	miRNA	TGF-¦Â1	peritoneal fibrosis	human peritoneal mesothelial cells (i.e. HMrSV5 cells)	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31431501
2089	Human	hsa-miR-145	miRNA	curcumin (Cur)	prostate cancer	"PC3, DU145 and LNCaP cells"	curcumin treatment	upregulated	28391715
2090	Human	hsa-miR-145	miRNA	curcumin (Cur)	prostate cancer	HuPCaSCs	curcumin treatment	upregulated	28843521
2091	Human	hsa-miR-145	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	30195228
2092	Human	hsa-miR-145	miRNA	TGF-¦Â1	renal fibrosis	human renal proximal tubular epithelial (HK2) cells	TGF-¦Â1 treatment	MALAT1 functions by acting as a miR-145 sponge in HK2 cells treated with TGF-¦Â1	32203053
2093	Human	hsa-miR-145	miRNA	hypoxia	renal injury	human renal inner medullary CD133+ progenitors	hypoxia treatment	downregulated	21900452
2094	Human	hsa-miR-145	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	TGF-¦Â1 treatment	downregulated	31863776
2095	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	human fibroblast-like synoviocyte line MH7A	lipopolysaccharides (LPS) treatment	downregulated	30191608
2096	Human	hsa-miR-145	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
2097	Human	hsa-miR-145	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
2098	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	30784922
2099	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	BEAS-2B cells	lipopolysaccharide (LPS) treatment	downregulated	30841464
2100	Human	hsa-miR-145	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
2101	Human	hsa-miR-145	miRNA	TGF-¦Â1	subconjunctival fibrosis	Human tenon's capsule fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	31081880
2102	Human	hsa-miR-145	miRNA	ultraviolet (UV) irradiation	systemic lupus erythematosus (SLE)	HaCaT cells	UVB treatment	miR-145 was upregulated by UVB irradiation	30198366
2103	Human	hsa-miR-145	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
2104	Human	hsa-miR-145	miRNA	acetylated Low density lipoprotein (Ac-LDL)	type 2 diabetes mellitus (T2DM)	THP-1 cells; peripheral blood mononuclear cells (PBMCs)	acetylated Low density lipoprotein (Ac-LDL) treatment	upregulated	30941422
2105	Human	hsa-miR-145	miRNA	acetylated Low density lipoprotein (Ac-LDL) and high glucose (HG)	type 2 diabetes mellitus (T2DM)	THP-1 cells; peripheral blood mononuclear cells (PBMCs)	acetylated Low density lipoprotein (Ac-LDL) treatment	upregulated	30941422
2106	Human	hsa-miR-145	miRNA	free fatty acids (FFA)	type 2 diabetes mellitus (T2DM)	THP-1 cells;peripheral blood mononuclear cells	free fatty acid (FFA) treatment	upregulated	30941422
2107	Human	hsa-miR-145	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	THP-1 cells;peripheral blood mononuclear cells	high glucose (HG) treatment	upregulated	30941422
2108	Human	hsa-miR-145	miRNA	TGF-¦Â	type 2 diabetes mellitus (T2DM)	Vascular smooth muscle cells (SMC) from T2DM	exposure of ND-SMC to transforming growth factor beta (TGF¦Â) treatment	upregulated	24927876
2109	Human	hsa-miR-145	miRNA	mechanical stretch	vascular disease	HASMCs	mechanical stretch treatment	downregulated	24848371
2110	Human	hsa-miR-145	miRNA	high glucose (HG)	vascular injury	smooth muscle cells (VSMCs)	high glucose treatment	downregulated	26181633
2111	Human	hsa-miR-145	miRNA	homocysteine (Hcy)	vascular smooth muscle cell proliferation	Human vascular smooth muscle cell line (VSMCs)	Homocysteine (Hcy) treatment	Hcy decreased the expression of miR-145 in VSMCs.	32124010
2112	Human	hsa-miR-145	miRNA	TGF-¦Â and bleomycin A5	venous malformations (VMs)	human umbilical vein endothelial cells (HUVECs)	recombinant human TGF-¦Â and bleomycin A5 treatment	upregulated	28104472
2113	Human	hsa-miR-145-3p	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	macrophage polarization	THP1-derived macrophages	IFN-gamma and LPS treatment	downregulated	30634164
2114	Human	hsa-miR-145-3p	miRNA	IL-4 and IL-13	macrophage polarization	THP1-derived macrophages	IL-4 and IL-13 treatment	upregulated	30634164
2115	Human	hsa-miR-145-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	downregulated	33602903
2116	Human	hsa-miR-145-5p	miRNA	cigarette smoke (CS)	airway diseases	Normal human bronchial epithelial (NHBE) air-liquid interface (ALI) cultures	cigarette smoke (CS) exposure	upregulated	30595527
2117	Human	hsa-miR-145-5p	miRNA	TGF-¦Â	airway diseases	Normal human bronchial epithelial (NHBE) air-liquid interface (ALI) cultures	TGF-¦Â treatment	upregulated	30595527
2118	Human	hsa-miR-145-5p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	human lung tissues samples	cigarette smoke (CS) exposure	downregulated	30639269
2119	Human	hsa-miR-145-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human pulmonary microvascular endothelial cells HPMECs and bronchial epithelial cells BEAS-2B	cigarette smoke extract (CSE) treatment	downregulated	33248690
2120	Human	hsa-miR-145-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HPMECs and BEAS-2B cells	cigarette smoke extract (CSE) exposure	"Hsa_circ_0006872 facilitated CSE-triggered apoptosis, inflammation and oxidative stress in HPMECs and BEAS-2B cells by regulating miR-145-5p/NF-¦ÊB pathway."	33248690
2121	Human	hsa-miR-145-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human pulmonary microvascular endothelial cells HPMECs	cigarette smoke extract (CSE) treatment	"CircANKRD11 and BRD4 expression were increased, whereas miR-145-5p expression was decreased in the lung tissues of smokers with or without COPD and CSE-induced HPMECs"	33833509
2122	Human	hsa-miR-145-5p	miRNA	TGF-¦Â	chronic obstructive pulmonary disease (COPD)	Primary human bronchial epithelial cells	Transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	30595527
2123	Human	hsa-miR-145-5p	miRNA	puerarin	diabetic nephropathy (DN)	HK2 cells	puerarin treatment	upregulated	33122931
2124	Human	hsa-miR-145-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	?progesterone (P4) treatment	upregulated	29661100
2125	Human	hsa-miR-145-5p	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
2126	Human	hsa-miR-145-5p	miRNA	rapamycin	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	upregulated	29579170
2127	Human	hsa-miR-145-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	freshly-frozen specimens in the ESCC tumors	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26254350
2128	Human	hsa-miR-145-5p	miRNA	TGF-¦Â1	gastric cancer (GC)	AGS and MKN45 cancer cells	transforming growth factor ¦Â1 (TGF-¦Â1) secretion by MSCs treatment	downregulated	30742067
2129	Human	hsa-miR-145-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
2130	Human	hsa-miR-145-5p	miRNA	dexamethasone (DEX)	glucocorticoid-induced osteoporosis (GIOP)	Bone tissue	dexamethasone (DEX) treatment	hsa_circ_0006393 increases the expression levels of osteogenic genes during bone remodeling by sponging miR-145-5p and upregulating FOXO1.	31322188
2131	Human	hsa-miR-145-5p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
2132	Human	hsa-miR-145-5p	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	human peripheral blood mononuclear cells (PBMC)	HIV-1 infection treatment	downregulated	25295610
2133	Human	hsa-miR-145-5p	miRNA	dihydroartemisinin (DHA)	hypertrophic scars (HS)	human Tenon's capsule fibroblasts (HTFs)	dihydroartemisinin (DHA) treatment	DHA notably increased the expression of microRNA (miR)-145-5p in HTFs in a dose-dependent manner.	33688170
2134	Human	hsa-miR-145-5p	miRNA	high fat diet (HFD)	inflammation	plasma	high fat diet (HFD) feed	upregulated	30885503
2135	Human	hsa-miR-145-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic heart disease (IHD)	human cardiomyocytes (HCM)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-145-5p inhibition reversed the effects of silencing circ_0010729 on OGD-induced injury and mTOR and MEK/ERK pathways	31482388
2136	Human	hsa-miR-145-5p	miRNA	cisplatin and pemetrexed	lung adenocarcinoma (LUAD)	A549/DR cells	cisplatin and pemetrexed treatment	circPVT1 contributes to cisplatin and pemetrexed chemotherapy resistance through miR-145-5p/ABCC1 axis.	31986409
2137	Human	hsa-miR-145-5p	miRNA	particulate matter (PM2.5)	PM2.5-induced carcinogenesis	human bronchial epithelial (HBE) cells	fine particulate matter (PM2.2) treatment	downregulated	33545377
2138	Human	hsa-miR-145-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	preeclampsia (PE)	HTR-8/SVneo cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30081007
2139	Human	hsa-miR-145-5p	miRNA	bromocriptine	prolactinoma	prolactinoma clinical samples and prolactinoma cell line MMQ/BRC	bromocriptine treatment	downregulated	30370446
2140	Human	hsa-miR-145-5p	miRNA	docetaxel (DTX)	prostate cancer	PC-3 cells	docetaxel (DTX) treatment	miR-145-5p in PC3-DTX cell was markedly lower than that of PC3 cells.	29633510
2141	Human	hsa-miR-145-5p	miRNA	hantaan virus (HTNV)	hemorrhagic fever with renal syndrome (HFRS)	exosomes derived from HTNV-infected human vascular endothelial cells (HUVECs) (Exo-HV)	Hantaan virus (HTNV) infection	upregulated	32808389
2142	Human	hsa-miR-145-5p	miRNA	valproic acid (VPA)	thyroid cancer (TC)	TC1889 cells	VPA treatment	upregulated	28486946
2143	Human	hsa-miR-145-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	VSMCs proliferation and migration	vascular smooth muscle cells (VSMCs)	PDGF-bb treatment	miR-145-5p is downregulated in PDGF-mediated VSMCs in both time- and dose-dependent manners	30007992
2144	Human	hsa-miR-146	miRNA	docosahexaenoic acid (DHA)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	docosahexaenoic acid (DHA) treatment	upregulated	25182732
2145	Human	hsa-miR-146	miRNA	gamma-linolenic acid (GLA)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	GLA treatment	upregulated	25182732
2146	Human	hsa-miR-146	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	irradiation treatment	upregulated	25182732
2147	Human	hsa-miR-146	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
2148	Human	hsa-miR-146	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
2149	Human	hsa-miR-146	miRNA	carbamylated albumin	renal cell carcinoma (RCC)	human renal cell carcinoma cells	Carbamylated albumin treatment	upregulated	21472233
2150	Human	hsa-miR-146	miRNA	lipopolysaccharide (LPS)	inflammation	human vascular endothelial cell line EA. hy926 cells	lipopolysaccharide (LPS) treatment	downregulated	29442046
2151	Human	hsa-miR-146	miRNA	thrombin	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	were transfect miRNA mimics or antimiRs and thrombin treatment	upregulated	24985472
2152	Human	hsa-miR-146	miRNA	TNF-a and MMP13	osteoarthritis (OA)	human OA cartilage and bone	TNF-a and MMP13 treatment	downregulated	19008124
2153	Human	hsa-miR-146	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
2154	Human	hsa-miR-1468-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
2155	Human	hsa-miR-1468-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
2156	Human	hsa-miR-1468-5p	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	vascular endothelial cell growth factor (VEGF) treatment	downregulated	30414893
2157	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	falls and fractures among the elderly	THP-1 cells	lipopolysaccharide (LPS)	lipopolysaccharide (LPS) induces a reactive oxygen species-/NF-kappaB-dependent pathway which increases the expression of the anti-inflammatory miR-146a	19390647
2158	Human	hsa-miR-146a	miRNA	6-mer HA oligosaccharides as sodium salt	6-mer HA-induced inflammation	chondrocytes	6-mer HA oligosaccharides as sodium salt treatment	upregulated	31583475
2159	Human	hsa-miR-146a	miRNA	cutibacterium acnes (C. acnes)	acne	acne lesions or human keratinocytes	cutibacterium acnes (C. acnes) infection	upregulated	31194941
2160	Human	hsa-miR-146a	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
2161	Human	hsa-miR-146a	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
2162	Human	hsa-miR-146a	miRNA	IL-1¦Â	acute inflammatory response	Human Lung Alveolar Epithelial Cells	IL-1¦Â treatment	upregulated	18390754
2163	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32399391
2164	Human	hsa-miR-146a	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	The human promyelocytic cell line NB4£» humanembryonic kidney cell line 293T	retinoid acid? treatment	downregulated	20577838
2165	Human	hsa-miR-146a	miRNA	human T-cell leukemia virus type 1 (HTLV-1)	adult T-cell leukemia (ATL)	CD4£«T cell	human T-cell leukemia virus type 1 (HTLV-1) infection	upregulated	20017139
2166	Human	hsa-miR-146a	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-146a was inversely associated with PM25 exposure during the 2nd trimester of pregnancy	27104955
2167	Human	hsa-miR-146a	miRNA	chitin	allergic airway diseases (AAD)	bronchial epithelial cells and in A549 and H292 lung carcinoma cells	chitin treatment	upregulated	27463381
2168	Human	hsa-miR-146a	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	N9 microglial cell line	amyloid-¦Â (A¦Â) treatment	upregulated	27797173
2169	Human	hsa-miR-146a	miRNA	amyloid-¦Â (A¦Â) 42	Alzheimer's disease (AD)	human neuronal-glial primary cell	amyloid-¦Â (A¦Â) 42 peptide metal treatment	upregulated	22043907
2170	Human	hsa-miR-146a	miRNA	dipeptidyl vinyl sulfone (VS)	Alzheimer's disease (AD)	N9 microglial cell line treated with A¦Â	VS treatment	downregulated	27797173
2171	Human	hsa-miR-146a	miRNA	neurotoxic metal	Alzheimer's disease (AD)	human neuronal-glial primary cell	neurotoxic metal treatment	upregulated	22043907
2172	Human	hsa-miR-146a	miRNA	proinflammatory cytokines	Alzheimer's disease (AD)	human neuronal-glial primary cell	pro-inflammatory cytokine treatment	upregulated	22043907
2173	Human	hsa-miR-146a	miRNA	herpes simplex virus 1 (HSV-1)	alzheimer-type inflammatory	HN cells	Herpes simplex virus type-1 (HSV-1) infection	upregulated	19801956
2174	Human	hsa-miR-146a	miRNA	nanocurcumin	ankylosing spondylitis (AS)	peripheral blood mononuclear cells (PBMCs)	nanocurcumin treatment	upregulated	31074089
2175	Human	hsa-miR-146a	miRNA	"dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)"	anti-inflammatory responses	primary astrocyte cultures derived from human brains stimulated with IL-1¦Â	"pretreat with DMF, MMF"	downregulated	28589165
2176	Human	hsa-miR-146a	miRNA	immunoglobulin	anti-inflammatory responses	LPS-activated human monocytes	intravenous immunoglobulin (IVIG)	downregulated	28288804
2177	Human	hsa-miR-146a	miRNA	mechanical pressure of 10 MPa	apoptosis	human chondrocytes	mechanical pressure of 10 Mpa for 60 min treatment	upregulated	24939082
2178	Human	hsa-miR-146a	miRNA	epstein-barr virus (EBV)	asthma	"U2932,BL28 and BL41, BL28 E95A and BL41 E95C,BL28 EHRA and BL41 EHRA,Oma 4 ,Bjab and the B95-8"	Epstein-Barr virus (EBV)	downregulated	22614176
2179	Human	hsa-miR-146a	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	asthma	human airway smooth muscle cells (hASMCs)	"cytomix (IL-1¦Â, TNF-¦Á, and IFN¦Ã) treatment"	upregulated	25217662
2180	Human	hsa-miR-146a	miRNA	IL-17A	asthma	primary conventional human bronchial epithelial cells (HBECs) culture	IL-17A treatment	upregulated	31798831
2181	Human	hsa-miR-146a	miRNA	IL-1¦Â	asthma	airway smooth muscle cells (ASMCs) from asthmatic patients	IL-1¦Â treatment	downregulated	29946002
2182	Human	hsa-miR-146a	miRNA	IL-4	asthma	primary conventional human bronchial epithelial cells (HBECs) culture	IL-4 treatment	upregulated	31798831
2183	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	asthma	primary conventional human bronchial epithelial cells (HBECs) culture	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31798831
2184	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharides (LPS) treatment	upregulated	30710793
2185	Human	hsa-miR-146a	miRNA	olive leaf extract (OLE)	atherosclerosis (AS)	Serum amyloid A (SAA)-induced human coronary artery endothelial cells (HCAEC)	Olive leaf extract (OLE) treatment	downregulated	31157238
2186	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
2187	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human macrophage THP-1 cells exosomes	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31416388
2188	Human	hsa-miR-146a	miRNA	serum amyloid A (SAA)	atherosclerosis (AS)	human coronary artery endothelial cells (HCAEC)	Serum amyloid A (SAA) treatment	upregulated	31157238
2189	Human	hsa-miR-146a	miRNA	TNF-¦Á£¬IGF-1	atherosclerosis (AS)	smooth muscle cell	TNF-¦Á£¬IGF-1 treatment	upregulated	26047583
2190	Human	hsa-miR-146a	miRNA	ortho-silicic acid	bone defects	human mesenchymal stem cells (hMSCs)	orthosilicic acid (Si(OH)4) treatment	upregulated	27163405
2191	Human	hsa-miR-146a	miRNA	coenzyme Q10 (CoQ10)	breast cancer	primary human umbilical vein endothelial cells (HUVECs)	coenzyme Q10 (CoQ10H?) treatment	downregulated	23727324
2192	Human	hsa-miR-146a	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
2193	Human	hsa-miR-146a	miRNA	quercetin	breast cancer	human breast cancer cell lines MCF-7 and MDA-MB-231	quercetin treatment	upregulated	25596948
2194	Human	hsa-miR-146a	miRNA	triptolide (TPL)	breast cancer	MDA-MB-231 breast cancer cells	triptolide (TPL) treatment	upregulated	31072418
2195	Human	hsa-miR-146a	miRNA	atorvastatin	coronary artery disease (CAD)	PBMCs (peripheral blood mononuclear cells)	atorvastatin and telmisartan or atorvastatin treatment	downregulated	20524934
2196	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cardiac dysfunction	cardiomyocyte cell line of human origin (AC16)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26112171
2197	Human	hsa-miR-146a	miRNA	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)	cardiac hypertrophy	human breast cancer? cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23647548
2198	Human	hsa-miR-146a	miRNA	doxorubicin (DOX)	cardiotoxicity	AC16 cardiomyocytes	Doxorubicin (DOX) treatment	upregulated	31511497
2199	Human	hsa-miR-146a	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
2200	Human	hsa-miR-146a	miRNA	gliadinN	celiac disease (CD)	PBMCs; monocytes	gliadinN treatment	upregulated	31781909
2201	Human	hsa-miR-146a	miRNA	CoCl2	cell-based therapies	human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)	CoCl2 treatment	CoCl2 leads to increased expression of microRNA- (miR-) 146a.	30254683
2202	Human	hsa-miR-146a	miRNA	chikungunya virus	chronic infection	human synovial fibroblasts	infect with chikungunya virus treatment	upregulated	25083878
2203	Human	hsa-miR-146a	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	upregulated	20460641
2204	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	corticosteroid-dependent dermatitis (CDD)	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	29913408
2205	Human	hsa-miR-146a	miRNA	tripterine	corticosteroid-dependent dermatitis (CDD)	LPS-treated HaCaT cells	Tripterine treatment	upregulated	29913408
2206	Human	hsa-miR-146a	miRNA	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV)	cryptosporidium parvum infection	Human Umbilical Vein Endothelial Cells (HUVEC)	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) treatment	upregulated	20023696
2207	Human	hsa-miR-146a	miRNA	bisphenol A (BPA)	cytotoxicity	human placental cells	bisphenol A (BPA) treatment	upregulated	20417706
2208	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	dementia	human gastric epithelial cells	Helicobacter pylori (H. pylori) infection	?H. pylori infection upregulated the expression of miR-146a in gastric epithelial cells	20542134
2209	Human	hsa-miR-146a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human REC	high glucose (HG) treatment	downregulated	26997759
2210	Human	hsa-miR-146a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
2211	Human	hsa-miR-146a	miRNA	portland cement (PC)	cell differentiation	human periodontal ligament cells	PC treatment	upregulated	28528141
2212	Human	hsa-miR-146a	miRNA	portland cement (PC)	cell differentiation	PDL cells	Portland cement (PC) treatment	"PC enhances the differentiation of PDL cells, especially osteogenic through miR-146a upregulation"	28528141
2213	Human	hsa-miR-146a	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma extracellular vesicle (EV)	doxorubicin (Dox) treatment	downregulated	32255536
2214	Human	hsa-miR-146a	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
2215	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell migration	THP-1 cell	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	21329689
2216	Human	hsa-miR-146a	miRNA	phorbol-12-myristate-13-acetate(PMA)	angiogenesis 	HMVECs	PMA treatment	PMA induced miR-146a expression in human microvascular endothelial cells	19944095
2217	Human	hsa-miR-146a	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
2218	Human	hsa-miR-146a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	L02 hepatocytes	TGF-¦Â1 treatment	downregulated	30711634
2219	Human	hsa-miR-146a	miRNA	cyanobacterial lipopolysaccharide antagonist (CyP)	endotoxin cross-tolerance	THP-1 cells and human monocytes	cyanobacterial lipopolysaccharide antagonist (CyP) treatment	upregulated	30054544
2220	Human	hsa-miR-146a	miRNA	enterovirus 71 (EV71)	enterovirus infection	human rhabdomyosarcoma cells line (RD)	EV71 infection treatment	upregulated	24561744
2221	Human	hsa-miR-146a	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	human RPE cells	interferon-¦Ã treatment	upregulated	23592910
2222	Human	hsa-miR-146a	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	human RPE cells	IL-1¦Â treatment	upregulated	23592910
2223	Human	hsa-miR-146a	miRNA	Kr¨¹ppel-like factor 8 (KLF8)	epithelial-mesenchymal transition (EMT)	"MCF-10A, MCF-7 , T47D, MDA-MB-231, Hs578T and BT-549 cell lines and the MCF-10A line"	Kr¨¹ppel-like factor 8 treatment	upregulated	23977446
2224	Human	hsa-miR-146a	miRNA	"TGF-¦Â1 plus cytomix (a mixture of IL-1beta, IFN-gamma and TNF-alpha)"	epithelial-mesenchymal transition (EMT)	HBECs	cytokine treatment	"miRNA-146a was upregulated in human bronchial epithelial cells (HBECs) in response to stimulation by TGF-?1 plus cytomix (a mixture of IL-1?, IFN-c and TNF-a)"	19167348
2225	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	epithelial-mesenchymal transition (EMT)	human RPE cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23592910
2226	Human	hsa-miR-146a	miRNA	epstein-barr virus (EBV)	Epstein-Barr virus (EBV) infection	B-cells	Epstein-Barr virus (EBV) infection	downregulated	19001862
2227	Human	hsa-miR-146a	miRNA	porphyromonas gingivalis	experimental periodontal disease	human THP-1 monocytes	Porphyromonas gingivalis treatment	downregulated	21263019
2228	Human	hsa-miR-146a	miRNA	purified lipooligosaccharides (LOS)	facilitate bacterial survival and dissemination	human monocytic THP-1 cells and primary monocytes	LOS re of cells treatment	upregulated	24442429
2229	Human	hsa-miR-146a	miRNA	neutrophil elastase (NE)	fat	16HBE cells	neutrophil elastase (NE) treatment	NE exerts a dose- and time-dependent induction of both MUC5AC and miR-146a in human bronchial epithelial cells (16HBE)	21773870
2230	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	gastritis	gastric lesions	Helicobacter pylori treatment	upregulated	30219037
2231	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	gingival inflammation	Human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	29407755
2232	Human	hsa-miR-146a	miRNA	monosodium urate (MSU)	gouty tophus	human monocytic THP-1 cells	monosodium urate (MSU) treatment	downregulated	25646371
2233	Human	hsa-miR-146a	miRNA	IL-1¦Â	graves' orbitopathy (GO)	GO orbital adipose	IL-1¦Âtreatment	upregulated	27494344
2234	Human	hsa-miR-146a	miRNA	TGF-¦Â	graves' orbitopathy (GO)	orbital fibroblasts from patients with Graves' orbitopathy (GO)	TGF-¦Â treatment	upregulated	29101123
2235	Human	hsa-miR-146a	miRNA	TGF-¦Â	graves' orbitopathy (GO)	orbital fibroblasts from patients with GO	TGF-¦Â treatment	upregulated	29101123
2236	Human	hsa-miR-146a	miRNA	IL-10	hepatocellular carcinoma (HCC)	NK cells from CHB and HCC patients	"IL-10 ,transforming growth factor-¦Â treatment"	upregulated	26996068
2237	Human	hsa-miR-146a	miRNA	"IL-12, IFN-¦Á and IFN-¦Â"	hepatocellular carcinoma (HCC)	NK cells from CHB and HCC patients	"IL-12,IFN-¦Á , IFN-¦Â treatment"	downregulated	26996068
2238	Human	hsa-miR-146a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	NK cells from CHB and HCC patients	"IL-10 ,transforming growth factor-¦Â treatment"	upregulated	26996068
2239	Human	hsa-miR-146a	miRNA	recombinant Schistosoma japonicum protein P40 (rSjP40)	liver fibrosis	LX-2 cells	recombinant Schistosoma japonicum protein P40 (rSjP40) treatment	rSjP40 could induce miR-146a expression in LX-2 cells	29953648
2240	Human	hsa-miR-146a	miRNA	angiotensin-(1-7)	hepatocellular carcinoma (HCC)	human aortic endothelial cells (HAECs)	angiotensin-(1-7) treatment	downregulated	23246834
2241	Human	hsa-miR-146a	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	HCC cell	Paclitaxe treatment	upregulated	25973036
2242	Human	hsa-miR-146a	miRNA	hantaan virus (HTNV)	hantaan virus (HTNV) infection	human umbilical vein endothelial cells (HUVECs)	infect with HTNV	upregulated	28843856
2243	Human	hsa-miR-146a	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells (PBMCs)	human immunodeficiency virus (HIV)-1 infection	upregulated	31827152
2244	Human	hsa-miR-146a	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
2245	Human	hsa-miR-146a	miRNA	simvastatin	hyperlipidemia	blood	Simvastatin treatment	downregulated	25727911
2246	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	upregulated	24863965
2247	Human	hsa-miR-146a	miRNA	type I interferon (IFN)	hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	type I interferon (IFN) treatment	upregulated	23650597
2248	Human	hsa-miR-146a	miRNA	vibrio cholerae O1	infection of Vibrio cholerae O1	colon carcinoma cell line T84	infect with Vibrio cholerae O1 treatment	upregulated at acute stage of V cholerae infection and declined to normal at convalescent stage	28319200
2249	Human	hsa-miR-146a	miRNA	alternariol (AOH)	inflammation	THP-1 cells	alternariol (AOH) treatment	downregulated	30175388
2250	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	inflammation	human gastric epithelial cells	Helicobacter pylori (H. pylori) infection	upregulated	21947847
2251	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	inflammation	human gastric mucosa	Helicobacter pylori (H. pylori) infection	upregulated	30535468
2252	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	inflammation	human gastric mucosa	Helicobacter pylori (H. pylori) infection	upregulated	30535468
2253	Human	hsa-miR-146a	miRNA	IL-17A	inflammation	SGC-7901 cells	IL-17A treatment	upregulated	30535468
2254	Human	hsa-miR-146a	miRNA	IL-17A	inflammation	SGC-7901 cells	interleukin (IL)-17A treatment	upregulated	30535468
2255	Human	hsa-miR-146a	miRNA	IL-1¦Â	inflammation	human lung fibroblasts	IL-1¦Â treatment	downregulated	30619270
2256	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	inflammation	human microvascular endothelial cells (HMECs)	lipopolysaccharides (LPS) treatment	upregulated	31291804
2257	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	inflammation	THP-1 monocytes	lipopolysaccharide (LPS) treatment	upregulated	21178010
2258	Human	hsa-miR-146a	miRNA	outer membrane vesicles (OMVs)	inflammation	human intestinal epithelial cells T84	Vibrio cholerae outer membrane vesicles (OMVs) treatment	upregulated	31076615
2259	Human	hsa-miR-146a	miRNA	particulate matter (PM1)	inflammation	human lung bronchial epithelial BEAS-2B cells	particulate matter (PM1) treatment	upregulated	29667303
2260	Human	hsa-miR-146a	miRNA	"PD98059, TPCA-1 and LY294002"	inflammation	A549 cells	"exposure to PD98059, TPCA-1 and LY294002 treatment"	downregulated	25183503
2261	Human	hsa-miR-146a	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	human adipocytes	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
2262	Human	hsa-miR-146a	miRNA	Tnf¦Á and Gm-csf	heart failure (HF)	cardiomyocyte cell line H9C2	Tnf¦Á and Gm-csf treatment	upregulated	29258606
2263	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	colonic epithelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26752469
2264	Human	hsa-miR-146a	miRNA	IL-1¦Â	inflammatory diseases	THP-1 cells	IL-1¦Â treatment	upregulated	25896300
2265	Human	hsa-miR-146a	miRNA	IL-1¦Â	inflammatory injury	human umbilical cord-derived mesenchymal stem cells (MSCs)	IL-1¦Â treatment	upregulated	28090688
2266	Human	hsa-miR-146a	miRNA	candida albicans (C. albicans)	inflammatory response	THP-1 cells	candida albicans infection	upregulated	28454101
2267	Human	hsa-miR-146a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	Influenza A virus (IAV) infection	upregulated	30611999
2268	Human	hsa-miR-146a	miRNA	"TLR2 ligand zymosan, the TLR3 ligand poly(I:C) or the TLR5 ligand flagellin"	innate immune response	keratinocytes	"TLR2 ligand zymosan, the TLR3 ligand poly(I:C) or the TLR5 ligand flagellin treatment"	upregulated	24588688
2269	Human	hsa-miR-146a	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
2270	Human	hsa-miR-146a	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
2271	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	downregulated	28161709
2272	Human	hsa-miR-146a	miRNA	IL-1¦Â	intestinal inflammation	Caco-2 cells	IL-1¦Â treatment	upregulated	30478292
2273	Human	hsa-miR-146a	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	serum	Japanese encephalitis virus (JEV) infection	miR-146a was found significantly decreased (p?=?0.0008) in JEV infected patients as compared to healthy controls.	30196835
2274	Human	hsa-miR-146a	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	human microglial CHME3 cells	JEV-infected treatment	upregulated	24885259
2275	Human	hsa-miR-146a	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
2276	Human	hsa-miR-146a	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
2277	Human	hsa-miR-146a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	linesprostate cancer	LNCaP£¬PC3 cell	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24885368
2278	Human	hsa-miR-146a	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	upregulated	24431000
2279	Human	hsa-miR-146a	miRNA	TGF-¦Â1	liver fibrosis	L02 hepatocytes	TGF-¦Â1 treatment	downregulated	30711634
2280	Human	hsa-miR-146a	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
2281	Human	hsa-miR-146a	miRNA	IL-1¦Â	lung cancer	human airway smooth muscle (HASM) cells	IL-1¦Â treatment	upregulated	20525168
2282	Human	hsa-miR-146a	miRNA	M2000 (¦Â-d-mannuronic acid)	inflammatory response	HEK-Blue hTLR2 cells	M2000 at low and high doses (5 and 25¦Ìg/well)	downregulated	28324845
2283	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	macrophage maturation	Human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	"oxLDL positively regulates miR-146a via the JNK and NF-¦ÊB pathways in macrophages, and that miR-146a inhibits inflammatory activation."	26718614
2284	Human	hsa-miR-146a	miRNA	mechanotransduction and pressure	mechanically induced inflammation	Primary human small airway epithelial cells (HSAEpCs)	mechanotransduction and pressure treatment	MiR-146a is a mechanosensitive miRNA that is rapidly upregulated by oscillatory pressure and plays an important role in regulating mechanically induced inflammation in lung epithelia.	22593544
2285	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	migration of human dental pulp cells	human dental pulp cells	lipopolysaccharide (LPS) treatment	upregulated	23146644
2286	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	monocytic differentiation	monocyte	lipopolysaccharide (LPS) treatment	dysregulated	25148686
2287	Human	hsa-miR-146a	miRNA	"TNF¦Á , IFN¦Ã"	multiple sclerosis (MS)	human cerebral microvascular endothelial cells (hCMEC/D3)	TNF¦Á and IFN¦Ã treatment	upregulated	25515214
2288	Human	hsa-miR-146a	miRNA	Toll-like receptor (TLR)	neurological diseases	U251 human astrocytoma cell line	Toll-like receptor (TLR) treatment	upregulated	25957996
2289	Human	hsa-miR-146a	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
2290	Human	hsa-miR-146a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
2291	Human	hsa-miR-146a	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
2292	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	HaCaT cells	lipopolysaccharide (LPS) treatment	The expression of miR-146a was upregulated in OLP tissues and in lipopolysaccharide (LPS)-incubated HaCaT cells.	30125971
2293	Human	hsa-miR-146a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteoarthritis (OA)	OA chondrocytes and synoviocytes	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31077718
2294	Human	hsa-miR-146a	miRNA	dendrobine	osteoarthritis (OA)	synovial cells (OA-FLS) isolated from stage-IV-OA patients	dendrobine treatment	upregulated	25052989
2295	Human	hsa-miR-146a	miRNA	H2O2	osteoarthritis (OA)	human OA chondrocytes	H2O2 treatment	downregulated (miR-146a) ; upregulated(miR-34a)	29292727
2296	Human	hsa-miR-146a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	hydrostatic pressure (HP) treatment	upregulated	32455798
2297	Human	hsa-miR-146a	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
2298	Human	hsa-miR-146a	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
2299	Human	hsa-miR-146a	miRNA	resistin	osteoarthritis (OA)	human OA synovial fibroblasts	resistin treatment	upregulated	31635187
2300	Human	hsa-miR-146a	miRNA	visfatin	osteoarthritis (OA)	human OA synovial fibroblasts	visfatin treatment	upregulated	31635187
2301	Human	hsa-miR-146a	miRNA	IL-1¦Â	osteoporosis	A549 cells	IL-1¦Â treatment	downregulated	19786024
2302	Human	hsa-miR-146a	miRNA	proinflammatory cytokines	otitis media (OM)	Human middle ear epithelial cells	proinflammatory cytokines treatment	upregulated	27497395
2303	Human	hsa-miR-146a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	oxygen-glucose deprivation/reoxygenation (OGD/R) injury	SK-N-SH cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	27449900
2304	Human	hsa-miR-146a	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	Colo357; Panc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	20124483
2305	Human	hsa-miR-146a	miRNA	BxPC-3-conditioned medium (BxCM)	pancreatic cancer (PC)	human CD14£«monocyte-derived DCs	BxPC-3-conditioned medium (BxCM) treatment	"aberrant miRNA-146a expression is one of main factors responsible for inhibition of DC maturation and antigen presentation function, and this inhibitory effect on DCs may be due to the repression of Smad4 mediated signal pathway by BxCM"	22311263
2306	Human	hsa-miR-146a	miRNA	curcumin-derived analogue CDF	pancreatic cancer (PC)	"human PC cell lines AsPC-1, BxPC-3, COLO-357, L3.6pl, PANC-1, PANC-28, MIAPaCa-2, MIAPaCa-2-GR"	curcumin-derived analogue CDF treatment	upregulated	24839931
2307	Human	hsa-miR-146a	miRNA	isoflavone	pancreatic cancer (PC)	Colo357; Panc-1 cells	isoflavone treatment	upregulated	20124483
2308	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	pancreatic ductal adenocarcinoma (PDAC)	THP-1 cells	lipopolysaccharide (LPS) treatment	upregulated	19840932
2309	Human	hsa-miR-146a	miRNA	paraquat poisoning	paraquat poisoning-induced lung injury	"pulmonary macrophages, PBMCs and serum"	paraquat poisoning treatment	downregulated	29896267
2310	Human	hsa-miR-146a	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
2311	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide (LPS) treatment	upregulated	25948157
2312	Human	hsa-miR-146a	miRNA	porphyromonas gingivalis	periodontitis	Human periodontal ligament fibroblasts (HPDLFs)	Porphyromonas gingivialis (P. gingivalis) infection treatment	upregulated	30378773
2313	Human	hsa-miR-146a	miRNA	porphyromonas gingivalis	periodontitis	Human periodontal ligament fibroblasts (HPDLFs)	Porphyromonas gingivialis (P. gingivalis) infection treatment	upregulated	30378773
2314	Human	hsa-miR-146a	miRNA	Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS)	periodontitis	Human periodontal ligament fibroblasts (HPDLFs)	Porphyromonas gingivialis (P. gingivalis) LPS treatment	upregulated	30378773
2315	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	peripheral inflammation	mesenchymal stem cells (MSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	over expression	20049872
2316	Human	hsa-miR-146a	miRNA	TGF-¦Â1	cell differentiation	human dermal fibroblasts	TGF-¦Â1 treatment	upregulated	21968601
2317	Human	hsa-miR-146a	miRNA	TGF-¦Â1	podocyte injury	Alexa Fluor 568-labeled phalloidin and HCS CellMask blue	TGF-¦Â1 treatment	downregulated	27913625
2318	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	preeclampsia (PE)	HTR8 cells; SVneo cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TRAIL downregulated the expressions of miR-146a	32090966
2319	Human	hsa-miR-146a	miRNA	TPCA-1	pro-inflammatory activity	human gingival fibroblasts (HGFs)	high concentration (10 ¦ÌM) of IRAK1/4 inhibitor or the NF-¦ÊB inhibitor treatment	downregulated	25598707
2320	Human	hsa-miR-146a	miRNA	hepatitis C virus (HCV)	promote regulatory T-cell development	Human peripheral blood mononuclear cells (PBMCs)	hepatitis C virus (HCV) infection	upregulated	27004559
2321	Human	hsa-miR-146a	miRNA	ascorbic acid	angiogenesis	?I-PDL cells and primary PDL cells	ascorbic acid?treatment	upregulated	20110513
2322	Human	hsa-miR-146a	miRNA	epstein-barr virus (EBV)	prostate cancer	Burkitt's lymphoma cells	Epstein-Barr Virus (EBV)?infection	upregulated	18347435
2323	Human	hsa-miR-146a	miRNA	IL-17A	psoriasis	human primary keratinocytes	IL-17A treatment	upregulated	31630447
2324	Human	hsa-miR-146a	miRNA	methotrexate (MTX)	psoriasis	Blood	methotrexate treatment	downregulated	26604920
2325	Human	hsa-miR-146a	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in plasma	27535005
2326	Human	hsa-miR-146a	miRNA	NB-UVB	psoriasis	Blood	NB-UVB treatment	downregulated	26604920
2327	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	human primary keratinocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31630447
2328	Human	hsa-miR-146a	miRNA	ionizing radiation (IR)	radiation-induced acute and chronic complications	EA.hy926 cells	ionizing radiation (IR) treatment	downregulated	32532422
2329	Human	hsa-miR-146a	miRNA	iguratimod	rheumatoid arthritis (RA)	rheumatoid arthritis-fibroblast-like synoviocytes (RA-FLS)	iguratimod treatment	upregulated	32662411
2330	Human	hsa-miR-146a	miRNA	quercetin	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLSs)	quercetin treatment	Quercetin treatment elevated the RNA level of miR-146a.	32216502
2331	Human	hsa-miR-146a	miRNA	tripterygium wilfordii Hook F (TwHF)	rheumatoid arthritis (RA)	RA patients peripheral blood mononuclear cells (PBMCs)	TwHF treatment	downregulated in peripheral blood mononuclear cells (PBMCs)	28514293
2332	Human	hsa-miR-146a	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
2333	Human	hsa-miR-146a	miRNA	severe fever with thrombocytopenia syndrome virus (SFTSV)	severe fever with thrombocytopenia syndrome (SFTS)	Human monocyte cell line (THP-1)-derived macrophages	Severe fever with thrombocytopenia syndrome virus (SFTSV) infection treatment	upregulated	31156641
2334	Human	hsa-miR-146a	miRNA	hydroxychloroquine	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	hydroxychloroquine treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs."	24121037
2335	Human	hsa-miR-146a	miRNA	prednisone	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	prednisone treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs"	24121037
2336	Human	hsa-miR-146a	miRNA	IFN	systemic lupus erythematosus (SLE)	THP-1 cells	interferon (IFN) treatment	downregulated	26315540
2337	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	31572547
2338	Human	hsa-miR-146a	miRNA	mycophenolic acid (MPA)	systemic lupus erythematosus (SLE)	lupus CD4(+)T cells	Mycophenolic acid (MPA) treatment	upregulated	25661834
2339	Human	hsa-miR-146a	miRNA	IL-15	T cell immunotherapy	na?ve CD8+ T cells	IL-15 treatment	upregulated	25331734
2340	Human	hsa-miR-146a	miRNA	IL-2	T cell immunotherapy	na?ve CD8+ T cells	IL-2 treatment	upregulated	25331734
2341	Human	hsa-miR-146a	miRNA	human immunodeficiency virus (HIV)-1	thyroid cancer (TC)	primary human fetal microglial cells	HIV-1 infection	upregulated	20181935
2342	Human	hsa-miR-146a	miRNA	thyroid stimulating hormone	thyroid eye disease (TED)	orbital fibroblasts (OFs)	thyroid stimulating hormone treatment	upregulated	31622470
2343	Human	hsa-miR-146a	miRNA	IL-1¦Â	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	interleukin (IL)-1¦Â treatment	downregulated	29467762
2344	Human	hsa-miR-146a	miRNA	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	LPS-treated primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) treatment	downregulated	29467762
2345	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	lipopolysaccharide (LPS) treatment	upregulated	29467762
2346	Human	hsa-miR-146a	miRNA	acyclovir	type 2 diabetes mellitus (T2DM)	human primary brain cells	acyclovir treatment	downregulated	20683212
2347	Human	hsa-miR-146a	miRNA	amyloid-¦Â (A¦Â) 42	type 2 diabetes mellitus (T2DM)	human primary brain cells	amyloid-¦Â (A¦Â) 44 peptide metal treatment	downregulated	20683212
2348	Human	hsa-miR-146a	miRNA	butyrate and inulin	type 2 diabetes mellitus (T2DM)	peripheral blood mononuclear cells (PBMCs)	butyrate and inulin treatment	butyrate and concomitant use of butyrate and inulin caused a significant increase in the fold change of miR-146a and miR-9 compared with the placebo group.	32315958
2349	Human	hsa-miR-146a	miRNA	IL-1¦Â and TNF-¦Á	type 2 diabetes mellitus (T2DM)	human pancreatic islets	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
2350	Human	hsa-miR-146a	miRNA	chuyou yuyang granule (CYYY)	ulcer relapse	Helicobacter pylori (HP) infected Peptic ulcert patients blood	Chuyou Yuyang granule (CYYY) four weeks or six weeks treatment	downregulated	31034651
2351	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	urethral stricture	human umbilical cord-derived mesenchymal stem cells (MSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	"Exosomes derived from MSCs pretreated with TNF-¦Á were more effective in suppressing urethral fibrosis and stricture than exosomes from untreated MSCs We found that miR-146a, an anti-inflammatory miRNA, was strongly upregulated in TNF-¦Á-stimulated MSCs and was selectively packaged into exosomes"	31144307
2352	Human	hsa-miR-146a	miRNA	baicalin (BAI)	influenza A virus (IAV) infection	IVA-infected A549 cells	baicalin (BAI) treatment	downregulated	31638222
2353	Human	hsa-miR-146a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	H1N1 and H3N2 viruses infection	upregulated	31638222
2354	Human	hsa-miR-146a	miRNA	zinc	zinc deficiency illnesses	Jurkat T cells	zinc deficiency treatment	downregulated	30316032
2355	Human	hsa-miR-146a	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	primary human monocytes; THP-1 cells	dengue virus (DENV)infection	upregulated	23685241
2356	Human	hsa-miR-146a	miRNA	histone deacetylase inhibitor (HDACi)	osteoarthritis (OA)	fibroblast-like synoviocytes (OA-FLS)	Histone deacetylase inhibitors?treatment	upregulated	24107356
2357	Human	hsa-miR-146a	miRNA	hepatitis B virus (HBV)	vascular smooth muscle cell calcification	HepG2.2.15 cells	hepatitis B virus (HBV) infection	MiR146a was upregulated in HBV+ HepG2.2.15 cells	23890093
2358	Human	hsa-miR-146a-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Human normal lung epithelial cell line BEAS-2B	lipopolysaccharide (LPS) treatment	Reduced SIRT1 and raised miR-146a-3p were found in LPS-induced BEAS-2B cells and ALI rats.	33185125
2359	Human	hsa-miR-146a-3p	miRNA	lipoteichoic acid (LTA)	lower respiratory tract infections	BEAS-2B cells	lipoteichoic acid (LTA) treatment	upregulated	31837465
2360	Human	hsa-miR-146a-3p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	lower respiratory tract infections	BEAS-2B cells	poly(I:C) treatment	upregulated	31837465
2361	Human	hsa-miR-146a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	lower respiratory tract infections	BEAS-2B cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31837465
2362	Human	hsa-miR-146a-5p	miRNA	zhenbao pill	acute spinal cord injury (ASCI)	hypoxia-induced SH-SY5Y cells	zhenbao pill treatment	upregulated	29187582
2363	Human	hsa-miR-146a-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	LINC01311 was downregulated whereas hsa-miR-146a-5p upregulated in AB1-42 treated SH-SY5Y cells.	33830627
2364	Human	hsa-miR-146a-5p	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	asthma	A549 cells	"cytokine mixture containing IFN-¦Ã, IL-1¦Â and TNF-¦Á treatment"	upregulated	31698144
2365	Human	hsa-miR-146a-5p	miRNA	long-chain polyunsaturated fatty acids (LCPUFAs)	asthma	"cytokine mixture containing IFN-¦Ã, IL-1¦Â and TNF-¦Á-treated A549 cells"	long-chain polyunsaturated fatty acids (LCPUFAs) treatment	upregulated	31698144
2366	Human	hsa-miR-146a-5p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	downregulated	30245930
2367	Human	hsa-miR-146a-5p	miRNA	doxorubicin (DOX)	breast cancer	MDA-MB-231 cells	doxorubicin treatment	downregulated	30245930
2368	Human	hsa-miR-146a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MCF-7 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	downregulated	30245930
2369	Human	hsa-miR-146a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MDA-MB-231 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	downregulated	30245930
2370	Human	hsa-miR-146a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
2371	Human	hsa-miR-146a-5p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
2372	Human	hsa-miR-146a-5p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	downregulated	28749179
2373	Human	hsa-miR-146a-5p	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	"Human hepatic cell line, THLE-2"	hepatitis B virus (HBV) infection	upregulated	31018043
2374	Human	hsa-miR-146a-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	dental pulp in?ammation	human dental pulp cells (hDPCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30952010
2375	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	dental pulp in?ammation	human dental pulp cells (hDPCs)	lipopolysaccharide (LPS) treatment	upregulated	30952010
2376	Human	hsa-miR-146a-5p	miRNA	hypoxia	diabetic retinopathy (DR)	ARPE©\19 cells	hypoxia treatment	downregulated	31094072
2377	Human	hsa-miR-146a-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
2378	Human	hsa-miR-146a-5p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
2379	Human	hsa-miR-146a-5p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	30197683
2380	Human	hsa-miR-146a-5p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â1 treatment	CHRF and L1CAM expression were significantly upregulated and promoted the EMT process in A549 after treatment of TGF-¦Â1	33754922
2381	Human	hsa-miR-146a-5p	miRNA	dexamethasone (DEX)	inflammation	"TNF-¦Á-treated A549 human lung carcinoma cell, NuLi-1 immortalized, normal human bronchial epithelial cells"	dexamethasone (DEX) treatment	downregulated	30300399
2382	Human	hsa-miR-146a-5p	miRNA	particulate matter (PM2.5)	inflammation	THP-1 cells	particulate matter (PM2.5) treatment	upregulated	33160737
2383	Human	hsa-miR-146a-5p	miRNA	particulate matter (PM2.5)	inflammation	human monocytic leukemia cell line (THP-1)	PM2.5?extracts?treatment treatment	"?we observed expression of miR-146a-5p was significantly increased, with the maximal response of six folds in WN group"	33160737
2384	Human	hsa-miR-146a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	"A549 human lung carcinoma cell, NuLi-1 immortalized, normal human bronchial epithelial cells"	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30300399
2385	Human	hsa-miR-146a-5p	miRNA	high glucose (HG)	diabetic vasculopathy	human aortic endothelial cells (HAECs)	high glucose (HG)	downregulated	28824448
2386	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	inflammatory response	macrophages	lipolysaccharide (LPS) treatment	upregulated	25805648
2387	Human	hsa-miR-146a-5p	miRNA	hepatitis A virus (HAV)	innate immune response	The human embryonic lung fbroblast cell line KMB17	hepatitis A virus (HAV) infection	HAV infection upregulates the expression of hsa-miR-146a-5p	33459883
2388	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	liver fibrosis	human HSC line LX-2	LPS treatment	downregulated	28739486
2389	Human	hsa-miR-146a-5p	miRNA	TGF-¦Â1	liver fibrosis	human HSC line LX-2	TGF¦Â1 treatment	downregulated	28739486
2390	Human	hsa-miR-146a-5p	miRNA	TGF-¦Â1	liver fibrosis	human hepatic stellate cell line LX2	TGF-¦Â1 treatment	downregulated	31560641
2391	Human	hsa-miR-146a-5p	miRNA	X rays	liver fibrosis	human hepatic stellate cell line LX2	LX2 cells were stimulated with 8 Gy of X rays treatment	downregulated	31560641
2392	Human	hsa-miR-146a-5p	miRNA	BRAF and MEK inhibitor	melanoma	LM16R cells; LM69 cells; LM70 cells	BRAF and MEK inhibitor treatment	miR-146a-5p expression was reduced in BRAF and MEK inhibitor-resistant melanoma cells and tissues.	31915008
2393	Human	hsa-miR-146a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
2394	Human	hsa-miR-146a-5p	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	downregulated	31484042
2395	Human	hsa-miR-146a-5p	miRNA	CXCR4 antagonist TN14003	osteoarthritis (OA)	SDF-1-treated OA chondrocytes	CXCR4 antagonist TN14003 treatment	upregulated	30942441
2396	Human	hsa-miR-146a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-9¦Â treatment	dysregulated	29123165
2397	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	human lung fibroblasts cell WI-38	lipopolysaccharide (LPS) treatment	SNHG16 regulated LPS-induced inflammation injury in WI-38 cells through competitively binding miR-146a-5p with CCL5 further mediating JNK and NF-¦ÊB pathways	31071307
2398	Human	hsa-miR-146a-5p	miRNA	ethanol (EtOH)	prostate cancer	cancer-associated fibroblasts (CAFs)	ethanol (ETOH) treatment	MiR-146a-5p level in exosomes from ETOH-treated CAFs was significantly reduced.	33317606
2399	Human	hsa-miR-146a-5p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
2400	Human	hsa-miR-146a-5p	miRNA	adalimumab(ADA)	psoriasis	circulating angiogenic cells (CACs)	adalimumab treatment	downregulated	26943583
2401	Human	hsa-miR-146a-5p	miRNA	ionizing radiation (IR)	radiation-induced liver disease (RILD)	LX-2 cells	ionizing radiation (IR) treatment	upregulated	29348414
2402	Human	hsa-miR-146a-5p	miRNA	irradiation and lipopolysaccharide (LPS)	radiation-induced liver disease (RILD)	LX-2 cells	irradiation and lipopolysaccharide (LPS) treatment	Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway.	32097101
2403	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	radiation-induced liver disease (RILD)	LX-2 cells	lipopolysaccharide (LPS) treatment	upregulated	29348414
2404	Human	hsa-miR-146a-5p	miRNA	radiation	radiation-induced liver disease (RILD)	LX2 cells	radiation treatment	downregulated	31960423
2405	Human	hsa-miR-146a-5p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
2406	Human	hsa-miR-146a-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	whole-blood	methotrexate (MTX) treatment	downregulated	30511295
2407	Human	hsa-miR-146a-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	RA patients whole-blood	methotrexate (MTX) treatment	upregulated	30511295
2408	Human	hsa-miR-146a-5p	miRNA	resolvin D1 (RvD1)	rheumatoid arthritis (RA)	fibroblast-like synoviocyte (FLS)	resolvin D1 (RvD1) treatment	RvD1 upregulated miRNA-146a-5p	32216830
2409	Human	hsa-miR-146a-5p	miRNA	sulforaphane (SFN)	staphylococcus aureus infection	THP-1 cells	sulforaphane (SFN) treatment	SFN pretreatment of the THP-1-derived macrophages significantly attenuated the S aureus-mediated increased expression levels of miR-146a-5p	32323751
2410	Human	hsa-miR-146a-5p	miRNA	ultraviolet (UV) irradiation	skin photoaging	human dermal fibroblasts (HDFs)	UVA irradiation treatment	downregulated	33025709
2411	Human	hsa-miR-146b	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
2412	Human	hsa-miR-146b	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	asthma	human airway smooth muscle cells (hASMCs)	"cytomix (IL-1¦Â, TNF-¦Á, and IFN¦Ã) treatment"	upregulated	25217662
2413	Human	hsa-miR-146b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31479774
2414	Human	hsa-miR-146b	miRNA	atorvastatin	coronary artery disease (CAD)	PBMCs (peripheral blood mononuclear cells)	atorvastatin and telmisartan or atorvastatin treatment	downregulated	20524934
2415	Human	hsa-miR-146b	miRNA	suberoylanilide hydroxamic acid (SAHA)	tumorigenesis	MEG-01 cells; HEK-293 cells	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	23543665
2416	Human	hsa-miR-146b	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
2417	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	gingival inflammation	Human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	29407755
2418	Human	hsa-miR-146b	miRNA	TGF-¦Â	intestinal cell differentiation	intestinal epithelial cell (IEC-6)	Growth factor TGF-¦Â?treatment treatment	miR-146b expression increased rapidly	22570175
2419	Human	hsa-miR-146b	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
2420	Human	hsa-miR-146b	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
2421	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	Human renal mesangial cells (HRMCs)	lipopolysaccharide (LPS) treatment	"NEAT1 accelerated renal mesangial cell injury via directly targeting miR-146b, promoting the expression of TRAF6, and activating the NF-¦ÊB signaling in lupus nephritis."	32710276
2422	Human	hsa-miR-146b	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
2423	Human	hsa-miR-146b	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
2424	Human	hsa-miR-146b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid (PA) treatment	downregulated	32143184
2425	Human	hsa-miR-146b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	downregulated	32143184
2426	Human	hsa-miR-146b	miRNA	TNF-¦Á and IL-6	obesity	mature human adipocytes	TNF-¦Á and IL-6 treatment	upregulated	24428800
2427	Human	hsa-miR-146b	miRNA	platelet-derived growth factor (PDGF)	oral cavity cancer	U118-MG cells£»U87-MG glioblastoma cells£» human WI-38 fibroblasts?£» ovarian cells C272/hTert/E7	Platelet derived growth factor (PDGF)? treatment	upregulated	21266476
2428	Human	hsa-miR-146b	miRNA	IL-1¦Â	osteoporosis	A549 cells	IL-1¦Â treatment	downregulated	19786024
2429	Human	hsa-miR-146b	miRNA	proinflammatory cytokines	otitis media (OM)	Human middle ear epithelial cells	proinflammatory cytokines treatment	upregulated	27497395
2430	Human	hsa-miR-146b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
2431	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 human lung fibroblasts cells	lipopolysaccharide (LPS) treatment	downregulated	31583932
2432	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	miR-146b was downregulated in WI-38 cells treated with LPS.	31583932
2433	Human	hsa-miR-146b	miRNA	TPCA-1	pro-inflammatory activity	human gingival fibroblasts (HGFs)	high concentration (10 ¦ÌM) of IRAK1/4 inhibitor or the NF-¦ÊB inhibitor treatment	downregulated	25598707
2434	Human	hsa-miR-146b	miRNA	Salmonella Typhimurium	salmonella typhimurium infection	human HeLa cells	Salmonella Typhimurium infection treatment	upregulated	21468030
2435	Human	hsa-miR-146b	miRNA	severe fever with thrombocytopenia syndrome virus (SFTSV)	severe fever with thrombocytopenia syndrome (SFTS)	Human monocyte cell line (THP-1)-derived macrophages	Severe fever with thrombocytopenia syndrome virus (SFTSV) infection treatment	upregulated	31156641
2436	Human	hsa-miR-146b	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	plasma and myocardial cells	coxsackievirus B3 (CVB3) treatment	upregulated	25815880
2437	Human	hsa-miR-146b-3p	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
2438	Human	hsa-miR-146b-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	thrombosis	THP-1 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32337281
2439	Human	hsa-miR-146b-5p	miRNA	ultraviolet (UV) irradiation	DNA damage	U2OS;EH1; EH2 cell lines	ultraviolet light treatment	upregulated	24163379
2440	Human	hsa-miR-146b-5p	miRNA	TNF-¦Á£¬IGF-1	atherosclerosis (AS)	smooth muscle cell	TNF-¦Á£¬IGF-1 treatment	upregulated	26047583
2441	Human	hsa-miR-146b-5p	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
2442	Human	hsa-miR-146b-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell differentiation	THP-1 cells stimulated with phorbol 12-myristate 13-acetate (100 nM)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29201219
2443	Human	hsa-miR-146b-5p	miRNA	"cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)"	diffuse large B-cell lymphoma (DLBCL)	patients with DLBCL	CHOP treatment	downregulated	24931464
2444	Human	hsa-miR-146b-5p	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
2445	Human	hsa-miR-146b-5p	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
2446	Human	hsa-miR-146b-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	human Ishikawa cells	Progesterone treatment	miR-146b-5p was notably decreased in Ishikawa cells while upregulated after treatment with progesterone	30452118
2447	Human	hsa-miR-146b-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	progesterone treatment	miR-146b-5p was notably decreased in Ishikawa cells	30452118
2448	Human	hsa-miR-146b-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec4A cells	Progesterone treatment	upregulated	22543862
2449	Human	hsa-miR-146b-5p	miRNA	p-cresol (PcEMV)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	p-cresol (PcEMV) treatment	upregulated	32606426
2450	Human	hsa-miR-146b-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	human RPE cells	interferon-¦Ã treatment	upregulated	23592910
2451	Human	hsa-miR-146b-5p	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	human RPE cells	IL-1¦Â treatment	upregulated	23592910
2452	Human	hsa-miR-146b-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	papillary thyroid carcinoma cell line BCPAP	TGF-¦Â1 treatment	upregulated	24946010
2453	Human	hsa-miR-146b-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	epithelial-mesenchymal transition (EMT)	human RPE cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23592910
2454	Human	hsa-miR-146b-5p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	U87-MG and U251 cells	Sevoflurane (Sev) treatment	upregulated	31385537
2455	Human	hsa-miR-146b-5p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	A172 cells; U251 cells	sevoflurane (Sev) treatment	"KCNQ1OT1 knockdown mediated the role of Sev in glioma cell proliferation, apoptosis, migration, and invasion both in vitro and in vivo through miR-146b-5p/STC1 pathway"	32996777
2456	Human	hsa-miR-146b-5p	miRNA	IL-6	hepatocarcinogenesis	non-transformed liver-derived PH5CH8 and THLE2 cells and in Huh-7 hepatoma cells	Interleukin-6 (IL-6) treatment	upregulated	30145833
2457	Human	hsa-miR-146b-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
2458	Human	hsa-miR-146b-5p	miRNA	EGFR tyrosine kinase inhibitors (TKIs)	lung cancer	lung cancer cells	EGFR tyrosine kinase inhibitors (TKIs) treatment	miR-146b-5p expression in lung cancer cells isolated from pleural effusions of treatment-naive patients was significantly higher than that after acquiring resistance to EGFR TKI treatment.	33230450
2459	Human	hsa-miR-146b-5p	miRNA	hypoxia	myocardial infarction (MI)	serum	hypoxia treatment	"Herein, miR-146b-5p was found to be upregulated in the infarcted myocardium of mice and the serum of myocardial ischemia patients."	32845445
2460	Human	hsa-miR-146b-5p	miRNA	dioxin	neuroblastoma (NB)	SK-N-SH cells	dioxin treatment	upregulated	29406108
2461	Human	hsa-miR-146b-5p	miRNA	dioxin	neuroblastoma (NB)	SK-N-SH cells	dioxin treatment	upregulated	29406108
2462	Human	hsa-miR-146b-5p	miRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	BxPC-3 cells; HPAC cells	cucurbitacin B (CuB) treatment	MiR-146b-5p is expressed differentially after CuB treatment and is associated with the EGFR.	30206930
2463	Human	hsa-miR-146b-5p	miRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	"Human PC cell lines, ASPC©\1, BxPC©\3, HPAC, MiaPaCa©\2"	cucurbitacin B (CuB) treatment	CuB-induced high miR-146b-5p expression and inhibited the expression of AFAP1-AS1.	30206930
2464	Human	hsa-miR-146b-5p	miRNA	p16 INK4A	cell senescence	human fibroblast and epithelial cells	p16 INK4A treatment	upregulated	27596953
2465	Human	hsa-miR-147	miRNA	hypoxia	breakdown of blood-brain barrier (BBB)	PC12 cells	hypoxia treatment	downregulated	29130945
2466	Human	hsa-miR-147	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
2467	Human	hsa-miR-147	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
2468	Human	hsa-miR-147	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	blood	Metformin treatment	upregulated	30297296
2469	Human	hsa-miR-1470	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose treatment	downregulated	30784065
2470	Human	hsa-miR-1471	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
2471	Human	hsa-miR-147a	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	cervical cancer (CC)	HeLa cells; ATCC cells; CCL-2 cells	HIF1¦Á treatment	upregulated	27260617
2472	Human	hsa-miR-147a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	downregulated	33009725
2473	Human	hsa-miR-147a	miRNA	sodium new houttuyfonate (SNH)	non-small cell lung cancer (NSCLC)	A549 and NCI-H1299 cells	sodium new houttuyfonate (SNH) treatment	upregulated	30971296
2474	Human	hsa-miR-147b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	MiR-147b was downregulated in lipopolysaccharide (LPS)-induced ALI rats and LPS-treated A549 cells	33660808
2475	Human	hsa-miR-147b	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (VSMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	30060075
2476	Human	hsa-miR-148-3p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	downregulated	29901102
2477	Human	hsa-miR-148-3p	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	upregulated	32028542
2478	Human	hsa-miR-148-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
2479	Human	hsa-miR-148a	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
2480	Human	hsa-miR-148a	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	human monocyte leukemia cell line THP-1	homocysteine	upregulated	28472596
2481	Human	hsa-miR-148a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	tamoxifen sensitive (TamS) MCF-7 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28063929
2482	Human	hsa-miR-148a	miRNA	ailanthone (AIL)	breast cancer	DA-MB-231 cells	ailanthone (AIL) treatment	upregulated	30551356
2483	Human	hsa-miR-148a	miRNA	ailanthone (AIL)	breast cancer	MDA-MB-231 cells	ailanthone (AIL) treatment	upregulated	30551356
2484	Human	hsa-miR-148a	miRNA	estradiol	breast cancer	breast cancer cells	Estradiol treatment	downregulated	25928008
2485	Human	hsa-miR-148a	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-7 and MDA-MB-231 cells	estradiol-17¦Â (E2) treatment	upregulated	25063027
2486	Human	hsa-miR-148a	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
2487	Human	hsa-miR-148a	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 and Hs-578T breast cancer cell lines	Glabridin (GLA) treatment	upregulated	25980823
2488	Human	hsa-miR-148a	miRNA	glabridin (GLA)	breast cancer	human breast cancer (MDA-MB-231 and Hs-578T) cells	glabridin (GLA)	downregulated	28464803
2489	Human	hsa-miR-148a	miRNA	caffeic acid	tumorigenesis	Human TNBC cell line	caffeic acid (CA) treatment	upregulated	26106521
2490	Human	hsa-miR-148a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human bone mesenchymal stromal cells (hBMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28656724
2491	Human	hsa-miR-148a	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
2492	Human	hsa-miR-148a	miRNA	radiation	cervical cancer (CC)	SiHa cells; Hela cells	radiation treatment	LncRNA SNHG12 promoted CDK1 expression to regulate the sensitivity of CC cells to radiation through sponging miR-148a	33292254
2493	Human	hsa-miR-148a	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	p53-mutant MEG-01 cells	fludarabine treatment	specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets	20504344
2494	Human	hsa-miR-148a	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cell line	cisplatin treatment	MicroRNA (miRNA) array and qRT-PCR assay identified the downregulated of miR-148a in cisplatin-resistant SW480 cells.	30551544
2495	Human	hsa-miR-148a	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cells	criplatin (DPP) treatment	downregulated	30551544
2496	Human	hsa-miR-148a	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
2497	Human	hsa-miR-148a	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	SGC-7901 cells	Helicobacter pylori £¨H. pylori£©infection	downregulated	29604247
2498	Human	hsa-miR-148a	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
2499	Human	hsa-miR-148a	miRNA	nuclear factor kappa-B (NF-¦ÊB)	glioblastoma multiforme (GBM)	glioblastoma cells	NF-¦ÊB treatment	upregulated	25971746
2500	Human	hsa-miR-148a	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	drug resistant (MDR) Bel-7402 cells (BelMDR) cells	arsenic trioxide (ATO) treatment	upregulated	31759055
2501	Human	hsa-miR-148a	miRNA	rhamnetin	hepatocellular carcinoma (HCC)	HCC cells	rhamnetin treatment	rhamnetin increased expression of miR-148a (which is tumor-suppressive) in a P53-dependent manner	33570057
2502	Human	hsa-miR-148a	miRNA	serum-free MSCM	inflammation	human adipose tissue-derived mesenchymal stem cells (hMSCs-Ad)	human adipose tissue-derived mesenchymal stem cells (hMSCs-Ad) treatment	upregulation	27878286
2503	Human	hsa-miR-148a	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	downregulated	30186499
2504	Human	hsa-miR-148a	miRNA	estradiol	intrahepatic cholestasis of pregnancy (ICP)	LO2 cells	estradiol treatment	upregulated	28575098
2505	Human	hsa-miR-148a	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) X protein (HBx) treatment	downregulated	23321675
2506	Human	hsa-miR-148a	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	Dendritic cells (DCs)	lipopolysaccharide (LPS) treatment	downregulated	27714813
2507	Human	hsa-miR-148a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
2508	Human	hsa-miR-148a	miRNA	Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS)	periodontitis	periodontal ligament stem cells (PDLSCs)	Porphyromonas gingivalis lipopolysaccharide (LPS) treatment	upregulated	31809209
2509	Human	hsa-miR-148a	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	hepatocellular carcinoma (HCC)	CD14+ peripheral blood mononuclear cells (PBMCs)	receptor activator of nuclear factor-¦ÊB ligand (RANKL) treatment	upregulated	23225151
2510	Human	hsa-miR-148a	miRNA	macrophage colony stimulating factor (M-CSF)	osteoporosis	CD14+ PBMCs	macrophage colony stimulating factor (M-CSF) treatment	upregulated	23225151
2511	Human	hsa-miR-148a-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
2512	Human	hsa-miR-148a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRECs)	high glucose (HG) treatment	HG treatment reduced miR-148a-3p level in HRECs.	32661705
2513	Human	hsa-miR-148a-3p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
2514	Human	hsa-miR-148a-3p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	upregulated	31176168
2515	Human	hsa-miR-148a-5p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	upregulated	32582989
2516	Human	hsa-miR-148a-5p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	upregulated	31176168
2517	Human	hsa-miR-148a-5p	miRNA	metformin (Met)	preeclampsia (PE)	Trophoblast and HUVEC cells	Metformin (Met) treatment	upregulated	31203154
2518	Human	hsa-miR-148b	miRNA	statins	asthma	Immortalized lymphoblastoid cell lines (LCLs)	statins? treatment	upregulated	25266681
2519	Human	hsa-miR-148b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs).	oxidized low-density lipoprotein (ox-LDL) treatment	The level of H19 was increased and miR-148b expression was decreased in human AS patient serums and oxidized low-density lipoprotein (ox-LDL)-stimulated human aorta vascular smooth muscle cells (HA-VSMCs).	29415742
2520	Human	hsa-miR-148b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human VSMC; human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 knockdown attenuated ox-LDL-induced injury through regulating proliferation and apoptosis of VSMC and HUVEC by miR-148b/IGF2 axis	31926240
2521	Human	hsa-miR-148b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Proliferation and migration were modified by MIAT/miR-148b/PAPPA axis in ox-LDL induced AS cell model.	32470448
2522	Human	hsa-miR-148b	miRNA	radiation	breast cancer	MCF-7 cells; MDA-MB-231 cells	radiation treatment	Radiation treatment triggered a significant increase in CCAT1 and an obvious decrease in miR-148b	29024383
2523	Human	hsa-miR-148b	miRNA	X-rays	breast cancer	human breast cancer cell lines MCF-7 and MDA-MB-231	radiation treatment	downregulated	29024383
2524	Human	hsa-miR-148b	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
2525	Human	hsa-miR-148b	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	patients with chronic myeloid leukemia (CML)	discontinuing imatinib mesylate (IM) treatment	downregulated	25187697
2526	Human	hsa-miR-148b	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
2527	Human	hsa-miR-148b	miRNA	remnant-like lipoproteins (RLPs)	ePCs senescence	Total peripheral mononuclear cells (PB-MNCs)	Remnant-like lipoproteins (RLPs) treatment	miR-148b and miR-155 were upregulated while miR-574-3p was downregulated	23044309
2528	Human	hsa-miR-148b	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
2529	Human	hsa-miR-148b	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	Dendritic cells (DCs)	lipopolysaccharide (LPS) treatment	downregulated	27714813
2530	Human	hsa-miR-148b-3p	miRNA	hypoxia	hypoxia-induced injury	human hepatic sinusoidal endothelial cells (HHSEC)	hypoxia induce	downregulated	31082428
2531	Human	hsa-miR-148b-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
2532	Human	hsa-miR-148b-3p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
2533	Human	hsa-miR-148b-3p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-148b-3p was downregulated in treated patients when compared with untreated patients.	29523324
2534	Human	hsa-miR-149	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	33428703
2535	Human	hsa-miR-149	miRNA	platelet activating factor (PAF)	asthma	Human small airway epithelial cells (HSAECs)	platelet activating factor (PAF) treatment	LncRNA PVT1 exacerbates the inflammation and cell-barrier injury during asthma by regulating miR-149	32830409
2536	Human	hsa-miR-149	miRNA	TmPyP4 (Porphyrin)	breast cancer	MCF-7 breast cancer cells	TmPyP4 (Porphyrin) treatment	upregulated	30585723
2537	Human	hsa-miR-149	miRNA	formononetin	colorectal cancer (CRC)	colon carcinoma cell lines SW1116 and HCT116	Formononetin (Form) treatment	upregulated	29620230
2538	Human	hsa-miR-149	miRNA	bisphenol A (BPA)	endometrial cancer (EC)	human endometrial cancer RL95-2 cells	bisphenol A (BPA) treatment	downregulated	28238728
2539	Human	hsa-miR-149	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	Eahy926 and HUVEC	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	24299952
2540	Human	hsa-miR-149	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	Eahy926 endothelial cells and HUVEC	TNF¦Á treatment	downregulated	24299952
2541	Human	hsa-mir-149	miRNA	fibroblast growth factor 2 (FGF2)	fine tunes the angiogenic	endothelial cells (ECs)	FGF2 treatment	upregulated	24463821
2542	Human	hsa-miR-149	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer (GC) tissues; AGS cells	5-fluorouracil (5-FU) treatment	miR-149 was significantly increased in 5-FU resistant tumor tissues and cells.	32977944
2543	Human	hsa-miR-149	miRNA	paeoniflorin	gastric cancer (GC)	Paired gastric normal fifbroblast (GNF) and gastric cancer associated fibroblasts (GCAFs) cultures	Paeoniflorin (PF) treatment	upregulated	30361813
2544	Human	hsa-miR-149	miRNA	paeoniflorin	gastric cancer (GC)	gastric cancer associated fibroblasts (GCAFs)	Paeoniflorin (PF) treatment	Paeoniflorin suppressed IL-6 production and secretion by up-regulating microRNA149 expression in GCAFs	30361813
2545	Human	hsa-miR-149	miRNA	triptolide (TPL)	gastric cancer (GC)	gastric cancer-associated fibroblasts (GCAFs)	triptolide (TPL) treatment	downregulated miR-301a expression and upregulated miR-149	29049979
2546	Human	hsa-miR-149	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	human glioma-derived cell lines U251 and U87	TMZ treatment	downregulated	25017996
2547	Human	hsa-miR-149	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hypermethylation	U87MG cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"Treatment of U87MG cells with 5-aza-dC reversed the hypermethylation status of miR-149,"	27783537
2548	Human	hsa-miR-149	miRNA	glucocorticoid (GC)	myeloma	sensitive RPMI-8226 cell line	chronic glucocorticoid exposure	downregulated	28035377
2549	Human	hsa-miR-149	miRNA	"N,N'-dinitrosopiperazine (DNP)"	nasopharyngeal carcinoma (NPC)	6-10B cells	"N,N'-dinitrosopiperazine (DNP) treatment"	upregulated	30144176
2550	Human	hsa-miR-149	miRNA	long-chain fatty acid	nonalcoholic fatty liver disease (NAFLD)	liver cells genotyped as TT	long-chain fatty acid treatment	upregulated	28507283
2551	Human	hsa-miR-149	miRNA	IL-1¦Â	osteoarthritis (OA)	Human normal chondrocytes	IL-1¦Â treatment	downregulated	29524885
2552	Human	hsa-miR-149	miRNA	Silica	lung fibrosis	"A549 , HBE cell"	silica treatment	downregulated	24641842
2553	Human	hsa-miR-149*	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
2554	Human	hsa-miR-149-3p	miRNA	quinidine	cell proliferation and apoptosis	human glioma U87-MG cells	quinidine treatment	the upregulation of miR-149-3p and downregulated of miR-424-5p	25420507
2555	Human	hsa-miR-149-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HBE135-E6E7 cells	cigarette smoke extract (CSE) treatment	MEG3 promoted proliferation and inhibited apoptosis by regulating the NF-¦ÊB signal pathway via miR-149-3p in CSE-treated HBE cells.	33365060
2556	Human	hsa-miR-149-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	THP-1 cells	cigarette smoke?extract?(CSE) treatment	downregulated	28260877
2557	Human	hsa-miR-149-3p	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	"HCT116, SW480 and SW620 cells"	?cisplatin treatment	downregulated	31866582
2558	Human	hsa-miR-149-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
2559	Human	hsa-miR-149-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
2560	Human	hsa-miR-149-3p	miRNA	maimendong and qianjinweijing tang (Jin formula)	lung cancer	A549 cells; H1299 cells	Maimendong and Qianjinweijing Tang (Jin formula) treatment	Maimendong and Qianjinweijing Tang (Jin formula) suppresses lung cancer by regulation of miR-149-3p.	32344160
2561	Human	hsa-miR-149-3P	miRNA	dioscin	pancreatic cancer (PC)	ASPC-1 and PANC-1 cell	dioscin treatment	upregulated	28095588
2562	Human	hsa-miR-149-5p	miRNA	oxaliplatin	advanced colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer	33251049
2563	Human	hsa-miR-149-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circular RNA circ_0124644 exacerbates the ox-LDL-induced endothelial injury in human vascular endothelial cells through regulating PAPP-A by acting as a sponge of miR-149-5p.	32500475
2564	Human	hsa-miR-149-5p	miRNA	ursolic acid (UA)	breast cancer	MDA-MB-231 (231) and MDA-MB-231/PTX-resistance (231/PTX) cells	ursolic acid (UA) treatment	upregulated	31259152
2565	Human	hsa-miR-149-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	vascular smooth muscle cells (VSMCs)	PDGF-bb treatment	downregulated	31595884
2566	Human	hsa-miR-149-5p	miRNA	serum samples from patients with T2DM	endoplasmic reticulum stress (ERS)	human umbilical vein endothelial cells (HUVECs)	incubated with serum samples from patients with T2DM treatment	downregulated	28848152
2567	Human	hsa-miR-149-5p	miRNA	lipoteichoic acid (LTA)	inflammation	BEAS-2B cells	?lipoteichoic acid treatment	downregulated	31837465
2568	Human	hsa-miR-149-5p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	inflammation	BEAS-2B cells	viral dsRNA analogue poly(I:C) treatment	downregulated	31837465
2569	Human	hsa-miR-149-5p	miRNA	lipoteichoic acid (LTA)	lower respiratory tract infections	BEAS-2B cells	lipoteichoic acid (LTA) treatment	downregulated	31837465
2570	Human	hsa-miR-149-5p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	lower respiratory tract infections	BEAS-2B cells	poly(I:C) treatment	downregulated	31837465
2571	Human	hsa-miR-149-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	lower respiratory tract infections	BEAS-2B cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31837465
2572	Human	hsa-miR-149-5p	miRNA	IL-6	osteoarthritis (OA)	human chondrocyte-articular (HC-a) cells	IL-6?treatment	downregulated	32141427
2573	Human	hsa-miR-149-5p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human ¦Â-cells	cytokines IL-1¦Â plus IFN-¦Ã treatment	dysregulated	27737950
2574	Human	hsa-miR-149-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	vascular restenosis	human aortic vascular smooth muscle cell (HA-VSMC)	platelet derived growth factor-BB (PDGF-BB) treatment	downregulated	32736703
2575	Human	hsa-miR-15	miRNA	ginsenoside Rg1	angiogenesis	human umbilical vein endothelial cells (HUVECs)	ginsenoside-Rg1 treatment	downregulated	23688497
2576	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	bedsore	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	31692058
2577	Human	hsa-miR-15	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
2578	Human	hsa-miR-15	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells	5-fluorouracil (5-FU) treatment	miR-15 expression was significantly upregulated in HCT116 cells treated with 5-Fu.	29467857
2579	Human	hsa-miR-15	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells	oxaliplatin (OXA) treatment	miR-15 expression was significantly upregulated in HCT116 cells treated with OX.	29467857
2580	Human	hsa-miR-15	miRNA	fibroblast growth factor 4 (FGF4)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	FGF4 treatment	upregulated	30753902
2581	Human	hsa-miR-15	miRNA	hepatocyte growth factor (HGF)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	HGF treatment	upregulated	30753902
2582	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	inflammation	Human WI©\38 cells	lipopolysaccharide (LPS) treatment	"MIAT2 reversely regulated miR-15 and miR-15 mimic could reverse the effects of MIAT2. Finally, MIAT2 restrained the p38MAPK and NF-¦ÊB pathways by downregulating miR-15."	31566734
2583	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	inflammatory injury	HaCaT cells	lipopolysaccharide (LPS) treatment	circANKRD36 remitted cell inflammatory damage upregulating miR-15/MyD88 via the NF-¦ÊB pathway in HaCaT cells.	31692058
2584	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	MIAT2 restrained the p38MAPK and NF-¦ÊB pathways by downregulating miR-15.	31566734
2585	Human	hsa-miR-15	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	human RA fibroblast-like synoviocyte (FLS) cell line MH7A cells	IL-1¦Â treatment	downregulated	31611200
2586	Human	hsa-miR-150	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	nucleus pulposus cells	IL-1¦Â treatment	downregulated	31726456
2587	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cell	lipopolysaccharide (LPS) treatment	downregulated	31398659
2588	Human	hsa-miR-150	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
2589	Human	hsa-miR-150	miRNA	oxidized low density lipoprotein (ox-LDL)	angiogenesis	human umbilical vein endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28254813
2590	Human	hsa-miR-150	miRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	airway smooth muscle cells (ASMCs)	platelet-derived growth factor BB (PDGF-BB) treatment	downregulated	31695627
2591	Human	hsa-miR-150	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	27216461
2592	Human	hsa-miR-150	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical cord vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28110404
2593	Human	hsa-miR-150	miRNA	ozone (O3)	cardiovascular disease (CVD)	plasma samples	ozone (O3) exopusure	upregulated	32414303
2594	Human	hsa-miR-150	miRNA	dextran sodium sulfate (DSS)	chronic inflammatory bowel diseases (IBDs)	colonic epithelial HT29 cells	dextran sulphate sodium (DSS)? treatment	upregulated	21590770
2595	Human	hsa-miR-150	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	upregulated	20460641
2596	Human	hsa-miR-150	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	BEAS-2B airway epithelial cells	cigarette smoke extract (CSE) treatment	downregulated	29205062
2597	Human	hsa-miR-150	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human airway epithelial cells BEAS-2B cells	cigarette smoke extract (CSE) treatment	downregulated	29205062
2598	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	sepsis	HUVECs	lipopolysaccharide (LPS) treatment	miR-150 affects sepsis-induced endothelial injury by regulating ER stress and inflammation via MALAT1-mediated NF-¦ÊB pathway.	33181172
2599	Human	hsa-miR-150	miRNA	Marek's disease virus (MDV)	diabetes mellitus (DM)	seven independentCD4+T-lymphoma cell line	Marek's disease virus (MDV) treatment	downregulated	19297609
2600	Human	hsa-miR-150	miRNA	TGF-¦Â	"fibrotic diseases, myofibroblast activation"	"human fetal lung fibroblast (HFL1, ECACC)"	"human fetal lung fibroblast (HFL1, ECACC) treatment"	upregulation	27226027
2601	Human	hsa-miR-150	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissues	5-fluorouracil (5-FU) treatment	upregulated	27081844
2602	Human	hsa-miR-150	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
2603	Human	hsa-miR-150	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
2604	Human	hsa-miR-150	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
2605	Human	hsa-miR-150	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	human cardiomyocytes (HCMs)	hypoxia treatment	downregulated	29328381
2606	Human	hsa-miR-150	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	human adipocytes	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
2607	Human	hsa-miR-150	miRNA	celastrol	insulin resistance (IR)	palmitic acid (PA) treated HepG2 cells	celastrol treatment	upregulated	30287053
2608	Human	hsa-miR-150	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
2609	Human	hsa-miR-150	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
2610	Human	hsa-miR-150	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
2611	Human	hsa-miR-150	miRNA	rapamycin	malignancies of the lymphocyte lineage	human Jurkat T-cell acute lymphoblastic leukemia (T-ALL) cells	rapamycin treatment	upregulated	30269036
2612	Human	hsa-miR-150	miRNA	natalizumab	multiple sclerosis (MS)	MS patients	natalizumab treatment	downregulated in cell-free CSF	27144214
2613	Human	hsa-miR-150	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	Ionizing irradiation treatment	upregulated	29516971
2614	Human	hsa-miR-150	miRNA	carbon disulfide (CS2)	nerve system injury	workers	experienced injury to nerve system from carbon disulfide (CS2) treatment	upregulated	25224332
2615	Human	hsa-miR-150	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	human hepatocarcinoma cell line (HepG2)	oleic acid (OA) treatment	upregulated	31966555
2616	Human	hsa-miR-150	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	K562 cells	cisplatin (DPP) treatment	miR-106 and miR-150 were downregulated	20428827
2617	Human	hsa-miR-150	miRNA	hpoxia	pancreatic cancer (PC)	pancreatic	Hypoxia treatment	downregulated	26622579
2618	Human	hsa-miR-150	miRNA	hypoxia	pancreatic cancer (PC)	CaPan2 human pancreatic cancer cell line	hypoxia treatment	downregulated	26622579
2619	Human	hsa-miR-150	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
2620	Human	hsa-miR-150	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
2621	Human	hsa-miR-150	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	downregulated	28715868
2622	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	29689269
2623	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	MiR-150 was downregulated in LPS-induced HUVECs.	33181172
2624	Human	hsa-miR-150-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	bone loss	human bone marrow cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26935950
2625	Human	hsa-miR-150-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	MALAT1 silencing can potentially suppress HPMEC apoptosis and alleviate lung injury in ARDS via miR-150-5p-targeted ICAM-1.	32315984
2626	Human	hsa-miR-150-5p	miRNA	oxaliplatin	advanced colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer	33251049
2627	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33278458
2628	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis	33278458
2629	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs.	33278458
2630	Human	hsa-miR-150-5p	miRNA	Trypanosoma cruzi (T. cruzi)	cardiac fibrosis	human AC16 cardiomyocytes	Trypanosoma cruzi (T. cruzi) infection treatment	downregulated	31122130
2631	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell proliferation and migration	human aortic smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31468685
2632	Human	hsa-miR-150-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16	high glucose (HG) treatment	Overexpression of NORAD protects DCM development via miRNA-150-5p/ZEB1 axis.	33215445
2633	Human	hsa-miR-150-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"Our results showed that NEAT1 and Drp1 levels were upregulated, while miR-150-5p level was downregulated in HK-2 cells in response to HG."	33914383
2634	Human	hsa-miR-150-5p	miRNA	simvastatin	endometriosis	Serum	simvastatin treatment	downregulated	29587611
2635	Human	hsa-miR-150-5p	miRNA	free fatty acids (FFA)	hepatic steatosis	LO2 cells	free fatty acid (FFA) treatment	upregulated	31191607
2636	Human	hsa-miR-150-5p	miRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	SMMC-7721 cells; Huh7 cells	astragaloside IV (AS-IV) treatment	AS-IV treatment was supposed to significantly increase miR-150-5p level.	32417721
2637	Human	hsa-miR-150-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 and HUH7 cells	sorafenib treatment	upregulated	31210410
2638	Human	hsa-miR-150-5p	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	Hypoxia exposure caused a downregulated of miR-150-5p in AC16 cells.	32973515
2639	Human	hsa-miR-150-5P	miRNA	marathon	inflammation	blood	marathon treatment	upregulated	25997943
2640	Human	hsa-miR-150-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
2641	Human	hsa-miR-150-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	liver fibrosis	LX-2 cells	platelet derived growth factor-BB (PDGF-BB) treatment	downregulated	31833387
2642	Human	hsa-miR-150-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	31833387
2643	Human	hsa-miR-150-5p	miRNA	physical exercise	myasthenia gravis (MG)	MG patients serum	performed supervised aerobic and resistance training twice weekly for 12 weeks treatment	downregulated	27935072
2644	Human	hsa-miR-150-5p	miRNA	rituximab (RTX)	myasthenia gravis (MG)	serum exosome	rituximab (RTX) treatment	RTX decreased the serum exosomal miR-150-5p	32961347
2645	Human	hsa-miR-150-5p	miRNA	trichloroethylene (TCE)	non-Hodgkin lymphoma (NHL)	serum	trichloroethylene (TCE) exposure treatment	downregulated	31161417
2646	Human	hsa-miR-150-5p	miRNA	adipokine apelin (APLN)	osteoarthritis (OA)	human OA synovial fibroblasts (OASFs)	adipokine apelin (APLN) treatment	APLN inhibited levels of microRNA-150-5p (miR-150-5p).	32131466
2647	Human	hsa-miR-150-5p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	CAOV3 cells; SKOV3 cells	paclitaxel (Tax) treatment	downregulated	33156701
2648	Human	hsa-miR-150-5p	miRNA	TGF-¦Â1	lung fibrosis	HFL1 cells	TGF-¦Â1 treatment	upregulated	32453709
2649	Human	hsa-miR-151	miRNA	genistein	head and neck squamous cell carcinoma (HNSCC)	LNCaP cells;PC-3 cells; DU145 cells; RWPE-1 cells	Genistein? treatment	downregulated	22928040
2650	Human	hsa-miR-151-3p	miRNA	dexamethasone (DEX)	Alzheimer's disease (AD)	SH-SY5Ycells	dexamethasone (DEX) treatment	upregulated of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against ¦Â-amyloid by targeting DAPK-1 and TP53.	33275947
2651	Human	hsa-miR-151-3p	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 11¡ã HDT bed rest experiment	downregulated	28261104
2652	Human	hsa-miR-151-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	miR-151-3p was decreased in HG-induced HK-2 cells.	32982348
2653	Human	hsa-miR-151-3p	miRNA	hydroxyurea	sickle cell anemia (SCA)	Circulating erythroid cells	Hydroxyurea treatment	upregulated	21921042
2654	Human	hsa-miR-151-5p	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 10¡ã HDT bed rest experiment	downregulated	28261104
2655	Human	hsa-miR-151-5p	miRNA	hantaan virus (HTNV)	hantaan virus (HTNV) infection	A549 cells	hantavirus(HTNV)treatment	upregulated	24074584
2656	Human	hsa-miR-151-5p	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
2657	Human	hsa-miR-15-16	miRNA	hypoxia	colorectal cancer (CRC)	colorectal carcinoma cell lines	hypoxia treatment	upregulated	24704828
2658	Human	hsa-miR-151a	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
2659	Human	hsa-miR-151a-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"Five human GBM cell lines (U87, LN229, A172, T98, U251)"	temozolomide (TMZ) treatment	downregulated	30992025
2660	Human	hsa-miR-151a-3p	miRNA	BIX01294	lung cancer	human NSCLC cells	BIX01294 treatment	downregulated	24932239
2661	Human	hsa-miR-151a-5p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	downregulated	28749179
2662	Human	hsa-miR-151a-5p	miRNA	l-carnitine	male infertility	sperm	l-carnitine treatment	upregulated	31749176
2663	Human	hsa-miR-151b	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	downregulated	32587527
2664	Human	hsa-miR-152	miRNA	statins	asthma	Immortalized lymphoblastoid cell lines (LCLs)	statins? treatment	upregulated	25266681
2665	Human	hsa-miR-152	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	human monocyte leukemia cell line THP-1	homocysteine	upregulated	28472596
2666	Human	hsa-miR-152	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	lipopolysaccharide (LPS) treatment	downregulated	22295098
2667	Human	hsa-miR-152	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	tamoxifen sensitive (TamS) MCF-7 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28063929
2668	Human	hsa-miR-152	miRNA	insulin-like growth factor 1 (IGF-1)	breast cancer	"human breast cancer cells MCF7, MDA-MB-231, T47D, MDA-MB-453"	IGF-1 treatment	upregulated	29162853
2669	Human	hsa-miR-152	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high glucose treatment	miR-152/LIN28B axis modulates high-glucose-induced angiogenesis in human retinal endothelial cells via VEGF signaling	31609010
2670	Human	hsa-miR-152	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs) and retinal microvascular endothelial cell line (hRMECs)	high-glucose (HG) treatment	downregulated	31609010
2671	Human	hsa-miR-152	miRNA	progesterone (P4)	endometrial cancer (EC)	"human endometrial cancer cell lines (Ishikawa, HEC-1-b, and KLE)"	P4 treatment	upregulated	28122483
2672	Human	hsa-miR-152	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
2673	Human	hsa-miR-152	miRNA	TGF-¦Â	gastric cancer (GC)	BGC823 and SGC7901	TGF-¦Âtreatment treatment	downregulated	26627200
2674	Human	hsa-miR-152	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	human gastric carcinoma (AGS) cells	infect with HP	downregulated	28056089
2675	Human	hsa-miR-152	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
2676	Human	hsa-miR-152	miRNA	nickel sulfide (NiS)	inflammation	human bronchial epithelial (16HBE) cells	nickel sulfide (NiS) treatment	downregulated	23125218
2677	Human	hsa-miR-152	miRNA	TGF-¦Â	liver fibrosis	LX2 cells	TGF-¦Â treatment	downregulated	31258681
2678	Human	hsa-miR-152	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
2679	Human	hsa-miR-152	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	downregulated	31611969
2680	Human	hsa-miR-152	miRNA	gemcitabine (GEM)	osteosarcoma (OS)	LncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells.	gemcitabine treatment	"lncRNA PVT1 played a contributory role in chemoresistance of osteosarcoma cells through c-MET/PI3K/AKT pathway activation, which was largely dependent on miR-152."	30661902
2681	Human	hsa-miR-152	miRNA	"dietary 3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	"human pancreatic adenocarcinoma cell lines CaPan-1, CaPan-2, AsPC-1, BxPC-3, Hs766T, MiaPaCa-2, PANC-1, PANC-28, PANC-48, PaTu8902, FG, Colo357, L3.7"	diet containing 2000 ppm of Bio-DIM for 6w	upregulated	28659310
2682	Human	hsa-miR-152	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
2683	Human	hsa-miR-152	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	prostate cancer	AA and CA derived prostate cancer cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25004396
2684	Human	hsa-miR-152	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
2685	Human	hsa-miR-152	miRNA	TGF-¦Â	renal fibrosis	"human HK2, HEK293 cells"	TGF¦Â treatment	downregulated	28285987
2686	Human	hsa-miR-152	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	miR-152 expression was significantly reduced in TGF-¦Â1-treated HK-2 cells	29620271
2687	Human	hsa-miR-152	miRNA	vitamin D	type 2 diabetes mellitus (T2DM)	type 2 diabetes patients	vitamin D treatment	dysregulated	28945992
2688	Human	hsa-miR-152-3p	miRNA	melatonin	breast cancer	MDA-MB-231 cells	melatonin treatment	melatonin treatment increases the gene expression of miR-152-3p.	29990486
2689	Human	hsa-miR-152-3p	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	Paclitaxel treatment	downregulated	32913475
2690	Human	hsa-miR-152-3p	miRNA	high glucose (HG)	diabetic foot ulcer (DFU)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	Inhibition of miRNA-152-3p enhances diabetic wound repair via upregulation of PTEN	32620711
2691	Human	hsa-miR-152-3p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
2692	Human	hsa-miR-152-3p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
2693	Human	hsa-miR-152-3p	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cell lines PANC-1 and BxPC-3	Metformin treatment	dysregulated	28875433
2694	Human	hsa-miR-152-3p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
2695	Human	hsa-miR-153	miRNA	estradiol	breast cancer	human breast cell lines	estradiol treatment	upregulated	27012032
2696	Human	hsa-miR-153	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
2697	Human	hsa-miR-153	miRNA	4-phenylbutyric acid and 5-aza-2-deoxycytidine	glioblastoma multiforme (GBM)	DBTRG-05MG cells; T98G cells	4-phenylbutyric acid and 5-aza-20-deoxycytidine treatment	upregulated	21213215
2698	Human	hsa-miR-153	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
2699	Human	hsa-miR-153	miRNA	olea europaea leaf extract (OLE)	glioblastoma multiforme (GBM)	GBM cell lines	olea europaea leaf extract (OLE) treatment	upregulation	25232498
2700	Human	hsa-miR-153	miRNA	paraquat (PQ)	neurotoxicity	SH-SY5Y neuroblastoma cells	paraquat (PQ) treatment	upregulated	24866057
2701	Human	hsa-miR-153	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG4 cells	high glucose (HG) treatment	downregulated	31889412
2702	Human	hsa-miR-153	miRNA	hypoxia	pancreatic cancer (PC)	NK cells	hypoxia induce	downregulated	31402756
2703	Human	hsa-miR-153	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	SH-SY5Y cells treatment	miR-153 was significantly increased in MPP+-induced SH-SY5Y cells.	31949812
2704	Human	hsa-miR-153	miRNA	mechanical stretch	cell proliferation	vascular smooth muscle cells (VSMCs)	mechanical stretch-stimulated treatment	downregulated	23046980
2705	Human	hsa-miR-153	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
2706	Human	hsa-miR-153	miRNA	mifepristone (MIF)	triple negative breast cancer (TNBC)	MCF10A cells	mifepristone (MIF) treatment	upregulation	26941846
2707	Human	hsa-miR-153	miRNA	arsenic trioxide (ATO)	glioblastoma and ovarian cancer	K562 cells	arsenic trioxide (As2O3) treatment	downregulated	21267675
2708	Human	hsa-miR-153-3p	miRNA	nutritional stress	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	low nutritional (LN) condition induce	Upregulation of LINC00641 and downregulated of miR-153-3p are detected in NP cells under nutritional stress.	30378116
2709	Human	hsa-miR-153-3p	miRNA	imatinib	chronic myeloid leukemia (CML)	KBM5 cells; K562 cells	imatinib (IM) treatment	miR-153-3p was identified to be downregulated in IM-resistant CML cells.	32342278
2710	Human	hsa-miR-153-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
2711	Human	hsa-miR-153-3p	miRNA	hypoxia	ischemic stroke (IS)	HUVECs	hypoxia treatment	downregulated	28985553
2712	Human	hsa-miR-153-3p	miRNA	cisplatin (DDP)	osteosarcoma (OS)	"OS tissues, MG63/DDP, and U2OS/DDP cells."	cisplatin treatment	downregulated	31539112
2713	Human	hsa-miR-153-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	SNHG1 aggravates MPP+-induced cellular toxicity in SH-SY5Y cells by regulating PTEN/AKT/mTOR signaling via sponging miR-153-3p.	31907031
2714	Human	hsa-miR-1539	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
2715	Human	hsa-miR-1539	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
2716	Human	hsa-miR-1539	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2717	Human	hsa-miR-154	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	downregulated	27709720
2718	Human	hsa-miR-154	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	downregulated	31359876
2719	Human	hsa-miR-155	miRNA	francisella tularensis	microbial infection	PBMCs (peripheral blood mononuclear cells)	Francisella tularensis infection	induction of miR-155	22919664
2720	Human	hsa-miR-155	miRNA	aspergillus fumigatus (A. fumigatus)	Aspergillus fumigatus infection	human monocytes and dendritic cells (DCs)	infect with A. fumigatus	upregulated	24841251
2721	Human	hsa-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	active tuberculosis (ATB)	PBMCs (peripheral blood mononuclear cells)	Mycobacterium tuberculosis (MTB) infection	upregulated	22037148
2722	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute coronary syndrome (ACS)	peripheral blood mononuclear cell (PBMC) of ACS patients	lipopolysaccharide (LPS) treatment	upregulated	28407320
2723	Human	hsa-miR-155	miRNA	rosuvastatin	acute coronary syndrome (ACS)	patients with ACS	rosuvastatin treatment	downregulated in serum	25319951
2724	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	acute graft-versus-host disease (aGVHD)	human umbilical vein endothelial cells (EA.hy926)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28423578
2725	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	human monocytic cells	lipopolysaccharide (LPS) treatment	upregulated	19596814
2726	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS administration increased miR-155 levels in tubular epithelial cells in vitro.	32243922
2727	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	32323747
2728	Human	hsa-miR-155	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	upregulated	32359033
2729	Human	hsa-miR-155	miRNA	sulforaphane (SFN)	acute myeloid leukemia (AML)	"acute myelogenous leukemia cells U937, KG-1, HL-60, and NB-4"	sulforaphane treatment	downregulated	30350234
2730	Human	hsa-miR-155	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	age-related macular degeneration (AMD)	human retinal pigment epithelial (HRPE) cell	"IFN-¦Ã, TNF-¦Á and IL-1¦Â treatment"	upregulated	20950585
2731	Human	hsa-miR-155	miRNA	chitin	allergic airway diseases (AAD)	bronchial epithelial cells and in A549 and H292 lung carcinoma cells	chitin treatment	upregulated	27463381
2732	Human	hsa-miR-155	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	N9 microglial cell line	amyloid-¦Â (A¦Â) treatment	upregulated	27797173
2733	Human	hsa-miR-155	miRNA	dipeptidyl vinyl sulfone (VS)	Alzheimer's disease (AD)	N9 microglial cell line treated with A¦Â	VS treatment	downregulated	27797173
2734	Human	hsa-miR-155	miRNA	arsenic trioxide (ATO)	anti-cancer therapy	human prostate cancer PC-3 and LNCaP cells	arsenic trioxide (As2O3) treatment	upregulated	25283513
2735	Human	hsa-miR-155	miRNA	oxysophocarpine (OSC)	anti-inflammatory responses	NCI-H292 and human primary airway epithelial cells	Oxysophocarpine (OSC) treatment	"The expression of miR-155 could be dramatically induced by LPS treatment in NCI-H292 cells, which could be attenuated by OSC treatment"	32603606
2736	Human	hsa-miR-155	miRNA	"dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)"	anti-inflammatory responses	primary astrocyte cultures derived from human brains stimulated with IL-1¦Â	"pretreat with DMF, MMF"	downregulated	28589165
2737	Human	hsa-miR-155	miRNA	M2000 (¦Â-d-mannuronic acid)	anti-inflammatory responses	LPS treated PBMCs	5 and 25 ¦Ìg/ml of M2000 in duplicates	downregulated	28090274
2738	Human	hsa-miR-155	miRNA	pitavastatin (Pit)	anti-inflammatory responses	LPS pretreated HUVECs	"Pit (0.01, 0.1, 1 ¦Ìmol/L) treatment"	downregulated	28664667
2739	Human	hsa-miR-155	miRNA	H2O2	apoptosis	Human umbilical vein endothelial cells (HUVEC)	H2O2 treatment	"endothelial cell proliferation was promoted, and oxidant-induced injury was decreased when the expression of miR-155 was inhibited."	30675289
2740	Human	hsa-miR-155	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
2741	Human	hsa-miR-155	miRNA	cockroach extract (CRE)	asthma	human bronchial epithelial cells	cockroach extract (CRE) treatment	upregulated	29967100
2742	Human	hsa-miR-155	miRNA	glucocorticoid (GC)	asthma	CD4+ T-cells	glucocorticoids treatment	Mir-155 is dysregulated in allergic T-cells exposed to DM extract compared to in non-allergic cells and it is inhibited by glucocorticoids.	30245919
2743	Human	hsa-miR-155	miRNA	"toluene 2,4-diisocyanate (TDI)"	asthma	human bronchial epithelial cells (HBEC)	"toluene 2,4-diisocyanate (TDI) treatment"	upregulated	32499335
2744	Human	hsa-miR-155	miRNA	imatinib	atheroprotective	Macrophages	imatinib treatment	upregulated	26721343
2745	Human	hsa-miR-155	miRNA	conjugated linoleic acid (CLA)	atherosclerosis (AS)	THP-1 cells	conjugated linoleic acid (CLA) treatment	CLA blend also decreased miR-155 expression in vitro in human THP-1 polarized macrophages.	33391256
2746	Human	hsa-miR-155	miRNA	genistein	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	"genistein (10, 100, and 1000 nM) for 6 h"	downregulated	28550396
2747	Human	hsa-miR-155	miRNA	imatinib	atherosclerosis (AS)	human macrophages	imatinib treatment	upregulated	26721343
2748	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human endothelial cells surrogate EA.hy926 lines (EA.hy926 cells)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29017169
2749	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	HUVECs	TNF¦Á ed HUVECs treatment	upregulated	24905663
2750	Human	hsa-miR-155	miRNA	TNF-¦Á£¬IGF-1	atherosclerosis (AS)	smooth muscle cell	TNF-¦Á£¬IGF-1 treatment	upregulated	26047583
2751	Human	hsa-miR-155	miRNA	H2O2	autophagy	Human umbilical vein endothelial cells (HUVEC)	H2O2 treatment	"endothelial cell proliferation was promoted, and oxidant-induced injury was decreased when the expression of miR-155 was inhibited."	30675289
2752	Human	hsa-miR-155	miRNA	hypoxia	autophagy	CNE (human nasopharyngeal cancer) or HeLa (human cervical cancer) cells	1% O2 treatment	upregulated	24262949
2753	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28659666
2754	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30015881
2755	Human	hsa-miR-155	miRNA	wogonin	B lymphoma	human cell line Raji	wogonin treatment	downregulated	28222771
2756	Human	hsa-miR-155	miRNA	camptothecin	biologic and molecular activity of camptothecin	hypoxic-human cancer cells	camptothecin treatment	upregulated	24252850
2757	Human	hsa-miR-155	miRNA	hedyotis diffusa plus scutellaria barbata	bladder cancer	human bladder cancer cell lines 5637 and T24	Hedyotis diffusa plus Scutellaria barbata treatment	Further experiments showed that miR-155 was reduced by the herb-pair and miRNA-155 inhibitor induced cell apoptosis and suppressed Akt activation.	26989427
2758	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	blood-brain barrier (BBB) dysfunction	human brain endothelium	lipopolysaccharide (LPS) treatment	upregulated	24604078
2759	Human	hsa-miR-155	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-7 cells	estradiol-17¦Â (E2) treatment	upregulated	23568502
2760	Human	hsa-miR-155	miRNA	genistein	breast cancer	MDA-MB-435 and Hs578t breast cancer cells	genistein treatment	downregulated	26771440
2761	Human	hsa-miR-155	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
2762	Human	hsa-miR-155	miRNA	mastectomy	breast cancer	breast cancer tissues	mastectomy treatment	upregulated	25503185
2763	Human	hsa-miR-155	miRNA	oleuropein (OL)	breast cancer	MCF-7 cells	oleuropein treatment	Oleuropein significantly decreased expression of both miR-21 and miR-155 over time in a dose-dependent manner.	29905007
2764	Human	hsa-miR-155	miRNA	pomegranate polyphenolics	breast cancer	Human mammary carcinoma cell lines BT474 and MDA-MB-231	pomegranate polyphenolics treatment	downregulated	22941571
2765	Human	hsa-miR-155	miRNA	schizandrin A (SchA)	breast cancer	MDA-MB-231 cells	schizandrin A (SchA) treatment	SchA strikingly decreases miR-155.	32623835
2766	Human	hsa-miR-155	miRNA	silibinin (SB)	breast cancer	MCF-7 breast cancer cells	Silibinin treatment	downregulated	27066095
2767	Human	hsa-miR-155	miRNA	tamoxifen (TAM)	breast cancer	Human breast cancer tissues	Tamoxifen treatment	upregulated	26692956
2768	Human	hsa-miR-155	miRNA	wound fluids (WFs) from breast cancer patients	breast cancer	human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line	WFs treatment	upregulated	28943910
2769	Human	hsa-miR-155	miRNA	brucella Omp25	brucellosis	human Monocyte/Macrophages	brucella Omp25 treatment	upregulated	28694807
2770	Human	hsa-miR-155	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
2771	Human	hsa-miR-155	miRNA	polycyclic aromatic hydrocarbons (PAHs)	cardiovascular disease (CVD)	human umbilical cord vein cells (HUVECs)	polycyclic aromatic hydrocarbons (PAHs) treatment	upregulated	30144390
2772	Human	hsa-miR-155	miRNA	gliadinN	celiac disease (CD)	PBMCs; monocytes	gliadinN treatment	upregulated	31781909
2773	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell-to-cell communication	human aortic endothelial cells (ECs) and their transfer to recipient cells	tumor necrosis factor alpha (TNF-¦Á) treatment	differently regulation	25315114
2774	Human	hsa-miR-155	miRNA	diesel exhaust particle (DEP)	cellular protection and tumorigenesis	"A549, H358 and 293 T cell lines"	diesel exhaust particle (DEP) exposure	downregulated	28315615
2775	Human	hsa-miR-155	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32090104
2776	Human	hsa-miR-155	miRNA	telbivudine	chronic hepatitis B virus (HBV) infection	CHB patients peripheral blood mononuclear cells (PBMCs)	telbivudine treatment	upregulated in peripheral blood mononuclear cells (PBMCs)	29018442
2777	Human	hsa-miR-155	miRNA	telbivudine or peg-IFN-¦Á-2a	chronic hepatitis B virus (HBV) infection	CHB patients peripheral blood mononuclear cells (PBMCs)	telbivudine or peg-IFN-¦Á-2a treatment	downregulated in peripheral blood mononuclear cells (PBMCs)	29018442
2778	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	chronic inflammatory diseases	human bronchial epithelial cells 16HBE	lipopolysaccharide (LPS) treatment	upregulated	30905633
2779	Human	hsa-miR-155	miRNA	hypoxia	chronic kidney disease (CKD)	HK-2 cells	chronic intermittent hypoxia (CIH) treatment	upregulated	29953588
2780	Human	hsa-miR-155	miRNA	IL-4	chronic lymphocytic leukemia (CLL)	MEC-1 cells	interleukin (IL)-4 treatment	upregulated	31289477
2781	Human	hsa-miR-155	miRNA	smoking	chronic obstructive pulmonary disease (COPD)	lung tissues	smoking treatment	MiR-155 expression was significantly increased in lung tissue of smokers and patients with COPD compared to never smokers	31819170
2782	Human	hsa-miR-155	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	human colorectal cancer HCT-116 and HT-29 cells	5-fluorouracil (5-FU) treatment	downregulated	28515355
2783	Human	hsa-miR-155	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
2784	Human	hsa-miR-155	miRNA	TGF-¦Â1	colorectal cancer (CRC)	colorectal cancer cells	TGF-¦Â1 treatment	upregulated	27626488
2785	Human	hsa-miR-155	miRNA	surgery and chemotherapy	colorectal cancer (CRC)	patients blood	surgery and chemotherapy for 3years treatment	upregulated	24310813
2786	Human	hsa-miR-155	miRNA	NOD2-agonist muramyl dipeptide	crohn disease (CD)	Crohn's disease patients without NOD2 mutations monocytes	NOD2-agonist muramyl dipeptide treatment	downregulated in monocytes	29263823
2787	Human	hsa-miR-155	miRNA	Staphylococcus aureus enterotoxins (SE)	cutaneous T-cell lymphoma (CTCL)	primary malignant T cells	Staphylococcus aureus enterotoxins (SE) treatment	"Here, we show that SE induce expression of the oncogenic microRNA mir-155 in primary malignant T cells"	33862068
2788	Human	hsa-miR-155	miRNA	oligosaccharide nanomedicine of alginate sodium (ONAS)	degenerative lumbar disease (DLD)	serum	oral administration of 100 mg ONAS daily)	downregulated	29200854
2789	Human	hsa-miR-155	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	Huh-7 cells	dengue virus (DENV) infection	downregulated	32277848
2790	Human	hsa-miR-155	miRNA	high glucose (HG)	diabetic foot ulcer (DFU)	primary endothelial progenitor cells (EPCs)	high glucose treatment	upregulated	29545091
2791	Human	hsa-miR-155	miRNA	angiotensin II (Ang II)	diabetic nephropathy (DN)	human vascular endothelial cells	angiotensin II (Ang II) treatment	downregulated	23174997
2792	Human	hsa-miR-155	miRNA	high glucose and free fatty acids (HG-FFA)	diabetic osteoporosis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	high glucose and free fatty acids (HG-FFA) treatment	miR-155 levels in hBMSCs increased corresponding to the time of exposure to HG-FFA treatment.	32248286
2793	Human	hsa-miR-155	miRNA	vincristine (VCR)	diffuse large B-cell lymphoma (DLBCL)	DLBCL cell lines	vincristine treatment	miR-155 as highly expressed in vincristine-sensitive DLBCL cell lines compared with resistant ones	30967394
2794	Human	hsa-miR-155	miRNA	hydroquinone (HQ)	DNA damage	TK6 lymphoblastoid cells	Hydroquinone (HQ) treatment	upregulated	30448557
2795	Human	hsa-miR-155	miRNA	hydroquinone (HQ)	DNA damage	TK6 lymphoblastoid cells	Hydroquinone (HQ) treatment	miR-155 was significantly increased.	30448557
2796	Human	hsa-miR-155	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
2797	Human	hsa-miR-155	miRNA	angiotensin II (Ang II)	endothelial inflammation and migration	human umbilical vein endothelial cells (HUVECs) ;vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	upregulated	21310411
2798	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial senescence	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31752013
2799	Human	hsa-miR-155	miRNA	TGF-¦Â	cardiac fibrosis	human coronary artery endothelial cells (HCAECs)	TGF-¦Â treatment	upregulated	28607031
2800	Human	hsa-miR-155	miRNA	dexamethasone (DEX)	eosinophilic chronic rhinosinusitis with nasal polyps	rhinal tissues	dexamethasone (DEX) treatment	DEX treatment inhibited the expression of cytokines and decreased the relapse rate of Eos CRSwNP via inhibiting NF-kappaB/miR-155.	32614806
2801	Human	hsa-miR-155	miRNA	remnant-like lipoproteins (RLPs)	ePCs senescence	Total peripheral mononuclear cells (PB-MNCs)	Remnant-like lipoproteins (RLPs) treatment	miR-148b and miR-155 were upregulated while miR-574-3p was downregulated	23044309
2802	Human	hsa-miR-155	miRNA	F. novicida	F. novicida?infection	Human peripheral blood monocytes (PBM)	F. novicida?infection	downregulated	20041145
2803	Human	hsa-miR-155	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
2804	Human	hsa-miR-155	miRNA	fluoride	fluorosis	sodium fluoride (NaF) treated human osteosarcoma (HOS) cells	fluoride treatment	miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor ¦Ê-B ligand (RANKL) genes	26339601
2805	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	follicle development and oocyte maturation	human endothelial cells	TNF¦Á treatment	upregulated	21982894
2806	Human	hsa-miR-155	miRNA	phorbol-12-myristate-13-acetate(PMA)	functions of human macrophages	U937 cells	phorbol 12-myristate 13-acetate (PMA) treatment	upregulated	33268675
2807	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GES-1 cells	Helicobacter pylori (H. pylori) infection	upregulated	31162747
2808	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	gastritis	Blood	H. pylori treatment	upregulated	26191144
2809	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	gastritis	gastric lesions	Helicobacter pylori treatment	upregulated	30219037
2810	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	gingival inflammation	Human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	29407755
2811	Human	hsa-miR-155	miRNA	metformin (Met)	glioblastoma multiforme (GBM)	U87 cells	metformin(Met) treatment	downregulated	33059952
2812	Human	hsa-miR-155	miRNA	melatonin	glioblastoma multiforme (GBM)	"human glioma cell lines U87, U373 and U251"	"melatonin (100¦ÌM, 1¦ÌM and 1nM)"	downregulated	28724215
2813	Human	hsa-miR-155	miRNA	monosodium urate (MSU)	gout	Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) from acute gouty arthritis patients	monosodium urate (MSU) treatment	upregulated	24708712
2814	Human	hsa-miR-155	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	human	hepatitis B virus (HBV)infection	downregulated	27110261
2815	Human	hsa-miR-155	miRNA	borna disease virus (BDV)	borna disease virus (BDV) infection	human oligodendroglial	borna disease virus (BDV)?infection	downregulated	23428672
2816	Human	hsa-miR-155	miRNA	recombinant Schistosoma japonicum egg antigen P40 (rSjP40)	liver fibrosis	LX-2 cells	recombinant Schistosoma japonicum egg antigen P40 (rSjP40) treatment	microRNA-155 was raised in rSjP40-treated HSCs	30091834
2817	Human	hsa-miR-155	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	HepG2 cells	hepatitis B virus (HBV) infection	miR-155 was inhibited on HBV infection.	31930529
2818	Human	hsa-miR-155	miRNA	arsenite	hepatocellular carcinoma (HCC)	L-02 cells	arsenite exposure	upregulated	29240254
2819	Human	hsa-miR-155	miRNA	pegylated interferon-¦Á (PEG-IFN)	hepatocellular carcinoma (HCC)	HepG2 cells	pegylated interferon-¦Á (PEG-IFN) treatment	downregulated	31036495
2820	Human	hsa-miR-155	miRNA	hepatitis C virus (HCV)	liver damage	monocytes	hepatitis C virus (HCV) infection	Serum levels of miR-122 were elevated in cHCV patients and correlated with increased ALT and AST levels and serum miR-155 levels	22846613
2821	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	herpes simplex virus 1 (HSV-1) infection	human umbilical vein endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23108656
2822	Human	hsa-miR-155	miRNA	Shenqi pollen capsules (SPCs)	high-altitude deacclimatization syndrome (HADAS)	serum	Shenqi pollen capsules (SPCs) treatment	downregulated	31828172
2823	Human	hsa-miR-155	miRNA	follicle stimulating hormone (FSH)	high-grade serous ovarian carcinomas (HGSOC)	fallopian tube secretory epithelial cells (FTSECs)	follicular fluid (FF) treatment	upregulated	32614381
2824	Human	hsa-miR-155	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
2825	Human	hsa-miR-155	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
2826	Human	hsa-miR-155	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
2827	Human	hsa-miR-155	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
2828	Human	hsa-miR-155	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
2829	Human	hsa-miR-155	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
2830	Human	hsa-miR-155	miRNA	S-amlodipine	hypertension	human umbilical vein endothelial cells (HUVECs)	S-amlodipine treatment	downregulated	30951948
2831	Human	hsa-miR-155	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	upregulated	29516639
2832	Human	hsa-miR-155	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	downregulated	29516639
2833	Human	hsa-miR-155	miRNA	Ig-like transcript 3 (ILT3)	immune inflammatory	human CD8(+) T suppressor cells	Ig-like transcript 3 (ILT3) treatment	upregulated	22387553
2834	Human	hsa-miR-155	miRNA	IFN-¦Ã	immunoregulatory function	MSCs	IFN¦Ã treatment	upregulated	23449975
2835	Human	hsa-miR-155	miRNA	IL-1¦Â	immunoregulatory function	MSCs	IL-1¦Â treatment	upregulated	23449975
2836	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	immunoregulatory function	MSCs	TNF¦Á treatment	upregulated	23449975
2837	Human	hsa-miR-155	miRNA	steroids	immune thrombocytopenic purpura (ITP)	peripheral blood mononuclear cells of ITP patients	steroid therapy treatment	downregulated	25413124
2838	Human	hsa-miR-155	miRNA	corticosterone	immunosuppression	Su-DHL4 cells	corticosterone (CORT) treatment	downregulated	30414952
2839	Human	hsa-miR-155	miRNA	cocaine	HIV-induced immunopathogenesis	peripheral blood mononuclear cells (PBMC)	Cocaine treatment	downregulated	24391808
2840	Human	hsa-miR-155	miRNA	vibrio cholerae O1	infection of Vibrio cholerae O1	colon carcinoma cell line T84	infect with Vibrio cholerae O1 treatment	upregulated at acute stage of V cholerae infection and declined to normal at convalescent stage	28319200
2841	Human	hsa-miR-155	miRNA	alternariol (AOH)	inflammation	THP-1 cells	alternariol (AOH) treatment	upregulated	30175388
2842	Human	hsa-miR-155	miRNA	cold	inflammation	LPS-induced human monocytes	exposure to cold (32¡ãC) treatment	upregulated	25231976
2843	Human	hsa-miR-155	miRNA	crataegus special extract WS 1442	inflammation	Human umbilical vein endothelial cells (HUVECs)	Crataegus Special Extract WS 1442 treatment	upregulated	29660753
2844	Human	hsa-miR-155	miRNA	curcumin (Cur)	inflammation	LPS-induced THP-1 cells	curcumin treatment	downregulated	28264607
2845	Human	hsa-miR-155	miRNA	glucocorticoid (GC)	inflammation	RAW264.7 cells	Glucocorticoids (GCs) treatment	downregulated	22326887
2846	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	inflammation	Human gastric cancer cell line AGS and human embryonickidney HEK-293 cell	Helicobacter pylori infection	upregulated	20219467
2847	Human	hsa-miR-155	miRNA	interferon regulatory factor 3 (IRF3)	inflammation	primary human astrocytes	Interferon regulatory factor 3 (IRF3) treatment	downregulated	22170100
2848	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	HUVECs	lipopolysaccharide (LPS) treatment	upregulated	28664667
2849	Human	hsa-miR-155	miRNA	nitric oxide (NO)	inflammation	human liver epithelial (HepG2) cells	the NO-releasing S-nitroso-N-acetylpenicillamine (SNAP) 100 ¦ÌM for 4 h treatment	MiR-155 was the only miRNA of the 887 arrayed that showed a change in expression after SNAP ment.	24687397
2850	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	PMA-preprocessed THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	"overexpression of miR-155 promoted the activation of the ox-LDL-induced NLRP3 inflammasome, which could also be blocked by the ERK inhibitor U0126."	31865729
2851	Human	hsa-miR-155	miRNA	IFN-¦Ã and TNF-¦Á	inflammation	human dermal lymphatic endothelial cells (HDLECs)	HDLECs with the treatment	upregulated	29066622
2852	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	Human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29660753
2853	Human	hsa-miR-155	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	human adipocytes	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
2854	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	colonic epithelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26752469
2855	Human	hsa-miR-155	miRNA	IFN-¦Ã and TNF-¦Á	inflammatory response	Normal human mesangial cells	IFN-¦Ã and TNF-¦Á treatment	upregulated	20948191
2856	Human	hsa-miR-155	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human pulmonary microvascular endothelial cells (HPMECs)	influenza A virus strain H1N1 infection	MiR-155 was elevated in response to the H1N1 infection in HPMECs (24 h post-infection.	32889908
2857	Human	hsa-miR-155	miRNA	candida albicans (C. albicans)	innate immune response	monocytes derived dendritic cells (DCs)	candida albicans infection	upregulated	32042774
2858	Human	hsa-miR-155	miRNA	"ferrylhemoglobin (ferrylHb, Fe4+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"ferrylhemoglobin (ferrylHb, Fe4+) treatment"	upregulated	32961661
2859	Human	hsa-miR-155	miRNA	heme	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	heme treatment	upregulated	32961661
2860	Human	hsa-miR-155	miRNA	"methemoglobin (metHb, Fe3+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"methemoglobin (metHb, Fe3+) treatment"	upregulated	32961661
2861	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32961661
2862	Human	hsa-miR-155	miRNA	panax notoginseng saponins (PNS)	ischemic stroke (IS)	SH-SY5Y cells	panax notoginseng saponins (PNS) treatment	"In OGD/R-induced SH-SY5Y cells, 160??g/mL PNS treatment promoted cell proliferation and cell cycle progression, as well as decreased inhibited apoptosis and miR-155 expression"	30587668
2863	Human	hsa-miR-155	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells	JEV infection treatment	upregulated	24522920
2864	Human	hsa-miR-155	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	human microglial CHME3 cells	JEV-infected treatment	upregulated	24885259
2865	Human	hsa-miR-155	miRNA	epstein-barr virus (EBV)	large B-cell lymphomas (DLBCLs)	"EBV-positive BL cell lines Mutu I; Mutu III; Namalwa; Raji,;the EBV-positive DLBCL cell line IBL-1; EBV-negative BJAB cell line;EBV-infected human peripheral blood mononuclear cells (PBMCs) and 293T cells"	Epstein-Barr virus (EBV) treatment	upregulated	20844043
2866	Human	hsa-miR-155	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
2867	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6e	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6e treatment	upregulated	29970309
2868	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6g	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6g treatment	downregulated	29970309
2869	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6u	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6u treatment	upregulated	29970309
2870	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6v	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6v treatment	downregulated	29970309
2871	Human	hsa-miR-155	miRNA	listeria monocytogenes (L. monocytogenes)	Listeria infection	Human epithelial cells (Caco-2)	Listeria infection	downregulated	22312311
2872	Human	hsa-miR-155	miRNA	arsenite	hepatocellular carcinoma (HCC)	L-02 and THLE-3 cells	arsenite exposure	upregulated	27913196
2873	Human	hsa-miR-155	miRNA	arsenite	hepatocellular carcinoma (HCC)	L-02 cells	arsenite exposure	upregulated	29240254
2874	Human	hsa-miR-155	miRNA	hypoxia	hepatocellular carcinoma (HCC)	A549 cells	hypoxia trreatment	upregulated	22027557
2875	Human	hsa-miR-155	miRNA	NO-releasing S-nitroso-N-acetylpenicillamine	liver inflammation and cancer	human liver epithelial (HepG2) cells	NO-releasing S-nitroso-N-acetylpenicillamine (SNAP) 100 ¦ÌM for 4 h a treatment	differerntlly expressed	24687397
2876	Human	hsa-miR-155	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
2877	Human	hsa-miR-155	miRNA	arsenic trioxide (ATO)	lung cancer	human lung adenocarcinoma cell line A549 cells	arsenic trioxide (ATO) treatment	downregulated	29260515
2878	Human	hsa-miR-155	miRNA	poly-lactic acid nanoparticles (PLA-NP)	lung cancer	human lung epithelial A549 cells	"PLA-NP for 24, 48 and 72 h treatment"	downregulated	28143572
2879	Human	hsa-miR-155	miRNA	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	NCI cells; FaDu cells	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment	upregulated	32326378
2880	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	Dendritic cells (DCs)	lipopolysaccharide (LPS) treatment	upregulated	27714813
2881	Human	hsa-miR-155	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
2882	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	monocytic differentiation	monocyte	lipopolysaccharide (LPS) treatment	dysregulated	25148686
2883	Human	hsa-miR-155	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	myeloma cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	in vitro methylation of part of the promoter and first exon abrogated the miR-155 expression	25497370
2884	Human	hsa-miR-155	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
2885	Human	hsa-miR-155	miRNA	autologous hematopoietic SCT(AHSCT)	multiple sclerosis (MS)	MS patients	AHSCT treatment	upregulated in T- and B-cell	25486582
2886	Human	hsa-miR-155	miRNA	torpedo acetylcholine receptor (T-AChR)	myasthenia gravis (MG)	B cells of MG patients	T-AChR treatment	upregulated	24387321
2887	Human	hsa-miR-155	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	myeloma	MM cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25497370
2888	Human	hsa-miR-155	miRNA	RNA-directed DNA methylation	myeloma	MM cell lines	Nucleofection with 141 siRNAs at a 20 nM concentration treatment	downregulated	25497370
2889	Human	hsa-miR-155	miRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma cell	EBV?infection	upregulated	24241359
2890	Human	hsa-miR-155	miRNA	latent membrane protein 1 (LMP1)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	latent membrane protein 1 (LMP1) treatment	upregulated	27123134
2891	Human	hsa-miR-155	miRNA	calcium oxalate (CaOx)	nephrolithiasis	HK-2 cells	calcium oxalate (CaOx) treatment	CaOx treatment caused upregulated of miR-155 and induced autophagy in renal tubular epithelial cells.	32417393
2892	Human	hsa-miR-155	miRNA	Toll-like receptor (TLR)	neurological diseases	U251 human astrocytoma cell line	Toll-like receptor (TLR) treatment	upregulated	25957996
2893	Human	hsa-miR-155	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
2894	Human	hsa-miR-155	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
2895	Human	hsa-miR-155	miRNA	chemoradiation therapy (CRT)	non-small cell lung cancer (NSCLC)	patients with stage IIIB-IV NSCLC	CRT treatment	upregulated	25466375
2896	Human	hsa-miR-155	miRNA	IFN-¦Ã	oral lichen planus (OLP)	EOLP CD4(+) T cells	IFN-¦Ã treatment	upregulated	26594049
2897	Human	hsa-miR-155	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human OA chondrocyte	"exposure to three hours of a cyclic HP (1-5 MPa, frequency 0.25 Hz)"	downregulated	29150345
2898	Human	hsa-miR-155	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	chondrocytes	hydrostatic pressure (HP) treatment	miR-155 and miR-181a resulted significantly downregulated immediately after pressurization (T0) in OA cells.	29150345
2899	Human	hsa-miR-155	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	The expression level of miR-155 in primary chondrocytes was drastically induced upon IL-1¦Â treatment.	32562373
2900	Human	hsa-miR-155	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
2901	Human	hsa-miR-155	miRNA	"rapamycin,2-deoxyglucose (2-DG)"	osteoarthritis (OA)	primary human articular chondrocytes and the T/C28a2 human chondrocyte cell line	primary human articular chondrocytes and the T/C28a2 human chondrocyte cell line treatment	upregulation	26805019
2902	Human	hsa-miR-155	miRNA	tanshinone IIA (Tan IIA)	osteoarthritis (OA)	human articular chondrocytes	?tanshinone IIA treatment	tanshinone IIA ameliorates inflammation response in OA via inhibition of the miR-155/FOXO3 axis	33395681
2903	Human	hsa-miR-155	miRNA	hepatitis C virus (HCV)	osteoblastic differentiation	Human hepatic tis-sues	hepatitis C virus (HCV) infection	upregulated	22610915
2904	Human	hsa-miR-155	miRNA	IFN-¦Â	osteoclast-mediated diseases	HEK293T cells	Interferon-¦Â treatment	upregulated	22771905
2905	Human	hsa-miR-155	miRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis from preosteoblasts	preosteoblast cell line MC3T3-E1	bone morphogenetic protein 2 (BMP2) treatment	downregulated	28473977
2906	Human	hsa-miR-155	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx9 treatment"	downregulated	21572246
2907	Human	hsa-miR-155	miRNA	adriamycin (ADR)	osteosarcoma (OS)	MG-63 cells	adriamycin (ADR) treatment	upregulated	29412697
2908	Human	hsa-miR-155	miRNA	cisplatin (DDP)	osteosarcoma (OS)	Human osteosarcoma cell lines (Saos-2 and MG-63)	cisplatin (DDP) treatment	upregulated	25009614
2909	Human	hsa-miR-155	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	Human osteosarcoma cell lines (Saos-2 and MG-63)	?doxorubicin (DOX) treatment	upregulated	25009614
2910	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteosarcoma (OS)	U2OS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31669646
2911	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteosarcoma (OS)	U2OS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á upregulated the miR-155 expression in U2OS cells	31669646
2912	Human	hsa-miR-155	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	human pancreatic cancer PANC-1 cells	gemcitabine (GEM) treatment	upregulated	20871480
2913	Human	hsa-miR-155	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
2914	Human	hsa-miR-155	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"PDAC cell lines (Panc1, MiaPaCa2, and PSN1 cell lines)"	long-term exposure of GEM	upregulated	28198398
2915	Human	hsa-miR-155	miRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	TPC-1 cells; IHH-4 cells	Radioiodine (131I) treatment	CASC2 increases 131I sensitivity in PTC by sponging miR-155	33134385
2916	Human	hsa-miR-155	miRNA	sevoflurane (SEV)	papillary thyroid cancer (PTC)	Human PTC cell lines (TPC-1 and IHH-4)	?Sevoflurane treatment	downregulated	31378899
2917	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	periodontitis	THP-1 cells	lipopolysaccharide (LPS) from porphyromonas gingivalis (Pg-LPS) treatment	downregulated	30012943
2918	Human	hsa-miR-155	miRNA	Staphylococcus aureus	post-viral bacterial pneumonia	lung macrophages	staphylococcus aureus (CA-MRSA) infection treatment	upregulated	26589478
2919	Human	hsa-miR-155	miRNA	aspirin	preeclampsia (PE)	TNF-¦Á-mediated human umbilical vein endothelial cells (HUVECs)	aspirin treatment	downregulated	28087411
2920	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	preeclampsia (PE)	HTR-8 cells;SVneo cells	?injection of lipopolysaccharides (LPS)	upregulated	21515911
2921	Human	hsa-miR-155	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
2922	Human	hsa-miR-155	miRNA	arsenite	pro-inflammatory activity	human hepatic epithelial (L-02) cells	arsenic exposure	upregulated	27913196
2923	Human	hsa-miR-155	miRNA	paclitaxel (PTX)	prostate cancer	DU145 and PC-3 cells	paclitaxel treatment	downregulated	28599307
2924	Human	hsa-miR-155	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in PBMCs	27535005
2925	Human	hsa-miR-155	miRNA	TGF-¦Â	lung fibrosis	human pulmonary fibroblasts	TGF-¦Â treatment	miR-155 expression was decreased in human pulmonary fibroblasts by TGF-¦Â treatment	31556264
2926	Human	hsa-miR-155	miRNA	porphyromonas gingivalis	pyroptosis	The immortalized human monocyte cell line U937	Porphyromonas gingivalis infection treatment	upregulated	31529565
2927	Human	hsa-miR-155	miRNA	hypoxia	renal fibrosis	HK-2 cells	Hypoxia treatment	upregulated	25672593
2928	Human	hsa-miR-155	miRNA	tanshinone IIA (Tan IIA)	renal fibrosis	HCT116 cells; HT-29 cells	TanshinoneIIA treatment	upregulated	22982040
2929	Human	hsa-miR-155	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	30080287
2930	Human	hsa-miR-155	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	28006785
2931	Human	hsa-miR-155	miRNA	particulate matter (PM2.5)	respiratory injury	human bronchial epithelial (HBE) cells	"fine particulate matter (PM2.5, particles <2.5?¦Ìm in size) exposure treatment"	upregulated	31185220
2932	Human	hsa-miR-155	miRNA	hepatitis C virus (HCV)	rheumatoid arthritis (RA)	serum	hepatitis C virus (HCV) infection	The exo-miR-155 levels were significantly increased in RA patients with HCV infection compared with those without infection	29575671
2933	Human	hsa-miR-155	miRNA	silibinin (SB)	rheumatoid arthritis (RA)	peripheral blood T lymphocytes	silibinin treatment	downregulated	30174672
2934	Human	hsa-miR-155	miRNA	TGF-¦Â	rheumatoid arthritis (RA)	RA fibroblast-like synoviocytes (FLS)	50 ng/mL of tumor necrosis factor alpha (TNF-¦Á) for 1 h treatment	downregulated	28401267
2935	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29693176
2936	Human	hsa-miR-155	miRNA	triptolide (TPL)	rheumatoid arthritis (RA)	monocytes pre-stimulated by lipopolysaccharide (LPS) from rheumatoid arthritis (RA) patients	triptolide (TPL) treatment	downregulated	24909288
2937	Human	hsa-miR-155	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
2938	Human	hsa-miR-155	miRNA	Salmonella Typhimurium	salmonella typhimurium infection	human HeLa cells	Salmonella Typhimurium infection treatment	upregulated	21468030
2939	Human	hsa-miR-155	miRNA	valproic acid (VPA)	seizure	cerebrospinal fluid (CSF)	valproic acid (VPA) treatment	downregulated	29115566
2940	Human	hsa-miR-155	miRNA	dexamethasone (DEX)	septic shock	T lymphocytes	dexamethasone (DEX) treatment	downregulated	28105104
2941	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	septic shock	human internal mammary artery (hIMA) rings	lipopolysaccharide (LPS) treatment	upregulated	29979224
2942	Human	hsa-miR-155	miRNA	hydroxychloroquine	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	hydroxychloroquine treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs."	24121037
2943	Human	hsa-miR-155	miRNA	prednisone	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	prednisone treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs"	24121037
2944	Human	hsa-miR-155	miRNA	IFN-¦Á	systemic lupus erythematosus (SLE)	HUVECs	IFN-¦Á treatment	upregulated	28779021
2945	Human	hsa-miR-155	miRNA	thyroid stimulating hormone	thyroid eye disease (TED)	orbital fibroblasts (OFs)	thyroid stimulating hormone treatment	upregulated	31622470
2946	Human	hsa-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	serum	Mycobacterium tuberculosis (M.TB) treatment	downregulated	28061948
2947	Human	hsa-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human primary dendritic cells (DC)	?Mycobacterium tuberculosis (Mtb) infection	upregulated	29300789
2948	Human	hsa-miR-155	miRNA	IL-1¦Â	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	interleukin (IL)-1¦Â treatment	downregulated	29467762
2949	Human	hsa-miR-155	miRNA	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	LPS-treated primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) treatment	downregulated	29467762
2950	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	lipopolysaccharide (LPS) treatment	upregulated	29467762
2951	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	type 2 diabetes mellitus (T2DM)	peripheral blood mononuclear cells (PBMC)	lipopolysaccharide (LPS) treatment	downregulated	23616185
2952	Human	hsa-miR-155	miRNA	propofol (PPF)	unilateral ureteral obstruction (UUO)	HK-2 cells	HK-2 cells treatment	downregulated	27158339
2953	Human	hsa-miR-155	miRNA	alprostadil	uremia	peripheral blood	alprostadil treatment	downregulated	26267685
2954	Human	hsa-miR-155	miRNA	palmitate	vascular endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	palmitate treatment	downregulated	31485611
2955	Human	hsa-miR-155	miRNA	adrenaline	vascular injury	HT29 cells	adrenaline treatment	upregulated	23036199
2956	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	vascular injury	human endothelial	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	24769202
2957	Human	hsa-miR-155	miRNA	everolimus	waldenstrom macroglobulinemia	Primary Waldenstrom macroglobulinemia cells	Everolimus treatment	downregulated	23048077
2958	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	21030878
2959	Human	hsa-miR-155	miRNA	hypoxia	autophagy	CNE cells ;HeLa cells	hypoxia treatment	upregulated	24262949
2960	Human	hsa-miR-155	miRNA	IL-10	breast cancer	human bronchial epithelial cells (hBECs)	IL-10 treatment	downregulated	23967196
2961	Human	hsa-miR-155	miRNA	IL-4	cell differentiation	human embryonic stem cells	IL-4 ? treatment	downregulated	21388667
2962	Human	hsa-miR-155	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	lung fibroblasts	IL-1¦Â treatment	upregulated	19701459
2963	Human	hsa-miR-155	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	lung fibroblasts	?TGF-¦Â? treatment	downregulated	19701459
2964	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	epithelial-mesenchymal transition (EMT)	lung fibroblasts	tumor necrosis factor alpha (TNF-¦Á) treatment	up regulation	19701459
2965	Human	hsa-miR-155	miRNA	type I interferon (IFN)	hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	type I interferon (IFN) treatment	upregulated	23650597
2966	Human	hsa-miR-155*	miRNA	mycobacterium tuberculosis (Mtb)	active tuberculosis (ATB)	PBMCs (peripheral blood mononuclear cells)	Mycobacterium tuberculosis (MTB) infection	upregulated	22037148
2967	Human	hsa-miR-155*	miRNA	lipopolysaccharide (LPS)	B-cell lymphomas	HTR-8/SVneo cells	lipopolysaccharide (LPS)? treatment	upregulated	23684381
2968	Human	hsa-miR-155*	miRNA	interferon regulatory factor 3 (IRF3)	inflammation	primary human astrocytes	Interferon regulatory factor 3 (IRF3) treatment	downregulated	22170100
2969	Human	hsa-miR-155-2	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human thyroid	infect with HHV-6A	downregulated	28081700
2970	Human	hsa-miR-155-3p	miRNA	lithium (Li)	bipolar disorder (BD)	lymphoblastoid cell lines	Lithium treatment	dysregulated	31801218
2971	Human	hsa-miR-155-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	primary human monocyte-derived macrophages (1¡ãMDMs)	lipopolysaccharide (LPS) treatment	upregulated	31641696
2972	Human	hsa-miR-155-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	mantle cell lymphoma (MCL)	MCL cell line (REC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25211095
2973	Human	hsa-miR-155-3p	miRNA	"RESMENA (reduction of metabolic syndrome in Navarra, Spain)"	metabolic syndrome	MetS patients white blood cells (WBC)	RESMENA treatment	"miR-155-3p was decreased ,miR-Let-7b was strongly upregulated in white blood cells (WBC)"	26421388
2974	Human	hsa-miR-155-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
2975	Human	hsa-miR-155-5p	miRNA	H2O2	abdominal aortic aneurysm (AAA)	vascular smooth muscle cells (VSMCs)	H2O2 treatment	upregulated	30898623
2976	Human	hsa-miR-155-5p	miRNA	NaAsO2	abdominal aortic aneurysm (AAA)	vascular smooth muscle cells (VSMCs)	NaAsO2 treatment	upregulated	30898623
2977	Human	hsa-miR-155-5p	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
2978	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atopic dermatitis (AD)	HaCaT cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31767859
2979	Human	hsa-miR-155-5p	miRNA	lipopolysaccharide (LPS)	bronchopneumonia	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"NEAT1 and MyD88 were upregulated in BEAS-2B cells by LPS, while miR-155-5p was downregulated."	33719773
2980	Human	hsa-miR-155-5p	miRNA	oxalate and calcium	calcium oxalate (CaOx) stone	HK-2 cells	Oxalate and calcium treatment	miR-155-5p was significantly upregulated after oxalate and COM treated in HK-2 cells.	32215174
2981	Human	hsa-miR-155-5p	miRNA	(-)-epigallocatechin gallate (EGCG)	colorectal cancer (CRC)	"human colon carcinoma cell line-HCT-116, DLD1"	(-)-Epigallocatechin gallate (EGCG) treatment	upregulated	30741544
2982	Human	hsa-miR-155-5p	miRNA	enterotoxigenic bacteroides fragilis (ETBF)	colorectal cancer (CRC)	HCT-116 and DLD-1 cells	Enterotoxigenic Bacteroides fragilis (ETBF) infection	downregulated	31515468
2983	Human	hsa-miR-155-5p	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	human monocyte-derived macrophages (MDM) differentiated in absence or presence of vitamin D (D3-MDM)	dengue virus (DENV) infection	vitamin D in the control of inflammatory cytokine responses during DENV infection of human macrophages via the TLR4/NF-¦ÊB/miR-155-5p/SOCS-1 axis	30639520
2984	Human	hsa-miR-155-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	"CTBP1-AS2 attenuated HG-induced HGMC proliferation, oxidative stress, ECM accumulation, and inflammation through miR-155-5p/FOXO1 signaling."	32868076
2985	Human	hsa-miR-155-5p	miRNA	BAY11-7082	EBV-associated gastric cancer (EBVaGC)	GT39 cells	NF-¦ÊB inhibitor (BAY 11-7082) treatment	downregulated	31469179
2986	Human	hsa-miR-155-5p	miRNA	epstein-barr virus (EBV)	EBV-associated gastric cancer (EBVaGC)	SGC7901 cells	EBV-encoded latent membrane protein 2A (LMP2A) treatment	upregulated	31469179
2987	Human	hsa-miR-155-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal cancer (EC)	KYSE-30 cells; KYSE-140 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-155-5p was upregulated in the indicated ESCC cell lines following treatment with 5-aza-dC for 72 h.	32323857
2988	Human	hsa-miR-155-5p	miRNA	epstein-barr virus (EBV)	gastric cancer (GC)	GT38 cells; GT39 cells; SNU719 cells	Epstein-Barr virus (EBV) infection	The expression level of miR-155-5p in the EBV-positive cell lines was significantly higher than that in the EBV-negative cell lines	31469179
2989	Human	hsa-miR-155-5p	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	serum	Enterovirus 71 (EV71) infection	microRNA-155-5p (miR-155-5p) was found to be significantly upregulated in serum from patients with EV71 infection.	31856677
2990	Human	hsa-miR-155-5p	miRNA	R-pulegone (PUL)	hepatotoxicity	liver tissues	R-pulegone (PUL) treatment	downregulated	29921785
2991	Human	hsa-miR-155-5p	miRNA	olive oil polyphenol hydroxytyrosol (HT)	inflammation	TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	olive oil polyphenol hydroxytyrosol (HT) treatment	downregulated	31627295
2992	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31627295
2993	Human	hsa-miR-155-5p	miRNA	carbon monoxide-releasing compound CORM-2	inflammatory vascular disorders	TNF-¦Á-stimulated HUVECs	200?¦Ìm CORM-2 treatment	downregulated	29170479
2994	Human	hsa-miR-155-5p	miRNA	enterovirus 71 (EV71)	innate immune response	"serum from patients with EV71 infection, Vero, RD, HT-29, HeLa, and THP-1 cells"	Enterovirus 71 (EV71) infection	upregulated	31856677
2995	Human	hsa-miR-155-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-155-5p was upregulated in OGD/R-induced SH-SY5Y cells.	32096190
2996	Human	hsa-miR-155-5p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
2997	Human	hsa-miR-155-5p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
2998	Human	hsa-miR-155-5p	miRNA	X-rays	non-small cell lung cancer (NSCLC)	Human NSCLC A549 and H460 cells	"cells were irradiated using experimental X-ray irradiator (Gulmay Medical Inc., Atlanta, GA, xstrahl.com) at a rate of 2.4 Gy/min for the time required treatment"	upregulated	30901121
2999	Human	hsa-miR-155-5p	miRNA	oleacein (OA)	obesity	TNF-¦Á-treated Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleacein (OA) treatment	downregulated	31766503
3000	Human	hsa-miR-155-5p	miRNA	oleocanthal (OC)	obesity	TNF-¦Á-treated Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleocanthal (OC) treatment	downregulated	31766503
3001	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31766503
3002	Human	hsa-miR-155-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-10¦Â treatment	dysregulated	29123165
3003	Human	hsa-miR-155-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
3004	Human	hsa-miR-155-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oxidative stress	HTR-8/SVneo cell line	mono-(2-ethylhexyl) phthalate (MEHP) treatment	upregulation	26871967
3005	Human	hsa-miR-155-5p	miRNA	sulforaphane (SFN)	pancreatic cancer (PC)	Monocyte-Derived Dendritic Cells	sulforaphane (SFN) treatment	upregulated	33193420
3006	Human	hsa-miR-155-5p	miRNA	porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS)	periodontitis	The exosomes were extracted from periodontal ligament stem cells (PDLSCs)	Porphyromonas gingivalis lipopolysaccharide (LPS) treatment	downregulated	31016751
3007	Human	hsa-miR-155-5p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
3008	Human	hsa-miR-155-5p	miRNA	radiation	radiation-induced pulmonary fibrosis (RIPF)	BEAS-2B cells	radiation treatment	adiation downregulates miR-155-5p in alveolar epithelial cells that induces EMT	33259794
3009	Human	hsa-miR-155-5p	miRNA	radiation	radiation-induced pulmonary fibrosis (RIPF)	A549 cells; BEAS-2B cells	radiation treatment	we found that miR-155-5p was significantly downregulated through high-throughput sequencing	33259794
3010	Human	hsa-miR-155-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	whole-blood	methotrexate (MTX) treatment	downregulated	30511295
3011	Human	hsa-miR-155-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	RA patients whole-blood	methotrexate (MTX) treatment	upregulated	30511295
3012	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	Fibroblast-like synoviocytes (FLSs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-¦Á	32289665
3013	Human	hsa-miR-155-5p	miRNA	Korean Red ginseng extract (KRGE)	cell senescence	human umbilical vein endothelial cells (HUVECs)	Korean Red ginseng extract (KRGE) treatment	"miR-155-5p levels were increased in senescent HUVECs compared to young cells, and this increase was blocked by KRGE."	33841015
3014	Human	hsa-miR-155-5p	miRNA	nuclear factor kappa-B (NF-¦ÊB) inhibitor Bay11-708211	cell senescence	human umbilical vein endothelial cells (HUVECs)	NF-kB inhibitor Bay11-708211 treatment	"miR-155-5p levels were increased in senescent HUVECs compared to young cells, and this increase was blocked by the NF-kB inhibitor Bay11-708211."	33841015
3015	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	rheumatoid synovial fibroblasts (RASFs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28807007
3016	Human	hsa-miR-155-5p	miRNA	ARS labeled titanium dioxide nanoparticles (nano-TiO 2-ARS)	toxicity of nanoparticles	THP-1 cells	ARS labeled Titanium dioxide nanoparticles (nano-TiO 2-ARS) treatment	downregulated	32284792
3017	Human	hsa-miR-155-5p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
3018	Human	hsa-miR-155-5p	miRNA	bufalin	triple negative breast cancer (TNBC)	MDA-MB-231 and MCF-7/ADR TNBC cell lines	bufalin treatment	upregulated	26398931
3019	Human	hsa-miR-155-5p	miRNA	Indoxyl sulfate (IS)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	Indoxyl sulfate (IS) treatment	upregulated	32979364
3020	Human	hsa-miR-155-5p	miRNA	Korean Red ginseng extract (KRGE)	vascular disease	human umbilical vein endothelial cells (HUVECs)	korean red ginseng extract (KRGE)? treatment	The beneficial effects of KRGE were due to the induction of HO-1 and the inhibition of NF-¦ÊB-dependent biogenesis of miR-155-5p that led to the downregulated of eNOS.	33841015
3021	Human	hsa-miR-155a	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	hepatitis C virus (HCV) infection	miR-155a expression was upregulated in HCV-infected PBMC.	31696995
3022	Human	hsa-miR-155a	miRNA	chuyou yuyang granule (CYYY)	ulcer relapse	Helicobacter pylori (HP) infected Peptic ulcert patients blood	Chuyou Yuyang granule (CYYY) four weeks or six weeks treatment	downregulated	31034651
3023	Human	hsa-miR-1587	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
3024	Human	hsa-miR-1587	miRNA	botulinum toxin A (BTXA)	keloids	human skin keloid fibroblasts (HSFBs)	botulinum toxin A (BTXA) treatment	upregulated	31652445
3025	Human	hsa-miR-15a	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
3026	Human	hsa-miR-15a	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
3027	Human	hsa-miR-15a	miRNA	recombinant tissue plasminogen activator (rt-PA)	acute ischemic stroke (AIS)	AIS patients blood samples	rt-PA treatment	upregulation of let-7i and downregulated of miR-15a	28892656
3028	Human	hsa-miR-15a	miRNA	prednisolone	acute lymphoblastic leukemia (ALL)	CCRF-CEM cell line	Prednisolone treatment	upregulated	27281445
3029	Human	hsa-miR-15a	miRNA	resveratrol	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	resveratrol (RS) treatment	upregulated	26434860
3030	Human	hsa-miR-15a	miRNA	H2O2	age-related cataract (ARC)	"human lens epithelial B3 cells, HLE-B3 cells"	H2O2 treatment	upregulated	31737898
3031	Human	hsa-miR-15a	miRNA	BL-8040	apoptosis	human acute myeloid leukemia (AML) blasts	BL-8040 treatment	upregulated	28280274
3032	Human	hsa-miR-15a	miRNA	aloe-emodin (AE)	breast cancer	MCF-10AT cells; MCF-7 cells	aloe-emodin (AE) treatment	upregulated	32190086
3033	Human	hsa-miR-15a	miRNA	bleomycin (BLM)	breast cancer	human breast cancer cell lines MCF-7 cells and/or MDA-MB-231 cells	bleomycin (BLM) treatment	upregulated	28337296
3034	Human	hsa-miR-15a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin (diferuloylmethane)? treatment	upregulated	19908170
3035	Human	hsa-miR-15a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
3036	Human	hsa-miR-15a	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
3037	Human	hsa-miR-15a	miRNA	tripterine	breast cancer	MDA-MB-231 cells	Tripterine treatment	upregulated	30913029
3038	Human	hsa-miR-15a	miRNA	IL-23	cardiomyocyte apoptosis	B-acute lymphoblastic leukemia cells	IL-23 treatment	upregulated	20671120
3039	Human	hsa-miR-15a	miRNA	doxorubicin (DOX)	chemoresistance of lymphoma	Daudi and Namalwa cells	doxorubicin treatment	MCM3AP-AS1/miR-15a/EIF4E axis plays a role in the chemoresistance of Burkitt lymphoma	32765087
3040	Human	hsa-miR-15a	miRNA	imatinib	chronic myeloid leukemia (CML)	CML patients	imatinib (IM) treatment	differently regulated	24629639
3041	Human	hsa-miR-15a	miRNA	taxol	colorectal cancer (CRC)	HCT116 cells	taxol treatment	downregulated	30126852
3042	Human	hsa-miR-15a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Primary human retinal endothelial cells (REC)	high glucose (HG) treatment	downregulated	29339083
3043	Human	hsa-miR-15a	miRNA	resveratrol	diabetic retinopathy (DR)	high glucose-treated primary human retinal endothelial cells (REC)	resveratrol (RSV) treatment	upregulated	29339083
3044	Human	hsa-miR-15a	miRNA	D-glucose	epithelial-mesenchymal transition (EMT)	peritoneal mesothelial cells (PMCs)	D-glucose treatment	downregulated	25683944
3045	Human	hsa-miR-15a	miRNA	H2O2	gastric cancer (GC)	HGC-27 cells	H2O2 treatment	upregulated	33329376
3046	Human	hsa-miR-15a	miRNA	Helicobacter pylori (H. pylori) extract (HPE)	gastric cancer (GC)	HGC-27 cells	Helicobacter pylori (H. pylori) infection	upregulated	33065487
3047	Human	hsa-miR-15a	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
3048	Human	hsa-miR-15a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	30103211
3049	Human	hsa-miR-15a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; HepG2.2.15 cells; human normal liver cell line L-02	hepatitis B virus (HBV) infection	upregulated	24089558
3050	Human	hsa-miR-15a	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
3051	Human	hsa-miR-15a	miRNA	curcumin (Cur)	laryngeal cancer	human laryngeal cancer cells	curcumin treatment	upregulated	29085504
3052	Human	hsa-miR-15a	miRNA	curcumin (Cur)	leukemia	primary acute myeloid leukemia (AML) cells	Pure curcumin treatment	downregulated	22449094
3053	Human	hsa-miR-15a	miRNA	bortezomib	multiple myeloma (MM)	The human multiple myeloma cell lines U266 and NCI-H929	bortezomib? treatment	"via suppressing miRNA-15a expression, BMSCs provide survival support and protect myeloma cells from bortezomib induced apoptosis"	21534877
3054	Human	hsa-miR-15a	miRNA	IL-6	multiple myeloma (MM)	bone marrow mesenchymal stem cells(BMSCs)	interleukin-6 (IL-6) treatment	"via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells"	21936961
3055	Human	hsa-miR-15a	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
3056	Human	hsa-miR-15a	miRNA	hypoxia	osteosarcoma (OS)	MG63 human osteosarcoma cell line	hypoxia induce	downregulated	29484432
3057	Human	hsa-miR-15a	miRNA	lipopolysaccharide (LPS)	pneumonia	Human lung bronchial epithelial cell line BEAS-2B	lipopolysaccharide (LPS) treatment	upregulated	29710526
3058	Human	hsa-miR-15a	miRNA	xianyu decoction (XD)	pneumonia	LPS-treated human lung bronchial epithelial cell line BEAS-2B	Xianyu decoction (XD) treatment	downregulated	29710526
3059	Human	hsa-miR-15a	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
3060	Human	hsa-miR-15a	miRNA	protein kinase C (PKC) ¦Á	renal cell carcinoma (RCC)	"renal clear-cell carcinoma cells,CP renal carcinoma cells, renal papillary cell carcinoma cells, renal oncocytoma cells and Normal renal tissue cells"	protein kinase C (PKC) ¦Á treatment	upregulated	22429968
3061	Human	hsa-miR-15a	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
3062	Human	hsa-miR-15a	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
3063	Human	hsa-miR-15a	miRNA	retinoic acid (RA)	epithelial-mesenchymal transition (EMT)	NB4 cells£» HL-60U937 cells£»primary leukemic cells	retinoic acid treatment	upregulated	21838537
3064	Human	hsa-miR-15a-5p	miRNA	IL-13	allergic rhinitis (AR)	Human primary nasal epithelial cells (NECs)	IL-13 treatment	downregulated	31104300
3065	Human	hsa-miR-15a-5p	miRNA	IL-13	allergic rhinitis (AR)	Human nasal epithelial cells (HNECs)	IL-13 treatment	knockdown of ANRIL may suppress the production of inflammatory cytokines and mucin in IL-13-treated HNECs via regulation of the miR-15a-5p/JAK2 axis.	33325534
3066	Human	hsa-miR-15a-5p	miRNA	IL-13	allergic rhinitis (AR)	Human nasal epithelial cells (HNECs)	IL-13 treatment	"The expression levels of ANRIL and JAK2 were also upregulated in IL-13-induced HNECs, while the expression levels of miR-15a-5p were downregulated."	33325534
3067	Human	hsa-miR-15a-5p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
3068	Human	hsa-miR-15a-5p	miRNA	advanced glycation end product (AGE)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	advanced glycation end (AGE) product treatment	downregulated	30362573
3069	Human	hsa-miR-15a-5p	miRNA	high glucose (HG)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	high glucose (HG) treatment	downregulated	30362573
3070	Human	hsa-miR-15a-5p	miRNA	advanced glycation end product (AGE)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	advanced glycation end (AGE) product treatment	downregulated	30362573
3071	Human	hsa-miR-15a-5p	miRNA	high glucose (HG)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	high glucose treatment	downregulated	30362573
3072	Human	hsa-miR-15a-5p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
3073	Human	hsa-miR-15a-5p	miRNA	simvastatin	apoptosis	Myocardial tissue biopsies	Simvastatin treatment	downregulated	29985281
3074	Human	hsa-miR-15b	miRNA	paeoniflorin	breast cancer	MCF-7/4-hydroxytamoxifen (4-OHT)	paeoniflorin (Pae) treatment	downregulated	33519190
3075	Human	hsa-miR-15b	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
3076	Human	hsa-miR-15b	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	human T-ALL cell	Glucocorticoids (GCs) treatment	downregulated	19148136
3077	Human	hsa-miR-15b	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
3078	Human	hsa-miR-15b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
3079	Human	hsa-miR-15b	miRNA	hyperthermia	breast cancer	BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231	Hyperthermia treatment	downregulated	27380148
3080	Human	hsa-miR-15b	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
3081	Human	hsa-miR-15b	miRNA	triamcinolone	cell differentiation	hepatic induced stem cells	triamcinolone treatment	upregulated	29101812
3082	Human	hsa-miR-15b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells (REC)	high-glucose treatment	downregulated	25888955
3083	Human	hsa-miR-15B	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
3084	Human	hsa-miR-15b	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
3085	Human	hsa-miR-15b	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-15b was downregulated in propofol-treated group	24454982
3086	Human	hsa-miR-15b	miRNA	geniposide (GEN)	inflammation and apoptosis	Human umbilical vein endothelial cells (HUVECs)	ginsenosides treatment	upregulated	21872652
3087	Human	hsa-miR-15b	miRNA	morphine	inflammation and oxidative stress	peripheral blood mononuclear cells (PBMCs)	Morphine treatment	upregulated	20564181
3088	Human	hsa-miR-15b	miRNA	epigallocatechin-3-gallate (EGCG)	inflammation	human Jurkat E6.1 Cell Line	10 ¦ÌM EGCG	upregulated	27851983
3089	Human	hsa-miR-15b	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus cells	IL-1¦Â treatment	upregulated	28039556
3090	Human	hsa-miR-15b	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	NP cells	IL-1¦Â treatment	upregulated	28039556
3091	Human	hsa-miR-15b	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	?The expression of miR-15bwas decreased in TGF-¦Â1-stimulated LX-2 cells	33545201
3092	Human	hsa-miR-15b	miRNA	dexamethasone (DEX)	miRNA biogenesis	human endothelial cells	dexamethasone (Dex) treatment	downregulated	28523344
3093	Human	hsa-miR-15b	miRNA	ginsenoside Rg1	miRNA biogenesis	human endothelial cells	ginsenoside-Rg1 treatment	downregulated	28523344
3094	Human	hsa-mir-15b	miRNA	Copper(II) complex of quercetin Cu+Q	osteogenesis and angiogenesis	human osteoblast-like cells (MG-63)	Cu+Q(Neo)	upregulated	29208278
3095	Human	hsa-miR-15b	miRNA	lipopolysaccharide (LPS)	placentation	HTR-8/SVneo cell	lipopolysaccharides (LPS) treatment	upregulated	27208409
3096	Human	hsa-miR-15b	miRNA	ionizing radiation (IR)	radiation-induced lung disease	human bronchial epithelial cells	IR treatment	expression was highest after 2 h of IR and downregulated gradually	25092292
3097	Human	hsa-miR-15b	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
3098	Human	hsa-miR-15b	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
3099	Human	hsa-miR-15b*	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
3100	Human	hsa-miR-15b-3p	miRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line HL7702	"treatment with MC-LR at concentrations of 1, 2.5, 5 or 10 ¦ÌM"	upregulated	29265921
3101	Human	hsa-miR-15b-3p	miRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	human normal liver cell line HL7702	icrocystin-LR (MC-LR) treatment	upregulated	29265921
3102	Human	hsa-miR-15b-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
3103	Human	hsa-miR-15b-5p	miRNA	benzyl butyl phthalate (BBP)	acute myeloid leukemia (AML)	"The human acute monocytic leukemia AML U937 (isolated from the histiocytic lymph), Raji (lymphoblast Burkitt's lymph), and HL-60 (a promyelocytic cell line) cell lines"	benzyl butyl phthalate (BBP) treatment	downregulated	31629899
3104	Human	hsa-miR-15b-5p	miRNA	benzyl butyl phthalate (BBP)	acute Myeloid Leukemia (AML)	U937 cells	benzyl butyl phthalate (BBP) treatment	BBP can decrease the expression of miR-15b-5p in AML cells.	31629899
3105	Human	hsa-miR-15b-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
3106	Human	hsa-miR-15b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	downregulated	30842352
3107	Human	hsa-miR-15b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis	33298110
3108	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated lncRNA SNHG1 promotes MPP+ -induced cytotoxicity and ROS production through the miR-15b-5p/GSK3¦Â axis in human dopaminergic SH-SY5Y cells	30302821
3109	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	29217406
3110	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	29217406
3111	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	30302821
3112	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	miR-15b-5p level was nota- bly reduced in MPP+-challenged SK-N-SH cells in dose- and time-dependent patterns	33208053
3113	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells.	33208053
3114	Human	hsa-miR-15b-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
3115	Human	hsa-miR-15b-5p	miRNA	dexamethasone (DEX)	steatosis	HepG5 cells	dexamethasone (Dex) treatment	downregulated	29409992
3116	Human	hsa-miR-15b-5p	miRNA	dexamethasone (DEX)	steatosis	?HepG2 cell lines	dexamethasone (DEX) treatment	"ENST00000608794 plays an important role in dexamethasone induced steatosis, which was partly mediated by derepressing of PDK4 through competitively binding to miR-15b-5p."	31330194
3117	Human	hsa-miR-15b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
3118	Human	hsa-miR-16	miRNA	hyperoxia	acute lung injury (ALI)	primary human alveolar type II epithelial cells (AECII)	hyperoxia induce	downregulated	29484411
3119	Human	hsa-miR-16	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	30784935
3120	Human	hsa-miR-16	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	human T-ALL cell	Glucocorticoids (GCs) treatment	downregulated	19148136
3121	Human	hsa-miR-16	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	acute myeloid leukemia (AML)	"human myeloid leukemic cell line, AML-193"	GM-CSF treatment	downregulated	22015065
3122	Human	hsa-miR-16	miRNA	IL-13	allergic rhinitis (AR)	human nasal epithelial cells (JME/CF15)	IL-13 treatment	Interleukin (IL)-13 stimulation gradually decreased the levels of miR-16 in JME/CF15 cells.	30132525
3123	Human	hsa-miR-16	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
3124	Human	hsa-miR-16	miRNA	epigallocatechin-3-gallate (EGCG)	apoptosis	human hepatocellular carcinoma HepG2 cells	Epigallocatechin gallate (EGCG)?treatment	upregulated	19269153
3125	Human	hsa-miR-16	miRNA	puerarin	bladder cancer	T24 cells	Puerarin treatment	upregulated	29422113
3126	Human	hsa-miR-16	miRNA	estradiol	breast cancer	MCF-7 cells	estradiol (E?) treatment	"E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells"	22260523
3127	Human	hsa-miR-16	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
3128	Human	hsa-miR-16	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
3129	Human	hsa-miR-16	miRNA	hesperidin	breast cancer	MCF-7 cells	hesperidin treatment	upregulated	33050842
3130	Human	hsa-miR-16	miRNA	lipopolysaccharide (LPS)	breast cancer	human neonatal cardiomyocytes	lipopolysaccharide (LPS) treatment	downregulated	32369253
3131	Human	hsa-miR-16	miRNA	luteolin	breast cancer	MCF-7 cells	luteolin treatment	upregulated	33050842
3132	Human	hsa-miR-16	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
3133	Human	hsa-miR-16	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
3134	Human	hsa-miR-16	miRNA	VEGF or basic fibroblast growth factor (bFGF)	tumorigenesis	endothelial vascellum	VEGF or basic fibroblast growth factor (bFGF) treatment	upregulated	21885851
3135	Human	hsa-miR-16	miRNA	bothrops moojeni snake venom (BmooLAAO-I)	chronic myeloid leukemia (CML)	"Bcr-Abl+ cell lines (HL-60.Bcr-Abl, K562-S, and K562-R)"	bothrops moojeni snake venom (BmooLAAO-I) treatment	upregulated	33354202
3136	Human	hsa-miR-16	miRNA	nilotinib	chronic myeloid leukemia (CML)	HL-60.BCR-ABL cells	nilotinib (NIL) treatment	differently regulated	24629639
3137	Human	hsa-miR-16	miRNA	Protein Arginine Deiminases (PADs)	colorectal cancer (CRC)	HCT 116 wild-type (WT) colon cancer cells	Protein Arginine Deiminases (PADs)treatment treatment	"p53-dependent G1 arrest associated with PAD inhibition was, in turn, dependent on miRNA-16 expression"	23308284
3138	Human	hsa-miR-16	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-16 was downregulated in resistant patients when compared with sensitive patients	33072545
3139	Human	hsa-miR-16	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells (REC)	high-glucose treatment	downregulated	25888955
3140	Human	hsa-miR-16	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
3141	Human	hsa-miR-16	miRNA	nicotine	gastric cancer (GC)	Human gastric adenocarcinoma cells (AGS)	Nicotine treatment	"EP2 or EP4 siRNA or antagonists impaired the nicotine-mediated NF-kB activity, upregulation of miR-16 and miR-21 and cell proliferation."	21081469
3142	Human	hsa-miR-16	miRNA	osthole	glioblastoma multiforme (GBM)	"common glioma cell line, U87"	osthole treatment	upregulated	26082082
3143	Human	hsa-miR-16	miRNA	paeoniflorin	glioblastoma multiforme (GBM)	human glial cells	Paeoniflorin (PF) treatment	upregulated	25954855
3144	Human	hsa-miR-16	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	Human glioblastoma cell lines (U-138MG and A172)	Temozolomide (TMZ) treatment	downregulated	26722459
3145	Human	hsa-miR-16	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
3146	Human	hsa-miR-16	miRNA	microcystin-leucine arginine (MC-LR)	hepatitis	HepG2 cells	Microcystin-LR (MC-LR) treatment	miR-16 may play a vital role in the cell cycle alteration of HepG2 cells after MC-LR exposure.	32066005
3147	Human	hsa-miR-16	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; HepG2.2.15 cells; human normal liver cell line L-02	hepatitis B virus (HBV) infection	upregulated	24089558
3148	Human	hsa-miR-16	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	The human HepG2;SK-HEP-1; Huh7 HCC cell lines	Hepatitis B virus X protein (HBx)?treatment	downregulated	21629246
3149	Human	hsa-miR-16	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	serum	hepatitis C virus (HCV) infection	upregulated	29333940
3150	Human	hsa-miR-16	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
3151	Human	hsa-miR-16	miRNA	Pien Tze Huang (PZH)	hepatocellular carcinoma (HCC)	BEL-7402 HCC	PZH treatment	upregulated	29344256
3152	Human	hsa-miR-16	miRNA	sanguinarine	hepatocellular carcinoma (HCC)	"HepG2, Huh7, Hep3B cells"	sanguinarine treatment	"sanguinarine (SG), was capable of activating miR-16 in HCC cells with wildtype or mutated p53 expression but not in p53-deleted HCC cells"	31163195
3153	Human	hsa-miR-16	miRNA	fibroblast growth factor 4 (FGF4)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	FGF4 treatment	upregulated	30753902
3154	Human	hsa-miR-16	miRNA	hepatocyte growth factor (HGF)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	HGF treatment	upregulated	30753902
3155	Human	hsa-miR-16	miRNA	hepatitis C virus (HCV)	liver cirrhosis	liver	hepatitis C virus (HCV) infection	Serum miR-16 was significantly lower in HCC than in HCV patients (P = 0.033).	26133725
3156	Human	hsa-miR-16	miRNA	hepatitis C virus (HCV)	liver fibrosis	"liver cell line, QSG-7701"	hepatitis C virus (HCV) infection	upregulated	26071245
3157	Human	hsa-miR-16	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	?The expression of miR-16 was decreased in TGF-¦Â1-stimulated LX-2 cells	33545201
3158	Human	hsa-miR-16	miRNA	quercetin	lung adenocarcinoma (LUAD)	lung adenocarcinoma A549 cells	Quercetin treatment	upregulated	26061016
3159	Human	hsa-miR-16	miRNA	particulate matter (PM2.5)	lung cancer	human non-small cell lung cancer cell line A549	chronic (five passages) PM2.5 exposure treatment	downregulated	28846189
3160	Human	hsa-miR-16	miRNA	arctigenin	mechanical trauma injury	scratch-induced injury of human SH-SY5Y cells	arctigenin (ARC) treatment	upregulated	27389368
3161	Human	hsa-miR-16	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	monocytic differentiation	"HL60 cells,"	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	31232026
3162	Human	hsa-miR-16	miRNA	IL-6	multiple myeloma (MM)	bone marrow mesenchymal stem cells(BMSCs)	interleukin-6 (IL-6) treatment	"via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells"	21936961
3163	Human	hsa-miR-16	miRNA	autologous hematopoietic SCT(AHSCT)	multiple sclerosis (MS)	MS patients	AHSCT treatment	upregulated in T- and B-cell	25486582
3164	Human	hsa-miR-16	miRNA	nanocurcumin	multiple sclerosis (MS)	blood	nanocurcumin treatment	downregulated	30340096
3165	Human	hsa-miR-16	miRNA	hypoxia	expression regulation	ARPE-19 cells	hypoxia	downregulated	29237295
3166	Human	hsa-miR-16	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SH-SY5Y human neuroblastoma cells	Perfluorooctane sulfonate (PFOS) treatment	downregulated	26649298
3167	Human	hsa-miR-16	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SK-N-SH cells	PFOS treatment	upregulated	28441774
3168	Human	hsa-miR-16	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	compound C treatment	downregulated	32143184
3169	Human	hsa-miR-16	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	downregulated	32143184
3170	Human	hsa-miR-16	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
3171	Human	hsa-miR-16	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid treatment	downregulated	32143184
3172	Human	hsa-miR-16	miRNA	paclitaxel (PTX)	non-small cell lung cancer (NSCLC)	lung cancer cells	Paclitaxel treatment	downregulated	25435430
3173	Human	hsa-miR-16	miRNA	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np)	non-small cell lung cancer (NSCLC)	A549 cells	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) treatment	upregulated	31411213
3174	Human	hsa-miR-16	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	"human NSCLC cell lines A549, NCI-H1299 and HCC827"	TGF-¦Â treatment	downregulated	29138833
3175	Human	hsa-miR-16	miRNA	quercetin	oral cancer	"Oral cancer cell line HSC-6, SCC-9"	quercetin treatment	upregulated	30639311
3176	Human	hsa-miR-16	miRNA	cisplatin (DDP)	osteosarcoma (OS)	"osteosarcoma cell lines (SAOS2, U2OS)"	cisplatin (DPP) treatment	"SNHG16 enhanced the cisplatin resistance in osteosarcoma cell lines, while miR-16 reversed this impact."	31427084
3177	Human	hsa-miR-16	miRNA	p-glycoprotein	osteosarcoma (OS)	HepG2 cells; SK-HEP-1 cells ;MiHa cells	P-glycoprotein treatment	upregulated	21336967
3178	Human	hsa-miR-16	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	placental apoptosis	HTR-8/SVneo cell line	Mono-(2-ethylhexyl) phthalate treatment	upregulated	26597031
3179	Human	hsa-miR-16	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	placental apoptosis	HTR-8/SVneo cell line	Mono-(2-ethylhexyl) phthalate£¨MEHP£© treatment	"our study demonstrates for the first time that MEHP induces miR-16, which in turn, alters BCL-2/BAX ratio leading to increased apoptosis."	26597031
3180	Human	hsa-miR-16	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	selenium nanoparticles (SeNPs) treatment	upregulated	32357938
3181	Human	hsa-miR-16	miRNA	ionizing radiation (IR)	radiation-induced intestinal fibrosis (RIF)	human intestinal CCD-18Co fibroblasts cell lines;subepithelial SEMFs	"Ionizing radiation (IR) was done with 6 MV photons, 8 Gy/min by a linear accelerator (Varian, America) at room temperature."	downregulated	31262262
3182	Human	hsa-miR-16	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
3183	Human	hsa-miR-16	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
3184	Human	hsa-miR-16	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	serum	Mycobacterium tuberculosis (M.TB) treatment	upregulated	28061948
3185	Human	hsa-miR-16	miRNA	hypoxia	expression regulation	RPE-19 cells	hypoxia treatment	"After cultivating under hypoxia, the expression of microRNA-16 in ARPE-19 cells decreased."	29237295
3186	Human	hsa-miR-16	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin (diferuloylmethane)? treatment	upregulated	19908170
3187	Human	hsa-miR-16-1	miRNA	prednisolone	acute lymphoblastic leukemia (ALL)	CCRF-CEM cell line	Prednisolone treatment	upregulated	27281445
3188	Human	hsa-miR-16-1	miRNA	resveratrol	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	resveratrol (RS) treatment	upregulated	26434860
3189	Human	hsa-miR-16-1	miRNA	triptolide (TPL)	anastomotic fibrosis	primary fibroblasts were obtained from strictured anastomosis tissue (SAT) samples	triptolide (TPL) treatment	downregulated	30942423
3190	Human	hsa-miR-16-1	miRNA	BL-8040	apoptosis	human acute myeloid leukemia (AML) blasts	BL-8040 treatment	upregulated	28280274
3191	Human	hsa-miR-16-1	miRNA	aloe-emodin (AE)	breast cancer	MCF-10AT cells; MCF-7 cells	aloe-emodin (AE) treatment	upregulated	32190086
3192	Human	hsa-miR-16-1	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	colorectal cancer (CRC)	HCT-116 cells	Omega-3 fatty acid DHA treatment	upregulated	29619114
3193	Human	hsa-miR-16-1	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	30103211
3194	Human	hsa-miR-16-1	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
3195	Human	hsa-miR-16-1	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
3196	Human	hsa-miR-16-1	miRNA	candida albicans (C. albicans)	invasive candidiasis	respiratory epithelial cells	candida albicans infection	upregulated	26313489
3197	Human	hsa-miR-16-1	miRNA	curcumin (Cur)	leukemia	primary acute myeloid leukemia (AML) cells	Pure curcumin treatment	downregulated	22449094
3198	Human	hsa-miR-16-1	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
3199	Human	hsa-miR-16-1	miRNA	retinoic acid (RA)	epithelial-mesenchymal transition (EMT)	NB4 cells£» HL-60U937 cells£»primary leukemic cells	retinoic acid treatment	upregulated	21838537
3200	Human	hsa-miR-16-1*	miRNA	triptolide (TPL)	lymphocytic leukemia	Molt-4 cells	triptolide (TPL) treatment	downregulated	21441948
3201	Human	hsa-miR-16-1-3p	miRNA	particulate matter (PM2.5)	hepatocellular carcinoma (HCC)	human HCC cell line SMMC-7721	PM2.5 (particulate matter with an aerodynamic diameter less than 2.5 ¦Ìm) exposure treatment	downregulated	31572802
3202	Human	hsa-miR-16-2	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
3203	Human	hsa-miR-16-2-3p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
3204	Human	hsa-miR-16-5p	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	AC16 cells	hypoxia/re-oxygenation (H/R) treatment	miR-16-5p was elevated in H/R-treated AC16 cells.	31870262
3205	Human	hsa-miR-16-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) treatment	The expression levels of miR-16-5p and miR-19b-3p were reduced but BACE1 protein expression was enhanced in SH-SY5Y cells after treatment of amyloid ¦Â.	31876684
3206	Human	hsa-miR-16-5p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
3207	Human	hsa-miR-16-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
3208	Human	hsa-miR-16-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
3209	Human	hsa-miR-16-5p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
3210	Human	hsa-miR-16-5p	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
3211	Human	hsa-miR-16-5p	miRNA	etoposide (VP-16)	cell senescence	A549 and MCF-7 cells	etoposide treatment	downregulated	33141998
3212	Human	hsa-miR-16-5p	miRNA	radiation	cervical cancer (CC)	SiHa cells; Hela cells	radiation treatment	miR-16-5p expression was low in radio-resistant CC cells	31872565
3213	Human	hsa-miR-16-5p	miRNA	X-rays	cervical cancer (CC)	"Human cervical cancer cell lines (HeLa, C©\33A, CaSki, HeLa229, SiHa)"	X-ray exposure treatment	downregulated	31872565
3214	Human	hsa-miR-16-5p	miRNA	resistin	chondrosarcoma	The human chondrosarcoma cell line JJ012 and SW1353	resistin treatment	downregulated	30631040
3215	Human	hsa-miR-16-5p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
3216	Human	hsa-miR-16-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes (HPDCs)	high glucose (HG) treatment	downregulated	31568645
3217	Human	hsa-miR-16-5p	miRNA	melatonin	gastric cancer (GC)	BSG823 cells; SGC-7901	Melatonin treatment	melatonin administration enhanced the expression of miR-16-5p.	29359963
3218	Human	hsa-miR-16-5p	miRNA	tanshinone IIA (Tan IIA)	glioblastoma multiforme (GBM)	T98G cells; A172 cells	Tanshinone IIA (TIIA) treatment	"TIIA induced anti-glioma role, wherein miR-16-5p was upregulated"	33192091
3219	Human	hsa-miR-16-5p	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells and human astrocytoma (CCF-STTG1) cells	infect with EV71	upregulated	29180670
3220	Human	hsa-miR-16-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Bel7404; HepG2 cells	sorafenib treatment	LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1	33378944
3221	Human	hsa-miR-16-5p	miRNA	silybin	hepatoprotective	HepG2 cells	Silybin treatment	upregulated	31058823
3222	Human	hsa-miR-16-5p	miRNA	etoposide (VP-16)	lung adenocarcinoma (LUAD)	human senescent cells	etoposide treatment	?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells.	33141998
3223	Human	hsa-miR-16-5p	miRNA	lipopolysaccharide (LPS)	lung cancer	A549 cells	lipopolysaccharides (LPS) treatment	downregulated	30957556
3224	Human	hsa-miR-16-5p	miRNA	anti-programmed cell death protein 1 (anti-PD-1) antibody	malignant melanoma (MM)	serum	anti-programmed cell death protein 1 (anti-PD-1) antibody treatment	Serum expression levels of miR-16-5p was significantly higher in responders than in non-responders.	31843231
3225	Human	hsa-miR-16-5p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	upregulated	33071785
3226	Human	hsa-miR-16-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human articular chondrocytes-knee cells	IL-1¦Â treatment	SNHG1 alleviates the inflammation of IL-1¦Â-induced OA through the activation of miR-16-5p-mediated p38MAPK and NF-¦ÊB signaling pathway.	31383786
3227	Human	hsa-miR-16-5p	miRNA	ionizing radiation (IR)	prostate cancer	CaP LNCaP cells	ionizing radiation (IR) treatment	upregulated	30536619
3228	Human	hsa-miR-16-5p	miRNA	X-rays and heavy ions	prostate cancer	LNCaP cells	X-rays and heavy ions treatment	upregulated	30536619
3229	Human	hsa-miR-16-5p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
3230	Human	hsa-miR-16-5p	miRNA	etoposide (VP-16)	cell senescence	A549; MCF-7 cells	etoposide treatment	downregulated	33141998
3231	Human	hsa-miR-16-5p	miRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	¦Â-TC-tet cells	high glucose treatment	downregulated	32797474
3232	Human	hsa-miR-16a-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
3233	Human	hsa-miR-17	miRNA	levonorgestrel (LNG)	adenomyosis	endometrial stromal cells (ESCs)	levonorgestrel (LNG) treatment	LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway.	32921982
3234	Human	hsa-miR-17	miRNA	phosphatase of regenerating liver-3 (PRL-3)	angiogenesis	colon cancer cells	Phosphatase of regenerating liver-3 (PRL-3) treatment	"overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3"	22677902
3235	Human	hsa-miR-17	miRNA	nanocurcumin	ankylosing spondylitis (AS)	peripheral blood mononuclear cells (PBMCs)	nanocurcumin treatment	downregulated	31074089
3236	Human	hsa-miR-17	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
3237	Human	hsa-mir-17	miRNA	estrogen receptor-¦Á	breast cancer	breast cancer cells	The estrogen receptor-¦Á treatment	upregulated	19706389
3238	Human	hsa-miR-17	miRNA	phenethyl isothiocyanate	breast cancer	PCa cells	Phenethyl isothiocyanate treatment	downregulated	23661605
3239	Human	hsa-miR-17	miRNA	oridonin and the antileukemia drugs Ara-C and VP-16	chemoresistant leukemia	human leukemia cells	oridonin and the antileukemia drugs Ara-C and VP-16 treatment	downregulated	24872388
3240	Human	hsa-miR-17	miRNA	IL-6	chronic lymphocytic leukemia (CLL)	chronic lymphocytic leukemia (CLL) cells	IL-6 treatment	upregulated	26041742
3241	Human	hsa-miR-17	miRNA	calycosin	colorectal cancer (CRC)	HCT-116 cells	Calycosin treatment	downregulated	26215320
3242	Human	hsa-miR-17	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary heart disease (CHD)	Human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31296440
3243	Human	hsa-miR-17	miRNA	"IRE1¦Á, an ER bifunctional kinase/endoribonuclease (RNase)"	diabetes mellitus (DM)	Human THP-1 cells	IRE1¦Á treatment	downregulated	22883233
3244	Human	hsa-miR-17	miRNA	ruxolitinib	glioblastoma multiforme (GBM)	U87-MG cells	ruxolitinib treatment	Uxolitinib (195 nM) significantly increased miR-17 and miR-20a expression	31452174
3245	Human	hsa-miR-17	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) induced liver fibrosis	serum	hepatitis B virus (HBV) infection	Serum miR-17 level is highly expressed in HBV patients.	32572891
3246	Human	hsa-mir-17	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
3247	Human	hsa-miR-17	miRNA	lipopolysaccharide (LPS)	inflammation	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	29704506
3248	Human	hsa-miR-17	miRNA	resveratrol	inflammation	LPS-treated HaCaT cells	resveratrol (Res) treatment	upregulated	29704506
3249	Human	hsa-miR-17	miRNA	VEGF-immobilized microparticles (VEGF-MPs)	ischemic injury	outgrowth endothelial progenitor cells (OEPCs)	outgrowth endothelial progenitor cells (OEPCs) from human UCB sample treatment	downregulated	28963481
3250	Human	hsa-miR-17	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
3251	Human	hsa-miR-17	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells	lipopolysaccharide (LPS) treatment	upregulated	23562609
3252	Human	hsa-miR-17	miRNA	high glucose (HG)	myocardial infarction (MI)	myocardial infarction (MI)	high-glucose (HG) treatment	upregulated	31075259
3253	Human	hsa-miR-17	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; L02 cells	free fatty acids (FFA) treatment	downregulated	30338914
3254	Human	hsa-miR-17	miRNA	keratinocyte-derived exosomes (Ker-Exo)	osteoclast differentiation	osteoclast precursor cells	keratinocyte-derived exosomes (Ker-Exo) treatment	exosomes miRNA-17 secreted by keratinocytes in patients with middle ear cholesteatoma can up-regulate the expression of RANKL in fibroblasts and induce osteoclast differentiation.	32093888
3255	Human	hsa-miR-17	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
3256	Human	hsa-miR-17	miRNA	Sphingosine-1-phosphate (S1P)	papillary thyroid cancer (PTC)	thyroid follicular cancer cell lines (ML-1 and FTC-133)	Sphingosine-1-phosphate (S1P) treatment	downregulated	25748447
3257	Human	hsa-miR-17	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
3258	Human	hsa-miR-17	miRNA	natalizumab	multiple sclerosis (MS)	CD4+ T cells	natalizumab treatment	downregulated	24901013
3259	Human	hsa-miR-17	miRNA	decitabine	precursor B-cell acute lymphoblastic leukemia (B-ALL)	Nalm6 cell line	decitabine treatment	downregulated	30912184
3260	Human	hsa-miR-17	miRNA	hypoxia	pulmonary hypertension (PH)	human plasma	hypoxia treatment	upregulated	28971974
3261	Human	hsa-miR-17	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	rhabdomyosarcoma (RMS)	RD and Rh30 rhabdomyosarcoma (RMS) cells	"Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment"	downregulated	30610105
3262	Human	hsa-miR-17	miRNA	toxoplasma gondii (T. gondii)	toxoplasma gondii infection	primary human foreskin fibroblasts (HFFs)	toxoplasma gondii (T. gondii) infection treatment	upregulated	20090903
3263	Human	hsa-miR-17	miRNA	imatinib	chronic myeloid leukemia (CML)	chronic myeloid leukemia cells	imatinib? treatment	upregulated	23818358
3264	Human	hsa-miR-17?	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
3265	Human	hsa-miR-17-3p	miRNA	methyl-3-O-methyl gallate (M3OMG)	antioxidant enzymes	peripheral blood mononuclear cells and EVC-304 cells	M3OMG treatment	downregulated	24975036
3266	Human	hsa-miR-17-3p	miRNA	lipopolysaccharide (LPS)	breast cancer	HeLa cells	lipopolysaccharide (LPS) treatment	the expression of miR-17-3p and miR-106a is regulated by  LPS in HeLa cells	21370248
3267	Human	hsa-miR-17-3p	miRNA	racemate	endogenous antioxidant defenses	Caco-2 cells	subtoxic concentrations of racemate treatment	upregulated	28264488
3268	Human	hsa-miR-17-3p	miRNA	lipopolysaccharide (LPS)	inflammation	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"In HUVECs, LPS caused upregulation of miR-17-3p."	33623121
3269	Human	hsa-miR-17-3p	miRNA	candida albicans (C. albicans)	invasive candidiasis	respiratory epithelial cells infected by invasive Candida species	candida albicans infection	downregulated	26313489
3270	Human	hsa-miR-17-3p	miRNA	polyphenols	"iron bioavailability,iron absorption"	Caco-2 cells	polyphenols treatment	upregulated	25058155
3271	Human	hsa-miR-17-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human articular chondrocyte C28/I2 cells	lipopolysaccharide (LPS) treatment	downregulated	31966787
3272	Human	hsa-miR-17-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	miR-17-5p expression was downregulated and FOXA1 expression was upregulated in LPS-treated A549 cells	31257497
3273	Human	hsa-miR-17-5p	miRNA	influenza A virus (IAV)	acute respiratory distress syndrome (ARDS)	acute respiratory distress syndrome (ARDS) patients' BALF and in EVs of IAV-infected lung epithelial cells (A549)	Influenza A virus (IAV) infection	upregulated	30239899
3274	Human	hsa-miR-17-5p	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
3275	Human	hsa-miR-17-5p	miRNA	bortezomib	apoptosis	human endometrial cancer cells HTB-111£» Ishikawa cells	bortezomib? treatment	downregulated	23716467
3276	Human	hsa-miR-17-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophage-derived foam cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31646601
3277	Human	hsa-miR-17-5p	miRNA	hypoxia	autophagy	VSMCs	hypoxia treatment	upregulated	28450922
3278	Human	hsa-miR-17-5p	miRNA	sunitinib (SU)	autophagy	786-O-R cells; ACHN-R cells	sunitinib treatment	downregulated	32760216
3279	Human	hsa-miR-17-5p	miRNA	camptothecin	biologic and molecular activity of camptothecin	hypoxic-human cancer cells	camptothecin treatment	upregulated	24252850
3280	Human	hsa-miR-17-5p	miRNA	brown seaweed fucoidan	breast cancer	Human Breast Cancer Cells	brown seaweed fucoidan treatment	downregulated	27994679
3281	Human	hsa-miR-17-5p	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
3282	Human	hsa-miR-17-5p	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
3283	Human	hsa-miR-17-5p	miRNA	casiopeina II-gly (Cas-II-gly)	cervical cancer (CC)	HeLa and CaSki cells	Casiopeina II-gly (Cas-II-gly) treatment	upregulated	31524268
3284	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	chondrosarcoma	SW1353 human chondrosarcoma cells	IL-1¦Â treatment	downregulated	29434766
3285	Human	hsa-miR-17-5p	miRNA	curcumin (Cur)	colorectal cancer (CRC)	RKO; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts	curcumin treatment	downregulated	23194063
3286	Human	hsa-miR-17-5p	miRNA	diabetes mellitus macrophage-conditioned media (DM-MCM)	diabetes mellitus (DM)	HASMC	DM-MCM treatment	upregulated	25409512
3287	Human	hsa-miR-17-5p	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29786752
3288	Human	hsa-miR-17-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	miR-17-5p expression is upregulated in SGC7901/DDP cells compared with SGC7901 cells.	29541229
3289	Human	hsa-miR-17-5p	miRNA	H2O2	glaucoma	Human trabecular meshwork cells (HTMCs)	H2O2 treatment	downregulated	30816540
3290	Human	hsa-miR-17-5p	miRNA	X-rays	glioblastoma multiforme (GBM)	glioma patients serum samples	irradiation at a dose of 6.4 Gy with a high-energy X-ray accelerator (2 Gy/min) treatment	downregulated	28081732
3291	Human	hsa-miR-17-5p	miRNA	angiotensin II (Ang II)	glomerulonephritis	podocytes	angiotensin II (Ang II) treatment	RT-qPCR analysis showed that miR-17-5p was downregulated in Ang II-induced podocytes.	33835671
3292	Human	hsa-miR-17-5p	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	patients who were infected with hepatitis C virus genotype 1b	pegylated interferon-alpha and ribavirin combination therapy treatment	downregulated	24819603
3293	Human	hsa-miR-17-5p	miRNA	hypoglycemic	hepatocellular carcinoma (HCC)	HepG2 cells	hypoglycemic treatment	downregulated	27629773
3294	Human	hsa-miR-17-5p	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary arterial smooth muscle cell (PASMC)	hypoxia induce	upregulated	30305109
3295	Human	hsa-miR-17-5p	miRNA	anti-programmed cell death protein 1 (anti-PD-1) antibody	malignant melanoma (MM)	serum	anti-programmed cell death protein 1 (anti-PD-1) antibody treatment	Serum expression levels of miR-17-5p was significantly higher in responders than in non-responders.	31843231
3296	Human	hsa-miR-17-5p	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	A549 cells	erlotinib	downregulated	27633093
3297	Human	hsa-miR-17-5p	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	A549 cells	erlotinib treatment	downregulated	27633093
3298	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	downregulated	32765678
3299	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocytes	IL-1¦Â treatment	miR-17-5p was downregulated and FUT1 upregulated in OA cartilage tissues and IL-1¦Â-induced chondrocytes.	33093892
3300	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 human chondrosarcoma cells	interleukin-1¦Â treatment	downregulated	29434766
3301	Human	hsa-miR-17-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oxidative stress	HTR-8/SVneo cell line	mono-(2-ethylhexyl) phthalate (MEHP) treatment	upregulation	26871967
3302	Human	hsa-miR-17-5p	miRNA	ionizing radiation (IR)	pancreatic cancer (PC)	oral carcinoma cell line OC3	ionizing radiation treatment	upregulated	23780339
3303	Human	hsa-miR-17-5p	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
3304	Human	hsa-miR-17-5p	miRNA	hypoxia	pulmonary hypertension (PH)	hPASMCs	1% O2 for 48 h treatment	upregulated	24879052
3305	Human	hsa-miR-17-5p	miRNA	fractionated radiation	radiation-induced injury	human peripheral blood mononuclear cells	fractionated radiation treatment	upregulated	25313363
3306	Human	hsa-miR-17-5p	miRNA	lipopolysaccharide (LPS)	rhinitis	nasal epithelial RPMI2650 cells	lipopolysaccharide (LPS) treatment	upregulated	29433423
3307	Human	hsa-miR-17-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	32099901
3308	Human	hsa-miR-17-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
3309	Human	hsa-miR-17-92	miRNA	high iodine blocked BRAF(V600E)	iodine intake on BRAF-mediated oncogenesis	PCCl3 line	V600E treatment	upregulated	23998804
3310	Human	hsa-miR-17-92	miRNA	dexamethasone (DEX)	acute lymphoblastic leukemia (ALL)	"Pre-B ALL cell lines RS4;11, REH ;SUP-B15"	dexamethasone (DEX) treatment	downregulated	22475310
3311	Human	hsa-miR-17-92	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	downregulated	31264378
3312	Human	hsa-miR-17-92	miRNA	prostaglandin E2 (PGE2)	apoptosis	"human squamous cell carcinoma NSCLC cell line H157, H460 and RH2"	PGE2 treatment	upregulated	24469837
3313	Human	hsa-miR-17-92	miRNA	natalizumab	B lymphocytic leukemia	whole blood  lymphocytes	natalizumab treatment	downregulated	22659298
3314	Human	hsa-miR-17-92	miRNA	E. faecalis	bacterial infection	human gastric adenocarcinoma cell line MKN74	E. faecalis infection treatment	downregulated	25170597
3315	Human	hsa-miR-17-92	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
3316	Human	hsa-miR-17-92	miRNA	estrogen receptor ¦Â	colorectal cancer (CRC)	Cell lines (SW480;HT29 ;SW620)	Estrogen receptor ¦Â treatment	the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated	23436804
3317	Human	hsa-miR-17-92	miRNA	hypoxia	colorectal cancer (CRC)	Caco-2 ; HCT116 p53+/+?cells	Hypoxia treatment	downregulated	19696742
3318	Human	hsa-miR-17-92	miRNA	cycle-dependent kinase (CDK) inhibitor SNS-032	acute myeloid leukemia (AML)	AML HL-60 cells	cycle-dependent kinase (CDK) inhibitor SNS-032 treatment	downregulated	26038136
3319	Human	hsa-miR-17-92	miRNA	glucocorticoid (GC)	impair skeletal development	HCS-2/8 cells	GCs treatment	downregulated	24859019
3320	Human	hsa-miR-17-92	miRNA	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV)	kaposi's sarcoma (KS)	endothelial cells	KSHV treatment	upregulated	26545119
3321	Human	hsa-miR-17-92	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
3322	Human	hsa-miR-17-92	miRNA	dexamethasone (DEX)	lymphocyte apoptosis	The Jurkat GR¦Á cell line	dexamethasone (DEX) treatment	upregulated	20847043
3323	Human	hsa-miR-17-92a	miRNA	estrogen (ES)	estrogen protection of osteoblasts against apoptosis	osteoblasts	Estrogen treatment	upregulated	23264746
3324	Human	hsa-miR-18	miRNA	adherent-invasive escherichia coli (AIEC)	autophagy	human intestinal epithelial T84 cells	AIEC LF82 reference strain infection	upregulated	30634511
3325	Human	hsa-miR-18	miRNA	glucocorticoid (GC)	neuronal development	NS1 cells;A549 cells; COS-1cells	Glucocorticoids (GCs) treatment	upregulated	19131573
3326	Human	hsa-miR-181	miRNA	TGF-¦Â	breast cancer	breast cancer cells	Transforming growth factor (TGF)-¦Â treatment	upregulated	21102523
3327	Human	hsa-miR-181	miRNA	imatinib	chronic myeloid leukemia (CML)	MYL; MYL-R human CML cells;K562-R cells;HL-60 cells; HEK293T cells	?imatinib treatment	upregulated	20693279
3328	Human	hsa-miR-181	miRNA	tetra-arsenic tetra-sulfide (As4S4)	chronic myeloid leukemia (CML)	K562 cells	As4S4 treatment	downregulated	28072759
3329	Human	hsa-miR-181	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
3330	Human	hsa-miR-181	miRNA	aplysin	glioblastoma multiforme (GBM)	"human glioma cell lines U87 MG, U251 MG, U373 MG and M059J"	aplysin treatment	upregulated	33104845
3331	Human	hsa-miR-181	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
3332	Human	hsa-miR-181	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
3333	Human	hsa-miR-181	miRNA	high fat diet (HFD)	inflammation	human CD14? monocytes	high fat diet (HFD) feed	downregulated	24870697
3334	Human	hsa-miR-181	miRNA	lipopolysaccharide (LPS)	inflammation	TLR4/2+ primary human dental pulp fibroblasts	were stimulat Pg LPS treatment	downregulated	24848932
3335	Human	hsa-miR-181	miRNA	lipopolysaccharide (LPS)	inflammation	astrocytes	lipopolysaccharide (LPS) treatment	over expression	23650073
3336	Human	hsa-miR-181	miRNA	"anti-CD3, anti-CD28, IL-12, , IL-18"	innate and adaptive immune responses	PB CD4+ T cells	"co-stimulating with anti-CD3, anti-CD28, IL-12, and IL-18 treatment"	downregulated	24704866
3337	Human	hsa-miR-181	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
3338	Human	hsa-miR-181	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
3339	Human	hsa-miR-181	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human endometrial cell-lines	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	28499250
3340	Human	hsa-miR-181	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
3341	Human	hsa-miR-181-5p	miRNA	chlorpyrifos (CPF)	parkinson's disease (PD)	SH-SY5Y cells	chlorpyrifos (CPF) treatment	upregulated	30835941
3342	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
3343	Human	hsa-miR-181a	miRNA	5-fluorouracil (5-Fu)	5-fluorouracil (5-FU) induced nephrotoxicity	The immortalized human mesangial cell (HMC) line	5-fluorouracil (5-FU) treatment	upregulated	29795190
3344	Human	hsa-miR-181a	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	APL blasts and NB4 leukemia cells	all-trans retinoic acid (ATRA) treatment	downregulated	26041820
3345	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	apoptosis	HK-2 cells	cisplatin treatment	One pathway of DDP induces apoptosis of tubular epithelial cell by suppressing Bcl-2 expression is achieved by regulating the target gene of MicroRNA-181a.	22490414
3346	Human	hsa-miR-181a	miRNA	H2O2	atherosclerosis (AS)	HUVECs	H2O2 treatment	upregulated	27460740
3347	Human	hsa-miR-181a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29737518
3348	Human	hsa-miR-181a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30938884
3349	Human	hsa-miR-181a	miRNA	IFN-¦Ã	autophagy	human hepatoma Huh7 cells	IFN-¦Ë treatment	upregulated	28131804
3350	Human	hsa-miR-181a	miRNA	metformin (Met)	breast cancer	MCF-7 cells	metformin?treatment	downregulated	21368581
3351	Human	hsa-miR-181a	miRNA	IL-1¦Â	colorectal cancer (CRC)	colon cancer cell	IL-1¦Â treatment	upregulated	27264420
3352	Human	hsa-miR-181a	miRNA	high glucose (HG)	diabetic wound healing	Human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	upregulated	30565672
3353	Human	hsa-miR-181a	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	human hepatocyte cell line PH5CH8	TGF-¦Âtreatment treatment	upregulated	24576072
3354	Human	hsa-miR-181a	miRNA	kaempferol	gastric cancer (GC)	SNU-216 cells	kaempferol treatment	upregulated	30785478
3355	Human	hsa-miR-181a	miRNA	H2O2	glaucoma	trabecular meshwork (TM) cells	H2O2 treatment	"After the TM cells were treated with H2O2, miR-181a expression was significantly lower."	29616751
3356	Human	hsa-miR-181a	miRNA	docosahexaenoic acid (DHA)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	docosahexaenoic acid (DHA) treatment	upregulated	25182732
3357	Human	hsa-miR-181a	miRNA	TGF-¦Â	granular corneal dystrophy type 2 (GCD2)	Primary corneal fibroblasts	TGF-¦Âtreatment treatment	upregulated	26915797
3358	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	downregulated	21274007
3359	Human	hsa-miR-181a	miRNA	dichlorvos (DDVP)	hepatic cell toxicity	HepaRG cells	DDVP treatment	upregulated	31966431
3360	Human	hsa-miR-181a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells	HepG2 cells treatment	downregulated	273849772
3361	Human	hsa-miR-181a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	human hepatocyte cell line PH5CH8	TGF-¦Â treatment	upregulated	24576072
3362	Human	hsa-miR-181a	miRNA	"IFN-¦Á, IFN-¦Ã"	human immunodeficiency virus (HIV)-1 infection	astrocytes;microglia	IFN-¦Á and IFN-¦Ã treatment	downregulated	27219130
3363	Human	hsa-miR-181a	miRNA	8-bromo-cyclic adenosine monophosphate (8-bromo-cAMP) and medroxyprogesterone acetate (MPA)	human endometrial stromal cell decidualization	human endometrial stromal cell (hESC)	8-Br-cAMP and MPA treatment	upregulated	25889210
3364	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	infantile pneumonia (IP)	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	31889339
3365	Human	hsa-miR-181a	miRNA	type III interferon (IFN¦Ë)	inflammation	human epithelial cells	type III interferon (IFN¦Ë) treatment	upregulated	24098127
3366	Human	hsa-miR-181a	miRNA	adriamycin (ADR)	leukemia	HL-60 cells	adriamycin (ADR) treatment	downregulated	30964176
3367	Human	hsa-miR-181a	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
3368	Human	hsa-miR-181a	miRNA	TGF-¦Â	liver fibrosis	LX2 cells	TGF-¦Â treatment	upregulated	31166951
3369	Human	hsa-miR-181a	miRNA	piceatannol (PIC)	melanoma	"WM266-4 , A2058 cells"	treat with piceatannol treatment	upregulated	29187907
3370	Human	hsa-miR-181a	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell line RPMI8226	bortezomib? treatment	downregulated	26032093
3371	Human	hsa-miR-181a	miRNA	triptolide (TPL)	multiple myeloma (MM)	the dexamethasone-sensitive MM.1S human MM cell line	triptolide (TPL)? treatment	downregulated	22260163
3372	Human	hsa-miR-181a	miRNA	triptolide (TPL)	neuroblastoma (NB)	SH-SY5Y cells	triptolide (TPL) treatment	microRNA-181a (miR-181a) was upregulated after TPL treatment	29426375
3373	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	neuroinflammation	tongue squamous cell	cisplatin (DPP) treatment	downregulated	24148247
3374	Human	hsa-miR-181a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	LO-2 cells	palmitic acid (PA) treatment	upregulated	30558790
3375	Human	hsa-miR-181a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	The human normal liver cell line L02 cells	palmitic acid (PA) treatment	upregulated	30558790
3376	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) A549 cells	cisplatin treatment	upregulated	20145152
3377	Human	hsa-miR-181a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human OA chondrocyte	"exposure to three hours of a cyclic HP (1-5 MPa, frequency 0.25 Hz)"	downregulated	29150345
3378	Human	hsa-miR-181a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	chondrocytes	hydrostatic pressure (HP) treatment	miR-155 and miR-181a resulted significantly downregulated immediately after pressurization (T0) in OA cells.	29150345
3379	Human	hsa-miR-181a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	hydrostatic pressure (HP) treatment	upregulated	32455798
3380	Human	hsa-miR-181a	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
3381	Human	hsa-miR-181a	miRNA	resistin	osteoarthritis (OA)	human OA synovial fibroblasts	resistin treatment	upregulated	31635187
3382	Human	hsa-miR-181a	miRNA	visfatin	osteoarthritis (OA)	human OA chondrocytes	visfatin treatment	"upregulated, all the visfatin-caused effects were suppressed by using miR-34a and miR-181a inhibitors."	31405216
3383	Human	hsa-miR-181a	miRNA	triptolide (TPL)	osteosarcoma (OS)	SAOS2 and U2OS cells	"150?mol/L triptolide for 24, 48, and 72 h treatment"	upregulated	28381158
3384	Human	hsa-miR-181a	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
3385	Human	hsa-miR-181a	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
3386	Human	hsa-miR-181a	miRNA	H2O2	oxidative stress	KGN cells	H2O2 treatment	upregulated	31359035
3387	Human	hsa-miR-181a	miRNA	sphingosine-1-phosphate (S1P)	oxidative stress	H2O2 treated KGN cells	sphingosine-1-phosphate (S1P) treatment	downregulated	31359035
3388	Human	hsa-miR-181a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human SK-N-SH neuroblastoma cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	28365714
3389	Human	hsa-miR-181a	miRNA	bufalin	prostate cancer	Human prostate carcinoma PC-3 cells	?bufalin treatment	Bufalin was found to induce the expression of miR-181a	24267199
3390	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	sepsis	Monocytes	lipopolysaccharide (LPS) treatment	LPS stimulation in monocytes also led to a decrease in the expression of miR-181a.	32104257
3391	Human	hsa-miR-181a	miRNA	high glucose (HG)	wound healing	human dermal lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"ANRIL was downregulated, whereas miR-181a was upregulated in high glucose (HG)-induced LECs."	30565672
3392	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	pancreatic cancer (PC)	Pancreatic cancer cells	lipopolysaccharide (LPS) treatment	downregulated	24532253
3393	Human	hsa-miR-181a*	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
3394	Human	hsa-miR-181a-1?3p	miRNA	benzo(a)pyrene (BaP)	hepatocellular carcinoma (HCC)	HepG2	benzo(a)pyrene (BaP) exposure	upregulated	25690898
3395	Human	hsa-miR-181a-2*	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	downregulated	26640557
3396	Human	hsa-miR-181a-2-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
3397	Human	hsa-miR-181a-2-3p	miRNA	cadmium (Cd)	cadmium (Cd)-induced inflammatory responses	human bronchial epithelial cell line (BEAS-2B) and normal human bronchial epithelial (NHBE) cells	cadmium (Cd) treatment	downregulated	31463135
3398	Human	hsa-miR-181a-2-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	MEG3 expression was enhanced while miR-181a-2-3p abundance was reduced in the serum of patients with COPD and CSE-treated 16HBE cells.	33262837
3399	Human	hsa-miR-181a-2-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
3400	Human	hsa-miR-181a-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
3401	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	"si-CRNDE-1 and miR-181a-5p mimic were able to reverse the promoting effects of LPS on production of NF-kB, TNF-a, IL-1b and IL-6 by THP-1 cells."	31604377
3402	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33197806
3403	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33197806
3404	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33407436
3405	Human	hsa-miR-181a-5p	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells	irradiation treatment	upregulated	33529508
3406	Human	hsa-miR-181a-5p	miRNA	cisplatin (DDP)	esophageal adenocarcinoma (EAC)	OE19 cells	cisplatin treatment	miR-181a-5p was highly expressed while CBLB was lowly expressed in OE19 cell lines compared with OE19/CDDP cells.	32612385
3407	Human	hsa-miR-181a-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	downregulated	32968457
3408	Human	hsa-miR-181a-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCC patients serum	3 months after the initiation of sorafenib treatment	upregulated in serum	28275578
3409	Human	hsa-miR-181a-5p	miRNA	IL-17	non-small cell lung cancer (NSCLC)	H226 and H460 cells	interleukin-17 (IL-17) treatment	downregulated	28535543
3410	Human	hsa-miR-181a-5p	miRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 and H1975 cells	Xiaoji decoction (XJD) treatment	upregulated	31707347
3411	Human	hsa-miR-181a-5p	miRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 cells; H1975 cells	xiaoji decoction (XJD) treatment	XJD increased miR-181a-5p expressions.	31707347
3412	Human	hsa-miR-181a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 cells	IL-1¦Â treatment	IL-1¦Â increased hsa-miR-181a-5p and decreased SBP2 in a time- and dose-dependent manner.	30286747
3413	Human	hsa-miR-181a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Hyperplastic synovial fibroblasts (SFs)	interleukin-1¦Â treatment	upregulated	31777535
3414	Human	hsa-miR-181a-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells; SK-N- AS cessl	1-methyl-4-phenylpyridinium (MPP+) treatment	"We discovered that SNHG1 was significantly elevated, while miR-181a-5p was decreased in N-methyl-4-phenylpyridinium (MPP+)-treated neuroblastoma cells in dose-dependent manners."	33389428
3415	Human	hsa-miR-181a-5p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	downregulated	32921988
3416	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis.	31604377
3417	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	sepsis-induced renal injury	HK-2 and HEK293 cells	lipopolysaccharide (LPS) treatment	miR-181a-5p was significantly upregulated in sepsis models.	31877497
3418	Human	hsa-miR-181a-5p	miRNA	cisplatin (DDP) and?thiosemicarbazone compound 5	triple negative breast cancer (TNBC)	MDA-MB 231 breast cancer cell line	Cisplatin?+?thiosemicarbazone compound 4 treatment	upregulated	31541355
3419	Human	hsa-miR-181a-5p	miRNA	high glucose (HG)	tubulointerstitial fibrosis (TIF)	HK-2 cells	high glucose	downregulated	28077323
3420	Human	hsa-miR-181b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	upregulated	26622531
3421	Human	hsa-miR-181b	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	APL blasts and NB4 leukemia cells	all-trans retinoic acid (ATRA) treatment	downregulated	26041820
3422	Human	hsa-miR-181b	miRNA	arsenite	angiogenesis	EA.hy926 cells	arsenic (As) exposure	downregulated	21503876
3423	Human	hsa-miR-181b	miRNA	celastrol	apoptosis	A549 cells	celastrol treatment	upregulated	29434967
3424	Human	hsa-miR-181b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29136944
3425	Human	hsa-miR-181b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 suppression protects the endothelium from oxLDL-induced inflammation and oxidative stress in endothelial cells by upregulation of miR-181b and downregulated of TOX.	31949884
3426	Human	hsa-miR-181b	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
3427	Human	hsa-miR-181b	miRNA	curcumin (Cur)	breast cancer	human metastatic breast cancer cells MDA©\MB©\231	curcumin treatment	upregulated	24484937
3428	Human	hsa-miR-181b	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
3429	Human	hsa-miR-181b	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
3430	Human	hsa-miR-181b	miRNA	everolimus	endothelial dysfunction	TNF-¦Á treated human umbilical vein endothelial cell (HUVECs)	everolimus treatment	upregulated	29889836
3431	Human	hsa-miR-181b	miRNA	TGF-¦Â	endothelial dysfunction	HCC cell lines	TGFbeta treatment	upregulated	20023698
3432	Human	hsa-miR-181b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	human umbilical vein endothelial cell (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29889836
3433	Human	hsa-miR-181b	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissues	5-fluorouracil (5-FU) treatment	upregulated	27081844
3434	Human	hsa-miR-181b	miRNA	S-1/oxaliplatin	gastric cancer (GC)	gastric tumor specimens	?S-1/Oxaliplatin?(intravenous injection) treatment	miR-181b and miR-21 was significantly overexpressed in gastric tumors	21876743
3435	Human	hsa-miR-181b	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
3436	Human	hsa-miR-181b	miRNA	oleuropein (OL)	glioblastoma multiforme (GBM)	GBM cell line T98G	oleuropein (OL) treatment or OL+temozolomide (TMZ) combined treatment	upregulated	31169033
3437	Human	hsa-miR-181b	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	upregulated	28797462
3438	Human	hsa-miR-181b	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	upregulated	25837671
3439	Human	hsa-miR-181b	miRNA	hypoxia	hypoxia-induced injury	HK-2 cells	hypoxia induce	downregulated	30860638
3440	Human	hsa-miR-181b	miRNA	morphine	inflammation and oxidative stress	peripheral blood mononuclear cells (PBMCs)	Morphine treatment	downregulated	20564181
3441	Human	hsa-miR-181b	miRNA	"ferrylhemoglobin (ferrylHb, Fe4+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"ferrylhemoglobin (ferrylHb, Fe4+) treatment"	upregulated	32961661
3442	Human	hsa-miR-181b	miRNA	heme	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	heme treatment	upregulated	32961661
3443	Human	hsa-miR-181b	miRNA	"methemoglobin (metHb, Fe3+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"methemoglobin (metHb, Fe3+) treatment"	upregulated	32961661
3444	Human	hsa-miR-181b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32961661
3445	Human	hsa-miR-181b	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
3446	Human	hsa-miR-181b	miRNA	TGF-¦Â1	liver fibrosis	human LX-2 cell	transforming growth factor-¦Â1 treatment	upregulated	25148875
3447	Human	hsa-miR-181b	miRNA	celastrol	lung cancer	A549 cells; LTEP-a-2 cells	celastrol treatment	miR-181b was upregulated in celastrol-treated LTEP-a-2 cells.	29434967
3448	Human	hsa-miR-181b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	upregulated	28899784
3449	Human	hsa-miR-181b	miRNA	epidermal growth factor (EGF)	oral carcinogenesis	"HSC-3£¬OECM-1,SAS£¬NOK"	EGF treatment	upregulated	25229239
3450	Human	hsa-miR-181b	miRNA	decitabine	precursor B-cell acute lymphoblastic leukemia (B-ALL)	Nalm6 cell line	decitabine treatment	downregulated	30912184
3451	Human	hsa-miR-181b	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
3452	Human	hsa-miR-181b	miRNA	methotrexate (MTX)	vascular disease	human umbilical vein endothelial cells (HUVECs)	methotrexate (MTX) treatment	upregulated	33416495
3453	Human	hsa-miR-181b	miRNA	TGF-¦Â1	apoptosis	serum of cirrhosis patients	TGF-¦Â1 treatment	?miR-181b could be induced by TGF-¦Â1 and promote the growth of HSCs by directly targeting p27	22446332
3454	Human	hsa-miR-181b	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	retinoic acid treatment	downregulated	17260024
3455	Human	hsa-miR-181b1	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVEC)	TNF¦Á treatment	upregulated	29666964
3456	Human	hsa-miR-181b-5p	miRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	A549 cells	TGF-¦Â1 treatment	upregulated	28534939
3457	Human	hsa-miR-181b-5p	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	spontaneous preterm birth (SPB)	human syncytiotrophoblast	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	"miR-181b-5p and miR-26b-5p in term human syncytiotrophoblast were increased in response to treatment with 1,25(OH)2D."	30395535
3458	Human	hsa-miR-181c	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
3459	Human	hsa-miR-181c	miRNA	hypoxia	acute ischemic stroke (AIS)	Plasma	hypoxia treatment	downregulated	28053821
3460	Human	hsa-miR-181c	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
3461	Human	hsa-miR-181c	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
3462	Human	hsa-miR-181c	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
3463	Human	hsa-miR-181c	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	cigarette smoke (CS) exposure	downregulated	28806967
3464	Human	hsa-miR-181c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric and colorectal cancer	KATO-III cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	20080834
3465	Human	hsa-miR-181c	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	liver biopsy specimens and Huh7.5 cells	hepatitis C virus (HCV) infection	downregulated	31400158
3466	Human	hsa-miR-181c	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
3467	Human	hsa-miR-181c	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?12 cells	heme treatment	upregulated	23538684
3468	Human	hsa-miR-181c	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
3469	Human	hsa-miR-181c*	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
3470	Human	hsa-miR-181c-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29605252
3471	Human	hsa-miR-181c-5p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29605252
3472	Human	hsa-miR-181c-5p	miRNA	melatonin	osteogenic differentiation and calcification	Human jawbone-derived osteoblastic (hOB) cells	melatonin (MEL) treatment	upregulated	32945514
3473	Human	hsa-miR-181c-5p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
3474	Human	hsa-miR-181d	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
3475	Human	hsa-miR-181d	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
3476	Human	hsa-miR-181d	miRNA	garcinol	glioblastoma multiforme (GBM)	U87MG or GBM8401 cells	garcinol treatment	upregulated	31783691
3477	Human	hsa-miR-181d	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	glioblastoma CD133+ cancer stem cell	ionizing radiation (IR) treatment	downregulated	31226325
3478	Human	hsa-miR-181d	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	glioblastoma CD133+ cancer stem cell	temozolomide (TMZ) treatment	downregulated	31226325
3479	Human	hsa-miR-181d	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
3480	Human	hsa-miR-181d	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
3481	Human	hsa-miR-181d-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney ischemia/reperfusion injury (IRI)	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	"miR-181d-5p in the H/R group increased at 6¨C12 h, but started to decrease at 24 h."	32581828
3482	Human	hsa-miR-181d-5p	miRNA	t-butylhydroperoxide (t-BHP)	atherosclerotic coronary heart disease (CHD)	Primary HUVECs	t-butylhydroperoxide (t-BHP) treatment	downregulated	31352814
3483	Human	hsa-miR-181d-5p	miRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS)	inflammation	BEAS-2B cells	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS) treatment	"We identified a novel circRNA, circ_0035266, which was strongly upregulated in NNK+LPS-induced BEAS-2B cells and enhanced the inflammatory responses to NNK+LPS by regulating the secretion of pro-inflammatory cytokines interleukin (IL)-6 and IL-8."	33107911
3484	Human	hsa-miR-182	miRNA	isorhapontigenin (ISO)	bladder cancer	T24 cells	isorhapontigenin (ISO) treatment	downregulated	29409027
3485	Human	hsa-miR-182	miRNA	curcumin (Cur)	breast cancer	T47D breast cancer cells	curcumin treatment	48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells.	30467667
3486	Human	hsa-miR-182	miRNA	TGF-¦Â	cancer cell epithelial-mesenchymal transition (EMT)	breast tumour	TGF-¦Âtreatment treatment	"TGF¦Â activates the expression of microRNA-182 (miR-182), which suppresses SMAD7 protein"	27996004
3487	Human	hsa-miR-182	miRNA	fentanyl	colorectal cancer (CRC)	human colorectal carcinoma (HCT116) cells	Fentanyl treatment	downregulated	25755709
3488	Human	hsa-miR-182	miRNA	TGF-¦Â	gallbladder cancer (GBC)	GBC cells	TGF-¦Â induces expression in treatment	upregulated	24445397
3489	Human	hsa-miR-182	miRNA	metformin (Met)	glioblastoma multiforme (GBM)	U87 cells	metformin(Met) treatment	downregulated	33059952
3490	Human	hsa-miR-182	miRNA	TGF-¦Â1	liver fibrosis	human hepatocellular cell line LX-2	TGF-¦Â1 treatment	upregulated	29323718
3491	Human	hsa-miR-182	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	patients with advanced hepatocellular carcinoma (HCC)	cisplatin treatment	upregulated	24447717
3492	Human	hsa-miR-182	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCC cells	hypoxia treatment	upregulated	26126858
3493	Human	hsa-miR-182	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	293A and 293T cells	infect with HSV-1	upregulated	28783105
3494	Human	hsa-miR-182	miRNA	mangiferin	prostate cancer	PC3 human prostate cancer cells	Mangiferin treatment	upregulated	26870290
3495	Human	hsa-miR-182	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
3496	Human	hsa-miR-182	miRNA	glucocorticoid (GC)	lymphoblastic malignancies	Th e mouse myeloma cell line SP2/0; lymphocytic leu-kemia line L1210;T-lymphoma line EL-4 ;acute pre-B lym-phoblastic leukemia line SUP-B15; acute T-lymphoblastic leukemia line CCRF-CEM; cutaneous T-lymphocyte line HUT-78; Burkitt lymphoma line Daudi; acute T-cell leukemia line Molt-4 ; acute T-cell leukemia line J	Glucocorticoid (GC)treatment	upregulated	22582938
3497	Human	hsa-miR-182	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
3498	Human	hsa-miR-182	miRNA	low intensity pulsed ultrasound (LIPUS)	periodontal bone defect	human primary periodontal ligament cells (hPDLCs)	Low intensity pulsed ultrasound (LIPUS) treatment	downregulated	31401188
3499	Human	hsa-miR-182	miRNA	atorvastatin	prostate cancer	PC3 prostate cancer cells	atorvastatin? treatment	upregulated	23936432
3500	Human	hsa-miR-182	miRNA	mangiferin	prostate cancer	PC3 human prostate cancer cells	Mangiferin treatment	upregulated	26870290
3501	Human	hsa-miR-182	miRNA	light	retinal injury	retinal pigment epithelial (RPE) cells	light treatment	upregulated	25955435
3502	Human	hsa-miR-182	miRNA	curcumin (Cur)	schwannoma	RT4 schwannoma cells	curcumin treatment	upregulated	30534000
3503	Human	hsa-miR-182	miRNA	iodine-131 (131I)	thyroid cancer (TC)	FTC-133 cells; TPC-1 cells	iodine-131 (131I) treatment	MEG3 expression appeared a decline and miR-182 expression displayed an increase in 131I-resistant FTC-133 (res-FTC-133) and TPC-1 (res-TPC-1) cells.	30021359
3504	Human	hsa-miR-182-3p	miRNA	asymmetrical dimethylarginine	atherosclerosis (AS)	human aortic artery smooth muscle cell (SMC)	asymmetrical dimethylarginine treatment	downregulated	27199451
3505	Human	hsa-miR-182-3p	miRNA	vibrio parahaemolyticus flagellin	innate immune response	grouper spleen (GS) cells	Vibrio parahaemolyticus flagellin treatment	"miR-182-3p expression significantly downregulated at 3h and 6h, compared with control group After stimulation for 12h and 24h, the expression of miR-182-3p was significantly upregulated"	31351112
3506	Human	hsa-miR-1825	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
3507	Human	hsa-miR-182-5p	miRNA	tert-butyl hydroperoxide (TBHP)	intervertebral disc degeneration (IDD)	nucleus pulposus cells (NPCs)	tert-butyl hydroperoxide (TBHP) treatment	upregulated	31582722
3508	Human	hsa-miR-182-5p	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	cisplatin treatment	upregulated	33647908
3509	Human	hsa-miR-182-5p	miRNA	H2O2	age-related cataract (ARC)	HLE-B3 cells	H2O2 treatment	miR-182-5p expression was significantly decreased by the H2O2 exposure.	32552665
3510	Human	hsa-miR-182-5p	miRNA	ropivacaine	apoptosis	umbilical cord mesenchymal stem cells (UCMSCs)	ropivacaine treatment	downregulated	30773504
3511	Human	hsa-miR-182-5p	miRNA	Sufentanil	apoptosis	umbilical cord mesenchymal stem cells (UCMSCs)	Sufentanil treatment	upregulated	30773504
3512	Human	hsa-miR-182-5p	miRNA	arsenite	arsenic carcinogenesis	HK-2 human renal epithelial cells	arsenic exposure	downregulated	30334557
3513	Human	hsa-miR-182-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein smooth muscle cells (HUVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Knockdown of circ_USP36 alleviated ox-LDL-mediated injury of HUVSMCs by modulating miR-182-5p/KLF5 axis	33437365
3514	Human	hsa-miR-182-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	"The expression level of miR-182-5p decreased, while the expression level of PAPPA increased significantly in the ox-LDL treated HA-VSMC cells."	32684596
3515	Human	hsa-miR-182-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	human-induced pluripotent stem cell (hiPSC)	doxorubicin treatment	upregulated	26842497
3516	Human	hsa-miR-182-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
3517	Human	hsa-miR-182-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells; BGC823C cells	cisplatin treatment	circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5p.	31898357
3518	Human	hsa-miR-182-5p	miRNA	trichloroethylene (TCE)	hepatocarcinogenesis	human hepatoma cell line HepG2	Trichloroethylene (TCE) treatment	upregulated	31524101
3519	Human	hsa-miR-182-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B; SNU©\387; SNU©\449 cells	Sorafenib (SOR) treatment	lncRNA-POIR promotes EMT progression and suppresses SOR sensitivity simultaneously by sponging miR-182-5p	32951268
3520	Human	hsa-miR-182-5p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	human embryonic lung fibroblasts	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31884830
3521	Human	hsa-miR-182-5p	miRNA	human metapneumovirus (HMPV)	innate immune response	human dendritic cells	Human metapneumovirus (HMPV) infection	upregulated	29970194
3522	Human	hsa-miR-182-5p	miRNA	mechanical stress	intervertebral disc degeneration (IDD)	NP cells	mechanical stress treatment	upregulated	33195225
3523	Human	hsa-miR-182-5p	miRNA	TGF-¦Â1	lung fibrosis	human embryonic lung fibroblasts	TGF-¦Â1 treatment	miR-182-5p was upregulated in pulmonary fibrosis	31884830
3524	Human	hsa-miR-182-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
3525	Human	hsa-miR-182-5p	miRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	SH-SY5Y cells	lipopolysaccharide (LPS) treatment	HAGLR displayed high levels in spinal cords of CCI rats and in LPS treated SH-SY5Y cells.	33626373
3526	Human	hsa-miR-182-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
3527	Human	hsa-miR-182-5p	miRNA	matrine	papillary thyroid cancer (PTC)	TPC-1 cells; BCPAP cells	Matrine treatment	Matrine inhibited the expression of miR-182-5p.	32505823
3528	Human	hsa-miR-1826	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
3529	Human	hsa-miR-1827	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
3530	Human	hsa-miR-182a	miRNA	morphine	neurogenesis	hippocampal neural progenitor cell (hNPC) lineages	morphine treatment	upregulated	24964979
3531	Human	hsa-miR-183	miRNA	quinacrine	apoptosis	U937 cells	quinacrine treatment	upregulated	28867437
3532	Human	hsa-miR-183	miRNA	curcumin (Cur)	breast cancer	T47D breast cancer cells	curcumin treatment	48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells.	30467667
3533	Human	hsa-miR-183	miRNA	oxidized low density lipoprotein (ox-LDL)	cell damage	human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31210063
3534	Human	hsa-miR-183	miRNA	IL-8	cholesterol efflux	THP-1 macrophage-derived foam cells	IL-8 treatment	upregulated	29703573
3535	Human	hsa-miR-183	miRNA	CCL20 and CXCL8	colorectal cancer (CRC)	human CRC cell lines SW480 and Caco-2	?CCL20 and CXCL8 co-stimulation	"miR-183 was negatively regulated by circ_0026344, and the inhibitory effects of circ_0026344 overexpression on Wnt/¦Â-catenin pathway were reversed when miR-183 was overexpressed."	31608699
3536	Human	hsa-miR-183	miRNA	elevated CO(2) concentrations (hypercapnia)	helicobacter pylori infection	fibroblasts (N12); A549 cells	CO(2) treatment	upregulated	21903582
3537	Human	hsa-miR-183	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HCC cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28321157
3538	Human	hsa-miR-183	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	293A and 293T cells	infect with HSV-1	upregulated	28783105
3539	Human	hsa-miR-183	miRNA	TGF-¦Â	immunosuppression	human NK cells	TGF-¦Â treatment	upregulated	24586048
3540	Human	hsa-miR-183	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
3541	Human	hsa-miR-183	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
3542	Human	hsa-miR-183	miRNA	baicalin (BAI)	osteosarcoma (OS)	MG-63 and Saos-2 cells	baicalin (BAI) treatment	upregulated	29845278
3543	Human	hsa-miR-183	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	PDAC cells	gemcitabine treatment	downregulated	28849150
3544	Human	hsa-miR-183	miRNA	light	retinal injury	retinal pigment epithelial (RPE) cells	light treatment	upregulated	25955435
3545	Human	hsa-miR-183*	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
3546	Human	hsa-miR-183-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG15 knockdown protected against cerebral I/R injury via targeting miR-183-5p/FOXO1 axis	33194027
3547	Human	hsa-miR-183-5p	miRNA	cytomegalovirus (CMV)	cytomegalovirus infection	plasma	Cytomegalovirus (CMV) treatment	upregulated	27684416
3548	Human	hsa-miR-183-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
3549	Human	hsa-miR-183-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	Circ_DHRS3 expression was elevated in OA cartilage tissues and IL-1¦Â-treated chondrocytes.	33360372
3550	Human	hsa-miR-184	miRNA	adriamycin (ADR)	chronic lymphocytic leukemia (CLL)	human chronic myeloid leukemia cell line K562 and KCL22	adriamycin (ADR) treatment	upregulated	31180580
3551	Human	hsa-miR-184	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-184 was upregulated in resistant patients when compared with sensitive patients	33072545
3552	Human	hsa-miR-184	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	HLE-B3 cells	TGF-¦Â2 treatment	upregulated	32356563
3553	Human	hsa-miR-184	miRNA	cadmium (Cd)	keratinocytes (KCs) diferentiation	human primary epidermal keratinocytes (HPEK)	exogenous Ca2+ treatment	upregulated	31985037
3554	Human	hsa-miR-184	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	TGF-¦Â could induce miR-31 and suppress miR-184 levels in A549 cells	31874165
3555	Human	hsa-miR-184	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	downregulated	31874165
3556	Human	hsa-miR-184	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	BEAS-2B cells; A549 cells	TGF-¦Â1 treatment	downregulated	32989231
3557	Human	hsa-miR-184	miRNA	IL-22	inflammatory skin diseases	RHE cells; HaCaT cells	IL-22 treatment	cytokine-induced miR-184 attenuates AGO2 expression in keratinocytes	23696368
3558	Human	hsa-miR-184	miRNA	retinoic acid (RA)	neuroblastoma (NB)	Neuroblastoma tissue and cell lines	retinoic acid treatment	downregulated	17283129
3559	Human	hsa-miR-184	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	OS cell line U-2 OS and MG-63	Doxorubicin treatment	Doxorubicin induced time-dependent expression of miR-184 in OS cell line U-2 OS and MG-63.	27222034
3560	Human	hsa-miR-184	miRNA	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA)"	ovarian cancer (OC)	ovarian cancer cell lines SKOV-3 and A2780	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA) treatment"	upregulated	29324748
3561	Human	hsa-miR-184	miRNA	artesunate (ART)	prostate cancer	"DU145,LNCaP cells"	artesunate (ART) treatment	downregulated	28209917
3562	Human	hsa-miR-184	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
3563	Human	hsa-miR-185	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
3564	Human	hsa-miR-185	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
3565	Human	hsa-miR-185	miRNA	angiotensin II (Ang II)	HAVSMC dysfunction and hypertension	human aortic vascular smooth muscle cells (HAVSMCs)	angiotensin II (Ang II) treatment	downregulated	28277742
3566	Human	hsa-miR-185	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	29499960
3567	Human	hsa-miR-185	miRNA	TGF-¦Â1	liver fibrosis	LX-2 Cells	TGF-¦Â1 treatment	downregulated	29499960
3568	Human	hsa-miR-185	miRNA	CdSe/ZnS-GSH	lung cancer	A549 cells	CdSe/ZnS-GSH treatment	upregulated	31883144
3569	Human	hsa-miR-185	miRNA	CdSe/ZnS-MPA	lung cancer	A549 cells	CdSe/ZnS-MPA treatment	upregulated	31883144
3570	Human	hsa-miR-185	miRNA	hypoxia	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	30450725
3571	Human	hsa-miR-185	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	human HepG2 hepatocytes	palmitic acid treatment	downregulated	25548489
3572	Human	hsa-miR-185	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx4 treatment"	downregulated	21572246
3573	Human	hsa-miR-185	miRNA	dexmedetomidine (DEX)	ovarian cancer (OC)	"SKOV3 , HO-8910 cells"	dexamethasone (DEX) treatment	DEX promoted miR-185 but suppressed SOX9 expression in OC cells.	33818283
3574	Human	hsa-miR-185	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH5Y-SY cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	miR-185 was significantly downregulated in SH-SY5Y cells treated with MPTP.	29115479
3575	Human	hsa-miR-185	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH5Y-SY cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31814881
3576	Human	hsa-miR-185	miRNA	radiation	renal cell carcinoma (RCC)	renal cell carcinoma cells	radiation treatment	downregulated	23807228
3577	Human	hsa-miR-185	miRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	downregulated	30095214
3578	Human	hsa-miR-185-3p	miRNA	ursolic acid (UA)	breast cancer	MCF-7 cells	usnic acid treatment	downregulated	31549595
3579	Human	hsa-miR-185-3p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	upregulated	24927770
3580	Human	hsa-miR-185-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Human colorectal cancer cell line Caco-2	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30615124
3581	Human	hsa-miR-185-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
3582	Human	hsa-miR-185-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	Circ_WBSCR17 aggravates inflammatory responses and fibrosis by targeting miR-185-5p/SOX6 regulatory axis in high glucose-induced human kidney tubular cells	32798559
3583	Human	hsa-miR-185-5p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
3584	Human	hsa-miR-185-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
3585	Human	hsa-miR-185-5p	miRNA	palmitate	insulin resistance (IR)	Human HepG2 cells and primary hepatocytes	"To establish an insulin-resistant hepatocyte cell model, hepatocytes were stimulated by palmitate (0.25 mM, Sigma-Aldrich, St. Louis, MO, USA) for 24 h, and treated with insulin (100 nM) for 20 min before harvest. treatment"	but miR-185-5p was downregulated in palmitate-treated insulin resistance hepatocytes and HFD mice	31298399
3586	Human	hsa-miR-185-5p	miRNA	TNF-¦Á and IL-1¦Â	intervertebral disc degeneration (IDD)	NP cells	TNF-¦Á and IL-1¦Â treatment	circ-TIMP2 promoted TNF-¦Á- and IL-1¦Â-induced NP cell imbalance between ECM anabolism and catabolism via miR-185-5p-MMP2 signaling	32626912
3587	Human	hsa-miR-185-5p	miRNA	hypoxia	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	30450725
3588	Human	hsa-miR-185-5p	miRNA	noise	noise-induced hearing loss (NIHL)	plasma	noise treatment	downregulated	26278637
3589	Human	hsa-miR-185-5p	miRNA	fractionated radiation	radiation-induced injury	human peripheral blood mononuclear cells	fractionated radiation treatment	upregulated	25313363
3590	Human	hsa-miR-185-5p	miRNA	IFN-¦Â	relapsing-remitting multiple sclerosis (RRMS)	whole blood	IFN-¦Â treatment	miR-185¨C5p was downregulated in responders to IFN-¦Â therapy in RRMS patients.	32554287
3591	Human	hsa-miR-185-5p	miRNA	escitalopram	side effects of antidepressant drugs	peripheral	escitalopram treatment	upregulated	31819986
3592	Human	hsa-miR-186	miRNA	resistin	chondrosarcoma	lymphatic endothelial cells (LECs)	resistin treatment	downregulated	29730230
3593	Human	hsa-miR-186	miRNA	methotrexate (MTX)	colorectal cancer (CRC)	human colorectal cancer cell lines HT-29-P/HT-29-R cell and HCT-8 cells	methotrexate treatment	downregulated	28805722
3594	Human	hsa-miR-186	miRNA	hypoxia	hypoxia-induced injury	Human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	31511208
3595	Human	hsa-miR-186	miRNA	curcumin (Cur)	lung cancer	The A549 human lung adenocarcinoma cell line	curcumin treatment	Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186*signaling pathway	20878113
3596	Human	hsa-miR-186	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	renal tissue and podocyte cells	angiotensin II (Ang II) treatment	downregulated	26382839
3597	Human	hsa-miR-186	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	AC16 cells	hypoxia/reoxygenation (H/R) treatment	Knockdown of long non-coding RNA PVT1 protects human AC16 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis and autophagy by regulating miR-186/Beclin-1 axis.	32428696
3598	Human	hsa-miR-186	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
3599	Human	hsa-miR-186	miRNA	cyclosporine A (CsA)	nephrotoxicity	HEK293	cyclosporine A treatment	upregulated	28414804
3600	Human	hsa-miR-186	miRNA	lycorine	non-small cell lung cancer (NSCLC)	"NSCLC cell lines including A549, H1299 and H460, normal cell BEAS-2B"	Lycorine treatment	upregulated	31176784
3601	Human	hsa-miR-186	miRNA	repeatedly passed	premature senescence	lung fibroblast IMR-90 cells	repeatedly passed until a senescence-like state was observed treatment	upregulated	25139266
3602	Human	hsa-miR-186	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
3603	Human	hsa-miR-186	miRNA	aerobic exercise	vascular cognitive impairment (VCI)	serum	aerobic exercise training (AET) treatment	"Aerobic exercise could shorten the average time that mice reached the platform in the Morris water maze, increase the expression level of circRIMS2 and BDNF, reduce miR-186 expression, and inhibit neuronal apoptosis."	33413076
3604	Human	hsa-miR-186	miRNA	hypoxia	"vascular endothelial cell proliferation , apoptosis"	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	28571741
3605	Human	hsa-miR-186-5p	miRNA	ethanol (EtOH)	alcoholic cardiomyopathy (ACM)	AC16 cardiomyocytes	ethanol treatment	upregulated	30816481
3606	Human	hsa-miR-186-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	E2F1/SNHG7/miR-186-5p/MMP2 axis modulates the proliferation and migration of vascular endothelial cell in atherosclerosis	32603818
3607	Human	hsa-miR-186-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32735135
3608	Human	hsa-miR-186-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs); human mononuclear cells (U938)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32876518
3609	Human	hsa-miR-186-5p	miRNA	propofol (PPF)	heart failure (HF)	Human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs)	Propofol (PPF) treatment	miR-186-5p was downregulated in HiPSC-CMs treated by propofol (PPF)	32968636
3610	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	29399065
3611	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	miR-186-5p expression was downregulated in HG-treated cardiomyocytes.	30506923
3612	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	Human cardiomyocyte AC16 cells	high glucose (HG) treatment	downregulated	30506923
3613	Human	hsa-miR-186-5p	miRNA	hypoxia	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated of TTTY15 ameliorated hypoxia-induced cell injury by targeting miR-186-5p in HUVECs.	32271447
3614	Human	hsa-miR-186-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
3615	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	high glucose (HG)-induced cytotoxicity and apoptosis	AC16 cells	HG	downregulated	29399065
3616	Human	hsa-miR-186-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30443183
3617	Human	hsa-miR-186-5p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	Expression of miR-186-5p was downregulated in DDP resistant NSCLC tissues and cells (A549/DDP and H1299/DDP).	31686523
3618	Human	hsa-miR-186-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
3619	Human	hsa-miR-186-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	IL-1¦Â treatment significantly upregulated miR-186-5p expression in CHON-001 cells.	33537828
3620	Human	hsa-miR-187	miRNA	IL-10	anti-inflammatory responses	primary human monocytes	IL-10 treatment	downregulated	23071313
3621	Human	hsa-miR-187	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
3622	Human	hsa-miR-187	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
3623	Human	hsa-miR-187	miRNA	IL-17A	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
3624	Human	hsa-miR-187	miRNA	IL-1¦Â	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
3625	Human	hsa-miR-187	miRNA	IL-22	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
3626	Human	hsa-miR-187	miRNA	IL-6	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
3627	Human	hsa-miR-187	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30607907
3628	Human	hsa-miR-187-3p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	interferon-¦Ã (IFN-¦Ã) treatment	downregulated in PC-3M IE8 cells in the EMT induction model	31882179
3629	Human	hsa-miR-187-3p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	Hsa-miR-187-3p was downregulated in PC-3M IE8 cells treatment with IFN-¦Ã.	31882179
3630	Human	hsa-miR-187-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
3631	Human	hsa-miR-187a	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
3632	Human	hsa-miR-188	miRNA	iodixanol	contrast-induced acute kidney injury (CIAKI)	HK-2 cells	iodixanol treatment	upregulated	31555692
3633	Human	hsa-miR-188	miRNA	erythropoietin (EPO)	erythroid cell differentiation	The original UT-7 cell line	erythropoietin treatment	upregulated	18492109
3634	Human	hsa-miR-188-5p	miRNA	hypoxia	cardiomyocyte apoptosis	AC16 cells	hypoxia treatment	downregulated	32970504
3635	Human	hsa-miR-188-5p	miRNA	morin	chronic myeloid leukemia (CML)	CML cell lines K562 and KCL22	Morin treatment	downregulated	31515296
3636	Human	hsa-miR-188-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
3637	Human	hsa-miR-188-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose treatment	upregulated	30263007
3638	Human	hsa-miR-188-5p	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	high glucose-treated HK-2 cells	triptolide (TPL) treatment	downregulated	30263007
3639	Human	hsa-miR-188-5p	miRNA	berberine (BBR)	melanoma	A375 cells	berberine (BBR) treatment	The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression.	32915362
3640	Human	hsa-miR-188-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
3641	Human	hsa-miR-188-5p	miRNA	oxygen glucose deprivation (OGD)	stroke	human neural cell line HNC	oxygen glucose deprivation (OGD) treatment	The expressions of miR-188-5p and PTEN got increased with increasing OGD treatment time.	32745469
3642	Human	hsa-miR-189	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
3643	Human	hsa-miR-18a	miRNA	camptothecin	biologic and molecular activity of camptothecin	hypoxic-human cancer cells	camptothecin treatment	upregulated	24252850
3644	Human	hsa-miR-18a	miRNA	polyphyllin VI (PP-VI)	breast cancer	MDA-MB-231 cells	Polyphyllin VI (PP-VI) treatment	downregulated	30817902
3645	Human	hsa-miR-18a	miRNA	trastuzumab	breast cancer	SKBR-3 cells	trastuzumab treatment	downregulated	29408336
3646	Human	hsa-miR-18a	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
3647	Human	hsa-miR-18a	miRNA	AVM-derived brain endothelial cells Conditioned media (AVM-BEC-CM)	cerebral arteriovenous malformation (AVM)	brain-derived endothelial cells	AVM-BEC-CM treatment	upregulated	24837588
3648	Human	hsa-miR-18a	miRNA	radiation	cervical cancer (CC)	cervical cancer cells	radiation treatment	Higher expression of miR-18a in cervical cancer cells leads to more radiosensitivity	30308669
3649	Human	hsa-miR-18a	miRNA	hypoxia	gastric cancer (GC)	"Human gastric carcinoma cell lines, MGC-803 and HGC-27,"	Hypoxia treatment	downregulated	26622381
3650	Human	hsa-miR-18a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
3651	Human	hsa-miR-18a	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
3652	Human	hsa-miR-18a	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
3653	Human	hsa-miR-18a	miRNA	hypoxia	lymphoma	Human Burkitt lymphomas cell lines P3HR-1; Raji(EBV positive)	hypoixa induce	upregulated	30594162
3654	Human	hsa-miR-18a	miRNA	ultraviolet (UV) irradiation	lymphoma	"Human Burkitt lymphomas cell lines P3HR-1, Raji(EBV positive)"	UV irradiation treatment	upregulated	30594162
3655	Human	hsa-miR-18a	miRNA	¦Á-mangostin (¦ÁM) and ¦Ã-mangostin (¦ÃM)	pancreatic cancer (PC)	human pancreatic cancer cell lines MIA PaCa-2 and PANC-1	¦ÁM or ¦ÃM treatment	downregulated	28822990
3656	Human	hsa-miR-18a	miRNA	fractional CO(2) laser	prostate cancer	types I and III procollagen	treatment with a fractional CO(2) laser	miR-18a and miR-19a were dramatically upregulated	22907286
3657	Human	hsa-miR-18a	miRNA	¦Á-solanine	prostate cancer	Human normal prostate epithelial cell line RWPE-1 and PCa cell lines DU145 and PC-3	¦Á-Solanine treatment	downregulated	30970507
3658	Human	hsa-miR-18a-5p	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells and MDA-MB-231 cells	paclitaxel (PTX) treatment	downregulated	31352515
3659	Human	hsa-miR-18a-5p	miRNA	PXR ligand rifampicin	expression regulation	HepG2 cells	PXR ligand rifampicin treatment	upregulated	31998607
3660	Human	hsa-miR-18a-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
3661	Human	hsa-miR-18a-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	32585247
3662	Human	hsa-miR-18a-5p	miRNA	bleomycin (BLM)	lung fibrosis	human PMC line MeT-5A	bleomycin (BLM) treatment	downregulated	28131417
3663	Human	hsa-miR-18b	miRNA	bone morphogenetic protein 2 (BMP2)	tumorigenesis	NT2/D1 cells	"BMP-2 at 6, 12, and 24 h, and on days 6 and 10 treatment"	upregulated	24383669
3664	Human	hsa-miR-18b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	KCNQ1OT1 expression was increased and miR-18b expression was decreased in DN patients and HG-challenged HMCs.	32989627
3665	Human	hsa-miR-18b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose treatment	downregulated	26851511
3666	Human	hsa-miR-18b	miRNA	TGF-¦Â	cell differentiation	Human hair follicle mesenchymal stem cells (hHF-MSCs)	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	23916701
3667	Human	hsa-miR-18b	miRNA	cisplatin (DDP)	melanoma	A375/DDP; M8/DDP cells	cisplatin treatment	lncRNA H19 could influence DDP-resistance by modulating the miR-18b/IGF axis in melanoma cells.	32265386
3668	Human	hsa-miR-18b	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
3669	Human	hsa-miR-18b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
3670	Human	hsa-miR-19	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
3671	Human	hsa-miR-19	miRNA	estradiol-17¦Â (E2)	innate immune response	"THP-1 (human acute monocytic leukaemia cell line), U937 (Human monocytic [histiocytic lymphoma] cell line)"	estradiol-17¦Â (E2) treatment	upregulated	31266011
3672	Human	hsa-miR-19	miRNA	hydatid cyst fluid (HCF)	liver fibrosis	LX-2 cells	LX-2 cells treatment	downregulated	27177776
3673	Human	hsa-miR-19	miRNA	estradiol-17¦Â (E2)	lung diseases	human monocytic cells	estradiol-17¦Â (E2) treatment	E2 downregulated SLPI and upregulated miR-19 expression in monocytes.	31266011
3674	Human	hsa-miR-19	miRNA	aluminum maltolate (Al-malt)	neurodegenerative pathogenesis	neuroblastoma SH-SY5Y cells	aluminum maltolate (Al-malt) treatment	upregulated	26836165
3675	Human	hsa-miR-190	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
3676	Human	hsa-miR-190	miRNA	hypoxia	pulmonary hypertension (PH)	human plasma	hypoxia treatment	upregulated	28971974
3677	Human	hsa-miR-1907	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28804559
3678	Human	hsa-miR-1908	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
3679	Human	hsa-miR-1908	miRNA	adipokines	obesity-related complications	mature human adipocytes	resistin and leptin treatment	downregulated	24898511
3680	Human	hsa-miR-1908	miRNA	TNF-¦Á and IL-6	obesity-related complications	mature human adipocytes	TNF-¦Á and IL-6 treatment	upregulated	24898511
3681	Human	hsa-miR-1909*	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
3682	Human	hsa-miR-190a	miRNA	benzo(a)pyrene (BaP)	cell proliferation	primary cell cultures from normal endometrial tissue	benzo(a)pyrene (BaP) exposure	upregulated	30811740
3683	Human	hsa-miR-190a	miRNA	dichlorodiphenyltrichloroethane (DDT)	dichlorodiphenyltrichloroethane (DDT) exposure	normal endometrial cells	dichlorodiphenyltrichloroethane (DDT) exposure	upregulated	30421125
3684	Human	hsa-miR-190a	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
3685	Human	hsa-miR-190a-5p	miRNA	hypoxia	chronic obstructive pulmonary disease (COPD)	human pulmonary endothelial cells (HPECs)	hypoxia induce	upregulated	30538440
3686	Human	hsa-miR-190b	miRNA	tocotrienols (¦Ã and ¦ÄT3)	apoptosis	HeLa cells	tocotrienols (¦Ã and ¦ÄT3) treatment	Involvement of miR-190b in Xbp1 mRNA Splicing upon Tocotrienol Treatment	33396504
3687	Human	hsa-miR-190b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33378035
3688	Human	hsa-miR-190b	miRNA	single-walled carbon nanotubes (SWCNTs)	immune response	normal human astrocytes (line NHA/TS)	single-walled carbon nanotubes (SWCNTs) treatment	upregulated	29906516
3689	Human	hsa-miR-190b	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	LO-2 cells	free fatty acid treatment	upregulated	29575055
3690	Human	hsa-miR-191	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
3691	Human	hsa-miR-191	miRNA	inorganic arsenic (iAs)	arsenic poisoning	human liver epithelial L-02 cells	acute or chronic exposure to arsenite	upregulated	29277653
3692	Human	hsa-miR-191	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
3693	Human	hsa-miR-191	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenite exposure	upregulated	31775542
3694	Human	hsa-miR-191	miRNA	arsenite	arsenic-induced renal dysfunction	Plasma	arsenic (As) exposure	upregulated	31775542
3695	Human	hsa-miR-191	miRNA	arsenite	arsenicism	L-02 cells	arsenite exposure	upregulated	33743404
3696	Human	hsa-miR-191	miRNA	estradiol	breast cancer	MCF7 and T-47D cells	estradiol treatment	upregulated	29247596
3697	Human	hsa-miR-191	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
3698	Human	hsa-miR-191	miRNA	triptolide (TPL)	colorectal cancer (CRC)	Human CRC cell lines HT-29 and SW480	Triptolide (TPL) treatment	downregulated	30684462
3699	Human	hsa-miR-191	miRNA	¦Â-elemene	colorectal cancer (CRC)	colorectal carcinoma cells (HCT116 and HT29)	beta-elemene treatment	downregulated	29737579
3700	Human	hsa-miR-191	miRNA	cisplatin (DDP)	DNA damage	HeLa cells	cisplatin treatment	MicroRNA-191 modulates cisplatin-induced DNA damage response by targeting RCC2.	32803782
3701	Human	hsa-miR-191	miRNA	cigarette smoke extract (CSE)	hepatic insulin resistance	L-02 cells	cigarette smoke extract (CSE) exposure	CSE also increased miR-191 levels in L-02 cells.	28963693
3702	Human	hsa-miR-191	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO-2 cells	hypoxia induce	upregulated	29769640
3703	Human	hsa-miR-191	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO-2 cells	hypoxia/reperfusion (H/R)?induce	upregulated	29769640
3704	Human	hsa-miR-191	miRNA	arsenite	hepatocellular carcinoma (HCC)	human liver epithelial L-02 cells	arsenite exposure	upregulated	29277653
3705	Human	hsa-miR-191	miRNA	hypoxia inducible factor (HIF)-1	hypoxic breast tumors	MCF7 cells;MM231 cells; breast adenocarcinoma cells	hypoxia-inducible factor (HIF) treatment	upregulated	25867965
3706	Human	hsa-miR-191	miRNA	dioxin	kidney fibrosis	"Hep3B, SNU423, andHepG2 cell lines"	dioxin treatment	upregulated	20924108
3707	Human	hsa-miR-191	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
3708	Human	hsa-miR-191	miRNA	arsenite	lung cancer	human bronchial epithelial (HBE) cells	arsenite exposure	upregulated	25252218
3709	Human	hsa-miR-191	miRNA	arsenite	lung cancer	HBE cells	arsenite exposure	upregulated	25252218
3710	Human	hsa-miR-191	miRNA	radiation	lung cancer	A549 cells	radiation treatment	upregulated	32968458
3711	Human	hsa-miR-191	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	SK-MES-1cells; A549 cells; NCI-H460 cells;NSCLC cells	chronic hypoxia	upregulated	28075452
3712	Human	hsa-miR-191	miRNA	hypoxia	rheumatoid arthritis (RA)	rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)	hypoxia induce	upregulated	30894209
3713	Human	hsa-miR-191	miRNA	cigarette smoke (CS)	type 2 diabetes mellitus (T2DM)	L-02 cells	cigarette smoke (CS)?exposure	upregulated	28963693
3714	Human	hsa-miR-1910-3p	miRNA	metformin (Met)	polycystic ovarian syndrome (PCOS)	human Ishikawa cells	metformin treatment	downregulated	30599813
3715	Human	hsa-miR-1910-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
3716	Human	hsa-miR-191-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
3717	Human	hsa-miR-1914*	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
3718	Human	hsa-miR-1914-5p	miRNA	heptapeptide angiotensin-(1-7) [ang-(1-7)]	liver fibrosis	LX-2 cells	heptapeptide angiotensin-(1-7) [ang-(1-7)] treatment	upregulated	29524604
3719	Human	hsa-miR-1915	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GC tissues and GC cells SGC-7901 and MKN45	Helicobacter pylori (HP) infection	downregulated	30554489
3720	Human	hsa-miR-1915-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
3721	Human	hsa-miR-191-5p	miRNA	FTY-720	leukemia	OCI-AML3 cells	FTY-720 treatment	upregulated	24858343
3722	Human	hsa-miR-191-5p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	upregulated	27018851
3723	Human	hsa-miR-191-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	neutrophil	M.tb infection	downregulated	29477867
3724	Human	hsa-miR-192	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
3725	Human	hsa-miR-192	miRNA	silver nanoparticles (AgNPs)	apoptosis	lung cancer cell line (A549)	Silver nanoparticles (AgNPs) treatment	upregulated	30479160
3726	Human	hsa-miR-192	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
3727	Human	hsa-miR-192	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
3728	Human	hsa-miR-192	miRNA	TGF-¦Â1	breast cancer	Primary human renal epithelial PTCs (	Transforming growth factor ¦Â1 treatment	downregulated	22264233
3729	Human	hsa-miR-192	miRNA	lipopolysaccharide (LPS)	cervical cancer (CC)	HeLa cells	lipopolysaccharide (LPS) treatment	upregulated	31450920
3730	Human	hsa-miR-192	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	upregulated	24178909
3731	Human	hsa-miR-192	miRNA	suberoylanilide hydroxamic acid (SAHA)	chronic myeloid leukemia (CML)	K562 cells	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	29343029
3732	Human	hsa-miR-192	miRNA	simvastatin	colorectal cancer (CRC)	colon cancer HCT-116 cells	Simvastatin treatment	upregulated	30628692
3733	Human	hsa-miR-192	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
3734	Human	hsa-miR-192	miRNA	exendin-4 and high glucose (Ex-HG)	diabetic nephropathy (DN)	HK-2 cells	exendin-4 and high glucose (Ex-HG) treatment	HG and exendin-4 may have contributed to a decrease in miR-192 in both HK-2 cells and EVs in a p53-dependent manner.	29717107
3735	Human	hsa-miR-192	miRNA	bisphenol A (BPA)	hepatic steatosis and lipid accumulation	human HepG2 cells	bisphenol A (BPA) treatment	downregulated	28483554
3736	Human	hsa-miR-192	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV)-mediated hepatic fibrosis	human hepatic stellate cells (HSCs) line LX-2	hepatitis C virus (HCV) infection	upregulated	30753992
3737	Human	hsa-miR-192	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
3738	Human	hsa-miR-192	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	upregulated	29516639
3739	Human	hsa-miR-192	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	downregulated	29516639
3740	Human	hsa-miR-192	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
3741	Human	hsa-miR-192	miRNA	IL-17	multiple myeloma (MM)	MM cells	IL-17 treatment	downregulated	25489847
3742	Human	hsa-miR-192	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Huh7 cells exosomes	palmitic acid (PA) treatment	upregulated in exosomes	28623272
3743	Human	hsa-miR-192	miRNA	nicotine	non-small cell lung cancer (NSCLC)	A549 and NCI-H460 cells	nicotine treatment	downregulated	29518612
3744	Human	hsa-miR-192	miRNA	opisthorchis viverrini	opisthorchis viverrini infection	human urine	infect with Opisthorchis viverrini	upregulated in the urine	26456596
3745	Human	hsa-miR-192	miRNA	acetaminophen (APAP)	prostate cancer	serum	acetaminophen (APAP) treatment	?Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients	22045675
3746	Human	hsa-miR-192	miRNA	acidic bile salt	reflux esophagitis	Het-1A cells	acidic bile salt treatment	upregulated	24006894
3747	Human	hsa-miR-192	miRNA	astragaloside IV (AS-IV)	renal fibrosis	TGF-¦Â1-treated HK-2 cells	astragaloside (AS-IV) treatment	downregulated	31497219
3748	Human	hsa-miR-192	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	31497219
3749	Human	hsa-miR-192	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
3750	Human	hsa-miR-192	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
3751	Human	hsa-miR-192	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	The human renal epithelial cells (293T cells)	metformin treatment	differently regulated in circulating	24478399
3752	Human	hsa-miR-192-5p	miRNA	vancomycin (VAN)	acute kidney injury (AKI)	human renal tubular +H57epithelial cell line (HK-2)	human renal tubular +H57epithelial cell line (HK-2) treatment	upregulation	27941921
3753	Human	hsa-miR-192-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
3754	Human	hsa-miR-192-5p	miRNA	oleic acid (OA)	diabetes-associated metabolic disorders	HepG2 cells	oleate treatment	circHIPK3 contributes to hyperglycemia and insulin resistance by sponging miR-192-5p and up-regulating FOXO1.	31875589
3755	Human	hsa-miR-192-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
3756	Human	hsa-miR-192-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	downregulated	30854110
3757	Human	hsa-miR-192-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
3758	Human	hsa-miR-192-5p	miRNA	"N,N-dimethylformamide (DMF)"	hepatotoxicity	HL-7702 liver cells	"N,N-dimethylformamide (DMF) treatment"	"Aberrant expression of miRNA-192-5p contributes to N,N-dimethylformamide-induced hepatic apoptosis."	32648274
3759	Human	hsa-miR-192-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
3760	Human	hsa-miR-192-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
3761	Human	hsa-miR-192-5p	miRNA	oleic acid (OA)	hyperglycemia and insulin resistance	HepG2 cells	oleate treatment	downregulated	31875589
3762	Human	hsa-miR-192-5p	miRNA	metformin (Met)	melanoma	"The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951"	Metformin treatment	upregulated	30754729
3763	Human	hsa-miR-192-5p	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Huh7 cells	palmitic acid (PA) treatment	upregulated	29290651
3764	Human	hsa-miR-192-5p	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer cells	curcumin treatment	upregulated	26351877
3765	Human	hsa-miR-192-5p	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	A427 cells; A549 cells	curcumin treatment	Curcumin treatment promoting the expression levels of miR-192-5p.	32626956
3766	Human	hsa-miR-192-5p	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	H460 and A427 cells	curcumin treatment	upregulated	25444916
3767	Human	hsa-miR-192-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
3768	Human	hsa-miR-192-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
3769	Human	hsa-miR-192b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
3770	Human	hsa-miR-193	miRNA	cisplatin (DDP)	esophageal cancer (EC)	TE-1 cells	cisplatin treatment	upregulated	32369495
3771	Human	hsa-miR-193	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 and T98G cells	temozolomide (TMZ) treatment	miR-93 and -193 decreased cell cycling quiescence and induced resistance to TMZ.	30853911
3772	Human	hsa-miR-193-5p	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
3773	Human	hsa-miR-193-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
3774	Human	hsa-miR-193-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
3775	Human	hsa-miR-193a	miRNA	high glucose (HG)	diabetic podocytopathy	Human podocytes (PDs)	high glucose (HG) treatment	upregulated	29357419
3776	Human	hsa-miR-193a	miRNA	D-glucose	epithelial-mesenchymal transition (EMT)	peritoneal mesothelial cells (PMCs)	D-glucose treatment	upregulated	25683944
3777	Human	hsa-miR-193a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	lung cancer	NSCLC A549 cells	5-aza-20-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A treatment	upregulated	22282464
3778	Human	hsa-miR-193a-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31857133
3779	Human	hsa-miR-193a-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	miR-193a-3p was significantly downregulated in SH-SY5Y cells.	31857133
3780	Human	hsa-miR-193a-3p	miRNA	dextran sodium sulfate (DSS)	colitis	Human intestinal epithelial Caco2	dextran sodium sulfate (DSS) treatment	"Intracolonic delivery of miR-193a-3p significantly ameliorated dextran sodium sulfate-induced colitis, whereas the overexpression of colonic PepT1 via PepT1 3'-untranslated region mutant lentivirus vector abolished the anti-inflammatory effect of miR-193a-3p"	25931122
3781	Human	hsa-miR-193a-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
3782	Human	hsa-miR-193a-3p	miRNA	activin A	liver fibrosis	LX-2 cells	activin A treatment	downregulated	30945448
3783	Human	hsa-miR-193a-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	30945448
3784	Human	hsa-miR-193a-3p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	upregulated	33071785
3785	Human	hsa-miR-193a-3p	miRNA	intermittent hypoxia (IH)	obstructive sleep apnea (OSA)	human umbilical vein endothelial cells (HUVECs)	intermittent hypoxia(IH) treatment	miR-193a-3p was upregulated in HUVECs exposed to IH.	32003752
3786	Human	hsa-miR-193a-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	31632562
3787	Human	hsa-miR-193a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31210318
3788	Human	hsa-miR-193a-5p	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
3789	Human	hsa-miR-193a-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	cigarette smoke extract (CSE) treatment	"Circ-OSBPL2 was highly expressed in lung tissues of smokers without or with COPD, particularly in smokers with COPD."	33854310
3790	Human	hsa-miR-193a-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U257 cells; U87 cells	temozolomide (TMZ) treatment	upregulated	29136760
3791	Human	hsa-miR-193a-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
3792	Human	hsa-miR-193a-5p	miRNA	docetaxel (DTX)	prostate cancer	PC3 cells	docetaxel (DTX) treatment	upregulated	29216925
3793	Human	hsa-miR-193b	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	upregulated	33197057
3794	Human	hsa-miR-193b	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
3795	Human	hsa-miR-193b	miRNA	TGF-¦Â1	gastric cancer (GC)	BGC-823 cells; SGC7901 cells; MKN28 cell	TGF-¦Â1 treatment	downregulated	23372348
3796	Human	hsa-miR-193b	miRNA	metformin (Met)	triple negative breast cancer (TNBC)	triple-negative breast cancer (TNBC) cell lines	metformin treatment	upregulated	25213330
3797	Human	hsa-miR-193b	miRNA	IL-4	monocytic differentiation	monocyte	IL-4 treatment	dysregulated	25148686
3798	Human	hsa-miR-193b	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec8A cells	Progesterone treatment	downregulated	22543862
3799	Human	hsa-miR-193b*	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
3800	Human	hsa-miR-193b-3p	miRNA	IL-1¦Â	chondrogenesis and metabolism	primary human chondrocytes (PHCs)	IL-1¦Â treatment	IL-1¦Â stimulation resulted in decreased miR-193b-3p expression.	29344280
3801	Human	hsa-miR-193b-3p	miRNA	activin A	liver fibrosis	LX-2 cells	activin A treatment	downregulated	30945448
3802	Human	hsa-miR-193b-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	30945448
3803	Human	hsa-miR-193b-3p	miRNA	triptolide (TPL)	nephroblastoma	human nephroblastoma cells (G-401 and WiT49)	triptolide (TPL) treatment	upregulated	30978333
3804	Human	hsa-miR-193b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	downregulated	29323744
3805	Human	hsa-miR-193b-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes (PHCs)	IL-1¦Â treatment	downregulated	30854734
3806	Human	hsa-miR-19-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
3807	Human	hsa-miR-194	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	LO2 cells	ethanol treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)."	33068587
3808	Human	hsa-miR-194	miRNA	yangonin (Yan)	alcoholic liver disease (ALD)	LO2 cells	Yangonin (Yan) treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yan"	33068587
3809	Human	hsa-miR-194	miRNA	yangonin (Yan)	alcoholic liver disease (ALD)	ethanol-induced LO2 cells	Yangonin (Yan) treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)"	33068587
3810	Human	hsa-miR-194	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
3811	Human	hsa-miR-194	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
3812	Human	hsa-miR-194	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells	docosahexaenoic acid (DHA) fatty acids treatment	MDA-MB-231 cells with DHA caused an increase in the miR-194 expression.	31713924
3813	Human	hsa-miR-194	miRNA	trastuzumab	breast cancer	BT474 cells;SKBr3 cells; MDA-MB-361 cells;MDA-MB-231 cells	Trastuzumab treatment	trastuzumab treatment upregulates miR-194 expression and may exert its cell migration-inhibitory effect through miR-194-mediated downregulated of cytoskeleton protein talin2 in HER2-overexpressing human breast cancer cells	22829924
3814	Human	hsa-miR-194	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	plasma or liver tissues of CHB patients	hepatitis B virus (HBV)infection	upregulated	30044042
3815	Human	hsa-miR-194	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
3816	Human	hsa-miR-194	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
3817	Human	hsa-miR-194	miRNA	palmitic acid (PA)	inflammatory response	Human THP-1 cells	palmitic acid (PA) treatment	downregulated	25984739
3818	Human	hsa-miR-194	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 alveolar epithelial cells (AECs)	infec with IAV/Beijing/501/2009 (BJ501)	downregulated	29163456
3819	Human	hsa-miR-194	miRNA	high glucose (HG)	lung cancer	Human lung cancer cell lines A549 and H1299	high glucose (HG) treatment	downregulated	30900402
3820	Human	hsa-miR-194	miRNA	green tea (GT)	nonalcoholic fatty liver disease (NAFLD)	TNF-¦Á-treated HepG2 cells	green tea (GT) treatment	upregulated	31885789
3821	Human	hsa-miR-194	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	human derived HepG2 cell	palmitic acid treatment	upregulated	28951211
3822	Human	hsa-miR-194	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31885789
3823	Human	hsa-miR-194	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3ip1 cells; HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
3824	Human	hsa-miR-194	miRNA	acidic bile salt	reflux esophagitis	Het-1A cells	acidic bile salt treatment	upregulated	24006894
3825	Human	hsa-miR-194	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK-2 cells	hypoxia/reperfusion (H/R) treatment	miR-194 was decreased in H/R-induced HK-2 cells.	30485514
3826	Human	hsa-miR-194	miRNA	lycium barbarum polysaccharide (LBP)	spinal cord injury (SCI)	SH-SY5Y cells	Lycium barbarum polysaccharides (LBPs) treatment	downregulated	30308510
3827	Human	hsa-miR-194	miRNA	docosahexaenoic acid (DHA)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	Docosahexaenoic acid (DHA) treatment	upregulated	31713924
3828	Human	hsa-miR-194	miRNA	hepatocyte nuclear factor-1 ¦Á	intestinal cell differentiation	Caco-2 cells	hepatocyte nuclear factor-1 ¦Á	upregulated	18492795
3829	Human	hsa-miR-194-3p	miRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	Human bronchial epithelial cells (HBEpiCs)	Fine particulate matter (PM2.5) exposure treatment	downregulated	30122914
3830	Human	hsa-miR-194-3p	miRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	blood	Fine particulate exposure (PM2.5) treatment	miR-194-3p was decreased significantly after fine particulate exposure (PM25) exposure	30746254
3831	Human	hsa-miR-194-3p	miRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	embryo implantation	human trophoblast Swan 71 cells	"benzo[a]pyrene-7, 8-diol-9, 10-epoxide (BPDE) treatment"	upregulated	30011042
3832	Human	hsa-miR-194-5p	miRNA	IL-6 and TNF-¦Á	intervertebral disc degeneration (IDD)	"human osteoblast cells (hFOB1.19), nucleus pulposus cells (hNPCs), and annulus fibrosus cells (hAFCs)"	IL-6 and TNF-¦Á treatment	downregulated	30945295
3833	Human	hsa-miR-194-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary alveolar epithelial cells (HPAEpiC)	lipopolysaccharide (LPS) treatment	MALAT1 knockdown alleviated HPAEpiC apoptosis by competitively binding to miR-194-5p and then elevating the inhibitory effect on its target FOXP2.	33117815
3834	Human	hsa-miR-194-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	bladder cancer	bladder cancer cell lines T24 and 5637	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30925453
3835	Human	hsa-miR-194-5p	miRNA	cisplatin (DDP)	bladder cancer	bladder cancer cell lines T24 and 5637	?cisplatin treatment	upregulated	30925453
3836	Human	hsa-miR-194-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
3837	Human	hsa-miR-194-5p	miRNA	histone deacetylase inhibitor SAHA	leukemogenesis and drug resistance	"U937, NB4, K562 and Molm-14 cells"	SAHA	upregulated	28216661
3838	Human	hsa-miR-194-5p	miRNA	lipopolysaccharide (LPS)	neurodegenerative diseases	human astrocytes	lipopolysaccharide (LPS) treatment	miR-194-5p was downregulated in LPS-induced astrocytes.	32533463
3839	Human	hsa-miR-194-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin treatment	"Compared to cisplatin-sensitive ovarian cancer cells, higher miR-194-5p expression and lower SLC40A1 expression were found in cisplatin-resistant ovarian cancer cells."	32534701
3840	Human	hsa-miR-194-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
3841	Human	hsa-miR-194-5p	miRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	downregulated	33393621
3842	Human	hsa-miR-195	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute stroke	SH-SY5Y neural cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30775405
3843	Human	hsa-miR-195	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
3844	Human	hsa-miR-195	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	22802111
3845	Human	hsa-miR-195	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
3846	Human	hsa-miR-195	miRNA	mastectomy	breast cancer	breast cancer tissues	mastectomy treatment	upregulated	25503185
3847	Human	hsa-miR-195	miRNA	H2O2	cardiomyocyte apoptosis	human cardiomyocytes (HCMs)	Hydrogen peroxide (H2O2) treatment	upregulated	30355909
3848	Human	hsa-miR-195	miRNA	doxorubicin (DOX)	cardiotoxicity	human AC16 cardiomyocytes	Doxorubicin (DOX)? treatment	"SNHG1 could counteract the inhibitory effect of miR-195 on Bcl-2, and miR-195 restoration blocked the beneficial effect of SNHG1 against DOX toxicity in AC16 cells"	31300525
3849	Human	hsa-miR-195	miRNA	triamcinolone	cell differentiation	hepatic induced stem cells	triamcinolone treatment	upregulated	29101812
3850	Human	hsa-miR-195	miRNA	hypoxia	cerebral ischemia injury (CII)	HUVECs	hypoxia treatment	downregulated	28849133
3851	Human	hsa-miR-195	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissues	cigarette smoke (CS) exposure	upregulated	29223853
3852	Human	hsa-miR-195	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	TE-1/DDP	cisplatin treatment	Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis	31558183
3853	Human	hsa-miR-195	miRNA	Schizandrin A (SchA)	colorectal cancer (CRC)	HCT116 and SW480 cells	Schizandrin A (SchA) treatment	upregulated	29331856
3854	Human	hsa-miR-195	miRNA	hypoxia	deep vein thrombosis (DVT)	human EPCs (hEPCs)	hypoxia treatment	upregulated	27623937
3855	Human	hsa-miR-195	miRNA	astragalus polysaccharide (APS)	diabetic retinopathy (DR)	high glucose (HG)-treated ARPE-19 cells	astragalus polysaccharide (APS) treatment	downregulated	31117931
3856	Human	hsa-miR-195	miRNA	H2O2	diabetic retinopathy (DR)	human umbilical vein endothelial cells (HUVECs); human retinal endothelial cells (HMRECs)	H2O2 treatment	upregulated	28487236
3857	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human umbilical vein endothelial cells (HUVECs); human retinal endothelial cells (HMRECs)	high glucose (HG) treatment	upregulated	28487236
3858	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	upregulated	31117931
3859	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic retinopathy (DR)	"human retinal and dermal microvascular ECs (HRECs, HMECs)"	"exposure to 25 mmol/l glucose (high glucose, HG) treatment"	upregulation	24570140
3860	Human	hsa-miR-195	miRNA	H2O2	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HMRECs)	H2O2 treatment	We confirmed that over-expression of SNGH16 attenuated H2O2-induced angiogenesis by HMRECs.	33530902
3861	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31115479
3862	Human	hsa-miR-195	miRNA	cisplatin (DDP)	esophageal squamous cell carcinoma (ESCC)	The human ESCC cell line TE-1	cisplatin treatment	downregulated	31558183
3863	Human	hsa-miR-195	miRNA	propofol (PPF)	gastric cancer (GC)	MKN45 cells	propofol treatment	The expression of miR-195 was increased after propofol treatment	30171944
3864	Human	hsa-miR-195	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	temozolomide (TMZ) treatment	The expression levels of miR-195 were drastically higher in both U87TR and U251TR cell lines	30442884
3865	Human	hsa-miR-195	miRNA	cyclosporine A (CsA)	glioblastoma multiforme (GBM)	human glioblastoma cells	cyclosporine A treatment	downregulated	26537083
3866	Human	hsa-miR-195	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell line U87	glioma cell line U87 treatment	"downregulated(miR-205), upregulation(miR-195)"	27574009
3867	Human	hsa-miR-195	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
3868	Human	hsa-miR-195	miRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	"human hepatocellular carcinoma cell line, BEL-7402"	5-fluorouracil (5-FU) treatment	upregulated	21947305
3869	Human	hsa-miR-195	miRNA	enterovirus 71 (EV71)	infant encephalitis	SH-SY5Y cells	Enterovirus 71 (EV71) infection	MicroRNA-195 suppresses enterovirus A71-induced pyroptosis in human neuroblastoma cells through targeting NLRX1	33253716
3870	Human	hsa-miR-195	miRNA	"MS-275, a histone deacetylase inhibitor"	lung adenocarcinoma (LUAD)	A549 and HCC827 cell lines	MS-275 treatment	upregulated	31090206
3871	Human	hsa-miR-195	miRNA	ailanthone (AIL)	lung cancer	A549 cells	ailanthone (AIL) treatment	upregulated	30565729
3872	Human	hsa-miR-195	miRNA	chronic brain hypoperfusion (CBH)	murine atherosclerosis and vascular smooth muscle cell proliferation	plasma	chronic brain hypoperfusion (CBH) treatment	downregulated	23447608
3873	Human	hsa-miR-195	miRNA	paraquat (PQ)	neural degenerative diseases	"human embryonic stem cell-derived neural progenitor cells, hESC-NPCs"	paraquat (PQ) treatment	upregulated	23807224
3874	Human	hsa-miR-195	miRNA	salidroside (SAL)	non-small cell lung cancer (NSCLC)	A549 cells	Salidroside treatment	upregulated	30880481
3875	Human	hsa-miR-195	miRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	primary chondrocytes	interleukin-1 beta (IL-1¦Â) and tumor necrosis factor-alpha (TNF-¦Á) treatment	downregulated	30575896
3876	Human	hsa-miR-195	miRNA	enterovirus 71 (EV71)	pyroptosis	SH-SY5Y cells	Enterovirus 71 (EV71) infection	miR-195 was significantly down-regulate in EV-A71-infected SH-SY5Y human neuroblastoma cells.	33253716
3877	Human	hsa-miR-195	miRNA	lipopolysaccharide (LPS)	sepsis	NCM460 cells	lipopolysaccharide (LPS) treatment	upregulated	31894250
3878	Human	hsa-miR-195	miRNA	lipopolysaccharide (LPS)	sepsis	human intestinal epithelial cells	lipopolysaccharide (LPS) treatment	miR-195 was significantly upregulated following LPS treatment.	31894250
3879	Human	hsa-miR-195	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-195 expression in CMS-treated PLL cells was restored by a demethylation reagent 5-aza-2'-deoxycytidine (AZA).	32432317
3880	Human	hsa-miR-195	miRNA	cyclic mechanical stretch (CMS)	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	cyclic mechanical stress (CMS) treatment	miR-195 was downregulated in treated PLL cells.	32432317
3881	Human	hsa-miR-195	miRNA	transretinoic acid/hydrocortisone (tRA/H)	thyroid cancer (TC)	MCF-7 human breast cancer cells	tRA/H treatment	downregulated	25404690
3882	Human	hsa-miR-195	miRNA	resistanceor endurance training	type 2 diabetes mellitus (T2DM)	middle-aged Polynesian men and women with morbid obesity (44 kg/m(2) ¡À 10) and Type 2 diabetes	16 wk of resistanceor endurance training treatment	dysregulated	25138607
3883	Human	hsa-miR-195-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
3884	Human	hsa-miR-195-5p	miRNA	caerulein (Cae)	acute pancreatitis (AP)	Human pancreatic duct epithelial cells (HPDE)	caerulein (Cae) treatment	"As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased."	32856219
3885	Human	hsa-miR-195-5p	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	homocysteine (HCY) treatment	downregulated	31629816
3886	Human	hsa-miR-195-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA CTBP1-AS2 may serve a role in AS by inhibiting the proliferation and promoting the autophagy of VSMCs through ATG14 modulation via miR-195-5p.	32626936
3887	Human	hsa-miR-195-5p	miRNA	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT)	cervical cancer (CC)	serum	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) treatment	upregulated	32851067
3888	Human	hsa-miR-195-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
3889	Human	hsa-miR-195-5p	miRNA	propofol (PPF)	gastric cancer (GC)	HGC-27 cells; AGS cells	Propofol treatment	"Propofol inhibited the proliferation and invasion, but enhanced the apoptosis of GC cells by regulating the circ-PVT1/miR-195-5p/ETS1 axis"	32945521
3890	Human	hsa-miR-195-5p	miRNA	microwave ablation (MWA)	hepatocellular carcinoma (HCC)	HCC cell lines	microwave ablation (MWA) treatment	SP1-induced upregulation of lncRNA CTBP1-AS2 accelerates the hepatocellular carcinoma tumorigenesis through targeting CEP55 via sponging miR-195-5p.	32988587
3891	Human	hsa-miR-195-5p	miRNA	lipopolysaccharide (LPS)	lung injury	human small airway epithelial cells (HSAECs)	Lipopolysaccharide (LPS) treatment	CASC9 protects lung epithelial cells from sepsis-induced injury via regulating miR-195-5p/PDK4 axis.	32221619
3892	Human	hsa-miR-195-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
3893	Human	hsa-miR-195-5p	miRNA	simulated tension strain	osteogenic differentiation and bone formation	human periodontal ligament cells (PDLCs)	simulated tension strain treatment	downregulated	28181691
3894	Human	hsa-miR-195-5p	miRNA	treponema pallidum (T. pallidum) infection	treponema pallidum (Tp) infection	peripheral blood mononuclear cells (PBMCs)	treponema pallidum (T. pallidum) infection treatment	upregulated	32087699
3895	Human	hsa-miR-195a	miRNA	endothelin-1 (ET-1)	sickle cell disease (SCD)	THP-1 cells and human peripheral blood monocytes	Endothelin-1 treatment	downregulated	20952681
3896	Human	hsa-miR-195a	miRNA	advanced glycation end product (AGE)	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPC)	advanced glycation end product (AGE) treatment	downregulated	32850952
3897	Human	hsa-miR-196	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
3898	Human	hsa-miR-196	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
3899	Human	hsa-miR-196	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?8 cells	heme treatment	upregulated	23538684
3900	Human	hsa-miR-196-5p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	"HCC (HCCLM3, SMMC7721, HepG2, Huh7, and Hep3B) cell lines"	hypoxia induce	downregulated	31713780
3901	Human	hsa-miR-196a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA SNHG1 regulates vascular endothelial cell proliferation and angiogenesis via miR-196a	32297149
3902	Human	hsa-miR-196a	miRNA	hemin	erythropoiesis	K562 cells	hemin treatment	miR-196a overexpression inhibits apoptosis in hemin-induced K562 cells through downregulating p27kip1.	31913716
3903	Human	hsa-miR-196a	miRNA	hypoxia	glioblastoma multiforme (GBM)	Glioblastoma (GBM)	hypoxia treatment	We identified miR-196a as a hypoxia-inducible and hypoxia-inducible factor (HIF)-regulated miRNA that plays an oncogenic role in GBM.	33469841
3904	Human	hsa-miR-196a	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
3905	Human	hsa-miR-196a	miRNA	hepatitis C virus (HCV) core protein	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 HCC cell lines	hepatitis C virus (HCV) core protein treatment	upregulated	27108614
3906	Human	hsa-miR-196a	miRNA	vascular endothelial growth factor (VEGF)	hepatocellular carcinoma (HCC)	Human umbilical vein endothelial cells (HUVECs)	treatment treatment	downregulated	22773844
3907	Human	hsa-miR-196a	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-196a was upregulated in propofol-treated group	24454982
3908	Human	hsa-miR-196a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
3909	Human	hsa-miR-196a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
3910	Human	hsa-miR-196a	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	upregulated	30182520
3911	Human	hsa-miR-196a-1	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cervical cancer (CC)	"cervical cell lines SiHa, CaSki and HeLa"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31326568
3912	Human	hsa-miR-196a2	miRNA	cisplatin (DDP)	myeloproliferative disorder	Blood samples	gemcitabine or cisplatin treatment	the SNP might affect mature?miR©\196a?expression and binding of mature?hsa©\miR©\196a2¨C3p	23143626
3913	Human	hsa-miR-196a2	miRNA	gemcitabine (GEM)	myeloproliferative disorder	Blood samples	gemcitabine or cisplatin treatment	the SNP might affect mature?miR©\196a?expression and binding of mature?hsa©\miR©\196a2¨C3p	23143626
3914	Human	hsa-miR-196a-5p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
3915	Human	hsa-miR-196a-5p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
3916	Human	hsa-miR-196a-5p	miRNA	anti-microbial peptide LL-37	rosacea	skin tissues	LL37 treatment	downregulated	33678493
3917	Human	hsa-miR-196b	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
3918	Human	hsa-miR-196b	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
3919	Human	hsa-miR-196b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
3920	Human	hsa-miR-196b	miRNA	curcumin (Cur)	chronic myeloid leukemia (CML)	Chronic Myelogenous Leukemia (CML) cells	curcumin treatment	upregulated	26116834
3921	Human	hsa-miR-196b	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	downregulated	31744065
3922	Human	hsa-miR-196b	miRNA	5-aza-2'-deoxycytidine and trichostatin A	leukemia	human leukemia cell lines	5-aza-deoxycytidine and trichostatin A treatment	upregulated	27570640
3923	Human	hsa-miR-196b	miRNA	platinum	lung adenocarcinoma (LUAD)	LADC tissues	platinum-based doublet chemotherapy treatment	dysregulated	25142144
3924	Human	hsa-miR-196b	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
3925	Human	hsa-miR-196b	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
3926	Human	hsa-miR-196b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	primary gastric tumors	U937;K562; HL60; Hep3B; HepG2;Huh-7; HT29; MDA-MB231; MCF-7; HeLa;LNCap; MRC5; H1299; GBM-8901; GBM-8401;U87; SHY5Y; HCS3; Cal27; MIA paca2; NCCIT;293T; GM05387; AGS; AZ-521; HR; TSGH;NUGC	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	20662076
3927	Human	hsa-miR-196b	miRNA	bacillus calmette-guerin (BCG)	tuberculosis (TB)	TB patients	bacillus calmette-guerin (BCG) treatment	downregulated	24586438
3928	Human	hsa-miR-196-b	miRNA	suberoylanilide hydroxamic acid (SAHA)	neuroblastoma (NB)	SH-SY5Y cells	suberoylanilide hydroxamic acid (SAHA) treatment	downregulated	30091530
3929	Human	hsa-miR-196b-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer (GC) tissues	Helicobacter pylori (H. pylori) infection	Patients with H. pylori infection had a higher expression of hsa-miR-196b-3p and CALML4 than those without H. pylori infection.	32802507
3930	Human	hsa-miR-196b-5p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
3931	Human	hsa-miR-196b-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	interferon-¦Ã (IFN-¦Ã) treatment	upregulated in PC-3M IE8 cells in the EMT induction model	31882179
3932	Human	hsa-miR-196b-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	Hsa-miR-196b-5p was upregulated in PC-3M IE8 cells treatment with IFN-¦Ã.	31882179
3933	Human	hsa-miR-196b-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
3934	Human	hsa-miR-196b-5p	miRNA	aldosterone	renal injury	HK-2 cells	aldosterone treatment	upregulated	32727744
3935	Human	hsa-miR-197	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
3936	Human	hsa-miR-197	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
3937	Human	hsa-miR-197	miRNA	aspirin	atherothrombotic risk in type 2 diabetes mellitus	blood	aspirin treatment	Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p?=?0.039) or prasugrel.	31910903
3938	Human	hsa-miR-197	miRNA	prasugrel	atherothrombotic risk in type 2 diabetes mellitus	blood	prasugrel treatmrnt treatment	Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p?=?0039) or prasugrel	31910903
3939	Human	hsa-miR-197	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	Peripheral Blood Mononuclear Cells(PBMC)	hepatitis B virus (HBV) infection	downregulated	23710316
3940	Human	hsa-miR-197	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
3941	Human	hsa-miR-197	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	31108165
3942	Human	hsa-miR-197	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
3943	Human	hsa-miR-197	miRNA	docetaxel (DTX)	head and neck squamous cell carcinoma (HNSCC)	UMSCC-1 cells;SQ20B cells	docetaxel (DTX) treatment	downregulated	21560177
3944	Human	hsa-miR-197	miRNA	IL-6 and signal transducers and activators of transcription 3 (STAT3)	hepatocellular carcinoma (HCC)	human HCC cell lines HepG2	IL-6/STAT3 treatment	downregulated	26451302
3945	Human	hsa-miR-197	miRNA	proanthocyanidin extract (GSPE)	hepatocellular carcinoma (HCC)	HepG2 cells	proanthocyanidin extract (GSPE) treatment	upregulated	21998738
3946	Human	hsa-miR-197	miRNA	quercetin	meningioma	HBL-52 meningioma cells	quercetin treatment	Quercetin treatment increases miR-197 mRNA	32585423
3947	Human	hsa-miR-197	miRNA	taxol	ovarian cancer (OC)	ovarian cancer cells	Taxol resistance treatment	upregulated	25833695
3948	Human	hsa-miR-197	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
3949	Human	hsa-miR-197	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
3950	Human	hsa-miR-197	miRNA	enterovirus 71 (EV71)	severe central nervous system complications	"Human rhabdomyosarcoma (RD) cells,human embryonic kidney (HEK293T) cells"	Enterovirus 71 (EV71) treatment	downregulated	26581983
3951	Human	hsa-miR-1972	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
3952	Human	hsa-miR-1972	miRNA	cisplatin (DDP)	ovarian cancer (OC)	OC lines (SKOV-3 and A2780)	cisplatin treatment	upregulated	31865363
3953	Human	hsa-miR-1973	miRNA	hantaan virus (HTNV)	hantaan virus (HTNV) infection	A549 cells	hantavirus(HTNV)treatment	upregulated	24074584
3954	Human	hsa-miR-1973	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
3955	Human	hsa-miR-1973	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
3956	Human	hsa-miR-197-3p	miRNA	asbestos fibers	malignant pleural mesothelioma (MPM)	serum	ex-exposed to asbestos fibers (WEA)	downegulated	27716620
3957	Human	hsa-miR-197-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	neutrophil	M.tb infection	downregulated	29477867
3958	Human	hsa-miR-1975	miRNA	influenza A virus (IAV)	innate immune response	A549 cells	Influenza virus A (IVA) infection	upregulated	31416454
3959	Human	hsa-miR-198	miRNA	bortezomib	diffuse large B-cell lymphoma (DLBCL)	DLBCL CRL-2630 cells	bortezomib? treatment	upregulated	30216798
3960	Human	hsa-miR-198	miRNA	cisplatin (DDP)	gastric cancer (GC)	"GC tissues and cells SGC7901, BGC823"	cisplatin treatment	downregulated	30927924
3961	Human	hsa-miR-198	miRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	glioblastoma cells	TGF-¦Â1 treatment	?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling	32813021
3962	Human	hsa-miR-198	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
3963	Human	hsa-miR-199	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	human nucleus pulposus cells injury	Human nucleus pulposus cells	tumor necrosis factor alpha (TNF-¦Á) treatment	miR-199 was extremely decreased in Human nucleus pulposus cells after TNF-¦Á treatment	30309653
3964	Human	hsa-miR-199	miRNA	molecular hydrogen	inflammatory injury	Retinal Microglia cells	Molecular hydrogen?treatment	upregulated	23826519
3965	Human	hsa-miR-199	miRNA	TGF-¦Â1	myofibroblast proliferation	foreskins of unidentified normal neonates tissue	Transforming growth factor-¦Â1 treatment	"TGF-¦Â1 downregulated HGF in primary human adult pulmonary fibroblasts (HLFb) and increased the expression of miR-199a-3p, a microRNA (miRNA) associated with fibrotic remodeling"	23657814
3966	Human	hsa-miR-199a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	lipopolysaccharide (LPS) treatment	The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells	32069473
3967	Human	hsa-miR-199a	miRNA	propofol (PPF)	apoptosis	HepG2 cells	Propofol?treatment treatment	Propofol significantly elevated the expression of miR-199a and inhibited the invasiveness of HepG2 cells	23742776
3968	Human	hsa-miR-199a	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
3969	Human	hsa-miR-199a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
3970	Human	hsa-miR-199a	miRNA	hypoxia	epithelial ovarian cancer (EOC)	EOCC	1-3% O2 treatment	upregulated	24706848
3971	Human	hsa-miR-199a	miRNA	reactive oxygen species (ROS)	Epstein-Barr virus (EBV) infection	ovarian cancer cells	reactive oxygen species (ROS) treatment	downregulated	23146892
3972	Human	hsa-miR-199a	miRNA	hypoxia	fat	non-small cell lung cancer cells	hypoxia treatment	downregulated	22119803
3973	Human	hsa-miR-199a	miRNA	dauricine (Dau)	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 HCC cells	Dauricine (Dau) treatment	upregulated	30171973
3974	Human	hsa-miR-199a	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma cells	Propofol treatment	upregulated	23319430
3975	Human	hsa-miR-199a	miRNA	hypoxia	hypoxia-induced injury	human dermal microvascular endothelial cells (hDMECs)	hypoxia induce	downregulated	31537150
3976	Human	hsa-miR-199a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
3977	Human	hsa-miR-199a	miRNA	sodium selenite and Se-methylselenocysteine (MSC)	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite and Se-methylselenocysteine (MSC) treatment	downregulated	32656599
3978	Human	hsa-miR-199a	miRNA	hepatitis C virus (HCV)	liver cirrhosis	liver	hepatitis C virus (HCV) infection	The serum level of miR-199a in chronic HCV patients was significantly lower than in healthy controls (P = 0.001).	26133725
3979	Human	hsa-miR-199a	miRNA	chemokine CCL5	malignant bone cancer	JJ012/CCL5 cells	CCL5 treatment	downregulated	25444917
3980	Human	hsa-miR-199a	miRNA	arctigenin	mechanical trauma injury	scratch-induced injury of human SH-SY5Y cells	arctigenin (ARC) treatment	upregulated	27389368
3981	Human	hsa-miR-199a	miRNA	nitric oxide donors	nitrate tolerance	human umbilical vein endothelial cells	nitric oxide donors treatment	upregulated	29431644
3982	Human	hsa-miR-199a	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
3983	Human	hsa-miR-199a	miRNA	curcumin (Cur)	pancreatic cancer (PC)	The BxPC-3 human pancreatic carcinoma cell line	curcumin (diferuloylmethane)? treatment	downregulated	18347134
3984	Human	hsa-miR-199a	miRNA	dexamethasone (DEX)	steatosis	HepG3 cells	dexamethasone (Dex) treatment	downregulated	29409992
3985	Human	hsa-miR-199a	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	testicular germ cell tumors (TGCTs)	NTERA2 and NCCIT cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	upregulated	31802647
3986	Human	hsa-miR-199a	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	testicular germ cell tumors (TGCTs)	NTERA2 cells; NCCIT cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	miR-199a was decreased in TGCTs but was increased by PG in a dose-dependent manner.	31802647
3987	Human	hsa-miR-199a*	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
3988	Human	hsa-miR-199a*	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
3989	Human	hsa-miR-199a2	miRNA	placenta growth factor (PlGF)	hypertension	endothelial cells	PlGF treatment	downregulated	25389292
3990	Human	hsa-miR-199a-3p	miRNA	p53	acute kidney injury (AKI)	HK-2 human renal tubular epithelial cells	p53 deficiency treatment	downregulated	31148231
3991	Human	hsa-miR-199a-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human epithelial cell line A549 and the human macrophage cell line U937	?lipopolysaccharide (LPS) treatment	downregulated	31754335
3992	Human	hsa-miR-199a-3p	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 12¡ã HDT bed rest experiment	downregulated	28261104
3993	Human	hsa-miR-199a-3p	miRNA	CL 316243 disodium salt	brown adipocyte differentiation	human brown adipocyte	CL 316243 disodium salt treatment	downregulated	29753771
3994	Human	hsa-miR-199a-3p	miRNA	forskolin (FSK)	brown adipocyte differentiation	human brown adipocyte	forskolin (FSK) treatment	downregulated	29753771
3995	Human	hsa-miR-199a-3p	miRNA	H2O2	brown adipocyte differentiation	human brown adipocyte	H2O2 treatment	upregulated	29753771
3996	Human	hsa-miR-199a-3p	miRNA	norepinephrine (NE)	brown adipocyte differentiation	human brown adipocyte	norepinephrine treatment	downregulated	29753771
3997	Human	hsa-miR-199a-3p	miRNA	lipopolysaccharide (LPS)	cervical remodeling	ect1/e6e7 cells; end1/e6e7 cells	lipopolysaccharide (LPS) treatment	downregulated	32468045
3998	Human	hsa-miR-199a-3p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
3999	Human	hsa-miR-199a-3p	miRNA	bone morphogenetic protein 2 (BMP2)	glioblastoma multiforme (GBM)	Glioblastoma stem-like cells (GSCs) cell U87S	bone morphogenetic protein 2 (BMP2) treatment	upregulated	32884997
4000	Human	hsa-miR-199a-3p	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	Hepatic stem-like epithelial cells (LE/6)	hepatitis B virus X protein (HBx) treatment	upregulated	31740785
4001	Human	hsa-miR-199a-3p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	SNU-182 cells; HUH7 cells	hypoxia treatment	downregulated	32670881
4002	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â1	hepatocellular carcinoma (HCC)	Hepatic stem-like epithelial cells (LE/6)	TGF-¦Â1 treatment	upregulated	31740785
4003	Human	hsa-miR-199a-3p	miRNA	dapagliflozin	hypertensive patients with type 2 diabetes	plasma	dapagliflozin treatment	downregulated	31162549
4004	Human	hsa-miR-199a-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
4005	Human	hsa-miR-199a-3p	miRNA	dextran-capped nanosized europium(III) hydroxides [Eu(OH)3] nanoclusters (NCs)	ischemic heart/limb diseases and tissue regeneration	human umbilical vein endothelial cells (HUVECs)	dextran-capped nanosized europium(III) hydroxides [Eu(OH)3] nanoclusters (NCs) treatment	upregulated	30148600
4006	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
4007	Human	hsa-miR-199a-3p	miRNA	gambogic acid (GA)	melanoma	A375 cells	gambogic acid (GA) treatment	upregulated	29959879
4008	Human	hsa-miR-199a-3p	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	Hepa1-6 cells	oleic acid treatment	downregulated	28469795
4009	Human	hsa-miR-199a-3p	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Hepa1-6 cells	palmitic acid (PA) treatment	downregulated	28469795
4010	Human	hsa-miR-199a-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	33494069
4011	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â and EGF	pterygium	human conjunctival epithelial cells (HCEs)	TGF-¦Â and EGF treatment	TGF-¦Â and EGF induce EMT of HCEs through miR-199a-3p/5p-DUSP5/MAP3K11 axes	32867783
4012	Human	hsa-miR-199a-3p	miRNA	high glucose (HG)	renal tubular epithelial cells (RTEC) injury	HK-2 cells	high glucose (HG) treatment	miR-199a-3p expression was time-dependently decreased in the HG-induced cell damage model.	33125105
4013	Human	hsa-miR-199a-3p	miRNA	Bt2cAMP	type II pneumocyte differentiation	cultured human fetal lung (HFL) epithelial cells	Bt2cAMP treatment	downregulated	29507184
4014	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â1	unilateral ureteral obstruction (UUO)	human kidney tubular epithelial cells (HK-2)	TGF-¦Â1 treatment	upregulated	28240316
4015	Human	hsa-miR-199a-5p	miRNA	human serum albumin (HSA)	diabetic nephropathy (DN)	extracellular vesicles from HSA-induced HK-2 cells	human serum albumin (HSA) treatment	upregulated	31208912
4016	Human	hsa-miR-199a-5p	miRNA	alpha-1 antitrypsin (AAT)	anti-inflammatory responses	monocytes of AAT deficient (ZZ) individuals	alpha-1 antitrypsin (AAT) treatment	downregulated	29062067
4017	Human	hsa-miR-199a-5p	miRNA	peroxisome proliferator activated receptor gamma (PPAR¦Ã)	aplastic anemia (AA)	bone marrow-derived mesenchymal stem cells (BM-MSCs)	PPAR gamma (PPAR¦Ã) treatment	upregulated	31400610
4018	Human	hsa-miR-199a-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	arsenite-induced carcinogenesis	arsenic-exposured lung epithelial cells (BEAS-2B and HLF1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31170415
4019	Human	hsa-miR-199a-5p	miRNA	arsenite	arsenite-induced carcinogenesis	lung epithelial cells (BEAS-2B and HLF1)	arsenic exposure	downregulated	31170415
4020	Human	hsa-miR-199a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32339345
4021	Human	hsa-miR-199a-5p	miRNA	hypoxia	cardiac dysfunction	serum	chronic hypoxia at high altitudes	"The level of miR-199a-5p was significantly higher in individuals with poor exercise capacity at 3,800 m, compared with those with good exercise capacity"	33633582
4022	Human	hsa-miR-199a-5p	miRNA	human cytomegalovirus (HCMV)	cell migration and tube formation	Human umbilical vein endothelial cells (HUVECs)	human cytomegalovirus infection	upregulated	23760629
4023	Human	hsa-miR-199a-5p	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	K562 cells	Imatinib (IM) treatment	downregulated	29890129
4024	Human	hsa-miR-199a-5p	miRNA	steroids	endometriosis	ovarian endometrial	steroid hormones treatment	upregulated	26819477
4025	Human	hsa-miR-199a-5p	miRNA	hypoxia	endoplasmic reticulum stress (ERS)	Human umbilical vein endothelial cells (HUVECs) and derived exosomes	hypoxia induce	upregulated	31634452
4026	Human	hsa-miR-199a-5p	miRNA	hypoxia/reoxygenation (H/R)	endoplasmic reticulum stress (ERS)	human umbilical vein endothelial cells (HUVEC)	hypoxia/re-oxygenation (H/R) treatment	H/R administration increased miR-199a-5p levels both in HUVECs and exosomes.	31634452
4027	Human	hsa-miR-199a-5p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells; SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
4028	Human	hsa-miR-199a-5p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
4029	Human	hsa-miR-199a-5p	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	?human HCC cell lines	cisplatin (DPP) treatment	downregulated	22713463
4030	Human	hsa-miR-199a-5p	miRNA	hypoxia	multiple myeloma (MM)	multiple myeloma (MM) cells	hypoxia treatment	downregulated	24839982
4031	Human	hsa-miR-199a-5p	miRNA	deoxycholic acid (DCA)	non-small cell lung cancer (NSCLC)	human primary colonic epithelial cells	The deoxycholic acid? treatment	downregulated	22903020
4032	Human	hsa-miR-199a-5p	miRNA	visfatin	osteoarthritis (OA)	human OA synovial fibroblasts (OASFs)	visfatin treatment	downregulated	29316707
4033	Human	hsa-miR-199a-5p	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cell lines PANC-1 and BxPC-3	Metformin treatment	dysregulated	28875433
4034	Human	hsa-miR-199a-5p	miRNA	high glucose (HG)	peritoneal dialysis (PD)	human peritoneal mesothelial cells (HPMCs)	high-glucose (HG)	upregulated	28428333
4035	Human	hsa-miR-199a-5p	miRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	LUCAT1 likely promotes HG-induced EMT through ZEB1 by sponging miR-199a-5p.	33426083
4036	Human	hsa-miR-199a-5p	miRNA	hypoxia	seizure	epileptic brain	hypoxia treatment	downregulated	25539181
4037	Human	hsa-miR-199a-5p	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
4038	Human	hsa-miR-199a-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
4039	Human	hsa-miR-199a-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
4040	Human	hsa-miR-199a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	"CircVMA21 and NRP1 were decreased, and miR-199a-5p was increased in LPS-induced THP-1 cells."	33647793
4041	Human	hsa-miR-199a-5p	miRNA	arsenite	arsenite-induced carcinogenesis	human lung epithelial BEAS-2B cells	arsenic exposure	upregulated	24413338
4042	Human	hsa-miR-199a-5p	miRNA	Bt2cAMP	type II pneumocyte differentiation	cultured human fetal lung (HFL) epithelial cells	Bt2cAMP treatment	downregulated	29507184
4043	Human	hsa-miR-199b	miRNA	lipopolysaccharide (LPS)	acute spinal cord injury (ASCI)	primary microglia	lipopolysaccharide (LPS) treatment	miR-199b was significantly decreased in microglia stimulated by LPS.	29631367
4044	Human	hsa-miR-199b	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	miR-199b was highly expressed in TGF-¦Â1-treated HK-2 cells	30125566
4045	Human	hsa-miR-199b	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
4046	Human	hsa-miR-199b	miRNA	trichloroethylene (TCE)	liver damage	human HL-7702 cells	Trichloroethylene (TCE) treatment	downregulated	31140026
4047	Human	hsa-miR-199b	miRNA	5-fluorouracil (5-Fu)	locally advanced rectal cancer (LARC)	SW480 cells	5-fluorouracil (5-FU) treatment	downregulated	32580513
4048	Human	hsa-miR-199b	miRNA	nitric oxide donors	nitrate tolerance	human umbilical vein endothelial cells	nitric oxide donors treatment	upregulated	29431644
4049	Human	hsa-miR-199b-5p	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	K562 cells	Imatinib (IM) treatment	downregulated	29890129
4050	Human	hsa-miR-199b-5p	miRNA	atrasentan	diabetic nephropathy (DN)	Human renal proximal tubular epithelial HK-2 cells	atractylon (Atr)?treatment	downregulated	29623952
4051	Human	hsa-miR-199b-5p	miRNA	tigecycline (TGC)	malignant glioma	U87 glioma cells	tigecycline treatment	upregulated	26823491
4052	Human	hsa-miR-199b-5p	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
4053	Human	hsa-miR-199b-5p	miRNA	lipopolysaccharide (LPS)	rejection after lung transplantation	THP-1 monocytes	lipopolysaccharide (LPS) treatment	downregulated	29779167
4054	Human	hsa-miR-199b-5p	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	downregulated	20460641
4055	Human	hsa-miR-19a	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver failure (ALF)	primary hepatocyte and hepatocytes line HL-7702	D-GalN and LPS treatment	upregulated	28586153
4056	Human	hsa-miR-19a	miRNA	phosphatase of regenerating liver-3 (PRL-3)	angiogenesis	colon cancer cells	Phosphatase of regenerating liver-3 (PRL-3) treatment	"overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3"	22677902
4057	Human	hsa-miR-19a	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	autophagy	primary human hepatocytes; HL-7702 cells	D-galactosamine (D-GalN) and lipopolysaccharide (LPS) treatment	upregulated	28586153
4058	Human	hsa-miR-19a	miRNA	arsenic trioxide (ATO)	bladder cancer	T24 human bladder carcinoma cells	arsenic trioxide?treatment	downregulated	20857258
4059	Human	hsa-miR-19a	miRNA	bisphenol A (BPA)	breast cancer	MCF-7 human breast cancer cells	bisphenol A (BPA) treatment	upregulated	24831732
4060	Human	hsa-miR-19a	miRNA	butyl benzyl phthalate (BBP)	breast cancer	MCF-7 cells; MDA-MB-231 cells	Butyl benzyl phthalate (BBP) treatment	BBP significantly induced the expression of miR-19a.	29864457
4061	Human	hsa-miR-19a	miRNA	cold atmospheric plasma (CAP)	breast cancer	MCF-7 breast cancer cell	Cold atmospheric plasma (CAP) treatment	downregulated	27445062
4062	Human	hsa-miR-19a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	downregulated	29189128
4063	Human	hsa-miR-19a	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
4064	Human	hsa-miR-19a	miRNA	hypoxia	cell proliferation and migration	human pulmonary arterial smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	31682848
4065	Human	hsa-miR-19a	miRNA	IL-6	chronic lymphocytic leukemia (CLL)	chronic lymphocytic leukemia (CLL) cells	IL-6 treatment	upregulated	26041742
4066	Human	hsa-miR-19a	miRNA	hepatitis C virus (HCV)	cognitive impairment	monocyte-derived exosome	hepatitis C virus (HCV) infection	upregulated	32157304
4067	Human	hsa-miR-19a	miRNA	human immunodeficiency virus (HIV)-1	cognitive impairment	monocyte-derived exosome	human immunodeficiency virus (HIV)-1 infectiom	upregulated	32157304
4068	Human	hsa-miR-19a	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HT29 cells	Oxaliplatin treatment	miR-19a was significantly increased in SW480/R and HT29/R compared to their parental SW480 and HT29	32209726
4069	Human	hsa-miR-19a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	colorectal cancer (CRC) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26302825
4070	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	apoptosis	HUVECs and EAhy926 cells	lipopolysaccharide (LPS) treatment	downregulated	25982447
4071	Human	hsa-miR-19a	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell	Deacetylase inhibitors (DACi)treatment	downregulated	24375802
4072	Human	hsa-miR-19a	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell lines	Deacetylase inhibitors (DACi) treatment	downregulated	24375802
4073	Human	hsa-miR-19a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
4074	Human	hsa-miR-19a	miRNA	pterostilbene	hepatocellular carcinoma (HCC)	SMMC-7721 HCC cells	Pterostilbene (Pter) treatment	miR-19a expression was decreased by Pter treatment in a dose-depen-dent manner in SMMC-7721 cells	29393488
4075	Human	hsa-miR-19a	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
4076	Human	hsa-miR-19a	miRNA	berberine (BBR)	multiple myeloma (MM)	RPMI-8266 cells; U266 cells	berberine (BBR) treatment	Berberine downregulated miR-19a expression in multiple myeloma (MM) cells.	29687521
4077	Human	hsa-miR-19a	miRNA	aluminum maltolate (Al-malt)	neurodegenerative pathogenesis	neuroblastoma SH-SY5Y cells	aluminum maltolate (Al-malt) treatment	downregulated	26836165
4078	Human	hsa-miR-19a	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"lung tissues, A549 and H460 cells"	?cisplatin treatment	lncRNA-AC0788833/miR-19a/PTEN/AKT pathway contributed to the development of chemoresistance against cisplatin	31111480
4079	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human primary chondrocytes	lipopolysaccharide (LPS) treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
4080	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human primary chondrocytes	lipopolysaccharide (LPS)? treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
4081	Human	hsa-miR-19a	miRNA	Rh-endostatin	pancreatic cancer (PC)	ASPC-1 cells	Rh-endostatin treatment	downregulated	26041879
4082	Human	hsa-miR-19a	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity	HTR-8/SVneo cells	Perfluorooctane sulfonic acid (PFOS) treatment	downregulated	32738709
4083	Human	hsa-miR-19a	miRNA	fractional CO(2) laser	prostate cancer	types I and III procollagen	treatment with a fractional CO(2) laser	miR-18a and miR-19a were dramatically upregulated	22907286
4084	Human	hsa-miR-19a	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
4085	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	sepsis	human bronchial epithelial cells (HBEpCs)	lipopolysaccharide (LPS) treatment	"THRIL is upregulated in sepsis and may sponge miR-19a to upregulate TNF-¦Á, thereby promoting lung cell apoptosis."	32944003
4086	Human	hsa-miR-19a	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	human colon tissue with UC and DSS-treated mice colitis tissues	dextran sodium sulfate (DSS) treatment	downregulated	23795660
4087	Human	hsa-miR-19a-3p	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
4088	Human	hsa-miR-19a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	H19 was upregulated whereas miR-19a-3p was downregulated in I/R tissues and OGD/R induced cells	32335212
4089	Human	hsa-miR-19a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-19a-3p was significantly upregulated in rat I/R brain tissues and OGD/R induced SH-SY5Y cells.	32312329
4090	Human	hsa-miR-19a-3p	miRNA	baicalin (BAI)	cervical cancer (CC)	Human CC cell lines (HeLa and SiHa)	baicalin (BAI) treatment	downregulated	33603395
4091	Human	hsa-miR-19a-3p	miRNA	TGF-¦Â1	fibrogenesis	human cardiac fibroblasts	TGF-¦Â1? treatment	downregulated	27098600
4092	Human	hsa-miR-19a-3p	miRNA	shock wave therapy (SWT)	ischemic heart disease (IHD)	human umbilical vein endothelial cells (HUVECs)	shock wave therapy (SWT) treatment	miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy	31410448
4093	Human	hsa-miR-19b	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
4094	Human	hsa-miR-19b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	Endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	26459935
4095	Human	hsa-miR-19b	miRNA	bisphenol A (BPA)	breast cancer	MCF-7 human breast cancer cells	bisphenol A (BPA) treatment	upregulated	24831732
4096	Human	hsa-miR-19b	miRNA	butyl benzyl phthalate (BBP)	breast cancer	MCF-7 cells; MDA-MB-231 cells	Butyl benzyl phthalate (BBP) treatment	BBP significantly induced the expression of miR-19b.	29864457
4097	Human	hsa-miR-19b	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	downregulated	29189128
4098	Human	hsa-miR-19b	miRNA	glucagon-like peptide-1 (GLP-1)	cholesterol-induced lipotoxicity	HepG2 cells	Glucagon-like peptide-1 (GLP-1) treatment	downregulated	30308521
4099	Human	hsa-miR-19b	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	upregulated	31226416
4100	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	downregulated	31226416
4101	Human	hsa-miR-19b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	upregulated	32519748
4102	Human	hsa-miR-19b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression.	33022863
4103	Human	hsa-miR-19b	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	human LO2 cells	?acetaminophen (APAP) treatment	downregulated	31077331
4104	Human	hsa-miR-19b	miRNA	mechanical stretch	epithelial-mesenchymal transition (EMT)	primary human alveolar epithelial type II (AEII) cells	mechanical stretch	upregulated	27508324
4105	Human	hsa-miR-19b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
4106	Human	hsa-miR-19b	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
4107	Human	hsa-miR-19b	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells of LTNPs	Human immunodeficiency virus (HIV) infection	The levels of microRNA-19b (miR-19b) were found to be significantly increased in peripheral blood mononuclear cells of LTNPs with lower rather than higher viral load.	30687333
4108	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	upregulated	28213977
4109	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	upregulated	28213977
4110	Human	hsa-miR-19b	miRNA	alcohol	liver damage	LX2 cells	alcohol exposure	downregulated	27291156
4111	Human	hsa-miR-19b	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	downregulated	25552929
4112	Human	hsa-miR-19b	miRNA	AZD8055	neuroblastoma (NB)	neuroblastoma cells	AZD8055 treatment	downregulated	27492819
4113	Human	hsa-miR-19b	miRNA	rapamycin	neuroblastoma (NB)	neuroblastoma cells	rapamycin treatment	upregulated	27492819
4114	Human	hsa-miR-19b	miRNA	aluminum maltolate (Al-malt)	neurodegenerative pathogenesis	neuroblastoma SH-SY5Y cells	aluminum maltolate (Al-malt) treatment	downregulated	26836165
4115	Human	hsa-miR-19b	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity	HTR-8/SVneo cells	Perfluorooctane sulfonic acid (PFOS) treatment	downregulated	32738709
4116	Human	hsa-miR-19b	miRNA	herbal formula HQT	rheumatoid arthritis (RA)	fibroblast-like synoviocytes	herbal formula HQT treatment	downregulated	32696503
4117	Human	hsa-mir-19b	miRNA	Tongbi formula (HQT)	rheumatoid arthritis (RA)	RA-derived human fibroblast-like synoviocytes (HFLS-RA)	Tongbi formula (HQT) treatment	downregulated	32696503
4118	Human	hsa-miR-19b	miRNA	H2O2	skin wound healing	Human adipose-derived mesenchymal stem cells (ADMSCs)	H2O2 treatment	"Exosomal miR-19b derived from ADMSCs regulates the TGF-¦Â pathway by targeting CCL1, thereby promoting the healing of skin wounds."	33364805
4119	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	Caco2 cells	lipopolysaccharide (LPS) treatment	"LPS significantly induced Caco2 cell inflammatory injury, downregulated miR-19b expression."	30178853
4120	Human	hsa-miR-19b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	"Our results showed that lncRNA H19 and SIRT1 were reduced, while miR-19b was increased in ARPE-19 cells with HG condition."	33022863
4121	Human	hsa-miR-19b1	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell	Deacetylase inhibitors (DACi)treatment	downregulated	24375802
4122	Human	hsa-miR-19b-1	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
4123	Human	hsa-miR-19b1	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell lines	Deacetylase inhibitors (DACi) treatment	downregulated	24375802
4124	Human	hsa-miR-19b-1-5p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
4125	Human	hsa-miR-19b-3p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) treatment	The expression levels of miR-16-5p and miR-19b-3p were reduced but BACE1 protein expression was enhanced in SH-SY5Y cells after treatment of amyloid ¦Â.	31876684
4126	Human	hsa-miR-19b-3p	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
4127	Human	hsa-miR-19b-3p	miRNA	hypoxia	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	31933110
4128	Human	hsa-miR-19b-3p	miRNA	TGF-¦Â1	fibrogenesis	human cardiac fibroblasts	TGF-¦Â1? treatment	downregulated	27098600
4129	Human	hsa-miR-19b-3p	miRNA	matrine	melanoma	A375 cells; SK-MEL-2 melanoma cells	Matrine treatment	downregulated	29845233
4130	Human	hsa-miR-19b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	miR-19b-3p prevent osteoarthritis progression by targeting EZH2.	32765678
4131	Human	hsa-miR-2	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	colorectal cancer (CRC)	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28100780
4132	Human	hsa-miR-20	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
4133	Human	hsa-miR-200	miRNA	busulfan	anti-osteosarcoma effect	human osteosarcoma U2OS and MG63 cells lines	busulfan treatment	upregulated	24815002
4134	Human	hsa-miR-200	miRNA	retinoic acid (RA)	breast cancer	MDA-MB-231 breast cancer cells	retinoic acid treatment	upregulated	23904188
4135	Human	hsa-miR-200	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells	Tamoxifen treatment	upregulated	29738694
4136	Human	hsa-miR-200	miRNA	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	colorectal cancer (CRC)	HCT116 cells£»HT29 cells£»SW480 cells£» SW620 cells	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	upregulated	22983985
4137	Human	hsa-miR-200	miRNA	catalpol	colorectal cancer (CRC)	human HCT116 colorectal cancer cells	catalpol treatment	upregulated	28927141
4138	Human	hsa-miR-200	miRNA	NPV-LDE-225 (Erismodegib)	human immunodeficiency virus (HIV)-1 infection	Glioblastoma initiating cells (GICs)	NPV-LDE-225 (Erismodegib) treatment	downregulated	23482671
4139	Human	hsa-miR-200	miRNA	"3,3'-diindolylmethane (DIM)"	human cytomegalovirus (HCMV) infection	Breast cancer cell lines SKBR3£» MDA-MB-468 cells	"?3, 3'-diindolylmethane (DIM) treatment"	upregulated	23372748
4140	Human	hsa-miR-200	miRNA	high fat diet (HFD)	inflammation	plasma	high fat diet (HFD) feed	upregulated	30885503
4141	Human	hsa-miR-200	miRNA	triacetyl resveratrol (TCRV)	pancreatic cancer (PC)	human pancreatic cancer AsPC-1 and PANC-1 cells	triacetyl resveratrol (TCRV) treatment	upregulated	30720134
4142	Human	hsa-miR-200	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
4143	Human	hsa-miR-200	miRNA	tamoxifen (TAM)	epithelial-mesenchymal transition (EMT)	Endometrial epithelial cancer ECC-1 cells	Although tamoxifen treatment	TAM can repress the miR-200 family and induce EMT via the upregulated of c-Myc in endometrial cancer cells	23295740
4144	Human	hsa-miR-200-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	miR-200-3p suppresses cell proliferation and reduces apoptosis in diabetic retinopathy via blocking the TGF-¦Â2/Smad pathway	33150936
4145	Human	hsa-miR-200a	miRNA	Pien Tze Huang (PZH)	anti-cancer therapy	human colorectal carcinoma HCT-8 cells	PZH treatment	upregulated	25422078
4146	Human	hsa-miR-200a	miRNA	curcumin (Cur)	breast cancer	MCF-10F cells	curcumin (Cur) treatment	upregulated	31894298
4147	Human	hsa-miR-200a	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4148	Human	hsa-miR-200a	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 breast cancer cells	Glabridin treatment	upregulated	24754877
4149	Human	hsa-miR-200a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
4150	Human	hsa-miR-200a	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
4151	Human	hsa-miR-200a	miRNA	estrogen receptor ¦Â	colorectal cancer (CRC)	Cell lines (SW480;HT29 ;SW620)	Estrogen receptor ¦Â treatment	the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated	23436804
4152	Human	hsa-miR-200a	miRNA	astaxanthin	colorectal cancer (CRC)	The human colon cancer cell HCT116	astaxanthin (ATX) treatment	upregulated	31263239
4153	Human	hsa-miR-200a	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human colorectal carcinoma HCT-8 cells	Pien Tze Huang (PZH) treatment	upregulated	25422078
4154	Human	hsa-miR-200a	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 116 cells	RM (Root methanol) treatment	upregulated	32691634
4155	Human	hsa-miR-200a	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HCT-8 cells	Ursolic acid (UA) treatment	upregulated	31452805
4156	Human	hsa-miR-200a	miRNA	LEFTY2	endometrial cancer (EC)	Ishikawa cells	LEFTY2 treatment	upregulated	27497669
4157	Human	hsa-miR-200a	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
4158	Human	hsa-miR-200a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-200a towards the control level.	32387379
4159	Human	hsa-miR-200a	miRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	SW480 cells; HCT116 cells	metformin treatment	upregulated	30017802
4160	Human	hsa-miR-200a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	HK-2 cells	treat with TGF ¦Â1 treatment	downregulated	28817830
4161	Human	hsa-miR-200a	miRNA	dexamethasone (DEX)	femoral head necrosis (FHN)	human osteoblasts	dexamethasone (DEX) treatment	downregulated	29285219
4162	Human	hsa-miR-200a	miRNA	allopurinol	fructose-induced hepatic inflammation	fructose-induced rats HepG2 cells	allopurinol treatemnt	upregulated	30248460
4163	Human	hsa-miR-200a	miRNA	curcumin (Cur)	fructose-induced hepatic inflammation	fructose-induced rats HepG2 cells	curcumin treatment	upregulated	30248460
4164	Human	hsa-miR-200a	miRNA	fructose	fructose-induced hepatic inflammation	HepG2 cells	fructose treatment	downregulated	30248460
4165	Human	hsa-miR-200a	miRNA	toosendanin (TSN)	gastric cancer (GC)	SGC-7901 cells	TSN treatment	upregulated	29048657
4166	Human	hsa-miR-200a	miRNA	TGF-¦Â	glaucoma filtration surgery (GFS)	primary human Tenon's capsule fibroblasts (HTFs)	TGF-¦Â treatment	H19 exerted its effects by interacting with miR-200a in TGF-¦Â-treated HTFs	31877306
4167	Human	hsa-miR-200a	miRNA	radiotherapy	head and neck squamous cell carcinoma (HNSCC)	neck squamous cell carcinoma patients saliva samples	radiotherapy treatment	upregulated in saliva samples	28677748
4168	Human	hsa-miR-200a	miRNA	TGF-¦Â1	liver fibrosis	Hepatic stellate cell (HSC)	TGF-¦Â1 treatment	downregulated	24242045
4169	Human	hsa-miR-200a	miRNA	HepG2-CORE cells conditioned media (CM)	hepatitis C virus (HCV)-related liver fibrosis	LX-2 cells	treated with HepG2-CORE CM	downregulated	28302418
4170	Human	hsa-miR-200a	miRNA	histone deacetylase 4 (HDAC4)	hepatocellular carcinoma (HCC)	Human HCC Tissues	histone deacetylase 4 (HDAC4)? treatment	downregulated	21837748
4171	Human	hsa-miR-200a	miRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia induce	"LncRNA MALAT1 was involved in proliferation, migration, invasion, and apoptosis by interacting with miR-200a in hypoxic Hep3B cells, revealing a new mechanism of MALAT1 involved in hypoxic HCC progression."	31347327
4172	Human	hsa-miR-200a	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
4173	Human	hsa-miR-200a	miRNA	angiotensin II (Ang II)	hypertension and diabetes	AB8/13 cells	angiotensin II (Ang II) treatment	upregulated	32887498
4174	Human	hsa-miR-200a	miRNA	high glucose (HG)	hypertension and diabetes	AB8/13 cells	high glucose (HG) treatment	upregulated	32887498
4175	Human	hsa-miR-200a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
4176	Human	hsa-miR-200a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	LX-2 cells	carbon tetrachloride (CCl4) treatment	miR-200a was significantly reduced in liver tissues of a carbon tetrachloride (CCl4)- activated LX2 cells.	32319630
4177	Human	hsa-miR-200a	miRNA	gefitinib	lung cancer	A549 cells	gefitinib treatment	"MALAT1 promoted the proliferation and gefitinib resistance of lung cancer cells by sponging miR-200a, which regulates expression of ZEB1 in the A549 cells."	31133357
4178	Human	hsa-miR-200a	miRNA	arsenite	melanoma	human keratinocyte HaCaT cell line	arsenic (As) exposure	upregulated	27054085
4179	Human	hsa-miR-200a	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
4180	Human	hsa-miR-200a	miRNA	beraprost sodium	metabolic disorders	C57BL/7JNju mice	beraprost sodium	downregulated	28732575
4181	Human	hsa-miR-200a	miRNA	beraprost sodium	metabolic disorders	human-derived HepG3 cells	beraprost sodium	downregulated	28732575
4182	Human	hsa-miR-200a	miRNA	thymosin ¦Â4 (T¦Â4)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced cardiac microvascular endothelial cells (CMECs)	Thymosin ¦Â-4 (T¦Â4) treatment	upregulated	31265170
4183	Human	hsa-miR-200a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	neurodegenerative diseases	SH5Y-SY cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	29936262
4184	Human	hsa-miR-200a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
4185	Human	hsa-miR-200a	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
4186	Human	hsa-miR-200a	miRNA	high fructose	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high fructose treatment	downregulated	30014902
4187	Human	hsa-miR-200a	miRNA	polydatin (PD)	nonalcoholic fatty liver disease (NAFLD)	high fructose-induced HepG2 cells	"Polydatin (3,4',5-trihydroxy-stilbene-3-¦Â-D-glucoside) treatment"	upregulated	30014902
4188	Human	hsa-miR-200a	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-16B cells	human papillomaviruses (HPVs) 16 treatment	downregulated	31911577
4189	Human	hsa-miR-200a	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
4190	Human	hsa-miR-200a	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
4191	Human	hsa-miR-200a	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
4192	Human	hsa-miR-200a	miRNA	IL-9	pancreatic cancer (PC)	PANC-1;AsPC-1 cells line	IL-9 treatment	downregulated	28349057
4193	Human	hsa-miR-200a	miRNA	TGF-¦Â1	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	transforming growth factor (TGF)-¦Â1 treatment	downregulated	29357421
4194	Human	hsa-miR-200a	miRNA	docetaxel (DTX)	prostate cancer	CRP patients	docetaxel (DTX) treatment	"miR-200b levels, miR-20a levels, were independent predictors of overall survival"	24714754
4195	Human	hsa-miR-200a	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
4196	Human	hsa-miR-200a	miRNA	arsenite	urothelial carcinoma	HUC1 cells	arsenic (As) exposure	downregulated	25586904
4197	Human	hsa-miR-200a-3p	miRNA	hypoxia/reoxygenation (H/R)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (H/R) treatment	upregulated	32572929
4198	Human	hsa-miR-200a-3p	miRNA	enterotoxigenic bacteroides fragilis (ETBF)	colorectal cancer (CRC)	HCT-116 and DLD-1 cells	Enterotoxigenic Bacteroides fragilis (ETBF) infection	downregulated	31515468
4199	Human	hsa-miR-200a-3p	miRNA	hepatitis B virus X protein (HBx)	HBV-associated tumorigenesis	LO2 cells	hepatitis B virus X protein (HBx) treatment	HBX downregulated miR-200a-3p mRNA expression	29231260
4200	Human	hsa-miR-200a-3p	miRNA	metformin (Met)	HBV-associated tumorigenesis	LO2 cells	metformin treatment	Metformin enhanced miR-200a-3p mRNA expression	29231260
4201	Human	hsa-miR-200a-3p	miRNA	free fatty acids (FFA)	hepatic steatosis	LO2 cells	free fatty acid (FFA) treatment	upregulated	31191607
4202	Human	hsa-miR-200a-3p	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	upregulated	30100735
4203	Human	hsa-miR-200a-3p	miRNA	TGF-¦Â	lung cancer	A549	Transforming growth factor ¦Â (TGF¦Â) treatment	LINC00273 promoted TGF¦Â-induced lung cancer EMT through miR-200a-3p/ZEB1 feedback loop	32017082
4204	Human	hsa-miR-200a-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced brain injury (SIBI)	human brain microvascular endothelial cells	lipopolysaccharide (LPS) treatment	overexpression of miRNA-200a-3p promoted inflammation in sepsis-induced brain injury through reactive oxygen species-induced NLRP3.	31485604
4205	Human	hsa-miR-200a-c	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
4206	Human	hsa-miR-200b	miRNA	esomeprazole	adeno and squamous-cell-carcinoma	human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines	esomeprazole treatment	upregulated	25175076
4207	Human	hsa-miR-200b	miRNA	Pien Tze Huang (PZH)	anti-cancer therapy	human colorectal carcinoma HCT-8 cells	PZH treatment	upregulated	25422078
4208	Human	hsa-miR-200b	miRNA	TGF-¦Â1	bladder cancer	HTB9 and T24 bladder cancer cells	TGF-¦Â1 treatment	downregulated	25017509
4209	Human	hsa-miR-200b	miRNA	artemisinin (ART)	breast cancer	MCF-7/DDP cells	artemisinin treatment	upregulated	28361857
4210	Human	hsa-miR-200b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4211	Human	hsa-miR-200b	miRNA	epstein-barr virus (EBV)	tumorigenesis	EBV-positive B-lymphocytic cell lines;Epithelial gastric carcinoma AGSB95.8 cells;MCF-7 cells (ATCC)	Epstein-Barr Virus (EBV) infection	downregulated	20668090
4212	Human	hsa-miR-200b	miRNA	suberoylanilide hydroxamic acid (SAHA)	tumorigenesis	MEG-01 cells; HEK-293 cells	suberoylanilide hydroxamic acid (SAHA) treatment	downregulated	23543665
4213	Human	hsa-miR-200b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
4214	Human	hsa-miR-200b	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
4215	Human	hsa-miR-200b	miRNA	5-fluorouracil (5-Fu)	tumorigenesis	human colon cancer cells	5-fluorouracil (5-FU) treatment	downregulated	17702597
4216	Human	hsa-miR-200b	miRNA	carbon tetrachloride (CCl4)	chondrosarcoma	human chondrosarcoma cell line (JJ012)	CCl4 treatment	downregulated	25301739
4217	Human	hsa-miR-200b	miRNA	hypoxia	chronic hypoxia	human endothelial cells	binder CO2/O2 incubator treatment	upregulated	25550463
4218	Human	hsa-miR-200b	miRNA	bone morphogenetic protein 2 (BMP2)	chronic pancreatitis (CP)	human primary pancreatic stellate cells; human primary pancreatic fibroblast (hPFBs)	bone morphogenetic protein 2 (BMP2) treatment	upregulated	29303912
4219	Human	hsa-miR-200b	miRNA	TGF-¦Â	chronic pancreatitis (CP)	human primary pancreatic fibroblast (hPFBs)	TGF-¦Â treatment	downregulated	29303912
4220	Human	hsa-miR-200b	miRNA	estrogen receptor ¦Â	colorectal cancer (CRC)	Cell lines (SW480;HT29 ;SW620)	Estrogen receptor ¦Â treatment	the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated	23436804
4221	Human	hsa-miR-200b	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human colorectal carcinoma HCT-8 cells	Pien Tze Huang (PZH) treatment	upregulated	25422078
4222	Human	hsa-miR-200b	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 117 cells	RM (Root methanol) treatment	upregulated	32691634
4223	Human	hsa-miR-200b	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HCT-8 cells	Ursolic acid (UA) treatment	upregulated	31452805
4224	Human	hsa-miR-200b	miRNA	cyclosporine A (CsA)	cyclosporine A (CsA)-induced gingival overgrowth	normal human gingival fibroblasts (HGFs)	cyclosporine A (CsA) treatment	downregulated	30449457
4225	Human	hsa-miR-200b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	We found that SNHG4 was downregulated in DR.	33822671
4226	Human	hsa-miR-200b	miRNA	hyperglycemia	diabetic wound angiogenesis	human microvascular endothelial cells (HMECs)	HG	downregulated	29037594
4227	Human	hsa-miR-200b	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
4228	Human	hsa-miR-200b	miRNA	glucose and TGF¦Â1	epithelial-mesenchymal transition (EMT)	human retinal microvascular endothelial cells	25 mM glucose with TGF¦Â1 treatment	upregulated	25335984
4229	Human	hsa-miR-200b	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
4230	Human	hsa-miR-200b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-200b towards the control level.	32387379
4231	Human	hsa-miR-200b	miRNA	erythropoietin (EPO)	epithelial-mesenchymal transition (EMT)	HK-2 cells	EPO treatment	upregulated	28535509
4232	Human	hsa-miR-200b	miRNA	TGF-¦Â1	fibrosis	human Tenon's fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	30512998
4233	Human	hsa-miR-200b	miRNA	TGF-¦Â1	fibrosis	human Tenon's fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	30512998
4234	Human	hsa-miR-200b	miRNA	diallyl disulfide (DADS)	gastric cancer (GC)	Five gastric cancer cell lines (MGC-803; BGC-823; MKN-28; SGC-7901; HGC-27; AGS)	diallyl disulfide treatment	upregulated	23851184
4235	Human	hsa-miR-200b	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	human gastric carcinoma (AGS) cells	infect with HP	downregulated	28056089
4236	Human	hsa-miR-200b	miRNA	TGF-¦Â1	glaucoma	human Tenon's capsule fibroblasts	were various doses of TGF-¦Â1 for 24 hours treatment	upregulated	24667864
4237	Human	hsa-miR-200b	miRNA	TGF-¦Â1	hepatic steatosis	intestinal epithelial cells (IECs)	TGF-¦Â1 treatment	downregulated	23492772
4238	Human	hsa-miR-200b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HCC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26919246
4239	Human	hsa-miR-200b	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	downregulated	26500110
4240	Human	hsa-miR-200b	miRNA	hypoxia	hypoxic-related diseases	primary human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	miR-200b and miR-429 are upregulated in response to hypoxia.	29737439
4241	Human	hsa-miR-200b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Caco-2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	27979826
4242	Human	hsa-miR-200b	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	upregulated	28347920
4243	Human	hsa-miR-200b	miRNA	tobacco carcinogens	lung cancer	HBECs	tobacco carcinogens treatment	"EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205"	21363915
4244	Human	hsa-miR-200b	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
4245	Human	hsa-miR-200b	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
4246	Human	hsa-miR-200b	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
4247	Human	hsa-miR-200b	miRNA	arecoline	oral submucous fibrosis (OSF)	human buccal mucosal fibroblasts (BMFs)	arecoline treatment	downregulated	29893466
4248	Human	hsa-miR-200b	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-17B cells	human papillomaviruses (HPVs) 17 treatment	downregulated	31911577
4249	Human	hsa-miR-200b	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human chondrocytes	lipopolysaccharide (LPS) treatment	"The expression level of miR-200b was downregulated, and that of FUT4 was upregulated in OA cartilage tissues and LPS-treated normal chondrocytes compared with normal cartilage tissues and chondrocytes."	33692838
4250	Human	hsa-miR-200b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
4251	Human	hsa-miR-200b	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
4252	Human	hsa-miR-200b	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	"Capan-1, Capan-2, Panc-1, MIAPaCa-2, BxPC-3 and PL45 cells"	Gemcitabine (GEM) treatment	the expression of miR-200b correlated positively with chemosensitivity.	30628651
4253	Human	hsa-miR-200b	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
4254	Human	hsa-miR-200b	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
4255	Human	hsa-miR-200b	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	PDAC cells	gemcitabine treatment	downregulated	28849150
4256	Human	hsa-miR-200b	miRNA	hypoxia	proangiogenic function	human endothelial cells	a CO2/O2 incubator for hypoxia research (Tri-gas Binder CB150)	upregulated	29042072
4257	Human	hsa-miR-200b	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
4258	Human	hsa-miR-200b	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
4259	Human	hsa-miR-200b	miRNA	docetaxel (DTX)	prostate cancer	CRP patients	docetaxel (DTX) treatment	"miR-200b levels, miR-20a levels, were independent predictors of overall survival"	24714754
4260	Human	hsa-miR-200b	miRNA	lactoferrin (LF)	prostate cancer	DU-145 cells	lactoferrin (LF) treatment	upregulated	30285009
4261	Human	hsa-miR-200b	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	human retinal endothelial cells (HRECs)	high glucose	downregulated	28122089
4262	Human	hsa-miR-200b	miRNA	arsenite	urothelial carcinoma	HUC1 cells	arsenic (As) exposure	downregulated	25586904
4263	Human	hsa-miR-200b	miRNA	hypoxia	inflammatory bowel disease (IBD)	human microvascular endothelial cells (HMECs)	hypoxia? treatment	downregulated	21081489
4264	Human	hsa-miR-200b-3p	miRNA	copper (Cu)	Alzheimer's disease (AD)	human primary microvascular endothelial cells (MVECs)	chronic exposure to copper	"In human primary microvascular endothelial cells (MVECs), microRNA-200b-3p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure."	30923833
4265	Human	hsa-miR-200b-3p	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	Immortalized primary bronchial epithelial cell line (BEAS-2B cells)	transforming growth factor-¦Â (TGF-¦Â) treatment	downregulated	31283671
4266	Human	hsa-miR-200b-3p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
4267	Human	hsa-miR-200b-3p	miRNA	xiaoai Jiedu recipe (XJR)	hepatocellular carcinoma (HCC)	HepG2 cells	Xiaoai Jiedu recipe (XJR) treatment	XJR could effectively inhibit HCC and might exert its antitumor effect through the miR-200b-3p/Notch1 axis	33173345
4268	Human	hsa-miR-200b-3p	miRNA	oridonin	pancreatic cancer (PC)	The BxPC-3 and PANC-1 human pancreatic cancer cell lines	Oridonin treatment	downregulated	27878247
4269	Human	hsa-miR-200b-3p	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells; KHOS cells; U2OS cells	doxorubicin treatment	miR-200b-3p expression was greatly downregulated in the chemo-resistant OS tissues.	30204936
4270	Human	hsa-miR-200b-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
4271	Human	hsa-miR-200b-3p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
4272	Human	hsa-miR-200b-3p	miRNA	¦Â-glycerophosphate (¦Â-GP)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	¦Â-glycerophosphate (¦Â-GP) treatment	upregulated	32818704
4273	Human	hsa-miR-200b-5p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	30197683
4274	Human	hsa-miR-200c	miRNA	H2O2	endothelial cell apoptosis and senescence	Human umbilical vein endothelial cells (HUVEC)	H2O2 treatment	upregulated	21527937
4275	Human	hsa-miR-200c	miRNA	Pien Tze Huang (PZH)	anti-cancer therapy	human colorectal carcinoma HCT-8 cells	PZH treatment	upregulated	25422078
4276	Human	hsa-miR-200c	miRNA	arsenic trioxide (ATO)	breast cancer	breast cancer cells	arsenic trioxide (As(2)O(3)) treatment	upregulated	24729530
4277	Human	hsa-miR-200c	miRNA	arsenic trioxide (ATO)	breast cancer	MDA-MB-231 cells	arsenic trioxide (As2O3) treatment	upregulated	24729530
4278	Human	hsa-miR-200c	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4279	Human	hsa-miR-200c	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 breast cancer cells	Glabridin treatment	upregulated	24754877
4280	Human	hsa-miR-200c	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
4281	Human	hsa-miR-200c	miRNA	SK228	breast cancer	MDA-MB-231 human breast cancer cell lines	SK228 treatment	upregulated	24967704
4282	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
4283	Human	hsa-miR-200c	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
4284	Human	hsa-miR-200c	miRNA	doxorubicin (DOX)	cardiotoxicity	human cardiac mesenchymal progenitor cells	DOXO	upregulated	28837147
4285	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	clear cell renal cell carcinoma (ccRCC)	ccRCC cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27123083
4286	Human	hsa-miR-200c	miRNA	Clostridium butyricum (C. butyricum)	colitis-associated colon cancer (CAC)	human intestinal cell line Vaco2-BBE	infect with C. butyricum	upregulated	28478805
4287	Human	hsa-miR-200c	miRNA	bicotine	colorectal cancer (CRC)	SW620 and HT-29 cells	nicotine treatment	downregulated	30076725
4288	Human	hsa-miR-200c	miRNA	nicotine	colorectal cancer (CRC)	CRC tissues and cell lines SW620 and HT-29	cigarette smoking exposure	downregulated	30076725
4289	Human	hsa-miR-200c	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human colorectal carcinoma HCT-8 cells	Pien Tze Huang (PZH) treatment	upregulated	25422078
4290	Human	hsa-miR-200c	miRNA	resveratrol	colorectal cancer (CRC)	NA-anti-miR-200c transfected HCT-116 cells	resveratrol (RS) treatment	upregulated	27918105
4291	Human	hsa-miR-200c	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 118 cells	RM (Root methanol) treatment	upregulated	32691634
4292	Human	hsa-miR-200c	miRNA	Short-chain fatty acid sodium butyrate (NaB)	colorectal cancer (CRC)	HCT116 and LOVO CRC cells	Short-chain fatty acid sodium butyrate (NaB) treatment	upregulated	29418071
4293	Human	hsa-miR-200c	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HCT-8 cells	Ursolic acid (UA) treatment	upregulated	31452805
4294	Human	hsa-miR-200c	miRNA	surgery and chemotherapy	colorectal cancer (CRC)	patients blood	surgery and chemotherapy for 3years treatment	upregulated	24310813
4295	Human	hsa-miR-200c	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
4296	Human	hsa-miR-200c	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
4297	Human	hsa-miR-200c	miRNA	antcin A (ATA)	epithelial-mesenchymal transition (EMT)	"Human breast cancer cell lines, MCF-7 and MDA-MB-231"	Antcin-A (ATA) treatment	upregulated	31185503
4298	Human	hsa-miR-200c	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
4299	Human	hsa-miR-200c	miRNA	insulin-like growth factor 1 (IGF-1)	epithelial-mesenchymal transition (EMT)	human gastric cell lines MGC803;SGC-7901	IGF-I treatment	downregulated	24885194
4300	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-200c towards the control level.	32387379
4301	Human	hsa-miR-200c	miRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	SW480 cells; HCT116 cells	metformin treatment	upregulated	30017802
4302	Human	hsa-miR-200c	miRNA	platinum-based chemotherapy	esophageal squamous cell carcinoma (ESCC)	Venous blood samples	platinum-based chemotherapy treatment	upregulated	24349623
4303	Human	hsa-miR-200c	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
4304	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human GC cell lines NCI-N87, SGC7901 ,AGS ,HGC27 and MGC803"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27498672
4305	Human	hsa-miR-200c	miRNA	decitabine	gastric cancer (GC)	SGC-7902 cells	decitabine treatment	upregulated	25502084
4306	Human	hsa-miR-200c	miRNA	decitabine	gastric cancer (GC)	SGC-7901 cells	the chemotherapeutic agent decitabine treatment	upregulated	25502084
4307	Human	hsa-miR-200c	miRNA	TGF-¦Â	gastric cancer (GC)	SGC-7902 cells	TGF-¦Â treatment	downregulated	25502084
4308	Human	hsa-miR-200c	miRNA	hepatocyte growth factor (HGF)	head and neck squamous cell carcinoma (HNSCC)	HNSCC; adjacent normal squamous epithelial tissues	Hepatocyte growth factor (HGF) treatment	downregulated	21899661
4309	Human	hsa-miR-200c	miRNA	lanthionine	lanthionine toxicity	EA.hy926 cell cultures	lanthionine treatment	upregulated	31071929
4310	Human	hsa-miR-200c	miRNA	hypoxia	lung cancer	"The human cell lines A549 (lung carcinoma), NCI-H460 (lung carcinoma)"	hypoxia induce	downregulated	31061665
4311	Human	hsa-miR-200c	miRNA	paclitaxel (PTX)	lung cancer	A549 cells	paclitaxel treatment	"miRNA-200c was significantly lower in A549/TAX cells, which are paclitaxel-resistant A549 cells"	29219949
4312	Human	hsa-miR-200c	miRNA	tobacco carcinogens	lung cancer	HBECs	tobacco carcinogens treatment	"EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205"	21363915
4313	Human	hsa-miR-200c	miRNA	silica	lung function decline	blood	silica treatment	downregulated	29280772
4314	Human	hsa-miR-200c	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
4315	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
4316	Human	hsa-miR-200c	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
4317	Human	hsa-miR-200c	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	erlotinib-sensitive PC9 cells	TGF¦Â treatment	dysregulated	28646226
4318	Human	hsa-miR-200c	miRNA	sulforaphane (SFN)	oral squamous cell carcinoma (OSCC)	OSCC cancer stem cells (CSCs)isolated from SAS and GNM cells	sulforaphane treatment	upregulated	26879838
4319	Human	hsa-miR-200c	miRNA	arecoline	oral submucous fibrosis (OSF)	fibrotic buccal mucosal fibroblasts (fBMFs	arecoline treatment	downregulated	29958727
4320	Human	hsa-miR-200c	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-18B cells	human papillomaviruses (HPVs) 18 treatment	downregulated	31911577
4321	Human	hsa-miR-200c	miRNA	methotrexate (MTX)	osteosarcoma (OS)	MG63 cells; HOS cells	methotrexate (MTX) treatment	miR-200c was downregulated in methotrexate resistance osteosarcoma cells	29170124
4322	Human	hsa-miR-200c	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines (MG-63, U2OS, HOS and SAOS-2)"	methotrexate treatment	downregulated	29170124
4323	Human	hsa-miR-200c	miRNA	olaparib	ovarian cancer (OC)	UWB cells; UWB-BRCA cells	olaparib treatment	downregulated	31898520
4324	Human	hsa-miR-200c	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3ip1 cells	paclitaxel (PTX) treatment	downregulated	33028939
4325	Human	hsa-miR-200c	miRNA	H2O2	oxidative stress	human renal tubular epithelium (HK-2) cells	hydrogen peroxide (H2O2) treatment	upregulated	31199854
4326	Human	hsa-miR-200c	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
4327	Human	hsa-miR-200c	miRNA	garcinol	pancreatic cancer (PC)	PANC-1 SP cells	Garcinol treatment	upregulated	26400206
4328	Human	hsa-miR-200c	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
4329	Human	hsa-miR-200c	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
4330	Human	hsa-miR-200c	miRNA	TGF-¦Â1	peritoneal fibrosis	Immortalized human mesothelial cells (Met-5A cells)	TGF-¦Â1 treatment	downregulated	31226520
4331	Human	hsa-miR-200c	miRNA	hydrogen sulfide (H2S)	preeclampsia (PE)	placental cells obtained from pregnant women with preeclampsia	placental cells obtained from pregnant women with preeclampsia treatment	downregulated	26992682
4332	Human	hsa-miR-200c	miRNA	endothelin-1 (ET-1)	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	endothelin-1 (ET-1) treatment	upregulated	29044995
4333	Human	hsa-miR-200c	miRNA	neoadjuvant chemoradiotherapy (CRT)	rectal cancer	patients with rectal cancer	received neoadjuvant chemoradiotherapy treatment	downregulated	24617665
4334	Human	hsa-miR-200c	miRNA	docetaxel (DTX)	tongue squamous cell carcinoma (TSCC)	HSC-3 cells	docetaxel (DTX) treatment	downregulated	32310826
4335	Human	hsa-miR-200c	miRNA	isoliquiritigenin	triple negative breast cancer (TNBC)	BT-549 cells; MDA-MB-231 cells	isoliquiritigenin (ISL)?treatment	"In this study, PCR array screened a significant increase of miR-200c in BT-549 and MDA-MB-231 cells after ISL treatment, and ISH exerted that miR-200c was expressed at a low level in breast cancer tissue of patients."	33641651
4336	Human	hsa-miR-200c	miRNA	tamoxifen (TAM)	triple negative breast cancer (TNBC)	TNBC cells (MCF-7/ADR and MDA-MB-231)	TAM treatment	downregulated	28724364
4337	Human	hsa-miR-200c	miRNA	arsenite	urothelial carcinoma	HUC1 cells	arsenic (As) exposure	downregulated	25586904
4338	Human	hsa-miR-200c	miRNA	sulforaphane (SFN)	oral squamous cell carcinoma (OSCC)	"normal oral epithelial cells (SG) and SAS or GNM cells,OSCC-CSCs"	sulforaphane treatment	upregulated	26879838
4339	Human	hsa-miR-200c*	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
4340	Human	hsa-miR-200c-3p	miRNA	influenza virus	acute respiratory distress syndrome (ARDS)	A549 cells	infect with H5N1	upregulated	28690868
4341	Human	hsa-miR-200c-3p	miRNA	copper (Cu)	Alzheimer's disease (AD)	human primary microvascular endothelial cells (MVECs)	chronic exposure to copper	"In human primary microvascular endothelial cells (MVECs), microRNA-200c-3p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure."	30923833
4342	Human	hsa-miR-200c-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
4343	Human	hsa-miR-200c-3p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
4344	Human	hsa-miR-200c-3p	miRNA	yin yang 1 (YY1)	cholangiocarcinoma (CCA)	CCLP-1 and QBC939 cells	yin yang 1 (YY1) treatment	downregulated	33040228
4345	Human	hsa-miR-200c-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
4346	Human	hsa-miR-200c-3p	miRNA	H2O2	glaucoma	human trabecular meshwork (HTM) cells	H2O2 treatment	downregulated	32626945
4347	Human	hsa-miR-200c-3p	miRNA	ferulic acid (FA)	intestinal barrier dysfunction	Caco-2 cells	Ferulic acid (FA) treatment	"LPS stimulation decreased miR-200c-3p expression, whereas this decrease was inhibited by FA pretreatment."	32308620
4348	Human	hsa-miR-200c-3p	miRNA	IL-1B	intestinal inflammation	Caco-2 cells	IL-1B treatment	MIR200C-3p was rapidly increased in Caco-2 cells incubated with IL-1B.	32569770
4349	Human	hsa-miR-200c-3p	miRNA	ultrasound (US)	multidrug resistance (MDR)	MCF-7/ADR and HEPG2/ADM cells	ultrasound (US) irradiation treatment	upregulated	30231924
4350	Human	hsa-miR-200c-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
4351	Human	hsa-miR-200c-3p	miRNA	NaF	skeletal fluorosis	SaoS2 cells	NaF treatment	upregulated	29471239
4352	Human	hsa-miR-200s	miRNA	estradiol-17¦Â (E2)	endometriosis	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	downregulated	30500775
4353	Human	hsa-miR-200s	miRNA	estradiol-17¦Â (E2)	epithelial-mesenchymal transition (EMT)	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	downregulated	30500775
4354	Human	hsa-miR-200s	miRNA	TGF-¦Â	tumorigenicity	glioma stem-like cell (GSC)	TGF-¦Â treatment	downregulated	31599491
4355	Human	hsa-miR-201	miRNA	catalpol	proliferation and apoptosis	OVCAR-3 cells	catalpol treatment	upregulated	25347277
4356	Human	hsa-miR-202	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
4357	Human	hsa-miR-202	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
4358	Human	hsa-miR-202	miRNA	angiotensin II (Ang II)	liver fibrosis	hepatic stellate cells (HSC)	angiotensin II (Ang II) treatment	The expression level of miR-202 significantly increased after hepatic stellate cells (HSC) were stimulated by AngII.	32270431
4359	Human	hsa-miR-202	miRNA	TGF-¦Â1	osteosarcoma (OS)	high grade osteosarcom	TGF-¦Â1 treatment	upregulated	26276504
4360	Human	hsa-miR-202	miRNA	bone morphogenetic protein 4 (BMP4)	varicose vein	human venous smooth muscle cells (HUVSMCs)	bone morphogenetic protein 4 (BMP4) treatment	downregulated	30556158
4361	Human	hsa-miR-202	miRNA	platelet-derived growth factor (PDGF)	varicose vein	human venous smooth muscle cells (HUVSMCs)	platelet-derived growth factor (PDGF) treatment	upregulated	30556158
4362	Human	hsa-miR-202	miRNA	TGF-¦Â	varicose vein	human venous smooth muscle cells (HUVSMCs)	TGF©\¦Â treatment	upregulated	30556158
4363	Human	hsa-miR-202-3p	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP)	interleukin-1¦Â (IL-1¦Â) treatment	downregulated	30458287
4364	Human	hsa-miR-202-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary heart disease (CHD)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	Oxidized low-density lipoprotein (ox-LDL) induced miR-202-3p expression.	31956131
4365	Human	hsa-miR-202-3p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
4366	Human	hsa-miR-202-3p	miRNA	angiotensin II (Ang II)	essential hypertension (EH)	THP-1 cells	angiotensin II (Ang II) treatment	upregulated	32338289
4367	Human	hsa-miR-202-3p	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	IL-1¦Â treatment	downregulated	30458287
4368	Human	hsa-miR-202-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
4369	Human	hsa-miR-203	miRNA	nickel	esophageal cancer (EC)	NSTCs	nickel treatment	downregulated	23968727
4370	Human	hsa-miR-203	miRNA	curcumin (Cur)	bladder cancer	"Non-malignant human uroepithelial cell line (SV-HUC-1)£» bladder cancer cell lines (T24, J82£»TCCSUP)"	curcumin (CUR) treatment	downregulated	21836020
4371	Human	hsa-miR-203	miRNA	lead (Pb)	blood-cerebrospinal fluid barrier (BCB)	choroidal epithelial cells	(Pb) exposure	upregulated	25975750
4372	Human	hsa-miR-203	miRNA	estradiol	breast cancer	MCF-7 cells	estradiol (E?) treatment	"E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells"	22260523
4373	Human	hsa-miR-203	miRNA	estradiol	breast cancer	ER¦Á-positive breast cancer MCF-7 cells	estradiol treatment	downregulated	28962215
4374	Human	hsa-miR-203	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4375	Human	hsa-miR-203	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4376	Human	hsa-miR-203	miRNA	huaier extract	breast cancer	tamoxifen-resistant cells (M7-TR) and fulvestrant-resistant cells (M7-FR)	Huaier extract	downregulated	28779143
4377	Human	hsa-miR-203	miRNA	luteolin	breast cancer	MDA-MB-453 and MCF-7 cells	luteolin treatment	upregulated	31368817
4378	Human	hsa-miR-203	miRNA	paclitaxel (PTX)	breast cancer	"HER2-positive cell lines, BT-474 and SKBR3"	paclitaxel treatment	upregulated	28509576
4379	Human	hsa-miR-203	miRNA	sevoflurane (SEV)	breast cancer	MDA-MB-231 cells	sevoflurane treatment	upregulated	29750301
4380	Human	hsa-miR-203	miRNA	folic acid	cervical cancer (CC)	CaSki cells	folic acid treatment	upregulated	27313708
4381	Human	hsa-miR-203	miRNA	adriamycin (ADR)	colorectal cancer (CRC)	HCT116	adriamycin (ADR) treatment	upregulated	26397233
4382	Human	hsa-miR-203	miRNA	sevoflurane (SEV)	colorectal cancer (CRC)	SW620 and HCT116 cells	sevoflurane treatment	upregulated	30685432
4383	Human	hsa-miR-203	miRNA	sodium butyrate (NaB)	colorectal cancer (CRC)	HT-29 and Caco-2 cell lines	sodium butyrate (NaBt) treatment	upregulated	27771718
4384	Human	hsa-miR-203	miRNA	AZD6244	cytotoxicity	breast cancer cell lines MDA-MB-231 and HCC1937	10¦ÌM AZD6244 for 24 h treatment	upregulated	24938872
4385	Human	hsa-miR-203	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
4386	Human	hsa-miR-203	miRNA	glycolaldehyde-modified advanced glycation end product (AGE)	diabetic foot ulcer (DFU)	The immortalized human keratinocyte lines HaCaT and HFF1	glycolaldehyde-modified advanced glycation end product (AGE) treatment	upregulated	31707396
4387	Human	hsa-miR-203	miRNA	human papilloma virus (HPV)	cell differentiation	Normal human foreskin keratinocytes (NHKs)	Human papillomaviruses (HPV)?infection	downregulated	20219920
4388	Human	hsa-miR-203	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
4389	Human	hsa-miR-203	miRNA	berberine (BBR)	gastric cancer (GC)	Gastric cancer cell lines SGC-7901 and BGC-823	berberine (BBR) treatment	upregulated	27142767
4390	Human	hsa-miR-203	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	GBM patients tissues and serum	TMZ treatment	upregulated	28187000
4391	Human	hsa-miR-203	miRNA	bufalin	glioblastoma multiforme (GBM)	U251 and U87 cells	bufalin treatment	upregulated	29169175
4392	Human	hsa-miR-203	miRNA	TGF-¦Â	head and neck squamous cell carcinoma (HNSCC)	MSCC-1 and MSCC-inv1 cells	TGF-¦Â treatment	downregulated	26882562
4393	Human	hsa-miR-203	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
4394	Human	hsa-miR-203	miRNA	lipopolysaccharide (LPS)	liver fibrosis	Human HSC line LX2 cells	lipopolysaccharide (LPS) treatment	downregulated	31719209
4395	Human	hsa-miR-203	miRNA	TGF-¦Â	liver fibrosis	Human HSC line LX2 cells	TGF-¦Â treatment	downregulated	31719209
4396	Human	hsa-miR-203	miRNA	human papilloma viruses (HPVs) 16	human papillomaviruses (HPV) infection	human foreskin keratinocytes(HFKs)	human papillomavirus type 16 (HPV16) infection	downregulated	20702634
4397	Human	hsa-miR-203	miRNA	platelet derived growth factor-BB (PDGF-BB) and insulin-like growth factor (IGF)-1	idiopathic pulmonary fibrosis (IPF)	human fibroblastic cell line (LL-24)	PDGF-BB and IGF-1 treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2	32694556
4398	Human	hsa-miR-203	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	Primary human lung fibroblasts	TGF¦Â1 treatment	upregulated	31488543
4399	Human	hsa-miR-203	miRNA	sulfur mustard (SM)	impaired tissue regeneration	normal human epidermal keratinocytes (NHEK)	sulfur mustard (SM) treatment	upregulated	26383628
4400	Human	hsa-miR-203	miRNA	kaempferol	inflammation	LPS or AngII-disposed human aortic endothelial cells (HAECs)	Kaempferol (KAE)?treatment	upregulated	31022599
4401	Human	hsa-miR-203	miRNA	TGF-¦Â	inflammation	breast cancer cells	transforming growth factor ¦Â (TGF-¦Â)? treatment	downregulated	23447531
4402	Human	hsa-miR-203	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	29717211
4403	Human	hsa-miR-203	miRNA	oleic acid (OA)	keratinocytes (KCs) diferentiation	neonatal human epidermal keratinocytes (HEKn)	oleic acid (OA) treatment	OA increased the expression of miR-203.	29638027
4404	Human	hsa-miR-203	miRNA	imatinib	leukemia	The K562 cells; HL-60 cells; the KU812 cells	imatinib treatment	demethylation of miR-203 is one of the molecular mechanisms of imatinib-induced inhibition of BCR-ABL1-positive leukemic cells	23953880
4405	Human	hsa-miR-203	miRNA	TGF-¦Â	lung adenocarcinoma (LUAD)	A549 cell	TGF¦Â treatment	upregulated	31131047
4406	Human	hsa-miR-203	miRNA	Sendai virus (SeV)	lung cancer	A549 cells	Sendai Virus treatment	"miR-203isanIFN-inducible miRNA that can negatively regulate a number of cellular mRNAs,including an IFN-stimulated gene target,IFIT1/ISG56,by destabilizing its mRNA transcript"	23785202
4407	Human	hsa-miR-203	miRNA	temozolomide (TMZ)	malignant melanoma (MM)	human MM cells	TMZ treatment	downregulated	28597996
4408	Human	hsa-miR-203	miRNA	aspirin	nasopharyngeal carcinoma (NPC)	"Human NPC cell line C666-1, C2089"	aspirin treatment	upregulated	31265948
4409	Human	hsa-miR-203	miRNA	X-rays	nasopharyngeal carcinoma (NPC)	5-8F; SUNE-1 cells	4 Gy radiation treatment	LINC00114 contributed to NPC development and radioresistance through the regulation of ERK/JNK signaling pathway and the mediation of miR-203	32196600
4410	Human	hsa-miR-203	miRNA	riboflavin (RF)	neuroprotective effects	SH-SY5Y neuroblostoma cell line	RF treatment	upregulated	24884571
4411	Human	hsa-miR-203	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	Tca8113 cells	cisplatin treatment	downregulated	26946357
4412	Human	hsa-miR-203	miRNA	arecoline	oral submucous fibrosis (OSF)	human buccal mucosal fibroblasts	arecoline treatment	downregulated	25872484
4413	Human	hsa-miR-203	miRNA	prednisolone	oral submucous fibrosis (OSF)	OSF-fibroblast cells	were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment	upregulated	24921400
4414	Human	hsa-miR-203	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	IL-1¦Â stimulation induced the expression of miR-203.	31894489
4415	Human	hsa-miR-203	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human cartilage C28/I2 cells	lipopolysaccharide (LPS) treatment	upregulated	28764893
4416	Human	hsa-miR-203	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	SW1990 cells	cisplatin treatment	downregulated	31696470
4417	Human	hsa-miR-203	miRNA	hypoxia	pathological retinal neovascularization disease	human retinal microvascular endothelial cells (HRMECs)	hypoxia treatment	downregulated	32084532
4418	Human	hsa-miR-203	miRNA	IL-17	psoriasis	HaCaT cells	IL-17 treatment	upregulated	29039484
4419	Human	hsa-miR-203	miRNA	Kr¨¹ppel-like factor 4 (KLF4)	cell senescence	pluripotent stem (iPS) cells	Kr¨¹ppel-like factor 4 (KLF4) treatment	upregulated	27531889
4420	Human	hsa-miR-203	miRNA	COTI-2	T-cell acute lymphoblastic leukemia (T-ALL)	Jurkat cells	COTI-2 treatment	upregulated	32063077
4421	Human	hsa-miR-203	miRNA	sulfur mustard (SM)	tissue injury	human epidermal keratinocytes (NHEK)	sulfur mustard (SM) treatment	upregulated	26383628
4422	Human	hsa-miR-203	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	type 2 diabetes mellitus (T2DM)	"human hepatocytes (JHH5, JHH7, and HepG2)"	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	28955777
4423	Human	hsa-miR-203a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	esophageal cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
4424	Human	hsa-miR-203a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, Yes-2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
4425	Human	hsa-miR-203a	miRNA	hepatitis C virus (HCV) core protein	hepatocellular carcinoma (HCC)	"human hepatoblastoma cell line, HepG2"	Hepatitis C virus (HCV) Core protein treatment	downregulated	26210453
4426	Human	hsa-miR-203a	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2 cells	hypoxia treatment	downregulated	32468055
4427	Human	hsa-miR-203a	miRNA	cadmium (Cd)	epidermal development	HaCaT Cells	cadmium (Cd) treatment	upregulated	28754589
4428	Human	hsa-miR-203a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	murine chondrogenic ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	29679904
4429	Human	hsa-miR-203a	miRNA	tanshinone IIA (Tan IIA)	osteoarthritis (OA)	LPS-treated murine chondrogenic ATDC5 cells	Tanshinone IIA (Tan IIA) treatment	downregulated	29679904
4430	Human	hsa-miR-203a-3p	miRNA	acidosis	acidosis	R3327-AT-1 prostate	incubated at pH 6.6	downregulated	28685435
4431	Human	hsa-miR-203a-3p	miRNA	TGF-¦Â1	asthma	BEAS-2B cells; 16HBE cells	TGF-¦Â1 treatment	Transforming growth factor-¦Â1 (TGF-¦Â1) treatment induced the reduction of miR-203a-3p in BEAS-2B and 16HBE cells in a time-dependent manner	32065213
4432	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	MALAT1 affect angiogenesis by sponging miR-203a-3p in DR.	31689123
4433	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31689123
4434	Human	hsa-miR-203a-3p	miRNA	atorvastatin	endothelial senescence	ox-LDL treated HUVECs	atorvastatin treatment	downregulated	29248491
4435	Human	hsa-miR-203a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial senescence	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
4436	Human	hsa-miR-203a-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
4437	Human	hsa-miR-203a-3p	miRNA	steviol	gastrointestinal cancer	HCT-116 cells	steviol treatment	upregulated	29899860
4438	Human	hsa-miR-203a-3p	miRNA	atorvastatin	hyperlipidemia	HUVECs	atorvastatin treatment	downregulated	29248491
4439	Human	hsa-miR-203a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	hyperlipidemia	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
4440	Human	hsa-miR-203a-3p	miRNA	carnosic acid (CA)	liver fibrosis	LX-2 cells	carnosic acid (CA) treatment	Inhibition of p66Shc Oxidative Signaling via CA-Induced Upregulation of miR-203a-3p Alleviates Liver Fibrosis Progression.	32781430
4441	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	proliferative diabetic retinopathy (PDR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31408201
4442	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	proliferative diabetic retinopathy (PDR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31408201
4443	Human	hsa-miR-203a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell senescence	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28347692
4444	Human	hsa-miR-203b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	esophageal cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
4445	Human	hsa-miR-203b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, Yes-2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
4446	Human	hsa-miR-204	miRNA	arsenic trioxide (ATO)	acute myeloid leukemia (AML)	"Human AML cell lines, AML-5 and HL-60"	arsenic trioxide (ATO) treatment	upregulated	30982490
4447	Human	hsa-miR-204	miRNA	high inorganic phosphate (Pi)	arterial calcification	Human aorta vascular smooth muscle cells (HA-VSMCs)	high phosphate treatment	downregulated	29850805
4448	Human	hsa-miR-204	miRNA	trichostatin A (TSA)	breast cancer	MCF-7 and ;MDA-MB-231 cells	Trichostatin A (TSA) treatment	downregulated	26436206
4449	Human	hsa-miR-204	miRNA	triiodo-l-thyronine (T3)	breast cancer	BC cell lines MCF-7 and T47-D	Triiodothyronine (T3) treatment	downregulated	30406874
4450	Human	hsa-miR-204	miRNA	TGF-¦Â1 or bone morphogenetic protein 2 (BMP-2)	calcific aortic valve disease (CAVD)	human aortic valve interstitial cells (AVICs)	"TGF-¦Â1,BMP-2 treatment"	dysregulated	28377507
4451	Human	hsa-miR-204	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
4452	Human	hsa-miR-204	miRNA	hypoxia	cervical spondylotic	Human neuronal cell lines	hypoxia treatment	upregulated	26350953
4453	Human	hsa-miR-204	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116; HT-29; SW620; SW480; DLD-1; RKO; LoVo cells	5-fluorouracil (5-FU) treatment	PCAT6 knockdown attenuated CRC chemoresistance to 5-FU through miR-204/HMGA2/PI3K; miR-204 inhibition could partially reverse the effect of PCAT6 knockdown.	30938104
4454	Human	hsa-miR-204	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	downregulated	30131392
4455	Human	hsa-miR-204	miRNA	melatonin	diabetic retinopathy (DR)	MIO-M1 cells	melatonin (MEL) treatment	miR-204 increased in HG-treated MIO-M1 cells and that melatonin (MEL) inhibited miR-204 expression	32324260
4456	Human	hsa-miR-204	miRNA	particulate matter (PM2.5)	epithelial-mesenchymal transition (EMT)	human bronchial epithelial cell lines (HBE and BEAS-2B)	Organic extracts of PM2.5 treatment	"NF-¦ÊB transcriptionally regulates MALAT1, which, by binding with miR-204 and releasing ZEB1, promotes the EMT"	31042084
4457	Human	hsa-miR-204	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human LECs (HLECs)	TGF-¦Â2 treatment	"TGF-¦Â2 induces NEAT1 overexpression, which in turn suggests that NEAT1 acts as a ceRNA targeting Snail1 or Zeb1 by binding miR-34a or miR-204"	32596382
4458	Human	hsa-miR-204	miRNA	Sinomenine (SIN)	gastric cancer (GC)	MKN45 and SGC-7901 cells	Sinomenine (SIN) treatment	upregulated	31243880
4459	Human	hsa-miR-204	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	miR-204 was downregulated in U251MG-resistant (-R) cells	29725461
4460	Human	hsa-miR-204	miRNA	hypoxia	hepatocellular carcinoma (HCC)	LO2 cells;Hep3B cells;Huh7 cells	hypoxia induce	downregulated	30279729
4461	Human	hsa-miR-204	miRNA	vemurafenib	melanoma	A375 melanoma cells	vemurafenib treatment	upregulated	28445987
4462	Human	hsa-miR-204	miRNA	IL-1¦Â	osteoarthritis (OA)	human OA chondrocytes;chondrogenic SW1353 cells	IL-12¦Â treatment	downregulated	29441883
4463	Human	hsa-miR-204	miRNA	metformin (Met)	preeclampsia (PE)	HUVEC and HPASMC cells	Metformin treatment	upregulated	31582211
4464	Human	hsa-miR-204	miRNA	propofol (PPF)	expression regulation	human adipocyte stem cells	"50 ?M propofol, or 100 ?M propofol in culture media for 3 hours treatment"	"The lowest expression was seen for miR-204, The highest expression was seen for miR-208b"	25568843
4465	Human	hsa-miR-204	miRNA	oxibendazole (OBZ)	prostate cancer	22Rv1 cells; PC-3 cells	oxibendazole (OBZ) treatment	OBZ increased the expression of microRNA-204 (miR-204)	29434928
4466	Human	hsa-miR-204	miRNA	dehydroepiandrosterone (DHEA)	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cell (PASMC)	Dehydroepiandrosterone (DHEA) treatment	upregulated	21890685
4467	Human	hsa-miR-204	miRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary artery endothelial cells (HPAECs)	hypoxia induce	downregulated	31542480
4468	Human	hsa-miR-204	miRNA	lipopolysaccharide (LPS)	sepsis	rats lung tissues	lipopolysaccharide (LPS) treatment	downregulated	28901393
4469	Human	hsa-miR-204	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
4470	Human	hsa-miR-204	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN cells; P12 cells	hypoxia treatment	"The expression of MALAT1 and Bcl-2 was decreased, while miRNA-204 (miR-204) was upregulated in rats SCIRI model and neurocyte lines under hypoxic conditions."	29998804
4471	Human	hsa-miR-2042	miRNA	IL-6	epithelial ovarian cancer (EOC)	human ovarian cancer cell line A2780;its related cDDP-resistant cell lines (ACRP)	interleukin-6 (IL-6) treatment	downregulated	28388577
4472	Human	hsa-miR-204-3p	miRNA	lipopolysaccharide (LPS)	familial Mediterranean fever	THP-1 cells	lipopolysaccharide (LPS) treatment	The expression of miR-204-3p was suppressed by LPS stimulation in the macrophages derived from THP-1 cells	29294109
4473	Human	hsa-miR-204-5p	miRNA	TGF-¦Â1	asthma	human airway smooth muscle cells	TGF-¦Â1 treatment	MiR-204-5p was downregulated notably in asthmatic airway smooth muscle cells as well as cells stimulated with TGF-¦Â1	31955160
4474	Human	hsa-miR-204-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"silence of XIST displayed a protective role in ox-LDL-induced injury in HUVECs by regulating miR-204-5p/TLR4 axis, providing a novel mechanism for understanding the pathogenesis of atherosclerosis."	32345778
4475	Human	hsa-miR-204-5p	miRNA	¦Ã-rays	ionizing radiation (IR) injury	whole blood samples from healthy donors extracellular vesicles (ELVs)	irradiate with 2 Gy gamma rays treatment	upregulated	28264626
4476	Human	hsa-miR-204-5p	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
4477	Human	hsa-miR-204-5p	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	human lens epithelial cells (LECs)	TGF-¦Â2 treatment	downregulated	33327804
4478	Human	hsa-miR-204-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HBMEC;bEnd.3 cells	oxygen-glucose deprivation (OGD) treatment	downregulated	33607153
4479	Human	hsa-miR-204-5p	miRNA	vemurafenib	melanoma	A375 cells	vemurafenib treatment	upregulated	29229605
4480	Human	hsa-miR-204-5p	miRNA	triptolide (TPL)	non-small cell lung cancer (NSCLC)	A549 cells	triptolide (TPL) treatment	TL upregulated miR204-5p mRNA expression in NSCLC	32733649
4481	Human	hsa-miR-204-5p	miRNA	docetaxel (DTX)	prostate cancer	PCa samples; PC3 cells; DU145 cells	docetaxel (DTX) treatment	downregulated	31672604
4482	Human	hsa-miR-204-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	RA-FLS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"We found that NEAT1 was upregulated, and miR-204-5p was downregulated in the RA patients' synovial tissue and TNF-¦Á treated RA-FLSs"	33394349
4483	Human	hsa-miR-204-5p	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"LPS impaired cell viability, and promoted cell apoptosis, inflammatory response and oxidative stress in HUVECs by regulating HULC/miR-204-5p/TRPM7 axis."	32484206
4484	Human	hsa-miR-204-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	B cells	M.tb infection	upregulated	29477867
4485	Human	hsa-miR-205	miRNA	garcinol	acute myocardial infarction (AMI)	Human myocardial cell line (AC16)	Garcinol treatment	garcinol enhanced the expression of microRNA-205	33809417
4486	Human	hsa-miR-205	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells	lipopolysaccharide (LPS) treatment	"SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice."	33170429
4487	Human	hsa-miR-205	miRNA	transglutaminase 2 (TG2)	breast cancer	"MCF-7, MDA-MB-231 breast cancer cells"	transglutaminase 2 (TG2) overexpression	downregulated	30949413
4488	Human	hsa-miR-205	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	upregulated	24396484
4489	Human	hsa-miR-205	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
4490	Human	hsa-miR-205	miRNA	entinostat	breast cancer	MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells	entinostat treatment	downregulated	23519125
4491	Human	hsa-miR-205	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
4492	Human	hsa-miR-205	miRNA	MEK inhibitor U0126 or PD98059	breast cancer	ErbB2-overexpressing nontumorigenic human breast epithelial cell line MCF10A	U0126 or PD98059	upregulated	28781955
4493	Human	hsa-miR-205	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells; MDA-MB-231 cells	paclitaxel treatment	downregulated	30019863
4494	Human	hsa-miR-205	miRNA	paclitaxel (PTX)	breast cancer	BT-474 cells	paclitaxel treatment	upregulated	30019863
4495	Human	hsa-miR-205	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
4496	Human	hsa-miR-205	miRNA	arsenite	tumorigenesis	derivative normal stem cell (SC) line	arsenite exposure	downregulated	24431212
4497	Human	hsa-miR-205	miRNA	particulate matter (PM2.5)	cardiovascular disease (CVD)	AC16 cells	fine particulate matter (PM 2.5) treatment	miR-205 was decreased in the PM25 group	32880505
4498	Human	hsa-miR-205	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (HASMC)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	31441592
4499	Human	hsa-miR-205	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
4500	Human	hsa-miR-205	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cellular stress response	prostate cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-205 and miR-31	21368878
4501	Human	hsa-miR-205	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
4502	Human	hsa-miR-205	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
4503	Human	hsa-miR-205	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
4504	Human	hsa-miR-205	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	glioblastoma U87MG cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28792704
4505	Human	hsa-miR-205	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell line U87	glioma cell line U87 treatment	"downregulated(miR-205), upregulation(miR-195)"	27574009
4506	Human	hsa-miR-205	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Hepatoma cell lines HepG2	hepatitis B virus (HBV) infection	downregulated	24339740
4507	Human	hsa-miR-205	miRNA	gemcitabine (GEM)	hepatocellular carcinoma (HCC)	HuCCT1 cells; HuH28 cells	Gemcitabine treatment	upregulated	24147037
4508	Human	hsa-miR-205	miRNA	carboplatin (CBP)	lung cancer	A549 and H1975 lung cancer cells	carboplatin (CBP) treatment	upregulated	25917317
4509	Human	hsa-miR-205	miRNA	tobacco carcinogens	lung cancer	HBECs	tobacco carcinogens treatment	"EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205"	21363915
4510	Human	hsa-miR-205	miRNA	oleacein (OA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	oleic acid (OA) treatment	upregulated	31799678
4511	Human	hsa-miR-205	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
4512	Human	hsa-miR-205	miRNA	¦Â-glycerophosphate (¦Â-GP)	osteogenesis	human aortic smooth muscle cells (HASMCs)	¦Â-glycerophosphate treatment	downregulated	25012146
4513	Human	hsa-miR-205	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
4514	Human	hsa-miR-205	miRNA	cancer-associated fibroblasts (CAFs)	prostate cancer	prostate cancer (PCa) cells	PCa cells upon CAF stimulation treatment	downregulated	23924028
4515	Human	hsa-miR-205	miRNA	hypoxia	prostate cancer	DU145 and LNCaP cells	hypoxia treatment	downregulated	27160121
4516	Human	hsa-miR-205	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
4517	Human	hsa-miR-205	miRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	HK-2 cells	hypoxia induce	downregulated	31934284
4518	Human	hsa-miR-205	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
4519	Human	hsa-miR-205	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	TapSAKI was upregulated and miR-205 was downregulated in LPS-induced HK-2 cells.	33869780
4520	Human	hsa-miR-205	miRNA	tumor resection	squamous cell carcinoma (SQCC) and adenocarcinoma (ADC£©	SQCC and ADC patients	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28634901
4521	Human	hsa-miR-205	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
4522	Human	hsa-miR-205-3p	miRNA	ultraviolet (UV) irradiation	corneal damage	human corneal epithelial cells	ultraviolet (UV) radiation treatment	upregulated	32633336
4523	Human	hsa-miR-205-3p	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell lines	TGF-¦Â treatment	downregulated	31558707
4524	Human	hsa-miR-205-3p	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	upregulated	29899866
4525	Human	hsa-miR-205-5p	miRNA	copper (Cu)	Alzheimer's disease (AD)	human primary microvascular endothelial cells (MVECs)	chronic exposure to copper	"In human primary microvascular endothelial cells (MVECs), microRNA-205-5p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure."	30923833
4526	Human	hsa-miR-205-5p	miRNA	anabolic-androgenic ateroids (AASs)	anabolic-Androgenic Steroids (AASs)-induced renal damage	kidney tissues	anabolic-androgenic ateroids (AASs) treatment	upregulated	33041804
4527	Human	hsa-miR-205-5p	miRNA	H2O2	angiogenesis	The ARPE-19 human cell line	H2O2 treatment	upregulated	31863632
4528	Human	hsa-miR-205-5p	miRNA	N-acetyl-L-cysteine (NAC)	angiogenesis	H2O2-treated the ARPE-19 human cell line	N-acetylcysteine (NAC) treatment	downregulated	31863632
4529	Human	hsa-miR-205-5p	miRNA	gemcitabine (GEM)	breast cancer	MDA-MB-231 and BT549 cells	Gemcitabine (GEM) treatment	Overexpression of miR-205-5p significantly augmented cytotoxicity effects of gemcitabine treatment in MDA-MB-231 and BT549 cells.	31602229
4530	Human	hsa-miR-205-5p	miRNA	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT)	cervical cancer (CC)	serum	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) treatment	upregulated	32851067
4531	Human	hsa-miR-205-5p	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
4532	Human	hsa-miR-205-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
4533	Human	hsa-miR-205-5p	miRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	Bel-7402 (Bel) cells	5-fluorouracil (5-FU) treatment	upregulated	28979703
4534	Human	hsa-miR-205-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
4535	Human	hsa-miR-205-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	32057949
4536	Human	hsa-miR-205-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30853343
4537	Human	hsa-miR-205-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32217110
4538	Human	hsa-miR-20-5p	miRNA	H2O2	cell senescence	multipotent stromal cells	H2O2 treatment	downregulated	32174776
4539	Human	hsa-miR-206	miRNA	thyroid hormone	hepatocellular carcinoma (HCC)	skeletal muscle	thyroid hormone (TH) treatment	downregulated	19567520
4540	Human	hsa-miR-206	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33635017
4541	Human	hsa-miR-206	miRNA	IL-1¦Â and forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	IL-1¦Â and forskolin (Fsk) treatment	downregulated	33508847
4542	Human	hsa-miR-206	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cell line	oxidized low-density lipoprotein (ox-LDL) treatment	"miR-206 was predicted as a target of UCA1 and knockdown of UCA1 was able to repress miR-206 expression. Furthermore, overexpression of miR-206 inhibited oxidative stress process and it was reversed by UCA1 upregulation in vitro."	30633352
4543	Human	hsa-miR-206	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1-derived macrophages and differentiated human monocyte-derived macrophages (hMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33526034
4544	Human	hsa-miR-206	miRNA	IL-1¦Â	autoimmune thyroiditis (AIT)	Nthy-ori 3-1 cells	IL-1¦Â treatment	downregulated	33452572
4545	Human	hsa-miR-206	miRNA	ursolic acid (UA)	autoimmune thyroiditis (AIT)	IL-1¦Â-treated Nthy-ori 3-1 cells	ursolic acid (UA) treatment	upregulated	33452572
4546	Human	hsa-miR-206	miRNA	acetyl-11-keto-¦Â-boswellic acid (AKBA)	breast cancer	MCF-10AT cells	Acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment	AKBA could induce cell apoptosis and G1-phase arrest and inhibit ER-¦Á expression via LINC00707/miR-206 in MCF-10AT cells.	32013235
4547	Human	hsa-miR-206	miRNA	physical activity	breast cancer	MCF-7 cells	physical activity treatment	upregulated	32547708
4548	Human	hsa-miR-206	miRNA	antrodia cinnamomea	cancer treatment	"THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68"	antrodia cinnamomea treatment	downregulated	28602756
4549	Human	hsa-miR-206	miRNA	tocotrienol-rich fraction (TRF)	cell differentiation	senescent human skeletal muscle myoblasts (HSMM)	senescent human skeletal muscle myoblasts (HSMM) were treated with 50 ¦Ìg/mL TRF for 24 h treatment	upregulated	30519366
4550	Human	hsa-miR-206	miRNA	high glucose (HG)	cell proliferation and extracellular matrix (ECM) deposition	?human glomerular mesangial cells (hMCs)	high glucose (HG) treatment	downregulated	31880296
4551	Human	hsa-miR-206	miRNA	amphiregulin	chondrosarcoma	human chondrosarcoma cells	amphiregulin treatment	downregulated	27826039
4552	Human	hsa-miR-206	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cells (HPMECs)	cigarette smoke extract (CSE) treatment	upregulated	30335896
4553	Human	hsa-miR-206	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cells (HPMECs)	cigarette smoke extract (CSE) exposure	upregulated	30335896
4554	Human	hsa-miR-206	miRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	MRC-5 cells	lipopolysaccharide (LPS) treatment	upregulated	31279225
4555	Human	hsa-miR-206	miRNA	prostaglandin E2 (PGE2)	colorectal cancer (CRC)	HCT-116 and Caco-2 cells	prostaglandin E2 (PGE2) treatment	downregulated	30135139
4556	Human	hsa-miR-206	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	31608712
4557	Human	hsa-miR-206	miRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	OV2008 cells	cisplatin treatment	miR-206 expression was increased in primary platinum-resistant EOC.	33292230
4558	Human	hsa-miR-206	miRNA	propofol (PPF)	glioblastoma multiforme (GBM)	U251 cells; LN229 cells	propofol treatment	"MiR-206 was decreased in glioma tissues and cells, while propofol exposure induced the upregulation of miR-206 in glioma cells."	32021281
4559	Human	hsa-miR-206	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
4560	Human	hsa-miR-206	miRNA	high fat diet (HFD)	hepatosteatosis and hyperglycemia	human hepatocytes	high fat diet (HFD) feed	downregulated	28025059
4561	Human	hsa-miR-206	miRNA	lipopolysaccharide (LPS)	inflammation	human astrocytes	lipopolysaccharide (LPS) treatment	upregulated	25452104
4562	Human	hsa-miR-206	miRNA	dexamethasone (DEX)	legg Calve Perthes disease (LCPD)	chondrocytes obtained from patients with LCPD	dexamethasone (DEX) treatment	upregulated	29387248
4563	Human	hsa-miR-206	miRNA	dexamethasone (DEX)	left ventricular hypertrophy (LVH)	primary chondrocytes of the LCPD and normal control group	dexamethasone (DEX) treatment	upregulated	29387248
4564	Human	hsa-miR-206	miRNA	active pterocarpanquinone LQB-118 	active pterocarpanquinone LQB-118 cytotoxicity	"PC3, LNCaP, and LAPC4 PCa cells"	LQB-118	downregulated	29105806
4565	Human	hsa-miR-206	miRNA	hepatocyte growth factor (HGF)	lung cancer	lung cancer cells PC-9 and HCC-827	Hepatocyte growth factor (HGF) treatment	downregulated	29664235
4566	Human	hsa-miR-206	miRNA	l-carnitine	male infertility	sperm	l-carnitine treatment	upregulated	31749176
4567	Human	hsa-miR-206	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
4568	Human	hsa-miR-206	miRNA	GW501516	nasopharyngeal carcinoma (NPC)	C666-1 cells	GW501516 treatment	upregulated	30982495
4569	Human	hsa-miR-206	miRNA	propofol (PPF)	neurotoxicity	human embryonic stem cells (hESCs)	expose to propofol (50 ¦ÌM) for 6 hr treatment	upregulated	28869449
4570	Human	hsa-miR-206	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	A549 cells	curcumin treatment	"Curcumin significantly inhibited migration and invasion in A549 cells, accompanied by significantly elevated miR-206 expression."	32074070
4571	Human	hsa-miR-206	miRNA	prednisolone	oral submucous fibrosis (OSF)	OSF-fibroblast cells	were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment	upregulated	24921400
4572	Human	hsa-miR-206	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	upregulated	22366961
4573	Human	hsa-miR-206	miRNA	particulate matter (PM2.5)	pulmonary arterial hypertension (PAH)	plasma	particulate matter (PM2.5) treatment	"Based on microarray analyses, we found that microRNA-206 may be involved in asthma induced PAH stimulated by PM25"	33086901
4574	Human	hsa-miR-206	miRNA	hypoxia	pulmonary hypertension (PH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	downregulated	23628900
4575	Human	hsa-miR-206	miRNA	artesunate (ART)	rhabdomyosarcoma (RMS)	ERMS cell lines	artesunate (ARS) treatment	downregulated	26153023
4576	Human	hsa-miR-206	miRNA	tin protoporphyrin	rhabdomyosarcoma (RMS)	RD and SMS-CTR cells	RD and SMS-CTR cells treatment	downregulated	27488535
4577	Human	hsa-miR-206	miRNA	"vincristine, dactinomycin, cyclophosphamide (VAC)"	rhabdomyosarcoma (RMS)	rhabdomyosarcoma patients	VAC treatment	upregulated	28834127
4578	Human	hsa-miR-206	miRNA	triiodo-l-thyronine (T3)	thyroid hormone-induced disorders of lipid metabolism	HepG2 cells	triiodothyronine (T3) treatment	downregulated	29484422
4579	Human	hsa-miR-206	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (M.tb) treatment	upregulated	27291149
4580	Human	hsa-miR-206	miRNA	mesalamine	ulcerative colitis (UC)	HT29 colon cells	mesalamine treatment	downregulated	30204869
4581	Human	hsa-miR-206	miRNA	mood stabilizers	bipolar disorder type I (BD-I)	blood	mood stabilizers treatment	downregulated	24767015
4582	Human	hsa-miR-206-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	THP-1 cells	"4,4'-methylene diphenyl diisocyanate (MDI) treatment"	Both in vivo murine MDI aerosol exposure and in vitro MDI-GSH exposures in THP-1 macrophages result in downregulated of endogenous miR-206-3p and miR-381-3p and upregulation of PPP3CA and iNOS expression.	31609387
4583	Human	hsa-miR-208	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
4584	Human	hsa-miR-208a	miRNA	coronary artery bypass graft (CABG)	acute coronary syndrome (ACS)	acute coronary syndrome patients heart	CABG treatment	upregulated	29506853
4585	Human	hsa-miR-208a	miRNA	caffeine	cardiovascular disease (CVD)	HL-1 and primary embryonic cardiomyocytes	exposure to physiologically relevant doses of caffeine treatment	downregulated	25354728
4586	Human	hsa-miR-208a	miRNA	cyclic mechanical stretch (CMS)	cardiovascular disease (CVD)	human cardiac fibroblasts-adult atrial (HCF-aa)	cyclic stretching treatment	"MiR208a was upregulated early by stretching and returned to normal levels with longer stretching cycles, whereas the expression of miR499 and Bcl-2 was upregulated by longer stretching times."	33605072
4587	Human	hsa-miR-208a	miRNA	H2O2	myocardial injury	AC16 cardiomyocytes	H2O2 treatment	"miR-208a mimic aggravated H2O2-induced apoptosis and oxidative injury in cardiomyocytes, while miR-208a inhibitor hadan inverse effect."	31545986
4588	Human	hsa-miR-208b	miRNA	caffeine	cardiovascular disease (CVD)	HL-1 and primary embryonic cardiomyocytes	exposure to physiologically relevant doses of caffeine treatment	upregulated	25354728
4589	Human	hsa-miR-208b	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7 cells	hepatitis C virus (HCV) infection	upregulated	24241692
4590	Human	hsa-miR-208b	miRNA	propofol (PPF)	expression regulation	human adipocyte stem cells	"50 ?M propofol, or 100 ?M propofol in culture media for 3 hours treatment"	"The lowest expression was seen for miR-204, The highest expression was seen for miR-208b"	25568843
4591	Human	hsa-miR-20a	miRNA	hypoxia	paracrine function	Primary human adipose-derived stem cells (ADSCs)	hypoxia induce	downregulated	31368162
4592	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	31874343
4593	Human	hsa-miR-20a	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
4594	Human	hsa-miR-20a	miRNA	hypoxia	acute tubular injury	HK-2 cells-derived exosomes	hypoxia treatment	upregulated	32808649
4595	Human	hsa-miR-20a	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-20a was positively associated with 1st trimester exposure	27104955
4596	Human	hsa-miR-20a	miRNA	hypoxia	angiogenesis	adipose-derived stem cells (ADSCs)	hypoxia treatment	miR-20a expression was significantly downregulated compared to that under normoxia.	31368162
4597	Human	hsa-miR-20a	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	HUVECs	vascular endothelial growth factor (VEGF) treatment	upregulated	28097093
4598	Human	hsa-miR-20a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29653364
4599	Human	hsa-miR-20a	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 13¡ã HDT bed rest experiment	downregulated	28261104
4600	Human	hsa-miR-20a	miRNA	rapamycin	breast cancer	breast cancer cells	rapamycin treatment	over expression	26829385
4601	Human	hsa-miR-20a	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
4602	Human	hsa-miR-20a	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
4603	Human	hsa-miR-20a	miRNA	oridonin and the antileukemia drugs Ara-C and VP-16	chemoresistant leukemia	human leukemia cells	oridonin and the antileukemia drugs Ara-C and VP-16 treatment	downregulated	24872388
4604	Human	hsa-miR-20a	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	upregulated	24178909
4605	Human	hsa-miR-20a	miRNA	curcumin (Cur)	colorectal cancer (CRC)	RKO ; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts	curcumin treatment	downregulated	23194063
4606	Human	hsa-miR-20a	miRNA	hypoxia	colorectal cancer (CRC)	The human colon cancer cell lines LoVo and SW48	hypoxia induce	downregulated	30883936
4607	Human	hsa-miR-20a	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
4608	Human	hsa-miR-20a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose treatment	downregulated	32868134
4609	Human	hsa-miR-20a	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN45 cells	docetaxel (DTX) treatment	downregulated	31368060
4610	Human	hsa-miR-20a	miRNA	ruxolitinib	glioblastoma multiforme (GBM)	U87-MG cells	ruxolitinib treatment	upregulated	31452174
4611	Human	hsa-miR-20a	miRNA	endothelial-monocyte-activating polypeptide-II (EMAP-II)	glioblastoma multiforme (GBM)	U-87 and U-251 cells	endothelial-monocyte-activating polypeptide-II (EMAP-II) treatment	downregulated	27242439
4612	Human	hsa-miR-20a	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO2 cells	hypoxia induce	downregulated	31566731
4613	Human	hsa-miR-20a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
4614	Human	hsa-miR-20a	miRNA	vascular endothelial growth factor (VEGF)	inflammation	endothelial cell	vascular endothelial growth factor (VEGF)treatment treatment	?miR-20a expression is increased by VEGF	22696064
4615	Human	hsa-miR-20a	miRNA	sulfur mustard (SM)	lung diseases	plasma and serum	Sulfur mustard (SM) treatment	downregulated	26525353
4616	Human	hsa-miR-20a	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
4617	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells	lipopolysaccharide (LPS) treatment	upregulated	23562609
4618	Human	hsa-miR-20a	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell line RPMI8226	bortezomib? treatment	downregulated	26032093
4619	Human	hsa-miR-20a	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; L02 cells	free fatty acids (FFA) treatment	downregulated	30338914
4620	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	cultured chondrocytes	lipopolysaccharides (LPS) treatment	upregulated	31451219
4621	Human	hsa-miR-20a	miRNA	"phorbol-12-myristate-13-acetate (PMA), macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-¦ÊB ligand RANKL"	osteoclastogenesis	THP-1 human acute monocytic leukemia cells	"phorbol-12-myristate-13-acetate (PMA), macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-¦ÊB ligand RANKL treatment"	downregulated	31545439
4622	Human	hsa-miR-20a	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx2 treatment"	downregulated	21572246
4623	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	pediatric pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	29115456
4624	Human	hsa-miR-20a	miRNA	hypoxia	pelvic endometriosis	stromal cells	Hypoxia treatment	Levels of miR20a were upregulated in endometriotic stromal cells. Elevation of miR20a was upregulated by hypoxia inducible factor-1¦Á	22648654
4625	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	periodontal inflammation	Primary human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	downregulated	31552681
4626	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	29115456
4627	Human	hsa-miR-20a	miRNA	hydrogen sulfide (H2S)	preeclampsia (PE)	placental cells obtained from pregnant women with preeclampsia	placental cells obtained from pregnant women with preeclampsia treatment	downregulated	26992682
4628	Human	hsa-miR-20a	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
4629	Human	hsa-miR-20a	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	rhabdomyosarcoma (RMS)	RD and Rh30 rhabdomyosarcoma (RMS) cells	"Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment"	downregulated	30610105
4630	Human	hsa-miR-20a-3p	miRNA	IL-22	psoriasis	HaCaT cells (human keratinocyte cell line)	Interleukin-22 (IL-22) treatment	downregulated	29886071
4631	Human	hsa-miR-20a-5p	miRNA	phorbol-12-myristate-13-acetate(PMA)	allergic inflammation	HMC-1 mast cells	PMA/A23187 treatment	downregulated	30684894
4632	Human	hsa-miR-20a-5p	miRNA	mycobacterium tuberculosis (Mtb)	active tuberculosis (ATB)	human macrophages	Mycobacterium tuberculosis (Mtb) infection	downregulated	27494776
4633	Human	hsa-miR-20a-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	"PVT1 expression was significantly increased, whereas miR-20a-5p expression was significantly decreased in sepsis model mice and LPS-induced HK-2 cells compared with sham mice and control HK-2 cells"	33576456
4634	Human	hsa-miR-20a-5p	miRNA	TGF-¦Â1	asthma	BEAS-2B cells	TGF-¦Â1 treatment	MiR-20a-5p was downregulated in TGF-¦Â1-treated human bronchial epithelial cells	31883454
4635	Human	hsa-miR-20a-5p	miRNA	TGF-¦Â1	asthma	human bronchial epithelial BEAS-2B cells	transforming growth factor (TGF)-¦Â1 treatment	downregulated	31883454
4636	Human	hsa-miR-20a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
4637	Human	hsa-miR-20a-5p	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
4638	Human	hsa-miR-20a-5p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
4639	Human	hsa-miR-20a-5p	miRNA	pks+ E. coli	colorectal cancer (CRC)	HCT116 cells	colonised by pks+ E. coli treatment	upregulated	24658599
4640	Human	hsa-miR-20a-5p	miRNA	high glucose (HG)	dysfunction of endothelial progenitor cells (EPCs)	human endothelial progenitor cells (EPCs)	high glucose (HG) treatment	Circ-ADAM9 targeting PTEN and ATG7 promotes autophagy and apoptosis of diabetic endothelial progenitor cells by sponging mir-20a-5p.	32661238
4641	Human	hsa-miR-20a-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	Hsa-miR-196b-5p was downregulated in PC-3M IE8 cells treatment with IFN-¦Ã.	31882179
4642	Human	hsa-miR-20a-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
4643	Human	hsa-miR-20a-5p	miRNA	hypoglycemic	hepatocellular carcinoma (HCC)	HepG2 cells	hypoglycemic treatment	downregulated	27629773
4644	Human	hsa-miR-20a-5p	miRNA	anti-programmed cell death protein 1 (anti-PD-1) antibody	malignant melanoma (MM)	serum	anti-programmed cell death protein 1 (anti-PD-1) antibody treatment	Serum expression levels of miR-20a-5p was significantly higher in responders than in non-responders.	31843231
4645	Human	hsa-miR-20a-5p	miRNA	IFN-¦Â	multiple sclerosis (MS)	RRMS patients blood sample	IFN-¦Â treatment	downregulated	27752929
4646	Human	hsa-miR-20a-5p	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acid (FFA) treatment	downregulated	33344451
4647	Human	hsa-miR-20b	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
4648	Human	hsa-miR-20b	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
4649	Human	hsa-miR-20b	miRNA	propofol (PPF)	autophagic cell death	Human umbilical vein endothelial cells (HUVECs)	propofol treatment	Propofol promoted the expression of miR-20b	32826852
4650	Human	hsa-miR-20b	miRNA	BAY11-7082	autophagy	Mycobacterium tuberculosis (Mtb)-infected THP-1 cells	BAY 11-7082 treatment	upregulated	30011088
4651	Human	hsa-miR-20b	miRNA	rapamycin	breast cancer	breast cancer cells	rapamycin treatment	over expression	26829385
4652	Human	hsa-miR-20b	miRNA	hypoxia	cerebral ischemia injury (CII)	Human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	30628668
4653	Human	hsa-miR-20b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial senescence	human pulmonary microvascular endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28595801
4654	Human	hsa-miR-20b	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-20b was upregulated in propofol-treated group	24454982
4655	Human	hsa-miR-20b	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
4656	Human	hsa-miR-20b	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
4657	Human	hsa-miR-20b	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
4658	Human	hsa-miR-20b	miRNA	triptolide (TPL)	osteoarthritis (OA)	LPS-induced human monocytic cell line THP-1	triptolide (TPL) treatment	downregulated	29974310
4659	Human	hsa-miR-20b	miRNA	triptolide (TPL)	osteoarthritis (OA)	LPS-treated human monocytic cell line THP-1	triptolide (TPL) treatment	downregulated	29974310
4660	Human	hsa-miR-20b	miRNA	hydrogen sulfide (H2S)	preeclampsia (PE)	placental cells obtained from pregnant women with preeclampsia	placental cells obtained from pregnant women with preeclampsia treatment	downregulated	26992682
4661	Human	hsa-miR-20b	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (Mtb) infection	downregulated	30011088
4662	Human	hsa-miR-20b-3p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
4663	Human	hsa-miR-20b-3p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
4664	Human	hsa-miR-20b-3p	miRNA	temozolomide (TMZ)	temozolomide (TMZ) resistance in glioblastoma (GBM)	"LN229, U251, 551 W, and HG7 cells"	temozolomide (TMZ) treatment	lnc-TALC correlated with TMZ resistance via competitively binding miR-20b-3p to facilitate c-Met expression	31053733
4665	Human	hsa-miR-20b-5p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
4666	Human	hsa-miR-20b-5p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
4667	Human	hsa-miR-20b-5p	miRNA	platelet-derived growth factor (PDGF)	asthma	fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	downregulated	29549727
4668	Human	hsa-miR-20b-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	High Glucose (HG) treatment	upregulated	31636010
4669	Human	hsa-miR-20b-5p	miRNA	propofol (PPF)	ischemia/reperfusion (I/R) injury	human umbilical vein endothelial cells (HUVECs)	propofol treatment	miR-20b-5p was significantly higher and ULK1 was lower in propofol-preconditioned HUVECs with HR injury than in HUVECs with HR injury only	32098914
4670	Human	hsa-miR-20b-5p	miRNA	fractionated radiation	radiation-induced injury	human peripheral blood mononuclear cells	fractionated radiation treatment	upregulated	25313363
4671	Human	hsa-miR-21	miRNA	"3,3'-diindolylmethane (DIM)"	adipogenesis	MCF-7 cells	"3,3'-Diindolylmethane (DIM) treatment"	treatment of MCF-7 cells with DIM increased miR-21 expression and downregulated Cdc25A	21761201
4672	Human	hsa-miR-21	miRNA	taxol	breast cancer	The human breast adenocarcinoma MCF-7 cells	taxol treatment	downregulated	20082533
4673	Human	hsa-miR-21	miRNA	thymic stromal lymphopoietin (TSLP)	fungal keratitis	dendritic cells (DCs) from peripheral blood of healthy volunteers	thymic stromal lymphopoietin (TSLP)?treatment treatment	miR-21 was highly expressed in exosomes from TSLP-treated DCs	33253708
4674	Human	hsa-miR-21	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
4675	Human	hsa-miR-21	miRNA	resveratrol	inflammation	glioma cells	resveratrol (Res) treatment	downregulated	23793554
4676	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	cell division	human peripheral blood mononuclear cells	LPS treatment	upregulated	17700064
4677	Human	hsa-miR-21	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	?SSc fibroblasts	TGF-¦Â treatment	upregulated	23657402
4678	Human	hsa-miR-21	miRNA	docosahexaenoic acid (DHA)	osteogenesis	human breast cancer cell lines MDA-MB-231 ;MCF-7	docosahexaenoic acid (DHA) treatment	downregulated	22678116
4679	Human	hsa-miR-21	miRNA	5-fluorouracil (5-Fu)	pancreatic cancer (PC)	HT-29 cells	5-fluorouracil (5-FU) treatment	downregulated	24275137
4680	Human	hsa-miR-21	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
4681	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	acute coronary syndrome (ACS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30233677
4682	Human	hsa-miR-21	miRNA	CoCl2	acute kidney injury (AKI)	Human proximal tubular cell lines (HK-2 cells)	CoCl2 treatment	upregulated	30013485
4683	Human	hsa-miR-21	miRNA	CoCl2	acute kidney injury (AKI)	human umbilical vein endothelial cells (HUVECs)	treated with CoCl2	upregulated	28677811
4684	Human	hsa-miR-21	miRNA	hypoxia	acute kidney injury (AKI)	Human proximal tubular cell lines (HK-2 cells)	hypoxia induce	upregulated	30013485
4685	Human	hsa-miR-21	miRNA	L-mimosine	acute kidney injury (AKI)	Human proximal tubular cell lines (HK-2 cells)	L-Mimosine treatment	upregulated	30013485
4686	Human	hsa-miR-21	miRNA	kanglaite	advanced lung cancer	serum	Kanglaite treatment	Kanglaite injection on serum miRNA-21 in patients with advanced lung cancer was shown to significantly reduce the expression of miRNA-21.	29735968
4687	Human	hsa-miR-21	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-21 was inversely associated with PM25 exposure during the 2nd trimester of pregnancy	27104955
4688	Human	hsa-miR-21	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-21 was positively associated with 1st trimester exposure	27104955
4689	Human	hsa-miR-21	miRNA	budesonide	airway remodeling	Human bronchial fibroblasts	?budesonide treatment	downregulated	31204163
4690	Human	hsa-miR-21	miRNA	calcitriol	airway remodeling	Human bronchial fibroblasts	calcitriol treatment	downregulated	31204163
4691	Human	hsa-miR-21	miRNA	receptor inhibitor (SB431542)	airway remodeling	human bronchial fibroblasts (HBFs)	receptor inhibitor (SB431542) treatment	The high expression of miR-21 induced by TGF¦Â1 was reduced following the treatment with the SB431542 in HBFs.	29621415
4692	Human	hsa-miR-21	miRNA	SB431542	airway remodeling	TGF¦Â1-treated human bronchial fibroblasts (HBFs)	SB431542 treatment	downregulated	29621415
4693	Human	hsa-miR-21	miRNA	TGF-¦Â1	airway remodeling	human bronchial fibroblasts (HBFs)	TGF-¦Â3 treatment	upregulated	29621415
4694	Human	hsa-miR-21	miRNA	alcohol	alcohol stress	alcohol consumption in heavy drinkers	were allowed to drink up to 750 cc of beer? treatment	upregulated	25421511
4695	Human	hsa-miR-21	miRNA	chitin	allergic airway diseases (AAD)	bronchial epithelial cells and in A549 and H292 lung carcinoma cells	chitin treatment	upregulated	27463381
4696	Human	hsa-miR-21	miRNA	hepatitis C virus (HCV)	allergies and bronchial asthma	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	23633945
4697	Human	hsa-miR-21	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	29635890
4698	Human	hsa-miR-21	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
4699	Human	hsa-miR-21	miRNA	propofol (PPF)	anesthesia-induced neural cytotoxicity	human embryonic stem cell	propofol treatment	downregulated	24950164
4700	Human	hsa-miR-21	miRNA	ionizing radiation (IR)	angiogenesis	HUVEC cells	ionizing radiation (IR) treatment	upregulated	31128066
4701	Human	hsa-miR-21	miRNA	phosphatase of regenerating liver-3 (PRL-3)	angiogenesis	colon cancer cells	Phosphatase of regenerating liver-3 (PRL-3) treatment	"overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3"	22677902
4702	Human	hsa-miR-21	miRNA	sulfasalazine	ankylosing spondylitis (AS)	patients blood	sulfasalazine treatment	upregulated	24786924
4703	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	ankylosing spondylitis (AS)	fibroblasts	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32009856
4704	Human	hsa-miR-21	miRNA	metformin (Met)	anti-cancer therapy	"human skin keratinocyte cell line, HaCaT"	metformin treatment	downregulated	29286158
4705	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	anti-inflammatory responses	myocardial cell line H9c2(2-1)	exposed to LPS treatment	upregulated	25131238
4706	Human	hsa-miR-21	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
4707	Human	hsa-miR-21	miRNA	CC2238/¦ÁANP	apoptosis	CASMCs	CC2238/¦ÁANP treatment	downregulated	25401746
4708	Human	hsa-miR-21	miRNA	contrast medium (CM)	apoptosis	human renal proximal tubular epithelial (HK-2) cells	contrast medium (CM) treatment	downregulated	28901491
4709	Human	hsa-miR-21	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31966898
4710	Human	hsa-miR-21	miRNA	temozolomide (TMZ)	apoptosis	human glioblastoma U87MG cells	temozolomide treatment	over-express miR-21 in U87MG cells could significantly reduce TMZ-induced apoptosis	20633539
4711	Human	hsa-miR-21	miRNA	resveratrol	apoptosis	pancreatic cancers cells	resveratrol (RS) treatment	downregulated	23359184
4712	Human	hsa-miR-21	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
4713	Human	hsa-miR-21	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
4714	Human	hsa-miR-21	miRNA	arsenic trioxide (ATO)	As2O3 cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
4715	Human	hsa-miR-21	miRNA	inhaled corticosteroids	asthma	bronchial epidermal cells from asthma patients	inhaled corticosteroids treatment	downregulated	24995087
4716	Human	hsa-miR-21	miRNA	angiotensin II (Ang II)	atherosclerosis (AS)	human microvascular endothelial cells (HMECs)	angiotensin II (Ang II) treatment	upregulated	30950039
4717	Human	hsa-miR-21	miRNA	dihydromyricetin (DHM)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	dihydromyricetin (DMY) treatment	DMY decreases microRNA-21 (miR-21).	32301289
4718	Human	hsa-miR-21	miRNA	geniposide (GEN)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	geniposide treatment	geniposide pretreatment significantly increased miR-21 level in human umbilical vein endothelial cells (HUVECs) under ox-LDL condition.	32323738
4719	Human	hsa-miR-21	miRNA	teniposide	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HASMCs)	teniposide treatment	upregulated	30409428
4720	Human	hsa-miR-21	miRNA	tongxinluo (TXL)	atherosclerosis (AS)	normal human proximal tubular epithelial cells (HKCs) £» serum	Tongxinluo? treatment	downregulated	24370587
4721	Human	hsa-miR-21	miRNA	angiotensin II (Ang II)	atrial fibrosis	Neonatal cardiac fibroblasts	angiotensin II (Ang II) treatment	upregulated	22760500
4722	Human	hsa-miR-21	miRNA	connective tissue growth factor (CTGF)	atrial fibrosis	Neonatal cardiac fibroblasts	CTGF treatment	upregulated	22760500
4723	Human	hsa-miR-21	miRNA	arsenite	autophagy	L-02 cells	arsenite exposure	upregulated	27107786
4724	Human	hsa-miR-21	miRNA	isoflavone formononetin	bladder cancer	T24 cells	formononetin	downregulated	28139790
4725	Human	hsa-miR-21	miRNA	resveratrol	bladder cancer	T24 and 5637 cells	resveratrol (RS) treatment	downregulated	24535223
4726	Human	hsa-miR-21	miRNA	benzo(a)pyrene (BaP)	breast cancer	MDA-MB-231 cells	benzo(a)pyrene (BaP) exposure	downregulated	30155724
4727	Human	hsa-miR-21	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	upregulated	25120778
4728	Human	hsa-miR-21	miRNA	collagenase-2	breast cancer	breast cancer cells	collagenase-2?treatment	downregulated	23851508
4729	Human	hsa-miR-21	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	downregulated	28599484
4730	Human	hsa-miR-21	miRNA	DDT and BPA	breast cancer	MCF-7 breast cancer cells	DDT and BPA treatment	upregulated	22403704
4731	Human	hsa-miR-21	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4732	Human	hsa-miR-21	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4733	Human	hsa-miR-21	miRNA	hesperidin	breast cancer	MCF-7 cells	hesperidin treatment	downregulated	33050842
4734	Human	hsa-miR-21	miRNA	luteolin	breast cancer	MCF-7 cells	luteolin treatment	downregulated	33050842
4735	Human	hsa-miR-21	miRNA	oleuropein (OL)	breast cancer	MCF-7 cells	oleuropein treatment	Oleuropein significantly decreased expression of both miR-21 and miR-155 over time in a dose-dependent manner.	29905007
4736	Human	hsa-miR-21	miRNA	paclitaxel (PTX)	breast cancer	"HER2-positive cell lines, BT-474 and SKBR3"	paclitaxel treatment	upregulated	28509576
4737	Human	hsa-miR-21	miRNA	propofol (PPF)	breast cancer	MCF-7 cells	Propofol treatment	downregulated	30942630
4738	Human	hsa-miR-21	miRNA	silibinin (SB)	breast cancer	MCF-7 breast cancer cells	Silibinin treatment	downregulated	27066095
4739	Human	hsa-miR-21	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
4740	Human	hsa-miR-21	miRNA	TGF-¦Â	breast cancer	tumor samples of breast cancer	transforming growth factor-beta (TGF-beta) treatment	upregulated	18932017
4741	Human	hsa-miR-21	miRNA	TGF-¦Â1	breast cancer	MCF-7 cell line	TGF-¦Â1 treatment	upregulated	29151919
4742	Human	hsa-miR-21	miRNA	trastuzumab	breast cancer	BT474 cells	trastuzumab treatment	upregulated	29981261
4743	Human	hsa-miR-21	miRNA	trastuzumab	breast cancer	serum	Trastuzumab treatment	downregulated	30246355
4744	Human	hsa-miR-21	miRNA	trastuzumab or lapatinib	breast cancer	patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer	chemotherapy combin either trastuzumab or lapatinib treatment	upregulated	25086636
4745	Human	hsa-miR-21	miRNA	wound fluids (WFs) from breast cancer patients	breast cancer	human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line	WFs treatment	upregulated	28943910
4746	Human	hsa-miR-21	miRNA	zoledronic acid (ZA)	breast cancer	human breast cancer cell lines	zoledronic acid (ZA) treatment	downregulated	26905520
4747	Human	hsa-miR-21	miRNA	¦Á-linolenic acid (ALA)	breast cancer	MCF-7 cells	¦Á-linolenic acid (ALA) treatment	ALA reduced miR-21 expression	29342901
4748	Human	hsa-miR-21	miRNA	X-irradiated	bystander effect	HaCaT cells	X-irradiated treatment	downregulated	26080011
4749	Human	hsa-miR-21	miRNA	radiation	bystander effect	human fetal lung MRC-5 fibroblasts	different types of radiation treatment	upregulation	25483031
4750	Human	hsa-miR-21	miRNA	arsenite	tumorigenesis	HBE cells; A549 cells;HUVEC cells	arsenite exposure	upregulated	24012885
4751	Human	hsa-miR-21	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells by a low concentration (1.0¦ÌM) of arsenite	arsenic exposure	upregulated	25445583
4752	Human	hsa-miR-21	miRNA	high glucose (HG)	cardiac fibrosis	Human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31680453
4753	Human	hsa-miR-21	miRNA	polychlorinated biphenyls (PCBs)	cardiac injury	HUVECs	polychlorinated biphenyls (PCBs) treatment	upregulated	27288564
4754	Human	hsa-miR-21	miRNA	IFN	cardiomyocyte apoptosis	prostate cancer cells	IFN? treatment	cytokine IFN rapidly induces miR-21 expression in cells	20813833
4755	Human	hsa-miR-21	miRNA	kaempferol	cardioprotective therapy	vascular smooth muscle cell (VSMC)	Bioflavonoids treatment	"Kaempferol activates the BMP signaling pathway, induces miR-21 expression and downregulates DOCK4, 5, and 7, leading to inhibition of cell migration."	26048714
4756	Human	hsa-miR-21	miRNA	arsenic trioxide (ATO)	cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
4757	Human	hsa-miR-21	miRNA	hypoxia	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	22282338
4758	Human	hsa-miR-21	miRNA	H2O2	cataract	HLECs	H2O2 treatment	lncRNA ANRIL attenuated H2O2-induced cell injury in HELCs via up-regulating miR-21 via the activation of AMPK and ¦Â-catenin.	32310822
4759	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell differentiation	human dental pulp stem cells (DPSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	"the expression of miR-21 and STAT3 increased gradually in low concentration (1-10?ng/mL) of TNF-¦Á, while they were suppressed in high concentration (50-100?ng/mL)"	29620442
4760	Human	hsa-miR-21	miRNA	high glucose (HG)	cell proliferation	human aortic vascular smooth muscle cells (HASMCs)	high glucose treatment	upregulated	31672498
4761	Human	hsa-miR-21	miRNA	metformin (Met)	cell proliferation	"human skin keratinocyte cell line, HaCaT"	Metformin treatment	downregulated	29286158
4762	Human	hsa-miR-21	miRNA	substance P (SP)	cell proliferation	exosomes from human colonic epithelial cells (NCM460 and NCM460-NK1R)	substance P (SP) treatment	upregulated	31545921
4763	Human	hsa-miR-21	miRNA	tanshinone IIA (Tan IIA)	cell proliferation	high glucose-treated human aortic vascular smooth muscle cells (HASMCs)	Tanshinone IIA treatment	downregulated	31672498
4764	Human	hsa-miR-21	miRNA	arsenite	cell transformation	Immortalized HELF cells	arsenic exposure	upregulated	22387281
4765	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell-to-cell communication	human aortic endothelial cells (ECs) and their transfer to recipient cells	tumor necrosis factor alpha (TNF-¦Á) treatment	differently regulation	25315114
4766	Human	hsa-miR-21	miRNA	H2O2	cellular oxidative injury	human umbilical vein endothelial cells (HUVECs)	hydrogen peroxide (H2O2) treatment	upregulated	30037352
4767	Human	hsa-miR-21	miRNA	high glucose (HG)	cellular oxidative injury	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	30037352
4768	Human	hsa-miR-21	miRNA	oscillating glucose	cellular oxidative injury	human umbilical vein endothelial cells (HUVECs)	oscillating glucose treatment	upregulated	30037352
4769	Human	hsa-miR-21	miRNA	cisplatin (DDP)	cervical cancer (CC)	Human cervical adenocarcinoma cell Hela;human cervical squamous cancer cell line Siha	cisplatin treatment	downregulated	30352127
4770	Human	hsa-miR-21	miRNA	human papilloma viruses 16 (HPV16) E6	cervical cancer (CC)	SiHa cells	human papillomavirus E6 oncoprotein treatment	dysregulated	25539644
4771	Human	hsa-miR-21	miRNA	N-nitroso carcinogen N-methyl-N-nitro-N'-nitrosoguanidine (MNNG)	chemical carcinogenesis	GES-1 cells	MNNG treatment	upregulated	24821435
4772	Human	hsa-miR-21	miRNA	prostaglandin E2 (PGE2)	cholangiocarcinoma (CCA)	human cholangiocarcinoma cells	PGE2 treatment	upregulated	24699315
4773	Human	hsa-miR-21	miRNA	galangin	cholangiocarcinoma (CCA)	HCCC9810 cells	Galangin treatment	downregulated	32626749
4774	Human	hsa-miR-21	miRNA	HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA)	chronic heart failure (CHF)	human aortic endothelial cells	HDLNYHA treatment	downregulated	24958738
4775	Human	hsa-miR-21	miRNA	quercetin	chronic kidney disease (CKD)	HK-2 cells	quercetin treatment	Quercetin treatment significantly inhibited TGF-¦Â-induced miR-21 upregulation	30210596
4776	Human	hsa-miR-21	miRNA	berberine (BBR)	chronic lymphocytic leukemia (CLL)	peripheral blood mononuclear cells (PBMCs)	berberine (BBR) treatment	berberine could reduce the expression of miR-21 in comparison to the untreated group.	33174291
4777	Human	hsa-miR-21	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	p53-mutant MEG-01 cells	fludarabine treatment	specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets	20504344
4778	Human	hsa-miR-21	miRNA	berberine (BBR)	chronic lymphocytic leukemia (CLL)	peripheral blood mononuclear cells (PBMCs) of CLL patients	berberine (BBR) treatment	"Interestingly, berberine could reduce the expression of miR-21 in comparison to the untreated group."	33174291
4779	Human	hsa-miR-21	miRNA	curcumin (Cur)	chronic myeloid leukemia (CML)	K562 and LAMA84 cells	curcumin treatment	upregulated	27050372
4780	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (16HBE) cells	cigarette smoke extract (CSE) exposure	upregulated	29543496
4781	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells; bronchial fibroblasts (MRC-5 cells)	cigarette smoke extract (CSE) exposure	miR-21 levels were increased in CSE-treated HBE cells and in MRC-5 cells	30555555
4782	Human	hsa-miR-21	miRNA	bone morphogenetic protein 2 (BMP2)	chronic pancreatitis (CP)	human primary pancreatic stellate cells; human primary pancreatic fibroblast (hPFBs)	bone morphogenetic protein 2 (BMP2) treatment	downregulated	29303912
4783	Human	hsa-miR-21	miRNA	TGF-¦Â1	chronic rhinosinusitis with nasal polyps (CRSwNP)	Primary human nasal epithelial cells (PHNECs)	TGF-¦Â1 treatment	upregulated	30982052
4784	Human	hsa-miR-21	miRNA	TGF-¦Â1	chronic rhinosinusitis with nasal polyps (CRSwNP)	epithelial-mesenchymal transition (EMT)	TGF-¦Â1 treatment	upregulated	30982052
4785	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL"	23725219
4786	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL."	23725219
4787	Human	hsa-miR-21	miRNA	p-Cresyl sulfate (pCS)	clear cell renal cell carcinoma (ccRCC)	A498 and 786-O cells of ccRCC	p-Cresyl sulfate (pCS) treatment	upregulated	30824757
4788	Human	hsa-miR-21	miRNA	berberine (BBR)	colorectal cancer (CRC)	HCT116 cells	berberine (BBR) treatment	Berberine inhibited miR-21 expression.	29564000
4789	Human	hsa-miR-21	miRNA	epidermal growth factor (EGF)	colorectal cancer (CRC)	colon cancer cells (HT29; SW480; Caco-2)	epidermal growth factor (EGF) treatment	downregulated	23827854
4790	Human	hsa-miR-21	miRNA	TGF-¦Â	colorectal cancer (CRC)	OVCAR3 cells; Hela cells; HCT116 cells; MRC-5 cells; OSE cells; Human ovarian cancer tissue specimens and Primary fibroblast	TGF-¦Â treatment	upregulated	20533548
4791	Human	hsa-miR-21	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	U251 cells	Ursolic acid treatment	downregulated	22028478
4792	Human	hsa-miR-21	miRNA	butylcycloheptyl prodiginine (bPGN)	colorectal cancer (CRC)	HCT-116 colorectal cancer cells	butylcycloheptyl prodiginine (bPGN) treatment	downregulated	31155509
4793	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	colorectal cancer (CRC)	human colorectal adenocarcinoma cell line (Caco-2)	cigarette smoke extract (CSE) exposure	upregulated	31574306
4794	Human	hsa-miR-21	miRNA	curcumol	colorectal cancer (CRC)	"Human colorectal cancer cells lines LoVo, HCT-116, SW480"	curcumol treatment	downregulated	30811964
4795	Human	hsa-miR-21	miRNA	docosahexaenoic acid (DHA)	colorectal cancer (CRC)	HCT-116 and HCT-8 cells	docosahexaenoic acid (DHA) treatment	downregulated	26853468
4796	Human	hsa-miR-21	miRNA	fusobacterium nucleatum (F. nucleatum)	colorectal cancer (CRC)	"HCT116, HT29, LoVo, and SW480 CRC cell lines"	Fusobacterium nucleatum	upregulated	27876571
4797	Human	hsa-miR-21	miRNA	gambogic acid (GA)	colorectal cancer (CRC)	HT-29 cells	gambogic acid (GA) treatment	treatment with GA significantly decreased miR-21 expression in these cells.	30186399
4798	Human	hsa-miR-21	miRNA	hypoxia	colorectal cancer (CRC)	"CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)"	1 and 0.2% oxygen	upregulated	28207045
4799	Human	hsa-miR-21	miRNA	"JQ-1, Bromodoamin and extraterminal (BET) protein inhibitor"	colorectal cancer (CRC)	SW480 colon cancer cells	"JQ-1, Bromodoamin and extraterminal (BET) protein inhibitor treatment"	downregulated	29600711
4800	Human	hsa-miR-21	miRNA	pomegranate juice (PJ)	colorectal cancer (CRC)	?prostate cancer cells	Pomegranate juice (PJ) treatment	downregulated	21594291
4801	Human	hsa-miR-21	miRNA	sulforaphane (SFN)	colorectal cancer (CRC)	Human RKO colon cancer cells	Sulforaphane (SFN) treatment	downregulated	28176652
4802	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	HT29 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28192117
4803	Human	hsa-miR-21	miRNA	COX-2 inhibitor NS398	colorectal cancer (CRC)	HCA-7 cell	COX-2 inhibitor NS398 significantly decreased treatment	downregulated	25310697
4804	Human	hsa-miR-21	miRNA	metformin and 5-fluorouracil and oxaliplatin (FuOx)	colorectal cancer (CRC)	human colon cancer cells HT-29 and HCT-116	combinatorial treatment	upregulated	24465408
4805	Human	hsa-miR-21	miRNA	acute exercise	congestive heart failure (CHF)	CHF patients	acute exercise treatment	upregulated	26799589
4806	Human	hsa-miR-21	miRNA	AS1411	corneal neovascularization (CNV)	human limbus stroma (HLSC)	AS1411 treatment	AS1411 treatment also significantly reduced VEGF-stimulated induction of miR-21 and miR-221 in HLSC.	32081668
4807	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	coronary artery disease (CAD)	human endothelial cell from umbilical vein (HU-VECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28804550
4808	Human	hsa-miR-21	miRNA	thrombospondin-1 (TSP-1)	coronary heart disease (CHD)	Human aortic VSMCs	Thrombospondin-1 (TSP-1)?treatment treatment	?Acute inhibition of miR-21 led to a decrease in VSMC migration and proliferation caused by TSP-1	24314882
4809	Human	hsa-miR-21	miRNA	corticosteroid	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	corticosteroid treatment	CASC7 increased corticosteroid sensitivity by inhibiting the PI3K/AKT signaling pathway via targeting miR-21.	31412983
4810	Human	hsa-miR-21	miRNA	dexamethasone (DEX)	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	dexamethasone (DEX) treatment	Overexpression of CASC7 suppressed the PI3K/AKT signaling pathway and promoted the inhibition effects of dexamethasone on cell proliferation and cytokines secretion via targeting miR-21.	31412983
4811	Human	hsa-miR-21	miRNA	coxsackievirus B3 (CVB3)	coxsackievirus B3 (CVB3) infection disease	Hela cells	CVB3 infection	upregulated	31585536
4812	Human	hsa-miR-21	miRNA	matrine	sorafenib-induced cytotoxicity	HepG2 cells;Hep3B cells	exposure to matrine treatment	downregulated	25721136
4813	Human	hsa-miR-21	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	HepG2 (liver) cells	DENV infection	dysregulated	28365456
4814	Human	hsa-miR-21	miRNA	hyperglycemia	diabetes-induced retinal pathology	ARPE-19 cells	"hyperglycemic condition (high glucose, 33mM)"	upregulated	28465657
4815	Human	hsa-miR-21	miRNA	atrasentan	diabetic nephropathy (DN)	high glucose (HG)-induced podocytes	atractylon (Atr)?treatment	downregulated	30876973
4816	Human	hsa-miR-21	miRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	upregulated	30876973
4817	Human	hsa-miR-21	miRNA	tongxinluo (TXL)	diabetic nephropathy (DN)	human proximal tubular epithelial cell (HKCs) line	TXL treatment	downregulated	24370587
4818	Human	hsa-miR-21	miRNA	paclitaxel (PTX)	drug resistance	Human Gastric Adenocarcinoma Cell Line	paclitaxel treatment	expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901	27040946
4819	Human	hsa-miR-21	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	downregulated	30692507
4820	Human	hsa-miR-21	miRNA	acidic microenvironment	early-stage hepatocellular carcinoma (E-HCC)	The human HCC cell lines SMMC-7721 and Hep3B	acidic microenvironment treatment	upregulated	31037150
4821	Human	hsa-miR-21	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec2A cells	Progesterone treatment	upregulated	22543862
4822	Human	hsa-miR-21	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
4823	Human	hsa-miR-21	miRNA	high glucose (HG)	endothelial cytotoxicity	The blood samples from diabetes patients	high glucose treatment	upregulated	23771797
4824	Human	hsa-miR-21	miRNA	dihydromyricetin (DHM)	endothelial dysfunction	TNF-¦Á treated human umbilical vein endothelial cells (HUVECs)	dihydromyricetin (DMY) treatment	downregulated	29682517
4825	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29682517
4826	Human	hsa-miR-21	miRNA	propofol (PPF)	epithelial-mesenchymal transition (EMT)	MCF-7 cells	Propofol treatment	downregulated	30942630
4827	Human	hsa-miR-21	miRNA	Smilax glabra Roxb (PTFS)	epithelial-mesenchymal transition (EMT)	TGF-¦Â1-treated HK-2 cells	Smilax glabra Roxb (PTFS) treatment	downregulated	30304552
4828	Human	hsa-miR-21	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	High glucose (HG) upregulated miR-21 and induced EndMT in ECs	31680453
4829	Human	hsa-miR-21	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	Human umbilical vein endothelial cells (HUVECs)	TGF-¦Â treatment	upregulated	22095988
4830	Human	hsa-miR-21	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	HT-29 cells	TGF-¦Â treatment	upregulated	23483606
4831	Human	hsa-miR-21	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
4832	Human	hsa-miR-21	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human peritoneal mesothelial cells (HPMCs)	high glucose (HG) treatment	HG upregulated miRNA-21 expression and downregulated PTEN expression.	30210695
4833	Human	hsa-miR-21	miRNA	nicotine	esophageal cancer (EC)	human esophageal cells	nicotine treatment	upregulated	24756761
4834	Human	hsa-miR-21	miRNA	zinc deficiency	esophageal cancer (EC)	human ESCC and OSCC	zinc deficiency? treatment	upregulated	22689922
4835	Human	hsa-miR-21	miRNA	isoalantolactone	esophageal squamous cell carcinoma (ESCC)	ECA-109 cells; KYSE30 cells	Isoalantolactone treatment	downregulated	29781054
4836	Human	hsa-miR-21	miRNA	radiation	esophageal squamous cell carcinoma (ESCC)	TE-1 cells; esophageal squamous cell carcinoma (ESCC) tissues	radiation treatment	miR-21 expression is much lower in radiation sensitive ESCC tissues than radiation resistant tissues	31866421
4837	Human	hsa-miR-21	miRNA	radiation	esophageal squamous cell carcinoma (ESCC)	esophageal squamous cell carcinoma (ESCC) tumor tissues; ESCC TE-1 cells	radiation treatment	MiR-21 levels were increased in radiation-resistant compared with radiation-sensitive patients	32268810
4838	Human	hsa-miR-21	miRNA	X-rays	esophageal squamous cell carcinoma (ESCC)	ESCC tissues and TE-1 celss	2 Gy X-ray treatment	downregulated	31866421
4839	Human	hsa-miR-21	miRNA	curcumin (Cur)	fat	esophageal cancer cell lines	curcumin treatment	downregulated	22363450
4840	Human	hsa-miR-21	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
4841	Human	hsa-miR-21	miRNA	TGF-¦Â	fibrosis	Dermal fibroblasts	TGF-¦Â treatment	upregulated	31155965
4842	Human	hsa-miR-21	miRNA	matrine	follicular thyroid cancer	FTC-133 follicular thyroid cancer cells	Matrine treatment	downregulated	31579406
4843	Human	hsa-miR-21	miRNA	thrombospondin-1 (TSP-1)	fungal keratitis	exosomes of dendritic cells (DCs)	Thymic stromal lymphopoietin (TSLP) treatment	miR-21 was highly expressed in exosomes from TSLP-treated DCs	33253708
4844	Human	hsa-miR-21	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
4845	Human	hsa-miR-21	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	31572012
4846	Human	hsa-miR-21	miRNA	celastrol	gastric cancer (GC)	human gastric cancer cell line MKN45	celastrol treatment	downregulated	30989726
4847	Human	hsa-miR-21	miRNA	celastrol	gastric cancer (GC)	"human gastric adenocarcinoma cell line BGC-823, gastric mucinous adenocarcinoma cell line MGC-803"	celastrol treatment	upregulated	24434352
4848	Human	hsa-miR-21	miRNA	chidamide	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	chidamide treatment	downregulated	31572012
4849	Human	hsa-miR-21	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells	cisplatin treatment	DDP-resistant GC cells expressed higher levels of miR-21 compared with the parent cells.	31913198
4850	Human	hsa-miR-21	miRNA	curcumin (Cur)	gastric cancer (GC)	MGC-803 cell line	curcumin treatment	downregulated	30727807
4851	Human	hsa-miR-21	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN-45 cells	docetaxel (DTX) treatment	upregulated	33416185
4852	Human	hsa-miR-21	miRNA	H2O2	gastric cancer (GC)	HGC-27 cells	H2O2 treatment	upregulated	33329376
4853	Human	hsa-miR-21	miRNA	nicotine	gastric cancer (GC)	Human gastric adenocarcinoma cells (AGS)	Nicotine treatment	"EP2 or EP4 siRNA or antagonists impaired the nicotine-mediated NF-kB activity, upregulation of miR-16 and miR-21 and cell proliferation."	21081469
4854	Human	hsa-miR-21	miRNA	S-1/oxaliplatin	gastric cancer (GC)	gastric tumor specimens	?S-1/Oxaliplatin?(intravenous injection) treatment	miR-181b and miR-21 was significantly overexpressed in gastric tumors	21876743
4855	Human	hsa-miR-21	miRNA	myricetin-loaded mixed micelles (MYR-MCs)	glioblastoma multiforme (GBM)	human glioblastoma cells	myricetin-loaded mixed micelles (MYR-MCs) treatment	downregulated	27757032
4856	Human	hsa-miR-21	miRNA	temozolomide and irradiation	glioblastoma multiforme (GBM)	primary glioblastoma cells; U87MG cells; U251MG cells; U118MG cells	temozolomide and irradiation treatment	upregulated	33082482
4857	Human	hsa-miR-21	miRNA	type I interferon (IFN)	glioblastoma multiforme (GBM)	T98 cells; SKMG1 cells; U251MG cells; U87MG cells	Type I IFNs treatment	The Modulation of MicroRNAs by Type I IFN through the Activation of Signal Transducers and Activators of Transcription 3 in Human Glioma	19934272
4858	Human	hsa-miR-21	miRNA	Cl-amidine	glioblastoma multiforme (GBM)	LN18 and LN229 cells	Cl-amidine treatment	downregulated	30597867
4859	Human	hsa-miR-21	miRNA	metformin (Met)	glioblastoma multiforme (GBM)	U87 cells	metformin(Met) treatment	downregulated	33059952
4860	Human	hsa-miR-21	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma-derived exosomes (GDEs)	hypoxia treatment	The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN).	29713056
4861	Human	hsa-miR-21	miRNA	si wei xiao xiu yin	glioblastoma multiforme (GBM)	U87 cells	Si wei xiao xiu yin treatment	downregulated	32448616
4862	Human	hsa-miR-21	miRNA	TGF-¦Â	granular corneal dystrophy type 2 (GCD2)	Primary corneal fibroblasts	TGF-¦Âtreatment treatment	upregulated	26915797
4863	Human	hsa-miR-21	miRNA	sophocarpine (SC)	head and neck squamous cell carcinoma (HNSCC)	UM-SCC-22B and UM-SCC-47 cells	SC treatment	downregulated	28571917
4864	Human	hsa-miR-21	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	downregulated	27874954
4865	Human	hsa-miR-21	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells £¬ HepG2.2.15 cells.	hepatitis B virus X protein (HBx) treatment	downregulated	25260533
4866	Human	hsa-miR-21	miRNA	mineral pitch (MP)	hepatocellular carcinoma (HCC)	Huh-7 cells	Mineral Pitch (MP) treatment	downregulated	27233240
4867	Human	hsa-miR-21	miRNA	TGF-¦Â1	liver fibrosis	QSG-7701 cells	TGF-¦Â1 treatment	upregulated	25661333
4868	Human	hsa-miR-21	miRNA	"3,3'-diindolylmethane (DIM)"	liver fibrosis	HSC-T6 cell line and primary hepatic stellate cells (HSCs)	"3,3'-Diindolylmethane (DIM) treatment"	downregulated	23902531
4869	Human	hsa-miR-21	miRNA	compound astragalus and salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	TGF-¦Â1-stimulated HepG2 cells	Compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	downregulated	30412748
4870	Human	hsa-miR-21	miRNA	compound Astragalus and Salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	HepG2 cells	compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	CASE downregulated miR-21 expression in TGF-¦Â 1-stimulated HepG2 cells.	30412748
4871	Human	hsa-mir-21	miRNA	dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S)	hepatocellular carcinoma (HCC)	HepG2 human hepatoma cells	10nM DHEA and DHEA-S treatment	upregulated	24845419
4872	Human	hsa-miR-21	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
4873	Human	hsa-miR-21	miRNA	indole-3-carbinol (I3C)	hepatocellular carcinoma (HCC)	"human HCC cell lines, SK-Hep-1 and SNU-449"	I3C treatment	downregulated	25447674
4874	Human	hsa-miR-21	miRNA	kaempferol	hepatocellular carcinoma (HCC)	HepG2 cells	kaempferol treatment	downregulated	30477356
4875	Human	hsa-miR-21	miRNA	mycobacterium leprae	hepatocellular carcinoma (HCC)	monocytes	Mycobacterium leprae treatment	"The most dysregulated miRNA in L-lep lesions, hsa-mir-21, was upregulated in Mycobacterium leprae-infected monocytes"	22286305
4876	Human	hsa-miR-21	miRNA	notoginsenoside R1 (NGR1)	hepatocellular carcinoma (HCC)	"human HCC cell lines MHCC97H, BEL7402, Huh7, HepG2, PLC/PRF/5 (PLC), and SMMC7721"	Notoginsenoside R1 (NG-R1) treatment	downregulated	31559550
4877	Human	hsa-miR-21	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
4878	Human	hsa-miR-21	miRNA	polysaccharides (PRP1£©	hepatocellular carcinoma (HCC)	HepG2 cells	polysaccharides (PRP1£©treatment	downregulated	32380108
4879	Human	hsa-miR-21	miRNA	pSG5-HBx plasmid	hepatocellular carcinoma (HCC)	Huh 7 and Hep G2 cells	transfect treatment	upregulated	24633222
4880	Human	hsa-miR-21	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Human HCC HepG2 and Huh7 cells, and SR-HCC cells"	sorafenib treatment	"Sorafenib induced translocation of miR-21 to the nucleus, where it promoted the expression of SNHG1"	31053148
4881	Human	hsa-miR-21	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
4882	Human	hsa-miR-21	miRNA	visfatin	hepatocellular carcinoma (HCC)	HepG2 cells	visfatin treatment	upregulated	29808800
4883	Human	hsa-miR-21	miRNA	Shenqi pollen capsules (SPCs)	high-altitude deacclimatization syndrome (HADAS)	serum	Shenqi pollen capsules (SPCs) treatment	upregulated	31828172
4884	Human	hsa-miR-21	miRNA	NPV-LDE-225 (Erismodegib)	human immunodeficiency virus (HIV)-1 infection	Glioblastoma initiating cells (GICs)	NPV-LDE-225 (Erismodegib) treatment	downregulated	23482671
4885	Human	hsa-miR-21	miRNA	epigallocatechin-3-gallate (EGCG)	hormone refractory prostate cancer (HRPC)	LNCaP and 22R¦Í cells	Green tea polyphenol EGCG treatment	downregulated	21177307
4886	Human	hsa-miR-21	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
4887	Human	hsa-miR-21	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
4888	Human	hsa-miR-21	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
4889	Human	hsa-miR-21	miRNA	platelet derived growth factor-BB (PDGF-BB)	hypertension	vascular smooth muscle cells (VSMCs)	PDGF©\bb treatment	"?GAS5 inhibits PDGF-bb-induced VSMC proliferation and migration, partly through acting as a competing endogenous RNA of miR-21"	31069831
4890	Human	hsa-miR-21	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	upregulated	26500110
4891	Human	hsa-miR-21	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	upregulated	29516639
4892	Human	hsa-miR-21	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	downregulated	29516639
4893	Human	hsa-miR-21	miRNA	intermittent hypoxia (IH)	hypoxemia	blood	intermittent (HI) hypoxia treatment	miR-21 was upregulated in intermittent (HI) hypoxia treatment group.	30416683
4894	Human	hsa-miR-21	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary artery smooth muscle cells	hypoxia treatment	miR-21 expression was upregulated in hypoxia cell models.	29198701
4895	Human	hsa-miR-21	miRNA	hypoxia	hypoxic brain injury	human neural stem cells (hNSCs)	oxygen and glucose deprivation (OGD) treatment	upregulated	30291880
4896	Human	hsa-miR-21	miRNA	imatinib	imatinib resistance	human acute lymphoblastic leukemia cell line Sup-b15	imatinib treatment	upregulated	25451263
4897	Human	hsa-miR-21	miRNA	Ig-like transcript 3 (ILT3)	immune inflammatory	human CD8(+) T suppressor cells	Ig-like transcript 3 (ILT3) treatment	upregulated	22387553
4898	Human	hsa-miR-21	miRNA	medroxyprogesterone acetate (MPA)	impaired decidualization	human endometrial stromal cell (hESC)	medroxyprogesterone acetate (MPA) treatment	downregulated	30772912
4899	Human	hsa-miR-21	miRNA	collagen IV and vascular endothelial growth factor (VEGF)	cell differentiation	pluripotent stem cells (iPSC)	collagen IV and VEGF treatment	upregulated	24356956
4900	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	infantile pneumonia (IP)	MRC5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	NKILA weakens TNF-¦Á-induced inflammation of MRC-5 cells by miR-21 upregulated	32013579
4901	Human	hsa-miR-21	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
4902	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	inflammation	Airway normal and cancer epithelial cells (16HBE and A549)	cigarette smoke extracts (CSE) exposure	upregulated	31054160
4903	Human	hsa-miR-21	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
4904	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
4905	Human	hsa-miR-21	miRNA	molecular hydrogen	inflammatory injury	Retinal Microglia cells	Molecular hydrogen?treatment	downregulated	23826519
4906	Human	hsa-miR-21	miRNA	propofol (PPF)	inflammatory response	human umbilical vein endothelial cells (HUVECs)	propofol treatment	upregulated	29039542
4907	Human	hsa-miR-21	miRNA	retinoic acid (RA)	inflammatory response	"breast carcinoma cells,MCF-7 Cells"	retinoic acid? treatment	upregulated	21131358
4908	Human	hsa-miR-21	miRNA	extract of Celastrus orbiculatus (COE)	inflammatory response	H. pylori-infected GES-1 cells	The extract of Celastrus orbiculatus (COE) treatment	downregulated	31035975
4909	Human	hsa-miR-21	miRNA	helicobacter pylori (H. pylori)	inflammatory response	GES-1 cells	Helicobacter pylori (H. pylori) infection	upregulated	31035975
4910	Human	hsa-miR-21	miRNA	gemcitabine (GEM)	insulin resistance accompanies obesity	?serum	gemcitabine treatment	downregulated	23177026
4911	Human	hsa-miR-21	miRNA	galla chinensis ointment	keloids	human keloid-derived fibroblasts	Galla chinensis ointment treatment	Galla chinensis inhibited the expression of miR-21.	32216491
4912	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	kidney damage	HK-2 cell	lipopolysaccharide (LPS) treatment	upregulated	28821165
4913	Human	hsa-miR-21	miRNA	calcium oxalate monohydrate (COM)	kidney stone disease	HK-2 cells	calcium oxalate monohydrate (COM) treatment	MiR-21 promotes calcium oxalate-induced renal tubular cell injury by targeting PPARA.	32628541
4914	Human	hsa-miR-21	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
4915	Human	hsa-miR-21	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
4916	Human	hsa-miR-21	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
4917	Human	hsa-miR-21	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
4918	Human	hsa-miR-21	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
4919	Human	hsa-miR-21	miRNA	leukemia microvesicles	leukemia	healthy hematopoietic stem cells	leukemia microvesicles transformation	upregulated	28218044
4920	Human	hsa-miR-21	miRNA	leukemia microvesicles	leukemia	hematopoietic stem progenitor cells (HSPCs)	leukemia microvesicles treatment	upregulated	31429853
4921	Human	hsa-miR-21	miRNA	decabromodiphenyl ether (BDE-209)	lipid accumulation	THP-1 macrophages	decabromodiphenyl ether (BDE-209) treatment	downregulated	30597220
4922	Human	hsa-miR-21	miRNA	decabromodiphenyl ether (BDE-209)	lipid uptake	THP-1 cells	decabromodiphenyl ether (BDE-209) treatment	"miR-21 were significantly suppressed by BDE-209?at concentrations of 6.25, 12.5 and 25?¦ÌM."	30597220
4923	Human	hsa-miR-21	miRNA	berberine (BBR)	inflammation	human dental pulp fibroblast	berberine (BBR) treatment	downregulated	31837588
4924	Human	hsa-miR-21	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
4925	Human	hsa-miR-21	miRNA	coptidis rhizoma aqueous extract	hepatocellular carcinoma (HCC)	human hcc mhcc97-l cells	Coptidis rhizoma aqueous extract treatment	upregulated	22977465
4926	Human	hsa-miR-21	miRNA	microcystin-leucine arginine (MC-LR)	hepatocellular carcinoma (HCC)	WRL-68 cells	microcystin-LR treatment	upregulated	22265967
4927	Human	hsa-miR-21	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	downregulated	24431000
4928	Human	hsa-miR-21	miRNA	trichloroethylene (TCE)	liver damage	human HL-7702 cells	Trichloroethylene (TCE) treatment	downregulated	31140026
4929	Human	hsa-miR-21	miRNA	angiotensin-(1-7)	liver fibrosis	HEK-293 cells	angiotensin-(1-7) treatment	downregulated	27502441
4930	Human	hsa-miR-21	miRNA	corilagin	liver fibrosis	hepatic stellate LX2 cell line	Corilagin treatment	downregulated	31752524
4931	Human	hsa-miR-21	miRNA	5-fluorouracil (5-Fu)	lung cancer	A549 cells	5-fluorouracil (5-FU) treatment	"Our findings demonstrated that the overexpression of miR-21 decreased 5-fluorouracil-induced apoptosis and necrosis, and the opposite effects were obtained by the suppression of miR-21."	31934061
4932	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	29501572
4933	Human	hsa-miR-21	miRNA	cisplatin (DDP)	lung cancer	A549 cells	cisplatin treatment	upregulated	30644017
4934	Human	hsa-miR-21	miRNA	clopidogrel	lung cancer	NCI cells; FaDu cells	clopidogrel treatment	upregulated	32326378
4935	Human	hsa-miR-21	miRNA	curcumin (Cur)	lung cancer	Human lung adenocarcinoma A549 cells	curcumin treatment	downregulated	24293118
4936	Human	hsa-miR-21	miRNA	curcumin (Cur)	lung cancer	A549 cells	curcumin treatment	upregulated	24293118
4937	Human	hsa-miR-21	miRNA	lidocaine	lung cancer	A549/DDP cells	Lidocaine (Lido) treatment	downregulated	30644017
4938	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	lung cancer	primary human lung cancer cells	lipopolysaccharide (LPS) treatment	upregulated	27286259
4939	Human	hsa-miR-21	miRNA	Sinomenine (SIN)	lung cancer	A549 cells; H1299 cells	Sinomenine treatment	Sinomenine downregulates oncogenic microRNA-21 (miR-21)	32349289
4940	Human	hsa-miR-21	miRNA	Skullcapflavone I (SF I)	lung cancer	A549 and H1975 cells	Skullcapflavone I treatment	downregulated	31301304
4941	Human	hsa-miR-21	miRNA	solasonine (SS)	lung cancer	human lung cancer cell A5492	solasodine treatment	downregulated	28283413
4942	Human	hsa-miR-21	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
4943	Human	hsa-miR-21	miRNA	¦Â-adrenergic agonist and Epac activator	malignant astrocytic gliomas	human glioblasoma cell line U87MG and human astrocytoma cell line 1321N1	¦Â-adrenergic agonist and Epac activator treatment	downregulated	27504157
4944	Human	hsa-miR-21	miRNA	prolactin (PRL)	mammary development	HC11 mammary cells	levels increased in upon prolactin treatment	upregulated	24497923
4945	Human	hsa-miR-21	miRNA	Penetratin-tagged STAT3-NTD inhibitor (S3-NTDi)	medulloblastoma	"MB cell lines DAOY (SHH-TP53-mutated) and D341 (Group 3, Non-WNT/SHH), HD-MB03 cells (Group 3, Non-WNT/SHH, MYC amplified)"	Penetratin-tagged STAT3-NTD inhibitor (S3-NTDi) treatment	downregulated	29280516
4946	Human	hsa-miR-21	miRNA	Akt inhibitor and the EGFR inhibitor (Gefitinib)	melanogenesis	A375.S2 cells	gefitinib	downregulated	28398611
4947	Human	hsa-miR-21	miRNA	ultraviolet (UV) irradiation	melanogenesis	A375.S2 cells	UV treatment	upregulated	28398611
4948	Human	hsa-miR-21	miRNA	arsenite	melanoma	human keratinocyte HaCaT cell line	arsenic (As) exposure	upregulated	27054085
4949	Human	hsa-miR-21	miRNA	cantharidin (CTD)	melanoma	A375 cells	cantharidin (CTD) treatment	CTD treatment reduced microRNA (miR)-21 expression.	30221692
4950	Human	hsa-miR-21	miRNA	cordycepin	migration of renal cell carcinoma	Caki-1 cells	cordycepin	downregulated	29070781
4951	Human	hsa-miR-21	miRNA	ibrutinib	multiple myeloma (MM)	"Human MM cell lines, LP-1, U266, MM.1S, and MM.1R, Primary patient MM (ppMM) cells"	ibrutinib treatment	downregulated	29320977
4952	Human	hsa-miR-21	miRNA	berberine (BBR)	multiple myeloma (MM)	human multiple myeloma cells	berberine (BBR) treatment	downregulated	23247593
4953	Human	hsa-miR-21	miRNA	berberine (BBR)	multiple myeloma (MM)	multiple myeloma cells	berberine (BBR) treatment	upregulated	25000828
4954	Human	hsa-miR-21	miRNA	hypoxia	multiple myeloma (MM)	U266 cells	hypoxia treatment	upregulated	29158801
4955	Human	hsa-miR-21	miRNA	fumaric acid esters	multiple sclerosis (MS)	T helper-17 cells	fumaric acid esters treatment	downregulated	30698680
4956	Human	hsa-miR-21	miRNA	TGF-¦Â	myelodysplastic syndrome (MDS)	MDS marrow samples	?TGF-¦Â treatment	upregulated	23390194
4957	Human	hsa-miR-21	miRNA	arsenic trioxide (ATO)	myeloid leukemia	HL60 cells;K562 cells	arsenic trioxide (ATO) treatment	"pre-miR-21 expression increased resistance to ATO, nevertheless not affecting cell growth alone. miRNA-21 by targeting PDCD4 may play a functional role in modulating ATO-induced cell death."	20143188
4958	Human	hsa-miR-21	miRNA	hypoxia	myocardial ischaemic injury	H9c2 cells;HL-1 cells;HCM cells	cells under hypoxic conditions (2% O2 or CoCl2) treatment	upregulated	24983504
4959	Human	hsa-miR-21	miRNA	graphene oxide (GO)	nanoparticles toxicity	MCF-7 cells	graphene oxide (GO) treatment	upregulated	32070776
4960	Human	hsa-miR-21	miRNA	graphene oxide (GO)	nanoparticles toxicity	KMBC/71 cells	graphene oxide (GO) treatment	downregulated	32070776
4961	Human	hsa-miR-21	miRNA	graphene oxide (GO)	nanoparticles toxicity	human umbilical vein endothelial cells (HUVECs)	graphene oxide (GO) treatment	upregulated	32070776
4962	Human	hsa-miR-21	miRNA	graphene quantum dots (GQDs)	nanoparticles toxicity	MCF-7 cells	graphene quantum dots (GQDs) treatment	downregulated	32070776
4963	Human	hsa-miR-21	miRNA	graphene quantum dots (GQDs)	nanoparticles toxicity	KMBC/71 cells	graphene quantum dots (GQDs) treatment	downregulated	32070776
4964	Human	hsa-miR-21	miRNA	latent membrane protein 1 (LMP1)	nasopharyngeal carcinoma (NPC)	cancer stem cells (CSCs) in NPC	latent membrane protein 1 (LMP1) treatment	upregulated	26568302
4965	Human	hsa-miR-21	miRNA	cyclosporine A (CsA)	nephrotoxicity	HEK293	cyclosporine A treatment	upregulated	28414804
4966	Human	hsa-miR-21	miRNA	cyclosporine A (CsA)	nephrotoxicity	human proximal tubular epithelial cells (HPTECs)	exposure to cyclosporine A (CsA) treatment	upregulated	25266172
4967	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	bladder cancer	"bladder cancer cells,T24 cells"	doxorubicin treatment	upregulated	21468550
4968	Human	hsa-miR-21	miRNA	lycopene	nonalcoholic fatty liver disease (NAFLD)	Hepa 1¨C6 cells	Lycopene treatment	downregulated	22968990
4969	Human	hsa-miR-21	miRNA	epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)	non-small cell lung cancer (NSCLC)	NSCLC patients	EGFR-TKI treatment	upregulated	24331411
4970	Human	hsa-miR-21	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	NCI-H460 cells; A549 cells	ionizing radiation (IR) treatment	IR enhanced the interaction between lncRNA GAS5 and the miR-21/PTEN/Akt axis.	32020207
4971	Human	hsa-miR-21	miRNA	osimertinib	non-small cell lung cancer (NSCLC)	H1975 cells	osimertinib treatment	The relative expression levels of miR-21 was significantly upregulated after treated with 100 nM osimertinib for 24 h.	32375124
4972	Human	hsa-miR-21	miRNA	propofol (PPF)	non-small cell lung cancer (NSCLC)	A549 cells	Propofol treatment	Propofol inhibited miR-21 expression	32925348
4973	Human	hsa-miR-21	miRNA	triptolide (TPL)	non-small cell lung cancer (NSCLC)	The human lung cancer cell line PC-9	triptolide (TPL) treatment	upregulated	26847601
4974	Human	hsa-miR-21	miRNA	oxidized low density lipoprotein (ox-LDL)	breast cancer	human mammary epithelial cells (MCF10A)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	23091604
4975	Human	hsa-miR-21	miRNA	"TNF-¦Á, IL-6, leptin, resistin , free fatty acids (FFAs)"	obesity and obesity-associated insulin resistance	human mature adipocytes	"TNF-¦Á, IL-6, leptin, resistin , FFAs treatment"	upregulated	28627656
4976	Human	hsa-miR-21	miRNA	thyroid hormone	opioid tolerance	hepatoma cells	Thyroid hormone (T(3))? treatment	over expression	23442323
4977	Human	hsa-miR-21	miRNA	opisthorchis viverrini	opisthorchis viverrini infection	human urine	infect with Opisthorchis viverrini	upregulated in the urine	26456596
4978	Human	hsa-miR-21	miRNA	curcumin (Cur)	oral cancer	oral cancer stem cells of UD-SCC2 (HPV+ve) and UPCI:SCC131 and UPCI: SCC 84(HPV¨Cve) cell lines	curcumin treatment	downregulated	30319975
4979	Human	hsa-miR-21	miRNA	hypoxia	oral squamous cell carcinoma (OSCC)	oral squamous cell carcinoma (OSCC) cells	hypoxia treatment	upregulated	26992424
4980	Human	hsa-miR-21	miRNA	porphyromonas gingivalis	oral squamous cell carcinoma (OSCC)	OSCC Tca8113 cells	Porphyromonas gingivalis infection treatment	upregulated	31243990
4981	Human	hsa-miR-21	miRNA	arecoline	oral submucous fibrosis (OSF)	buccal mucosal fibroblasts (BMFs)	arecoline treatment	MiR-21 expression was induced in BMFs by arecoline treatment in a dose-dependent manner.	33191095
4982	Human	hsa-miR-21	miRNA	hypoxia	orthodontic tooth movement	Periodontal ligament cells (PDLCs)	hypoxia induce	upregulated	30930976
4983	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	orthopedic diseases	osteoblastic hFOB1.19 cells	lipopolysaccharide (LPS) treatment	downregulated	26516113
4984	Human	hsa-miR-21	miRNA	mechanical stretch	osteogenesis	human periodontal ligament stem cells (PDLSCs)	exposed to mechanical stretch treatment	upregulated	25203845
4985	Human	hsa-miR-21	miRNA	honokiol	osteosarcoma (OS)	Saos-2 cells; Mg-63 cells	honokiol (HNK) treatment	"HNK was able to induce aberrant expression of miRNAs in human OS cells, and miR-21 was one of the miRNAs that was most significantly downregulated."	29393336
4986	Human	hsa-miR-21	miRNA	Piceatannol (Pice)	osteosarcoma (OS)	MG-63; Saos-2 cells	Piceatannol (Pice) treatment	downregulated	32901863
4987	Human	hsa-miR-21	miRNA	celastrol	ovarian cancer (OC)	human ovarian carcinoma cells	celastrol treatment	downregulated	27840916
4988	Human	hsa-miR-21	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
4989	Human	hsa-miR-21	miRNA	TGF-¦Â1	ovarian cancer (OC)	human fibroblasts	TGF-¦Â1 treatment	"In primary cultured fibroblasts, mature miR-21 increases after TGF-¦Â1 treatment"	23784029
4990	Human	hsa-miR-21	miRNA	caudatin	oxidative stress	human gastric carcinoma cell lines	caudatin? treatment	downregulated	23708208
4991	Human	hsa-miR-21	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	oxidative stress	human lung carcinoma cell line (A549)	NPs treatment	downregulated	28400205
4992	Human	hsa-miR-21	miRNA	hypoxia	pancreatic cancer (PC)	human pancreatic cancer (PC) cells	Hypoxia treatment	upregulated	23272057
4993	Human	hsa-miR-21	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
4994	Human	hsa-miR-21	miRNA	propofol (PPF)	pancreatic cancer (PC)	PANC-1 pancreatic cancer cells	Propofol treatment	downregulated	27829997
4995	Human	hsa-miR-21	miRNA	epidermal growth factor (EGF)	pancreatic ductal adenocarcinoma (PDAC)	PANC-1 cells	epidermal growth factor (EGF) treatment	upregulated	30464258
4996	Human	hsa-miR-21	miRNA	H2O2	pancreatic ductal adenocarcinoma (PDAC)	primary human pancreatic stellate cells (PSCs)	?H2O2 treatment	upregulated	29854071
4997	Human	hsa-miR-21	miRNA	N-acetyl-L-cysteine (NAC)	pancreatic ductal adenocarcinoma (PDAC)	?H2O2-treated primary human pancreatic stellate cells (PSCs)	N-acetyl-L-cysteine (NAC) treatment	downregulated	29854071
4998	Human	hsa-miR-21	miRNA	resveratrol	pancreatic ductal adenocarcinoma (PDAC)	?H2O2-treated primary human pancreatic stellate cells (PSCs)	resveratrol (Res) treatment	downregulated	29854071
4999	Human	hsa-miR-21	miRNA	matrine	papillary thyroid cancer (PTC)	TPC-1 cells	matrine treatment	downregulated	30127885
5000	Human	hsa-miR-21	miRNA	docosahexaenoic acid (DHA)	parkinson's disease (PD)	SH-Y5Y cells	docosahexaenoic acid (DHA) treatment	downregulated	28346830
5001	Human	hsa-miR-21	miRNA	high glucose (HG)	peritoneal fibrosis	human peritoneal mesothelial cell lines HMrSV5 cells	high glucose (HG) treatment	upregulated	29207016
5002	Human	hsa-miR-21	miRNA	glucocorticoid (GC)	polymyositis (PM)	PM patients	glucocorticoids	upregulated	26873848
5003	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	postoperative peritoneal adhesion (PPA)	The human peritoneal mesothelium cells (HPMCs)	lipopolysaccharide (LPS) treatment	the effect of Cox-2 on LPS induced HPMCs injury was achieved by negatively regulation of miR-21 and targeted TLR4 through NF-¦ÊB pathway axis.	31885500
5004	Human	hsa-miR-21	miRNA	vitamin D	preeclampsia (PE)	HTR-8/SVneo cells	Vitamin D treatment	downregulated	31068287
5005	Human	hsa-miR-21	miRNA	emodin	pressure ulcer (PU)	HaCaT cells	Emodin treatment	upregulated	31250665
5006	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	pressure ulcer (PU)	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	31250665
5007	Human	hsa-miR-21	miRNA	"4', 5, 7-trihydroxy-3', 5'-dimethoxyflavone (Tricin)"	prostate cancer	PC3 cell line	"4', 5, 7-Trihydroxy-3', 5'-dimethoxyflavone (Tricin) treatment"	downregulated	29447469
5008	Human	hsa-miR-21	miRNA	docetaxel (DTX)	prostate cancer	"The human androgen-insensitive prostate carcinoma cell line, PC3"	docetaxel (DTX) treatment	upregulated	20581857
5009	Human	hsa-miR-21	miRNA	hyperoside and quercetin in combination (QH; 1:1)	prostate cancer	human prostate cancer cells	QH treatment	downregulated	25354548
5010	Human	hsa-miR-21	miRNA	methylated urolithin A	prostate cancer	human prostate cancer cells	Methylated urolithin A treatment	downregulated	27725205
5011	Human	hsa-miR-21	miRNA	TGF-¦Â	prostate cancer	HASCs	TGF-¦Â treatment	upregulated	19816956
5012	Human	hsa-miR-21	miRNA	¦Á-solanine	prostate cancer	human prostate cancer cell PC-3	¦Á-solanine treatment	downregulated	25116803
5013	Human	hsa-miR-21	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in plasma	27535005
5014	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	HaCaT and NHEKs cell lines	tumor necrosis factor alpha (TNF-¦Á) treatment	"MEG3/miR-21 axis may regulate the expression of caspase-8, and further influence the proliferation and apoptosis of psoriasis keratinocyte, Act-HaCaT and Act- HHEK"	31660855
5015	Human	hsa-miR-21	miRNA	SB431542	lung fibrosis	IMR-90 cells	SB431542 treatment	"miR-21 expression was promoted by single TGF¦Â1 treatment, whereas reduced by SB431542"	30213983
5016	Human	hsa-miR-21	miRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary artery smooth muscle cell	hypoxia treatment	upregulated	29198701
5017	Human	hsa-miR-21	miRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary microvascular endothelial cells (HPECs)	hypoxia treatment	miR-21 was upregulated in the hypoxia-treated HPECs and its conditioned media in a time-dependent manner.	30449992
5018	Human	hsa-miR-21	miRNA	berberine (BBR)	pulpitis	LPS treated human dental pulp fibroblast (HDPF)	berberine (BBR) treatment	upregulated	31837588
5019	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp fibroblast (HDPF)	lipopolysaccharide (LPS) treatment	downregulated	31837588
5020	Human	hsa-miR-21	miRNA	gemcitabine (GEM)	renal cell carcinoma (RCC)	Panc-1 cells	gemcitabine treatment	downregulated	23564788
5021	Human	hsa-miR-21	miRNA	eupatilin	renal cell carcinoma (RCC)	786-O cells	Eupatilin treatment	downregulated	31179326
5022	Human	hsa-miR-21	miRNA	insulin-like growth factor 1 (IGF-1)	renal cell carcinoma (RCC)	human renal cell carcinoma cell	IGF-I treatment	upregulated	28453463
5023	Human	hsa-miR-21	miRNA	metformin (Met)	renal cell carcinoma (RCC)	CAKI-1 and CAKI-2 cells	Metformin (MET) treatment	downregulated	26496641
5024	Human	hsa-miR-21	miRNA	sorafenib (SOR)	renal cell carcinoma (RCC)	"Human RCC cell lines, OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P"	sorafenib treatment	GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis	29895198
5025	Human	hsa-miR-21	miRNA	angiotensin II (Ang II)	renal fibrosis	HK-2 cells	angiotensin II (Ang II) treatment	upregulated	31611175
5026	Human	hsa-miR-21	miRNA	bone morphogenetic protein 4 (BMP4)	renal fibrosis	vascular smooth muscle cell (vSMC)	?bone morphogenetic protein 4 (BMP4)? treatment	upregulated	22158624
5027	Human	hsa-miR-21	miRNA	high glucose (HG)	renal interstitial fibrosis (RIF)	human kidney-2 (HK-2) cells	high glucose (HG) treatment	upregulated	31389582
5028	Human	hsa-miR-21	miRNA	pure total flavonoids from Smilax glabra Roxb (PTFS)	renal interstitial fibrosis (RIF)	HK-2 cells	pure total flavonoids from Smilax glabra Roxb (PTFS) treatment	PTFS treatment inhibited TGF-¦Â1-induced EMT progress by blocking miR-21/PTEN/PI3K/Akt signaling	30304552
5029	Human	hsa-miR-21	miRNA	Smilax glabra Roxb (PTFS)	renal interstitial fibrosis (RIF)	TGF-¦Â1-treated HK-2 cells	Smilax glabra Roxb (PTFS) treatment	downregulated	30304552
5030	Human	hsa-miR-21	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK-2 cell	hypoxia/reoxygenation	upregulated	27030384
5031	Human	hsa-miR-21	miRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	human umbilical vein endothelial cells	hypoxia (1% O2 for 24 hours)	upregulated	28737660
5032	Human	hsa-miR-21	miRNA	aspirin	residual platelet reactivity	DAMI cell	aspirin treatment	Aspirin induces the modulation of platelet miR-21 expression levels.	30046765
5033	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	glioblastomas (GBMs)	"GBM cell lines A172, U87MG"	DOX treatment	downregulated	25628933
5034	Human	hsa-miR-21	miRNA	IL-34	rheumatoid arthritis (RA)	fibroblast-like synovial cells (FLS) of RA and OA patients	IL-34 treatment	upregulated	27084907
5035	Human	hsa-miR-21	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
5036	Human	hsa-miR-21	miRNA	mitomycin C (MMC)	scar adhesion after joint surgery	primary fibroblasts	mitomycin C (MMC) treatment	MMC induced apoptosis of fibroblasts and decreased the expression of miR-21.	31669961
5037	Human	hsa-miR-21	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
5038	Human	hsa-miR-21	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
5039	Human	hsa-miR-21	miRNA	hepatitis C virus (HCV)	short bowel syndrome (SBS)	human liver	hepatitis C virus (HCV) infection	downregulated	20625373
5040	Human	hsa-miR-21	miRNA	arsenite	skin cancer	HaCaT	arsenic (As) exposure	upregulated	28069514
5041	Human	hsa-miR-21	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	downregulated	30182520
5042	Human	hsa-miR-21	miRNA	ultraviolet (UV) irradiation	skin pigmentation disorders	melanocytes exosome	ultraviolet (UV) irradiation treatment	upregulated	31909885
5043	Human	hsa-miR-21	miRNA	TGF-¦Â1	skin wound healing	HaCaT cells	TGF-¦Â1 treatment	upregulated	27735045
5044	Human	hsa-miR-21	miRNA	rapamycin	squamous cell carcinoma (SCC)	HUVECs	Rapamycin treatment	Rapamycin treatment increased the expression of miR-21 in HUVECs	23313253
5045	Human	hsa-miR-21	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
5046	Human	hsa-miR-21	miRNA	rapamycin	subependymal giant cell astrocytoma (SEGA)	primary cultures of SEGA-derived cells	rapamycin (mTOR) treatment	upregulated	30509037
5047	Human	hsa-miR-21	miRNA	hydroxychloroquine	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	hydroxychloroquine treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs."	24121037
5048	Human	hsa-miR-21	miRNA	prednisone	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	prednisone treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs"	24121037
5049	Human	hsa-miR-21	miRNA	IL-1¦Â	systemic sclerosis (SSc)	fibroblasts	IL-1¦Â treatment	"Performing microRNA (miRNA) inhibition experiments in the presence of TGF-¦Â1, we showed that the pro-fibrotic effect of IL-1¦Â may be mediated by a miRNA-21/TGF-¦Â receptor II axis"	33662666
5050	Human	hsa-miR-21	miRNA	TGF-¦Â	testicular lesion	human renal glomerular mesangial cells	TGF¦Â treatment	upregulated	22879939
5051	Human	hsa-miR-21	miRNA	baicalin (BAI)	cell differentiation	human lung fibroblasts	baicalin (BAI) treatment	"Baicalein diminished the expression of miR-21, and miR-21 mimics partially antagonized the effects of baicalein."	30201452
5052	Human	hsa-miR-21	miRNA	hypoxia	transplacental clastogenic and epigenetic effects	pancreatic cancer cells	hypoxia treatment	Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells	23726431
5053	Human	hsa-miR-21	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
5054	Human	hsa-miR-21	miRNA	carboplatin (CBP)	triple negative breast cancer (TNBC)	human TNBC cell lines MDA©\MB©\231 and BT©\ 20	carboplatin (CBP) treatment	miR-21 overexpression led to promoted cancer cells proliferation and improved cancer cell viability under carboplatin treatment.	31033015
5055	Human	hsa-miR-21	miRNA	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO)	triple negative breast cancer (TNBC)	TNBC cell line MDA-MB-231	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) treatment	downregulated	33405856
5056	Human	hsa-miR-21	miRNA	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO)	triple negative breast cancer (TNBC)	"TNBC cell line ,MDAMB-231"	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) treatment	downregulated	33405856
5057	Human	hsa-miR-21	miRNA	rapamycin	tuberous sclerosis complex (TSC)	serum	rapamycin (mTOR) treatment	upregulated	30509037
5058	Human	hsa-miR-21	miRNA	TGF-¦Â	renal fibrosis	tubular epithelial cells (TECs)	TGF-¦Â treatment	upregulated	21852586
5059	Human	hsa-miR-21	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	type 1 diabetes mellitus (T1DM)	INS-1 832/13 beta cells	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	upregulated	28280903
5060	Human	hsa-miR-21	miRNA	IL-1¦Â and TNF-¦Á	type 2 diabetes mellitus (T2DM)	human pancreatic islets	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
5061	Human	hsa-miR-21	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	metformin treatment	downregulated	28230206
5062	Human	hsa-miR-21	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
5063	Human	hsa-miR-21	miRNA	ailanthone (AIL)	vestibular schwannomas (VSs)	human primary vestibular schwannomas (VSs) cells	ailanthone (AIL) treatment	miR-21 was lowly expressed in AIL-treated cells.	29298734
5064	Human	hsa-miR-21	miRNA	centrin gene deleted Leishmania donovani parasites (LdCen?/?)	visceral leishmaniasis	human macrophages	LdCen-/- parasites infection	LdCen-/- infection suppresses the expression of microRNA-21 (miR-21) in human macrophages compared to LdWT infection.	31608064
5065	Human	hsa-miR-21	miRNA	TGF-¦Â1	wound healing	mesenchymal stem cells (MSCs)	TGF-¦Â1 treatment	Higher TGF-¦Â1concentrations (1¨C10 ng/ml) in the culture medium led to reduced miR-21 expression	32080965
5066	Human	hsa-miR-21	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19264808
5067	Human	hsa-miR-21	miRNA	TGF-¦Â1	cardiac hypertrophy	HaCaT cell	TGF-¦Â1 treatment	upregulated	21647251
5068	Human	hsa-miR-21	miRNA	arsenite	epithelial-mesenchymal transition (EMT)	human bronchial epithelial cells	?Arsenite treatment	upregulated	24004609
5069	Human	hsa-miR-21	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	Rko cells; HCT116 cells	curcumin (diferuloylmethane)? treatment	downregulated	20815812
5070	Human	hsa-miR-21	miRNA	cisplatin (DDP)	liver fibrosis	A549 cell	cisplatin (DPP) treatment	downregulated	23485110
5071	Human	hsa-miR-21	miRNA	hypoxia	pulmonary artery smooth muscle cell proliferation and migration	pulmonary artery smooth muscle cell (PASMC)	hypoxia treatment	upregulated	20693317
5072	Human	hsa-miR-21*	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	allergic inflammation	Peripheral blood eosinophils	GM-CSF treatment	"the increased in vitro viability of GM-CSF-treated eosinophils and upregulated expression of miRNA-21* (miR-21*), a complementary miRNA of miR-21, in GM-CSF-treated eosinophils."	22698984
5073	Human	hsa-miR-210	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HEK (humanembryonic kidney) 293T;SMMC-7721; Huh-7 cells	Hypoxia treatment	upregulated	22144109
5074	Human	hsa-miR-210	miRNA	radiation	radiation enteropathy	intestinal samples;fibrotic cultured cells	radiation treatment	miR-210 overexpression	24290534
5075	Human	hsa-miR-210	miRNA	sulfated polysaccharide that inhibits angiogenesis(WSS25)	adipogenesis	HMEC-1 cells	WSS25 treatment	down-regulating microRNA-210	23322395
5076	Human	hsa-miR-210	miRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells	gemcitabine (GEM) treatment	Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.	31713003
5077	Human	hsa-miR-210	miRNA	connective tissue growth factor (CTGF)	angiogenesis	human synovial fibroblasts	CTGF treatment	upregulated	25341039
5078	Human	hsa-miR-210	miRNA	hypoxia	angiogenesis	K562 cells£» ¦Â-thalassemia/HbE progenitor cells	?hypoxia treatment	upregulated	23623309
5079	Human	hsa-miR-210	miRNA	rosuvastatin	apoptosis	factor-¦Á induced human mesenchymal stem cells (MSCs)	rosuvastatin treatment	upregulated	25620256
5080	Human	hsa-miR-210	miRNA	IL-13	asthma	human bronchial epithelial cells (NHBE)	IL-13 treatment	upregulated	31386204
5081	Human	hsa-miR-210	miRNA	hypoxia	autophagy	human colon cancer cell lines SW480;SW620 cells	hypoxia treatment	upregulated	25385144
5082	Human	hsa-miR-210	miRNA	hypoxia	breast cancer	SKBR-3 cells; MCF-7 cells; MDA-MB-231 cells	hypoxia treatment	upregulated	32945512
5083	Human	hsa-miR-210	miRNA	hypoxia	breast cancer	breast adenocarcinoma cell line MCF7£» hepatoblastoma cell line Hep3B; uterine cervix adenocarcinoma cell line HeLa£» renal cancer cell line RCC4	Hypoxia treatment	upregulated	18316553
5084	Human	hsa-miR-210	miRNA	trastuzumab or lapatinib	breast cancer	patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer	chemotherapy combin either trastuzumab or lapatinib treatment	upregulated	25086636
5085	Human	hsa-miR-210	miRNA	hypoxia	tumorigenesis	neural progenitor cells (NPCs)	?hypoxia treatment	upregulated	23039253
5086	Human	hsa-miR-210	miRNA	natural compound 1'S-1'-acetoxychavicol acetate (ACA)	cervical cancer (CC)	human cervical cancer cells Ca Ski and SiHa	ACA	downregulated	28401751
5087	Human	hsa-miR-210	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	peripheral blood monocytes (PBMs) and serum of patients with CHB	hepatitis B virus (HBV) infection	downregulated	30592291
5088	Human	hsa-miR-210	miRNA	acute exercise	chronic kidney disease (CKD)	blood	acute exercise treatment	downregulated	26475583
5089	Human	hsa-miR-210	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	cigarette smoke extract (CSE) treatment	upregulated	26563733
5090	Human	hsa-miR-210	miRNA	hypoxia	colorectal cancer (CRC)	"CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)"	1 and 0.2% oxygen	upregulated	28207045
5091	Human	hsa-miR-210	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
5092	Human	hsa-miR-210	miRNA	surgery and chemotherapy	colorectal cancer (CRC)	patients blood	surgery and chemotherapy for 3years treatment	upregulated	24310813
5093	Human	hsa-miR-210	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32498701
5094	Human	hsa-miR-210	miRNA	hypoxia	endometriosis	CRL-7566 cells	hypoxia treatment	upregulated	26914112
5095	Human	hsa-miR-210	miRNA	paraquat (PQ)	epithelial-mesenchymal transition (EMT)	human lung adenocarcinoma epithelial cells (A549)	paraquat (PQ) treatment	upregulated	28699703
5096	Human	hsa-miR-210	miRNA	erythropoietin (EPO)	erythroid cell differentiation	The original UT-7 cell line	erythropoietin treatment	upregulated	18492109
5097	Human	hsa-miR-210	miRNA	hypoxia	esophageal cancer (EC)	Eca-109 and HEK 293t/17 cells	under hypoxic conditions in ESCC treatment	upregulated	25069478
5098	Human	hsa-miR-210	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
5099	Human	hsa-miR-210	miRNA	hypoxia	gastric cancer (GC)	gastric cancer cell line AGS cells	hypoxia treatment	upregulated	26548949
5100	Human	hsa-miR-210	miRNA	phosphatase of regenerating liver-3 (PRL-3)	gastric cancer (GC)	Gastric cancer cell line AGS	Phosphatase of regenerating liver-3 (PRL-3) treatment	upregulated	26548949
5101	Human	hsa-miR-210	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
5102	Human	hsa-miR-210	miRNA	hypoxia	glioblastoma multiforme (GBM)	human glioma cell lines U87;SHG44	hypoxia treatment	upregulated	24930954
5103	Human	hsa-miR-210	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	L02 cells	hypoxia treatment	downregulated	32155285
5104	Human	hsa-miR-210	miRNA	zeaxanthin dipalmitate (ZD)	hepatic tissue-repairing	human adipose-derived mesenchymal stem cells (hADMSCs)	ZD treatment	upregulated	27983913
5105	Human	hsa-miR-210	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	neural progenitor cells (NPCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	23039253
5106	Human	hsa-miR-210	miRNA	nickel oxide nanoparticles (NiO NPs)	hepatocellular carcinoma (HCC)	HepG2 cells	Nickel oxide nanoparticles (NiO-NPs) treatment	upregulated	31812053
5107	Human	hsa-miR-210	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	transarterial chemoembolization treatment	upregulated in serum	24935355
5108	Human	hsa-miR-101	miRNA	influenza A virus (IAV) 	host-Influenza A virus (IAV) infection	A549 cells	"The X-31 virus, a reassortant between PR8 and A/Aichi/68(H3N2) IAV strain ifection"	downregulated	32326380
5109	Human	hsa-miR-210	miRNA	hypoxia	cell proliferation	Primary human pulmonary arterial smooth muscle cells (HPASMC)	hypoxia treatment	"miR-210 as a hypoxia-inducible miRNA both in vitro and in vivo, which inhibits pulmonary vascular smooth muscle cell apoptosis in hypoxia by specifically repressing E2F3 expression."	22886504
5110	Human	hsa-miR-210	miRNA	hypoxia	hypoxia-induced injury	C28/I2 human chondrocytes	hypoxia treatment	upregulated	24790587
5111	Human	hsa-miR-210	miRNA	hypoxia	hypoxia-induced cell death	human umbilical vein endothelial cells (HUVEC)	hypoxia treatment	both ROD1 mRNA and protein were down-modulated upon hypoxia in a miR-210 dependent manner. ROD1 targeting by miR-210 was biologically significant: the rescue of ROD1 inhibition significantly increased hypoxia-induced cell death	23024754
5112	Human	hsa-miR-210	miRNA	hypoxia	hypoxia-induced renal tubular cell apoptosis	human renal tubular HK-2 cells	hypoxia treatment	upregulated	29387863
5113	Human	hsa-miR-210	miRNA	hypoxia	idiopathic pulmonary fibrosis (IPF)	IPF fibroblasts	hypoxia treatment	upregulated	24951777
5114	Human	hsa-miR-210	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	HNSCC	hypoxia?treatment	the level of hsa-miR-210 was significantly correlated with other markers of hypoxia	20187102
5115	Human	hsa-miR-210	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
5116	Human	hsa-miR-210	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
5117	Human	hsa-miR-210	miRNA	leishmania	leishmaniasis	?human primary macrophages	Leishmania (L.) infection	upregulated	24098824
5118	Human	hsa-miR-210	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
5119	Human	hsa-miR-210	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	"miR-210 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM"	32656599
5120	Human	hsa-miR-210	miRNA	pemetrexed	lung adenocarcinoma (LUAD)	serum	pemetrexed treatment	"Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations"	26687391
5121	Human	hsa-miR-210	miRNA	epigallocatechin-3-gallate (EGCG)	lung cancer	lung cancer cells	Green tea polyphenol EGCG treatment	upregulated	21965273
5122	Human	hsa-miR-210	miRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	HK-2 cells	lipopolysaccharide (LPS) treatment	miR-210 level in LPS-treated cells was elevated by ALK.	30372870
5123	Human	hsa-miR-210	miRNA	hypoxia	myocardial infarction (MI)	human mesenchymal stem cells (hMSCs)	hypoxia treatment	upregulated	23388440
5124	Human	hsa-miR-210	miRNA	hypoxia	myocardial infarction (MI)	human cardiosphere-derived cells (CDCs) exosomes	hypoxia induce	upregulated	29243842
5125	Human	hsa-miR-210	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
5126	Human	hsa-miR-210	miRNA	melatonin	nickel toxicity	BEAS-2B cells	melatonin treatment	"NiCl2 induced a sharp increase in miR210 expression, while melatonin treatment signifi- cantly repressed miR210 overexpression."	32566089
5127	Human	hsa-miR-210	miRNA	vascular endothelial growth factor (VEGF)	obesity	haematopoietic stem cells (HSCs)	vascular endothelial growth factor? treatment	upregulated	22360314
5128	Human	hsa-miR-210	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	apoptosis	primary cardiomyocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	29461605
5129	Human	hsa-miR-210	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteonecrosis of femoral head (ONFH)	SONFH tissues (ONs) and the adjacent normal tissues (NLs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26805628
5130	Human	hsa-miR-210	miRNA	lipopolysaccharide (LPS)	otitis media with effusion (OME)	human middle ear epithelial cells (HMEECs)	lipopolysaccharide (LPS) treatment	the miR-210 level is significantly reduced in culture supernatant of lipopolysaccharide (LPS) treated human middle ear epithelial cells (HMEECs).	33248692
5131	Human	hsa-miR-210	miRNA	lipopolysaccharide (LPS)	otitis media with effusion (OME)	human middle ear epithelial cells (HMEECs)	lipopolysaccharides (LPS) treatment	downregulated	33248692
5132	Human	hsa-miR-210	miRNA	hypoxia	ovarian cancer (OC)	"OVCAR-3 , SK-OV-3 EOC cell lines"	hypoxia treatment	upregulated	24715221
5133	Human	hsa-miR-210	miRNA	sevoflurane (SEV)	ovarian cancer (OC)	SKOV3 cells	sevoflurane treatment	"miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane"	33673181
5134	Human	hsa-miR-210	miRNA	CoCl2	ovulation and corpus luteum (CL) formation	human primary (hGLCs) and immortalized (SVOG) granulosa-lutein cells	CoCl2 treatment	upregulated	29301980
5135	Human	hsa-miR-210	miRNA	hypoxia	ovulation and corpus luteum (CL) formation	human primary (hGLCs) and immortalized (SVOG) granulosa-lutein cells	hypoxia induce	upregulated	29301980
5136	Human	hsa-miR-210	miRNA	ginsenoside Rb1	oxidative stress	H2O2-treated human endothelial EA.hy926 cells	Ginsenoside Rb1 (Rb1) treatment	upregulated	31359794
5137	Human	hsa-miR-210	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2	upregulated	28367268
5138	Human	hsa-miR-210	miRNA	H2O2	oxidative stress	Human endothelial EA.hy926 cells	H2O2 treatment	downregulated	31359794
5139	Human	hsa-miR-210	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
5140	Human	hsa-miR-210	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
5141	Human	hsa-miR-210	miRNA	curcumin-derived analogue CDF	pancreatic cancer (PC)	human pancreatic cancer (PC) cells	curcumin-derived analogue CDF treatment	downregulated	23272057
5142	Human	hsa-miR-210	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	BxS and PANC-1 cells	Gemcitabine (GEM) treatment	upregulated	31713003
5143	Human	hsa-miR-210	miRNA	hypoxia	pancreatic cancer (PC)	"PC cell lines (AsPC-1, BxPC-3, MIAPaCa-2, PANC-1, Su86.86 and SW1990)"	hypoxia treatment	upregulated	22672828
5144	Human	hsa-miR-210	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells	hypoxia induce	upregulated	31875764
5145	Human	hsa-miR-210	miRNA	lapatinib and 5-fluorouracil (5-Fu)	pancreatic cancer (PC)	PANC-1 and MIA PaCa-2 cells	lapatinib and 5-FU treatment	upregulated	26998056
5146	Human	hsa-miR-210	miRNA	hypoxia	preeclampsia (PE)	placental	hypoxia treatment	upregulated	27746364
5147	Human	hsa-miR-210	miRNA	hypoxia	pregnancy complication preeclampsia	trophoblasts	hypoxia treatment	upregulated	31616934
5148	Human	hsa-miR-210	miRNA	hypoxia	prostate cancer	"NCaP, 22RV1, and PC3"	hypoxia treatment	Hypoxia-induced miR-210 expression can contribute to prostate cancer.	31975433
5149	Human	hsa-miR-210	miRNA	hypoxia	prostate cancer	human prostate fibroblasts (HPFs)	hypoxia treatment	upregulated	25091736
5150	Human	hsa-miR-210	miRNA	radiation	radiation enteropathy	enteropathy and fibrotic cultured cells	radiation treatment	upregulated	24290534
5151	Human	hsa-miR-210	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
5152	Human	hsa-miR-210	miRNA	hypoxia	squamous cell carcinoma (SCC)	SCC2 and SCC38 cell lines	hypoxia treatment	upregulated	28099149
5153	Human	hsa-miR-210	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
5154	Human	hsa-miR-210	miRNA	hypoxia	tumor-initiating cells (TICs) activation	HCT116 cells;HT29 cells;LS174t cells	hypoxia treatment	upregulated	27589845
5155	Human	hsa-miR-210	miRNA	propranolol (PRO)	Von Hippel-Lindau (VHL) disease	VHL patients plasma	administered 120 mg propranolol daily treatment	downregulated	28662711
5156	Human	hsa-miR-210	miRNA	trastuzumab	H1N1 influenza virus infection	Plasma	trastuzumab treatment	upregulated	22370716
5157	Human	hsa-miR-210	miRNA	hypoxia	cardiac hypertrophy	SMMC-7721 cells; HepG2 cells; HuH7 cells	hypoxia?treatment	downregulated	22387901
5158	Human	hsa-miR-210-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	angiogenesis	Endothelial progenitor cells (EPCs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31164807
5159	Human	hsa-miR-210-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31680642
5160	Human	hsa-miR-210-3p	miRNA	cytomegalovirus (CMV)	cytomegalovirus infection	plasma	Cytomegalovirus (CMV) treatment	upregulated	27684416
5161	Human	hsa-miR-210-3p	miRNA	hypoxia	elective intrauterine growth restriction (sIUGR)	The human extravillous trophoblast cell line HTR©\8/SVneo	hypoxia induce	upregulated	30993882
5162	Human	hsa-miR-210-3p	miRNA	hypoxia	endometriosis	primary endometrial stromal cells (ESCs) and Ishikawa cells	hypoxia induce	upregulated	30760709
5163	Human	hsa-miR-210-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
5164	Human	hsa-miR-210-3p	miRNA	candida albicans (C. albicans)	inflammatory response	THP-1 cells	candida albicans infection	upregulated	28454101
5165	Human	hsa-miR-210-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV-3 cells	cisplatin treatment	downregulated	30957179
5166	Human	hsa-miR-210-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
5167	Human	hsa-miR-210a	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	serum	liraglutide treatment	upregulated	33008044
5168	Human	hsa-miR-211	miRNA	hypoxia	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia induce	downregulated	31589383
5169	Human	hsa-miR-211	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia-inducible factor 1¦Á (HIF-1¦Á) treatment	downregulated	31589383
5170	Human	hsa-miR-211	miRNA	vemurafenib	melanoma	A375 melanoma cells	vemurafenib treatment	upregulated	28445987
5171	Human	hsa-miR-211	miRNA	4-nitroquinoline 1-oxide (4NQO)	oral squamous cell carcinoma (OSCC)	human oral squamous cell carcinoma (OSCC) cells	4-nitroquinoline 1-oxide (4NQO) treatment	upregulated	27221705
5172	Human	hsa-miR-211	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	miR-211 expression could be significantly inhibited by IL-1¦Â stimulation.	30005876
5173	Human	hsa-miR-211	miRNA	ligustrazine (Lig)	ovarian cancer (OC)	"SK-OV-3 , OVCAR-3 cells"	Ligustrazine (Lig) treatment	LSZ could significantly increase the expression of miR-211 in both SK-OV-3 and OVCAR-3	33245099
5174	Human	hsa-miR-211	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	human Pancreatic Cancer tissue	gemcitabine treatment	upregulated	23155457
5175	Human	hsa-miR-211	miRNA	ultraviolet (UV) irradiation	repigmentation outcomes	human melanocytes	UVB treatment	downegulated	31985026
5176	Human	hsa-miR-211	miRNA	lipopolysaccharide (LPS)	sepsis	rats lung tissues	lipopolysaccharide (LPS) treatment	downregulated	28901393
5177	Human	hsa-miR-211	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	normal human astrocytes (NHAs)	lipopolysaccharide (LPS) treatment	downregulated	28790168
5178	Human	hsa-miR-2113	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	downregulated	29393545
5179	Human	hsa-miR-2113	miRNA	high glucose (HG)	diabetic retinopathy (DR)	MIO-M1 cells	high glucose (HG) treatment	downregulated	29654764
5180	Human	hsa-miR-211-3p	miRNA	lipopolysaccharide (LPS)	endoplasmic reticulum stress (ERS)	ccultured human skin fibroblasts	lipopolysaccharide (LPS) treatment	downregulated	31221950
5181	Human	hsa-miR-2115?	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
5182	Human	hsa-miR-211-5p	miRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2.2.15 cells	HBx-induce	upregulated	31880390
5183	Human	hsa-miR-211-5p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV) infection	upregulated	31880390
5184	Human	hsa-miR-211-5p	miRNA	BRAF	melanoma	melanoma cell lines MML-1 and A375	BRAF treatment	upregulated	28684402
5185	Human	hsa-miR-211-5p	miRNA	vemurafenib	melanoma	A375 cells	vemurafenib treatment	upregulated	29229605
5186	Human	hsa-miR-211-5p	miRNA	alpinetin (ALP)	oral squamous cell carcinoma (OSCC)	Human OSCC cell lines (CAL-27 and TCA-8113)	alpinetin (ALP) treatment	upregulated	31403340
5187	Human	hsa-miR-211-5p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	"KCNQ1OT1 and TCF4 were highly expressed in the cartilage tissues of patients with OA and C28/I2 cells treated with LPS (OA cells), whereas miR-211-5p was downregulated concomitantly in OA tissues and cells."	33747189
5188	Human	hsa-miR-211-5p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
5189	Human	hsa-miR-211-5p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human islets	(IL-1¦Â+IFN-¦Ã) treatment	downregulated	31277072
5190	Human	hsa-miR-2116-3p	miRNA	omeprazole	barrett's esophagus	Barrett's esophagus (BE) organoids	omeprazole treatment	upregulated	30705106
5191	Human	hsa-miR-2116-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
5192	Human	hsa-miR-212	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y; IMR-32 cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	32474742
5193	Human	hsa-miR-212	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29174964
5194	Human	hsa-miR-212	miRNA	hypoxia	blood-brain barrier (BBB) dysfunction	human brain microvascular endothelial cells (BMEC)	hypoxia induce	upregulated	30617994
5195	Human	hsa-miR-212	miRNA	4?-12-O-tetradecanoylphorbol-13-acetate (TPA)	carcinoma of nasopharyngeal epithelial (CNE)	NSCLC cell lines	4?-12-O-tetradecanoylphorbol-13-acetate (TPA) treatment	upregulated	22357618
5196	Human	hsa-miR-212	miRNA	doxorubicin (DOX)	cardiotoxicity	human iPSC-derived cardiomyocytes	doxorubicin treatment	"In vitro, overexpression of the pro-hypertrophic miR-212/132 cluster in primary rodent and human iPSC-derived cardiomyocytes inhibited doxorubicin-induced toxicity."	30527757
5197	Human	hsa-miR-212	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
5198	Human	hsa-miR-212	miRNA	imatinib	chronic myeloid leukemia (CML)	human immortalized myelogenous leukemia line K-562 cells	imatinib treatment	downregulated	22241070
5199	Human	hsa-miR-212	miRNA	lipopolysaccharide (LPS)	delayed union of femoral neck fracture	MG-63 cells	lipopolysaccharide (LPS) treatment	downregulated	33725277
5200	Human	hsa-miR-212	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human gastric cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	21053104
5201	Human	hsa-miR-212	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	U251 cells	irradiation treatment	miR-212 is downregulated in human glioma U251 cells following irradiation.	29286157
5202	Human	hsa-miR-212	miRNA	hepatitis B virus (HBV)	HBV-infection-related liver diseases	serum	hepatitis B virus (HBV) infection	upregulated	31608838
5203	Human	hsa-miR-212	miRNA	lactobacillus plantarum dy-1 (LFBE)	hepatocellular carcinoma (HCC)	HepG2 cells	Lactobacillus plantarum dy-1 (LFBE) treatment	LFBE and VA normalized the upregulaton of miR-212.	30369345
5204	Human	hsa-miR-212	miRNA	angiotensin II (Ang II)	hypertension	human breast artery tissues	angiotensin II (Ang II) treatment	upregulated	23712358
5205	Human	hsa-miR-212	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
5206	Human	hsa-miR-212	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	29611404
5207	Human	hsa-miR-212	miRNA	alcohol	gut leakiness	Caco-2 cells; colon biopsy tissue	alcohol exposure	upregulated	18162065
5208	Human	hsa-miR-212*	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
5209	Human	hsa-miR-212-3p	miRNA	macrocalyxin C	gastric cancer (GC)	"AGS, MKN45, SGC7901 cells"	macrocalyxin C treatment	upregulated	31726103
5210	Human	hsa-miR-212-3p	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	Huh7 cells	paclitaxel (PTX) treatment	downregulated	32774496
5211	Human	hsa-miR-212-3p	miRNA	mycobacterium tuberculosis (Mtb)	latent tuberculosis infection (LTBI)	peripheral blood mononuclear cells (PBMCs) of TB patients and individuals with LTBI	Mycobacterium tuberculosis (M.tb) infection	upregulated	31082644
5212	Human	hsa-miR-212-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
5213	Human	hsa-miR-212-3p	miRNA	zoledronic acid (ZA)	osteosarcoma (OS)	The KHOS/NP and U2OS OS cell lines	Zoledronic acid (ZOL) treatment	upregulated	31752184
5214	Human	hsa-miR-212-3p	miRNA	IL-1¦Â	preterm labour	human myometrial smooth muscle cells	interleukin (IL)1B treatment	upregulated	30892651
5215	Human	hsa-miR-212-3p	miRNA	IL-6	preterm labour	human myometrial smooth muscle cells	IL-6 treatment	upregulated	30892651
5216	Human	hsa-miR-212-3p	miRNA	helicobacter pylori (H. pylori)	sophageal carcinogenesis	human esophageal cell line HET-1A	Helicobacter pylori infection	miR-212-3p was significantly decreased in HET-1A cells exposure to H. pylor.	30783439
5217	Human	hsa-miR-212-5p	miRNA	H2O2	abdominal aortic aneurysm (AAA)	human vascular smooth muscle cells (VSMCs)	H2O2 treatment	LINC00473 inhibits vascular smooth muscle cell viability to promote aneurysm formation via miR-212-5p/BASP1 axis.	31954705
5218	Human	hsa-miR-212-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	NCI-H292 cells	cigarette smoke extract (CSE) treatment	downregulated	30695677
5219	Human	hsa-miR-212-5p	miRNA	candida albicans (C. albicans) and aspergillus fumigatus (A. fumigatus)	fungal infection	human monocyte-derived dendritic cells	6 and 12 h of infection with C. albicans and A. fumigatus as well as treatment with lipopolysaccharides (LPS)	dysregulated	28280489
5220	Human	hsa-miR-21-3p	miRNA	lipopolysaccharide (LPS)	age-related macular degeneration (AMD)	human retinal pigment epithelial (ARPE-19) cells	lipopolysaccharide (LPS) treatment	upregulated	31330059
5221	Human	hsa-miR-21-3p	miRNA	berberine (BBR)	breast cancer	estrogen receptor (ER)¦Á(+) MCF-7 breast cancer cells	berberine (BBR) treatment	upregulated	29143794
5222	Human	hsa-miR-21-3p	miRNA	IL-4	chronic lymphocytic leukemia (CLL)	Peripheral blood	Interleukin 4 (IL-4) treatment	upregulated	25909590
5223	Human	hsa-miR-21-3p	miRNA	TGF-¦Â	chronic obstructive pulmonary disease (COPD)	primary parenchymal lung fibroblasts	TGF-¦Â treatment	upregulated	28910321
5224	Human	hsa-miR-21-3p	miRNA	high glucose (HG)	diabetic atherosclerosis	Human aortic VSMCs; vascular endothelial cells (VECs)	high glucose (HG) treatment	The high-glucose medium induced the downregulated of ADAM10 via excessive production of miR-21-3p in the vascular endothelial cells (VECs).	32196704
5225	Human	hsa-miR-21-3p	miRNA	D-glucose	diabetic foot ulcer (DFU)	Human skin fibroblasts	D-glucose treatment	miR-21-3p may treat DFU by reducing SPRY1.	32634115
5226	Human	hsa-miR-21-3p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
5227	Human	hsa-miR-21-3p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) cyclosporine A (CYCA) treatment	upregulated	31198949
5228	Human	hsa-miR-21-3p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
5229	Human	hsa-miR-21-3p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
5230	Human	hsa-miR-21-3p	miRNA	oxidized glycerophospholipids (oxGPs) and IL-1¦Â	inflammation	human aortic endothelial cells (HAECs)	oxGPs and interleukin 1¦Â (IL-1¦Â) treatment	upregulated	25327529
5231	Human	hsa-miR-21-3p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
5232	Human	hsa-miR-21-3p	miRNA	platinum-based chemotherapy	ovarian tumours	ovarian cancer cell line A2780	cisplatin and carboplatin treatment	upregulated	25579119
5233	Human	hsa-miR-21-3p	miRNA	ultraviolet (UV) irradiation	skin inflammation	epidermis	UV exposure treatment	upregulated	27250636
5234	Human	hsa-miR-214	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	Lipopolysaccharide (LPS) treatment	DANCR Suppressed Lipopolysaccharide-Induced Septic Acute Kidney Injury by Regulating miR-214 in HK-2 Cells	32222722
5235	Human	hsa-miR-214	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
5236	Human	hsa-miR-214	miRNA	berberine (BBR)	alveolar bone regeneration	human alveolar osteoblasts (HAOBs)	berberine (BBR) treatment	miR-214 was reduced as BBR concentrations increased.	32688361
5237	Human	hsa-miR-214	miRNA	berberine (BBR)	alveolar bone regeneration	primary human alveolar osteoblasts (HAOBs)	berberine (BBR) treatment	downregulated	32688361
5238	Human	hsa-miR-214	miRNA	isoflurane	anesthesia-induced neural cytotoxicity	human neuroblastoma cell line SH-SY5Y	Isoflurane treatment	downregulated	31704096
5239	Human	hsa-miR-214	miRNA	ginsenoside Rg1	angiogenesis	human umbilical vein endothelial cells (HUVECs)	ginsenoside-Rg1 treatment	downregulated	19733659
5240	Human	hsa-miR-214	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
5241	Human	hsa-miR-214	miRNA	IFN-¦Ã	autophagy	human hepatoma Huh7 cells	IFN-¦Ë treatment	upregulated	28131804
5242	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	upregulated	31678133
5243	Human	hsa-miR-214	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
5244	Human	hsa-miR-214	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
5245	Human	hsa-miR-214	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
5246	Human	hsa-miR-214	miRNA	lipopolysaccharide (LPS)	calcific aortic valve disease (CAVD)	aortic valve interstitial cells (AVICs)	lipopolysaccharide (LPS) treatment	upregulated	30519780
5247	Human	hsa-miR-214	miRNA	H2O2	cataract	SRA01/04 cell lines	H2O2 treatment	downregulated	28535504
5248	Human	hsa-miR-214	miRNA	hypoxia	chronic obstructive pulmonary disease (COPD)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	27381447
5249	Human	hsa-miR-214	miRNA	hypoxia	chronic obstructive pulmonary disease (COPD)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	28684904
5250	Human	hsa-miR-214	miRNA	5-aza-2'-deoxycytidine and trichostatin A	colonic inflammation	Squamous cell carcinoma (SCC) cell line	5-aza-deoxycytidine and trichostatin A treatment	downregulated	22828925
5251	Human	hsa-miR-214	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	Two colon cancer cell lines were used: HT-29 and LoVo	5-fluorouracil (5-FU) treatment	"miR-214 is downregulated in 5-FU-resistant colon cancer cells compared to normal cells. In vitro, miR-214 could sensitize non-resistant colon cancer cells and 5-FU-resistant colon cancer cellsto 5-FU."	30915129
5252	Human	hsa-miR-214	miRNA	high glucose (HG)	diabetic corneal endothelial keratopathy	HCEC-B4G12 cells	treatment	downregulated	31693400
5253	Human	hsa-miR-214	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human proximal tubular epithelial cells HK2	high glucose (HG) treatment	upregulated	31240704
5254	Human	hsa-miR-214	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
5255	Human	hsa-miR-214	miRNA	steroids	eosinophilic esophagitis (EoE)	esophageal mucosal tissue	Steroids treatment	upregulated	22815788
5256	Human	hsa-miR-214	miRNA	astragaloside IV (AS-IV)	gastric cancer (GC)	gastric cancer-associated fibroblast (GCAF)	astragaloside (AS-IV) treatment	upregulated	29358859
5257	Human	hsa-miR-214	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	upregulated	29456019
5258	Human	hsa-miR-214	miRNA	hypoxia	gastric cancer (GC)	human gastric cancer cells	hypoxia treatment	upregulated	29129783
5259	Human	hsa-miR-214	miRNA	hypoxia	gastric cancer (GC)	MKN-45 cells	hypoxia induce	upregulated	29129783
5260	Human	hsa-miR-214	miRNA	carvedilol	heart failure (HF)	serum	carvedilol treatment	upregulated	32943906
5261	Human	hsa-miR-214	miRNA	H2O2	cardiac dysfunction	human cardiomyocyte (HCM)	H2O2 treatment	downregulated	28849090
5262	Human	hsa-miR-214	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
5263	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	left ventricular hypertrophy (LVH)	human articular chondrocytes and immortalized costal chondrocytes (TC28 cells)	dexamethasone (DEX) treatment	downregulated	31180556
5264	Human	hsa-miR-214	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
5265	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	miRNA biogenesis	human endothelial cells	dexamethasone (Dex) treatment	downregulated	28523344
5266	Human	hsa-miR-214	miRNA	ginsenoside Rg1	miRNA biogenesis	human endothelial cells	ginsenoside-Rg1 treatment	downregulated	28523344
5267	Human	hsa-miR-214	miRNA	¦Â-glycerophosphate + ascorbic acid + dexamethasone	osteogenesis	human Bone marrow mesenchymal stem cells (BMSCs)	"10 mM ¦Â-glycerophosphate (Sigma-Aldrich, USA), 200 ¦ÌM ascorbic acid (Sigma-Aldrich, USA) and 100 nM dexamethasone (Sigma-Aldrich, USA) treatment"	KCNQ1OT1 was significantly upregulated during the process of osteogenic induction while miR-214 was contrarily downregulated	30703347
5268	Human	hsa-miR-214	miRNA	curcumin (Cur)	ovarian cancer (OC)	cisplatin-resistant A2780cp cells	curcumin treatment	downregulated	28175963
5269	Human	hsa-miR-214	miRNA	TGF-¦Â	ovarian cancer (OC)	A2780 cells; SKOV3 cells	TGF-¦Â treatment	Knockdown of DANCR Suppressed the Biological Behaviors of Ovarian Cancer Cells Treated with Transforming Growth Factor-¦Â (TGF-¦Â) by Sponging MiR-214	32417846
5270	Human	hsa-miR-214	miRNA	ethanol (EtOH)	oxidative stress	"human hepatoma cell (Bel7402), human embryonic kidney 293 cell (HEK293),"	ethanol (EtOH) treatment	upregulated	23905773
5271	Human	hsa-miR-214	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	downregulated	30896848
5272	Human	hsa-miR-214	miRNA	advanced glycation end product (AGE)	apoptosis	THP-1 cells	advanced glycation end products (AGEs) treatment	"Overexpression of pre¨CmiR-214 led to impaired PTEN expression and delayed apoptosis of THP-1 cells, whereas knockdown of miR-214 level largely abolished AGE-induced cell survival."	21228352
5273	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	steroid-induced avascular necrosis of femoral head (SANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	upregulated	31678133
5274	Human	hsa-miR-214	miRNA	Bt2cAMP	type II pneumocyte differentiation	cultured human fetal lung (HFL) epithelial cells	Bt2cAMP treatment	downregulated	29507184
5275	Human	hsa-miR-214	miRNA	IL-6	ulcerative colitis (UC)	NCM460 cells	IL-6 treatment	upregulated	31382166
5276	Human	hsa-miR-214	miRNA	limonin	ulcerative colitis (UC)	IL-6-treated NCM460 cells	limonin treatment	downregulated	31382166
5277	Human	hsa-miR-214	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	plasma and myocardial cells	coxsackievirus B3 (CVB3) treatment	upregulated	25815880
5278	Human	hsa-miR-214	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	Pulmonary artery smooth muscle cells (hPASMCs)	hypoxia treatment	upregulated	27144530
5279	Human	hsa-miR-214-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	33197504
5280	Human	hsa-miR-214-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease.	33197504
5281	Human	hsa-miR-214-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circ_CHFR contributed to the progression of AS through the miR-214-3p/Wnt3/¦Â-catenin signals.	32271446
5282	Human	hsa-miR-214-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33818550
5283	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	brain injury in diabetes mellitus (DM)	SH-SY5Y cells	high glucose (HG) treatment	MicroRNA-214-3p (miR-214-3p) was decreased in HG-treated cells.	32910484
5284	Human	hsa-miR-214-3p	miRNA	melatonin	brain injury in diabetes mellitus (DM)	SH-SY5Y cells	melatonin (MEL) treatment	"MicroRNA-214-3p (miR-214-3p) was decreased in DM mice and HG-treated cells, and such a downregulated was corrected by melatonin"	32910484
5285	Human	hsa-miR-214-3p	miRNA	bone morphogenetic protein 2 (BMP2)	cell differentiation	maxillary sinus membrane stem cells (MSMSCs)	bone morphogenetic protein 2 (BMP2) treatment	Hsa_circRNA_33287 promotes the osteogenic differentiation of maxillary sinus membrane stem cells via miR-214-3p/Runx3.	30551425
5286	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	30355944
5287	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	?high glucose (HG) induce treatment	lncRNA?PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via miR-214-3p/MMP2 axis	31755246
5288	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	high glucose (HG) treatment	downregulated	31755246
5289	Human	hsa-miR-214-3p	miRNA	"3,3'5-tri-iodo-L-thyronine (T3)"	hepatocellular carcinoma (HCC)	HepG2 cells	"3,3'5-tri-iodo-L-thyronine (T3) treatment"	upregulated	29093516
5290	Human	hsa-miR-214-3p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	downregulated	33071785
5291	Human	hsa-miR-214-3p	miRNA	bisphenol A (BPA)	nasopharyngeal carcinoma (NPC)	CNE1 cell; 5-8F cells	bisphenol A (BPA) treatment	BPA treatment also decreased the expression of miR-214-3p in both CNE1 and 5-8F cells.	32360864
5292	Human	hsa-miR-214-3p	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neuroblastoma (NB)	neuroblastoma cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
5293	Human	hsa-miR-214-3p	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neurological disorders	SK-N-SH cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
5294	Human	hsa-miR-214-3p	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	"The normal human oral keratinocyte (NHOK) and OSCC cell lines, including TSCCA, CAL-27, SCC-9, and Tca8113"	cisplatin treatment	downregulated	31275988
5295	Human	hsa-miR-214-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 and SW 1990 cells	gemcitabine (GEM) treatment	downregulated	31632071
5296	Human	hsa-miR-214-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	33071725
5297	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	peritoneal dialysis (PD)	human peritoneal mesothelial cells (HPMCs)	high-glucose (HG)	upregulated	28428333
5298	Human	hsa-miR-214-3p	miRNA	hypoxia	renal fibrosis	HK-2 cells	hypoxia treatment	upregulated	29277613
5299	Human	hsa-miR-214-3p	miRNA	hypoxia	renal fibrosis	?HK-2?cells	hypoxia induce	upregulated	29277613
5300	Human	hsa-miR-214-5p	miRNA	hypoxia	cervical cancer (CC)	HeLa and C-33A cells	hypoxia induce	downregulated	33394293
5301	Human	hsa-miR-214-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
5302	Human	hsa-miR-214-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human primary chondrocytes	IL-1¦Â treatment	"The results showed that SNHG7 was distinctly downregulated, while miR-214-5p was significantly upregulated in OA patients and primary chondrocytes treated with IL-1¦Â."	33296783
5303	Human	hsa-miR-214-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary chondrocytes	IL-1¦Â treatment	SNHG7 prevents IL-1¦Â induced OA by inhibiting NLRP3 inflammasome and apoptosis through miR-214-5p/PPARGC1B axis.	33296783
5304	Human	hsa-miR-214-5p	miRNA	dexamethasone (DEX)	postmenopausal osteoporosis (PMOP)	human bone marrow stem cells (BMSCs)	dexamethasone (DEX) treatment	upregulated	29532880
5305	Human	hsa-miR-215	miRNA	hypoxia	colorectal cancer (CRC)	"Cancer stem cells, also known as tumor-initiating cells (TICs)"	hypoxia induce	upregulated	30790680
5306	Human	hsa-miR-215	miRNA	adriamycin (ADR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) subcel	adriamycin (ADR) treatment	upregulated	26135967
5307	Human	hsa-miR-215	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	H460 and A427 cells	curcumin treatment	upregulated	25444916
5308	Human	hsa-miR-215	miRNA	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA)"	ovarian cancer (OC)	ovarian cancer cell lines SKOV-3 and A2780	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA) treatment"	upregulated	29324748
5309	Human	hsa-miR-215	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
5310	Human	hsa-miR-215	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	CCD-18Co cells	lipopolysaccharide (LPS) treatment	knockdown of miR-215 alleviated oxidative stress and inflammatory response in LPS-treated CCD-18Co cells by upregulating GDF11 expression and inactivating the TLR4/NF-¦ÊB and JNK/p38 signaling pathways.	33146403
5311	Human	hsa-miR-215-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
5312	Human	hsa-miR-215-5p	miRNA	melatonin	colorectal cancer (CRC)	"Human colon cancer cell lines HCT116, SW480, COLO320, DLD-1, HT29, RKO, CaCO2, and SW620"	melatonin treatment	upregulated	30590435
5313	Human	hsa-miR-215-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
5314	Human	hsa-miR-215-5p	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	upregulated	32587527
5315	Human	hsa-miR-215-5p	miRNA	particulate matter (PM2.5)	PM2.5-induced carcinogenesis	human bronchial epithelial (HBE) cells	fine particulate matter (PM2.4) treatment	upregulated	33545377
5316	Human	hsa-miR-215-5p	miRNA	IL-17A	psoriasis	HaCaT cells	IL-17A treatment	downregulated	32881074
5317	Human	hsa-miR-215-5p	miRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	downregulated	32881074
5318	Human	hsa-miR-215-5p	miRNA	IL-6	psoriasis	HaCaT cells	IL-6?treatment	downregulated	32881074
5319	Human	hsa-miR-215-5p	miRNA	imiquimod (IMQ)	psoriasis	skin tissues	imiquimod (IMQ) treatment	The expression of miR-215-5p was downregulated in imiquimod (IMQ)-treated skin tissues.	32881074
5320	Human	hsa-miR-21-5p	miRNA	immunoglobulin E (IgE)	airway remodeling	human primary airway smooth muscle cell (ASMC)	immunoglobulin E (IgE) treatment	upregulated	30781615
5321	Human	hsa-miR-21-5p	miRNA	anabolic-androgenic ateroids (AASs)	anabolic-Androgenic Steroids (AASs)-induced renal damage	kidney tissues	anabolic-androgenic ateroids (AASs) treatment	upregulated	33041804
5322	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	angiogenesis	human retinal microvascular endothelial cells (HRMECs)	high glucose treatment	upregulated	29658404
5323	Human	hsa-miR-21-5p	miRNA	KHCO3	bone resorption of alkali	human serum	potassium bicarbonate [(KHCO3); 81 mmol/d; n = 12] vs placebo (n = 12) for 84 days	upregulated in serum	29264553
5324	Human	hsa-miR-21-5p	miRNA	ethanol extract of antrodia cinnamomea (AC)	breast cancer	MCF-7 and tamoxifen-resistant MCF-7 cells	ethanol extract of antrodia cinnamomea (AC) treatment	upregulated	29743060
5325	Human	hsa-miR-21-5p	miRNA	brucella Omp25	brucellosis	human Monocyte/Macrophages	brucella Omp25 treatment	upregulated	28694807
5326	Human	hsa-miR-21-5p	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	"hepatic tissues from HCV-infected patients, Huh-7 cells"	hepatitis C virus (HCV) infection	upregulated	30938910
5327	Human	hsa-miR-21-5p	miRNA	IL-4	chronic lymphocytic leukemia (CLL)	Peripheral blood	Interleukin 4 (IL-4) treatment	upregulated	25909590
5328	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	GAS5 could competitively bind with miR-21-5p and miR-21-5p inhibition alleviated the beneficial effects of GAS5 knockdown against HG stimulation.	31865425
5329	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human cardiomyocyte-like AC16 cells	high glucose (HG) treatment	downregulated	31865425
5330	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial ARPE-19 cells	high-glucose (HG) treatment	"XIST, likely through competitive binding of hsa-miR-21-5p, provides protection against hyperglycemia-associated injury in human retinal pigment epithelial cells."	32106367
5331	Human	hsa-miR-21-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
5332	Human	hsa-miR-21-5p	miRNA	saponin extract	endometriosis	human endometrial stromal cells (HESCs) obtained from patients with endometriosis	saponin extract treatment	downregulated	28558522
5333	Human	hsa-miR-21-5p	miRNA	atorvastatin	endothelial senescence	ox-LDL treated HUVECs	atorvastatin treatment	downregulated	29248491
5334	Human	hsa-miR-21-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial senescence	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
5335	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
5336	Human	hsa-miR-21-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
5337	Human	hsa-miR-21-5p	miRNA	hypoxia	flap surgeries	human umbilical vein endothelial cells (HUVEC)	hypoxia treatment	upregulated	28880208
5338	Human	hsa-miR-21-5p	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
5339	Human	hsa-miR-21-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
5340	Human	hsa-miR-21-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
5341	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
5342	Human	hsa-miR-21-5p	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	Hep3B cells; Huh-7 cells	curcumin treatment	miR-21-5p level was decreased in curcumin-treated cells.	32757994
5343	Human	hsa-miR-21-5p	miRNA	atorvastatin	hyperlipidemia	HUVECs	atorvastatin treatment	downregulated	29248491
5344	Human	hsa-miR-21-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	hyperlipidemia	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
5345	Human	hsa-miR-21-5p	miRNA	metformin (Met)	hypopharyngeal cancer	human hypopharyngeal carcinoma cell line (FaDu)	metformin treatment	downregulated	27688683
5346	Human	hsa-miR-21-5p	miRNA	electron beam (EB) irradiation	keloids	keloid fibroblast	Electron beam (EB) irradiation	downregulated	31558773
5347	Human	hsa-miR-21-5p	miRNA	electron beam (EB) irradiation	keloids	keloid fibroblasts	Electron beam (EB) irradiation treatment	MiR-21-5p expression was found to be significantly downregulated after keloid fibroblasts were exposed to 20 Gy of EB irradiation.	31558773
5348	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	liver fibrosis	NTCP-Huh7.5.1 cells	TGF-¦Â1 treatment	TGF-¦Â1 incubation significantly increased miR-21-5p levels	33456536
5349	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	TGF-¦Â1 incubation significantly increased miR-21-5p levels	33456536
5350	Human	hsa-miR-21-5p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
5351	Human	hsa-miR-21-5p	miRNA	physical exercise	myasthenia gravis (MG)	MG patients serum	performed supervised aerobic and resistance training twice weekly for 12 weeks treatment	downregulated	27935072
5352	Human	hsa-miR-21-5p	miRNA	prednisone	myasthenia gravis (MG)	serum	prednisone treatment	Levels of miR-21-5p displayed a negative correlation with the prednisone dose within the prednisone-only group	29511707
5353	Human	hsa-miR-21-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
5354	Human	hsa-miR-21-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
5355	Human	hsa-miR-21-5p	miRNA	ovatodiolide (OV)	oral squamous cell carcinoma (OSCC)	cancer stem cell-derived extracellular vesicles (CSC_EVs) generated from CAL27 and SCC-15 OSCC cells	ovatodiolide (OV) treatment	downregulated	31878245
5356	Human	hsa-miR-21-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	downregulated	31053150
5357	Human	hsa-miR-21-5p	miRNA	pulsed electromagnetic field (PEMF)	osteoblastic differentiation	human bone marrow stromal cells (hBMSCs)	PEMFs treatment	upregulated	28512472
5358	Human	hsa-miR-21-5p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	upregulated	26987780
5359	Human	hsa-miR-21-5p	miRNA	lectin	prostate cancer	Prostate cancer (PC) cell lines	lectin treatment	upregulated	26417675
5360	Human	hsa-miR-21-5p	miRNA	radiation	prostate cancer	serum	curative radiotherapy (RT) treatment	upregulated	30103771
5361	Human	hsa-miR-21-5p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-21-5p was downregulated in treated patients when compared with untreated patients.	29523324
5362	Human	hsa-miR-21-5p	miRNA	lipopolysaccharide (LPS)	pulpal inflammation	human dental pulp cells (hDPCs)	lipopolysaccharide (LPS) treatment	upregulated	31042008
5363	Human	hsa-miR-21-5p	miRNA	pioglitazone	renal fibrosis	TGF-¦Â1-treated HK-2 cells	Pioglitazone treatment	downregulated	31254585
5364	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	31254585
5365	Human	hsa-miR-21-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell senescence	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28347692
5366	Human	hsa-miR-21-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
5367	Human	hsa-miR-21-5p	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	type 1 diabetes mellitus (T1DM)	EndoC-¦ÂH1 beta cell lines and human islets	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	upregulated	29445851
5368	Human	hsa-miR-21-5p	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	"SUM159PT, MCF-7, BT-474 and BT-549"	metformin treatment	downregulated	28698800
5369	Human	hsa-miR-216	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
5370	Human	hsa-miR-216	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
5371	Human	hsa-miR-216	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
5372	Human	hsa-miR-216	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
5373	Human	hsa-miR-216	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
5374	Human	hsa-miR-216-3p	miRNA	metformin (Met)	preeclampsia (PE)	Trophoblast and HUVEC cells	Metformin (Met) treatment	upregulated	31203154
5375	Human	hsa-miR-216a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS)	downregulated	31784954
5376	Human	hsa-miR-216a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	31784954
5377	Human	hsa-miR-216a	miRNA	ginsenoside Rb2	inflammation	human umbilical vein endothelial cells (HUVECs); human aortic endothelial cells	Ginsenoside Rb2 (Rb2) treatment	Rb2 decreased the expression of endogenous miR-216a.	33786633
5378	Human	hsa-miR-216a	miRNA	lipopolysaccharide (LPS)	macrophage polarization	THP-1 derived macrophage	1 ng/ml lipopolysaccharide (LPS) and 20 ng/ml interferon (IFN)-¦Ã treatment	upregulated	29940270
5379	Human	hsa-miR-216a	miRNA	dihydrotestosterone (DHT)	prostate cancer	LNCaP cells	dihydrotestosterone treatment	upregulated	26506397
5380	Human	hsa-miR-216a-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
5381	Human	hsa-miR-216a-5p	miRNA	H2O2	asthma	human bronchial epithelial cell (16HBE)	H2O2 treatment	downregulated	30502088
5382	Human	hsa-miR-216a-5p	miRNA	H2O2	asthma	16HBE cells	H2O2 treatment	downregulated	30502088
5383	Human	hsa-miR-216a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31029709
5384	Human	hsa-miR-216a-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose treatment	ZEB1-AS1 suppressed HG-induced EMT and fibrogenesis by regulating miR-216a-5p and BMP-7.	32294702
5385	Human	hsa-miR-216a-5p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	upregulated	24927770
5386	Human	hsa-miR-216a-5p	miRNA	treponema pallidum (T. pallidum) infection	syphilis	plasma	Treponema pallidum (T. pallidum) infectionn treatment	downregulated	31358689
5387	Human	hsa-miR-216b	miRNA	Cetuximab	colorectal cancer (CRC)	CRC cells	cetuximab treatment	downregulated	27158405
5388	Human	hsa-miR-216b	miRNA	ethanol extract of Salviamiltiorrhiza (SM)	endoplasmic reticulum stress (ERS)	U266 and U937 cells	ethanol extract of Salviamiltiorrhiza (SM) treatment	upregulated	29671785
5389	Human	hsa-miR-216b	miRNA	cigarette smoke condensate (CSC)	non-small cell lung cancer (NSCLC)	HPL1A cells	cigarette smoke condensate (CSC) treatment	upregulated	32668597
5390	Human	hsa-miR-216b	miRNA	paclitaxel (PTX)	non-small cell lung cancer (NSCLC)	NSCLC cells	paclitaxel treatment	downregulated	26852748
5391	Human	hsa-miR-216b	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrosarcoma cells (SW1353)	IL-1¦Â treatment	upregulated	28356485
5392	Human	hsa-miR-216b	miRNA	oxygen glucose deprivation (OGD)	spinal cord injury (SCI)	human SY-SH-5Y cells	oxygen-glucose deprivation treatment	"TCTN2 was downregulated in the spinal cord tissues of a rat model of SCI and in oxygen-glucose deprivation-induced hypoxic SY-SH-5Y cells, while microRNA-216b (miR-216b) was upregulated"	31050183
5393	Human	hsa-miR-217	miRNA	arsenite	acceleration of the cell cycle and carcinogenesis	HaCaT cells	arsenic exposure	upregulated	28062277
5394	Human	hsa-miR-217	miRNA	human cytomegalovirus (HCMV)	acute myeloid leukemia (AML)	endothelial cells(ECs)	Human cytomegalovirus(HCMV)? infection	upregulated	24376725
5395	Human	hsa-miR-217	miRNA	TGF-¦Â1	asthma	Human airway smooth muscle cells (ASMCs)	transforming growth factor-¦Â (TGF-¦Â1) treatment	downregulated	30212709
5396	Human	hsa-miR-217	miRNA	TGF-¦Â1	asthma	human bronchial epithelial cells BEAS-2B	TGF-¦Â1 treatment	"TGF-¦Â1, GAS5, HDAC4 were upregulated, while miR-217 was downregulated in bronchial mucosal tissues of asthmatic children and TGF-¦Â1-treated BEAS-2B cells"	33864612
5397	Human	hsa-miR-217	miRNA	high glucose (HG)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	miR-217 was found to be upregulated in VSMCs treated by high glucose and aorta VSMCs of diabetic rats.	33283391
5398	Human	hsa-miR-217	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 acute monocytic leukemia cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31432137
5399	Human	hsa-miR-217	miRNA	arsenite	bladder cancer	Normal bladder SV-HUC-1 cells	?arsenite treatment	downregulated	33386469
5400	Human	hsa-miR-217	miRNA	dasatinib	chronic myeloid leukemia (CML)	K562 cells	dasatinib treatment	miR-217 was significantly downregulated in K562 cells.	30195077
5401	Human	hsa-miR-217	miRNA	baicalin (BAI)	colorectal cancer (CRC)	DLD1 and HCT-116 cells	baicalin (BAI) treatment	downregulated	30737617
5402	Human	hsa-miR-217	miRNA	high glucose (HG)	diabetes mellitus (DM)	human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model."	33865922
5403	Human	hsa-miR-217	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	upregulated	31702814
5404	Human	hsa-miR-217	miRNA	rapamycin	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	upregulated	29579170
5405	Human	hsa-miR-217	miRNA	cigarette smoke condensate (CSC)	esophageal adenocarcinoma (EAC)	esophageal adenocarcinoma (EAC) cells	cigarette smoke condensate (CSC) treatment	downregulated	25703328
5406	Human	hsa-miR-217	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	HCV patients	IFN/RBV for 12 months treatment	upregulated	24033414
5407	Human	hsa-miR-217	miRNA	orafenib	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU-387; SNU-449	orafenib treatment	Lnc HOTAIR could increase sorafenib resistance in HCC by inhibiting miR-217.	32462038
5408	Human	hsa-miR-217	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammatory injury	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-217 ameliorates inflammatory damage of endothelial cells induced by oxidized LDL by targeting EGR1.	32737769
5409	Human	hsa-miR-217	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	downregulated	26415832
5410	Human	hsa-miR-217	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	Conditionally immortalized human podocyte cell line AB8/13	angiotensin II (Ang II) treatment	downregulated	30414341
5411	Human	hsa-miR-217	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
5412	Human	hsa-miR-217	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
5413	Human	hsa-miR-217	miRNA	TGF-¦Â1	pancreatic cancer (PC)	"The human pancreatic cancer cell lines BxPC-3, PANC-1"	TGF-¦Â1 treatment	downregulated	25172416
5414	Human	hsa-miR-217	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31737212
5415	Human	hsa-miR-217	miRNA	dasatinib and 5-Aza-2'-deoxycytidine	chronic myeloid leukemia (CML)	K562 cells	exposure to dasatinib (10 nM) together with 5-AzadC(0.1 ¦ÌM) treatment	upregulated	24350829
5416	Human	hsa-miR-217-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells	oxidized low-density lipoprotein (OX-LDL) treatment	downregulated	31744714
5417	Human	hsa-miR-217-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The level of miR-217-5p was significantly decreased in SH-SY5Y cells following OGD/R treatment	32683553
5418	Human	hsa-miR-218	miRNA	cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC)	advanced gastric cancers (AGCs)	advanced gastric cancers patients	CRS and HIPEC treatment	upregulated	25170221
5419	Human	hsa-miR-218	miRNA	triptolide (TPL)	benign prostatic hypertrophy (BPH)	BPH-1 cells	triptolide (TPL) treatment	upregulated	30453799
5420	Human	hsa-miR-218	miRNA	ionizing radiation (IR)	breast cancer	breast cancer cells and tissues	ionizing radiation treatment	upregulated	30429228
5421	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	carcinogenesis of cigarette smoke	human bronchial epithelial (HBE) cells	cigarette smoke?extract?(CSE) treatment	upregulated	25526925
5422	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells	cigarette smoke?extract?(CSE) treatment	downregulated	28864214
5423	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	downregulated	31668807
5424	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	CSE-treated 16HBE cells	cigarette smoke extract (CSE) treatment	MiR-218 was downregulated in COPD tissues and CSE-treated or MEG3 overexpressed 16HBE cells. MiR-218 overexpression attenuated CSE-blocked proliferation and CSE-induced apoptosis or inflammation.	31668807
5425	Human	hsa-miR-218	miRNA	smoking	chronic obstructive pulmonary disease (COPD)	lung tissues	smoking treatment	MiR-218 was downregulated in COPD tissues	31668807
5426	Human	hsa-miR-218	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	miR-218 was highly expressed in renal proximal tubule under high-glucose conditions.	32028854
5427	Human	hsa-miR-218	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelium (RPE) cells (ARPE-19)	high glucose (HG) treatment	upregulated	31830266
5428	Human	hsa-miR-218	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
5429	Human	hsa-miR-218	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29693114
5430	Human	hsa-miR-218	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)		"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26610476
5431	Human	hsa-miR-218	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	criplatin treatment	miR-218 was decreased in cisplatin resistant SGC7901/DDP cells.	30542435
5432	Human	hsa-miR-218	miRNA	thermo-chemotherapy	gastric cancer (GC)	SGC7901 cells	thermo-chemotherapy treatment	upregulated	25694126
5433	Human	hsa-miR-218	miRNA	propofol (PPF)	glioblastoma multiforme (GBM)	U373 glioblastoma cell	Propofol treatment	upregulated	26133092
5434	Human	hsa-miR-218	miRNA	genistein	gliosarcoma	human gliosarcoma cells (U251)	exposed to genistein (12.5-200 ¦Ìg) for 24 h	upregulated	28776680
5435	Human	hsa-miR-218	miRNA	cigarette smoke condensate (CSC)	glomerulosclerosis	primary bronchial epithelial cells and H1299 cells	cigarette smoke condensate (CSC) treatment	mir-218 expression is reduced in primary bronchial epithelium exposed to cigarette smoke condensate (CSC)	19168627
5436	Human	hsa-miR-218	miRNA	benzophenone-3 (BP-3)	hirschsprung's disease (HSCR)	maternal urine	benzophenone-3 (BP-3) treatment	BP-3 influenced cell migration via SLIT2/ROBO1-miR-218-RET/PLAG1 pathway	26454118
5437	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	human bronchial epithelial (HBE) cells injury	human bronchial epithelial (HBE) cells	cigarette smoke?extract?(CSE) treatment	downregulated	25526925
5438	Human	hsa-miR-218	miRNA	Legionella pneumophila (L. pneumophila)	Legionella pneumophila (L. pneumophila) infection	u937 cells	L. pneumophila infection	L. pneumophila infection upregulated the expression of miR-218.	30509489
5439	Human	hsa-miR-218	miRNA	"1,6,7-trihydroxyxanthone (THA)"	hepatocellular carcinoma (HCC)	liver cancer cell lines HepG2	"1,6,7-trihydroxyxanthone (THA) treatment"	upregulated	25416134
5440	Human	hsa-miR-218	miRNA	andes hantavirus (ANDV)	liver damage	human endothelial cells (ECs)	andes hantavirus (ANDV) infection	downregulated	20844033
5441	Human	hsa-miR-218	miRNA	andrographolide	lung cancer	human alveolar epithelial A549 cells	andrographolide treatment	upregulated	24298938
5442	Human	hsa-miR-218	miRNA	carboplatin (CBP)	lung cancer	A549 and H1975 lung cancer cells	carboplatin (CBP) treatment	downregulated	25917317
5443	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	downregulated	27212446
5444	Human	hsa-miR-218	miRNA	human papilloma virus (HPV)	malignant transformation of esophageal epithelial cells	Het-1A cells	HPV and MNNG treatment	downregulated	33189795
5445	Human	hsa-miR-218	miRNA	andrographolide	oral cancer	human oral cancer stem cells (OCSCs)	andrographolide treatment	upregulated	27926533
5446	Human	hsa-miR-218	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
5447	Human	hsa-miR-218	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells	gemcitabine (GEM) treatment	downregulated	26157323
5448	Human	hsa-miR-218	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament progenitor cells	lipopolysaccharide (LPS) treatment	downregulated	30444938
5449	Human	hsa-miR-218	miRNA	Legionella pneumophila (L. pneumophila)	pneumonia	The human macrophage-like cell line U937	Legionella pneumophila infection	upregulated	30509489
5450	Human	hsa-miR-218	miRNA	hypoxia	preeclampsia (PE)	cell line HTR-8/Svneo;the trophoblast-derived choriocarcinoma cell line JEG-3	exposed to 0.5% O2	upregulated	28412444
5451	Human	hsa-miR-218	miRNA	hypoxia	renal cell carcinoma (RCC)	renal cell carcinoma cell lines	hypoxia treatment	downregulated	27133059
5452	Human	hsa-miR-218	miRNA	cisplatin (DDP)	small-cell lung cancer (SCLC)	NCI-H69 cells	cisplatin treatment	Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression	31477834
5453	Human	hsa-miR-218-2*	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
5454	Human	hsa-miR-218-5p	miRNA	IL-13	asthma	human bronchial epithelial (HBE) cells; BEAS-2B cells	IL-13 treatment	downregulated	31520422
5455	Human	hsa-miR-218-5p	miRNA	IL-13	asthma	HBE and BEAS-2B cells	interleukin 13 (IL-13) treatment	downregulated	31520422
5456	Human	hsa-miR-218-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
5457	Human	hsa-miR-218-5p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	plasma	cigarette smoke (CS) treatment	downregulated	30024625
5458	Human	hsa-miR-218-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cell (HPMECs)	cigarette smoke extract (CSE) treatment	downregulated	32129458
5459	Human	hsa-miR-218-5p	miRNA	KSHV-encoded viral interferon regulatory factor 1 (vIRF1)	kaposi's sarcoma (KS)	endothelial cell	KSHV-encoded viral interferon regulatory factor 1 (vIRF1) treatment	downregulated	30699189
5460	Human	hsa-miR-219	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
5461	Human	hsa-miR-219	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
5462	Human	hsa-miR-219	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	upregulated	32807750
5463	Human	hsa-miR-219-2-3p	miRNA	5-aza-2'-deoxycytidine and trichostatin A	gastric cancer (GC)	human GC cell lines MGC-803; HGC-27; MKN-45; SGC-7901	5-aza-2'-deoxycytidine and trichostatin A treatment	downregulated	23637748
5464	Human	hsa-miR-219-5p	miRNA	paraquat (PQ)	acute paraquat (PQ) poisoning	serum	paraquat (PQ) treatment	Serum miR-219-5p level was decreased and negatively correlated with TLR4 level in MODS patients.	33233960
5465	Human	hsa-miR-219-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial (RPE) cells	high glucose (HG) treatment	miR-219-5p was significantly upregulated by high glucose (HG) treatment.	29749515
5466	Human	hsa-miR-219-5p	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	Huh7 and SMMC7721 cells	Propofol treatment	upregulated	31104336
5467	Human	hsa-miR-219-5p	miRNA	AgNPs	toxicity of silver (Ag)	Jurkat T cells	AgNPs treatment	downregulated	24974767
5468	Human	hsa-miR-219-5p	miRNA	hypoxia	wound healing	HaCaTs	hypoxia treatment	MiR-219-5p was markedly increased in hypoxia group.	30338788
5469	Human	hsa-miR-21a-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
5470	Human	hsa-miR-22	miRNA	paclitaxel (PTX)	colorectal cancer (CRC)	HT-29 cells; HCT-15 cells	Paclitaxel treatment	over expression	21594648
5471	Human	hsa-miR-22	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
5472	Human	hsa-miR-22	miRNA	L©\arginine	acute edematous pancreatitis (AEP)	pancreatic acinar cell line (AR42J)	introperitoneal injection of L-arginine (150 mg/kg) treatment	upregulated	24710937
5473	Human	hsa-miR-22	miRNA	hypoxia	acute kidney injury (AKI)	Distal convoluted tubule cells (DCT)	hypoxia induce	upregulated	29791781
5474	Human	hsa-miR-22	miRNA	sodium butyrate (NaB)	apoptosis	Huh 7 cells	sodium butyrate treatment	upregulated	28288414
5475	Human	hsa-miR-22	miRNA	high glucose (HG)	atherosclerosis (AS)	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
5476	Human	hsa-miR-22	miRNA	myeloperoxidase oxidized LDL (Mox-LDL)	atherosclerosis (AS)	HUVEC Cells	Mox-LDL treatment	upregulated	25530680
5477	Human	hsa-miR-22	miRNA	lipopolysaccharide (LPS)	breast cancer	182R-6 fulvestrant-resistant breast cancer line	LPS treatment	downregulated	30057418
5478	Human	hsa-miR-22	miRNA	sc-514 (a selective IKK¦Â inhibitor)	breast cancer	LPS-treated 182R-6 fulvestrant-resistant breast cancer line	"sc-514, a selective IKK¦Â inhibitor treatment"	upregulated	30057418
5479	Human	hsa-miR-22	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	human bronchial epithelial cells 16HBE	"anti-benzo[a]pyrene-7,8-diol-9,10-epoxide treatment"	upregulated	20170724
5480	Human	hsa-miR-22	miRNA	high glucose (HG)	cell pyroptosis	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
5481	Human	hsa-miR-22	miRNA	salidroside (SAL)	cell senescence	50 population doubling (PD) of the 2BS cell line isolated from human fetal lung fibroblasts	salidroside (SAL) treatment	downregulated	31612074
5482	Human	hsa-miR-22	miRNA	ultraviolet (UV) irradiation	cellular stress response	Human embryonic kidney cell line HEK293T	UV radiation treatment	?UV radiation induces a significant increase of miR-22 expression	22166214
5483	Human	hsa-miR-22	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
5484	Human	hsa-miR-22	miRNA	phorbol-12-myristate-13-acetate(PMA)	chronic myeloid leukemia (CML)	CML cell line K562	20 nM PMA for 48 h in a 25 mm petri dish treatment	downregulated	27889568
5485	Human	hsa-miR-22	miRNA	phorbol-12-myristate-13-acetate(PMA)	chronic myeloid leukemia (CML)	CML cell line K562	CML cell line K562 treatment	upregulation	27889568
5486	Human	hsa-miR-22	miRNA	butyrate	colorectal cancer (CRC)	HCT116 and DLD-1 cells	butyrate treatment	upregulated	30252536
5487	Human	hsa-miR-22	miRNA	butyrate	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	butyrate treatment	upregulated	30252536
5488	Human	hsa-miR-22	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human CRC cell line (HCT-8/5-FU)	PZH treatment	upregulated	29042944
5489	Human	hsa-miR-22	miRNA	propionate	colorectal cancer (CRC)	HCT116 and DLD-1 cells	propionate treatment	upregulated	30252536
5490	Human	hsa-miR-22	miRNA	propionate	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	propionate treatment	upregulated	30252536
5491	Human	hsa-miR-22	miRNA	retinoic acid (RA)	colorectal cancer (CRC)	HCT116 and DLD-1 cells	retinoic acid (RA) treatment	upregulated	30252536
5492	Human	hsa-miR-22	miRNA	retinoic acid (RA)	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	retinoic acid (RA) treatment	upregulated	30252536
5493	Human	hsa-miR-22	miRNA	SAHA	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	SAHA treatment	upregulated	30252536
5494	Human	hsa-miR-22	miRNA	suberoylanilide hydroxamic acid (SAHA)	colorectal cancer (CRC)	HCT116 and DLD-1 cells	suberanilohydroxamic acid (SAHA) treatment	upregulated	30252536
5495	Human	hsa-miR-22	miRNA	valerate	colorectal cancer (CRC)	HCT116 and DLD-1 cells	valerate treatment	upregulated	30252536
5496	Human	hsa-miR-22	miRNA	valerate	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	valerate treatment	upregulated	30252536
5497	Human	hsa-miR-22	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	serum	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) treatment"	We showed a significant modulation of serum miR-22 after R-CHOP treatment.	29716630
5498	Human	hsa-miR-22	miRNA	endosulfan	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	endosulfan	upregulated	28161397
5499	Human	hsa-miR-22	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
5500	Human	hsa-miR-22	miRNA	simulated microgravity (SMG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	simulated microgravity (SMG) treatment	upregulated	30017544
5501	Human	hsa-miR-22	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
5502	Human	hsa-miR-22	miRNA	diallyl disulfide (DADS)	gastric cancer (GC)	Five gastric cancer cell lines (MGC-803; BGC-823; MKN-28; SGC-7901; HGC-27; AGS)	diallyl disulfide treatment	upregulated	23851184
5503	Human	hsa-miR-22	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"BGC-823, AGS and THP-1 cells"	Helicobacter pylori (H. pylori) infection	downregulated	29059152
5504	Human	hsa-miR-22	miRNA	IL-1¦Â	gastric cancer (GC)	"BGC-823, AGS and THP-1 cells"	IL-1¦Â treatment	downregulated	29059152
5505	Human	hsa-miR-22	miRNA	mineral pitch (MP)	hepatocellular carcinoma (HCC)	Huh-7 cells	Mineral Pitch (MP) treatment	upregulated	27233240
5506	Human	hsa-miR-22	miRNA	lipopolysaccharide (LPS)	kidney damage	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	30130540
5507	Human	hsa-miR-22	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 leukemia cell line	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	20214878
5508	Human	hsa-miR-22	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	"miR-22 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM"	32656599
5509	Human	hsa-miR-22	miRNA	haloperidol	neuroblastoma (NB)	SK-N-SH cell lines	haloperidol at 10¦Ìm concentration for 24 hours	downregulated	28886082
5510	Human	hsa-miR-22	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
5511	Human	hsa-miR-22	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SK-N-SH cells	PFOS treatment	upregulated	28441774
5512	Human	hsa-miR-22	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	L02 cells	free fatty acids (FFAs) treatment	Free fatty acids induced miR-22 upregulation and lipogenesis in human hepatocytes.	33159388
5513	Human	hsa-miR-22	miRNA	pemetrexed	non-small cell lung cancer (NSCLC)	NSCLC tissue	pemetrexed treatment	upregulated	23794259
5514	Human	hsa-miR-22	miRNA	quercetin	oral lichen planus (OLP)	human oral keratinocytes (HOKs)	quercetin treatment	"Quercetin can mitigate LPS-induced injury in HOKs by downregulating miR-22, thereby activating PI3K/AKT and JAK1/STAT3 cascades"	32329368
5515	Human	hsa-miR-22	miRNA	arecoline	oral squamous cell carcinoma (OSCC)	ORL-48(T) and ORL-136(T) cell lines	arecoline treatment	downregulated	29385191
5516	Human	hsa-miR-22	miRNA	quercetin	oral squamous cell carcinoma (OSCC)	Human normal oral keratinocytes (hNOK) and OSCC cell line Tca8113 and SAS cells	Quercetin (Que) treatment	upregulated	31257059
5517	Human	hsa-miR-22	miRNA	IL-1	osteoarthritis (OA)	primary cultured chondrocytes	?IL-1 treatment	miR-22 downregulated in patients with OA	30887601
5518	Human	hsa-miR-22	miRNA	osteogenic inductive cocktail	osteogenesis	human periodontal ligament stem cells (PDLSCs)	osteogenic inductive cocktail	upregulated	28195408
5519	Human	hsa-miR-22	miRNA	cisplatin (DDP)	osteosarcoma (OS)	human osteosarcoma cell lines (U-2 OS and MG-63)	cisplatin (DDP) treatment	upregulated	24609901
5520	Human	hsa-miR-22	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	human osteosarcoma cell lines (U-2 OS and MG-63)	doxorubicin (DOX) treatment	upregulated	24609901
5521	Human	hsa-miR-22	miRNA	isoflurane	ovarian cancer (OC)	SKOV3 cells;TOV21G cells	isoflurane treatments at 1 and 2 h	upregulated	28951521
5522	Human	hsa-miR-22	miRNA	curcumin (Cur)	pancreatic cancer (PC)	The BxPC-3 human pancreatic carcinoma cell line	curcumin (diferuloylmethane)? treatment	upregulated	18347134
5523	Human	hsa-miR-22	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
5524	Human	hsa-miR-22	miRNA	Hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	downregulated	20110569
5525	Human	hsa-mir-22	miRNA	hypoxia/reoxygenation (H/R)	reperfusion injury	Human iPS-derived cardiomyocytes (iPS-CM)	hypoxia and hypoxia-reoxygenation treatment	upregulated	32826883
5526	Human	hsa-miR-22	miRNA	curcumin (Cur)	retinoblastoma (RB)	human Y79 retinoblastoma cells	curcumin (CUR) treatment	upregulated	22510010
5527	Human	hsa-miR-22	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	"TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway."	30666657
5528	Human	hsa-miR-22	miRNA	IL-21	systemic lupus erythematosus (SLE)	normal and SLE B cells	IL-21 treatment	upregulated	25101889
5529	Human	hsa-miR-22	miRNA	perfluorooctane sulfonic acid (PFOS)	toxicity of perfluorooctane sulfonate (PFOS)	SH-SY5Y human neuroblastoma cells	Perfluorooctane sulfonate (PFOS) treatment	upregulated	26649298
5530	Human	hsa-miR-22	miRNA	vitamin D	colorectal cancer (CRC)	Human colon cancer SW480-ADH£»HCT116£»HT29£» LS174T£»DLD-1£»SW620£» SW1417£» SW480-R cell lines	?vitamin D? treatment	upregulated	22328083
5531	Human	hsa-miR-22*	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
5532	Human	hsa-miR-221	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	HUVECs	human immunodeficiency virus-1 (HIV-1) infection	downregulated	23555914
5533	Human	hsa-miR-221	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
5534	Human	hsa-miR-221	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
5535	Human	hsa-miR-221	miRNA	metformin (Met)	angiogenesis	human endothelial progenitor cells (EPCs)	metformin treatment	downregulated	31581911
5536	Human	hsa-miR-221	miRNA	resveratrol	anti-inflammatory responses	HUVECs treated with TNF-¦Á	resveratrol (RS) treatment	upregulated	28338009
5537	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	anti-inflammatory responses	HUVECs	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28338009
5538	Human	hsa-miR-221	miRNA	TGF-¦Â	asthma	ASM cells (ASMCs) from patients with severe asthma	TGF-¦Â treatment	upregulated	23944957
5539	Human	hsa-miR-221	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29859752
5540	Human	hsa-miR-221	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31565033
5541	Human	hsa-miR-221	miRNA	hydroquinone (HQ)	benzene-induced carcinogenesis	hydroquinone (HQ)-transformed 16HBE cells secreted exosomes	Hydroquinone (HQ) treatment	upregulated	31468561
5542	Human	hsa-miR-221	miRNA	IFN-¦Ã	biliary inflammation	H69 cells	interferon-gamma treatment	downregulated	20110463
5543	Human	hsa-miR-221	miRNA	necrosis factor related apoptosis-inducing ligand (TRAIL)	bladder cancer	T24 cells; RT4 cells;SV-HUC-1 cells	necrosis factor related apoptosis-inducing ligand (TRAIL) treatment	upregulated	19767219
5544	Human	hsa-miR-221	miRNA	leptin	borna disease virus (BDV)?infection	human pre-adipocytes	leptin treatment	downregulated	23756832
5545	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	borna disease virus (BDV)?infection	human pre-adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	23756832
5546	Human	hsa-miR-221	miRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	upregulated	31899608
5547	Human	hsa-miR-221	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
5548	Human	hsa-miR-221	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
5549	Human	hsa-miR-221	miRNA	TGF-¦Â	breast cancer	MCF-7 cells	MCF-7 cells treatment	upregulation	27174021
5550	Human	hsa-miR-221	miRNA	wound fluids (WFs) from breast cancer patients	breast cancer	human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line	WFs treatment	upregulated	28943910
5551	Human	hsa-miR-221	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	upregulated	30851420
5552	Human	hsa-miR-221	miRNA	minocycline (MNC)	cell proliferation	PDGF-BB-treated human aortic smooth muscle cell (SMC)	Minocycline treatment	downregulated	30716386
5553	Human	hsa-miR-221	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (SMC)	platelet-derived growth factor BB homodimer (PDGF-BB) treatment	upregulated	30716386
5554	Human	hsa-miR-221	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	25019494
5555	Human	hsa-miR-221	miRNA	TGF-¦Â1	chronic kidney disease (CKD)	?renal tubule epithelial cells	TGF-¦Â1 treatment	downregulated	26806834
5556	Human	hsa-miR-221	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	CML cell lines (K562 and imatinib-resistant K562/G)	imatinib treatment	"MiR-221 expression was markedly decreased in K562/G cells and peripheral blood mononuclear cells from patients with treatment failure, when compared to imatinib-sensitive CML cells and patients with optimal responses respectively."	30516071
5557	Human	hsa-miR-221	miRNA	hepatitis C virus (HCV)	cognitive impairment	monocyte-derived exosome	hepatitis C virus (HCV) infection	upregulated	32157304
5558	Human	hsa-miR-221	miRNA	human immunodeficiency virus (HIV)-1	cognitive impairment	monocyte-derived exosome	human immunodeficiency virus (HIV)-1 infectiom	upregulated	32157304
5559	Human	hsa-miR-221	miRNA	temozolomide (TMZ)	colorectal cancer (CRC)	"U87MG cells;T98G cells; LN428 cells; LN308 cells; A172 cells; HEK-293 cells cells;LN229 cells;T98G, U87MG, and LN229 ,LN428 cells; LN308 cells; A172 cells"	temozolomide (TMZ) treatment	upregulated	24147153
5560	Human	hsa-miR-221	miRNA	microcystin-leucine arginine (MC-LR)	colorectal cancer (CRC)	colon cell line DLD-1	microcystin-LR (MC-LR) treatment	upregulated	30312888
5561	Human	hsa-miR-221	miRNA	microcystin-leucine arginine (MC-LR)	colorectal cancer (CRC)	colon cell line DLD-1	microcystin-LR (MC-LR) treatment	upregulated	30312888
5562	Human	hsa-miR-221	miRNA	AS1411	corneal neovascularization (CNV)	human limbus stroma (HLSC)	AS1411 treatment	AS1411 treatment also significantly reduced VEGF-stimulated induction of miR-21 and miR-221 in HLSC.	32081668
5563	Human	hsa-miR-221	miRNA	estradiol	depression	MCF7 cells	estradiol (E2) treatment	miR-221/222 expression is increased in antiestrogen-resistant breast cancer cell lines and is upregulated by fulvestrant in antiestrogen-sensitive MCF7 cells	21057537
5564	Human	hsa-miR-221	miRNA	diabetes mellitus macrophage-conditioned media (DM-MCM)	diabetes mellitus (DM)	HASMC	DM-MCM treatment	upregulated	25409512
5565	Human	hsa-miR-221	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
5566	Human	hsa-miR-221	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	miR-221 in EVs mediated proximal tubule cells injury through Wnt/¦Â-catenin signaling.	32926967
5567	Human	hsa-miR-221	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMEC)	high glucose (HG) treatment	High glucose (HG) treatment enhanced expression of miR-221.	32698791
5568	Human	hsa-miR-221	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	"ox-LDL-induced apoptotic human umbilical cord vein endothelial cells. MiR-221/222 inhibition enhanced apoptosis in ECs, whereas over-expression of miR-221/222 could partly alleviate apoptotic cell death mediated by ox-LDL through suppression of Ets-1 and its downstream target p21."	25893733
5569	Human	hsa-miR-221	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	19351599
5570	Human	hsa-miR-221	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
5571	Human	hsa-miR-221	miRNA	atorvastatin	endothelial dysfunction	Human umbilical vein endothelial cells (HUVEC)	atorvastatin treatment	downregulated	25517390
5572	Human	hsa-miR-221	miRNA	ezetimibe	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	exposed to ezetimibe (0 to 5.0 ¦ÌM) treatment	downregulated	25517390
5573	Human	hsa-miR-221	miRNA	simvastatin	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	exposed to simvastatin (0 to 5.0 ¦ÌM) treatment	downregulated	25517390
5574	Human	hsa-miR-221	miRNA	angiotensin II (Ang II)	endothelial inflammation and migration	human umbilical vein endothelial cells (HUVECs) ;vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	upregulated	21310411
5575	Human	hsa-miR-221	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	upregulated	27081844
5576	Human	hsa-miR-221	miRNA	propofol (PPF)	gastric cancer (GC)	gastric cancer cells	Propofol treatment	downregulated	26214494
5577	Human	hsa-miR-221	miRNA	radiation	glioblastoma multiforme (GBM)	glioablastoma cells	radiation treatment	upregulated	24295494
5578	Human	hsa-miR-221	miRNA	platelet-derived growth factor (PDGF)	glioblastoma multiforme (GBM)	pancreatic cancer cells	platelet-derived growth factor (PDGF)?treatment treatment	downregulated	23967190
5579	Human	hsa-miR-221	miRNA	si wei xiao xiu yin	glioblastoma multiforme (GBM)	U87 cells	Si wei xiao xiu yin treatment	downregulated	32448616
5580	Human	hsa-miR-221	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
5581	Human	hsa-miR-221	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	HCV patients	IFN/RBV for 12 months treatment	upregulated	24033414
5582	Human	hsa-miR-221	miRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	HepG2 cells	astragaloside IV (AS-IV) treatment	downregulated	28179291
5583	Human	hsa-miR-221	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	HepG2 cells	curcumin treatment	downregulated	28179291
5584	Human	hsa-miR-221	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	HepG2 and Hep3B cell lines	doxorubicin treatment	upregulated	24324033
5585	Human	hsa-miR-221	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	serum	hepatitis C virus (HCV) infection	upregulated	29333940
5586	Human	hsa-miR-221	miRNA	indole-3-carbinol (I3C)	hepatocellular carcinoma (HCC)	"human HCC cell lines, SK-Hep-1 and SNU-449"	I3C treatment	downregulated	25447674
5587	Human	hsa-miR-221	miRNA	myrothecine A	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell line SMMC-7721	Myrothecine A treatment	downregulated	31376622
5588	Human	hsa-miR-221	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
5589	Human	hsa-miR-221	miRNA	¦Á-pinene	hepatocellular carcinoma (HCC)	HepG2 cells	¦Á-pinene treatment	¦Á-pinene treatment led to miR-221 and CDK1 downregulated.	30473536
5590	Human	hsa-miR-221	miRNA	hepatitis E virus (HEV)	hepatitis	HEK 293 cells(human embryonic kidney 293 cell line)	Hepatitis E virus (HEV)? infection	downregulated	23579640
5591	Human	hsa-miR-221	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	Neural Precursor Cells (NPCs)	Human cytomegalovirus (HCMV) infection	upregulated	31550968
5592	Human	hsa-miR-221	miRNA	"13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3)"	pancreatic ductal adenocarcinoma (PDAC)	pancreatic ductal adenocarcinoma (PDAC) cells	"13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3) treatment"	"Moreover, treatment of SP600125 (a specific inhibitor of JNK pathway) or cotreatment of 13-cis RA and 1,25-VD3 significantly induced a decreased expression of miR-221 and an increased expression of TIMP-3 protein."	33730072
5593	Human	hsa-miR-221	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
5594	Human	hsa-miR-221	miRNA	cryptosporidium parvum	IgA nephropathy (IgAN)	biliary epithelial cells	cryptosporidium parvum? infection	downregulated	21236259
5595	Human	hsa-miR-221	miRNA	extracts from wild bitter gourd fruit (WBGE)	inflammation	TNF-¦Á-treated alveolar epithelial (A549) cells	extracts from wild bitter gourd fruit (WBGE) treatment	upregulated	29655703
5596	Human	hsa-miR-221	miRNA	lipopolysaccharide (LPS)	inflammation	WI-38 lung fibroblasts	lipopolysaccharide (LPS) treatment	upregulated	30849307
5597	Human	hsa-miR-221	miRNA	quercetin	inflammation	LPS-induced WI-38 lung fibroblasts	quercetin treatment	downregulated	30849307
5598	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVEC)	TNF¦Á treatment	upregulated	29666964
5599	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	alveolar epithelial (A549) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29655703
5600	Human	hsa-miR-221	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
5601	Human	hsa-miR-221	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
5602	Human	hsa-miR-221	miRNA	eicosapentaenoic acid (EPA)	ischemic injury	human endothelial progenitor cells	EPA treatment	downregulated	24927915
5603	Human	hsa-miR-221	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
5604	Human	hsa-miR-221	miRNA	emodin	leukemia	K562 cells	Emodin treatment	downregulated	23744534
5605	Human	hsa-miR-221	miRNA	xenotropic murine leukemia virus-related retrovirus (XMRV)	leukemia	LNCaPcells; DU145 cells	Xenotropic murine leukemia virus-related retrovirus (XMRV) infection treatment	upregulated of miR-221 and miR-222 expression	21932423
5606	Human	hsa-miR-221	miRNA	gemcitabine (GEM)	hepatocellular carcinoma (HCC)	HuCCT1 cells; HuH28 cells	Gemcitabine treatment	upregulated	24147037
5607	Human	hsa-miR-221	miRNA	microcystin-leucine arginine (MC-LR)	hepatocellular carcinoma (HCC)	WRL-69 cells	microcystin-LR treatment	upregulated	22265967
5608	Human	hsa-miR-221	miRNA	hyperoxia	lung injury	human epithelial cells	human epithelial cells treatment	upregulation in derived microvesicles (MVs)	27731391
5609	Human	hsa-miR-221	miRNA	resveratrol	melanoma	melanoma cell lines (A375 and MV3)	resveratrol (Res) treatment	downregulated	28936555
5610	Human	hsa-miR-221	miRNA	dexamethasone (DEX)	multiple myeloma (MM)	"Human MM cell lines MM.1S, MM.1R, RPMI-8226, U266, NCIH929, and ARH-77"	dexamethasone (DEX) treatment	downregulated	30765325
5611	Human	hsa-miR-221	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human cardiomyocytes (HCM) cells	hypoxia/reoxygenation (H/R) induce	upregulated	31115025
5612	Human	hsa-miR-221	miRNA	organosulfur garlic compounds	neovasculogenesis	Human endothelial progenitor cells (EPCs)	Organosulfur garlic compounds treatment	downregulated	23663050
5613	Human	hsa-miR-221	miRNA	chemoradiation therapy (CRT)	non-small cell lung cancer (NSCLC)	patients with stage IIIB-IV NSCLC	CRT treatment	upregulated	25466375
5614	Human	hsa-miR-221	miRNA	palmitic acid (PA)	obesity	HepG2 cells	palmitic acid (PA) treatment	upregulated	31828133
5615	Human	hsa-miR-221	miRNA	adriamycin (ADR)	oral squamous cell carcinoma (OSCC)	Tca8113 and UM2 cells	adriamycin (ADR) treatment	upregulated	26796268
5616	Human	hsa-miR-221	miRNA	doxorubicin (DOX)	oral squamous cell carcinoma (OSCC)	SCC4 and SCC9 cells	doxorubicin treatment	upregulated	28677788
5617	Human	hsa-miR-221	miRNA	ginsenoside Rg3	oral squamous cell carcinoma (OSCC)	human OSCC SCC-9 and HSC-5?cells	Ginsenoside Rg3 treatment	downregulated	30928631
5618	Human	hsa-miR-221	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
5619	Human	hsa-miR-221	miRNA	lapatinib and 5-fluorouracil (5-Fu)	pancreatic cancer (PC)	PANC-1 and MIA PaCa-2 cells	lapatinib and 5-FU treatment	upregulated	26998056
5620	Human	hsa-miR-221	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer PANC-1 cells	metformin treatment	downregulated	25955843
5621	Human	hsa-miR-221	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
5622	Human	hsa-miR-221	miRNA	ovalbumin (OVA)	pediatric asthma	Lymphocytes	ovalbumin (OVA) treatment	Upregulated	22895815
5623	Human	hsa-miR-221	miRNA	"androgen receptor (AR) agonist, CI-4AS-1"	prostate cancer	prostate cancer cell line	AR agonists treatment	downregulated	25846647
5624	Human	hsa-miR-221	miRNA	IFN-¦Á	renal fibrosis	glioblastoma U251 cells	IFN-¦Á	downregulated	20428775
5625	Human	hsa-miR-221	miRNA	hydroxyurea	sickle cell disease (SCD)	human umbilical vein endothelial cell (HUVEC)	hydroxyurea treatment	dysregulated	24925859
5626	Human	hsa-miR-221	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN and SY-SH-5Y neuronal cell lines	oxygen-glucose deprivation (OGD) treatment	downregulated	29596155
5627	Human	hsa-miR-221	miRNA	Buyang Huanwu decoction (BYHWD)	stroke	mesenchymal stem cell (MSC)	Buyang Huanwu decoction (BYHWD) treatment	downregulated	25796380
5628	Human	hsa-miR-221	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
5629	Human	hsa-miR-221	miRNA	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG)	triple negative breast cancer (TNBC)	MDA-MB-157 and HCC1806 cells	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) dual treatment	downregulated	30591655
5630	Human	hsa-miR-221	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
5631	Human	hsa-miR-221-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL significantly inhibited the expression of miR-221-3p.	32401923
5632	Human	hsa-miR-221-3p	miRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	upregulated	32160712
5633	Human	hsa-miR-221-3p	miRNA	paroxetine	depression	serum	paroxetine treatment	downregulated	29791588
5634	Human	hsa-miR-221-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
5635	Human	hsa-miR-221-3p	miRNA	conditioned media (CM)	metabolic disease	human adipocytes	conditioned medium of lipopolysaccharide-stimulated macrophages	upregulated	28938482
5636	Human	hsa-miR-221-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-2¦Â treatment	downregulated	28236026
5637	Human	hsa-miR-221-5p	miRNA	P. longifolia leaf extract	apoptosis 	HeLa cells	P. longifolia leaf extract treatment	downregulated	32850286
5638	Human	hsa-miR-221-5p	miRNA	polyalthia longifolia	apoptosis 	HeLa cells	Polyalthia longifolia treatment	downregulated miR-221-5p was involved in regulating apoptosis in HeLa cancer cells	32110879
5639	Human	hsa-miR-221-5p	miRNA	polyalthia longifolia leaf extract	cell death	HeLa cells	Polyalthia longifolia leaf extract treatment	downregulated	31383043
5640	Human	hsa-miR-221-5p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
5641	Human	hsa-miR-222	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	HUVECs	human immunodeficiency virus-1 (HIV-1) infection	downregulated	23555914
5642	Human	hsa-miR-222	miRNA	neoadjuvant multimodality ment	adenocarcinomas	serum	received neoadjuvant therapy and subsequently underwent surgical resection treatment	upregulation	25429911
5643	Human	hsa-miR-222	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-222 was inversely associated with PM25 exposure during the 2nd trimester of pregnancy	27104955
5644	Human	hsa-miR-222	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
5645	Human	hsa-miR-222	miRNA	resveratrol	anti-inflammatory responses	HUVECs treated with TNF-¦Á	resveratrol (RS) treatment	upregulated	28338009
5646	Human	hsa-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	anti-inflammatory responses	HUVECs	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28338009
5647	Human	hsa-miR-222	miRNA	asbestos	asbestos toxicity	BEAS-2B cells	asbestos exposure	upregulated	32006662
5648	Human	hsa-miR-222	miRNA	asbestos	asbestos-related malignancies	serum	asbestos treatment	upregulated	30257964
5649	Human	hsa-miR-222	miRNA	TGF-¦Â	asthma	ASM cells (ASMCs) from patients with severe asthma	TGF-¦Â treatment	upregulated	23944957
5650	Human	hsa-miR-222	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
5651	Human	hsa-miR-222	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cancer cells	doxorubicin (DOX) treatment	upregulated	31273056
5652	Human	hsa-miR-222	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
5653	Human	hsa-miR-222	miRNA	helicobacter pylori (H. pylori)	tumorigenesis	Human gastric cancer cell line A	Helicobacter pylori (H. pylori) infection	upregulated	22321642
5654	Human	hsa-miR-222	miRNA	inorganic arsenic (iAs)	tumorigenesis	human Jurkat leukemic T cell	"Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment"	upregulated	24317173
5655	Human	hsa-miR-222	miRNA	minocycline (MNC)	cell proliferation	PDGF-BB-treated human aortic smooth muscle cell (SMC)	Minocycline treatment	downregulated	30716386
5656	Human	hsa-miR-222	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (SMC)	platelet-derived growth factor BB homodimer (PDGF-BB) treatment	upregulated	30716386
5657	Human	hsa-miR-222	miRNA	HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA)	chronic heart failure (CHF)	human aortic endothelial cells	HDLNYHA treatment	downregulated	24958738
5658	Human	hsa-miR-222	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	p53-mutant MEG-01 cells	fludarabine treatment	specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets	20504344
5659	Human	hsa-miR-222	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
5660	Human	hsa-miR-222	miRNA	temozolomide (TMZ)	colorectal cancer (CRC)	"U87MG cells;T98G cells; LN428 cells; LN308 cells; A172 cells; HEK-293 cells cells;LN229 cells;T98G, U87MG, and LN229 ,LN428 cells; LN308 cells; A172 cells"	temozolomide (TMZ) treatment	upregulated	24147153
5661	Human	hsa-miR-222	miRNA	estradiol	depression	MCF7 cells	estradiol (E2) treatment	miR-221/222 expression is increased in antiestrogen-resistant breast cancer cell lines and is upregulated by fulvestrant in antiestrogen-sensitive MCF7 cells	21057537
5662	Human	hsa-miR-222	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
5663	Human	hsa-miR-222	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	"ox-LDL-induced apoptotic human umbilical cord vein endothelial cells. MiR-221/222 inhibition enhanced apoptosis in ECs, whereas over-expression of miR-221/222 could partly alleviate apoptotic cell death mediated by ox-LDL through suppression of Ets-1 and its downstream target p21."	25893733
5664	Human	hsa-miR-222	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
5665	Human	hsa-miR-222	miRNA	atorvastatin	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	exposed to atorvastatin (0 to 5.0 ¦ÌM) treatment	downregulated	25517390
5666	Human	hsa-miR-222	miRNA	streptozocin (STZ)	gestational diabetes mellitus (GDM)	placenta tissues	streptozocin treatment	MiR-222 was increased while CXCR4 was decreased in GDM patients and mice	33278386
5667	Human	hsa-miR-222	miRNA	radiation	glioblastoma multiforme (GBM)	glioablastoma cells	radiation treatment	upregulated	24295494
5668	Human	hsa-miR-222	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
5669	Human	hsa-miR-222	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells £¬ HepG2.2.15 cells.	hepatitis B virus X protein (HBx) treatment	downregulated	25260533
5670	Human	hsa-miR-222	miRNA	indole-3-carbinol (I3C)	hepatocellular carcinoma (HCC)	"human HCC cell lines, SK-Hep-1 and SNU-449"	I3C treatment	downregulated	25447674
5671	Human	hsa-miR-222	miRNA	hepatitis E virus (HEV)	hepatitis	HEK 293 cells(human embryonic kidney 293 cell line)	Hepatitis E virus (HEV)? infection	downregulated	23579640
5672	Human	hsa-miR-222	miRNA	extracts from wild bitter gourd fruit (WBGE)	inflammation	TNF-¦Á-treated alveolar epithelial (A549) cells	extracts from wild bitter gourd fruit (WBGE) treatment	upregulated	29655703
5673	Human	hsa-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVEC)	TNF¦Á treatment	upregulated	29666964
5674	Human	hsa-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	alveolar epithelial (A549) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29655703
5675	Human	hsa-miR-222	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human intervertebral disc nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	upregulated	31432092
5676	Human	hsa-miR-222	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
5677	Human	hsa-miR-222	miRNA	emodin	leukemia	K562 cells	Emodin treatment	downregulated	23744534
5678	Human	hsa-miR-222	miRNA	xenotropic murine leukemia virus-related retrovirus (XMRV)	leukemia	LNCaP cells; DU145 cells	Xenotropic murine leukemia virus-related retrovirus (XMRV) infection treatment	upregulated of miR-221 and miR-222 expression	21932423
5679	Human	hsa-miR-222	miRNA	metformin (Met)	medulloblastoma	lung cancer cells	Metformin? treatment	downregulated	23974492
5680	Human	hsa-miR-222	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
5681	Human	hsa-miR-222	miRNA	IL-4	monocytic differentiation	monocyte	IL-4 treatment	dysregulated	25148686
5682	Human	hsa-miR-222	miRNA	dexamethasone (DEX)	multiple myeloma (MM)	"Human MM cell lines MM.1S, MM.1R, RPMI-8226, U266, NCIH929, and ARH-77"	dexamethasone (DEX) treatment	downregulated	30765325
5683	Human	hsa-miR-222	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
5684	Human	hsa-miR-222	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid (PA) treatment	downregulated	32143184
5685	Human	hsa-miR-222	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
5686	Human	hsa-miR-222	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
5687	Human	hsa-miR-222	miRNA	epidermal growth factor (EGF)	oral carcinogenesis	"HSC-3£¬OECM-1,SAS£¬NOK"	EGF treatment	upregulated	25229239
5688	Human	hsa-miR-222	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx10 treatment"	downregulated	21572246
5689	Human	hsa-miR-222	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
5690	Human	hsa-miR-222	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
5691	Human	hsa-miR-222	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
5692	Human	hsa-miR-222	miRNA	adenovirus (ADV)	prostate cancer	human prostate Cancer Cells	adenovirus treatment	downregulated	28114818
5693	Human	hsa-miR-222	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
5694	Human	hsa-miR-222	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	CASC2 attenuated hypoxia-induced PASMC proliferation and migration by regulating the miR-222/ING5 axis to prevent vascular remodeling and the development of PAH.	32206065
5695	Human	hsa-miR-222	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
5696	Human	hsa-miR-222	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
5697	Human	hsa-miR-222	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
5698	Human	hsa-miR-222	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
5699	Human	hsa-miR-222	miRNA	hydroxyurea	sickle cell disease (SCD)	human umbilical vein endothelial cell (HUVEC)	hydroxyurea treatment	dysregulated	24925859
5700	Human	hsa-miR-222	miRNA	Buyang Huanwu decoction (BYHWD)	stroke	mesenchymal stem cell (MSC)	Buyang Huanwu decoction (BYHWD) treatment	downregulated	25796380
5701	Human	hsa-miR-222	miRNA	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG)	triple negative breast cancer (TNBC)	MDA-MB-157 and HCC1806 cells	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) dual treatment	downregulated	30591655
5702	Human	hsa-miR-222	miRNA	arsenite	arsenite-induced carcinogenesis	human lung epithelial BEAS-2B cells	arsenic (As) exposure	upregulated	26909602
5703	Human	hsa-miR-222	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	The human renal epithelial cells (295T cells)	metformin treatment	differently regulated in circulating	24478399
5704	Human	hsa-miR-222*	miRNA	arsenic trioxide (ATO)	bladder cancer	T24 human bladder carcinoma cells	arsenic trioxide?treatment	upregulated	20857258
5705	Human	hsa-miR-222-3p	miRNA	H2O2	age-related cataract (ARC)	human lens epithelial B3 (HLE-B3) cells	H2O2 treatment	upregulated	33851769
5706	Human	hsa-miR-222-3p	miRNA	dexamethasone (DEX)	airway epithelial injury	9HTE cells	dexamethasone (Dex) treatment	downregulated	32202184
5707	Human	hsa-miR-222-3p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	upregulated	28749179
5708	Human	hsa-miR-222-3p	miRNA	doxorubicin (DOX)	colorectal cancer (CRC)	LoVo cells	Doxorubicin (DOX) treatment	miR-222-3p was upregulated in LoVo/ADR compared with the expression in LoVo/S cells.	30904920
5709	Human	hsa-miR-222-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells	high glucose (HG) treatment	Real-time PCR was performed to detect the relative NEAT1 and miR-222-3p expressions and further confirmed the relationship between NEAT1 and miR-222-3p.	33585566
5710	Human	hsa-miR-222-3p	miRNA	high glucose (HG)	endometrial cancer (EC)	"Human endometrial carcinoma cell lines (HEC1-B, HEC1-A and Ishikawa)"	high glucose (HG) treatment	upregulated	31105847
5711	Human	hsa-miR-222-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	Gastric cancer tissues and cells	Helicobacter pylori (H. pylori)?infection	upregulated	29227536
5712	Human	hsa-miR-222-3p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
5713	Human	hsa-miR-222-3p	miRNA	osteogenic differentiation medium	osteogenesis	Adipose-derived mesenchymal stem cells (ADSCs)	osteogenic differentiation media induce	downregulated	30511267
5714	Human	hsa-miR-222-3p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
5715	Human	hsa-miR-222-3p	miRNA	CoCl2	spinal cord injury (SCI)	AGE1.HN cells	?CoCl2 treatment	upregulated	33770577
5716	Human	hsa-miR-222-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	downregulated	28046107
5717	Human	hsa-miR-223	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
5718	Human	hsa-miR-223	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	human T-ALL cell	Glucocorticoids (GCs) treatment	downregulated	19148136
5719	Human	hsa-miR-223	miRNA	H2O2	age-related cataract (ARC)	SRA01/04 cells	H2O2 treatment	MEG3 promoted ARC progression by up-regulating TP53INP1 expression through suppressing miR-223 and promoting P53 expression.	32841649
5720	Human	hsa-miR-223	miRNA	baicalin (BAI)	age-related macular degeneration (AMD)	ARPE-19 cells	baicalin (BAI) treatment	Baicalin significantly induced upregulation of miR-223.	31578016
5721	Human	hsa-miR-223	miRNA	baicalin (BAI)	age-related macular degeneration (AMD)	A¦Â-envoked ARPE-19 cells	baicalin (BAI) treatment	upregulated	31578016
5722	Human	hsa-miR-223	miRNA	melatonin	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	melatonin treatment	upregulated	29024030
5723	Human	hsa-miR-223	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29024030
5724	Human	hsa-miR-223	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	33373321
5725	Human	hsa-miR-223	miRNA	arachidonic acid (AA)	breast cancer	platelet microvesicle (MV)	arachidonic acid (AA) treatment	upregulated	31665654
5726	Human	hsa-miR-223	miRNA	IL-4	breast cancer	CD4+ T cells;breast cancer cells	interleukin-4 (IL-4) treatment	upregulated	21939504
5727	Human	hsa-miR-223	miRNA	celastrol	breast cancer	human breast cancer cell line MCF-7 and prostate cancer PC3	celastrol treatment	upregulated	26552919
5728	Human	hsa-miR-223	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	NCI-H292 cells	cigarette smoke extract (CSE) treatment	downregulated	30695677
5729	Human	hsa-miR-223	miRNA	hepatitis C virus (HCV)	cognitive impairment	monocyte-derived exosome	hepatitis C virus (HCV) infection	upregulated	32157304
5730	Human	hsa-miR-223	miRNA	human immunodeficiency virus (HIV)-1	cognitive impairment	monocyte-derived exosome	human immunodeficiency virus (HIV)-1 infectiom	upregulated	32157304
5731	Human	hsa-miR-223	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	downregulated	31744065
5732	Human	hsa-miR-223	miRNA	clopidogrel	coronary artery disease (CAD)	patients with coronary artery disease (CAD)	clopidogrel treatment	upregulated	25350775
5733	Human	hsa-miR-223	miRNA	prasugrel/ticagrelor	coronary artery disease (CAD)	patients with coronary artery disease (CAD)	prasugrel/ticagrelor treatment	upregulated	25350775
5734	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	crohn disease (CD)	HT-29 colonic epithelial cell line	lipopolysaccharide (LPS) treatment	downregulated	30299179
5735	Human	hsa-miR-223	miRNA	high protein diet	diet-induced weight loss	human HDL constituents	high protein diet treatment	downregulated	26962854
5736	Human	hsa-miR-223	miRNA	acrolein	environmental pollutants	human umbilical vein endothelial cells	acrolein treatment	upregulated	24812010
5737	Human	hsa-miR-223	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
5738	Human	hsa-miR-223	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
5739	Human	hsa-miR-223	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 and U118 cells	TMZ treatment	upregulated	28035389
5740	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	liver fibrosis	Human HSC line LX2 cells	lipopolysaccharide (LPS) treatment	downregulated	31719209
5741	Human	hsa-miR-223	miRNA	TGF-¦Â	liver fibrosis	Human HSC line LX2 cells	TGF-¦Â treatment	downregulated	31719209
5742	Human	hsa-miR-223	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	"Human HCC cell lines (HepG2, Huh7, SNU387, and SNU449)"	doxorubicin treatment	downregulated	31695022
5743	Human	hsa-miR-223	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
5744	Human	hsa-miR-223	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Huh7, SNU387 and SNU449 cells"	sorafenib treatment	upregulated	30535501
5745	Human	hsa-miR-223	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
5746	Human	hsa-miR-223	miRNA	fibroblast growth factor (FGF) and the insulin-like growth factor receptor (IGF-1R)	human embryonic stem cell differentiation	human embryonic stem cells (hESCs)	fibroblast growth factor (FGF) and the insulin-like growth factor receptor (IGF-1R)? treatment	upregulated	24250812
5747	Human	hsa-miR-223	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
5748	Human	hsa-miR-223	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
5749	Human	hsa-miR-223	miRNA	medium prepared with pIgA from patients with glomerular endothelial proliferation	IgA nephropathy (IgAN)	glomerular endothelial cells (GEnCs)	incubate with the medium prepar pIgA from patients with glomerular endothelial proliferation treatment	downregulated	24284509
5750	Human	hsa-miR-223	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Colon mucosa	dextran sulfate sodium treatment	upregulated	26878986
5751	Human	hsa-miR-223	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	BEAS-2B cells; serum	Influenza A virus (IAV) infection	downregulated	33278394
5752	Human	hsa-miR-223	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
5753	Human	hsa-miR-223	miRNA	celastrol	insulin resistance (IR)	palmitic acid (PA) treated HepG2 cells	celastrol treatment	upregulated	30287053
5754	Human	hsa-miR-223	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
5755	Human	hsa-miR-223	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
5756	Human	hsa-miR-223	miRNA	"ferrylhemoglobin (ferrylHb, Fe4+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"ferrylhemoglobin (ferrylHb, Fe4+) treatment"	upregulated	32961661
5757	Human	hsa-miR-223	miRNA	heme	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	heme treatment	upregulated	32961661
5758	Human	hsa-miR-223	miRNA	"methemoglobin (metHb, Fe3+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"methemoglobin (metHb, Fe3+) treatment"	upregulated	32961661
5759	Human	hsa-miR-223	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32961661
5760	Human	hsa-miR-223	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
5761	Human	hsa-miR-223	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
5762	Human	hsa-miR-223	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
5763	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	HK2 cells	lipopolysaccharide (LPS) treatment	LPS treatment significantly enhanced the ex- pression of miR-223 in HK-2 cells.	29800915
5764	Human	hsa-miR-223	miRNA	mycobacterium tuberculosis (Mtb)	macrophage apoptosis	Human macrophages	Mycobacterium tuberculosis (Mtb) treatment	upregulated	26505221
5765	Human	hsa-miR-223	miRNA	estrogen (ES)	estrogen-mediated immune regulation	Splenic lymphocytes	Estrogen treatment	upregulated	18791161
5766	Human	hsa-miR-223	miRNA	inorganic phosphate (Pi)	migration of vascular smooth muscle cells	human aortic vascular smooth muscle cells (VSMCs)	inorganic phosphate (Pi) treatment	upregulated	23094093
5767	Human	hsa-miR-223	miRNA	radiation	nasopharyngeal carcinoma (NPC)	NP460; CNE2; CNE2R cells	radiation treatment	"MINCR diminished NPC cell radiosensitivity by sponging miR-223, increasing ZEB1 and activating the AKT/PI3K axis"	33290841
5768	Human	hsa-miR-223	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"The human NLCLC cell lines, A549, NCI-H460, NCI-H1299 and NCI-H358"	cisplatin (DPP) treatment	downregulated	30431074
5769	Human	hsa-miR-223	miRNA	clopidogrel	non-ST elevation acute coronary syndrome (NSTE-ACS)	patients with coronary heart disease	300 mg (for at least 24 h) or 75 mg clopidogel (for at least 5 days) plus aspirin treatment	downregulated	24202700
5770	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human ATDC5 cells	lipopolysaccharide (LPS) treatment	miR-223 expression was downregulated by lncRNA-ATB and miR-223 overexpression declined the protective effect of lncRNA-ATB on LPS-injured ATDC5 cells.	30771739
5771	Human	hsa-miR-223	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
5772	Human	hsa-miR-223	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	BXPC3 cells	cisplatin treatment	upregulated	31599414
5773	Human	hsa-miR-223	miRNA	genistein	pancreatic cancer (PC)	pancreatic cancer cells	Genistein? treatment	downregulated	23834147
5774	Human	hsa-miR-223	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
5775	Human	hsa-miR-223	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
5776	Human	hsa-miR-223	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
5777	Human	hsa-miR-223	miRNA	mechanical stretch	cell proliferation	vascular smooth muscle cells (VSMCs)	mechanical stretch-stimulated treatment	downregulated	23046980
5778	Human	hsa-miR-223	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in plasma	27535005
5779	Human	hsa-miR-223	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	CircATP2B4 potentiated hypoxia-induced proliferation and migration of PASMCs through the miR-223/ATR axis.	32926932
5780	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp fibroblasts (HDPFs)	lipopolysaccharide (LPS) treatment	downregulated	32966618
5781	Human	hsa-miR-223	miRNA	IL-6	traumatic brain injury (TBI)	Glomerular endothelial cells (GEnCs)	IL-6 treatment	downregulated	24284509
5782	Human	hsa-miR-223	miRNA	ellagic acid (EA)	type 2 diabetes mellitus (T2DM)	high glucose-exposed HepG2 cells	ellagic acid (EA) treatment	upregulated	30466006
5783	Human	hsa-miR-223	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	HepG2 cells	high glucose (HG) treatment	downregulated	30466006
5784	Human	hsa-miR-223	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	HepG2 cells	high glucose treatment	downregulated	30466006
5785	Human	hsa-miR-223	miRNA	ellagic acid (EA)	type 2 diabetes mellitus (T2DM)	HepG2 cells	Ellagic acid (EA) treatment	upregulated	30466006
5786	Human	hsa-miR-223	miRNA	clopidogrel	colorectal cancer (CRC)	purified platelets	clopidogrel treatment	downregulated	23498169
5787	Human	hsa-miR-223	miRNA	Marek's disease virus (MDV)	diabetes mellitus (DM)	seven independentCD4+T-lymphoma cell line	Marek's disease virus (MDV) treatment	downregulated	19297609
5788	Human	hsa-miR-223*	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
5789	Human	hsa-miR-223*	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
5790	Human	hsa-miR-223-3p	miRNA	colchicine	acute gouty arthritis (AGA)	plasma	colchicine treatment	Comparison of differences between pre- and 5-day post-treatment values confirmed that the upregulation of miR-223-3p and downregulated of IL-1¦Â induced by colchicine were more significant than etoricoxib.	31360199
5791	Human	hsa-miR-223-3p	miRNA	colchicine	acute gouty arthritis (AGA)	plasma	Colchicine treatment	"Colchicine could upregulate miR-223-3p and downregulate IL-1¦Â in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2."	31360199
5792	Human	hsa-miR-223-3p	miRNA	etoricoxib	acute gouty arthritis (AGA)	plasma	etoricoxib treatment	"Colchicine could upregulate miR-223-3p and downregulate IL-1¦Â in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2."	31360199
5793	Human	hsa-miR-223-3p	miRNA	baicalin (BAI)	acute kidney injury (AKI)	HK-2 cells	baicalin (BAI) treatment	Baicalin attenuates lipopolysaccharide-induced renal tubular epithelial cell injury by inhibiting the TXNIP/NLRP3 signalling pathway via increasing miR-223-3p expression	32392921
5794	Human	hsa-mir-223-3p	miRNA	high-density lipoproteins (HDL)	atherosclerosis (AS)	Polymorphonuclear neutrophils (PMNs) and human monocyte derived macrophages (HMDMs)	high-density lipoproteins (HDL) treatment	upregulated	31096070
5795	Human	hsa-miR-223-3p	miRNA	ginkgolide B (GB)	bladder cancer	bladder cancer cells	Ginkgolide B (GB) treatment	downregulated	27744452
5796	Human	hsa-miR-223-3p	miRNA	H2O2	cataract	human lens epithelial cells (SRA01/04)	H2O2 treatment	downregulated	33744257
5797	Human	hsa-miR-223-3p	miRNA	p-cresol (PcEMV)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	p-cresol (PcEMV) treatment	upregulated	32606426
5798	Human	hsa-miR-223-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells; BGC823C cells	cisplatin treatment	miR-223-3p was higher in cisplatin-resistant GC (CR-GC) cells than their parental cisplatin-sensitive GC (CS-GC) cells.	32516127
5799	Human	hsa-miR-223-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"AGS, BGC-823 and SGC-7901 cells"	Helicobacter pylori (H. pylori) infection	upregulated	29317648
5800	Human	hsa-miR-223-3p	miRNA	monosodium urate (MSU)	gouty inflammation	THP-1 cells	monosodium urate treatment	downregulated	33650318
5801	Human	hsa-miR-223-3p	miRNA	helicobacter pylori (H. pylori)	H. pylori infection	human immune cells	Helicobacter pylori infection	upregulated	29145789
5802	Human	hsa-miR-223-3p	miRNA	silybin	hepatoprotective	HepG2 cells	Silybin treatment	upregulated	31058823
5803	Human	hsa-miR-223-3p	miRNA	lipopolysaccharide (LPS)	inflammation	human adipose stem cells	lipopolysaccharide (LPS) treatment	downregulated	30807577
5804	Human	hsa-miR-223-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	kaposi's sarcoma (KS)	human coronary artery endothelial cells (HCAECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31396494
5805	Human	hsa-miR-223-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
5806	Human	hsa-miR-223-3p	miRNA	dexamethasone (DEX)	neuroprotective effects	human hippocampal neuronal cells	dexamethasone (DEX) treatment	upregulated	30569136
5807	Human	hsa-miR-223-3p	miRNA	dexamethasone (DEX)	neuroprotective effects	human hippocampal neuronal cells	dexamethasone (DEX) treatment	DEX enhanced the expression of miR-223-3p.	30569136
5808	Human	hsa-miR-223-3p	miRNA	dexmedetomidine (DEX)	oxidative stress	H2O2 treated human hippocampal neuronal cells	dexamethasone (DEX) treatment	upregulated	30569136
5809	Human	hsa-miR-223-3p	miRNA	H2O2	oxidative stress	human hippocampal neuronal cells	H2O2 treatment	downregulated	30569136
5810	Human	hsa-miR-223-3p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
5811	Human	hsa-miR-223-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32666494
5812	Human	hsa-miR-223-3p	miRNA	Treponema pallidum subsp pallidum (T pallidum)	syphilis	human umbilical vein endothelial cells (HUVECs)	Treponema pallidum subsp pallidum (T pallidum) infection treatment	MiR-223-3p inhibits rTp17-induced inflammasome activation and pyroptosis by targeting NLRP3	33145937
5813	Human	hsa-miR-223-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
5814	Human	hsa-miR-223-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (MTB) treatment	downregulated	32048448
5815	Human	hsa-miR-223-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	"?LINC00707 was increased, and miR-223-5p was decreased in LPS-treated MRC-5 cells."	33604647
5816	Human	hsa-miR-22-3p	miRNA	calcium oxalate monohydrate (COM)	kidney stone disease	human renal proximal tubular epithelial (HK-2) cells	?calcium oxalate monohydrate (COM)?treatment treatment	lncRNA LINC00339 promotes cell pyroptosis by sponging miR-22-3p to regulate NLRP3 expression in COM-treated HK-2 cells	30614043
5817	Human	hsa-miR-22-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	miR-22-3p was downregulated in LPS-stimulated HK-2 cells.	33335994
5818	Human	hsa-miR-22-3p	miRNA	lipopolysaccharide (LPS)	age-related macular degeneration (AMD)	"Human retinal pigment epithelial cell line, ARPE©\19 cells"	LPS combined with rotenone treatment	downregulated	30927257
5819	Human	hsa-miR-22-3p	miRNA	rotenone (ROT)	age-related macular degeneration (AMD)	"Human retinal pigment epithelial cell line, ARPE©\19 cells"	LPS combined with rotenone treatment	downregulated	30927257
5820	Human	hsa-miR-22-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	downregulated	31722571
5821	Human	hsa-miR-22-3p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	downregulated	28749179
5822	Human	hsa-miR-22-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
5823	Human	hsa-miR-22-3p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) cyclosporine A (CYCA) treatment	upregulated	31198949
5824	Human	hsa-miR-22-3p	miRNA	TGF-¦Â2	fibrotic cataract	human lens epithelial explants	TGF-¦Â2 treatment	miR-22-3p prevents lens fibrotic progression by targeting HDAC6 thereby promoting ¦Á-tubulin acetylation.	32985730
5825	Human	hsa-miR-22-3p	miRNA	oxaliplatin	gastric cancer (GC)	"GC tissues;Normal cells (GES-1); GC cells (SGC-7901, BGC-823); GC/OXA cells (SGC-7901/OXA; BCG-823/OXA"	oxaliplatin (OXA) treatment	MALAT1 modulates ZFP91 to promote GC cells OXA resistance via sponging miR-22-3p	32104001
5826	Human	hsa-miR-22-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
5827	Human	hsa-miR-22-3p	miRNA	monosodium urate (MSU)	gouty inflammation	THP-1 cells	monosodium urate treatment	downregulated	33650318
5828	Human	hsa-miR-22-3p	miRNA	betulinic acid (BA)	hepatocellular carcinoma (HCC)	PLC/PRF/5; MHCC97L	betulinic acid (BA) treatment	lncRNA MALAT1 functioned as a ceRNA (competing endogenous RNA) to contribute to BA-mediated degradation of IAPs by sponging miR-22-3p.	33135336
5829	Human	hsa-miR-22-3p	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HCC cells	?hepatitis B virus-encoded X (HBx) protein treatment	we found that translation regulatory lncRNA 1 (TRERNA1) upregulation by HBx not only promoted HCC cell proliferation by regulating the cell cycle in vitro and in vivo but also correlated positively with poor prognosis in HCC	33839325
5830	Human	hsa-miR-22-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
5831	Human	hsa-miR-22-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29505299
5832	Human	hsa-miR-22-3p	miRNA	nicotinamide	periodontitis	periodontal ligament stem cell (PDLSC)	nicotinamide treatment	upregulated	31769563
5833	Human	hsa-miR-22-3p	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	miR-22-3p was significantly downregulated LPS-induced sepsis model in HK-2 cells.	32412059
5834	Human	hsa-miR-224	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC) and EA.hy926 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	25463084
5835	Human	hsa-miR-224	miRNA	paclitaxel (PTX)	cervical cancer (CC)	SiHa cells	paclitaxel treatment	downregulated	26390698
5836	Human	hsa-miR-224	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
5837	Human	hsa-miR-224	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	upregulated	27081844
5838	Human	hsa-miR-224	miRNA	hypoxia	gastric cancer (GC)	human gastric cancer cell lines SGC-7901; MGC-803	"maintained with 5% CO2, 1% O2"	upregulated	28173803
5839	Human	hsa-miR-224	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	U87 MG cells	irradiation at a dose of 6Gy treatment	downregulated	24785373
5840	Human	hsa-miR-224	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	HCV patients	IFN/RBV for 12 months treatment	upregulated	24033414
5841	Human	hsa-miR-224	miRNA	geniposide (GEN)	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	geniposide (GEN) treatment	downregulated	31778668
5842	Human	hsa-miR-224	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
5843	Human	hsa-miR-224	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCC patients	Sorafenib treatment	upregulated	24804874
5844	Human	hsa-miR-224	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
5845	Human	hsa-miR-224	miRNA	oxygen glucose deprivation (OGD)	neuronal cell injury	HCN-2 cells	oxygen/glucose deprivation (OGD) treatment	upregulated	27165196
5846	Human	hsa-miR-224	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
5847	Human	hsa-miR-224	miRNA	palliative chemotherapy	non-small cell lung cancer (NSCLC)	NSCLC tissues	platinum derivatives in combination with paclitaxel or gemcitabine treatment	upregulated	29387235
5848	Human	hsa-miR-224	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
5849	Human	hsa-miR-224	miRNA	hypoxia	prostate cancer	NK cells	oxygen-glucose deprivation (OGD) treatment	upregulated	29885835
5850	Human	hsa-miR-224	miRNA	zinc(II) ions	prostate cancer	22Rv1 cell line	zinc(II) ions treatment	upregulated	23064315
5851	Human	hsa-miR-224-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic ECs (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33510945
5852	Human	hsa-miR-224-3p	miRNA	hypoxia	autophagy	Human glioblastoma multiforme	hypoxia treatment	downregulated	26536662
5853	Human	hsa-miR-224-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
5854	Human	hsa-miR-224-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma LN229 and astrocytoma U-251MG cell lines	hypoxia induce	downregulated	30569180
5855	Human	hsa-miR-224-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma LN229 and astrocytoma U-251MG cell lines	hypoxia induce	downregulated	30569180
5856	Human	hsa-miR-224-3p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	30197683
5857	Human	hsa-miR-224-3p	miRNA	thymosin ¦Á1 (T¦Á1)	non-segmental vitiligo (NSV)	peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV)	thymosin ¦Á1 (T¦Á1) treatment	upregulated	25495156
5858	Human	hsa-miR-224-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
5859	Human	hsa-miR-224-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	Human colorectal carcinoma HCT116 and human colorectal adenocarcinoma DLD-1 cells	5-fluorouracil (5-FU) treatment	he decrease in miR-224-5p expression in the 5-fluorouracil-resistant cells correlated with drug insensitivity due to its overexpression-induced drug-dependent apoptosis.	31810268
5860	Human	hsa-miR-224-5p	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
5861	Human	hsa-miR-224-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
5862	Human	hsa-miR-22-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
5863	Human	hsa-miR-2278	miRNA	cardenolide analog 3¦Â-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG)	renal cell carcinoma (RCC)	"renal cell carcinoma cell lines (786-O, Caki-2)"	AMANTADIG treatment	downregulated	28099931
5864	Human	hsa-miR-23	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human mesotheial peritoneal cells(HPMCs)	high glucose treatment	upregulated	28942023
5865	Human	hsa-miR-23	miRNA	intermittent hypoxia (IH)	hypoxemia	blood	intermittent (HI) hypoxia treatment	miR-23 was upregulated in intermittent (HI) hypoxia treatment group.	30416683
5866	Human	hsa-miR-23-3p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
5867	Human	hsa-miR-2355-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	upregulated	30817728
5868	Human	hsa-miR-2392	miRNA	botulinum toxin A (BTXA)	keloids	human skin keloid fibroblasts (HSFBs)	botulinum toxin A (BTXA) treatment	upregulated	31652445
5869	Human	hsa-miR-2392	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	SH-SY5Y human neuroblastoma cells	GDNF	downregulated	28829278
5870	Human	hsa-miR-23a	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	downregulated	27158236
5871	Human	hsa-miR-23a	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
5872	Human	hsa-miR-23a	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	downregulated	27158236
5873	Human	hsa-miR-23a	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
5874	Human	hsa-miR-23a	miRNA	arsenic trioxide (ATO)	As2O3 cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
5875	Human	hsa-miR-23a	miRNA	IL-4	asthma	BEAS©\2B cells	IL©\4 treatment	upregulated	31020662
5876	Human	hsa-miR-23a	miRNA	thymic stromal lymphopoietin (TSLP)	asthma	"Human lung fibroblasts, HFL©\1"	TSLP treatment	upregulated	31020662
5877	Human	hsa-miR-23a	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
5878	Human	hsa-miR-23a	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
5879	Human	hsa-miR-23a	miRNA	arsenic trioxide (ATO)	cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
5880	Human	hsa-miR-23a	miRNA	heat stress	cellular stress response	PErTA70 cells	circulating water bath at 43?¡ãC for 1?h treatment	upregulated	25429623
5881	Human	hsa-miR-23a	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
5882	Human	hsa-miR-23a	miRNA	hypoxia	colorectal cancer (CRC)	HT29 cells; SW480 cells; Caco2 cells	hypoxia treatment	upregulated	30393198
5883	Human	hsa-miR-23a	miRNA	hypoxia	colorectal cancer (CRC)	"HT-29, Caco2 and SW480 cells"	hypoxia induce	upregulated	30393198
5884	Human	hsa-miR-23a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	human HCT116 and HT29 colon carcinoma cell lines	5-fluorouracil (5-FU) treatment	upregulated	24249161
5885	Human	hsa-miR-23a	miRNA	IL-2	cytotoxicity	PBMCs or tumor cell line K562; lymphoblastoid cell line R69	IL-2 treatment	downregulated	24440757
5886	Human	hsa-miR-23a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	28707079
5887	Human	hsa-miR-23a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	human primary endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	22038739
5888	Human	hsa-miR-23a	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	HK2 cells	high glucose treatment	upregulated	28707079
5889	Human	hsa-miR-23a	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	A549 cells;PC9 cells; PC14 cells; LC2/ad; RERF-LC-KJ; RERF-LC-OK adenocarcinoma (AC) cell lines; PC1; PC10; LK2; SQ5 squamous cell carcinoma cell lines (SCC)	TGF-¦Â treatment	upregulated	22752005
5890	Human	hsa-miR-23a	miRNA	fas ligand (FasL)	gastric cancer (GC)	human GI cancer cell lines	Fas ligand (FasL) treatment	upregulated	23929433
5891	Human	hsa-miR-23a	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
5892	Human	hsa-miR-23a	miRNA	berberine (BBR)	hepatocellular carcinoma (HCC)	human HCC cells	berberine (BBR) treatment	upregulated	24942805
5893	Human	hsa-miR-23a	miRNA	estrogen (ES)	hepatocellular carcinoma (HCC)	human liver cancer cell lines	Estrogen (E2)treatment	upregulated	26439986
5894	Human	hsa-miR-23a	miRNA	etoposide (VP-16)	hepatocellular carcinoma (HCC)	HCC cells	etoposide treatment	upregulated	24103454
5895	Human	hsa-miR-23a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	31769216
5896	Human	hsa-miR-23a	miRNA	TGF-¦Â	endometrial endometrioid adenocarcinoma (EEC)	HEC-1-A cells	TGF-¦Â treatment	downregulated	27601936
5897	Human	hsa-miR-23a	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
5898	Human	hsa-miR-23a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
5899	Human	hsa-miR-23a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
5900	Human	hsa-miR-23a	miRNA	TGF-¦Â	immunoregulatory function	human CD8(+) T cells	TGF-¦Â treatment	upregulation	25030422
5901	Human	hsa-miR-23a	miRNA	coptidis rhizoma aqueous extract	hepatocellular carcinoma (HCC)	human hcc mhcc97-l cells	Coptidis rhizoma aqueous extract treatment	upregulated	22977465
5902	Human	hsa-miR-23a	miRNA	pristimerin	lung cancer	A549 and NCI-H446 cells	Pristimerin treatment	downregulated	30664149
5903	Human	hsa-miR-23a	miRNA	dexamethasone (DEX)	miRNA biogenesis	human endothelial cells	dexamethasone (Dex) treatment	downregulated	28523344
5904	Human	hsa-miR-23a	miRNA	ginsenoside Rg1	miRNA biogenesis	human endothelial cells	ginsenoside-Rg1 treatment	downregulated	28523344
5905	Human	hsa-miR-23a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoblasts apoptosis	"The clonal murine osteoblastic cell line, MC3T3-E1 £»Human embryonic kidney cell line (HEK-293)"	tumor necrosis factor alpha (TNF-¦Á) treatment	microRNA-23a depletion significantly enhances TNF-alpha-induced MC3T3-E1 cell apoptosis and over-expressing microRNA-23a remarkably attenuates this phenomenon	23804233
5906	Human	hsa-miR-23a	miRNA	dexamethasone (DEX)	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	dexamethasone (DEX) treatment	upregulated	24802236
5907	Human	hsa-miR-23a	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
5908	Human	hsa-miR-23a	miRNA	H2O2	oxidative stress	ARPE-19 cells	ARPE-19 cells treatment	upregulated	27411920
5909	Human	hsa-miR-23a	miRNA	Sinomenine (SIN)	prostate cancer	PC3 and LNCaP cells	Sinomenine (SIN) treatment	downregulated	30784907
5910	Human	hsa-miR-23a	miRNA	zinc(II) ions	prostate cancer	NCaP cells£» PC-3 human cell line£» 22Rv1 cell line	zinc(II) ions treatment	upregulated	23064315
5911	Human	hsa-miR-23a	miRNA	lipopolysaccharide (LPS)	psoriatic arthritis (PsA)	primary synovial fibroblasts (SFC)	lipopolysaccharide (LPS) treatment	downregulated	30181004
5912	Human	hsa-miR-23a	miRNA	lipopolysaccharide (LPS)	psoriatic arthritis (PsA)	PsA synovial fibroblasts (SFC)	lipopolysaccharide (LPS) treatment	downregulated	30181004
5913	Human	hsa-miR-23a	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	psoriatic arthritis (PsA)	PsA synovial fibroblasts (SFC)	poly I:C treatment	downregulated	30181004
5914	Human	hsa-miR-23a	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	psoriatic arthritis (PsA)	primary synovial fibroblasts (SFC)	poly(I:C) treatment	downregulated	30181004
5915	Human	hsa-miR-23a	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	29864909
5916	Human	hsa-miR-23a	miRNA	X-rays	stress response	human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A	a single dose of 5Gy ?-radiation	downregulated	28851536
5917	Human	hsa-miR-23a	miRNA	ultraviolet (UV) irradiation	UVB-induced injury	human keratinocyte cell line (HaCaT) cells	UVB-irradiated? treatment	upregulated	23158364
5918	Human	hsa-miR-23a	miRNA	2-deoxy glucose (2-DG) and thapsigargin (TG)	warburg effect	HeLa cells	2-Deoxy glucose (2-DG); Thapsigargin (TG) treatment	downregulated	29377281
5919	Human	hsa-miR-23a	miRNA	1'-acetoxychavicol acetate	extracellular signal-regulated kinase (ERK) phosphorylation	HN4 cells	1'-acetoxychavicol acetate treatment	downregulated	24317043
5920	Human	hsa-miR-23a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	Huh-7 cells	Transforming growth factor-beta (TGF-beta) treatment	upregulated	18508316
5921	Human	hsa-miR-23a-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
5922	Human	hsa-miR-23a-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
5923	Human	hsa-miR-23a-3p	miRNA	H2O2	cataract	human lens epithelial cells HLE-B3	H2O2 treatment	"The results of the present study revealed that the expression levels of miR-23a-3p were significantly upregulated, while the expression levels of BCL2 were significantly downregulated in H2O2-induced HLE-B3 cells compared to untreated control cells."	33777189
5924	Human	hsa-miR-23a-3p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
5925	Human	hsa-miR-23a-3p	miRNA	IL-17C	colorectal cancer (CRC)	DLD-1 cells	IL-17C treatment	"The expression of miR-23a-3p is higher in IL-17C (100 ng/mL, 3 h)-treated DLD-1 cells."	32492770
5926	Human	hsa-miR-23a-3p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
5927	Human	hsa-miR-23a-3p	miRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	33049089
5928	Human	hsa-miR-23a-3p	miRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	cardiomyocytes	high-glucose (HG) treatment	We observed that PVT1 and CASP10 were upregulated while miR-23a-3p was downregulated in high glucose-induced cardiomyocytes.	33049089
5929	Human	hsa-miR-23a-3p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
5930	Human	hsa-miR-23a-3p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	TSN upregulated the expression of miR-23a-3p	32582989
5931	Human	hsa-miR-23a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
5932	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	downregulated	27143365
5933	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
5934	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
5935	Human	hsa-miR-23a-3p	miRNA	osthole	prostate cancer	The PC3 and DU145 human AIPC cell lines	Osthole treatment	downregulated	26110567
5936	Human	hsa-miR-23a-3p	miRNA	dexamethasone (DEX)	steatosis	HepG4 cells	dexamethasone (Dex) treatment	downregulated	29409992
5937	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human ¦Â-cells	cytokines IL-1¦Â plus IFN-¦Ã treatment	dysregulated	27737950
5938	Human	hsa-miR-23a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
5939	Human	hsa-miR-23a-5p	miRNA	ultraviolet (UV) irradiation	cell senescence	human fibroblast	"the UVB irradiation output was monitored using a Waldmann UV meter (Waldmann, Villigen©\Schwenningen, Germany). UVB dose = UVB irradiance ¡Á time in second (s), with a distance of 15 cm between the lamp and cell culture dish. The UVB with 10 mJ/cm2 was delivered to cells daily for 5 days and at 48 hr after the last irradiation treatment"	"circRNA_100797 could target miR-23a-5p, their expression levels were inversely associated in fibroblasts, and the miR-23a-5p overexpression blocked the effect of the overexpression of circRNA_100797 in UVB-SIPS"	30908647
5940	Human	hsa-miR-23a-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	GEnCs	high glucose (HG) treatment	LncOR13C9 could regulate ABCA1 by inhibiting the action of miR-23a-5p in the LXR pathway.	33192550
5941	Human	hsa-miR-23a-5p	miRNA	prostaglandin E2 (PGE2)	liver fibrosis	TGF-¦Â1-treated LX-2 cells	PGE2 treatment	downregulated	29109031
5942	Human	hsa-miR-23a-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	upregulated	29109031
5943	Human	hsa-miR-23a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	The results of the present study revealed that the expression levels of miR-23a-5p were significantly downregulated in the plasma of patients with RA and in MH7A cells	33767774
5944	Human	hsa-miR-23b	miRNA	pulsatile shear (PS) flow	retinoblastoma (RB)	vascular endothelial cells (ECs)	pulsatile shear (PS) flow treatment	downregulated	20133741
5945	Human	hsa-miR-23b	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	downregulated	28886127
5946	Human	hsa-miR-23b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	"LINC01140 was downregulated, while p53 and miR-23b were upregulated in oxLDL-induced inflammatory response of macrophages."	31748847
5947	Human	hsa-miR-23b	miRNA	IL-17	autoimmune inflammation	human fibroblast-like synoviocytes£»astrocytes	IL-17 treatment	downregulated	22660635
5948	Human	hsa-miR-23b	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	downregulated	33197057
5949	Human	hsa-miR-23b	miRNA	genistein	breast cancer	MCF-7 cell	Genistein treatment	upregulated	26199568
5950	Human	hsa-miR-23b	miRNA	genistein	breast cancer	"MCF-7 cell, line"	genistein treatment	miR-23b was found to be upregulated 56.69 fold	26199568
5951	Human	hsa-miR-23b	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
5952	Human	hsa-miR-23b	miRNA	brucella Omp25	brucellosis	human Monocyte/Macrophages	brucella Omp25 treatment	upregulated	28694807
5953	Human	hsa-miR-23b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cervical cancer (CC)	"HeLa, SiHa, CaSki and C33A cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26622315
5954	Human	hsa-miR-23b	miRNA	oxaliplatin	colorectal cancer (CRC)	Human colorectal carcinoma HCT116 and human colorectal adenocarcinoma DLD-1 cells	oxaliplatin treatment	"miR-23b/27b/24-1 cluster was overexpressed in oxaliplatin-resistant cells The knockout of miR-23b led to the partial restoration of oxaliplatin susceptibility, showing the essential role of miR-23b in the development of drug resistance by this cluster"	31810268
5955	Human	hsa-miR-23b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	"human kidney proximal tubular epithelial cells ,HK2"	"human kidney proximal tubular epithelial cells ,HK2 treatment"	downregulated	26646104
5956	Human	hsa-miR-23b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human kidney proximal tubular epithelial cells (HK2)	high glucose (HG) treatment	downregulated	26646104
5957	Human	hsa-miR-23b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	HK-2 cells treatment	downregulated	26839366
5958	Human	hsa-miR-23b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	"glioma stem cells (GSCs) ,U87 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	22982144
5959	Human	hsa-miR-23b	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
5960	Human	hsa-miR-23b	miRNA	BAY11-7082	osteogenesis	TNF-¦Á-treated bone marrow mesenchymal stem cell (BMSC)	BAY 11-7082 treatment	downregulated	29234953
5961	Human	hsa-miR-23b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	bone marrow mesenchymal stem cell (BMSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29234953
5962	Human	hsa-miR-23b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	human bone marrow mesenchymal stem cell (BMSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29234953
5963	Human	hsa-miR-23b	miRNA	r-rays	pancreatic cancer (PC)	pancreatic cancer cell lines	radiation treatment	"In pancreatic cancer cells, reduced levels of the miRNA MIR23B increase levels of ATG12 and autophagy to promote radioresistance MIR23B might be used to increase the sensitivity of pancreatic cancer cells to radiation therapy"	23916944
5964	Human	hsa-miR-23b	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
5965	Human	hsa-miR-23b	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	31780861
5966	Human	hsa-miR-23b	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	downregulated	30182520
5967	Human	hsa-miR-23b	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
5968	Human	hsa-miR-23b	miRNA	retinoic acid (RA)	rhinovirus 1B (RV1B) infection	hela cells	Retinoic acid treatment	downregulated	21642441
5969	Human	hsa-miR-23b-3p	miRNA	angiotensin II (Ang II)	atrial fibrillation (AF)	Human atrial fibroblasts (HAFs)	angiotensin II (Ang II) treatment	upregulated	30729664
5970	Human	hsa-miR-23b-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
5971	Human	hsa-miR-23b-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
5972	Human	hsa-miR-23b-3p	miRNA	TGF-¦Â	cataract	lens epithelial cells (LECs)	TGF-¦Â treatment	upregulated	31235073
5973	Human	hsa-miR-23b-3p	miRNA	5-fluorouracil (5-Fu)	chemoresistance of 5-fluorouracil (5-FU)	SW480 and SW620	5-fluorouracil (5-FU) treatment	UCA1 mediated 5-FU resistance of CRC cells through facilitating autophagy and inhibiting apoptosis via miR-23b-3p/ZNF281 axis in vivo and in vitro.	32801774
5974	Human	hsa-miR-23b-3p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
5975	Human	hsa-miR-23b-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (MCs)	high glucose (HG) treatment	downregulated	32322310
5976	Human	hsa-miR-23b-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose treatment	upregulated	26687158
5977	Human	hsa-miR-23b-3p	miRNA	10-hydroxycamptothecin (HCPT)	epidural fibrosis	human fibroblasts	10-Hydroxycamptothecin (HCPT) treatment	upregulated	30720099
5978	Human	hsa-miR-23b-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
5979	Human	hsa-miR-23b-3p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
5980	Human	hsa-miR-23b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
5981	Human	hsa-miR-23b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocyte cell line CHON-001	IL-1¦Â treatment	upregulated	31440033
5982	Human	hsa-miR-23b-3p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human ¦Â-cells	cytokines IL-1¦Â plus IFN-¦Ã treatment	dysregulated	27737950
5983	Human	hsa-miR-23b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
5984	Human	hsa-miR-23c	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	downregulated	29393545
5985	Human	hsa-miR-23c	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
5986	Human	hsa-miR-23c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells		downregulated	27964927
5987	Human	hsa-miR-23c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	streptozotocin treatment	downregulated	27964927
5988	Human	hsa-miR-23c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	high glucose (HG) treatment	downregulated	32096162
5989	Human	hsa-miR-23c	miRNA	steviol	gastrointestinal cancer	MKN-45 cells	steviol treatment	downregulated	29899860
5990	Human	hsa-miR-24	miRNA	H2O2	age-related cataract (ARC)	human lens epithelial cells (LECs)	H2O2 treatment	upregulated	29393409
5991	Human	hsa-miR-24	miRNA	celastrol	apoptosis	A549 cells	celastrol treatment	upregulated	29434967
5992	Human	hsa-miR-24	miRNA	etoposide (VP-16)	apoptosis	highly differentiated CD8(+) T cells	etoposide treatment	upregulated	22435726
5993	Human	hsa-miR-24	miRNA	cholesterol	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	cholesterol treatment	downregulated	33755271
5994	Human	hsa-miR-24	miRNA	theaflavin (TF)	atherosclerosis (AS)	cholesterol-treated human umbilical vein endothelial cells (HUVECs)	theaflavin (TF)?treatment treatment	upregulated	33755271
5995	Human	hsa-miR-24	miRNA	hypoxia	brain injury	SH-SY5Y cells	hypoxia treatment	downregulated	27349868
5996	Human	hsa-miR-24	miRNA	propofol (PPF)	breast cancer	MDA-MB-435 cells	propofol treatment	downregulated	29103019
5997	Human	hsa-miR-24	miRNA	TGF-¦Â	breast cancer	"Human HaCaT keratinocytes, human embryonic kidney cells(HEK293) and thehuman cancer cell lines (MDAMB231, T47D, DU145, BT474,SKBR3 and MCF7)"	TGF-¦Â treatment	over expression	21986943
5998	Human	hsa-miR-24	miRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes	Phenylephrine (PE) treatment	upregulated	32898528
5999	Human	hsa-miR-24	miRNA	hypoxia/reoxygenation (H/R)	cerebral ischemia/reperfusion (I/R) injury	human umbilical cord MSCs (HMCs)-derived exosome	hypoxia/reoxygenation (H/R) treatment	upregulated	33258087
6000	Human	hsa-miR-24	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	The bronchial epithelial cells (BEAS-2B and 16HBE)	cigarette smoke extract (CSE) treatment	Circ_0006892 expression was reduced in lung tissues of smokers with COPD and CSE-stimulated bronchial epithelial cells.	33734482
6001	Human	hsa-miR-24	miRNA	melatonin	colorectal cancer (CRC)	HCT 116 and MCF-7 cells	melatonin treatment	downregulated	26967561
6002	Human	hsa-miR-24	miRNA	hypoxia	colorectal cancer (CRC)	"HT-29, Caco2 and SW480 cells"	hypoxia induce	upregulated	30393198
6003	Human	hsa-miR-24	miRNA	hypoxia	colorectal cancer (CRC)	HT29 cells; SW480 cells; Caco2 cells	hypoxia treatment	upregulated	30393198
6004	Human	hsa-miR-24	miRNA	Helicobacter pylori (H. pylori) extract (HPE)	gastric cancer (GC)	HGC-27 cells	Helicobacter pylori (H. pylori) infection	upregulated	33065487
6005	Human	hsa-miR-24	miRNA	cyclic mechanical stretch (CMS)	glaucoma	human trabecular meshwork cells	cyclic mechanical stress (CMS) treatment	downregulated	20945401
6006	Human	hsa-miR-24	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	downregulated	25837671
6007	Human	hsa-miR-24	miRNA	nicotine	idiopathic pulmonary fibrosis (IPF)	Normal human lung epithelial cells	nicotine treatment	downregulated	30446578
6008	Human	hsa-miR-24	miRNA	nicotine	idiopathic pulmonary fibrosis (IPF)	Primary human lung epithelial cells	nicotine treatment	downregulated	30446578
6009	Human	hsa-miR-24	miRNA	"anti-CD3, anti-CD28, IL-12, , IL-18"	innate and adaptive immune responses	PB CD4+ T cells	"co-stimulating with anti-CD3, anti-CD28, IL-12, and IL-18 treatment"	downregulated	24704866
6010	Human	hsa-miR-24	miRNA	trinitrobenzene sulfonic acid (TNBS)	irritable bowel syndrome (IBS)		trinitro-benzene-sulfonic acid (TNBS) treatment	upregulated	26631964
6011	Human	hsa-miR-24	miRNA	kidney transplantation	kidney transplantation	patients kidney	kidney transplantation treatment	upregulated	24854275
6012	Human	hsa-miR-24	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	"miR-24 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM"	32656599
6013	Human	hsa-miR-24	miRNA	celastrol	lung cancer	A549 cells; LTEP-a-2 cells	celastrol treatment	miR-24 was upregulated in celastrol-treated LTEP-a-2 cells.	29434967
6014	Human	hsa-miR-24	miRNA	noise	noise-induced hearing loss (NIHL)	plasma	noise treatment	downregulated	26278637
6015	Human	hsa-miR-24	miRNA	fatty acid	nonalcoholic fatty liver disease (NAFLD)	human hepatocytes	incubat fatty acid treatment	upregulated	24677249
6016	Human	hsa-miR-24	miRNA	pemetrexed	non-small cell lung cancer (NSCLC)	NSCLC tissue	pemetrexed treatment	upregulated	23794259
6017	Human	hsa-miR-24	miRNA	oleic acid (OA)	obesity	HepG2 cells	oleic acid (OA) treatment	downregulated	29787826
6018	Human	hsa-miR-24	miRNA	palmitic acid (PA)	obesity	HepG2 cells	palmitic acid (PA) treatment	upregulated	29787826
6019	Human	hsa-miR-24	miRNA	¦Ã- Mangostin (¦Ã-MS)	osteoarthritis (OA)	SW982 cells	¦Ã- Mangostin (¦Ã-MS) treatment	upregulated	32302289
6020	Human	hsa-miR-24	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
6021	Human	hsa-miR-24	miRNA	H2O2	periodontal tissue damage and repair	periodontal ligament cells (PDLCs)	H2O2 treatment	upregulated	27188727
6022	Human	hsa-miR-24	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
6023	Human	hsa-miR-24	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	prostate cancer	AfA cell line (MDA-PCa-2b)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28157714
6024	Human	hsa-miR-24	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
6025	Human	hsa-miR-24	miRNA	Staphylococcus aureus	staphylococcus aureus infection	human macrophage cell lines	infect with S. aureus treatment	downregulated	28303416
6026	Human	hsa-miR-24	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
6027	Human	hsa-mir-24	miRNA	stress	cell senescence	CD138+ plasma cells	stress treatment	mir-24 activity propagates stress-induced senescence by down regulating TOP1	26748253
6028	Human	hsa-miR-24	miRNA	IL-1¦Â	terminal chondrogenesis	primary OA chondrocytes;mesenchymal stem cells	IL-1-¦Â treatment	downregulated	24572376
6029	Human	hsa-miR-24-1	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
6030	Human	hsa-miR-24-1	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
6031	Human	hsa-miR-24-1-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
6032	Human	hsa-miR-24-2	miRNA	X-rays	stress response	human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A	a single dose of 5Gy ?-radiation	downregulated	28851536
6033	Human	hsa-miR-24-2-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
6034	Human	hsa-miR-24-2-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
6035	Human	hsa-miR-24-3p	miRNA	IL-6	spermatogonial differentiation	"primary B cells, plasma blasts, plasma cells, and in plasmacytoma cells"	interleukin-6 treatment	upregulated	23934711
6036	Human	hsa-miR-24-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	arteriosclerosis obliterans (ASO)	HASMCs	Platelet-derived growth factor BB (PDGF-BB) treatment	downregulated	26159387
6037	Human	hsa-miR-24-3p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
6038	Human	hsa-miR-24-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33675584
6039	Human	hsa-miR-24-3p	miRNA	etoposide (VP16) and cisplatin (DDP)	advanced-stage small-cell lung cancer (SCLC)	VP16-DDP-resistant SCLC cells (H446/EP)	etoposide (VP16) and cisplatin (DDP) treatment	dysregulated	25426560
6040	Human	hsa-miR-24-3p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
6041	Human	hsa-miR-24-3p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
6042	Human	hsa-miR-24-3p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
6043	Human	hsa-miR-24-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
6044	Human	hsa-miR-24-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
6045	Human	hsa-miR-24-3p	miRNA	paclitaxel (PTX)	paclitaxel (PTX) resistance	PC3-TXR cells; DU145-TXR cells	Paclitaxel (PTX) treatment	Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1	32089062
6046	Human	hsa-miR-24-3p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
6047	Human	hsa-miR-2467	miRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	cisplatin treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel.	31581131
6048	Human	hsa-miR-2467	miRNA	paclitaxel (PTX)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	paclitaxel treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel	31581131
6049	Human	hsa-miR-24a-3p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	lower respiratory tract infections	BEAS-2B cells	poly(I:C) treatment	downregulated	31837465
6050	Human	hsa-miR-25	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis and coronary heart disease	vascular smooth muscle cell	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	25672882
6051	Human	hsa-miR-25	miRNA	epigallocatechin-3-gallate (EGCG)	breast cancer	MCF-7 cells	epigallocatechin-3-gallate (EGCG) treatment	downregulated	31431131
6052	Human	hsa-miR-25	miRNA	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC)	chronic inflammatory diseases	human umbilical vein endothelial cells (HUVECs) exosomes	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment	upregulated	29161413
6053	Human	hsa-miR-25	miRNA	helicobacter pylori (H. pylori)	coronary heart disease (CHD)	gastric epithelial cells	Helicobacter pylori infection	upregulated	31750260
6054	Human	hsa-miR-25	miRNA	cyclopamine	cholangiocarcinoma (CCA)	human cholangiocyte cell line H69£»KMCH cells £»Mz-ChA-1 cells	cyclopamine treatment	downregulated	21953056
6055	Human	hsa-miR-25	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human kidney (HK-2) cells	high glucose treatment	downregulated	29031207
6056	Human	hsa-miR-25	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
6057	Human	hsa-miR-25	miRNA	suberoylanilide hydroxamic acid (SAHA)	hepatocellular carcinoma (HCC)	Hep3B and Huh7 HCC cell lines	suberanilohydroxamic acid (SAHA) treatment	upregulated	31092334
6058	Human	hsa-mir-25	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
6059	Human	hsa-miR-25	miRNA	oxygen glucose deprivation (OGD)	ischemia/reperfusion (I/R) injury	Human SH-SY5Y and IMR-32 cells	oxygen-glucose deprivation (OGD) treatment	downregulated	26768135
6060	Human	hsa-miR-25	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
6061	Human	hsa-miR-25	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
6062	Human	hsa-miR-25	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
6063	Human	hsa-miR-25	miRNA	pemetrexed	lung adenocarcinoma (LUAD)	serum	pemetrexed treatment	"Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations"	26687391
6064	Human	hsa-miR-25	miRNA	radiation	lung cancer	A549 cells	radiation treatment	upregulated	32968458
6065	Human	hsa-miR-25	miRNA	berberine (BBR)	multiple myeloma (MM)	"human multiple myeloma cell, RPMI-8266 and U266"	berberine (BBR) treatment	downregulated	27647143
6066	Human	hsa-miR-25	miRNA	methylmercury (MeHg)	neurotoxicity	human neural progenitor cells (ihNPCs)	methylmercury (MeHg) treatment	downregulated	27941687
6067	Human	hsa-miR-25	miRNA	diet	obesity	Plasma	diet treatment	"Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss."	32439373
6068	Human	hsa-miR-25	miRNA	ginsenoside Rb1	ovarian cancer (OC)	"human ovarian cancer cell lines, SKOV3 and 3AO"	Ginsenoside Rb1	downregulated	28928801
6069	Human	hsa-miR-25	miRNA	hypoxia	ovarian cancer (OC)	"human ovarian cancer cell lines, SKOV3 ;3AO"	hypoxia treatment	upregulated	28928801
6070	Human	hsa-miR-25	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	ovarian cancer (OC)	SKOV3 and OVCAR-3 cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	downregulated	31298363
6071	Human	hsa-miR-25	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
6072	Human	hsa-miR-25	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
6073	Human	hsa-miR-25	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
6074	Human	hsa-miR-25	miRNA	hypoxia	prostate cancer	PCa cell lines (LNCaP£» PC3)£»neural crest (NC) cells	hypoxia treatment	downregulated	24135225
6075	Human	hsa-miR-25	miRNA	hypoxia	prostate cancer	LNCaP cells	5% O2 treatment	upregulated	24135225
6076	Human	hsa-miR-25	miRNA	salvianolic acid B (Sal B)	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	Sal B treatment	upregulated	25094038
6077	Human	hsa-miR-25	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	TGF-¦Â1 treatment	downregulated	25094038
6078	Human	hsa-miR-25	miRNA	lipopolysaccharide (LPS)	sepsis	peripheral blood mononuclear cells (PBMCs) derived macrophages	lipopolysaccharide (LPS) treatment	downregulated	30250569
6079	Human	hsa-miR-25	miRNA	ginkgolide A (GA)	sepsis-induced renal injury	NRK-52E cells	Ginkgolide A (GA) treatment	The sepsis-induced decrease of miR-25 was enhanced by GA treatment.	33677255
6080	Human	hsa-miR-25	miRNA	lipopolysaccharide (LPS)	sepsis-induced renal injury	NRK-52E cells	lipopolysaccharide (LPS) treatment	The sepsis-induced decrease of miR-25 was enhanced by GA treatment.	33677255
6081	Human	hsa-miR-25	miRNA	ginsenoside Rb1	skin wrinkle formation	human dermal fibroblasts	Ginsenoside Rb1 treatemnt	downregulated	22692056
6082	Human	hsa-miR-25	miRNA	IL-23	thyroid cancer (TC)	thyroid cancer cells	IL-23 treatment	upregulated	26437444
6083	Human	hsa-miR-25	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
6084	Human	hsa-miR-25-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
6085	Human	hsa-miR-25-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
6086	Human	hsa-miR-25-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High-glucose inhibited METTL3 and miR-25-3p expressions in RPE cells.	32365051
6087	Human	hsa-miR-25-3p	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	NP cells	IL-1¦Â treatment	MicroRNA-25-3p therapy for intervertebral disc degeneration by targeting the IL-1¦Â/ZIP8/MTF1 signaling pathway with a novel thermo-responsive vector	33313245
6088	Human	hsa-miR-25-3p	miRNA	H2O2	mitophagy	HeLa and HEK 293T cells	H2O2 treatment	"We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions."	33627622
6089	Human	hsa-miR-25-3p	miRNA	cigarette smoke condensate (CSC)	pancreatic cancer (PC)	HPDE6-C7 cells	cigarette smoke condensate (CSC) treatment	upregulated	31015415
6090	Human	hsa-miR-25-3p	miRNA	particulate matter (PM2.5)	PM2.5-induced carcinogenesis	human bronchial epithelial (HBE) cells	fine particulate matter (PM2.3) treatment	upregulated	33545377
6091	Human	hsa-miR-25-5p	miRNA	thrombospondin-1 (TSP-1)	angiogenesis	vascular smooth muscle cell (VSMC)	Thrombospondin-1 (TSP-1) treatment	downregulated	26728995
6092	Human	hsa-miR-25-5p	miRNA	racemate	endogenous antioxidant defenses	Caco-2 cells	subtoxic concentrations of racemate treatment	upregulated	28264488
6093	Human	hsa-miR-25-5p	miRNA	curcumin (Cur)	lung cancer	human non-small cell lung cancer A549 cell line	curcumin treatment	dysregulated	28660665
6094	Human	hsa-miR-25-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
6095	Human	hsa-miR-25-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular disease	human brain microvessel endothelial cells (HBMECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31365884
6096	Human	hsa-miR-26	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
6097	Human	hsa-miR-26	miRNA	oxaliplatin	gastric cancer (GC)	HGC-27 cells; BGC-823 cells	oxaliplatin (OXA) treatment	downregulated	31617275
6098	Human	hsa-miR-26	miRNA	hypoxia	hypoxemia	blood	chronic hypoxia (CH)	miR-26 was upregulated in chronic hypoxia (CH) treatment group.	30416683
6099	Human	hsa-miR-26	miRNA	bushen yijing decoction (BSYJ)	systemic sclerosis (SSc)	primary skin fibroblasts	Bushen Yijing decoction (BSYJ)? treatment	BSYJ-containing rat serum suppressed miR-26a expression	33843426
6100	Human	hsa-miR-26-5p	miRNA	ethanol extract of antrodia cinnamomea (AC)	breast cancer	MCF-7 and tamoxifen-resistant MCF-7 cells	ethanol extract of antrodia cinnamomea (AC) treatment	upregulated	29743060
6101	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK-2 cells	cisplatin treatment	downregulated	31887787
6102	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK2 cells	cisplatin treatment	miR-26a was significantly downregulated during cisplatin-induced AKI and during cisplatin co-cultured HK2 cells.	31887787
6103	Human	hsa-miR-26a	miRNA	H2O2	acute respiratory distress syndrome (ARDS)	Type II alveolar epithelial cells (AEC-II)	H2O2 treatment	downregulated	29424907
6104	Human	hsa-miR-26a	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	HUVECs	VEGF treatment	downregulated	28602162
6105	Human	hsa-miR-26a	miRNA	mechanical stretch	asthma	human airway smooth muscle cells (HASMCs)	Mechanical stretch up treatment	upregulated	20525681
6106	Human	hsa-miR-26a	miRNA	tanshinol (TAN)	atherosclerosis (AS)	endothelial cells	tanshinol treatment	upregulated	27508018
6107	Human	hsa-miR-26a	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
6108	Human	hsa-miR-26a	miRNA	metformin (Met)	breast cancer	MCF-7 breast cancer cell lines	metformin treatment	upregulated	27517917
6109	Human	hsa-miR-26a	miRNA	trastuzumab	breast cancer	HER2-positive (SKBR3£» BT474) £» HER2-negetive (MCF7 £» MDA-MB-231) cells	Trastuzumab treatment	upregulated	22384020
6110	Human	hsa-miR-26a	miRNA	trastuzumab	breast cancer	BT474 wt cells	trastuzumab treatment	upregulated	28120942
6111	Human	hsa-miR-26a	miRNA	"dexamethasone (DEX), ascorbic acid, and ¦Â-glycerol phosphate"	cell differentiation	human adipose tissue¨Cderived stem cells(hADSCs)	"dexametha-sone, ascorbic acid, and ¦Â-glycerol phosphate treatment"	upregulated	18197755
6112	Human	hsa-miR-26a	miRNA	estrogen (ES)	cell proliferation	"MCF-7¡¢T47D¡¢MDA-MB-231 , BT549 cell"	estrogen treatment	downregulated	24735615
6113	Human	hsa-miR-26a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31486504
6114	Human	hsa-miR-26a	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	cholangiocarcinoma (CCA)	human cholangiocarcinoma cell	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) treatment	downregulated	25691459
6115	Human	hsa-miR-26a	miRNA	ginsenoside Rg1	diabetic retinopathy (DR)	high glucose (HG)-treated human retinal pigment epithelium cells (ARPE-19)	Ginsenoside Rg1 (Rg1) treatment	upregulated	30763577
6116	Human	hsa-miR-26a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelium cells (ARPE-19)	high glucose (HG) treatment	downregulated	30763577
6117	Human	hsa-miR-26a	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	HepG2 cells	thapsigargin (Tg) treatment	upregulated	32567701
6118	Human	hsa-miR-26a	miRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	HepG2 cells	tunicamycin (Tu) treatment	upregulated	32567701
6119	Human	hsa-miR-26a	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cells injury and autophagy dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 expression was upregulated and miR-26a was downregulated in the plasma samples of patients with atherosclerosis and ox-LDL-treated HAECs.	30468731
6120	Human	hsa-miR-26a	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"GAS5 knockdown inhibited cell apoptosis and activated autophagy flux, whereas inhibition of miR-26a reversed the effect of GAS5 in HAECs."	30468731
6121	Human	hsa-miR-26a	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human lens epithelial cells (LECs)	TGF-¦Â2 treatment	downregulated	31143769
6122	Human	hsa-miR-26a	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
6123	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC-7901 / DDP	cisplatin-resistant treatment	downregulated	26458859
6124	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	human glioblastoma cells	cisplatin treatment	downregulated	28499919
6125	Human	hsa-miR-26a	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia induce	upregulated	30425242
6126	Human	hsa-miR-26a	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	"HepG2,Huh-7, 293T"	DOX at a range of 0.5¨C25?¦ÌM over a period of 10 months	downregulated	28079894
6127	Human	hsa-miR-26a	miRNA	lipopolysaccharide (LPS)	inflammation	"Human renal proximal tubular epithelial cell lines, HK-2 and RPTECs"	lipopolysaccharide (LPS) treatment	downregulated	31158334
6128	Human	hsa-miR-26a	miRNA	notoginsenoside R1 (NGR1)	inflammation	"LPS-treated Human renal proximal tubular epithelial cell lines, HK-2 and RPTECs"	Notoginsenoside R1 (NGR1) treatment	upregulated	31158334
6129	Human	hsa-miR-26a	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	human mesenchymal stem cells (MSCs)	hypoxia treatment	"miRNA-26a was significantly increased in EV(HM), compared with EV(NM)."	29978610
6130	Human	hsa-miR-26a	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
6131	Human	hsa-miR-26a	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	upregulated	24431000
6132	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	31432162
6133	Human	hsa-miR-26a	miRNA	TLR9 ligand CpG-oligodeoxynucleotides (CpG-ODN)	lung cancer	H460 human lung cancer cells	CpG-ODN treatment	upregulated	24788552
6134	Human	hsa-miR-26a	miRNA	water-extracted PM10 (WE-PM10)	lung cancer	human lung adenocarcinoma A549 cells	exposure to 25 and 50 ¦Ìg/ml of WE-PM10 for 48 h treatment	downregulated	29222745
6135	Human	hsa-miR-26a	miRNA	IFN-¦Â	multiple sclerosis (MS)	MS patients	interferon-¦Â treatment	downregulated	28962897
6136	Human	hsa-miR-26a	miRNA	palmitic acid (PA)	myocardial lipotoxic injury	human cardiomyocytes (AC16 cells)	palmitic acid (PA) treatment	downregulated	31123414
6137	Human	hsa-miR-26a	miRNA	A23187	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	A23187 treatment	upregulated	32567701
6138	Human	hsa-miR-26a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
6139	Human	hsa-miR-26a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	compound C treatment	downregulated	32143184
6140	Human	hsa-miR-26a	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	oleate acid (OA) treatment	upregulated	32567701
6141	Human	hsa-miR-26a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	palmitate acid (PA) treatment	upregulated	32567701
6142	Human	hsa-miR-26a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid treatment	downregulated	32143184
6143	Human	hsa-miR-26a	miRNA	particulate matter (PM2.5)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	particular matters (PM) PM2.5 treatment	downregulated	30798028
6144	Human	hsa-miR-26a	miRNA	thapsigargin (Tg)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	thapsigargin (Tg) treatment	upregulated	32567701
6145	Human	hsa-miR-26a	miRNA	tunicamycin (TM)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	tunicamycin (Tu) treatment	upregulated	32567701
6146	Human	hsa-miR-26a	miRNA	pan-HDAC inhibitor ITF2357	non-Hodgkin lymphoma (NHL)	human B-cell non-Hodgkin lymphomas (B-NHLs)	pan-HDAC inhibitor ITF2357 treatment	upregulated	24648290
6147	Human	hsa-miR-26a	miRNA	metformin (Met)	oral cancer	KB human oral cancer cells	metformin treatment	upregulated	27082123
6148	Human	hsa-miR-26a	miRNA	IL-1¦Â	osteoarthritis (OA)	human Chondrocytes-articular	IL-1¦Â treatment	downregulated	28276108
6149	Human	hsa-miR-26a	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	downregulated	29208566
6150	Human	hsa-miR-26a	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 cells	IL-1¦Â treatment	upregulated	32522568
6151	Human	hsa-miR-26a	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
6152	Human	hsa-miR-26a	miRNA	cadmium (Cd)	preeclampsia (PE)	JEG-3 cells	cadmium (Cd) treatment	upregulated	28774740
6153	Human	hsa-miR-26a	miRNA	metformin (Met)	renal cancer	786-O cells	metformin treatment	upregulated	25419360
6154	Human	hsa-miR-26a	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	upregulated	17653614
6155	Human	hsa-miR-26a	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	downregulated	18573151
6156	Human	hsa-miR-26a	miRNA	S-adenosylhomocysteine hydrolase (AHCY)	prostate cancer	LNCaP-hr cells	AHCY treatment	upregulated	28705714
6157	Human	hsa-miR-26a	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	30542439
6158	Human	hsa-miR-26a	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	upregulated	21030674
6159	Human	hsa-miR-26a	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	caco-2?cell line	high glucose treatment	upregulated	31493868
6160	Human	hsa-miR-26a	miRNA	¦Â-glycerophosphate (¦Â-GP)	vascular calcification (VC)	vascular smooth muscle cells (VSMCs)	incubated with 10 mmol/L ¦Â-glycerol phos_x0002_phate (¦Â-GP) for 7 and 14 days treatment	downregulated	29050490
6161	Human	hsa-miR-26a	miRNA	TGF-¦Â1	wound healing	HaCaT cells; NHEK cells	TGF-¦Â1 treatment	The RNA expression of miR-26a was downregulated and ITGA5 protein expression was upregulated by TGF-¦Â1 treatment in HaCaT and NHEK cells in a time-dependent manner	32955094
6162	Human	hsa-miR-26a-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	32102754
6163	Human	hsa-miR-26a-5p	miRNA	IL-1¦Â	adrenal steroid production	NCI-H295R cells	IL-1¦Â treatment	downregulated	33508847
6164	Human	hsa-miR-26a-5p	miRNA	kaempferol	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	kaempferol treatment	Kaempferol upregulated miR-26a-5p expression in ox-LDL-stimulated HAECs.	30372882
6165	Human	hsa-miR-26a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31865360
6166	Human	hsa-miR-26a-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	RKO cells	5-fluorouracil (5-FU) treatment	SNHG6 may promote chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in CRC cells.	31516391
6167	Human	hsa-miR-26a-5p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	Di (2-ethylhexyl) phthalate (DEHP)-induced lung toxicity	A549 cells	di(2-ethylhexyl) phthalate (DEHP) treatment	MiR-26a-5p was significantly enriched in DEHP-elicited sEV.	33229049
6168	Human	hsa-miR-26a-5p	miRNA	high glucose (HG)	diabetic cataract (DC)	SRA01/04 cells	high glucose treatment	downregulated	32950535
6169	Human	hsa-miR-26a-5p	miRNA	bovine serum albumin (BSA)	diabetic nephropathy (DN)	HK-2 cells	bovine serum albumin (BSA) treatment	miR-26a-5p expression in exosomes secreted by BSA-treated HK-2 cells was significantly increased.	32853650
6170	Human	hsa-miR-26a-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
6171	Human	hsa-miR-26a-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
6172	Human	hsa-miR-26a-5p	miRNA	IFN-¦Â	multiple sclerosis (MS)	RRMS patients	IFN-¦Â treatment	upregulated	24885345
6173	Human	hsa-miR-26a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
6174	Human	hsa-miR-26a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
6175	Human	hsa-miR-26a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	synovial fibroblast	IL-1¦Â treatment	downregulated	31784400
6176	Human	hsa-miR-26a-5p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	upregulated	27018851
6177	Human	hsa-miR-26a-5p	miRNA	dexamethasone (DEX)	steroid-induced osteonecrosis of femoral head (ONFH)	human bone marrow-derived mesenchymal stem cells (hBMSCs)	dexamethasone (DEX) treatment	"NORAD expression was downregulated in SONFH tissues, while miR-26a-5p expression was upregulated."	33413642
6178	Human	hsa-miR-26b	miRNA	yin yang 1 (YY1)	acute myeloid leukemia (AML)	"Human AML cells U937, KG-1, THP-1, and HL-60"	yin yang 1 (YY1) treatment	downregulated	33318617
6179	Human	hsa-miR-26b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6180	Human	hsa-miR-26b	miRNA	ionizing radiation (IR)	breast cancer	MCF7 breast cancer cells	"Cells were given for IR 24 h after transfection and harvested by centrifugation at 13,201 x g for 3 min at room temperature for analysis. IR was delivered at a rate of 0.38 Gy/min (180 kV; 18 mA) using an XSZ-Z20/20 X-ray generator (Kang Jia Instrument Equipment Co., Ltd., Dandong, China)."	downregulated	29399189
6181	Human	hsa-miR-26b	miRNA	radiation	breast cancer	MCF7 breast cancer cells	radiation treatment	downregulated	29399189
6182	Human	hsa-miR-26b	miRNA	estrogen (ES)	cell proliferation	"MCF-7¡¢T47D¡¢MDA-MB-231 , BT549 cell"	estrogen treatment	downregulated	24735615
6183	Human	hsa-miR-26b	miRNA	chloroquine	chloroquine in inducing apoptosis of human hepatocellular carcinoma cells	HepG2 cells	chloroquine treatment	chloroquine significantly increased the expression of miR-26b and downregulated the expression of Mcl-1 in HepG2 cells.	29735440
6184	Human	hsa-miR-26b	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	cholangiocarcinoma (CCA)	human cholangiocarcinoma cell	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) treatment	downregulated	25691459
6185	Human	hsa-miR-26b	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
6186	Human	hsa-miR-26b	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
6187	Human	hsa-miR-26b	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	"HepG2,Huh-7, 293T"	DOX at a range of 0.5¨C25?¦ÌM over a period of 10 months	downregulated	28079894
6188	Human	hsa-miR-26b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell differentiation	Human preadipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	23275201
6189	Human	hsa-miR-26b	miRNA	arsenite	liver fibrosis	human hepatic (L-02) cells	arsenite exposure	exosomal MALAT1 derived from arsenite-treated L-02 cells promoted the activation of LX-2 cells via microRNA-26b regulation of COL1A2.	31513886
6190	Human	hsa-miR-26b	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	31432162
6191	Human	hsa-miR-26b	miRNA	¦Ã-rays	lung cancer	H1299 lung cancer cells	¦Ã-rays treatment	downregulated	21901137
6192	Human	hsa-miR-26b	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
6193	Human	hsa-miR-26b	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
6194	Human	hsa-miR-26b	miRNA	high glucose (HG)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	high-glucose (HG) treatment	downregulated	31625803
6195	Human	hsa-miR-26b	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	downregulated	29208566
6196	Human	hsa-miR-26b	miRNA	pioglitazone	osteoarthritis (OA)	high-glucose (HG) treated human osteoarthritis (OA) chondrocytes	pioglitazone (PGZ) treatment	upregulated	31625803
6197	Human	hsa-miR-26b	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	human PCO-attached lens epithelial cells (LECs) and SRA01/04 cells	TGF-¦Â2 treatment	downregulated	25063219
6198	Human	hsa-miR-26b	miRNA	epidermal growth factor (EGF)	posterior capsular opacification (PCO)	primary human lens epithelial cells (HLECs)	epidermal growth factor (EGF) treatment	downregulated	29977916
6199	Human	hsa-miR-26b	miRNA	lipopolysaccharide (LPS)	sepsis	Neonatal Polymorphonuclear Leukocytes	lipopolysaccharide (LPS) treatment	dysregulated	28655995
6200	Human	hsa-miR-26b	miRNA	hydroxyurea	sickle cell anemia (SCA)	Circulating erythroid cells	Hydroxyurea treatment	upregulated	21921042
6201	Human	hsa-miR-26b	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	caco-2?cell line	high glucose treatment	upregulated	31493868
6202	Human	hsa-miR-26b	miRNA	desferrioxamine (DFOM)	immune response	carcinoma of nasopharyngeal epithelial (CNE) cells	desferrioxamine (DFOM)	upregulated	20100477
6203	Human	hsa-miR-26b-3p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	downregulated	30197683
6204	Human	hsa-miR-26b-5p	miRNA	huaier	anti-cancer therapy	pulmonary adenocarcinoma A549 cells	huaier treatment	upregulated	24815696
6205	Human	hsa-miR-26b-5p	miRNA	high glucose (HG)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	LncRNA HCG11/miR-26b-5p/QKI5 feedback loop reversed high glucose-induced proliferation and angiogenesis inhibition of HUVECs.	33128346
6206	Human	hsa-miR-26b-5p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
6207	Human	hsa-miR-26b-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
6208	Human	hsa-miR-26b-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
6209	Human	hsa-miR-26b-5p	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	spontaneous preterm birth (SPB)	human syncytiotrophoblast	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	"miR-181b-5p and miR-26b-5p in term human syncytiotrophoblast were increased in response to treatment with 1,25(OH)2D."	30395535
6210	Human	hsa-miR-26b-5p	miRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HASMCs)	phosphorus treatment	upregulated	32347320
6211	Human	hsa-miR-27	miRNA	nanocurcumin	ankylosing spondylitis (AS)	peripheral blood mononuclear cells (PBMCs)	nanocurcumin treatment	downregulated	31074089
6212	Human	hsa-miR-27	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Huh7.5 cells	hepatitis C virus (HCV) infection	upregulated	23897856
6213	Human	hsa-miR-27	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	HT-29 cells	TGF-¦Â treatment	upregulated	23483606
6214	Human	hsa-miR-27	miRNA	hepatitis C virus (HCV)	hepatic steatosis	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	23897856
6215	Human	hsa-miR-27a	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
6216	Human	hsa-miR-27a	miRNA	alcohol	alcoholic liver disease (ALD)	monocyte	alcohol exposure	upregulated	25716995
6217	Human	hsa-miR-27a	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
6218	Human	hsa-miR-27a	miRNA	betulinic acid (BA)	atherosclerosis (AS)	The RKO and SW480 colon cancer cell lines	betulinic acid (BA) treatment	downregulated	21864401
6219	Human	hsa-miR-27a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1-derived macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31518965
6220	Human	hsa-miR-27a	miRNA	C8 fluoride derivative of cheliensisin A (ChlA-F)	bladder cancer	T24 cells	ChlA-F treatment	downregulated	30118841
6221	Human	hsa-miR-27a	miRNA	arsenic trioxide (ATO)	breast cancer	breast cancer cells	arsenic trioxide (ATO) treatment	downregulated	26592661
6222	Human	hsa-miR-27a	miRNA	arsenic trioxide (ATO)	breast cancer	MDA-MB-231 and SK-BR-3	arsenic trioxide (ATO) treatment	downregulated	26592661
6223	Human	hsa-miR-27a	miRNA	betulinic acid (BA)	breast cancer	Human mammary carcinoma cell lines MDA-MB-231£»MDA-MB-435£» BT474£»MDA-MB-468£»MDA-MB-453£»HS-578T	betulinic acid (BA) treatment	downregulated	22407812
6224	Human	hsa-miR-27a	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	upregulated	25120778
6225	Human	hsa-miR-27a	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
6226	Human	hsa-miR-27a	miRNA	liraglutide	breast cancer	MCF-7 cells	liraglutide treatment	liraglutide treatment downregulated miR-27a expression in MCF-7 cells.	29393459
6227	Human	hsa-miR-27a	miRNA	metformin (Met)	breast cancer	breast cancer MCF-7 cells	metformin treatment	downregulated	27779715
6228	Human	hsa-miR-27a	miRNA	pomegranate polyphenolics	breast cancer	Human mammary carcinoma cell lines BT474 and MDA-MB-231	pomegranate polyphenolics treatment	downregulated	22941571
6229	Human	hsa-miR-27a	miRNA	tamoxifen (TAM)	breast cancer	MCF7 cells; T47D luminal A breast cancer cells	tamoxifen treatment	Tamoxifen-resistant cells showed decreased expression of ER¦Á and miR-27a.	30415143
6230	Human	hsa-miR-27a	miRNA	tamoxifen (TAM)	breast cancer	MCF7 and T47D luminal A breast cancer cell lines	tamoxifen treatment	downregulated	30415143
6231	Human	hsa-miR-27a	miRNA	vascular endothelial growth factor (VEGF)	breast cancer	breast cancer stem like cells (BCSLCs)	vascular endothelial growth factor (VEGF) treatment	upregulated	23752185
6232	Human	hsa-miR-27a	miRNA	vascular endothelial growth factor (VEGF)	breast cancer	MDA-MB-231 breast cancer cell line	VEGF treatment	upregulated	23752185
6233	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	bronchopneumonia	BEAS-2B cells	lipopolysaccharide (LPS) treatment	upregulated	29772436
6234	Human	hsa-miR-27a	miRNA	tanshinone IIA (Tan IIA)	bronchopneumonia	LPS-treated BEAS-2B cells	Tanshinone IIA (Tan) treatment	downregulated	29772436
6235	Human	hsa-miR-27a	miRNA	SV40 small T antigen	tumorigenesis	human bronchial epithelial cells(HBERST)	SV40 small T antigen treatment	upregulated	21460851
6236	Human	hsa-miR-27a	miRNA	"ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094)"	candida albicans infection	RKO and SW480 colon cancer cells	"Ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094) treatment"	downregulated	21156786
6237	Human	hsa-miR-27a	miRNA	high glucose (HG)	cell damage	human renal tubular epithelial HK-2	high glucose (HG) treatment	miR-27a participates in the effects of GAS5 silencing on HG-stimulated HK-2 cells; BNIP3 is regulated by miR-27a and related to the HG toxicity to HK-2 cells.	31159592
6238	Human	hsa-miR-27a	miRNA	cholesterol	clear cell renal cell carcinoma (ccRCC)	The human ccRCC cell line 786-O	cholesterol treatment	upregulated	29782853
6239	Human	hsa-miR-27a	miRNA	"2,3-dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)]"	colorectal cancer (CRC)	colon cancer cells	"2,3-Dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)] treatment"	downregulated	24030632
6240	Human	hsa-miR-27a	miRNA	curcumin (Cur)	colorectal cancer (CRC)	RKO ; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts	curcumin treatment	downregulated	23194063
6241	Human	hsa-miR-27a	miRNA	curcuminoids	colorectal cancer (CRC)	colon cancer SW-480 cells	curcuminoids treatment	downregulated	23471840
6242	Human	hsa-miR-27a	miRNA	resveratrol and quercetin	colorectal cancer (CRC)	HT-29 cells	Resveratrol and quercetin treatment	downregulated	23530649
6243	Human	hsa-miR-27a	miRNA	hypoxia	colorectal cancer (CRC)	"HT-29, Caco2 and SW480 cells"	hypoxia induce	upregulated	30393198
6244	Human	hsa-miR-27a	miRNA	hypoxia	colorectal cancer (CRC)	HT29 cells; SW480 cells; Caco2 cells	hypoxia treatment	upregulated	30393198
6245	Human	hsa-miR-27a	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
6246	Human	hsa-miR-27a	miRNA	arbutin (ARB)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) and Arbutin (ARB) co-treatment	"MiR-27a expression was reduced in HG-treated cells, but was accelerated in HG and ARB co-treated HK-2 cells with the increased concentration."	31319730
6247	Human	hsa-miR-27a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial HK-2	high glucose (HG) treatment	miR-27a participates in the effects of GAS5 silencing on HG-stimulated HK-2 cells; BNIP3 is regulated by miR-27a and related to the HG toxicity to HK-2 cells.	31159592
6248	Human	hsa-miR-27a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"MiR-27a expression was reduced in HG-treated cells, but was accelerated in HG and ARB co-treated HK-2 cells with the increased concentration."	31319730
6249	Human	hsa-miR-27a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	RPE-1 cells	high glucose (HG) treatment	downregulated	29896271
6250	Human	hsa-miR-27a	miRNA	hemin	erythroid cell differentiation	K562 cells	hemin treatment	miR-27a levels gradually increased after 0 hours and decreased after the 24- hour time point during hemin-induced erythroid differentiation.	29590650
6251	Human	hsa-miR-27a	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
6252	Human	hsa-miR-27a	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	hepatic stellate cells (HSC) transdifferentiate into myofibroblasts	colon cancer cells	"Methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate (CDODA-Me) treatment"	downregulated	19582879
6253	Human	hsa-miR-27a	miRNA	genistein	hepatocellular carcinoma (HCC)	human uveal melanoma cells	Genistein?treatment	downregulated	19639204
6254	Human	hsa-miR-27a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
6255	Human	hsa-miR-27a	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
6256	Human	hsa-miR-27a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
6257	Human	hsa-miR-27a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
6258	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	hypothyroidism	The human thyroid follicular epithelial cells (Nthy-ori 3-1)	lipopolysaccharide (LPS) treatment	downregulated	30300656
6259	Human	hsa-miR-27a	miRNA	salidroside (SAL)	hypothyroidism	LPS-treated the human thyroid follicular epithelial cells (Nthy-ori 3-1)	salidroside (SAL) treatment	upregulated	30300656
6260	Human	hsa-miR-27a	miRNA	mycobacterium tuberculosis (Mtb)	immune response	THP-1 cells	infect with Mtb	downregulated	31966878
6261	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	inflammation	MRC-5 cells	lipopolysaccharide (LPS) treatment	LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression.	31735661
6262	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	inflammation	BMDMs	lipopolysaccharide (LPS) treatment	downregulated	24835395
6263	Human	hsa-miR-27a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human mitral valve interstitial cells (hMVICs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29694513
6264	Human	hsa-miR-27a	miRNA	quercetin and hyperoside (QH)	injury in vascular smooth muscle cells	renal cancer cells	quercetin and hyperoside treatment	downregulated	24173369
6265	Human	hsa-miR-27a	miRNA	doxorubicin (DOX)	leukemia	myeloid leukemic cell lines NB4; human promyelocytic leukaemia cell line;HL60	doxorubicin (DOX)? treatment	downregulated	21070600
6266	Human	hsa-miR-27a	miRNA	genistein	lung cancer	A549 cells	Genistein treatment	upregulated	27602162
6267	Human	hsa-miR-27a	miRNA	glucagon-like peptide-1 (GLP-1)	lung fibrosis	human embryonic lung fibroblast (MRC-5) cells	Glucagon-like peptide-1 (GLP-1) treatment	"After pretreating MRC-5 cells via GLP-1, with or without compound C (AMPK inhibitor), the expression of miR-27a in the GLP-1 treated group was significantly lower than that in Vehicle group."	33850889
6268	Human	hsa-miR-27a	miRNA	alcohol	macrophage activation	plasma	alcohol exposure	upregulated	26527689
6269	Human	hsa-miR-27a	miRNA	alcohol	macrophage activation	THP-1	alcohol exposure	upregulated	26527689
6270	Human	hsa-miR-27a	miRNA	metformin (Met)	pancreatic cancer (PC)	Panc1 cells;L3.6pL cells;Panc28 cells	Metformin? treatment	downregulated	23803693
6271	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	monocytic differentiation	monocyte	lipopolysaccharide (LPS) treatment	dysregulated	25148686
6272	Human	hsa-miR-27a	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose (HG) treatment	upregulated	31889412
6273	Human	hsa-miR-27a	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose (HG) treatment	upregulated	31889412
6274	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	human oral keratinocytes (HOKs)	lipopolysaccharide (LPS) treatment	downregulated	31942011
6275	Human	hsa-miR-27a	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrosarcoma (SW1353) cells and primary cultured articular chondrocytes	IL-1¦Â treatment	upregulated	31460867
6276	Human	hsa-miR-27a	miRNA	IL-1¦Â	osteoarthritis (OA)	OA cartilage tissues and primary human articular chondrocyte	IL-1¦Â treatment	upregulated	31520995
6277	Human	hsa-miR-27a	miRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	Chondrocytes	IL-1¦Â and TNF-¦Á treatment	CircTMBIM6 promotes osteoarthritis-induced chondrocyte extracellular matrix degradation via miR-27a/MMP13 axis.	32767318
6278	Human	hsa-miR-27a	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
6279	Human	hsa-miR-27a	miRNA	glucocorticoid (GC)	osteogenesis	human bone marrow stromal cells ( hBMSCs)	glucocorticoid (GC) treatment	miR-27a expression profiles were found to be downregulated in ONFH samples and GC-induced hBMSCs using microarray analysis and real-time quantitative polymerase chain reaction	33532936
6280	Human	hsa-miR-27a	miRNA	astragalus polysaccharide (APS)	ovarian cancer (OC)	OV-90 cells	astragalus polysaccharide (APS) treatment	APS dose-dependently decreased the levels of miR-27a in OV-90 cells.	32159214
6281	Human	hsa-miR-27a	miRNA	hypoxia	ovarian cancer (OC)	Skov3 cells	hypoxia treatment	The expression of the miR-27a was obviously upregulated under hypoxia and involved in hypoxia-induced paclitaxel resistance.	32190895
6282	Human	hsa-miR-27a	miRNA	H2O2	oxidative stress	human trabecular meshwork (HTM) cells	H2O2 treatment	downregulated	31062616
6283	Human	hsa-miR-27a	miRNA	salidroside (SAL)	oxidative stress	H2O2-treated human trabecular meshwork (HTM) cells	salidroside (SAL) treatment	upregulated	31062616
6284	Human	hsa-miR-27a	miRNA	genistein	pancreatic cancer (PC)	BxPC-3 and PANC-1 cell	genistein treatment	downregulated	24479798
6285	Human	hsa-miR-27a	miRNA	paraquat (PQ)	paraquat poisoning	serum	paraquat treatment	Decreased serum miR-27a level and increased IL-10 expression levels were detected in patients with paraquat poisoning compared with healthy controls	32104255
6286	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression.	31735661
6287	Human	hsa-miR-27a	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
6288	Human	hsa-miR-27a	miRNA	hemin	pulmonary hypertension (PH)	human pulmonary artery endothelial cells (HPAECs)	hemin for 72 hours	upregulated	27612006
6289	Human	hsa-miR-27a	miRNA	hypoxia	pulmonary hypertension (PH)	Human pulmonary artery endothelial cells (HPAECs)	hypoxia treatment	downregulated	24244514
6290	Human	hsa-miR-27a	miRNA	rosiglitazone	pulmonary hypertension (PH)	mouse	"rosiglitazone (RSG), 10 mg/kg/day treatment"	upregulated	27612006
6291	Human	hsa-miR-27a	miRNA	quercetin and hyperoside (QH)	renal cell carcinoma (RCC)	786-O renal cancer cells	quercetin and hyperoside (QH) in combination (1:1 ratio) treatment	downregulated	24173369
6292	Human	hsa-miR-27a	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	rhabdomyosarcoma (RMS)	RD and Rh30 rhabdomyosarcoma (RMS) cells	"Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment"	downregulated	30610105
6293	Human	hsa-miR-27a	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
6294	Human	hsa-miR-27a	miRNA	"haloperidol, clozapine and olanzapine"	schizophrenia (SZ)	"HepG2 (ATCC,CRL-1573)"	"haloperidol, clozapine , olanzapine treatment"	downregulated	28429622
6295	Human	hsa-miR-27a	miRNA	folate	squamous cell carcinoma (SCC)	HeLa cells; SiHa cells	Folate treatment	"There was a highly significant difference between the 200 and 500 nM folate groups, in which miR-27a expression levels were significantly downregulated between the 200 and 500 nM concentration groups."	31918266
6296	Human	hsa-miR-27a	miRNA	X-rays	stress response	human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A	a single dose of 5Gy ?-radiation	downregulated	28851536
6297	Human	hsa-miR-27a	miRNA	hypoxia	urothelial bladder carcinoma	human bladder cancer cell line (J82)	hypoxia treatment	upregulated	24462738
6298	Human	hsa-miR-27a-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells; BEAS-2B cells	lipopolysaccharide (LPS) treatment	MiR-27a-3p was downregulated in LPS-induced alveolar epithelial cells.	32993961
6299	Human	hsa-miR-27a-3p	miRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	Significantly higher miR-27a-3p expression was confirmed in MCF-7/ADR as compared with sensitive cell line MCF-7.	32764979
6300	Human	hsa-miR-27a-3p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
6301	Human	hsa-miR-27a-3p	miRNA	folate	cervical cancer (CC)	HeLa-GFP and SiHa cells	500nM Folate treatment	downregulated	31918266
6302	Human	hsa-miR-27a-3p	miRNA	lipopolysaccharide (LPS)	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"TUG1 could repress cell apoptosis, autophagy, and inflammatory response in LPS-treated HUVECs by sponging miR-27a-3p to target SLIT2."	32738556
6303	Human	hsa-miR-27a-3p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	downregulated	30503955
6304	Human	hsa-miR-27a-3p	miRNA	dihydrotestosterone (DHT)	cardiovascular disease (CVD)	EA.hy926	dihydrotestosterone treatment	downregulated	28240250
6305	Human	hsa-miR-27a-3p	miRNA	hypoxia	ischemic heart disease (IHD)	AC16 cell	hypoxia exposure	circ_0010729 knockdown alleviated hypoxia-induced AC16 cell injuries by mediating the miR-27a-3p/TRAF5 axis.	33010282
6306	Human	hsa-miR-27a-3p	miRNA	TGF-¦Â1	lung fibrosis	human lung fibroblasts	transforming growth factor-¦Â1 treatment	upregulated	26600197
6307	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	downregulated	27143365
6308	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
6309	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
6310	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	29749508
6311	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â and/or TNF-¦Á	osteoarthritis (OA)	Human cartilage C28/I2 cells	IL-1¦Â and/or TNF-¦Á treatment	FOXD2-AS1 upregulated the expression level of TLR4 by sponging miR-27a-3p.	30945573
6312	Human	hsa-miR-27a-3p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
6313	Human	hsa-miR-27a-3p	miRNA	insulin	polycystic ovarian syndrome (PCOS)	human granulosa-like tumor cell line (KGN)	insulin treatment	downregulated	29029022
6314	Human	hsa-miR-27a-3p	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32084559
6315	Human	hsa-miR-27a-3p	miRNA	adalimumab(ADA)	rheumatoid arthritis (RA)	plasma	adalimumab(ADA) treatment	"In the ADA group, a higher pretreatment level of miR-27a-3p was significantly associated with remission at 12 months. The level decreased in remitting patients between pretreatment and 3 months, and increased in nonremitting patients."	29142030
6316	Human	hsa-miR-27a-3p	miRNA	CoCl2	acute kidney injury (AKI)	human kidney tubular cells (HK-2)	CoCl2?-stimulated HK-2 cells	miR-27a-3p was downregulated in AKI patients compared with healthy control.	31090110
6317	Human	hsa-miR-27a-3p	miRNA	ischemia	acute kidney injury (AKI)	serum from AKI patients	ischemia©\induced AKI	The level of miR©\27a©\3p in HK©\2 cells treated with CoCl2 was decreased in a dose©\dependent manner.	31090110
6318	Human	hsa-miR-27a-5p	miRNA	TGF-¦Â1	against cancer	human natural killer (NK) cells	TGF-¦Â1 treatment	upregulated	28791023
6319	Human	hsa-miR-27a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
6320	Human	hsa-miR-27a-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
6321	Human	hsa-miR-27a-5p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	cyclosporine A (CYCA) treatment	upregulated	31198949
6322	Human	hsa-miR-27a-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
6323	Human	hsa-miR-27a-5p	miRNA	oxidized glycerophospholipids (oxGPs) and IL-1¦Â	inflammation	human aortic endothelial cells (HAECs)	oxGPs and interleukin 1¦Â (IL-1¦Â) treatment	upregulated	25327529
6324	Human	hsa-miR-27a-5p	miRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte primary cells (HCM)	hypoxia treatment	downregulated	32528555
6325	Human	hsa-miR-27a-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
6326	Human	hsa-miR-27a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	32546573
6327	Human	hsa-miR-27a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	sepsis	human pulmonary microvascular endothelial cells (HPMECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32546573
6328	Human	hsa-miR-27a-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
6329	Human	hsa-miR-27-a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine protects SH-SY5Y cells against oxygen-glucose deprivation and reoxygenation-induced injury partly through the inhibition of microRNA-27-a-5p and promotion of the Bach1/HO-1 signaling pathway.	32706194
6330	Human	hsa-miR-27b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6331	Human	hsa-miR-27b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	fibroblast-like synoviocytes (FLSs) cells (MH7A)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31124343
6332	Human	hsa-miR-27b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1-derived macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31518965
6333	Human	hsa-miR-27b	miRNA	leptin	bone malignancy	chondrosarcoma cells	Leptin treatment	"the expression of microRNA-27b was negatively regulated by leptin via the FAK, PI3K and Akt cascade."	27345723
6334	Human	hsa-miR-27b	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
6335	Human	hsa-miR-27b	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
6336	Human	hsa-miR-27b	miRNA	IL-6	breast cancer	MCF-7 and MDA-MB-231 cells	interleukin-6 (IL-6) treatment	downregulated	31515600
6337	Human	hsa-miR-27b	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	ARPE-19 cells	platelet-derived growth factor (PDGF)-BB treatment	downregulated	29858119
6338	Human	hsa-miR-27b	miRNA	adiponectin	chondrosarcoma	human lymphatic endothelial cells	adiponectin (ApN) treatment	downregulated	27252405
6339	Human	hsa-miR-27b	miRNA	IL-6	colorectal cancer (CRC)	HCT116 and SW480 cells	IL-6 treatment	downregulated	25333344
6340	Human	hsa-miR-27b	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
6341	Human	hsa-miR-27b	miRNA	alagebrium chloride (ALT711)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	alagebrium chloride (ALT711) treatment	upregulated	30972183
6342	Human	hsa-miR-27b	miRNA	N¦Å-carboxymethyl-lysine (CML)-BSA	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	N¦Å-carboxymethyl-lysine (CML)-BSA treatment	downregulated	30972183
6343	Human	hsa-miR-27b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high-glucose treatment	downregulated	29786744
6344	Human	hsa-miR-27b	miRNA	TGF-¦Â	fibrosis	A549 human alveolar epithelial cells	TGF-¦Â treatment	downregulated	24633904
6345	Human	hsa-miR-27b	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31046802
6346	Human	hsa-miR-27b	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	human glioma U251 cells	infect with HCMV	upregulated	28343438
6347	Human	hsa-miR-27b	miRNA	hepatocyte growth factor (HGF)	head and neck squamous cell carcinoma (HNSCC)	HNSCC; adjacent normal squamous epithelial tissues	Hepatocyte growth factor (HGF) treatment	downregulated	21899661
6348	Human	hsa-miR-27b	miRNA	tetrandrine	hypertrophic scars (HS)	human hypertrophic scar fibroblasts (HSFs)	tetrandrine treatment	upregulated	26909951
6349	Human	hsa-miR-27b	miRNA	insulin	insulin resistance (IR)	human mesenchymal stem cell (hMSC)-derived adipocytes	insulin treatment	upregulated	29455245
6350	Human	hsa-miR-27b	miRNA	fumonisin B?	hepatocellular carcinoma (HCC)	human hepatoma cell line (HepG2)	Fumonisin B? treatment	downregulated	24614526
6351	Human	hsa-miR-27b	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	upregulated	28347920
6352	Human	hsa-miR-27b	miRNA	(6)-gingerol (6G)	myeloid leukemia	U937 cells; K562 cells	(6)-gingerol (6G) treatment	upregulated	24378438
6353	Human	hsa-miR-27b	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	human oral keratinocytes (HOKs)	lipopolysaccharide (LPS) treatment	downregulated	31942011
6354	Human	hsa-miR-27b	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
6355	Human	hsa-miR-27b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
6356	Human	hsa-miR-27b	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial endothelial cells (HPAECs)	hypoxia treatment	The results revealed that PPAR¦Ã expression was downregulated and miR-27b expression was upregulated in the HPAECs exposed to hypoxia.	33907846
6357	Human	hsa-miR-27b	miRNA	lipopolysaccharide (LPS)	transitional cell carcinomas (TCCs)	primary human macrophages	lipopolysaccharide (LPS) treatment	upregulated	20164187
6358	Human	hsa-miR-27b	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	serum	liraglutide treatment	upregulated	33008044
6359	Human	hsa-miR-27b	miRNA	bisphenol A (BPA)	vascular endothelial dysfunction	primary cultured human endometrial stromal cells (HESCs)	bisphenol A (BPA) treatment	downregulated	30328349
6360	Human	hsa-miR-27b	miRNA	estradiol-17¦Â (E2)	vascular endothelial dysfunction	primary cultured human endometrial stromal cells (HESCs)	estradiol-17¦Â (E2) treatment	downregulated	30328349
6361	Human	hsa-miR-27b-3p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
6362	Human	hsa-miR-27b-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	aortic dissection (AD)	Human aortic smooth muscle cells (HASMCs)	platelet derived growth factor-BB (PDGF-BB) treatment	"In AD, PVT1 expression was upregulated, yet that of miR-27b-3p was downregulated"	33106979
6363	Human	hsa-miR-27b-3p	miRNA	house dust mite (HDM)	asthma	human	dust mite treatment	downregulated	30406061
6364	Human	hsa-miR-27b-3p	miRNA	angiotensin II (Ang II)	atrial fibrillation (AF)	Human atrial fibroblasts (HAFs)	angiotensin II (Ang II) treatment	upregulated	30729664
6365	Human	hsa-miR-27b-3p	miRNA	tamoxifen (TAM)	breast cancer	MCF-7/TAM-1 and T47D/TAM-1 cells	tamoxifen treatment	downregulated	27809310
6366	Human	hsa-miR-27b-3p	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells	Oxaliplatin (OXA) treatment	miR-27b-3p expression was significantly downregulated in oxaliplatin-resistant cell lines (SW480-OxR and HCT116-OxR)	32104496
6367	Human	hsa-miR-27b-3p	miRNA	geniposide (GEN)	diffuse large B-cell lymphoma (DLBCL)	OCI-LY7; OCI-LY3 cells	geniposide treatment	Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis	33162801
6368	Human	hsa-miR-27b-3p	miRNA	Rg3-enhanced red ginseng extract (Rg3E)	endometriosis	human endometrial stromal cells (HESCs)	400??L/mL Rg3E and cultured for 48?h treatment	downregulated	29247225
6369	Human	hsa-miR-27b-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	MKN-45 and SGC-7901 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31539861
6370	Human	hsa-miR-27b-3p	miRNA	radiation	gastric cancer (GC)	MKN-45 and AGS cells	radiation treatment	NEAT1 depletion enhanced radio-sensitivity of GC by negatively regulating miR-27b-3p in vitro and in vivo	33292252
6371	Human	hsa-miR-27b-3p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
6372	Human	hsa-miR-27b-3p	miRNA	dihydrotestosterone (DHT)	cardiovascular disease (CVD)	EA.hy926	dihydrotestosterone treatment	downregulated	28240250
6373	Human	hsa-miR-27b-3p	miRNA	l-carnitine	male infertility	sperm	l-carnitine treatment	upregulated	31749176
6374	Human	hsa-miR-27b-3p	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	oral squamous cell carcinoma (OSCC) cells	cisplatin treatment	downregulated	33191714
6375	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	downregulated	27143365
6376	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
6377	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
6378	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-7¦Â treatment	dysregulated	29123165
6379	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-11¦Â treatment	dysregulated	29123165
6380	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	31863917
6381	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human transformed chondrocytes C28/I2	IL-1¦Â treatment	downregulated	31863917
6382	Human	hsa-miR-27b-5p	miRNA	sulforaphane (SFN)	cancer treatment	NCI-60 cells	sulforaphane treatment	downregulated	32429039
6383	Human	hsa-miR-27b-5p	miRNA	IL-10	hemangioma (HA)	human primary HDEC	recombinant IL-10 (rIL-10) treatment	rIL-10 can increase expression of miR-27b-5p	32416101
6384	Human	hsa-miR-27b-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oral squamous cell carcinoma (OSCC)	SCC-4 cells	Mono-2-ethyhexyl phthalate (MEHP) treatment	downregulated	30858031
6385	Human	hsa-miR-27b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
6386	Human	hsa-miR-28	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
6387	Human	hsa-miR-28	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
6388	Human	hsa-miR-281	miRNA	platelet derived growth factor-BB (PDGF-BB)	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	29514810
6389	Human	hsa-miR-28-3p	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6390	Human	hsa-miR-28-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
6391	Human	hsa-miR-28-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
6392	Human	hsa-miR-28-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
6393	Human	hsa-miR-28-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	myeloma	human myeloma cell lines (HMCLs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28775176
6394	Human	hsa-miR-28-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
6395	Human	hsa-miR-28-5p	miRNA	"glucose,hydrogen peroxide"	oxidative stress	primary human tenocytes	high (17.5 mM) and 100 ¦ÌM hydrogen peroxide treatment	upregulated	24556689c
6396	Human	hsa-miR-28-5p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
6397	Human	hsa-miR-28-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
6398	Human	hsa-miR-28-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
6399	Human	hsa-miR-2861	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
6400	Human	hsa-miR-28a	miRNA	lithocholic acid (LCA)	glutathione synthesis and antioxidant capacity	Huh-7 cells	lithocholic acid (LCA) treatment	upregulated	25226452
6401	Human	hsa-miR-28a-5p	miRNA	prostaglandin E2 (PGE2)	liver fibrosis	TGF-¦Â1-treated LX-2 cells	PGE2 treatment	downregulated	29109031
6402	Human	hsa-miR-28a-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	upregulated	29109031
6403	Human	hsa-miR-28b	miRNA	dexamethasone (DEX)	central fat accumulation	primary SVF cells derived from human SAT and VAT	dexamethasone (DEX) treatment	upregulated	25187367
6404	Human	hsa-miR-28b	miRNA	lithocholic acid (LCA)	glutathione synthesis and antioxidant capacity	Huh-7 cells	lithocholic acid (LCA) treatment	upregulated	25226452
6405	Human	hsa-miR-28b	miRNA	ERK1/2 inhibitor	leukemia	TIB152 human leukemia cell line	ER¦Á-neutralizing antibody or ERK1/2 inhibitor treatment	downregulated	24974218
6406	Human	hsa-miR-28b	miRNA	ER¦Á-neutralizing antibody	leukemia	TIB152 human leukemia cell line	ER¦Á-neutralizing antibody or ERK1/2 inhibitor treatment	downregulated	24974218
6407	Human	hsa-miR-29	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
6408	Human	hsa-miR-29	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	burkitt lymphoma (BL)	The BL cell lines: Raji (EBV+) and BL41 (EBV-)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31173259
6409	Human	hsa-miR-29	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial cells (RPEs)	high glucose treatment	upregulated	32447557
6410	Human	hsa-miR-29	miRNA	progesterone (P4)	esophageal cancer (EC)	T47D cells; MCF7 cells	Progesterone treatment	progestin treatment decreases miR-29	22330642
6411	Human	hsa-miR-29	miRNA	TGF-¦Â	fibrosis	Dermal fibroblasts	TGF-¦Â treatment	downregulated	31155965
6412	Human	hsa-miR-29	miRNA	cisplatin and docetaxel	gastric cancer (GC)	gastric cancer cell	cisplatin and docetaxel treatment	upregulated	25634213
6413	Human	hsa-miR-29	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	human trabecular meshwork (HTM) cells	transforming growth factor-betas treatment	downregulated	21273536
6414	Human	hsa-miR-29	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
6415	Human	hsa-miR-29	miRNA	high glucose (HG)	hyperglycemia	human retinal pigment epithelial (RPE)	high glucose treatment	upregulated	26822433
6416	Human	hsa-miR-29	miRNA	TGF-¦Â2	innate immunity	trabecular meshwork (TM)	TGF-¦Â2 treatment	the incubation of TM cells with TGF-¦Â2 induced miR-29a and suppressed miR-29b levels	21330653
6417	Human	hsa-miR-29	miRNA	TGF-¦Â1	leprosy	human lung fibroblasts	TGF-¦Â1 treatment	Treatment of the human embryonic lung fibroblast cell line IMR90 with TGF¦Â1 caused a decrease in expression of miR-29a/b/c	23238947
6418	Human	hsa-miR-29	miRNA	TGF-¦Â1	lung cancer	proximal tubular cells; primary mesangial cells; podocytes	TGF-¦Â1 treatment	downregulated	22095944
6419	Human	hsa-miR-29	miRNA	IFN-¦Ã	melanoma	melanoma cell lines	?IFN-¦Ã?treatment treatment	downregulated	23245396
6420	Human	hsa-miR-29	miRNA	IFN-¦Â	multiple sclerosis (MS)	Peripheral blood mononuclear cells (PBMC)	Interferon-¦Â treatment	downregulated	23921681
6421	Human	hsa-miR-29	miRNA	TGF-¦Â1	orbital fibrosis	human orbital fibroblasts (OFs)	TGF-¦Â1 treatment	downregulated	25550793
6422	Human	hsa-miR-29	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human endometrial cell-lines	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	28499250
6423	Human	hsa-miR-29	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
6424	Human	hsa-miR-29	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	upregulated	30182520
6425	Human	hsa-miR-29	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	hepatic stellate cell (HSC)	hepatitis C virus (HCV) infection	downregulated	21606534
6426	Human	hsa-miR-29?b-1-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
6427	Human	hsa-miR-29*	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec7A cells	Progesterone treatment	upregulated	22543862
6428	Human	hsa-miR-2909	miRNA	lipopolysaccharide (LPS)	inflammation	human adipose stem cells	lipopolysaccharide (LPS) treatment	downregulated	30807577
6429	Human	hsa-miR-291	miRNA	"WIN55,212-2 (WIN)"	osteosarcoma (OS)	Human osteosarcoma MG63 cells	"WIN55,212-2 (WIN) treatment"	upregulated	31652569
6430	Human	hsa-miR-296	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	downregulated	24396484
6431	Human	hsa-miR-296	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
6432	Human	hsa-miR-296	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
6433	Human	hsa-miR-296	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
6434	Human	hsa-miR-296	miRNA	epigallocatechin-3-gallate (EGCG)	nasopharyngeal carcinoma (NPC)	TW01 cells; TW06 cells	Epigallocatechin gallate (EGCG) treatment	Involvement of MicroRNA-296 in the Inhibitory Effect of Epigallocatechin Gallate against the Migratory Properties of Anoikis-Resistant Nasopharyngeal Carcinoma Cells	32326395
6435	Human	hsa-miR-296	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	downregulated	24396484
6436	Human	hsa-miR-296-3p	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	HONE1 and SUNE1 cells	cisplatin treatment	downregulated	29525743
6437	Human	hsa-miR-296-3p	miRNA	nicotine	nasopharyngeal carcinoma (NPC)	HONE1 and SUNE1 cells	nicotine treatment	downregulated	29525743
6438	Human	hsa-miR-2965p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
6439	Human	hsa-miR-296-5p	miRNA	aloperine	colorectal cancer (CRC)	SW480 and HT29 cells	aloperine treatment	upregulated	33664565
6440	Human	hsa-miR-296-5p	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?11 cells	heme treatment	upregulated	23538684
6441	Human	hsa-miR-296-5p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"NSCLC tissues and cells (A549, H1650, A549/DDP, H1650/DDP)"	cisplatin treatment	downregulated	31647948
6442	Human	hsa-miR-296-5p	miRNA	Fusobacterium nucleatum (F. nucleatum)	oral squamous cell carcinoma (OSCC)	human immortalized oral epithelial cells (HIOECs); SCC-9 cells; HSC-4 cells	F. nucleatum infection	downregulated	31997506
6443	Human	hsa-miR-296-5p	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	vascular smooth muscle cell (VSMC)	high glucose (HG) treatment	upregulated	29386225
6444	Human	hsa-miR-296-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	type 2 diabetes mellitus (T2DM)	vascular smooth muscle cell (VSMC)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	29386225
6445	Human	hsa-miR-297	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	miR-297 was decreased in LPS-induced A549 cells.	31945608
6446	Human	hsa-miR-297	miRNA	hypoxia	myocardial ischaemic injury	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	"hsa_circ_0007623 can bind to miR-297, promote cardiac repair after acute myocardial ischemia, and protect cardiac function."	31973814
6447	Human	hsa-miR-297	miRNA	aluminum oxide nanoparticles (Al2O3 NPs)	pulmonary inflammation	human bronchial epithelial (HBE) cells	aluminum oxide nanoparticles (Al2O3 NPs) treatment	upregulated	31918133
6448	Human	hsa-miR-297	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	30921508
6449	Human	hsa-miR-298	miRNA	bufalin	gastric cancer (GC)	gastric cancer cells	bufalin treatment	downregulated	26064232
6450	Human	hsa-miR-299	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
6451	Human	hsa-miR-299	miRNA	hypoxia	ovarian cancer (OC)	human ovarian cancer cell lines Caov3;Skov3	hypoxia treatment	upregulated	28726915
6452	Human	hsa-miR-299	miRNA	oleuropein (OL)	ovarian cancer (OC)	Caov3 cells	oleuropein	upregulated	28726915
6453	Human	hsa-miR-299-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC-27 cells	cisplatin (DPP) treatment	"circ_0110805 knockdown increased the sensitivity of gastric cancer to cisplatin, which also repressed gastric cancer progression by sponging miR-299-3p to downregulate ENDOPDI expression."	33192077
6454	Human	hsa-miR-299-3p	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
6455	Human	hsa-miR-299-5p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	downregulated	30131392
6456	Human	hsa-miR-299-5p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
6457	Human	hsa-miR-299-5p	miRNA	6'-O-galloylpaeoniflorin (GPF)	non-small cell lung cancer (NSCLC)	A549 cells	6'-O-galloylpaeoniflorin (GPF) treatment	GPF up-regulates miR-299-5p expression via the AMPK pathway.	32014006
6458	Human	hsa-miR-29a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
6459	Human	hsa-miR-29a	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
6460	Human	hsa-miR-29a	miRNA	ultraviolet (UV) irradiation	age-related cataract (ARC)	Human lens epithelial cells (HLECs)	ultraviolet irradiation treatment	"the interaction among lncRNA H19, miR-29a and TDG is involved in early ARC lncRNA H19 could be a useful marker of early ARC and oxidative damage repair pathway of lncRNA H19/miR-29a/TDG may be a promising target for the treatment of ARC"	31282110
6461	Human	hsa-miR-29a	miRNA	klotho	Alzheimer's disease (AD)	human peripheral blood mononuclear cells (PBMCs) of AD patients	klotho treatment	upregulated	31197641
6462	Human	hsa-miR-29a	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29386999
6463	Human	hsa-miR-29a	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	29386999
6464	Human	hsa-miR-29a	miRNA	¦Â-hydroxybutyrate	Alzheimer's disease (AD)	SH-SY5Y cells	¦Â-hydroxybutyrate treatment	"microRNA-29a expression was downregulated in 2 ¦ÌM A¦Â25-35-exposed SH-SY5Y cells, but respectively decreased and upregulated in 10 ¦ÌM A¦Â25-35-exposed cells, which were all reversed by ¦Â-hydroxybutyrate"	29386999
6465	Human	hsa-miR-29a	miRNA	etanercept	ankylosing spondylitis (AS)	Blood	etanercept treatment	upregulated	26273623
6466	Human	hsa-miR-29a	miRNA	arsenite	arsenic induced senescence (AIS)	HEK 293 cells	arsenic (As) exposure	upregulated	29107899
6467	Human	hsa-miR-29a	miRNA	platelet derived growth factor-BB (PDGF-BB)	arteriosclerosis obliterans (ASO)	human arterial smooth muscle cells (HASMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	31614351
6468	Human	hsa-miR-29a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29074464
6469	Human	hsa-miR-29a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HASMCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29074464
6470	Human	hsa-miR-29a	miRNA	insulin	breast cancer	"human breast cancer cells, namely, MCF-7 and T47D cells"	human insulin treatment	upregulated	28427228
6471	Human	hsa-miR-29a	miRNA	isoflavone	apoptosis	PCa cells	isoflavone? treatment	downregulated	22805767
6472	Human	hsa-miR-29a	miRNA	dexamethasone (DEX)	cell differentiation	human multipotent adipose stem (hMADS) cells	dexamethasone (DEX) treatment	upregulated	30742779
6473	Human	hsa-miR-29a	miRNA	human papilloma virus (HPV)	cervical cancer (CC)	human foreskin keratinocytes (HFK)K-derived organotypic raft cultures	HPV infectionn	downregulated	33436409
6474	Human	hsa-miR-29a	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	downregulated	31226416
6475	Human	hsa-miR-29a	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	upregulated	31226416
6476	Human	hsa-miR-29a	miRNA	doxorubicin (DOX)	colorectal cancer (CRC)	HT29 cells	doxorubicin (DOX) treatment	miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via upregulated of PTEN in colon cancer cells	32416187
6477	Human	hsa-miR-29a	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
6478	Human	hsa-miR-29a	miRNA	photodynamic therapy (PDT)	colorectal cancer (CRC)	HCT116 cells	PDT treatment	downregulated	29807108
6479	Human	hsa-miR-29a	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	High Glucose (HG) treatment	downregulated	30520097
6480	Human	hsa-miR-29a	miRNA	high glucose (HG)	diabetes mellitus (DM)	HepG2 cells	high glucose (HG) treatment	upregulated	30296791
6481	Human	hsa-miR-29a	miRNA	morin	diabetes mellitus (DM)	high glucose (HG)-induced HepG2 cells	Morin treatment	downregulated	30296791
6482	Human	hsa-miR-29a	miRNA	TGF-¦Â2	diabetic nephropathy (DN)	human dermal microvascular endothelial cells (HMVECs)	TGF-¦Â2 treatment	Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT	33324218
6483	Human	hsa-miR-29a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
6484	Human	hsa-miR-29a	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
6485	Human	hsa-miR-29a	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
6486	Human	hsa-miR-29a	miRNA	high glucose (HG) and TGF-¦Â1	excess collagen deposition in PTCs	?HK-2 cells	high glucose /TGF-¦Â1 treatment	downregulated	20067797
6487	Human	hsa-miR-29a	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
6488	Human	hsa-miR-29a	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
6489	Human	hsa-miR-29a	miRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	T98G cells; U87MG cells	cisplatin (DPP) treatment	Cisplatin increased CD133 expression by suppressing miR-29a levels.	30267383
6490	Human	hsa-miR-29a	miRNA	sevoflurane (SEV)	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	sevoflurane (SEVO) treatment	upregulated	31190353
6491	Human	hsa-miR-29a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	human HCC cell lines	human HCC cell lines with TGF-¦Â treatment	downregulated	23789939
6492	Human	hsa-miR-29a	miRNA	xiaoai jiedu recipe (XJR)	hepatocellular carcinoma (HCC)	SK-Hep-1 cells; Hep3B cells	Xiaoai Jiedu Recipe (XJR) treatment	XJR treatment significantly increased the expression of miR-29a	32848411
6493	Human	hsa-miR-29a	miRNA	Intestinal Salmonella typhimurium	intestinal Salmonella typhimurium infection	human intestinal cells	Intestinal Salmonella typhimurium infection	upregulated	23826261
6494	Human	hsa-miR-29a	miRNA	leukemia microvesicles	leukemia	healthy hematopoietic stem cells	leukemia microvesicles transformation	upregulated	28218044
6495	Human	hsa-miR-29a	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	HepG-2 cells	arsenic trioxide?treatment	upregulated	21175813
6496	Human	hsa-miR-29a	miRNA	rosiglitazone	liver fibrosis	human hepatic stellate cell line LX-2	rosiglitazone (RSG) treatment	upregulated	30781750
6497	Human	hsa-miR-29a	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	upregulated	32933544
6498	Human	hsa-miR-29a	miRNA	graphene oxide (GO)	nanoparticles toxicity	MCF-7 cells	graphene oxide (GO) treatment	upregulated	32070776
6499	Human	hsa-miR-29a	miRNA	graphene oxide (GO)	nanoparticles toxicity	KMBC/71 cells	graphene oxide (GO) treatment	downregulated	32070776
6500	Human	hsa-miR-29a	miRNA	graphene quantum dots (GQDs)	nanoparticles toxicity	KMBC/71 cells	graphene quantum dots (GQDs) treatment	downregulated	32070776
6501	Human	hsa-miR-29a	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	"A radio-resistant sub-cell line, CNE-2R"	irradiation (IR) exposure	downregulated	31034464
6502	Human	hsa-miR-29a	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	upregulated	29619741
6503	Human	hsa-miR-29a	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	JFH-I-infected Huh-7 cells	oleic acid (OA) treatment	upregulated	28097097
6504	Human	hsa-miR-29a	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines, MG-63 and U2OS"	methotrexate (MTX) treatment	downregulated	30518744
6505	Human	hsa-miR-29a	miRNA	ischemia	peripheral arterial disease (PAD)	human umbilical vein endothelial cells (HUVEC)	"exposed to simulated ischemia (2% oxygen, BioSpherix, Lacona, NY and starvation medium)"	downregulated	28637396
6506	Human	hsa-miR-29a	miRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"miR-29a expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR-29a"	31694982
6507	Human	hsa-miR-29a	miRNA	TGF-¦Â1	pulmonary fibroblasts proliferation	IMR-90	TGF-¦Â1 treatment	downregulated	26410313
6508	Human	hsa-miR-29a	miRNA	radiation	radiation-induced lung injury (RILI)	HFL-1; WI-38	TGF-¦Â1 and radiation treatment	downregulated	33117089
6509	Human	hsa-miR-29a	miRNA	fibroblast growth factor 2 (FGF2)	regeneration of skeletal muscle	human myoblasts	fibroblast growth factor-2 (FGF2) treatment	we demonstrate using microRNA (miRNA) profiling in mouse and human myoblasts that the capacity of FGF2 to stimulate myoblast proliferation is mediated by miR-29a. FGF2 induces miR-29a expression and inhibition of miR-29a using pharmacological or genetic deletion decreases myoblast proliferation.	26731484
6510	Human	hsa-miR-29a	miRNA	arsenite	cell senescence	HEK 293 cells	arsenite exposure	upregulated	29107899
6511	Human	hsa-miR-29a	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	upregulated	21030674
6512	Human	hsa-miR-29a	miRNA	glucose	type 2 diabetes mellitus (T2DM)	INS-1E beta-cells; human islets of Langerhans	glucose treatment	upregulated	22940552
6513	Human	hsa-miR-29a	miRNA	resistanceor endurance training	type 2 diabetes mellitus (T2DM)	middle-aged Polynesian men and women with morbid obesity (44 kg/m(2) ¡À 10) and Type 2 diabetes	16 wk of resistanceor endurance training treatment	dysregulated	25138607
6514	Human	hsa-miR-29a	miRNA	phosphorus (Pi)	vascular calcification (VC)	vascular smooth muscle cell (VSMC)	phosphorus (Pi) treatment	upregulated	26610870
6515	Human	hsa-miR-29a	miRNA	high glucose (HG)	vascular injury	human umbilical vein endothelial cells (HUVEC)	high glucose (HG) treatment	72-hour exposure to HG-decreased hsa-miRNA-29a.	30520097
6516	Human	hsa-miR-29a	miRNA	"3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064)"	liver fibrosis	hepatic stellate cells (HSCs)	"3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064) treatment"	upregulated	21511916
6517	Human	hsa-miR-29a-3p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
6518	Human	hsa-miR-29a-3p	miRNA	hypoxia	cell differentiation	human (P3 and U87) glioma cell lines	hypoxia induce	upregulated	30536597
6519	Human	hsa-miR-29a-3p	miRNA	astaxanthin	colorectal cancer (CRC)	The human colon cancer cell HCT116	astaxanthin (ATX) treatment	upregulated	31263239
6520	Human	hsa-miR-29a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ACBRI-183 cells	high glucose (HG) treatment	upregulated	32343678
6521	Human	hsa-miR-29a-3p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
6522	Human	hsa-miR-29a-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric mucosa tissues and gastric cells BGC-823 and GES-1	Helicobacter pylori (H. pylori)?infection	upregulated	30485838
6523	Human	hsa-miR-29a-3p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
6524	Human	hsa-miR-29a-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	miR-29a-3p expression in LX-2 cells showed the greatest decrease among four candidate microRNAs in response to TGF-¦Â1 treatment	32819600
6525	Human	hsa-miR-29a-3p	miRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	downregulated	33165134
6526	Human	hsa-miR-29a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
6527	Human	hsa-miR-29a-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30711160
6528	Human	hsa-miR-29a-3p	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
6529	Human	hsa-miR-29a-5p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	downregulated	30197683
6530	Human	hsa-miR-29a-5p	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary alveolar epithelial cells (HPAECS)	hypoxia treatment	"MIAT was upregulated in both in vivo and in vitro HPH models, while miR-29a-5p was downregulated."	32964992
6531	Human	hsa-miR-29b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
6532	Human	hsa-miR-29b	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
6533	Human	hsa-miR-29b	miRNA	high glucose (HG)	inflammation	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
6534	Human	hsa-miR-29b	miRNA	AR-42	osteoblastic differentiation	Increased anti-leukemic activity of decitabine	AR-42 treatment	upregulated	23178755
6535	Human	hsa-miR-29b	miRNA	prostaglandin E2 (PGE2)	abdominal aortic aneurysm (AAA)	human aortic smooth muscle cells (HASMCs)	prostaglandin E2 (PGE2) treatment	upregulated	29896234
6536	Human	hsa-miR-29B	miRNA	transcription factor NRF2	acute myeloid leukemia (AML)	peripheral blood	Transcription factor NRF2 treatment	downregulated	25323587
6537	Human	hsa-miR-29b	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
6538	Human	hsa-miR-29b	miRNA	wear particles	adverse biological responses to prostheses wear particles	THP-1 cells	wear particles treatment	upregulated	27812842
6539	Human	hsa-miR-29b	miRNA	ethanol (EtOH)	alcoholic liver fibrosis (ALF)	Human HSC cells (LX-2)	ethanol treatment	downregulated	31418997
6540	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	angiotensin II (Ang II)-induced human glomerular mesangial cell (HGMC) activation	Human glomerular mesangial cells (HGMCs)	angiotensin II (Ang II) treatment	Treatment with Ang II led to upregulated of miR-29b in a time-dependent manner.	31630337
6541	Human	hsa-miR-29b	miRNA	epigallocatechin-3-gallate (EGCG)	anti-cancer therapy	AGS and SGC7901 GC cells	Epigallocatechin gallate (EGCG) treatment	Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis	32512188
6542	Human	hsa-miR-29b	miRNA	alginate oligosaccharide (AOS)	aortic aneurysmal disease	aortic aneurysm patients	oral administration 10-mg AOS daily	downregulated	28919708
6543	Human	hsa-miR-29b	miRNA	glucocorticoid (GC)	apoptosis	human plasmacytoid dendritic cells(pDCs)	Glucocorticoids (GCs) treatment	both of these miRNAs promoted pDC apoptosis by directly targeting Mcl-1 and Bcl-2 in human primary pDCs	23894561
6544	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	upregulated	29398368
6545	Human	hsa-miR-29b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	primary human aortic smooth muscle cell (HASMC)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	21266537
6546	Human	hsa-miR-29b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29398368
6547	Human	hsa-miR-29b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29398368
6548	Human	hsa-miR-29b	miRNA	IFN-¦Ã	atopic dermatitis (AD)	human keratinocytes	"treat with IFN-¦Ã (10 ng/ml for 12 h, 24 h and 48 h)"	upregulated	31966903
6549	Human	hsa-miR-29b	miRNA	benzo(a)pyrene (BaP)	breast cancer	MDA-MB-231 cells	benzo(a)pyrene (BaP) exposure	downregulated	30155724
6550	Human	hsa-miR-29b	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
6551	Human	hsa-miR-29b	miRNA	anthracycline (AC)	cardiotoxicity	children plasma	anthracycline (AC) treatment	upregulated	28377429
6552	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
6553	Human	hsa-miR-29b	miRNA	lovastatin	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	lovastatin	upregulated in time/dose-dependently	28061433
6554	Human	hsa-miR-29b	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
6555	Human	hsa-miR-29b	miRNA	cisplatin (DDP)	cervical cancer (CC)	human cervical caner cell lines (HeLa and Caski cells)	cisplatin treatment	upregulated	28122338
6556	Human	hsa-miR-29b	miRNA	indoxyl sulfate (IS)	chronic kidney disease (CKD)	human aortic smooth muscle cells (HASMCs)	indoxyl sulfate (IS) treatment	upregulated	29195902
6557	Human	hsa-miR-29b	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HBE cells	cigarette smoke extract (CSE) treatment	downregulated	30652495
6558	Human	hsa-miR-29b	miRNA	N-acetyl-L-cysteine (NAC)	chronic obstructive pulmonary disease (COPD)	cigarette smoke extract (CSE)-treated HBE cells	N-acetylcysteine treatment	upregulated	30652495
6559	Human	hsa-miR-29b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
6560	Human	hsa-miR-29b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	Circular RNA COL1A2 promotes angiogenesis via regulating miR-29b/VEGF axis in diabetic retinopathy.	32497630
6561	Human	hsa-miR-29b	miRNA	quercetin	diabetic retinopathy (DR)	ARPE-19 cells	quercetin treatment	"miR-29b was low expressed in high glucose-treated cell, but quercetin elevated its expression"	31960917
6562	Human	hsa-miR-29b	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
6563	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	endothelial cell injury	human umbilical vein endothelial cells (HUVEC)	lipopolysaccharide (LPS) treatment	MiR-29b was upregulated in LPS-treated HUVEC and Eahy926 cells.	29665646
6564	Human	hsa-miR-29b	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
6565	Human	hsa-miR-29b	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial (RPE) cells	TGF-¦Â2 treatment	downregulated	31850164
6566	Human	hsa-miR-29b	miRNA	H2O2	epithelial ovarian cancer (EOC)	human ovarian cancer cell lines SKOV3 and A2780	H2O2	downregulated	29050034
6567	Human	hsa-miR-29b	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
6568	Human	hsa-miR-29b	miRNA	TGF-¦Â	extracellular-matrix (ECM) and fibril formation	LX-2 cells	TGF-¦Â treatment	downregulated	24650661
6569	Human	hsa-miR-29b	miRNA	TGF-¦Â	fibrosis	human Tenon's fibroblasts (HTFs)	TGF-¦Â treatment	miR-29b in TGF-b treatment group was significantly decreased compared to that in blank group	32124130
6570	Human	hsa-miR-29b	miRNA	ochratoxin A (OTA)	fibrosis	human embryonic kidney cells (HEK293) cells	OTA treatment	downregulated	25091173
6571	Human	hsa-miR-29b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human gastric cancer cell lines including AGS, BGC-823, SGC-7901, and MGC-803"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29221174
6572	Human	hsa-miR-29b	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
6573	Human	hsa-miR-29b	miRNA	lithium chloride (LiCl)	glaucoma	human TM cells	incubat lithium chloride (LiCl) treatment	upregulated	25352117
6574	Human	hsa-miR-29b	miRNA	TGF-¦Â1	glaucoma	human subconjunctival fibroblasts	TGF-¦Â1 treatment	miR-29b acted as a suppressor of type I collagen gene by repressing the PI3K/Akt/Sp1 pathway in HTFs	22297492
6575	Human	hsa-miR-29b	miRNA	TGF-¦Â2	glaucoma	Tenon's capsule fibroblasts	TGF-¦Â2 treatment	downregulated	26191170
6576	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	henoch Sch?nlein purpura nephritis (HSPN)	human glomerular mesangial cell (HGMC)	angiotensin II (Ang II) treatment	upregulated	31630337
6577	Human	hsa-miR-29b	miRNA	fusaric acid (FA)	hepatocellular carcinoma (HCC)	HepG2 cells	Fusaric acid (FA) treatment	upregulated	31060424
6578	Human	hsa-miR-29b	miRNA	brucea javanica oil (BJO)	hepatocellular carcinoma (HCC)	HCC cells	brucea javanica oil (BJO) treatment	BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level and p53 expression.	33341052
6579	Human	hsa-miR-29b	miRNA	brusatol	hepatocellular carcinoma (HCC)	HCC cells	brusatol treatment	BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level and p53 expression.	33341052
6580	Human	hsa-miR-29b	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	plasma	HIV-1 infection	upregulated	25808800
6581	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
6582	Human	hsa-miR-29b	miRNA	dexamethasone (DEX)	ischemic brain injury	SK-N-SH cells	dexamethasone (DEX) treatment	Dex treatment could reduce miR-29b expression.	29087603
6583	Human	hsa-miR-29b	miRNA	dexmedetomidine (DEX)	ischemic brain injury	human neuroblastoma SK-N-SH cells subjected to oxygen-glucose deprivation (OGD)	dexamethasone (DEX) treatment	downregulated	29087603
6584	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	kidney damage	human podocytes	angiotensin II (Ang II) treatment	upregulated	26867059
6585	Human	hsa-miR-29b	miRNA	gemcitabine (GEM)	hepatocellular carcinoma (HCC)	HuCCT1 cells; HuH28 cells	Gemcitabine treatment	upregulated	24147037
6586	Human	hsa-miR-29b	miRNA	astaxanthin	liver fibrosis	human hepatic stellate cell (HSC) line LX-2	astaxanthin (AST) treatment	upregulated	30896849
6587	Human	hsa-miR-29b	miRNA	curcumin (Cur)	liver fibrosis	activated HSCs	curcumin? treatment	upregulated	24138392
6588	Human	hsa-miR-29b	miRNA	high glucose (HG)	memory impairment in diabetes	SH-SY5Y cells	high glucose (HG) treatment	downregulated	32198621
6589	Human	hsa-miR-29b	miRNA	bortezomib	multiple myeloma (MM)	Bone marrow	bortezomib? treatment	upregulated	30967527
6590	Human	hsa-miR-29b	miRNA	genistein	multiple myeloma (MM)	human MM cell line U266	Genistein treatment	upregulated	26718793
6591	Human	hsa-miR-29b	miRNA	genistein	multiple myeloma (MM)	U266 cells	genistein treatment	upregulated	26718793
6592	Human	hsa-miR-29b	miRNA	paeoniflorin	multiple myeloma (MM)	SKO-007 cells	Paeoniflorin (PF) treatment	upregulated	27430753
6593	Human	hsa-miR-29b	miRNA	berberine (BBR)	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	berberine (BBR) treatment	upregulated	28722488
6594	Human	hsa-miR-29b	miRNA	haloperidol	neuroblastoma (NB)	SK-N-SH cell lines	haloperidol at 10¦Ìm concentration for 24 hours	downregulated	28886082
6595	Human	hsa-miR-29b	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	upregulated	29619741
6596	Human	hsa-miR-29b	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines, MG-63 and U2OS"	methotrexate (MTX) treatment	downregulated	30518744
6597	Human	hsa-miR-29b	miRNA	oxymatrine	ovarian cancer (OC)	OVCAR-3 ovary cancer cell line	Oxymatrine treatment	upregulated	26099492
6598	Human	hsa-miR-29b	miRNA	high glucose (HG)	oxidative stress	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
6599	Human	hsa-miR-29b	miRNA	corticosteroid	pancreatic cancer (PC)	PC12 cells	corticosterone (CORT) treatment	downregulated	27501468
6600	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	lipopolysaccharide (LPS) treatment	downregulated	30855347
6601	Human	hsa-miR-29b	miRNA	matrine	peritoneal fibrosis	LPS-treated human peritoneal mesothelial cells (HPMCs)	matrine treatment	upregulated	30855347
6602	Human	hsa-miR-29b	miRNA	TGF-¦Â1	cell proliferation	ARPE-19 cells	TGF-¦Â1 treatment	downregulated	25263462
6603	Human	hsa-miR-29b	miRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"miR-29b expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR29b"	31694982
6604	Human	hsa-miR-29b	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	29662889
6605	Human	hsa-miR-29b	miRNA	TGF-¦Â1	pulmonary fibroblasts proliferation	IMR-90	TGF-¦Â1 treatment	downregulated	26410313
6606	Human	hsa-miR-29b	miRNA	infliximab	rheumatoid arthritis (RA)	peripheral blood monocytes (PBMs) from RA patients	infliximab treatment	downregulated	31473844
6607	Human	hsa-miR-29b	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
6608	Human	hsa-miR-29b	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
6609	Human	hsa-miR-29b	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
6610	Human	hsa-miR-29b	miRNA	silica	silicosis	A549 cells	silica treatment	miRNA-29b (miR-29b) was dynamically downregulated by silica	30529807
6611	Human	hsa-miR-29b	miRNA	indoxyl sulfate (IS)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	Indoxyl sulfate (IS) treatment	downregulated	29195902
6612	Human	hsa-miR-29b	miRNA	phosphorus (Pi)	vascular calcification (VC)	vascular smooth muscle cell (VSMC)	phosphorus (Pi) treatment	upregulated	26610870
6613	Human	hsa-miR-29b-1-5p	miRNA	sulforaphane (SFN)	cancer treatment	NCI-60 cells	sulforaphane treatment	downregulated	32429039
6614	Human	hsa-miR-29b-2	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	upregulated	25120778
6615	Human	hsa-miR-29b-2-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (hPASMCs)	hypoxia treatment	hsa_circNFXL1_009 directly sponged hsa-miR-29b-2-5p (miR-29b) and positively regulated the expression of voltage-gated potassium (K+) channel subfamily B member 1 (KCNB1) at the mRNA level.	33614247
6616	Human	hsa-miR-29b-3p	miRNA	walnut	benefits of walnuts	Plasma exosomes	walnuts treatment	upregulated	32979076
6617	Human	hsa-miR-29b-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
6618	Human	hsa-miR-29b-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
6619	Human	hsa-miR-29b-3p	miRNA	platelet lysate (PL)	chondrogenesis	human umbilical cord-derived mesenchymal stem cells (hUCMSCs)	platelet lysate (PL) treatment	PL induced chondrogenic differentiation of hUCMSCs by regulating the H19/miR-29b-3p/SOX9 axis	33058414
6620	Human	hsa-miR-29b-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
6621	Human	hsa-miR-29b-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells; HL-7702 cells	TGF-¦Â1 treatment	Transforming growth factor beta 1 (TGF-¦Â1)-induced hepatic stellate cell (HSC) activation significantly decreased miR-29b-3p expression	32653922
6622	Human	hsa-miR-29b-3p	miRNA	bortezomib	multiple myeloma (MM)	"Human MM cell lines H929, U266"	bortezomib? treatment	"H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis."	30728351
6623	Human	hsa-miR-29b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
6624	Human	hsa-miR-29b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models.	32037864
6625	Human	hsa-miR-29b-3p	miRNA	Bone morphogenetic protein 1 (BMP1)	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	BMP1 treatment	NEAT1 promotes osteogenic differentiation in hBMSCs by regulating miR-29b-3p/BMP1 axis.	30638953
6626	Human	hsa-miR-29b-3p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	A2780 cells; SK-OV-3 cells	Paclitaxel (PTX) treatment	TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells	32189969
6627	Human	hsa-miR-29b-3p	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	Human pancreatic cancer cell lines PANC-1 and BxPC-3	gemcitabine treatment	MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14.	30915884
6628	Human	hsa-miR-29b-3p	miRNA	radiation	prostate cancer	LNCaP cells	radiation treatment	miR-29b-3p expression is increased in response to IR in LNCaP cells	33033519
6629	Human	hsa-miR-29b-3p	miRNA	cigarette smoke extract (CSE)	smoke-induced lung injury (SILI)	A549 cells; H460 cells	cigarette smoke extract (CSE) treatment	upregulated	33523607
6630	Human	hsa-miR-29b-3p	miRNA	Rb3	smoke-induced lung injury (SILI)	A549 cells; H460 cells	Rb3 treatment	downregulated	33523607
6631	Human	hsa-miR-29c	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
6632	Human	hsa-miR-29c	miRNA	glucocorticoid (GC)	apoptosis	human plasmacytoid dendritic cells(pDCs)	Glucocorticoids (GCs) treatment	both of these miRNAs promoted pDC apoptosis by directly targeting Mcl-1 and Bcl-2 in human primary pDCs	23894561
6633	Human	hsa-miR-29c	miRNA	SGI-1027	biliary atresia-related fibrosis	HIBEpiC cells	SGI-1027 treatment	upregulated	30906331
6634	Human	hsa-miR-29c	miRNA	TGF-¦Â1	biliary atresia-related fibrosis	HIBEpiC cells	TGF-¦Â1 treatment	downregulated	30906331
6635	Human	hsa-miR-29c	miRNA	brown seaweed fucoidan	breast cancer	Human Breast Cancer Cells	brown seaweed fucoidan treatment	upregulated	27994679
6636	Human	hsa-miR-29c	miRNA	paclitaxel (PTX)	breast cancer	"The breast cancer cell lines (MDA-MB-231, MCF-7, Hs-578T, and T47D) and the immortalized breast epithelial cell line MCF-10A"	paclitaxel treatment	LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells by upregulating miR-29c	31047896
6637	Human	hsa-miR-29c	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
6638	Human	hsa-miR-29c	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patient cells	ibrutinib treatment	upregulated	28299881
6639	Human	hsa-miR-29c	miRNA	astragaloside IV (AS-IV)	colorectal cancer (CRC)	CRC cell lines (SW620 and HCT116)	astragaloside (AS-IV) treatment	upregulated	29710520
6640	Human	hsa-miR-29c	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec6A cells	Progesterone treatment	upregulated	22543862
6641	Human	hsa-miR-29c	miRNA	celecoxib	gastric cancer (GC)	AGS cells; MKN45 cells	celecoxib treatment	downregulated	23001726
6642	Human	hsa-miR-29c	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
6643	Human	hsa-miR-29c	miRNA	tumor necrosis factor alpha-induced protein 3 (TNFAIP3)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell line (HepG2)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	21763284
6644	Human	hsa-miR-29c	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	Influenza A virus treatment	upregulated	22850539
6645	Human	hsa-miR-29c	miRNA	influenza A virus (IAV)	innate immune response	human CRC cell lines SW620 and RKO	infect with IAVs treatment	upregulated	24953694
6646	Human	hsa-miR-29c	miRNA	"tranilast (N-3,4-dimethoxycinnamoyl anthranilic acid)"	leiomyoma	leiomyoma smooth muscle cells (LSMC) of leiomyoma patients	tranilast treatment	upregulated	28114878
6647	Human	hsa-miR-29c	miRNA	methamphetamine (METH)	locomotor sensitization	mouse nucleus accumbens (NAc) tissues	methamphetamine (METH) treatment	downregulated	30639389
6648	Human	hsa-miR-29c	miRNA	silica	lung function decline	blood	silica treatment	downregulated	29280772
6649	Human	hsa-miR-29c	miRNA	mycoplasma pneumoniae (M. pneumoniae)	mycoplasma pneumoniae pneumonia(MPP)	peripheral blood monouclear cells	Mycoplasma pneumoniae (M. pneumoniae) infection	downregulated	31088519
6650	Human	hsa-miR-29c	miRNA	paclitaxel (PTX)	nasopharyngeal carcinoma (NPC)	"human NPC cell lines, SUNE-1 and C666-1"	Paclitaxel (Taxol) treatment	downregulated	30779921
6651	Human	hsa-miR-29c	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	upregulated	29619741
6652	Human	hsa-miR-29c	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
6653	Human	hsa-miR-29c	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid treatment	downregulated	32143184
6654	Human	hsa-miR-29c	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines, MG-63 and U2OS"	methotrexate (MTX) treatment	downregulated	30518744
6655	Human	hsa-miR-29c	miRNA	palmitic acid (PA)	pancreatic cancer (PC)	human PC cells	palmitic acid (PA) treatment	downregulated	28088520
6656	Human	hsa-miR-29c	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	31732967
6657	Human	hsa-miR-29c	miRNA	TGF-¦Â1	pulmonary fibroblasts proliferation	IMR-90	TGF-¦Â1 treatment	downregulated	26410313
6658	Human	hsa-miR-29c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	triple negative breast cancer (TNBC)	MCF10A cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28160548
6659	Human	hsa-miR-29c	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	human dermal fibroblasts (HDFs)	ultraviolet radiation (UVA) treatment	upregulated	30378537
6660	Human	hsa-miR-29c	miRNA	tranilast	leiomyoma	leiomyoma smooth muscle cells (LSMC)	tranilast treatment	downregulated	28114878
6661	Human	hsa-miR-29c-3p	miRNA	TGF-¦Â2	age-related cataract (ARC)	SRA01/04 cells	TGF-¦Â2 traetment treatment	"miR-29c-3p regulated FOS to repress EMT, cell proliferation and facilitate apoptosis in TGF-¦Â2-treated SRA01/04 cells mediated by KCNQ1OT1"	32534225
6662	Human	hsa-miR-29c-3p	miRNA	sanguinarine	gastric cancer (GC)	BGC-823 cells	sanguinarine treatment	downregulated	31243669
6663	Human	hsa-miR-29c-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
6664	Human	hsa-miR-29c-3p	miRNA	cisplatin (DDP)	medulloblastoma	"Medulloblastoma cell lines D283, Daoy, D425, and D341"	cisplatin treatment	downregulated	31753063
6665	Human	hsa-miR-29c-3p	miRNA	cisplatin (DDP)	medulloblastoma	Daoy; D341	cisplatin (DDP) treatment	downregulated	31753063
6666	Human	hsa-miR-29c-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
6667	Human	hsa-miR-30	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
6668	Human	hsa-miR-30	miRNA	cadmium (Cd)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	cadmium (Cd) treatment	Cd exposure repressed miR-30 levels	33756289
6669	Human	hsa-miR-30	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	crohn disease (CD)	Caco2 and HIEC cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	33436852
6670	Human	hsa-miR-30	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
6671	Human	hsa-miR-30	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	human gastric cell line SNU-5	5-fluorouracil (5-FU) treatment	downregulated	26209295
6672	Human	hsa-miR-30	miRNA	cadmium (Cd)	lung diseases	BEAS-2B cells	cadmium (Cd) treatment	downregulated	30998937
6673	Human	hsa-miR-30	miRNA	high glucose (HG)	podocyte injury	?human podocyte cell	high glucose (HG) treatment	downregulated	33490186
6674	Human	hsa-miR-30	miRNA	lipopolysaccharide (LPS)	podocytopathy	human podocytes	lipopolysaccharide (LPS) treatment	downregulated	24029422
6675	Human	hsa-miR-30	miRNA	puromycin aminonucleoside (PAN)	podocytopathy	human podocytes	PAN treatment	downregulated	24029422
6676	Human	hsa-miR-30	miRNA	TGF-¦Â	podocytopathy	human podocytes	TGF-¦Â treatment	downregulated	24029422
6677	Human	hsa-miR-30	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	downregulated	20110569
6678	Human	hsa-miR-300	miRNA	Shikimic acid (SA)	breast cancer	MCF-7 and T47D cells	Shikimic acid (SA) treatment	upregulated	31048002
6679	Human	hsa-miR-300	miRNA	X-rays	gastric cancer (GC)	human gastric cancer tissue samples	"4 Gy of X-rays (6 MV, 0.8 Gy/min) treatment"	downregulated	24919435
6680	Human	hsa-miR-300	miRNA	ionizing radiation (IR)	lung cancer	human lung cancer cells	ionizing radiation (IR) treatment	upregulated	28895780
6681	Human	hsa-miR-300	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx3 treatment"	downregulated	21572246
6682	Human	hsa-miR-301	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
6683	Human	hsa-miR-301	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human cartilage ATDC5 cells	lipopolysaccharide (LPS) treatment	downregulated	29414810
6684	Human	hsa-miR-301	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
6685	Human	hsa-miR-301	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	Capan-2 and Panc-1	Gemcitabine (GEM) treatment	gemcitabine-resistant cells (Capan-2 and Panc-1) exhibited upregulated miR-301 expression and downregulated gemcitabine-induced apoptosis.	30628651
6686	Human	hsa-miR-301	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
6687	Human	hsa-miR-301	miRNA	luteolin	prostate cancer	PC3 and LNCaP cells	luteolin treatment	downregulated	27307749
6688	Human	hsa-miR-301a	miRNA	plasminogen activator inhibitor-1 (PAI-1)	apoptosis	human pulmonary endothelial cells	PAI-1 (plasminogen activator inhibitor-1) ? treatment	downregulated	21175428
6689	Human	hsa-miR-301a	miRNA	arsenite	arsenite-induced carcinogenesis	BEAS-2B cells	arsenic (As) exposure	upregulated	30185897
6690	Human	hsa-miR-301a	miRNA	astragaloside IV (AS-IV)	gastric cancer (GC)	gastric cancer-associated fibroblast (GCAF)	astragaloside (AS-IV) treatment	downregulated	29358859
6691	Human	hsa-miR-301a	miRNA	triptolide (TPL)	gastric cancer (GC)	gastric cancer-associated fibroblasts (GCAFs)	triptolide (TPL) treatment	downregulated miR-301a expression and upregulated miR-149	29049979
6692	Human	hsa-miR-301a	miRNA	placenta growth factor (PlGF)	lung fibrosis	endothelial cells	placenta growth factor (PlGF) treatment	downregulated	26460070
6693	Human	hsa-miR-301a	miRNA	hypoxia	pancreatic cancer (PC)	PaCa-2 and BxPC-3 cells	hypoxia induce	upregulated	29772221
6694	Human	hsa-miR-301a	miRNA	hypoxia	prostate cancer	Caco2-BBE cells	hypoxia treatment	upregulated	26813459
6695	Human	hsa-miR-301a	miRNA	TGF-¦Â	lung fibrosis	HFL1 cells	TGF-¦Â treatment	upregulated	32788629
6696	Human	hsa-miR-301a	miRNA	Japanese encephalitis virus (JEV)	viral-induced neuroinflammation	The human cell line of fetal microglial origin CHME3 and human brains	Japanese encephalitis virus (JEV) infection	upregulated	31527198
6697	Human	hsa-miR-301a-3p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29901102
6698	Human	hsa-miR-301a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-301a-3p expression is highly expressed in ox-LDL-induced HUVECs.	33850541
6699	Human	hsa-miR-301a-3p	miRNA	¦Â-elemene	non-small cell lung cancer (NSCLC)	A549 cells	¦Â-elemene treatment	¦Â-elemene suppressed the expression of miR-301a-3p	32463461
6700	Human	hsa-miR-301a-3p	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells and cell-derived exosomes	hypoxia induce	upregulated	29880482
6701	Human	hsa-miR-301b	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
6702	Human	hsa-miR-301b	miRNA	caffeine	inflammatory response	MLE-12 and MH-S cells	caffeine treatment	downregulated	27670114
6703	Human	hsa-miR-301b	miRNA	pseudomonas aeruginosa (PA)	inflammatory response	MLE-12 and MH-S cells	Pseudomonas aeruginosa treatment	upregulated	27670114
6704	Human	hsa-miR-301b	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
6705	Human	hsa-miR-301b	miRNA	isoliquiritigenin	melanoma	"Human melanoma cell line(A375, A2058)"	Isoliquiritigenin (ISL) treatment	downregulated	30081934
6706	Human	hsa-miR-301b	miRNA	hypoxia	prostate cancer	Caco2-BBE cells	hypoxia treatment	upregulated	26813459
6707	Human	hsa-miR-301b-3p	miRNA	hypoxia	prostate cancer	"Human prostate cancer cell lines (DU145, PC-3, LNCaP and IA8)"	hypoxia induce	upregulated	31442444
6708	Human	hsa-miR-302	miRNA	pulsatile shear stress	cerebral ischemia injury (CII)	SH-SY5Y cells	pulsatile shear stress?treatment treatment	downregulated	31096001
6709	Human	hsa-miR-302	miRNA	enterovirus 71 (EV71)	innate immune response	THP-1¨Cderived macrophages	Enterovirus 71 (EV71) infection	downregulated	29777028
6710	Human	hsa-miR-302	miRNA	zoledronic acid (ZA)	osteoporosis	serum	ZOL treatment	"?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment"	33637048
6711	Human	hsa-miR-302	miRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin treatment	miR-302 is downregulated in cisplatin-resistant ovarian cancer cells and involved in chemosensitivity.	32835657
6712	Human	hsa-miR-302	miRNA	sodium butyrate (NaB)	somatic cell reprogramming	human foreskin fibroblasts (HFFs)	NaB treatment	upregulated	24568633
6713	Human	hsa-miR-302a	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19 cells	H2O2 treatment	downregulated	31784665
6714	Human	hsa-miR-302a	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6715	Human	hsa-miR-302a	miRNA	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep)	gastric cancer (GC)	gastric and liver cancer cells	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) treatment	upregulated	24861464
6716	Human	hsa-miR-302a	miRNA	radiation	non-small cell lung cancer (NSCLC)	NCI-H1299 ; NCI-H1299R cells	radiation treatment	downregulated	31928130
6717	Human	hsa-miR-302a	miRNA	rapamycin	reperfusion injury in diabetic heart	human-pluripotent-stem-cells-derived cardiomyocytes (HG-hiPSC-CMs)	rapamycin (RAPA) treatment	Rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling	33319180
6718	Human	hsa-miR-302a-3p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	downregulated	25526515
6719	Human	hsa-miR-302a-3p	miRNA	brahma (BRM)	pancreatic cancer (PC)	BxPC-3 and T3M4 cells	brahma (BRM) dificiency	"silencing BRM reduced PC cell migration and invasion both in vivo and in vitro, accompanied by reduced level of miR-302a-3p."	30790683
6720	Human	hsa-miR-302a-3p	miRNA	cisplatin (DDP)	testicular germ cell tumors (TGCTs)	TGCT cell lines NT2-D1 and 833?K	cisplatin treatment	downregulated	31235829
6721	Human	hsa-miR-302b	miRNA	fentanyl	esophageal squamous cell carcinoma (ESCC)	ESCC Eca109 and TE1 cell lines	Fentanyl treatment	upregulated	29928433
6722	Human	hsa-miR-302b	miRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 MG cells	all-trans retinoic acid (ATRA) treatment	upregulated	25040912
6723	Human	hsa-miR-302b	miRNA	monosodium urate (MSU)	gouty arthritis	THP-1 cells	monosodium urate (MSU) crystal treatment	upregulated	29482609
6724	Human	hsa-miR-302b	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	Human OA chondrocytes (C28/12 cell line)	lipopolysaccharide (LPS) treatment	upregulated	29414803
6725	Human	hsa-miR-302b	miRNA	epirubicin	osteosarcoma (OS)	osteosarcoma MG-63cells; SAOS-2 cells; hFOB119 cells	Epirubicin treatment	"miR-302b, which is stably low-expressed in osteosarcoma, could be induced by the epirubicin"	23845851
6726	Human	hsa-miR-302b	miRNA	tetramethylpyrazine (TMP)	Periodontitis	human periodontal ligament stem cells (hPDLSCs)	tetramethylpyrazine (TMP) treatment	TMP downregulated microRNA (miR)-302b levels in LPS-stimulated cells.	32236610
6727	Human	hsa-miR-302b	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	cisplatin (DDP) treatment	miR-302b was significantly downregulated in UUO mouse kidney tissue and TGF-¦Â1-treated HK-2 cells	33503202
6728	Human	hsa-miR-302b	miRNA	ethanol (EtOH)	neuronal cell death	SH-SY5Y cells	ethanol treatment	upregulated	21878650
6729	Human	hsa-miR-302b*	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
6730	Human	hsa-miR-302b-3p	miRNA	cisplatin (DDP)	testicular germ cell tumors (TGCTs)	TGCT cell lines NT2-D1 and 833?K	cisplatin treatment	downregulated	31235829
6731	Human	hsa-miR-302c	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6732	Human	hsa-miR-302c	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	particulate matter (PM)treatment treatment	upregulated	24515752
6733	Human	hsa-miR-302c	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	PM-ed A549 pulmonary cell lines in v treatment	upregulated	24515752
6734	Human	hsa-miR-302c	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
6735	Human	hsa-miR-302c	miRNA	IL-8	gastric cancer (GC)	"Human gastric cancer cell lines, HGC-27, MGC80-3, AGS, NCI-N87, SGC-7901, and BGC-823"	IL8 expression	downregulated	26199092
6736	Human	hsa-miR-302c	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251MG-TMZ cells and LN229-TMZ cells	temozolomide (TMZ) treatment	downregulated	31409725
6737	Human	hsa-miR-302c	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
6738	Human	hsa-miR-302c	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	Human lung epithelial cells A549	influenza A virus (IAV) treatment	downregulated	26602079
6739	Human	hsa-miR-302c	miRNA	TGF-¦Â	liver fibrosis	LX-2 cells; primary hepatic stellate cells (HSCs)	TGF-¦Â treatment	Induction of E6AP by microRNA-302c dysregulation inhibits TGF-¦Â-dependent fibrogenesis in hepatic stellate cells	33037648
6740	Human	hsa-miR-302c	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	lung fibrosis	Kasumi-1 cells; K562 cells;MCF7 cells; MDA-MB-231 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	23820258
6741	Human	hsa-miR-302c	miRNA	TGF-¦Â1	mesothelial/epithelial-mesenchymal transition (MMT/EMT)	human peritoneal mesothelial cell line (HMrSV5)	TGF-¦Â1 treatment	downregulated	30693641
6742	Human	hsa-miR-302c	miRNA	proline-rich polypeptide 1 (PRP-1)	metastatic chondrosarcoma	human chondrosarcoma JJ012 cell line	"proline-rich polypeptide 1, (PRP-1) treatment"	downregulated	26094604
6743	Human	hsa-miR-302c-3p	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	HepG2©\hNTCP©\C4 cells	hepatitis B virus (HBV) infection	miR-302c-3p suppresses HBV replication and HBsAg production	30828831
6744	Human	hsa-miR-302c-3p	miRNA	cisplatin (DDP)	testicular germ cell tumors (TGCTs)	TGCT cell lines NT2-D1 and 833?K	cisplatin treatment	downregulated	31235829
6745	Human	hsa-miR-302e	miRNA	phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA)	allergic inflammation	HMC-1 cells	phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA) treatment	miR-302e was significantly decreased in response to phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA) stimulation	29748238
6746	Human	hsa-miR-302e	miRNA	sevoflurane (SEV)	neurotoxicity	human hippocampal cells (HN-h)	sevoflurane treatment	upregulated	30221705
6747	Human	hsa-miR-302f	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
6748	Human	hsa-miR-302f	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
6749	Human	hsa-miR-30-5p	miRNA	ethanol extract of antrodia cinnamomea (AC)	breast cancer	MCF-7 and tamoxifen-resistant MCF-7 cells	ethanol extract of antrodia cinnamomea (AC) treatment	upregulated	29743060
6750	Human	hsa-miR-30-5p	miRNA	candida albicans (C. albicans)	inflammatory response	THP-1 cells	candida albicans infection	upregulated	28454101
6751	Human	hsa-miR-3065-5p	miRNA	antrodia cinnamomea	cancer treatment	"THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68"	antrodia cinnamomea treatment	downregulated	28602756
6752	Human	hsa-miR-30a	miRNA	hypoxia	acute myocardial infarction (AMI)	Blood samples	hypoxia treatment	upregulated	26857375
6753	Human	hsa-miR-30a	miRNA	low-frequency electromagnetic fields (LF-EMF)	Alzheimer's disease (AD)	human neuroblastoma SH-SY5Y cells	low-frequency electromagnetic fields (LF-EMF) treatment	downregulated	24676932
6754	Human	hsa-miR-30a	miRNA	hepatitis B virus X protein (HBx)	autophagosome formation	liver	hepatitis B virus X protein treatment	"HBx induces autophagosome formation via beclin-1 expression, whereas miRNA-30a overexpression could successfully inhibit the beclin-1 expression induced by HBx, thereby modulating autophagosome formation in hepatic cells."	25620738
6755	Human	hsa-miR-30a	miRNA	cisplatin (DDP)	autophagy	HeLa cells£» MCF-7 cells£» HepG2 cells	cis-dichloro-diamine platinum (cis-DDP) treatment	upregulated	22157765
6756	Human	hsa-miR-30a	miRNA	taxol	autophagy	HeLa cells£» MCF-7 cells£» HepG2 cells	taxol treatment	upregulated	22157765
6757	Human	hsa-miR-30a	miRNA	BAY11-7082	bladder cancer	HTB-1 and T24 cells	The addition of BAY11-7082 into the tumor-associated macrophages (TAMs)/HTB-1 or T24 co-culture system	downregulated	31002892
6758	Human	hsa-miR-30a	miRNA	androgen	breast cancer	MDA-MB-453 breast cancer cells	androgen treatment	downregulated	29085503
6759	Human	hsa-miR-30a	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	peripheral blood mononuclear cells	Imatinib Mesylate treatment	miR-30a was over expressed and Beclin 1 was under expressed in imatinib responders compared to resistant cases.	31945609
6760	Human	hsa-miR-30a	miRNA	imatinib	chronic myeloid leukemia (CML)	?human chronic myeloid leukemia cells	?imatinib? treatment	upregulated	22395361
6761	Human	hsa-miR-30a	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC-7901 cells	cisplatin (DPP) treatment		29375703
6762	Human	hsa-miR-30a	miRNA	norcantharidin (NCTD)	giant cell tumor of bone (GCTB)	GCTB stromal tumor cells	norcantharidin (NCTD) treatment	Expression of miR-30a was significantly upregulated by NCTD treatment.	29710674
6763	Human	hsa-miR-30a	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	TMZ led to a significant reduction in miR-30a levels in a dose-dependent manner in U251 cells	29805498
6764	Human	hsa-miR-30a	miRNA	alcohol	head and neck squamous cell carcinoma (HNSCC)	normal oral keratinocytes	alcohol exposure	upregulated	26472042
6765	Human	hsa-miR-30a	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
6766	Human	hsa-miR-30a	miRNA	TGF-¦Â1	liver fibrosis	HSCs and LX-2 exosomes	TGF-¦Â1 treatment	downregulated in exosomes	28766848
6767	Human	hsa-miR-30a	miRNA	mycobacterium tuberculosis (Mtb)	mycobacterium tuberculosis (Mtb) infection	THP-1 human monocytes cells during infection	infect with MTB H37Rv	upregulated	28912881
6768	Human	hsa-miR-30a	miRNA	carbon disulfide (CS2)	nerve system injury	workers	experienced injury to nerve system from carbon disulfide (CS2) treatment	upregulated	25224332
6769	Human	hsa-miR-30a	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 and NCI-H292 cells	low-dose radiation (50 mGy) exposure	upregulated	30424954
6770	Human	hsa-miR-30a	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 cells	low-dose radiation (LDR) radiation	upregulated	30424954
6771	Human	hsa-miR-30a	miRNA	IL-1¦Â	osteoarthritis (OA)	human osteoarthritis	human osteoarthritis treatment	downregulated	27067395
6772	Human	hsa-miR-30a	miRNA	beclin-1	osteosarcoma (OS)	human osteosarcoma MG-63 cell	Beclin-1 treatment	downregulated	26708607
6773	Human	hsa-miR-30a	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	oxidative stress	human lung carcinoma cell line (A549)	NPs treatment	downregulated	28400205
6774	Human	hsa-miR-30a	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	The human lens epithelial cell line SRA01/04 and HLE B-3 cells	TGF-¦Â2 treatment	downregulated	31049834
6775	Human	hsa-miR-30a	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
6776	Human	hsa-miR-30a	miRNA	hypoxia	prostate cancer	DU145 and LNCaP cells	hypoxia treatment	downregulated	27160121
6777	Human	hsa-miR-30a	miRNA	metformin (Met)	prostate cancer	Vcap and PC-3 cells	metformin treatment	downregulated	25201727
6778	Human	hsa-miR-30a	miRNA	TGF-¦Â	renal fibrosis	"human HK2, HEK293 cells"	TGF¦Â treatment	downregulated	28285987
6779	Human	hsa-miR-30a	miRNA	dexamethasone (DEX)	steatosis	HepG2 cells	dexamethasone (Dex) treatment	downregulated	29409992
6780	Human	hsa-miR-30a-3p	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
6781	Human	hsa-miR-30a-3p	miRNA	metformin (Met)	anti-cancer therapy	CD8 + T cells	Metformin treatment	downregulated	32221038
6782	Human	hsa-miR-30a-3p	miRNA	recombinant early secreted antigenic target 6 (rESAT-6)	autophagy	Calcimycin-treated dTHP-1 cells	recombinant early secreted antigenic target 6 (rESAT-6) treatment	upregulated	31181223
6783	Human	hsa-miR-30a-3p	miRNA	TGF-¦Â	angiogenesis 	Human umbilical vein endothelial cells	TGF-¦Â treatment	downregulated	23960241
6784	Human	hsa-miR-30a-3p	miRNA	IFN-¦Ã	systemic sclerosis (SSc)	arthritis fibroblasts;SSc HDF	IFN-¦Ã treatment	downregulated	25360821
6785	Human	hsa-miR-30a-5p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
6786	Human	hsa-miR-30a-5p	miRNA	recombinant early secreted antigenic target 6 (rESAT-6)	autophagy	Calcimycin-treated dTHP-1 cells	recombinant early secreted antigenic target 6 (rESAT-6) treatment	downregulated	31181223
6787	Human	hsa-miR-30a-5p	miRNA	paclitaxel (PTX)	tumorigenesis	NCI60 cancer cell line£¬Ovarian cancer (OVCA) cell lines and Human stem cell lines (H9)	paclitaxel treatment	miR-367 upregulated and miR-30a-5p downregulated	24220856
6788	Human	hsa-miR-30a-5p	miRNA	curcumol	colorectal cancer (CRC)	HCT116 cells	curcumol treatment	Curcumol treatment was identified to increase miR-30a-5p expression	33732375
6789	Human	hsa-miR-30a-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
6790	Human	hsa-miR-30a-5p	miRNA	steroids	focal segmental glomerulosclerosis (FSGS)	urine	steroid treatment	downregulated	25107948
6791	Human	hsa-miR-30a-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
6792	Human	hsa-miR-30a-5p	miRNA	respiratory syncytial virus (RSV)	innate immune response	human dendritic cells	respiratory syncytial virus (RSV) infection treatment	upregulated	29970194
6793	Human	hsa-miR-30a-5p	miRNA	deoxycholic acid (DCA)	intestinal metaplasia	GES-1 cells	deoxycholic acid treatment	deoxycholic acid-induced macrophage-derived exosomes (D-Exos) may promote intestinal metaplasia and suppress proliferation of GES-1 cells via hsa-miR-30a-5p targeting FOXD1.	32950501
6794	Human	hsa-miR-30a-5p	miRNA	trichostatin A (TSA)	keloids	cultured keloid fibroblasts	Trichostatin A (TSA) treatment	downregulated	31059100
6795	Human	hsa-miR-30a-5p	miRNA	lithium (Li) and valproic acid (VPA)	neurodegeneration (ND)	human neuroblastoma cell line (SH-SY5Y)	L-glutamate and Li-VPA treatment	both L-glutamate and Li-VPA caused an increase in miR-30a-5p expression at 24 h of incubation and a downregulated at 48 h	25149854
6796	Human	hsa-miR-30a-5p	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SK-N-SH cells	PFOS treatment	upregulated	28441774
6797	Human	hsa-miR-30a-5p	miRNA	IL-6 and TNF-¦Á	osteoarthritis (OA)	chondrocytes	IL-6 and TNF-¦Á treatment	LINC00461 may modulate the development of OA by suppressing miR-30a-5p expression in chondrocytes.	32155130
6798	Human	hsa-miR-30a-5p	miRNA	L-dopa	parkinson's disease (PD)	Plasma and White Blood Cells	L-dopa-treated treatment	upregulated	28540642
6799	Human	hsa-miR-30a-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (HPAECs)	hypoxia induce	downregulated	31115541
6800	Human	hsa-miR-30a-5p	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
6801	Human	hsa-miR-30b	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	29635893
6802	Human	hsa-miR-30b	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
6803	Human	hsa-miR-30b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6804	Human	hsa-miR-30b	miRNA	androgen	breast cancer	MDA-MB-453 breast cancer cells	androgen treatment	downregulated	29085503
6805	Human	hsa-miR-30b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
6806	Human	hsa-miR-30b	miRNA	kynurenine	breast cancer	95D cells	Kynurenine (Kyn) treatment	downregulated	31093946
6807	Human	hsa-miR-30b	miRNA	trastuzumab	breast cancer	HER2-positive (SKBR3£» BT474)£» HER2-negetive (MCF7£» MDA-MB-231) cells	Trastuzumab treatment	upregulated	22384020
6808	Human	hsa-miR-30b	miRNA	trastuzumab	breast cancer	BT474 wt cells	trastuzumab treatment	upregulated	28120942
6809	Human	hsa-miR-30b	miRNA	vascular endothelial growth factor (VEGF)	capillary morphogenesis	human umbilical vein endothelial cells (HUVECs)	VEGF treatment	downregulated	28977001
6810	Human	hsa-miR-30b	miRNA	homocysteine (Hcy)	cardiovascular disease (CVD)	HCAECs	Homocysteine (Hcy) treatment	downregulated	26263983
6811	Human	hsa-miR-30b	miRNA	¦Ã-rays	cell senescence	CD34+ cells	¦Ã-radiation treatment	upregulated	23144934
6812	Human	hsa-miR-30b	miRNA	cisplatin (DDP)	gastric cancer (GC)	"The human GC cell line AGS,;HGC-27 cells"	cisplatin treatment	downregulated	30365113
6813	Human	hsa-miR-30b	miRNA	bone morphogenetic protein 2 (BMP2)	hepatocellular carcinoma (HCC)	vascular smooth muscle cell (VSMC)	bone morphogenetic protein 2 (BMP2) treatment	BMP-2 downregulates miR-30b and miR-30c to increase Runx2 expression in CASMCs and promote mineralization	23316327
6814	Human	hsa-miR-30b	miRNA	tanshinone IIA (Tan IIA)	hepatocellular carcinoma (HCC)	HepG2 cell	Tanshinone IIA treatment	downregulated	27894814
6815	Human	hsa-miR-30b	miRNA	tanshinone IIA (Tan IIA)	hepatocellular carcinoma (HCC)	HepG2 cells	Tanshinone IIA treatment	downregulated	27894814
6816	Human	hsa-miR-30b	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-30b was upregulated in propofol-treated group	24454982
6817	Human	hsa-miR-30b	miRNA	hypoxia	hypoxic-ischemic encephalopathy (HIE)	Human brain microvascular endothelial cells (HBMECs)	hypoxia treatment	"In hypoxia-induced HBMECs, the mRNA and protein expression levels of PAI-1 were significantly upregulated, while the miR-30b expression level was significantly downregulated."	33360521
6818	Human	hsa-miR-30b	miRNA	Ig-like transcript 3 (ILT3)	immune inflammatory	human CD8(+) T suppressor cells	Ig-like transcript 3 (ILT3) treatment	upregulated	22387553
6819	Human	hsa-miR-30b	miRNA	L-kynurenine (L-Kyn)	immune response	BCL-1 cells	L-kynurenine (L-Kyn) treatment	downregulated	26590946
6820	Human	hsa-miR-30b	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
6821	Human	hsa-miR-30b	miRNA	kynurenine	lung cancer	95D cells	50 ¦ÌM Kyn	downregulated	28905195
6822	Human	hsa-miR-30b	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
6823	Human	hsa-miR-30b	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	compound C treatment	downregulated	32143184
6824	Human	hsa-miR-30b	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
6825	Human	hsa-miR-30b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid treatment	downregulated	32143184
6826	Human	hsa-miR-30b	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 and NCI-H292 cells	low-dose radiation (50 mGy) exposure	upregulated	30424954
6827	Human	hsa-miR-30b	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 cells	low-dose radiation (LDR) radiation	upregulated	30424954
6828	Human	hsa-miR-30b	miRNA	TGF-¦Â1	ovarian cancer (OC)	SKOV3 and 3AO cells	TGF-¦Â1 treatment	downregulated	26501435
6829	Human	hsa-miR-30b	miRNA	perioglas (PG) and P-15	bone formation	osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	upregulated	17653614
6830	Human	hsa-miR-30b	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HAVSMC)	inorganic phosphate (Pi) treatment	downregulated	27419135
6831	Human	hsa-miR-30b*	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
6832	Human	hsa-miR-30b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	AC16 cells	angiotensin II (Ang II) treatment	upregulated	33130312
6833	Human	hsa-miR-30b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	human AC-16 cell lines	angiotensin II (Ang II) treatment	downregulated	33130312
6834	Human	hsa-miR-30b-3p	miRNA	ebola virus (EBOV)	Ebola virus (EBOV) therapy	293T cells	EBOV treatment	downregulated	29209594
6835	Human	hsa-miR-30b-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	Glioma stem-like cells (GSCs)	hypoxia treatment	The miRNA profiling revealed that miR-30b-3p was significantly upregulated in the EVs from hypoxic GSCs.	33408780
6836	Human	hsa-miR-30b-3p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
6837	Human	hsa-miR-30b-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cell line HAEC cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33812169
6838	Human	hsa-miR-30b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	renal tissues	high glucose (HG) treatment	"In high glucose induced HK-2 cells, expression levels of miR-30b-5p and E-cadherin were decreased, while SNAI1, a-SMA and Vimentin were increased."	33383483
6839	Human	hsa-miR-30b-5p	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
6840	Human	hsa-miR-30b-5p	miRNA	hypoxia	hypoxia-induced injury	AC16 human cardiomyocytes	hypoxia induce	upregulated	31768184
6841	Human	hsa-miR-30b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
6842	Human	hsa-miR-30b-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	33817304
6843	Human	hsa-miR-30b-5p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
6844	Human	hsa-miR-30c	miRNA	hypoxia	acute myeloid leukemia (AML)	human renal cell carcinoma	Hypoxia treatment	downregulated	24112779
6845	Human	hsa-miR-30c	miRNA	plasminogen activator inhibitor-1 (PAI-1)	apoptosis	human pulmonary endothelial cells	PAI-1 (plasminogen activator inhibitor-1) ? treatment	downregulated	21175428
6846	Human	hsa-miR-30c	miRNA	adriamycin (ADR)	breast cancer	"MCF-10A, MCF-7, and ZR-75-1 cells"	adriamycin (ADR) treatment	upregulated	31511498
6847	Human	hsa-miR-30c	miRNA	androgen	breast cancer	MDA-MB-453 breast cancer cells	androgen treatment	downregulated	29085503
6848	Human	hsa-miR-30c	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
6849	Human	hsa-miR-30c	miRNA	¦Ã-rays	cell senescence	CD34+ cells	¦Ã-radiation treatment	upregulated	23144934
6850	Human	hsa-miR-30c	miRNA	¦Ã-rays	cell senescence	human fetal osteoblast cell line (hFOB)	¦Ã-radiation treatment	downregulated	23144934
6851	Human	hsa-miR-30c	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
6852	Human	hsa-miR-30c	miRNA	coffee	colorectal cancer (CRC)	Caco-2 human colon carcinoma cells	coffee treatment	upregulated	28693281
6853	Human	hsa-miR-30c	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	intestinal epithelial cells T84 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	24148619
6854	Human	hsa-miR-30c	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	T84 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	32583714
6855	Human	hsa-miR-30c	miRNA	estradiol-17¦Â (E2)	endometrial cancer (EC)	ER-positive Ishikawa and ER-negative HEC-1-B cells	estradiol-17¦Â (E2) treatment	downregulated	24595016
6856	Human	hsa-miR-30c	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
6857	Human	hsa-miR-30c	miRNA	bone morphogenetic protein 2 (BMP2)	hepatocellular carcinoma (HCC)	vascular smooth muscle cell (VSMC)	bone morphogenetic protein 2 (BMP2) treatment	BMP-2 downregulates miR-30b and miR-30c to increase Runx2 expression in CASMCs and promote mineralization	23316327
6858	Human	hsa-miR-30c	miRNA	hepatitis C virus (HCV) core protein	hepatocellular carcinoma (HCC)	"human hepatoblastoma cell line, HepG2"	Hepatitis C virus (HCV) Core protein treatment	downregulated	26210453
6859	Human	hsa-miR-30c	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	downregulated	28213977
6860	Human	hsa-miR-30c	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	downregulated	28213977
6861	Human	hsa-miR-30c	miRNA	pravastatin	lipid homeostasis	subjects recruited from a lipid clinic	pravastatin for 1year treatment	upregulated	28062296
6862	Human	hsa-miR-30c	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
6863	Human	hsa-miR-30c	miRNA	cisplatin (DDP)	nephrotoxicity	HK-2 and NRK-52E cells	cisplatin treatment	downregulated	28796263
6864	Human	hsa-miR-30c	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
6865	Human	hsa-miR-30c	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	palmitic acid treatment	downregulated	32143184
6866	Human	hsa-miR-30c	miRNA	bevacizumab	non-small cell lung cancer (NSCLC)	Serum	bevacizumab treatment	Serum miR-30c level is elevated during bevacizumab chemotherapy.	29737469
6867	Human	hsa-miR-30c	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	Paclitaxel-resistant NSCLC cell lines of A549 and H460	curcumin treatment	upregulated	28443468
6868	Human	hsa-miR-30c	miRNA	TGF-¦Â1	ovarian cancer (OC)	SKOV3 and 3AO cells	TGF-¦Â1 treatment	downregulated	26501435
6869	Human	hsa-miR-30c	miRNA	NaSH	spinal cord ischemia/reperfusion injury (SCII)	SH5Y-SY cells	NaSH treatment	NaSH preprocessing upregulated CasC7 and downregulated miR-30c in OGD/R-induced SH5Y-SY cells.	29571256
6870	Human	hsa-miR-30c-1-3p	miRNA	benzo(a)pyrene (BaP)	lung fibrosis	BEAS-2B cells	benzo(a)pyrene (BaP) exposure	downregulated	30543962
6871	Human	hsa-miR-30c-1-3p	miRNA	benzo(a)pyrene (BaP)	lung fibrosis	BEAS-2B cells	benzo(a)pyrene (BaP) exposure	downregulated	30543962
6872	Human	hsa-miR-30c-1-3p	miRNA	sulfur dioxide (SO2)	lung fibrosis	BEAS-2B cells	SO2 treatment	downregulated	30543962
6873	Human	hsa-miR-30c-1-3p	miRNA	sulfur dioxide (SO2)	lung fibrosis	BEAS-2B cells	sulfur dioxide (SO2)?exposure treatment	downregulated	30543962
6874	Human	hsa-miR-30c-2*	miRNA	epidermal growth factor (EGF)	tumorigenesis	OVCAR-3;SKOV-3;A549 cells	The epidermal growth factor treatment	upregulated	22024689
6875	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophage line	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29016810
6876	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30119891
6877	Human	hsa-miR-30c-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	MiR-30c-5p was downregulated and JAK1 was upregulated in renal fibrosis tissue and HG stimulated HK2 cells.	32096183
6878	Human	hsa-miR-30c-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"Compared with the controls, DN tissues and high glucose-induced HK-2 cells had significantly reduced miR-30c-5p levels."	33817282
6879	Human	hsa-miR-30c-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	downregulated	31198949
6880	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	"Silence of LINC00657 repressed ox-LDL-induced injury via inhibiting EndMT, inflammatory response, and apoptosis in HUVEC cells by regulating miR-30c-5p/Wnt7b/¦Â-catenin."	32577947
6881	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	"PTEN was a target of miR-30c-5p, and its interference led to great inhibition of cell apoptosis and inflammatory response induced by ox-LDL in HUVEC, while this effect was attenuated by miR-30c-5p deficiency or XIST overexpression."	31539155
6882	Human	hsa-miR-30c-5p	miRNA	sodium oxalate	kidney stone disease	HK-2 cells	sodium oxalate treatment	downregulated	31894301
6883	Human	hsa-miR-30c-5p	miRNA	sodium oxalate	sodium oxalate-induced kidney stones	HK-2 cells	sodium oxalate treatment	miR-30c-5p expression was significantly downregulated by exposure to 750 ?M sodium oxalate.	31894301
6884	Human	hsa-miR-30d	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6885	Human	hsa-miR-30d	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
6886	Human	hsa-miR-30d	miRNA	¦Ã-rays	cell senescence	CD34+ cells	¦Ã-radiation treatment	upregulated	23144934
6887	Human	hsa-miR-30d	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL"	23725219
6888	Human	hsa-miR-30d	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL"	23725219
6889	Human	hsa-miR-30d	miRNA	hypoxia	colorectal cancer (CRC)	"CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)"	1 and 0.2% oxygen	upregulated	28207045
6890	Human	hsa-miR-30d	miRNA	lipopolysaccharide (LPS)	epithelial-mesenchymal transition (EMT)	hippocampus	lipopolysaccharide (LPS) treatment	The treatment of HBMECs with Meth or LPS significantly increased the circHECW2 expression in HBMECs.	29260931
6891	Human	hsa-miR-30d	miRNA	methamphetamine (METH)	epithelial-mesenchymal transition (EMT)	primary human brain microvascular endothelial cells (HBMECs)	methamphetamine (Meth) treatment	miR-30d was significantly downregulated	29260931
6892	Human	hsa-miR-30d	miRNA	methamphetamine (METH)	epithelial-mesenchymal transition (EMT)	primary human brain microvascular endothelial cells (HBMECs)	methamphetamine (Meth) treatment	The treatment of HBMECs with Meth or LPS significantly increased the circHECW2 expression in HBMECs.	29260931
6893	Human	hsa-miR-30d	miRNA	ricolinostat (ACY-1215)	esophageal squamous cell carcinoma (ESCC)	"The human cell lines EC109, KYSE150, TE-1, TE-13"	Ricolinostat (ACY-1215) treatment	upregulated	30050135
6894	Human	hsa-miR-30d	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Li-7 cells; Hep3B cells; HepG2 cells; Huh7 cells	sorafenib (SOR) treatment	upregulated	32724415
6895	Human	hsa-miR-30d	miRNA	methylmercury (MeHg)	neurotoxicity	human neural progenitor cells (ihNPCs)	methylmercury (MeHg) treatment	downregulated	27941687
6896	Human	hsa-miR-30d	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx5 treatment"	downregulated	21572246
6897	Human	hsa-miR-30d	miRNA	TGF-¦Â1	ovarian cancer (OC)	SKOV3 and 3AO cells	TGF-¦Â1 treatment	downregulated	26501435
6898	Human	hsa-miR-30d	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	downregulated	18573151
6899	Human	hsa-miR-30d	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
6900	Human	hsa-miR-30d	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	human AGS cells and GES-1 cells	Helicobacter pylori (H. pylori) infection	upregulated	27099441
6901	Human	hsa-miR-30d-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
6902	Human	hsa-miR-30d-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
6903	Human	hsa-miR-30d-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
6904	Human	hsa-miR-30e	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-30e was downregulated in resistant patients when compared with sensitive patients	33072545
6905	Human	hsa-miR-30e	miRNA	propofol (PPF)	gastric cancer (GC)	SGC7901/CDDP	propofol treatment	lncRNA MALAT1/miR-30e/ATG5 mediated autophagy-related chemoresistance in GC	32302291
6906	Human	hsa-miR-30e	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 cells	hepatitis C virus (HCV) infection	downregulated	31334444
6907	Human	hsa-miR-30e	miRNA	IFN-¦Á	immune tolerance of maternal-fetal interface	peripheral blood NK cells (PB-NK cells) and decidua NK cells (D-NK cells)	IFN-¦Á treatment	downregulated	30551399
6908	Human	hsa-miR-30e	miRNA	mycobacterium tuberculosis (Mtb)	mycobacterium tuberculosis (Mtb) infection	THP-1 human monocytes cells during infection	infect with MTB H37Rv	upregulated	28912881
6909	Human	hsa-miR-30e	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
6910	Human	hsa-miR-30e	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
6911	Human	hsa-miR-30e	miRNA	schisandrin B (Sch B)	tubulointerstitial fibrosis (TIF)	TGF-¦Â1-treated HK-2 cells	Schisandrin B (Sch B) treatment	upregulated	31697999
6912	Human	hsa-miR-30e	miRNA	TGF-¦Â1	tubulointerstitial fibrosis (TIF)	HK-2 cells	TGF-¦Â1 treatment	downregulated	31697999
6913	Human	hsa-miR-30e	miRNA	dexamethasone (DEX)	intestinal cell differentiation	?IEC-6 cells	dexamethasone (DEX) treatment	upregulated	20372961
6914	Human	hsa-miR-30e*	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	human monocyte cell line U937	DENV infection	upregulated	25122182
6915	Human	hsa-miR-30e*	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
6916	Human	hsa-miR-30e-3p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
6917	Human	hsa-miR-30e-5p	miRNA	hypoxia	coronary microembolization	human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)	hypoxia induce	downregulated	31182924
6918	Human	hsa-miR-30e-5p	miRNA	demethoxycurcumin	glioblastoma multiforme (GBM)	LN-229 and A172 cells	demethoxycurcumin treatment	upregulated	30305611
6919	Human	hsa-miR-30e-5p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
6920	Human	hsa-miR-30e-5p	miRNA	dapagliflozin	hypertensive patients with type 2 diabetes	plasma	dapagliflozin treatment	upregulated	31162549
6921	Human	hsa-miR-31	miRNA	puerarin	acute kidney injury (AKI)	HK-2 cells	puerarin treatment	Puerarin alleviates cisplatin-induced acute renal damage and upregulates microRNA-31-related signaling	32855680
6922	Human	hsa-miR-31	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	HUVECs	vascular endothelial growth factor (VEGF) treatment	upregulated	28097093
6923	Human	hsa-miR-31	miRNA	arsenite	arsenite-induced carcinogenesis	Beas-2B cells	arsenic (As) exposure	Arsenic downregulated miRNA-31.	29603397
6924	Human	hsa-miR-31	miRNA	promoted in platelet-derived growth factor (PDGF)-BB	arteriosclerosis obliterans (ASO)	human ASMCs (HASMCs)	(PDGF)-BB treatment	upregulated	29403548
6925	Human	hsa-miR-31	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	MDA-MB-231 cell	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27593563
6926	Human	hsa-miR-31	miRNA	halofuginone (HF)	breast cancer	MCF-7 cell	Halofuginone (HF) treatment	"miRNAs knockdown experiment in exosomes and the MCF-7 growth inhibition assay showed that exosomal microRNA-31 (miR-31) modulates MCF-7 cells growth by specially targeting the histone deacetylase 2 (HDAC2), which increases the levels of cyclin-dependent kinases 2 (CDK2) and cyclin D1 and suppresses the expression of p21."	30916359
6927	Human	hsa-miR-31	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cellular stress response	prostate cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-205 and miR-31	21368878
6928	Human	hsa-miR-31	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	downregulated	31226416
6929	Human	hsa-miR-31	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	upregulated	31226416
6930	Human	hsa-miR-31	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	RKO cells	kaempferol-3- O-glycoside treatment	downregulated	31441682
6931	Human	hsa-miR-31	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	Human colorectal malignant cell lines DLD©\1 and SW480	5-fluorouracil (5-FU) treatment	upregulated	31162779
6932	Human	hsa-miR-31	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
6933	Human	hsa-miR-31	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	colon cancer cell line (RKO)	kaempferol-3-O-glycoside treatment	downregulated	31441682
6934	Human	hsa-miR-31	miRNA	TGF-¦Â1	cutaneous lupus erythematosus	primary adult keratinocytes and PBMCs isolated from discoid lupus erythematosus (DLE) patients	TGF-¦Â1 treatment	upregulated	30130620
6935	Human	hsa-miR-31	miRNA	ultraviolet (UV) irradiation	cutaneous lupus erythematosus	primary adult keratinocytes and PBMCs isolated from discoid lupus erythematosus (DLE) patients	UV irradiation treatment	upregulated	30130620
6936	Human	hsa-miR-31	miRNA	TGF-¦Â1	discoid lupus erythematosus (DLE)	keratinocyte	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30130620
6937	Human	hsa-miR-31	miRNA	ultraviolet (UV) irradiation	discoid lupus erythematosus (DLE)	keratinocyte	UV radiation treatment	upregulated	30130620
6938	Human	hsa-miR-31	miRNA	high glucose (HG)	endothelial dysfunction	primary endothelial progenitor cells (EPCs)	high glucose treatment	upregulated	29566115
6939	Human	hsa-miR-31	miRNA	cigarette smoke condensate (CSC)	cell differentiation	normal human respiratory epithelia and lung cancer cells	cigarette smoke condensate (CSC) treatment	Cigarette smoke induces expression of miR-31 targeting several antagonists of cancer stem cell signaling in normal respiratory epithelia and lung cancer cells	21048943
6940	Human	hsa-miR-31	miRNA	zinc deficiency	esophageal cancer (EC)	human ESCC and OSCC	zinc deficiency? treatment	upregulated	22689922
6941	Human	hsa-miR-31	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
6942	Human	hsa-miR-31	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	TGF-¦Â could induce miR-31 and suppress miR-184 levels in A549 cells	31874165
6943	Human	hsa-miR-31	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	upregulated	31874165
6944	Human	hsa-miR-31	miRNA	polychlorinated biphenyls (PCBs)	inflammation	HUVECs	polychlorinated biphenyls (PCBs) treatment	upregulated	27288564
6945	Human	hsa-miR-31	miRNA	neoadjuvant chemoradiotherapy (CRT)	locally advanced rectal cancer (LARC)	Rectal Cancer tissues	neoadjuvant chemoradiotherapy (CRT) treatment	upregulation	27271609
6946	Human	hsa-miR-31	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
6947	Human	hsa-miR-31	miRNA	ginsenoside Rh2	medulloblastoma	human medulloblastoma cell line Daoy	ginsenoside Rh2 treatment	downregulated	29377269
6948	Human	hsa-miR-31	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
6949	Human	hsa-miR-31	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
6950	Human	hsa-miR-31	miRNA	epidermal growth factor (EGF)	oral carcinogenesis	"HSC-3£¬OECM-1,SAS£¬NOK"	EGF treatment	upregulated	25229239
6951	Human	hsa-miR-31	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	bone marrow stromal stem cells (BMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30132874
6952	Human	hsa-miR-31	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	ethanol-induced osteonecrosis bone marrow stromal stem cells (BMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30132874
6953	Human	hsa-miR-31	miRNA	estramustine phosphate	prostate cancer	PC3 cells	Estramustine phosphate treatment	MiR-31 level decreased after estramustine phosphate treatment.	29364469
6954	Human	hsa-miR-31	miRNA	mocetinostat	prostate cancer	primary prostate cancer stem cells	mocetinostat treatment	activation of miR-31 and downregulated of E2F6 constitute an important mechanism in mocetinostat-induced apoptosis in prostate cancer.	27551526
6955	Human	hsa-miR-31	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	downregulated	30182520
6956	Human	hsa-mir-31	miRNA	aminosulfonylarylisoxazole	transgenerational pancreatic impairment 	human embryonic kidney cells (HEK-293T)	aminosulfonylarylisoxazole	upregulated	28867213
6957	Human	hsa-miR-31	miRNA	aminosulfonylarylisoxazole	transgenerational pancreatic impairment 	human embryonic kidney cells (HEK-293T)	aminosulfonylarylisoxazole	downregulated	28867213
6958	Human	hsa-miR-31*	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
6959	Human	hsa-miR-3121-3p	miRNA	nilotinib	chronic myeloid leukemia (CML)	human umbilical vein derived EA.hy926 cells and human umbilical vein endothelial cells (HUVECs)	nilotinib treatment	downregulated	28501737
6960	Human	hsa-miR-3126-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
6961	Human	hsa-miR-3126-5p	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
6962	Human	hsa-miR-3129-5p	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	Human HCC cell line HepG2 and Huh7	Doxorubicin (DOX) treatment	downregulated	30615851
6963	Human	hsa-miR-3129-5p	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	Huh-7 cell; Hep3B cells	doxorubicin treatment	downregulated	32965597
6964	Human	hsa-miR-3131	miRNA	ganoderma lucidum polysaccharides (GLPs)	anti-cancer therapy	human hepatocarcinoma cells (HepG2)	GLPs treatment	upregulated	24528735
6965	Human	hsa-miR-3131	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
6966	Human	hsa-miR-3131	miRNA	ganoderma lucidum polysaccharides (GLPs)	hepatocellular carcinoma (HCC)	human hepatocarcinoma cells (HepG2)	Ganoderma lucidum polysaccharides (GLPs) treatment	upregulated	24528735
6967	Human	hsa-miR-3131	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
6968	Human	hsa-miR-3135b	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	upregulated	31824817
6969	Human	hsa-miR-3138	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
6970	Human	hsa-miR-31-3p	miRNA	ultraviolet (UV) irradiation	chronic actinic dermatitis (CAD)	HaCaT cells	ultraviolet (UV) irradiation treatment	The expression of hsa-miR-31-3p was increased after treated with UV irradiation for 48 h	32907715
6971	Human	hsa-miR-31-3p	miRNA	IFN-¦Ã	colitis	human colonic epithelial cells NCM460 cells	interferon-¦Ã(IFN-¦Ã) treatment	upregulated	29253460
6972	Human	hsa-miR-31-3p	miRNA	IL-6	colitis	human colonic epithelial cells NCM460 cells	IL-6 treatment	upregulated	29253460
6973	Human	hsa-miR-31-3p	miRNA	IL-8	colitis	human colonic epithelial cells NCM460 cells	IL8 treatment	upregulated	29253460
6974	Human	hsa-miR-31-3p	miRNA	jun N-terminal kinase inhibitor	colitis	Substance P (SP)-treated human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R)	Jun N-terminal kinase inhibitor treatment	downregulated	29253460
6975	Human	hsa-miR-31-3p	miRNA	substance P (SP)	colitis	human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R)	substance P (SP) treatment	upregulated	29253460
6976	Human	hsa-miR-31-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colitis	human colonic epithelial cells NCM460 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29253460
6977	Human	hsa-miR-31-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	downregulated	31793082
6978	Human	hsa-miR-31-3p	miRNA	sepsis	pneumonia	human embryonic lung fibroblast MRC-5 cell	human embryonic lung fibroblast MRC-5 cell injury irritated by lipopolysaccharide (LPS) treatment	"Silencing miR-31-3p mitigated the impacts of circANKRD36 silence on LPS-irritated MRC-5 cells Besides, MyD88 was a downstream target of miR-31-3p, and 3'UTR of IL-34 mRNA was targeted by miR-31-5p"	31793082
6979	Human	hsa-miR-31-3p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
6980	Human	hsa-miR-3148	miRNA	atropine	myopia	Human corneal epithelial cells	0.003% atropine treatment	dysregulated	31540331
6981	Human	hsa-miR-3148	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	downregulated	29409992
6982	Human	hsa-miR-3149	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
6983	Human	hsa-miR-3150a-3p	miRNA	melatonin	rheumatoid arthritis (RA)	human rheumatoid fibroblast-like synoviocytes	melatonin treatment	upregulated	30648758
6984	Human	hsa-miR-3150b-5p	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
6985	Human	hsa-miR-3154	miRNA	CCAAT/enhancer binding protein delta (CEBPD)	leukemia	human monocytic leukemic cell line THP-1 and the human myeloid cell line U937	CEBPD treatment	upregulated	29120412
6986	Human	hsa-miR-3156-5p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
6987	Human	hsa-miR-31-5p	miRNA	low-intensity pulsed ultrasound (LIPUS)	bone regeneration	hMSCs	low-intensity pulsed ultrasound (LIPUS) induce	upregulated	30925808
6988	Human	hsa-miR-31-5p	miRNA	¦Ã-rays	ionizing radiation (IR) injury	whole blood samples from healthy donors extracellular vesicles (ELVs)	irradiate with 2 Gy gamma rays treatment	upregulated	28264626
6989	Human	hsa-miR-31-5p	miRNA	IL-6	colitis-associated colon cancer (CAC)	THP-1 and Caco2 cells	IL-6 treatment	upregulated	31100679
6990	Human	hsa-miR-31-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colitis-associated colon cancer (CAC)	THP-1 and Caco2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31100679
6991	Human	hsa-miR-31-5p	miRNA	water extract of I. rotunda (WIR)	colitis-associated colon cancer (CAC)	IL-6/TNF-¦Á-treated THP-1 and Caco2 cells	water extract of I. rotunda (WIR) treatment	downregulated	31100679
6992	Human	hsa-miR-31-5p	miRNA	epidermal growth factor receptor (EGFR)	colorectal cancer (CRC)	FFPE tissues or colon cancer cell lines	epidermal growth factor receptor (EGFR) treatment	upregulated	25472647
6993	Human	hsa-miR-31-5p	miRNA	anti-EGFR therapy	colorectal cancer (CRC)	patients with CRC	anti-EGFR therapeutics treatment	upregulated	25472647
6994	Human	hsa-miR-31-5p	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells and Huh7 cells	cisplatin treatment	"When miR-31-5p was downregulated, the proliferation and invasion of HepG2 cells and Huh7 cells were enhanced and the cisplatin-induced apoptosis was inhibited, while LINC01234 knockdown could diminish the effects caused by miR-31-5p depletion."	31838274
6995	Human	hsa-miR-31-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	preeclampsia (PE)	human placental arterial vessels	tumor necrosis factor alpha (TNF-¦Á) treatment	miR-31-5p was upregulated in human endothelial cells treated with TNF¦Á	30279269
6996	Human	hsa-miR-31-5p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
6997	Human	hsa-miR-3162	miRNA	CCAAT/enhancer binding protein delta (CEBPD)	leukemia	human monocytic leukemic cell line THP-1 and the human myeloid cell line U937	CEBPD treatment	upregulated	29120412
6998	Human	hsa-miR-3162-3p	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	IIIB-MT2 cells	human immunodeficiency virus (HIV)-1 infection	downregulated	29627523
6999	Human	hsa-miR-3170	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
7000	Human	hsa-miR-3171	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	downregulated	31549595
7001	Human	hsa-miR-3178	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
7002	Human	hsa-miR-3178	miRNA	H2O2	primary open angle glaucoma (POAG)	Human trabecular meshwork cells (HTMCs)	H2O2 induced oxidative stress	"lncRNA-RP11-820 directly binds miR-3178, through which the expression of MYOD1 is regulated."	31495061
7003	Human	hsa-miR-318	miRNA	propofol (PPF)	pancreatic cancer (PC)	pancreatic cell lines Panc1 and Bxpc3	Propofol treatment	upregulated	30861616
7004	Human	hsa-miR-3180-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
7005	Human	hsa-miR-3182	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
7006	Human	hsa-miR-3182	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
7007	Human	hsa-miR-3182	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
7008	Human	hsa-miR-3184-5p	miRNA	p53 activator mithramycin A	cervical cancer (CC)	HeLa cells; SiHa cells	p53 activator Mithramycin A treatment	p53 activator Mithramycin A stimulated p53 and miR-3184-5p expression	33416166
7009	Human	hsa-miR-3188	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 derived macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29442044
7010	Human	hsa-miR-3189-3p	miRNA	fenofibrate	glioblastoma multiforme (GBM)	LN-229 and U87MG cells	fenofibrate treatment	upregulated	25645911
7011	Human	hsa-miR-3195	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
7012	Human	hsa-miR-3195	miRNA	melatonin	prostate cancer	hypoxic PC-3 cells	melatonin treatment	upregulated	25553085
7013	Human	hsa-miR-3197	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
7014	Human	hsa-miR-3197	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	downregulated	28534445
7015	Human	hsa-miR-3198	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	downregulated	31549595
7016	Human	hsa-miR-3198	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
7017	Human	hsa-miR-31a-5p	miRNA	high temperature	hypertrophic scars (HS)	human dermal fibroblast cells (CC-2511 cells)	CC-2511 cells were incubated at high temperature conditions (41?¡ãC-43?¡ãC for 1-3?h).	upregulated	30075370
7018	Human	hsa-miR-32	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	acute myeloid leukemia (AML)	HL60-G cells and U937 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	21816906
7019	Human	hsa-miR-32	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	AML cell lines	adriamycin (ADR) treatment	miR-32 was identified as the downstream target of SNHG5 and miR-32 inhibitor abrogated the inhibiting effects of downregulated SNHG5 on AML cell viability.	31884339
7020	Human	hsa-miR-32	miRNA	oridonin	colorectal cancer (CRC)	"Human colorectal carcinoma cell lines HCT-116, SW620 and HT-29"	Oridonin treatment	downregulated	26054686
7021	Human	hsa-miR-32	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
7022	Human	hsa-miR-32	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
7023	Human	hsa-miR-32	miRNA	particulate matter (PM2.5)	lung cancer	human lung cancer cells	PM2.5 treatment	upregulated	28601662
7024	Human	hsa-miR-32	miRNA	isoliquiritigenin	nasopharyngeal carcinoma (NPC)	"nasopharyngeal carcinoma cell lines, including C666-1 and CNE2"	isoliquiritigenin treatment	downregulated	31004603
7025	Human	hsa-miR-320	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
7026	Human	hsa-miR-320	miRNA	cardio-pulmonary bypass (CPB)	acute lung injury (ALI)	blood	cardio-pulmonary bypass (CPB) treatment	upregulated	25972997
7027	Human	hsa-miR-320	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29902461
7028	Human	hsa-miR-320	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	miR-320 expression was significantly downregulated.	31449822
7029	Human	hsa-miR-320	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	31449822
7030	Human	hsa-miR-320	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	M¨¹ller cells	streptozotocin (STZ) treatment	DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas	33762162
7031	Human	hsa-miR-320	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	MKN28 (human gastric epithelial cells)£»AGS (human gastric epithelial cells)	Helicobacter pylori infection	downregulated	24136787
7032	Human	hsa-miR-320	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	glioma tissues; U251 cells; U87 cells	ionizing radiation (IR) treatment	downregulated	29331678
7033	Human	hsa-miR-320	miRNA	IL-1¦Â	osteoarthritis (OA)	primary chondrocytes	IL-1¦Â treatment	downregulated	30280762
7034	Human	hsa-miR-320	miRNA	high-dose steroid	steroid-induced avascular necrosis of femoral head (SANFH)	bone tissues	high-dose steroid treatment	downregulated	29551500
7035	Human	hsa-miR-3200-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
7036	Human	hsa-miR-3202	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human T lymphocyte	cigarette smoke?extract?(CSE) treatment	downregulated	29208459
7037	Human	hsa-miR-3202	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	T lymphocytes	cigarette smoke extract (CSE) exposure	downregulated	29208459
7038	Human	hsa-miR-3202	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
7039	Human	hsa-miR-320a	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	children serum samples	acetaminophen(APAP) treatment	upregulated in serum samples	29067470
7040	Human	hsa-miR-320a	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
7041	Human	hsa-miR-320a	miRNA	acetaminophen (APAP)	acute liver failure (ALF)	serum	acetaminophen (APAP) treatment	hsa-miR-320a and hsa-miR-877-5p levels were significantly elevated in serum samples obtained from children with APAP overdose compared to health controls.	29067470
7042	Human	hsa-miR-320a	miRNA	alpha-1 antitrypsin (AAT)	anti-inflammatory responses	monocytes of AAT deficient (ZZ) individuals	alpha-1 antitrypsin (AAT) treatment	downregulated	29062067
7043	Human	hsa-miR-320a	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
7044	Human	hsa-miR-320a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	OIP5-AS1 knockdown modulated cell progression via regulating miR-320a/LOX1 axis in ox-LDL-treated HUVECs.	32072428
7045	Human	hsa-miR-320a	miRNA	lithium (Li)	bipolar disorder (BD)	lymphoblastoid cell lines	Lithium treatment	dysregulated	31801218
7046	Human	hsa-miR-320a	miRNA	artemisinin (ART)	breast cancer	MCF-7/Dox cells	artemisinin treatment	upregulated	28361857
7047	Human	hsa-miR-320a	miRNA	tamoxifen (TAM)	breast cancer	breast cancer cells	Tamoxifen treatment	downregulated	25736597
7048	Human	hsa-miR-320a	miRNA	¦¤Np63¦Á	cancer invasion	HaCaT and A431 cells	¦¤Np63¦Á deficiency treatment	downregulated	31515469
7049	Human	hsa-miR-320a	miRNA	oxidized low density lipoprotein (ox-LDL)	electrophilic stress response	human umbilical vein endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	24786516
7050	Human	hsa-miR-320a	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
7051	Human	hsa-miR-320a	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
7052	Human	hsa-miR-320a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	GC cell lines and tissues	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31662823
7053	Human	hsa-miR-320a	miRNA	rebamipide	gastric cancer (GC)	cancer-initiating cells (C-IC)	Rebamipide treatment	upregulated	27265143
7054	Human	hsa-miR-320a	miRNA	hydroxygenkwanin (HGK)	hepatocellular carcinoma (HCC)	The hepatocellular carcinoma cell lines HepG2 and Huh7	hydroxygenkwanin (HGK) treatment	upregulated	31877715
7055	Human	hsa-miR-320a	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
7056	Human	hsa-miR-320a	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cell (HUVEC)	hypoxia/reoxygenation (H/R) treatment	MALAT1 represses H/R-stimulated HUVEC injury by targeting the miR-320a/RAC1 axis.	31408432
7057	Human	hsa-miR-320a	miRNA	IL-33	inflammatory bowel disease (IBD)	Caco2 colonic intestinal epithelial cell (IEC) line	IL-33 treatment	upregulated	30224451
7058	Human	hsa-miR-320a	miRNA	hyperoxia	lung injury	human epithelial cells	human epithelial cells treatment	upregulation in derived microvesicles (MVs)	27731391
7059	Human	hsa-miR-320a	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
7060	Human	hsa-miR-320a	miRNA	IL-1¦Â	osteoarthritis (OA)	human cartilage cells (C28/I2)	IL-4¦Â treatment	upregulated	28404547
7061	Human	hsa-miR-320a	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx6 treatment"	downregulated	21572246
7062	Human	hsa-miR-320a	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
7063	Human	hsa-miR-320a	miRNA	insulin-like growth factor 1 (IGF-1)	polycystic ovarian syndrome (PCOS)	cumulus cells (CCs) of PCOS patients	IGF1 (10-8 M) treatment	upregulated	27965096
7064	Human	hsa-mir-320a	miRNA	ionizing radiation (IR)	radiosensitivity of cancer cells	HeLa cells	ionizing radiation (IR) treatment	Pri-miR-320a expression increased linearly with the IR dose and treatment duration.	30066913
7065	Human	hsa-miR-320a	miRNA	ionizing radiation (IR)	radiosensitivity of cancer cells	HeLa cells; HCT116 cells	ionizing radiation (IR) treatment	miR-320a expression increased linearly with the IR dose and treatment duration.	30066913
7066	Human	hsa-miR-320a	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	B cells	M.tb infection	upregulated	29477867
7067	Human	hsa-miR-320a	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
7068	Human	hsa-miR-320a-3p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	upregulated	30245930
7069	Human	hsa-miR-320a-3p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MCF-7 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	upregulated	30245930
7070	Human	hsa-miR-320a-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
7071	Human	hsa-miR-320a-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
7072	Human	hsa-miR-320b	miRNA	intermittent hypoxia (IH)	lung cancer	A549 cells; H1650 cells	intermittent hypoxia (IH) treatment	downregulated	33898105
7073	Human	hsa-miR-320b	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
7074	Human	hsa-miR-320b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
7075	Human	hsa-miR-320b	miRNA	androgen	prostate cancer	Human prostate cancer cell lines DU145	androgen stimulation	"the silencing of MALAT1 inactivated AR signaling by sponging miR-320b, and inhibited proliferation and cell cycle progression in prostate cancer cells"	30642743
7076	Human	hsa-miR-320c	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	The human pancreatic cell lines MiaPaCa2;PSN1	gemcitabine treatment	upregulated	23799850
7077	Human	hsa-miR-320c	miRNA	lipopolysaccharide (LPS)	pulmonary diseases	HL60 cells	lipopolysaccharide (LPS) treatment	lipopolysaccharide (LPS) showed increase in miR-320c expression in HL60 cells.	32439252
7078	Human	hsa-miR-320c	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
7079	Human	hsa-miR-320d	miRNA	"cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)"	diffuse large B-cell lymphoma (DLBCL)	patients with DLBCL	CHOP treatment	downregulated	24931464
7080	Human	hsa-miR-320d	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
7081	Human	hsa-miR-320d	miRNA	norcantharidin (NCTD)	prostate cancer	human prostate cancer cells	intraperitoneal injection of different concentration of NCTD treatment	upregulated	28760656
7082	Human	hsa-miR-320d	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	Exosomes derived from human primary melanocytes	ultraviolet B (UVB) irradiation treatment	upregulated	32785244
7083	Human	hsa-miR-322	miRNA	aluminum maltolate (Al-malt)	Alzheimer's disease (AD)	"human neuroblastoma cell line, SH-SY5Y"	treat with Al-Malt for 3 day	downregulated	28656195
7084	Human	hsa-miR-322	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	upregulated	20110569
7085	Human	hsa-miR-322/424	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	human liver tissue	CCl4 treatment	"miR-322/424 level in liver cirrhosis patients, mouse liver fibrosis induced by CCl4?and BDL, and rat liver fibrosis induced by CCl4?and dimethylnitrosamine was increased."	33333053
7086	Human	hsa-miR-323a-5p	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-323a-5p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
7087	Human	hsa-miR-323a-5p	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-323a-5p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
7088	Human	hsa-miR-323b-5p	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	fetal human cells (FHCs)	lipopolysaccharide (LPS) treatment	downregulated	30477744
7089	Human	hsa-miR-32-3p	miRNA	asbestos fibers	malignant pleural mesothelioma (MPM)	serum	ex-exposed to asbestos fibers (WEA)	downregulated	27716620
7090	Human	hsa-miR-324	miRNA	hypoxia	prostate cancer	LNCaP cells; LNCaP cells exosomes	hypoxia treatment	upregulated	29568403
7091	Human	hsa-miR-324-3p	miRNA	dexamethasone (DEX)	pulmonary inflammatory response	IL-1¦Â-treated A549 cells	dexamethasone (Dex) treatment	downregulated	33413425
7092	Human	hsa-miR-324-3p	miRNA	IL-1¦Â	pulmonary inflammatory response	A549 cells	IL-1¦Â treatment	upregulated	33413425
7093	Human	hsa-miR-324-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	29956723
7094	Human	hsa-miR-324-3p	miRNA	oxaliplatin	colorectal cancer (CRC)	CRC tissues; HCT116 cells; HCT8 cells	oxaliplatin (OXA) treatment	miR-324-3p was downregulated in Ox-resistant CRC tissues and cells	33005106
7095	Human	hsa-miR-324-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	HK-2 cells	High Glucose (HG) treatment	downregulated	31430717
7096	Human	hsa-miR-324-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
7097	Human	hsa-miR-324-5p	miRNA	oxaliplatin	colorectal cancer (CRC)	HT29 cells; HCT116 cells; HCT8 cells	oxaliplatin treatment	"hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-¦Á pathway in human colon cancer"	32243061
7098	Human	hsa-miR-324-5p	miRNA	high glucose (HG)	inflammatory response	VSMCs	high glucose (HG) treatment	MiRNA-324-5p exerts an inhibitory effect on T2DM-induced inflammation in blood vessels by negatively regulating CPT1A level and reducing the release of inflammatory factors.	33378033
7099	Human	hsa-miR-324-5p	miRNA	high glucose (HG)	inflammatory response	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	miRNA-324-5p was dose-dependently downregulated.	33378033
7100	Human	hsa-miR-324-5p	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
7101	Human	hsa-miR-324-5p	miRNA	H2O2	myocardial infarction (MI)	Endothelial progenitor cells (EPCs) derived from peripheral blood	H2O2 treatment	downregulated	31066044
7102	Human	hsa-miR-325	miRNA	cisplatin (DDP)	bladder cancer	5637 cells; T24 cells	cisplatin treatment	miR-325 was downregulated in 5637/R and T24/R cells compared to their parental 5637 and T24 cells.	33015771
7103	Human	hsa-miR-325-3p	miRNA	sevoflurane (SEV)	sevoflurane-induced neurotoxicity	HCN-2 cells	sevoflurane treatment	miR-325-3p is downregulated in HCN-2 cells exposed to sevoflurane	32191629
7104	Human	hsa-miR-32-5p	miRNA	walnut	benefits of walnuts	Plasma exosomes	walnuts treatment	upregulated	32979076
7105	Human	hsa-miR-32-5p	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-32-5p was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
7106	Human	hsa-miR-32-5p	miRNA	high glucose (HG)	cardiac fibrosis	human cardiac fibroblasts (CFs)	high glucose (HG) treatment	upregulated	31438862
7107	Human	hsa-miR-32-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
7108	Human	hsa-miR-32-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
7109	Human	hsa-miR-32-5p	miRNA	vmycobacterium tuberculosis (M.tb)	mycobacterium tuberculosis (Mtb) infection	THP-1 and U937 cells	infect with M.tb treatment	upregulated	28215633
7110	Human	hsa-miR-32-5p	miRNA	helicobacter pylori (H. pylori)	pediatric enteritis	"serum, human intestinal epithelial cell line HIEC-6"	Helicobacter pylori (H. pylori) infection	upregulated	31749593
7111	Human	hsa-miR-326	miRNA	H2O2	age-related cataract (ARC)	HLEC-B3 human lens epithelial cells	H2O2 treatment	upregulated	30268497
7112	Human	hsa-miR-326	miRNA	platelet-derived growth factor (PDGF)	airway remodeling	airway smooth muscle cells (ASMCs)	platelet-derived growth factor (PDGF) treatment	downregulated	32450169
7113	Human	hsa-miR-326	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	32336203
7114	Human	hsa-miR-326	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â25-35-induced ERS and apoptosis in SH-SY5Y cells can be attenuated by lncRNA RPPH1 through regulating miR-326/PKM2 axis.	32336203
7115	Human	hsa-miR-326	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
7116	Human	hsa-miR-326	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
7117	Human	hsa-miR-326	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
7118	Human	hsa-miR-326	miRNA	sulforaphane (SFN)	gastric cancer (GC)	MKN45 cells	sulforaphane treatment	upregulated	30096452
7119	Human	hsa-miR-326	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	curcumin (Cur) treatment	Curcumin promoted the expression of miR-326.	27819521
7120	Human	hsa-miR-326	miRNA	pyruvate kinase M2(PKM2)	glioblastoma multiforme (GBM)	"U87MG, U251MG, T98G, U373MG, and A172"	Pyruvate kinase M2(PKM2) treatment	"cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326"	20667897
7121	Human	hsa-miR-326	miRNA	sevoflurane (SEV)	lung cancer	H446 cells; H1975 cells	sevoflurane (Sev) treatment	upregulated	33987473
7122	Human	hsa-miR-326	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
7123	Human	hsa-miR-326	miRNA	propofol (PPF)	non-small cell lung cancer (NSCLC)	human bronchial epithelioid(16HBE)	Propofol treatment	"?Importantly, treatment with Propofol inhibited circ-RHOT1 expression in NSCLC cells"	33515563
7124	Human	hsa-miR-326	miRNA	resveratrol	cell proliferation and apoptosis	various tumor cells	resveratrol (Res) treatment	upregulated	27960279
7125	Human	hsa-miR-326-3p	miRNA	cadmium (Cd)	renal toxic	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
7126	Human	hsa-miR-326-3p	miRNA	cadmium (Cd)	toxic effects of cadmium	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
7127	Human	hsa-miR-328	miRNA	H2O2	apoptosis	H9c2 cells	H2O2 treatment	downregulated	28544404
7128	Human	hsa-miR-328	miRNA	sodium selenite	apoptosis	H9c2 cells	sodium selenite treatment	downregulated	28544404
7129	Human	hsa-miR-328	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30324654
7130	Human	hsa-miR-328	miRNA	arsenic trioxide (ATO)	breast cancer	MCF-7 cells	arsenic trioxide (As2O3) treatment	upregulated	25824027
7131	Human	hsa-miR-328	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	K562 cells	Imatinib treatment	downregulated	31701195
7132	Human	hsa-miR-328	miRNA	imatinib	chronic myeloid leukemia (CML)	human immortalized myelogenous leukemia line K-562 cells	imatinib treatment	downregulated	22241070
7133	Human	hsa-miR-328	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	29859985
7134	Human	hsa-miR-328	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric mucosa	H. pylori treatment	downregulated	25479940
7135	Human	hsa-miR-328	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin (DPP) treatment	upregulated	30221716
7136	Human	hsa-miR-328	miRNA	resveratrol	osteosarcoma (OS)	osteosarcoma cells	resveratrol (Res) treatment	upregulated	25605016
7137	Human	hsa-miR-328	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	TGF-¦Â1 could induce EMT expression and fibrogenesis and significantly downregulated the expression of miR-328	30160133
7138	Human	hsa-miR-328-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-328-3p expression was downregulated in oxidized low-density lipoprotein (ox-LDL) induced human umbilical vein endothelial cells (HUVECs).	32329448
7139	Human	hsa-miR-328-3p	miRNA	puerarin	bladder cancer	T24 cells; UM-UC-3 cells	puerarin treatment	upregulated	33016781
7140	Human	hsa-miR-328-3p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
7141	Human	hsa-miR-328-3p	miRNA	5¦Á©\dihydrotestosterone (DHT)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	5¦Á-dihydrotestosterone (DHT) treatment	upregulated	29964098
7142	Human	hsa-miR-328-5p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	APL cell line NB4	all-trans retinoic acid (ATRA) treatment	downregulated	30453015
7143	Human	hsa-miR-328-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	downregulated	32462517
7144	Human	hsa-miR-328-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	lipid accumulation	human acute monocytic leukemia cel (THP-1)	oxidized low-density lipoprotein (ox-LDL) treatment	The results showed that miR-328-5p expression was robustly decreased in oxidized low-density lipoprotein (ox-LDL)-treated macrophages.	33663010
7145	Human	hsa-miR-329-3p	miRNA	high glucose (HG)	endothelial cell injury	Human umbilical vein endothelial cells (HUVECs)	high glucose treatment	downregulated	33262815
7146	Human	hsa-miR-329-3p	miRNA	X-rays	glioblastoma multiforme (GBM)	U251 cells	X-ray radiation treatment	"XIST accelerates cell proliferation, invasion and inhibits cell apoptosis by repressing radio-sensitivity of glioma via enhancing CREB1 expression through sponging miR-329-3p"	32271437
7147	Human	hsa-miR-329-3p	miRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS;  LAN-6 cells	cisplatin (DPP) treatment	LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis.	32329857
7148	Human	hsa-miR-329-3p	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	"The results revealed that plasma miR-329-3p expression was decreased patients with T2DM compared with healthy controls, and in HUVECs treated with high glucose concentrations."	33262815
7149	Human	hsa-miR-33	miRNA	betulinic acid (BA)	alcoholic fatty liver disease	Human THP-1 macrophages	betulinic acid (BA) treatment	BA promoted ABCA1 expression via downregulated of miR-33s	24086374
7150	Human	hsa-miR-33	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid-¦Â (A¦Â) 25-35 treatment	miR-33 expression level was markedly upregulated in SH-SY5Y cells treated with A?25-35.	32119650
7151	Human	hsa-miR-33	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31933767
7152	Human	hsa-miR-33	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	ox-LDL-induced THP-1 macrophages	Tanshinone IIA (Tan) treatment	downregulated	31933767
7153	Human	hsa-miR-33	miRNA	citrus peel flavonoid extracts (CPFE)	lipid metabolism	HepG2 cells	citrus peel flavonoid extracts (CPFE) treatment	downregulated	31017523
7154	Human	hsa-miR-33	miRNA	resveratrol and epigallocatechin	hepatocellular carcinoma (HCC)	hepatic cell lines	resveratrol and epigallocatechin treatment		24165878
7155	Human	hsa-miR-330	miRNA	epigallocatechin-3-gallate (EGCG)	hormone refractory prostate cancer (HRPC)	LNCaP and 22R¦Í cells	Green tea polyphenol EGCG treatment	upregulated	21177307
7156	Human	hsa-miR-330	miRNA	fructose	kidney damage	HK-2 cells	fructose treatment	downregulated	28205387
7157	Human	hsa-miR-330-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
7158	Human	hsa-miR-330-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	temporomandibular joint osteoarthritis	synoviocyte	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	32332704
7159	Human	hsa-miR-330-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
7160	Human	hsa-miR-330-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
7161	Human	hsa-miR-330-5p	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
7162	Human	hsa-miR-330-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-330-5p was greatly decreased in THP-1 cells incubated with ox-LDL.	29698635
7163	Human	hsa-miR-330-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-330-5p was greatly decreased in THP-1 cells incubated with ox-LDL and overexpression of miR-330-5p was able to inhibit oxidative stress and inflammation process.	30187491
7164	Human	hsa-miR-330-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)	doxorubicin treatment	"The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a"	32392088
7165	Human	hsa-miR-330-5p	miRNA	curcumin (Cur)	lung cancer	human non-small cell lung cancer A549 cell line	curcumin treatment	dysregulated	28660665
7166	Human	hsa-miR-330-5p	miRNA	arsenic trioxide (ATO)	pancreatic cancer (PC)	Human PC cell lines Patu8988 and Panc-1	arsenic trioxide (ATO) treatment	upregulated	30847385
7167	Human	hsa-miR-330-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	Pancreatic cancer tissues	Gemcitabine (GEM) treatment	downregulated	32104074
7168	Human	hsa-miR-330-5p	miRNA	lipopolysaccharide (LPS)	pulmonary vascular endothelial cell (PVEC) injury	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	PRNCR1 was upregulated in LPS-induced PVEC and aggravated its injury via modulating the miR-330-5p/TLR4 axis.	33049095
7169	Human	hsa-miR-330-5p	miRNA	H2O2	thoracic aortic aneurysm (TAA)	mouse aortic smooth muscle cells (SMCs)	H2O2 treatment	long noncoding RNA (lncRNA) Sox2ot modulates the progression of TAA by regulating miR-330-5p/Myh11 axis.	32578852
7170	Human	hsa-miR-331	miRNA	particulate matter (PM2.5)	airway epithelial injury	human airway epithelial Beas-2B (B2B) cells	PM2.5 treatment	downregulated	28192748
7171	Human	hsa-miR-331	miRNA	platelet derived growth factor-BB (PDGF-BB)	proliferative vascular diseases	Human VSMCs	platelet derived growth factor-BB (PDGF-BB) treatment	circSFMBT2 plays a vital role in VSMC proliferation and migration through the miR-331/HDAC5/Aggf1 axis	33166591
7172	Human	hsa-miR-331-3p	miRNA	amyloid-¦Â (A¦Â) 1-40	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 1-40 treatment	"In AD patients and A¦Â1-40?treated SH-SY5Y cells, the expression of miR-331-3p was significantly downregulated."	33279668
7173	Human	hsa-miR-331-3p	miRNA	amyloid-¦Â (A¦Â) 1-40	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 1-40 treatment	"In A¦Â1-40 treated SH-SY5Y cells, the expression of miR-331-3p was significantly downregulated."	33279668
7174	Human	hsa-miR-331-3p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
7175	Human	hsa-miR-331-3p	miRNA	rapamycin and methylprednisolone (MP)	glucocorticoids (GCs) resistance	CCL-119 cells	rapamycin and methylprednisolone (MP) treatment	upregulated	32776229
7176	Human	hsa-miR-331-3p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HCC cell lines	hepatitis B virus (HBV) infection	upregulated	25750939
7177	Human	hsa-miR-331-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC1 cells; MIAPaCa2 cells; plasma	gemcitabine treatment	miR-331-3p is upregulated in gemcitabine-treated pancreatic cancer cells and plasma from chemotherapy patients.	32924881
7178	Human	hsa-miR-331-3p	miRNA	¦Ã-rays	prostate cancer	22RV1; DU145 cells	Gy radiation treatement	LncRNA UCA1 deletion suppressed the radioresistance to PCa by suppressing EIF4G1 expression via miR-331-3p.	32943997
7179	Human	hsa-miR-331-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	B cells	M.tb infection	upregulated	29477867
7180	Human	hsa-miR-331-5p	miRNA	doxorubicin (DOX)	leukemia	myeloid leukemic cell lines NB4; human promyelocytic leukaemia cell line;HL60	doxorubicin (DOX)? treatment	downregulated	21070600
7181	Human	hsa-miR-335	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	Mononuclear cells	glucocorticoid (GC) treatment	downregulated	23888996
7182	Human	hsa-miR-335	miRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	bone marrow aspirates	cytarabine (Ara-C) treatment	upregulated	26287405
7183	Human	hsa-miR-335	miRNA	hypoxia	aging	hMSCs	"hypoxia (3% O2, for 7 days) treatment"	downregulated	24648336
7184	Human	hsa-miR-335	miRNA	pro-inflammatory growth factors	aging	hMSCs	pro-inflammatory growth factors treatment	downregulated	24648336
7185	Human	hsa-miR-335	miRNA	¦Ã-rays	aging	hMSCs	¦Ã-irradiation (0.5¨C10 Gy) treatment	upregulated	24648336
7186	Human	hsa-miR-335	miRNA	platycodin D (PD)	bladder cancer	T24; RT4	Platycodin D (PD) treatment	"PD inhibited LncRNA-XIST expressions, while increased miR-335 expression levels in bladder cancer cells"	32919956
7187	Human	hsa-miR-335	miRNA	NT21MP2	breast cancer	MCF-7 and SKBR-3 cells	NT21MP2 treatment	downregulated	28731125
7188	Human	hsa-miR-335	miRNA	"TCDD and 6-methyl-1,3,-trichlorodibenzofuran (MCDF)"	breast cancer	MDA-MB-231 ;BT474 cells	"TCDD and 6-methyl-1,3,-trichlorodibenzofuran (MCDF)?treatment treatment"	Both TCDD and MCDF induced miR-335 in MDA-MB-231 and BT474 cells	22034498
7189	Human	hsa-miR-335	miRNA	"leptin, resistin, TNF-¦Á, and IL-6"	fat	human mature adipocytes	"leptin, resistin, TNF-¦Á, and IL-6 treatment"	upregulated	23801157
7190	Human	hsa-miR-335	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	gastric cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25520857
7191	Human	hsa-miR-335	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 or Bel7404	sorafenib (Sora) treatment	"lncRNA NEAT1 mediates Sora resistance of HCC cells by suppressing miR-335 expression, and disinhibition on c-Met-Akt signaling pathway"	30937906
7192	Human	hsa-miR-335	miRNA	decabromodiphenyl ether (BDE-209)	human embryonic development	human embryonic stem cell lines FY-hES-10 and FY-hES-26	Decabromodiphenyl ether (BDE-209) treatment	upregulated	26206603
7193	Human	hsa-miR-335	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
7194	Human	hsa-miR-335	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
7195	Human	hsa-miR-335	miRNA	gemcitabine (GEM)	renal cell carcinoma (RCC)	renal tissues or TK10 and UO31 cells	gemcitabine treatment	"Hsa-miR-335 is the target regulatory point of hsa_circ_0035483. In addition, hsa_circ_0035483 promotes autophagy and tumor growth and enhances gemcitabine resistance in RCC by regulating hsa-miR-335/CCNB1."	31492499
7196	Human	hsa-miR-335-3p	miRNA	H2O2	age-related nuclear cataract	human lens epithelial B3 (HLE-B3) cell	H2O2 treatment	downregulated	29653565
7197	Human	hsa-miR-335-3p	miRNA	TGF-¦Â	hereditary gingival fibromatosis (HGF)	human gingival fibroblasts (NHGFs)	transforming growth factor ¦Â (TGF-¦Â) treatment	downregulated	31323181
7198	Human	hsa-miR-335-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"miR-335-3p was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression."	32127962
7199	Human	hsa-miR-335-5p	miRNA	H2O2	atherosclerosis (AS)	human umbilical vein endothelial cells	H2O2 treatment	upregulated	30785341
7200	Human	hsa-miR-335-5p	miRNA	H2O2	preeclampsia (PE)	JEG-3 cells	H2O2 treatment	H2O2 significantly increased the intracellular ROS levels and miR-335-5p expression.	31894323
7201	Human	hsa-miR-335-5p	miRNA	H2O2	preeclampsia (PE)	JEG-3 cells	H2O2 treatment	upregulated	31894323
7202	Human	hsa-miR-337	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
7203	Human	hsa-miR-337	miRNA	high glucose (HG)	osteogenesis		?high-glucose (HG) treatment	High glucose inhibited osteogenic differentiation but increased the level of miR-337	33748908
7204	Human	hsa-miR-337	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
7205	Human	hsa-miR-337	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
7206	Human	hsa-miR-337-3p	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
7207	Human	hsa-miR-337-3p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	upregulated	33276753
7208	Human	hsa-miR-337-5p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
7209	Human	hsa-miR-338	miRNA	Iodine-125 (125I)	hepatocellular carcinoma (HCC)	HCCLM3 and SMMC-7721 cells	125I irradiation treatment	upregulated	31514072
7210	Human	hsa-miR-338-3p	miRNA	silver nanoparticles (AgNPs)	breast cancer	"MCF7, T47D and MDA-MB-231 cells"	silver nanoparticles (AgNPs)?treatment treatment	upregulated	33613979
7211	Human	hsa-miR-338-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	"RPMI-2650 cells, a human nasal epithelial cell line"	fine particulate matter (PM2.5) exposure treatment	The results showed that miR-338-3p was downregulated in both nasal mucosa of PM25-exacerbated AR rat models and PM25-treated RPMI-2650 cells	33770685
7212	Human	hsa-miR-338-3p	miRNA	mepolizumab	asthma	serum	6 patients with mepolizumab after 8 weeks of treatment	upregulated	33808110
7213	Human	hsa-miR-338-3p	miRNA	reslizumab	asthma	serum	10 patients treated with reslizumab for 8 weeks treatment	upregulated	33808110
7214	Human	hsa-miR-338-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVEC cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30556591
7215	Human	hsa-miR-338-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-338-3p was increased in patients with AS and oxidized low-density lipoprotein (ox-LDL)-induced HUVEC cells.	30556591
7216	Human	hsa-miR-338-3p	miRNA	baicalin (BAI)	breast cancer	"MCF-10A, MCF-7 and MDA-MB-231 cells"	baicalin (BAI) treatment	upregulated	31908485
7217	Human	hsa-miR-338-3p	miRNA	hypoxia	breast cancer	MCF7 cells; HCC1937 cells	hypoxia treatment	miR-338-3p level was decreased in a dose- and time-dependent manner after hypoxia treatment.	32726486
7218	Human	hsa-miR-338-3p	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
7219	Human	hsa-miR-338-3p	miRNA	radiation	colorectal cancer (CRC)	colon cancer tissues	radiation treatment	circ_0001313 was significantly upregulated and miR-338-3p was downregulated in radio-resistant colon cancer tissues compared to radio-sensitive tissues	30630646
7220	Human	hsa-miR-338-3p	miRNA	X-rays	colorectal cancer (CRC)	SW480 and SW620 cells	6-MV X-ray exposure	Radiation treatment in colon cells triggered a remarkable upregulation of circ_0001313 and a downregulated of miR-338-3p.	30630646
7221	Human	hsa-miR-338-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32680978
7222	Human	hsa-miR-338-3p	miRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS cells; SK-N-SH cells	cisplatin treatment	downregulated	32164348
7223	Human	hsa-miR-338-3p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
7224	Human	hsa-miR-338-3p	miRNA	resveratrol	osteoporosis	human osteoblast (HOB) cells	"Resveratrol (3,5,4-tri-hydroxystilbene; RESV) treatment"	downregulated	25845653
7225	Human	hsa-miR-338-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	16HBE cells	lipopolysaccharide (LPS) treatment	Circ_0038467 was upregulated and miR-338-3p was downregulated in LPS-treated 16HBE cells.	32181994
7226	Human	hsa-miR-338-5p	miRNA	hypoxia	colorectal cancer (CRC)	The human colon cancer cell lines HCT116 and HCT8	hypoxia induce	downregulated	31208913
7227	Human	hsa-miR-338-5p	miRNA	anticancer bioactive peptide-3 (ACBP-3)	gastric cancer (GC)	GC MKN45 cells	anticancer bioactive peptide-3 (ACBP-3) treatment	ACBP-3 induced the expression of miR-338-5p and the BAK and BIM proteins and promoted GCSC apoptosis.	27688872
7228	Human	hsa-miR-339	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
7229	Human	hsa-miR-339	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
7230	Human	hsa-miR-339-3p	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
7231	Human	hsa-miR-339-5p	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
7232	Human	hsa-miR-339-5p	miRNA	prolactin (PRL)	breast cancer	MCF-7 and T47D breast cancer cells	Prolactin (PRL) treatment	upregulated	27066093
7233	Human	hsa-miR-339-5p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
7234	Human	hsa-miR-339-5p	miRNA	high glucose (HG)	diabetic vasculopathy	human aortic endothelial cells (HAECs)	high glucose (HG)	downregulated	28824448
7235	Human	hsa-miR-339-5p	miRNA	hypoxia/reoxygenation (H/R)	intestinal ischemia/reperfusion (I/R) injury	Caco-2 cells	hypoxia/reoxygenation (H/R) treatment	circ-PRKCB/miR-339-5p/p66Shc signaling pathway in regulating oxidative stress in the I/R intestine.	32929374
7236	Human	hsa-miR-339-5p	miRNA	ionizing radiation (IR)	lung cancer	A549 cells; H460 cells	ionizing radiation (IR) treatment	upregulated	30462625
7237	Human	hsa-miR-339-5p	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	downregulated	26640557
7238	Human	hsa-miR-33a	miRNA	metformin (Met)	breast cancer	ALDHbright cells	metformin treatment	upregulated	24980829
7239	Human	hsa-miR-33a	miRNA	xuezhikang (XZK)	cellular cholesterol export	participating patients with low baseline levels of HDL cholesterol	"XZK capsule, 600 mg twice daily for 6 months treatment"	upregulated	24591767
7240	Human	hsa-miR-33a	miRNA	cholesterol	colorectal cancer (CRC)	HT-29 and SW480 cells	cholesterol treatment	downregulated	30827510
7241	Human	hsa-miR-33a	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
7242	Human	hsa-miR-33a	miRNA	grape pomace extract (GPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape pomace extract (GPE) treatment	GPE reduced miR-122 but increased miR-33a expression.	24165878
7243	Human	hsa-miR-33a	miRNA	grape seed proanthocyandin extract (GSPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape seed proanthocyandin extract (GSPE) treatment	GSPE reduced both miR-122 and miR-33a levels.	24165878
7244	Human	hsa-miR-33a	miRNA	curcumin (Cur)	formation of foam cells	THP-1 cells	curcumin treatment	"ox-LDL significantly promoted the expression of miR33a, while the expression of miR33a mRNA was significantly decreased in curcumin pre-treated cells."	32782494
7245	Human	hsa-miR-33a	miRNA	TGF-¦Â2	liver fibrosis	Lx-2 cells	TGF-¦Â2 treatment	upregulated	24100264
7246	Human	hsa-miR-33a	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2 cells;BEL-7402 cells	hypoxia treatment	downregulated	27460728
7247	Human	hsa-miR-33a	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
7248	Human	hsa-miR-33a	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
7249	Human	hsa-miR-33a	miRNA	aflatoxin B1 (AFB1)	ischemic injury	hepatocellular carcinoma (HCC) cells	aflatoxin B1 (AFB1) treatment	upregulated	24015284
7250	Human	hsa-miR-33a	miRNA	resistin	osteoarthritis (OA)	THP-1 cells	resistin treatment	downregulated	30845380
7251	Human	hsa-miR-33a	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx8 treatment"	downregulated	21572246
7252	Human	hsa-miR-33a	miRNA	lovastatin	osteosarcoma (OS)	MG63 cells; SaOS2 cells	lovastatin treatment	lovastatin increased the expression of SREBP-2 and miR-33a.	30466075
7253	Human	hsa-miR-33a	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"Human pancreatic carcinoma cells, SW1990 and MiaPaCa-2, and human embryonic kidney (HEK) 293 T cells"	gemcitabine (GEM) treatment	downregulated	26113407
7254	Human	hsa-miR-33a	miRNA	TGF-¦Â1	liver fibrosis	hepatic stellate cells (HSCs)	TGF-¦Â1? treatment	upregulated	24100264
7255	Human	hsa-miR-33a*	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
7256	Human	hsa-miR-33a-5p	miRNA	celastrol	lung adenocarcinoma (LUAD)	A549 and LTEP-a-2 cells	celastrol treatment	upregulated	29484434
7257	Human	hsa-miR-33a-5p	miRNA	PD-L1 inhibitor	glioblastoma multiforme (GBM)	U87 MG cells; U251 cells	PD-L1 inhibitor treatment	"PD-L1 inhibitor significantly decreased the expression of the target gene, miR-33a-5p"	32537433
7258	Human	hsa-miR-33a-5p	miRNA	high glucose (HG)	hyperglycemic ST-segment elevation myocardial infarction (STEMI)	Human aortic endothelial cells (HAECs; PCS©\100©\011?) and pulmonary artery endothelial cells (CPAEs; CCL©\209)	high glucose treatment	upregulated	31294459
7259	Human	hsa-miR-33a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	Human bonemarrow stromal cells (hBMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26785690
7260	Human	hsa-miR-33a-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
7261	Human	hsa-miR-33a-5p	miRNA	chidamide	triple negative breast cancer (TNBC)	The MDA-MB-231 and BT-20 TNBC cell lines	chidamide treatment	upregulated	31257519
7262	Human	hsa-miR-33b	miRNA	xuezhikang (XZK)	cellular cholesterol export	participating patients with low baseline levels of HDL cholesterol	"XZK capsule, 600 mg twice daily for 6 months treatment"	upregulated	24591767
7263	Human	hsa-miR-33b	miRNA	high glucose (HG)	hyperglycemic ST-segment elevation myocardial infarction (STEMI)	Human aortic endothelial cells (HAECs; PCS©\100©\011?) and pulmonary artery endothelial cells (CPAEs; CCL©\209)	high glucose treatment	upregulated	31294459
7264	Human	hsa-miR-33b	miRNA	MLN9708/2238	ischemia/reperfusion (I/R) injury	multiple myeloma (MM) cellls	proteasome inhibitor? treatment	upregulated	22983447
7265	Human	hsa-miR-33b	miRNA	high glucose (HG)	lipid accumulation	HepG2 cells	high glucose treatment	upregulated	31686542
7266	Human	hsa-miR-33b	miRNA	metformin (Met)	lipid accumulation	high glucose-induced HepG2 cells	Metformin treatment	downregulated	31686542
7267	Human	hsa-miR-33b	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
7268	Human	hsa-miR-33b	miRNA	cordycepin	malignant melanoma (MM)	highly-metastatic melanoma cell lines	cordycepin treatment	upregulated	25868853
7269	Human	hsa-miR-33b	miRNA	lovastatin	medulloblastoma	"HEK293T, D283;Daoy cells"	lovastatin? treatment	upregulated	22887866
7270	Human	hsa-miR-33b	miRNA	resistin	osteoarthritis (OA)	THP-1 cells	resistin treatment	downregulated	30845380
7271	Human	hsa-miR-33b-3p	miRNA	cisplatin (DDP)	lung cancer	A549 cells	cisplatin treatment	downregulated	27559850
7272	Human	hsa-miR-33b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	downregulated	31522815
7273	Human	hsa-miR-33b-3p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
7274	Human	hsa-miR-33b-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
7275	Human	hsa-miR-33b-5p	miRNA	rosuvastatin	atherosclerosis (AS)	atherosclerotic plaques	rosuvastatin treatment	downregulated	31409515
7276	Human	hsa-miR-33b-5p	miRNA	rosuvastatin	atherosclerosis (AS)	atherosclerotic plaques	rosuvastatin treatment	downregulated	31409515
7277	Human	hsa-miR-33b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
7278	Human	hsa-miR-34	miRNA	IL-13	autophagy	BEAS-2B cells	IL-13 treatment	upregulated	28796252
7279	Human	hsa-miR-34	miRNA	resveratrol	chronic obstructive pulmonary disease (COPD)	Peripheral blood	resveratrol (RS) treatment	upregulated	26191210
7280	Human	hsa-miR-34	miRNA	corticosteroid	erythroid cell differentiation	bronchial epithelial? cells	corticosteroids treatment	downregulated	22955319
7281	Human	hsa-miR-34	miRNA	curcumin (Cur)	ischemia/reperfusion (I/R) injury	colon cancer cell lines	curcumin (CUR) treatment	CDF was very effective in the re-expression of miR-34a and miR-34c	22992310
7282	Human	hsa-miR-34	miRNA	melatonin	primary biliary cholangitis (PBC)	H69 cells	melatonin treatment	downregulated	33352965
7283	Human	hsa-miR-34	miRNA	¦Ã-rays	renal disease	HeLa? cells	gamma radiation treatment	miR-34 is significantly induced by ¦Ã-radiation in HeLa cells	23091481
7284	Human	hsa-miR-340	miRNA	lipopolysaccharide (LPS)	acute liver injury (ALI)	Kupffer cells (KCs)	lipopolysaccharides (LPS) treatment	downregulated	33155227
7285	Human	hsa-miR-340	miRNA	tetrachloromethane (CCl4)	acute liver injury (ALI)	Kupffer cells (KCs)	tetrachloromethane (CCl4) treatment	downregulated	33155227
7286	Human	hsa-miR-340	miRNA	kaempferol	lung cancer	A549 cells	kaempferol treatment	miR-340 was upregulated by kaempferol treatment.	30253373
7287	Human	hsa-miR-340	miRNA	lentinan (LNT)	osteosarcoma (OS)	human OS MG63 cells	lentinan (LNT) treatment	upregulated	31949775
7288	Human	hsa-miR-340	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells	criplatin (DPP) treatment	downregulated	29494357
7289	Human	hsa-miR-340	miRNA	a moderate-carbohydrate and high glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and high glycemic index diet	downregulated	29233589
7290	Human	hsa-miR-340	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
7291	Human	hsa-miR-340	miRNA	curcumin (Cur)	pancreatic cancer (PC)	human pancreatic cancer cells	curcumin treatment	upregulated	28789415
7292	Human	hsa-miR-340	miRNA	ultraviolet (UV) irradiation	pigmentation	Pig-1 cells	ultraviolet B (UVB) irradiation treatment	Expression of miR-340 was reduced in human Pig-1 cells after UVB irradiation	33179560
7293	Human	hsa-miR-340	miRNA	ultraviolet (UV) irradiation	UVB-mediated retinal damage	retinal pigment epithelium (RPE) cells	ultraviolet B (UVB) treatment	UVB significantly increased miR-340 levels	29982095
7294	Human	hsa-miR-340-5p	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 and HepG2/CDDP	cisplatin treatment	downregulated	30030687
7295	Human	hsa-miR-340-5p	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus infection	downregulated	30753994
7296	Human	hsa-miR-340-5p	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	downregulated	25552929
7297	Human	hsa-miR-340-5p	miRNA	hypoxia	melanoma	melanoma stem-like cells	hypoxia treatment	downregulated	26554847
7298	Human	hsa-miR-340-5p	miRNA	Hypoxia	oesophageal squamous cell carcinoma (ESCC)	"human OSCC cell lines (Te13, Te1 , Eca109)"	Hypoxia treatment	miR-340-5p was highly expressed in hypoxic exosomes	33485367
7299	Human	hsa-miR-340-5p	miRNA	ferulic acid (FA)	osteogenesis	human bone marrow-derived mesenchymal stem cell (MSC)	FA	downregulated	28764862
7300	Human	hsa-miR-340-5p	miRNA	silver nanoparticles (AgNPs)	silver nanoparticles (SNPs) induced cytotoxicity	human dermal fibroblasts (HDFs)	silver nanoparticles (SNPs) treatment	upregulated	30305212
7301	Human	hsa-miR-342	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	MiR-342 attenuates lipopolysaccharide-induced acute lung injury via inhibiting MAPK1 expression.	32248545
7302	Human	hsa-miR-342	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
7303	Human	hsa-miR-342	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
7304	Human	hsa-miR-342	miRNA	all-trans retinoic acid (ATRA)	crohn disease (CD)	acute promyelocytic leukemia cells	?all-trans-retinoic acid (ATRA) treatment	upregulated	19151778
7305	Human	hsa-miR-342	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
7306	Human	hsa-miR-342	miRNA	paraquat (PQ)	lung injury	Beas-2B cells	paraquat (PQ) treatment	downregulated	32758486
7307	Human	hsa-miR-342	miRNA	palliative chemotherapy	non-small cell lung cancer (NSCLC)	NSCLC tissues	platinum derivatives in combination with paclitaxel or gemcitabine treatment	downregulated	29387235
7308	Human	hsa-miR-342-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 was significantly increased in THP-1 cells incubated with ox-LDL and meanwhile miR-342-3p was greatly decreased.	30259979
7309	Human	hsa-miR-342-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30259979
7310	Human	hsa-miR-342-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse renal mesangial cells (MCs)	high glucose (HG) treatment	miR-342-3p suppresses the progression of DKD by inducing the degradation of SOX6.	31746345
7311	Human	hsa-miR-342-3p	miRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	"MIAT and CASP1 expression were substantially increased, while that of miR-342-3p was decreased in AGE-BSA-treated HRPCs."	33065089
7312	Human	hsa-miR-342-3p	miRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	primary human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by mdulating miR-342-3p targeting of CASP1 in diabetic retinopathy.	33065089
7313	Human	hsa-miR-342-3p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
7314	Human	hsa-miR-342-3p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
7315	Human	hsa-miR-342-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	upregulated	27081844
7316	Human	hsa-miR-342-3p	miRNA	sophorae Fructus	hepatocellular carcinoma (HCC)	Huh7 cells	sophorae Fructus treatment	"Flavonoids of Sophorae Fructus could inhibite the proliferation, migration and invasion of hepatoma cells by regulating LncRNA FBXL19-AS1/miR-342-3p pathway"	33164374
7317	Human	hsa-miR-342-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	"KMS-12-PE , RPMI-8226R cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29242101
7318	Human	hsa-miR-342-3p	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"The human PDAC cell lines PANC-1, MiaPaCa-2 and the normal pancreatic ductal epithelial cell line HPDE6c7"	gemcitabine (GEM) treatment	"expression levels of obesity-associated miR-342-3p were significantly upregulated in gemcitabine (GEM)-resistant PDAC tissues and cells, and this upregulation was associated with poor postchemotherapy prognosis."	30638935
7319	Human	hsa-miR-342-5p	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
7320	Human	hsa-miR-344a-3p	miRNA	curcumin (Cur)	schwannoma	RT4 schwannoma cells	curcumin treatment	upregulated	30534000
7321	Human	hsa-miR-345	miRNA	"trans-3,5,4-trimethoxystilbene (TMS)"	non-small cell lung cancer (NSCLC)	H1299 and PC©\9/GR cells	"trans-3,5,4-trimethoxystilbene (TMS) treatment"	upregulated	30701693
7322	Human	hsa-miR-345-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (oxLDL) treatment	downregulated	31825793
7323	Human	hsa-miR-345-3p	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	upregulated	31824817
7324	Human	hsa-miR-345-5p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
7325	Human	hsa-miR-345-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
7326	Human	hsa-miR-346	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	human colon cancer cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	25192497
7327	Human	hsa-miR-346	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	HeLa cells	thapsigargin (Tg) treatment	upregulated	29107113
7328	Human	hsa-miR-346	miRNA	leishmania	leishmaniasis	U937 and/or THP-1 human monocytic cells	leishmania infection	upregulated	29867904
7329	Human	hsa-miR-346	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	oral lichen planus (OLP)	HaCat cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29335479
7330	Human	hsa-miR-34a	miRNA	TGF-¦Â	colitis	HepG2 cells; Hepa1-6 cells; WRL68 cells; CD4+CD25+ T cells;CD4+CD25- T cells	TGF-¦Â treatment	downregulated	22975373
7331	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT8; SW480 cells	5-fluorouracil (5-FU) treatment	LncRNA NEAT1 could target miR-34a and promote autophagy to facilitate 5-FU chemoresistance in CRC.	31802650
7332	Human	hsa-miR-34a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	Human bone marrow stromal cell line HS-5 and human AML cell line HL60	adriamycin (ADR) treatment	downregulated	30551433
7333	Human	hsa-miR-34a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	downregulated	30551433
7334	Human	hsa-miR-34a	miRNA	all-trans retinoic acid (ATRA)	acute myeloid leukemia (AML)	KG-1 cells	all-trans retinoic acid (ATRA) treatment	upregulated	32006898
7335	Human	hsa-miR-34a	miRNA	decitabine	acute myeloid leukemia (AML)	KG-1 cells	decitabine (DAC) treatment	upregulated	32006898
7336	Human	hsa-miR-34a	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19 cells	H2O2 treatment	upregulated	31249522
7337	Human	hsa-miR-34a	miRNA	flavonoids (TFs)	aging	human umbilical vein endothelial cells (HUVEC)	flavonoids (TFs) treatment	downregulated	31106472
7338	Human	hsa-miR-34a	miRNA	ethanol (EtOH) and lipopolysaccharide (LPS)	alcoholic liver injury	Normal human hepatocytes (N-Heps) £» human intrahepatic biliary epithelial cells (HiBECs)	ethanol and lipopolysaccharide treatment	upregulated	22841474
7339	Human	hsa-miR-34a	miRNA	amyloid-¦Â (A¦Â) 1-40	Alzheimer's disease (AD)	Human neuroblastoma SH-SY5Y cells	amyloid-¦Â (A¦Â) 1-40 treatment	downregulated	31281568
7340	Human	hsa-miR-34a	miRNA	advanced glycation end product (AGE)	apoptosis	endothelial progenitor cells	advanced glycation end products (AGEs) treatment	upregulated	31397599
7341	Human	hsa-miR-34a	miRNA	capsaicin	apoptosis	"human lung cancer cell lines, A549 and H1299"	capsaicin treatment	upregulated	24444609
7342	Human	hsa-miR-34a	miRNA	hyperthermia	apoptosis	colorectal carcinoma (CRC) HCT116 cells	exposure to hyperthermia (42¡ãC for 2-4 h)	upregulated	29285066
7343	Human	hsa-miR-34a	miRNA	hypofractionated radiotherapy	apoptosis	human NPC cells	hypofractionated radiotherapy treatment	upregulated	25231528
7344	Human	hsa-miR-34a	miRNA	metformin (Met)	apoptosis	MCF-7 cells	metformin treatment	upregulated	24970682
7345	Human	hsa-miR-34a	miRNA	temozolomide (TMZ)	apoptosis	peripheral blood lymphocytes (PBLs) obtained from oncology nurses handling antineoplastic drugs	TMZ treatment	upregulated	28944882
7346	Human	hsa-miR-34a	miRNA	thymosin ¦Â4 (T¦Â4)	apoptosis	advanced glycation endproducts (AGEs)-treated endothelial progenitor cells	thymosin beta 4 (T¦Â4) treatment	downregulated	31397599
7347	Human	hsa-miR-34a	miRNA	IL-13	asthma	human bronchial epithelial cells (NHBE)	IL-13 treatment	upregulated	31386204
7348	Human	hsa-miR-34a	miRNA	genistein	atherosclerosis (AS)	ox-LDL-treat human umbilical vein endothelial cells (HUVECs)	"pretreated with genistein at different concentrations (10nM, 100nM and 1000nM) for 6h"	downregulated	28688900
7349	Human	hsa-miR-34a	miRNA	H2O2	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	"miR-34a upregulation was accompanied with reduced SIRT1 expression in HUVECs, following H2O2?treatment."	33488795
7350	Human	hsa-miR-34a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29328474
7351	Human	hsa-miR-34a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29704100
7352	Human	hsa-miR-34a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL treatment significantly increased the levels of miR-34a in a dose-dependent manner in the HUVECs.	29750293
7353	Human	hsa-miR-34a	miRNA	sulforaphane (SFN)	atherosclerosis (AS)	H2O2-treated human umbilical vein endothelial cells (HUVECs)	sulforaphane (SFN) treatment	downregulated	33488795
7354	Human	hsa-miR-34a	miRNA	indoxyl sulfate (IS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs); human aortic vascular smooth muscle cells (HA-VSMCs)	indoxyl sulfate (IS) treatment	IS up-regulates the expression of miR-34a in vitro.	32593718
7355	Human	hsa-miR-34a	miRNA	dexamethasone (DEX)	B-cell malignant multiple myeloma£¨MM£©	MM cells	dexamethasone (DEX) treatment	downregulated	23759586
7356	Human	hsa-miR-34a	miRNA	benzene	benzene toxicity	workers blood	benzene treatment	upregulated	27939626
7357	Human	hsa-miR-34a	miRNA	etoposide (VP-16)	brain tumour	MHH-Med1 cells	etoposide? treatment	upregulated	25250818
7358	Human	hsa-miR-34a	miRNA	"3,6-dihydroxyflavone (3,6-DHF)"	breast cancer	MDA-MB-231 cells	"3,6-dihydroxyflavone (3,6-DHF) treatment"	upregulated	28870206
7359	Human	hsa-miR-34a	miRNA	adoMet	breast cancer	MCF-7 cells	adoMet treatment	upregulated	30533999
7360	Human	hsa-miR-34a	miRNA	artemisinin (ART)	breast cancer	MCF-7/S cells	artemisinin treatment	upregulated	28361857
7361	Human	hsa-miR-34a	miRNA	artemisinin and artesunate	breast cancer	Human breast cancer cells	artemisinin and artesunate treatment	upregulated	25789847
7362	Human	hsa-miR-34a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
7363	Human	hsa-miR-34a	miRNA	curcumin (Cur)	breast cancer	MCF-10F and MDA-MB-231 breast cell lines	curcumin treatment	upregulated	31894298
7364	Human	hsa-miR-34a	miRNA	curcumin (Cur)	breast cancer	MCF-10F cells	curcumin (Cur) treatment	upregulated	31894298
7365	Human	hsa-miR-34a	miRNA	delphinidin	breast cancer	"Breast cancer cells MDA©\MB©\231, MCF©\7, and MDA©\MB©\453 w"	delphinidin treatment	upregulated	31325197
7366	Human	hsa-miR-34a	miRNA	diallyl disulfide (DADS)	breast cancer	MDA-MB-231 cells	Diallyl disulfide (DADS) treatment	upregulated	25396727
7367	Human	hsa-miR-34a	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
7368	Human	hsa-miR-34a	miRNA	hesperidin	breast cancer	MCF-7 cells	hesperidin treatment	upregulated	33050842
7369	Human	hsa-miR-34a	miRNA	IL-6	breast cancer	DLD-1 cells;HT-29 CRC;MCF7 breast cancer cells	exposure to IL-6 treatment	downregulated	24642471
7370	Human	hsa-miR-34a	miRNA	Indolo-pyrido-isoquinolin based?alkaloid	breast cancer	breast cancer cells	Indolo-pyrido-isoquinolin based?alkaloid treatment	upregulated	27259808
7371	Human	hsa-miR-34a	miRNA	luteolin	breast cancer	MCF-7 cells	luteolin treatment	upregulated	33050842
7372	Human	hsa-miR-34a	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
7373	Human	hsa-miR-34a	miRNA	rhamnetin	breast cancer	MCF-7 cell	rhamnetin treatment	upregulated	30655816
7374	Human	hsa-miR-34a	miRNA	rhamnetin	breast cancer	MCF-7 cells	rhamnetin treatment	miR-34a expression in MCF-7 cells was significantly increased following treatment with 20 and 25 ¦ÌM rhamnetin for 48 h compared with the untreated cells	30655816
7375	Human	hsa-miR-34a	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
7376	Human	hsa-miR-34a	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
7377	Human	hsa-miR-34a	miRNA	"3,6-dihydroxyflavone (3,6-DHF)"	breast cancer	human breast epithelial MCF10A cells	"3,6-dihydroxyflavone (3,6-DHF) treatment"	upregulated	25784176
7378	Human	hsa-miR-34a	miRNA	radiation	cardiac radiation-associated injury	human cardiomyocytes	radiation treatment	miR-34a was significantly increased in HCMs exposed to radiation	30226567
7379	Human	hsa-miR-34a	miRNA	H2O2	cataract	HLE-B3 cells	H2O2 treatment	upregulated	27990356
7380	Human	hsa-miR-34a	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
7381	Human	hsa-miR-34a	miRNA	5-aminolevulinic acid photodynamic therapy(ALA-PDT)	cervical cancer (CC)	"HPV-positive Hela, SiHa, Caski and HPV-negative C33?A cervical cancer cell lines"	5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment	downregulated	30118903
7382	Human	hsa-miR-34a	miRNA	high-risk human papillomavirus (hrHPV)	cervical cancer (CC)	cervical epithelium	high-risk human papillomavirus (HR-HPV) infection	downregulated	20442590
7383	Human	hsa-miR-34a	miRNA	"(1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI)"	cervical cancer (CC)	HeLa cells	"(1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI) treatment"	upregulated	30362332
7384	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	cervical cancer (CC)	HeLa cells	cisplatin (DPP) treatment	upregulated	30362332
7385	Human	hsa-miR-34a	miRNA	doxorubicin (DOX)	cervical cancer (CC)	HeLa cells	doxorubicin (DOX) treatment	upregulated	30362332
7386	Human	hsa-miR-34a	miRNA	selective S-adenosyl-methionine-competitive small-molecule (GSK126) or 5-Aza-2'-deoxycytidine	cholangiocarcinoma (CCA)	human cholangiocarcinoma (CCA)	GSK126 or 5-Aza-2'-deoxycytidine treatment	upregulated	28923203
7387	Human	hsa-miR-34a	miRNA	cyclophosphamide (CP)	chronic lymphocytic leukemia (CLL)	"WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines"	cyclophosphamide treatment	upregulated	30111844
7388	Human	hsa-miR-34a	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	"WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines"	fludarabine treatment	upregulated	30111844
7389	Human	hsa-miR-34a	miRNA	rituximab (RTX)	chronic lymphocytic leukemia (CLL)	"WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines"	rituximab treatment	upregulated	30111844
7390	Human	hsa-miR-34a	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
7391	Human	hsa-miR-34a	miRNA	H2O2	chronic obstructive pulmonary disease (COPD)	BEAS2B cells (human airway epithelial)	BEAS2B cells (human airway epithelial) treatment	upregulated	27767101
7392	Human	hsa-miR-34a	miRNA	trichostatin A (TSA)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cells (HPMVEC)	trichostatin A (TSA) treatment	upregulated	21224215
7393	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	colon cancer cells	5-fluorouracil (5-FU) treatment	downregulated	25333573
7394	Human	hsa-miR-34a	miRNA	"epigallocatechin-3-gallate (EGCG), resveratrol (RES) and ¦Á-mangostin (¦Á-M)"	colorectal cancer (CRC)	Human colon cancer cell lines DLD-1;SW480 ;COLO201	"epigallocatechin-3-gallate (EGCG), resveratrol (RES) and ¦Á-mangostin (¦Á-M) treatment"	upregulated	23954321
7395	Human	hsa-miR-34a	miRNA	proteinase activated receptor 2 (PAR2)	colorectal cancer (CRC)	The human colonic epithelial cell line HT-29; Caco-2; HCT-116;RKO ;human lung adenocarcinoma A549 cell line	proteinase activated receptor 2 (PAR2) treatment	downregulated	23991105
7396	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"Human normal colonic epithelial cell line, FHC, and colorectal carcinoma cell lines, HT29, HCT8, HCT116, SW480, SW620"	5-fluorouracil (5-FU) treatment	Inhibition of miR-34a or overexpression of HMGB1 could effectively reverse elevated 5-FU sensitivity upon NEAT1 knockdown.	31802650
7397	Human	hsa-miR-34a	miRNA	desflurane	colorectal cancer (CRC)	DLD-1 cells	desflurane treatment	downregulated of miR-34a and upregulation of LOXL3 were required for desflurane-induced EMT in CRC cells.	32658033
7398	Human	hsa-miR-34a	miRNA	ethanol extract of Spica Prunellae (EESP)	colorectal cancer (CRC)	human colon carcinoma HCT-8 cells	EESP	upregulated	28713966
7399	Human	hsa-miR-34a	miRNA	melatonin	colorectal cancer (CRC)	HCT116 cells	melatonin treatment	"Compared with the control group, melatonin significantly enhanced the expression levels of the miR-34a/449a cluster"	33398374
7400	Human	hsa-miR-34a	miRNA	oxaliplatin	colorectal cancer (CRC)	CRC patients colorectal cancer (CRC) tissues	treated with OXA-based chemotherapy treatment	downregulated in colorectal cancer (CRC) tissues	28348487
7401	Human	hsa-miR-34a	miRNA	oxaliplatin	colorectal cancer (CRC)	Human colon cancer cell lines HCT116 and SW480	oxaliplatin (L-OHP) treatment	downregulated	31040703
7402	Human	hsa-miR-34a	miRNA	Scutellaria barbata D. Don (SB)	colorectal cancer (CRC)	human colon cancer HCT-8 cells	ECSB treatment	upregulated	28498458
7403	Human	hsa-miR-34a	miRNA	sevoflurane (SEV)	colorectal cancer (CRC)	HCT116 and SW480 cells	sevoflurane treatment	upregulated	31305122
7404	Human	hsa-miR-34a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	colorectal cancer (CRC)	LOVO colorectal cancer cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25422210
7405	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	parental 5-FU- sensitive DLD-1 cells	5-fluorouracil (5-FU) treatment	upregulated	24447928
7406	Human	hsa-miR-34a	miRNA	cyclin-dependent kinase 1 (CDK1)	neuroblastoma (NB)	Human SH-SY5Y£»BE(2)-M17neuroblastoma cells	Cyclin-dependent kinase 1 (CDK1) treatment	CDK1 inhibition caused elevation of microRNA-34a	22703967
7407	Human	hsa-miR-34a	miRNA	X-rays	dental pulp repair and regeneration	MCF-10A cells; T-47D cells; MCF-7 cells	"low dose, low energy X-ray? treatment"	upregulated	24094113
7408	Human	hsa-miR-34a	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
7409	Human	hsa-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cultured human adult cardiomyocytes	high glucose (HG) treatment	upregulated	29302057
7410	Human	hsa-miR-34a	miRNA	advanced glycation end product (AGE)	diabetic nephropathy (DN)	serum	advanced glycation end (AGE) treatment	"The expression of acetylated p53 and miR-34a was upregulated, SIRT1was downregulated in glomeruli from patients with DN and STZ induced diabetic mice, as well as in human podocytes treated with advanced glycation end (AGE)."	33932899
7411	Human	hsa-miR-34a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	HG stimulation notably upregulated miR-34a expression	33536772
7412	Human	hsa-miR-34a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression.	30529346
7413	Human	hsa-miR-34a	miRNA	yiqichutan	diffuse large B-cell lymphoma (DLBCL)	SUDHL-6 cells	Yiqichutan treatment	"Yiqichutan treatment increased miR-34a expression levels and induced apoptosis, as well as reducing Foxp1 expression level in SUDHL-6 cells"	32765691
7414	Human	hsa-miR-34a	miRNA	arsenite	DNA methylation	human keratinocytes	arsenic exposure	produces cumulative disruptions to epigenetic regulation of miR-34a expression	25281835
7415	Human	hsa-miR-34a	miRNA	cigarette smoke extract (CSE)	apoptosis	human pulmonary microvascular endothelial cells (HPMECs)	cigarette smoke extract (CSE) treatment	miR-34a was significantly increased in CSE-treated HPMECs.	29373969
7416	Human	hsa-miR-34a	miRNA	ionizing radiation (IR)	endothelial dysfunction	A172 glioblastoma cells	irradiation treatment	downregulated	23155233
7417	Human	hsa-miR-34a	miRNA	laminar shear stress	cell differentiation	human umbilical cord blood-derived EPCs	parallel plate flow chamber system treatment	upregulated	24792364
7418	Human	hsa-miR-34a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	XIST promotes TGF-¦Â1-induced EMT by regulating the miR-34a-YAP-EGFR axis in PC	31013436
7419	Human	hsa-miR-34a	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Human lens epithelial cells (LECs)	transforming growth factor (TGF)-¦Â2 treatment	downregulated	31158382
7420	Human	hsa-miR-34a	miRNA	bleomycin (BLM)	epithelial-mesenchymal transition (EMT)	A549/ABCA3 cells	bleomycin (BLM) treatment	upregulated	31603744
7421	Human	hsa-miR-34a	miRNA	methotrexate (MTX)	epithelial-mesenchymal transition (EMT)	A549/ABCA3 cells	methotrexate (MTX) treatment	upregulated	31603744
7422	Human	hsa-miR-34a	miRNA	curcumin (Cur)	fat	esophageal cancer cell lines	curcumin treatment	downregulated	22363450
7423	Human	hsa-miR-34a	miRNA	pterostilbene	fructose-induced hepatic lipid accumulation	HepG2 cells	Pterostilbene treatment	Pterostilbene recovered the fructose-disturbed miR-34a expression	31927917
7424	Human	hsa-miR-34a	miRNA	curcumin (Cur)	gastric cancer (GC)	Human gastric cancer cell line SGC-7901	curcumin treatment	upregulated	31539270
7425	Human	hsa-miR-34a	miRNA	diallyl disulfide (DADS)	gastric cancer (GC)	SGC-7901 cells	Diallyl disulfide (DADS) treatment	upregulated	27073535
7426	Human	hsa-miR-34a	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN-45 cells	docetaxel (DTX) treatment	downregulated	33416185
7427	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	gastric cancer cells	Luteolin treatment	upregulated	24988056
7428	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	AGS cells; BGC823 cells; SGC7901 cells	luteolin (LTL) treatment	miR-34a was found to be markedly upregulated in GC cells induced by luteolin and decreased miR-34a level was found in the artificial luteolin-resistant GC cells.	29054762
7429	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	"human gastric cancer cell lines AGS, BGC823 and SGC7901"	luteolin treatment	upregulated	29054762
7430	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	BGC-823 and SGC-7901 human gastric carcinoma cell lines	luteolin treatment	upregulated	24988056
7431	Human	hsa-miR-34a	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
7432	Human	hsa-miR-34a	miRNA	dexamethasone (DEX)	glucocorticoid-induced osteonecrosis of femoral head (GIONFH)	human umbilical vein endothelial cells (HUVECs)	dexamethasone (Dex) treatment	Dex inhibited mMSC proliferation and mir-34a expression.	28543623
7433	Human	hsa-miR-34a	miRNA	genistein	head and neck squamous cell carcinoma (HNSCC)	HNC-TICs -1; HNC-TICs-2	genistein treatment	Genistein induced ROS production through upregulation of miR-34a.	32610494
7434	Human	hsa-miR-34a	miRNA	benzene	hematotoxicity	workers	benzene treatment	upregulated	27939626
7435	Human	hsa-miR-34a	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	upregulated	28708282
7436	Human	hsa-miR-34a	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	downregulated	28708282
7437	Human	hsa-miR-34a	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	human HCC cell lines HepG2	aflatoxin B1 (AFB1) treatment	upregulated	26567713
7438	Human	hsa-miR-34a	miRNA	"DNA-damaging compound, 0404"	hepatocellular carcinoma (HCC)	HepG2 cells	404	downregulated	28667294
7439	Human	hsa-miR-34a	miRNA	emodin	hepatocellular carcinoma (HCC)	HepG2 cells	Emodin?treatment	upregulated	30976957
7440	Human	hsa-miR-34a	miRNA	emodin	hepatocellular carcinoma (HCC)	HepG2 cells	emodin treatment	Emodin inhibited the expression of SMAD2/4 in HepG2 cells by inducing the miR-34a level.	30976957
7441	Human	hsa-miR-34a	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	serum	hepatitis C virus (HCV) infection	upregulated	29333940
7442	Human	hsa-miR-34a	miRNA	low-intensity ultrasound (LIUS)	hepatocellular carcinoma (HCC)	Huh7 and HCCLM3 cell	low-intensity ultrasound (LIUS) treatment	upregulated	31115495
7443	Human	hsa-miR-34a	miRNA	nanocurcumin	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	nanocurcumin treatment	upregulation	27165229
7444	Human	hsa-miR-34a	miRNA	taxol	hepatocellular carcinoma (HCC)	HepG2/Taxol; SMMC7721/Taxol	Taxol treatment	LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a	32700738
7445	Human	hsa-miR-34a	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
7446	Human	hsa-miR-34a	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
7447	Human	hsa-miR-34a	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
7448	Human	hsa-miR-34a	miRNA	angiotensin II (Ang II)	hypertension and diabetes	AB8/13 cells	angiotensin II (Ang II) treatment	upregulated	32887498
7449	Human	hsa-miR-34a	miRNA	high glucose (HG)	hypertension and diabetes	AB8/13 cells	high glucose (HG) treatment	upregulated	32887498
7450	Human	hsa-miR-34a	miRNA	curcumin with emodin	hypertension	breast cancer cells	curcumin with emodin treatment	upregulated	23771315
7451	Human	hsa-miR-34a	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	downregulated	29516639
7452	Human	hsa-miR-34a	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	upregulated	29516639
7453	Human	hsa-miR-34a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus-infected	downregulated	27610823
7454	Human	hsa-miR-34a	miRNA	"2,4,5-trihydroxybenzaldehyde (TDB)"	ischemic vascular injuries	HUVEC cells following OGD/R	"2,4,5-trihydroxybenzaldehyde (TDB) treatment"	downregulated	27885275
7455	Human	hsa-miR-34a	miRNA	ingenol-mebutate	keloids	keloid fibroblasts	Ingenol-mebutate treatment	"In particular, the upregulation of miR-34a was detected in keloid fibroblasts during and following Ingenol-mebutate exposure."	29568916
7456	Human	hsa-miR-34a	miRNA	phorbol-12-myristate-13-acetate(PMA)	leukemia	human chronic myelocytic leukemia cell line K562	Phorbol 12-myristate 13-acetate (PMA) treatment	upregulated	20299489
7457	Human	hsa-miR-34a	miRNA	resistin	lipid metabolism	HepG2	resistin treatment	upregulated	29197627
7458	Human	hsa-miR-34a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	human HCC and adjacent non-tumoral liver tissues	sorafenib treatment	downregulated	23862748
7459	Human	hsa-miR-34a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	expression and chemoresistance has not been explored in HCC	sorafenib treatment	downregulated	23862748
7460	Human	hsa-miR-34a	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	upregulated	24431000
7461	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	lung cancer	"NSCLC cancer cells, including H226, H1299, A549, H1975 and HCC827"	cisplatin treatment	upregulated	27836543
7462	Human	hsa-miR-34a	miRNA	particulate matter (PM2.5)	lung cancer	human non-small cell lung cancer cell line A549	chronic (five passages) PM2.5 exposure treatment	downregulated	28846189
7463	Human	hsa-miR-34a	miRNA	PRIMA-1	lung cancer	human lung cancer cells	PRIMA-1 treatment	upregulated	19921694
7464	Human	hsa-miR-34a	miRNA	radiation	malignant mesothelioma (MM)	epithelial type M28K cells	radiation treatment	upregulated	22237142
7465	Human	hsa-miR-34a	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood CD14+ monocytes	lenalidomide treatment	upregulated	25287904
7466	Human	hsa-miR-34a	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood	Lenalidomide treatment	upregulated	25287904
7467	Human	hsa-miR-34a	miRNA	estradiol-17¦Â (E2)	myofibroblast differentiation	MCF-7 cells	estradiol-17¦Â (E2) treatment	"in MCF-7, which is an ER¦Á-positive breast cancer cell line, miR-34a is remarkably downregulated after E2 treatment"	24050776
7468	Human	hsa-miR-34a	miRNA	ethanol (EtOH)	neural differentiation	Neural crest cells (NCCs)	ethanol exposure	upregulated	31247197
7469	Human	hsa-miR-34a	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
7470	Human	hsa-miR-34a	miRNA	retinoic acid (RA)	neuroblastoma (NB)	SK-N-BE cell line	retinoic acid treatment	"miR-34a expression increases during retinoic acid-induced differentiation of the SK-N-BE cell line, whereas E2F3 protein levels decrease"	17297439
7471	Human	hsa-miR-34a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
7472	Human	hsa-miR-34a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	downregulated	32143184
7473	Human	hsa-miR-34a	miRNA	ursodeoxycholic acid (UDCA)	nonalcoholic fatty liver disease (NAFLD)	morbidly obese NAFLD-patients vesicle-free fraction in serum	UDCA treatment	downregulated in the vesicle-free fraction in serum	28853202
7474	Human	hsa-miR-34a	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	NSCLC cells	erlotinib treatment	upregulated	24551227
7475	Human	hsa-miR-34a	miRNA	nutlin-3a	non-small cell lung cancer (NSCLC)	normal human fibroblasts	Nutlin-3a treatment	upregulated	18451145
7476	Human	hsa-miR-34a	miRNA	palliative chemotherapy	non-small cell lung cancer (NSCLC)	NSCLC tissues	platinum derivatives in combination with paclitaxel or gemcitabine treatment	upregulated	29387235
7477	Human	hsa-miR-34a	miRNA	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np)	non-small cell lung cancer (NSCLC)	A549 cells	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) treatment	upregulated	31411213
7478	Human	hsa-miR-34a	miRNA	pemetrexed	non-small cell lung cancer (NSCLC)	NSCLC tissue	pemetrexed treatment	upregulated	23794259
7479	Human	hsa-miR-34a	miRNA	Rhamnetin and cirsiliol	non-small cell lung cancer (NSCLC)	"NSCLC cells, NCI-H1299 and NCI-H460"	Rhamnetin and cirsiliol treatment	upregulated	23902763
7480	Human	hsa-miR-34a	miRNA	Delta-tocotrienol	non-small cell lung cancer (NSCLC)	Human NSCLC cell lines (A549 and H1650)	Delta-tocotrienol treatment	upregulated	22438124
7481	Human	hsa-miR-34a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	nucleus pulposus cell (NPC)	tumor necrosis factor alpha (TNF-¦Á) treatment	MiR-34a is upregulated in TNF-¦Á- induced NPCs	30138895
7482	Human	hsa-miR-34a	miRNA	hypoxia	oropharyngeal squamous cell carcinoma (OPSCC)	SCC25 cells; SCC090 cells	hypoxia treatment	upregulated	32102296
7483	Human	hsa-miR-34a	miRNA	H2O2	osteoarthritis (OA)	human OA chondrocytes	H2O2 treatment	downregulated (miR-146a) ; upregulated(miR-34a)	29292727
7484	Human	hsa-miR-34a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	hydrostatic pressure (HP) treatment	upregulated	32455798
7485	Human	hsa-miR-34a	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	upregulated	29236314
7486	Human	hsa-miR-34a	miRNA	resistin	osteoarthritis (OA)	human OA synovial fibroblasts	resistin treatment	upregulated	31635187
7487	Human	hsa-miR-34a	miRNA	visfatin	osteoarthritis (OA)	human OA chondrocytes	visfatin treatment	"upregulated, all the visfatin-caused effects were suppressed by using miR-34a and miR-181a inhibitors."	31405216
7488	Human	hsa-miR-34a	miRNA	visfatin	osteoarthritis (OA)	human OA synovial fibroblasts	visfatin treatment	upregulated	31635187
7489	Human	hsa-miR-34a	miRNA	etoposide (VP-16)	osteosarcoma (OS)	human osteosarcoma cell lines	etoposide treatment	upregulated	25490093
7490	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells	cisplatin (DPP) treatment	downregulated	29561664
7491	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
7492	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
7493	Human	hsa-miR-34a	miRNA	H2O2	oxidative stress	Human bone marrow mesenchymal stromal/stem cells (hMSCs)	H2O2 treatment	upregulated	29331104
7494	Human	hsa-miR-34a	miRNA	H2O2	oxidative stress	Human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	upregulated	29992759
7495	Human	hsa-miR-34a	miRNA	kallistatin	oxidative stress	HEK293T cells	Kallistatin treatment	downregulated	28544111
7496	Human	hsa-miR-34a	miRNA	kallistatin	oxidative stress	H2O2-treated human umbilical vein endothelial cells (HUVECs)	Kallistatin treatment	downregulated	29992759
7497	Human	hsa-miR-34a	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
7498	Human	hsa-miR-34a	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
7499	Human	hsa-miR-34a	miRNA	genistein	pancreatic cancer (PC)	"Human PC cell lines, including AsPC-1 and MiaPaCa-2"	Genistein treatment	upregulated	21301871
7500	Human	hsa-miR-34a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
7501	Human	hsa-miR-34a	miRNA	propofol (PPF)	pancreatic cancer (PC)	PANC-1 cells	propofol treatment	"Propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression"	32303144
7502	Human	hsa-miR-34a	miRNA	TGF-¦Â1	pancreatic cancer (PC)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	XIST promotes TGF-¦Â1-induced EMT by regulating the miR-34a-YAP-EGFR axis in PC	31013436
7503	Human	hsa-miR-34a	miRNA	rotenone (ROT)	parkinson's disease (PD)	SH-SY5Y cell	rotenone treatment	downregulated	28259991
7504	Human	hsa-miR-34a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	30221494
7505	Human	hsa-miR-34a	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	Human lens epithelial cells (LECs)	transforming growth factor (TGF)-¦Â2 treatment	downregulated	31158382
7506	Human	hsa-miR-34a	miRNA	doxorubicin (DOX)	posterior capsular opacification (PCO)	human lens epithelial cell line HLE B3	doxorubicin treatment	upregulated	30980790
7507	Human	hsa-mir-34a	miRNA	hypoxia	preeclampsia (PE)	JEG-3 cells	hypoxia treatment	upregulated	24081307
7508	Human	hsa-miR-34a	miRNA	propofol (PPF)	propofol-induced neurotoxicity and cognitive dysfunction	SH-SY5Y cells	propofol treatment	microRNA-34a was upregulated after propofol treatment	29578002
7509	Human	hsa-miR-34a	miRNA	butyl benzyl phthalate (BBP)	prostate cancer	Human prostate cancer LNCaP and PC-3 cells	butyl benzyl phthalate (BBP) treatment	downregulated	30243731
7510	Human	hsa-miR-34a	miRNA	butyl benzyl phthalate (BBP)	prostate cancer	LNCaP and PC-3 cells	butyl benzyl phthalate (BBP) treatment	downregulated	30243731
7511	Human	hsa-miR-34a	miRNA	"codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone"	prostate cancer	"LNCaP, C4-2 , DU145 , and PC3 cells"	"codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone treatment"	upregulated	28428276
7512	Human	hsa-miR-34a	miRNA	curcumin (Cur)	prostate cancer	"Human prostate cancer 22RV1, PC©\3, and DU145 cells"	curcumin treatment	upregulated	31042325
7513	Human	hsa-miR-34a	miRNA	fractionated radiation	prostate cancer	Human Prostate Cancer Cells	radiation treatment	Tumor suppressor miR-34a and let-7 miRNAs were upregulated by fractionated radiation in radiosensitive LNCaP (p53 positive) and PC3 (p53-null) cells indicating	22827214
7514	Human	hsa-miR-34a	miRNA	genistein	prostate cancer	LNCaP cells£» PC3 cells£» DU145 cells£» RWPE-1 cells	genistein treatment	genistein inhibited PCa cell growth through downregulated of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a	23936419
7515	Human	hsa-miR-34a	miRNA	hypermethylation	prostate cancer	PCa tissues and cell lines	hypermethylation treatment	downregulated	26499184
7516	Human	hsa-miR-34a	miRNA	hypoxia	renal cell carcinoma (RCC)	HK-2 cells	hypoxia treatment	downregulated	22363487
7517	Human	hsa-miR-34a	miRNA	dihydromyricetin (DHM)	renal fibrosis	TGF-¦Â1-treated HK-2 cells	Dihydromyricetin (DHM) treatment	downregulated	30853453
7518	Human	hsa-miR-34a	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	transforming growth factor ¦Â1 (TGF-¦Â1) treatment	upregulated	30853453
7519	Human	hsa-miR-34a	miRNA	dioscin	renal injury	cisplatin (CDDP)-induced NRK-52E and HK-2 cells	dioscin treatment	upregulated	28514495
7520	Human	hsa-miR-34a	miRNA	vascular endothelial growth factor (VEGF)	retinal angiogenesis	human retinal microvascular endothelial cells (HRMECs)	vascular endothelial growth factor (VEGF) treatment	downregulated	30571142
7521	Human	hsa-miR-34a	miRNA	vascular endothelial growth factor (VEGF)	retinal angiogenesis	human retinal microvascular endothelial cells (HRMECs)	vascular endothelial growth factor (VEGF) treatment	downregulated	30571142
7522	Human	hsa-miR-34a	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
7523	Human	hsa-miR-34a	miRNA	lipopolysaccharide (LPS)	sepsis	U937 cells	lipopolysaccharide (LPS) treatment	miR-34a was upregulated in Lipopolysaccharide (LPS)-induced U937 cell lines.	30021364
7524	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	sinonasal squamous cell carcinoma	Tumor samples	cis-diamminedichloroplatinum treatment	downregulated	22624980
7525	Human	hsa-miR-34a	miRNA	high glucose (HG)	stress-associated premature senescence (SAPS)	Human retinal microvascular endothelial cells (HuREC)	high glucose (HG) treatment	upregulated	31443378
7526	Human	hsa-miR-34a	miRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	HK2 cells	lipopolysaccharide (LPS) treatment	LPS reduced the expression of miR-34a.	30414207
7527	Human	hsa-miR-34a	miRNA	IL-1¦Â and TNF-¦Á	type 2 diabetes mellitus (T2DM)	human pancreatic islets	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
7528	Human	hsa-miR-34a	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	"ACHN, 769-P, and A498 cells"	metformin treatment	upregulated	28045889
7529	Human	hsa-miR-34a	miRNA	lopinavir	vascular aging	vascular endothelial cells (ECs)	lopinavir treatment	upregulated	27889708
7530	Human	hsa-miR-34a	miRNA	ritonavir	vascular aging	vascular endothelial cells (ECs)	ritonavir treatment	upregulated	27889708
7531	Human	hsa-miR-34a	miRNA	high glucose (HG)	vascular endothelial dysfunction	human microvascular endothelial cell-1 (HMEC-1) cells	high glucose (HG) treatment	upregulated	31533227
7532	Human	hsa-miR-34a	miRNA	vaccarin (VAC)	vascular endothelial dysfunction	high glucose (HG)-treated human microvascular endothelial cell-1 (HMEC-1) cells	Vaccarin (VAC) treatment	downregulated	31533227
7533	Human	hsa-miR-34a	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
7534	Human	hsa-miR-34a	miRNA	hypoxia	wet age-related macular degeneration (wAMD)	ARPE-19 cells	hypoxia induce	HIF-1¦Á-dependent p53 activation upregulated miRNA-34a expression in ARPE-19 cells following hypoxia.	33438362
7535	Human	hsa-miR-34a	miRNA	adriamycin (ADR)	colorectal cancer (CRC)	human colon cancer cell line HCT 116	adriamycin (ADR) treatment	upregulated	17875987
7536	Human	hsa-miR-34a	miRNA	phorbol ester	megakaryocytic differentiation	K562 cells	phorbol ester treatment	upregulated	19584398
7537	Human	hsa-miR-34a	miRNA	thyroid hormone	renal tubular epithelial to mesenchymal transition	human proximal tubular epithelial cell line HK-2	Thyroid hormone?treatment treatment	downregulated	23770290
7538	Human	hsa-miR-34a*	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood CD14+ monocytes	lenalidomide treatment	upregulated	25287904
7539	Human	hsa-miR-34a*	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood	Lenalidomide treatment	upregulated	25287904
7540	Human	hsa-miR-34a-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer (GC) tissues	Helicobacter pylori (HP) treatment	downregulated	30242897
7541	Human	hsa-miR-34a-3p	miRNA	ultrasound (US)	multidrug resistance (MDR)	MCF-7/ADR and HEPG2/ADM cells	ultrasound (US) irradiation treatment	upregulated	30231924
7542	Human	hsa-miR-34a-3p	miRNA	metformin (Met)	cell senescence	dental pulp stem cells (DPSCs)	Metformin (Met) treatment	metformin significantly suppressed microRNA-34a-3p (miR-34a-3p) expression	33505470
7543	Human	hsa-miR-34a-5p	miRNA	H2O2	age-related nuclear cataract	human lens epithelial B3 (HLE-B3) cell	H2O2 treatment	upregulated	29653565
7544	Human	hsa-miR-34a-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
7545	Human	hsa-miR-34a-5p	miRNA	hypoxia	autophagy	"human coronary artery endothelial cells (HCAECs),"	?chronic intermittent hypoxia (CIH) induce	upregulated	31218746
7546	Human	hsa-miR-34a-5p	miRNA	doxorubicin (DOX)	breast cancer	MDA-MB-231 cells	doxorubicin treatment	downregulated	30245930
7547	Human	hsa-miR-34a-5p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (Dox) treatment	upregulated	30245930
7548	Human	hsa-miR-34a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MCF-7 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	upregulated	30245930
7549	Human	hsa-miR-34a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MDA-MB-231 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	upregulated	30245930
7550	Human	hsa-miR-34a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	breast cancer	MDA-MB-231 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin treatment	upregulated	30245930
7551	Human	hsa-miR-34a-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	K562 cells	imatinib treatment	downregulated	31923418
7552	Human	hsa-miR-34a-5p	miRNA	sevoflurane (SEV)	colorectal cancer (CRC)	SW480 cells; LOVO cells	sevoflurane treatment	sevoflurane inhibited colon cancer progression by modulating the exosome-transmitted circ-HMGCS1/miR-34a-5p/SGPP1 axis	33125091
7553	Human	hsa-miR-34a-5p	miRNA	paroxetine	depression	serum	paroxetine treatment	downregulated	29791588
7554	Human	hsa-miR-34a-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	diffuse large B-cell lymphoma (DLBCL)	HT and U2932 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24722400
7555	Human	hsa-miR-34a-5p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
7556	Human	hsa-miR-34a-5p	miRNA	steroids	endometriosis	ovarian endometrial	steroid hormones treatment	upregulated	26819477
7557	Human	hsa-miR-34a-5p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	upregulated	32582989
7558	Human	hsa-miR-34a-5p	miRNA	"cisplatin, N-ethyl-N-nitrosourea, etoposide, mitomycin C, methyl methanesulphonate, taxol, and X-ray radiation"	genotoxicity	TK6 cells	"cisplatin, N-ethyl-N-nitrosourea, etoposide, mitomycin C, methyl methanesulphonate, taxol, and X-ray radiation"	upregulated	32929177
7559	Human	hsa-miR-34a-5p	miRNA	olive oil polyphenol hydroxytyrosol (HT)	inflammation	TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	olive oil polyphenol hydroxytyrosol (HT) treatment	downregulated	31627295
7560	Human	hsa-miR-34a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31627295
7561	Human	hsa-miR-34a-5p	miRNA	compression force (CF)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	compression treatment	upregulated	32114390
7562	Human	hsa-miR-34a-5p	miRNA	hypoxia/reoxygenation (H/R)	intestinal hypoxia/reoxygenation injury	caco-2 cells	hypoxia-reoxygeneration (H/R) treatment	upregulated	26935288
7563	Human	hsa-miR-34a-5p	miRNA	lipopolysaccharide (LPS)	LPS-induced injury	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	MiR-34a-5p expression was significantly enhanced in HUVECs after 24 h of LPS treatment.	33155244
7564	Human	hsa-miR-34a-5p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	upregulated	33071785
7565	Human	hsa-miR-34a-5p	miRNA	hypoxia	myocardial infarction (MI)	human cardiac myocytes	hypoxia induce	upregulated	30312158
7566	Human	hsa-miR-34a-5p	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	human NPC cell lines CNE-1 and CNE-2	ionizing radiation	upregulated	28985197
7567	Human	hsa-miR-34a-5p	miRNA	luteolin	non-small cell lung cancer (NSCLC)	A549 cells; H460 cells	luteolin (LTL) treatment	miR-34a-5p was dramatically upregulated upon LTL treatment in tumor tissues.	29393891
7568	Human	hsa-miR-34a-5p	miRNA	oleacein (OA)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleacein (OA) treatment	downregulated	31766503
7569	Human	hsa-miR-34a-5p	miRNA	oleocanthal (OC)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleocanthal (OC) treatment	downregulated	31766503
7570	Human	hsa-miR-34a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31766503
7571	Human	hsa-miR-34a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Hyperplastic synovial fibroblasts (SFs)	interleukin-1¦Â treatment	upregulated	31777535
7572	Human	hsa-miR-34a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	"SNHG7 sponged miR-34a-5p to affect cell proliferation, apoptosis and autophagy through targeting SYVN1"	32066502
7573	Human	hsa-miR-34a-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells; A2780 cells	cisplatin treatment	miR-34a-5p was decreased in DDP-resistant cells.	31777260
7574	Human	hsa-miR-34a-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 and A2780 ovarian cancer cell lines	cisplatin treatment	downregulated	31777260
7575	Human	hsa-miR-34a-5p	miRNA	docetaxel (DTX)	prostate cancer	PCa samples; PC3 cells; DU145 cells	docetaxel (DTX) treatment	downregulated	31672604
7576	Human	hsa-miR-34a-5p	miRNA	high glucose (HG)	tubulointerstitial fibrosis (TIF)	human proximal tubule cell line(HK-2) cells	high glucose treatment	upregulated	29371016
7577	Human	hsa-miR-34a-c	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
7578	Human	hsa-miR-34b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	acute lymphoblastic leukemia (ALL)	HL-60 and K562 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26861642
7579	Human	hsa-miR-34b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	chronic lymphocytic leukemia (CLL)	MEC1 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24559316
7580	Human	hsa-miR-34b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"miR-34b overexpression inhibited apoptosis and expression levels of TNF-alpha, IL-1?, IL-6, and caspase-3 in HG-treated HK-2 cells."	31665127
7581	Human	hsa-miR-34b	miRNA	nanocurcumin	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	nanocurcumin treatment	upregulation	27165229
7582	Human	hsa-miR-34b	miRNA	CdSe/ZnS-GSH	lung cancer	A549 cells	CdSe/ZnS-GSH treatment	upregulated	31883144
7583	Human	hsa-miR-34b	miRNA	CdSe/ZnS-MPA	lung cancer	A549 cells	CdSe/ZnS-MPA treatment	upregulated	31883144
7584	Human	hsa-miR-34b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	melanoma	melanoma tissue	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	21949788
7585	Human	hsa-miR-34b	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegeneration (ND)	SH-SY5Y human neuroblastoma cells	ELF-MFs	downregulated	29039021
7586	Human	hsa-miR-34b	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegenerative diseases	SH-SY5Y human neuroblastoma cells	extremely low-frequency magnetic fields (ELF-MFs) treatment	downregulated	29039021
7587	Human	hsa-miR-34b	miRNA	nutlin-3a	non-small cell lung cancer (NSCLC)	normal human fibroblasts	Nutlin-3a treatment	upregulated	18451145
7588	Human	hsa-miR-34b	miRNA	sirolimus	osteosarcoma (OS)	Human OS cell line MG63/ADM	sirolimus treatment	upregulated	26924291
7589	Human	hsa-miR-34b-5p	miRNA	melatonin	oral cancer	SAS cells; SCC9 cells	Melatonin treatment	Melatonin reduced the drug resistance and promoted the apoptosis of VCR-resistant oral cancer cells through the upregulation of microRNA-892a (miR-892a) and miR-34b-5p expressions.	31982774
7590	Human	hsa-miR-34b-5p	miRNA	melatonin	vincristine (VCR) resistance	SAS cells; SCC9 cells	Melatonin treatment	upregulated	31982774
7591	Human	hsa-miR-34c	miRNA	high glucose (HG)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	MicroRNA-34c suppresses proliferation of vascular smooth muscle cell via modulating high mobility group box protein 1	32157741
7592	Human	hsa-miR-34c	miRNA	adoMet	breast cancer	MCF-7 cells	adoMet treatment	upregulated	30533999
7593	Human	hsa-miR-34c	miRNA	benzo(a)pyrene (BaP)	cell transformation	human bronchial epithelial (HBE) cells	benzo(a)pyrene (BaP) exposure	downregulated	24362009
7594	Human	hsa-miR-34c	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	cigarette smoke extract (CSE) treatment	LncRNA TUG1 knockdown mitigates inflammatory injury induced by cigarette smoke extract in chronic obstructive pulmonary disease via miR-34c/BRD4 axis	32812639
7595	Human	hsa-miR-34c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	CIHP-1 cells	high glucose (HG) treatment	CASC15 is upregulated in DCRF patients and promotes the apoptosis of podocytes by sponging miR-34c.	32053576
7596	Human	hsa-miR-34c	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
7597	Human	hsa-miR-34c	miRNA	zika virus (ZIKV)	glioblastoma multiforme (GBM)	glioblastoma stem cells (GSCs)	Zika virus (ZIKV) infection treatment	upregulated	30890698
7598	Human	hsa-miR-34c	miRNA	nanocurcumin	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	nanocurcumin treatment	upregulation	27165229
7599	Human	hsa-miR-34c	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegeneration (ND)	SH-SY5Y human neuroblastoma cells	ELF-MFs	downregulated	29039021
7600	Human	hsa-miR-34c	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegenerative diseases	SH-SY5Y human neuroblastoma cells	extremely low-frequency magnetic fields (ELF-MFs) treatment	downregulated	29039021
7601	Human	hsa-miR-34c	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
7602	Human	hsa-miR-34c	miRNA	nutlin-3a	non-small cell lung cancer (NSCLC)	normal human fibroblasts	Nutlin-3a treatment	upregulated	18451145
7603	Human	hsa-miR-34c	miRNA	radiation	prostate cancer	LNCaP cells;C4-2 cells	radiation treatment	upregulated	18668526
7604	Human	hsa-miR-34c	miRNA	doxycycline	reprogramming activity of somatic cell nuclear transfer (SCNT) embryos	Primary fibroblast cell cultures	doxycycline (DXC) treatment	upregulated	25437869
7605	Human	hsa-miR-34c	miRNA	S-adenosyl-L-methionine (AdoMet)	triple negative breast cancer (TNBC)	MDA-MB-231; MDA-MB-468 cells	S-adenosyl-L-methionine (AdoMet) treatment	AdoMet exerts its antitumor effects in TNBC cells through upregulating the expression of miR-34c and miR-449a	33396625
7606	Human	hsa-miR-34c-3p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
7607	Human	hsa-miR-34c-3p	miRNA	glargine	pancreatic cancer (PC)	pancreatic cancer cells	glargine treatment	upregulated	22690071
7608	Human	hsa-miR-34c-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
7609	Human	hsa-miR-34c-5p	miRNA	sodium valproate (VPA)	autophagy	SH-SY5Y cells	sodium valproate (VPA) treatment	upregulated	30613007
7610	Human	hsa-miR-34c-5p	miRNA	ultraviolet (UV) irradiation	breast cancer	normal human primary dermal fibroblasts	ultraviolet irradiation treatment	upregulated	23983607
7611	Human	hsa-miR-34c-5p	miRNA	arsenite	tumorigenesis	derivative normal stem cell (SC) line	arsenite exposure	downregulated	24431212
7612	Human	hsa-miR-34c-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	human-induced pluripotent stem cell (hiPSC)	doxorubicin treatment	upregulated	26842497
7613	Human	hsa-miR-34c-5p	miRNA	pirarubicin (THP)	cervical cancer (CC)	cervical cancer cells	Pirarubicin (THP)treatment	downregulated	27097054
7614	Human	hsa-miR-34c-5p	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	HCT-8 cells	PZH treatment	upregulated	29042999
7615	Human	hsa-miR-34c-5p	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
7616	Human	hsa-miR-34c-5p	miRNA	high glucose (HG)	vascular calcification (VC)	human aorta vascular smooth muscle cells (HA-VSMCs)	high glucose treatment	"Overexpression of miR-34c-5p alleviated calcification/senescence of HA-VSMCs, whereas inhibition of miR-34c-5p received the opposite results."	30654331
7617	Human	hsa-miR-351	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
7618	Human	hsa-miR-3605-5p	miRNA	coxsackievirus A16 (CVA16) and enterovirus 71(EV71)	hand-foot-mouth disease (HFMD)	human embryonic kidney 293T cells	infect with CVA16 and EV71	downregulated	28198671
7619	Human	hsa-miR-3607-3p	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular cells (HK-2)	TGF-¦Â1 treatment	downregulated	31455266
7620	Human	hsa-miR-3607-5p	miRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-4B"	particulate matter 2.5 (PM2.5) exosure treatment	"CircRNA104250 and lncRNAuc001dgp1 target miR-3607-5p and affect expression of interleukin 1 receptor 1 (IL1R1), which influences the nuclear factor ¦ÊB (NF-¦ÊB) signaling pathway"	31864925
7621	Human	hsa-miR-3609	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
7622	Human	hsa-miR-3609	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
7623	Human	hsa-miR-361	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
7624	Human	hsa-miR-361	miRNA	Somatostatin (SRIF)	antiangiogenic	human umbilical vein endothelial cells	Somatostatin (SRIF)? treatment	downregulated	23128854
7625	Human	hsa-miR-361	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
7626	Human	hsa-miR-361	miRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"miR-361 expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR-361"	31694982
7627	Human	hsa-miR-3610	miRNA	Traumatic brain injury (TBI)	hypopituitarism	blood	Traumatic brain injury (TBI) treatment	upregulated	27027233
7628	Human	hsa-miR-3613	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
7629	Human	hsa-miR-3613-3p	miRNA	palbociclib	triple negative breast cancer (TNBC)	MDA-MB-231 cells	palbociclib treatment	Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib	33330073
7630	Human	hsa-miR-3613-5p	miRNA	simvastatin	endometriosis	Serum	simvastatin treatment	upregulated	29587611
7631	Human	hsa-miR-3613-5p	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
7632	Human	hsa-miR-361-3p	miRNA	resveratrol	Alzheimer's disease (AD)	SK-N-SH cells; CHP-212 cells	resveratrol (Res) treatment	upregulated	32741808
7633	Human	hsa-miR-361-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cell (HUVEC)	high glucose (HG) treatment	Knockdown of MALAT1 inhibits HG-induced vascular endothelial injury through regulating miR-361-3p/SOCS3 axis.	32509100
7634	Human	hsa-miR-361-3p	miRNA	enzalutamide (Enz)	prostate cancer	C4-2 cells	enzalutamide (Enz) treatment	downregulated	32978369
7635	Human	hsa-miR-361-3p	miRNA	helicobacter pylori (H. pylori)	sophageal carcinogenesis	human esophageal cell line HET-1A	Helicobacter pylori infection	miR-361-3p was significantly decreased in HET-1A cells exposure to H. pylor.	30783439
7636	Human	hsa-miR-361-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31312370
7637	Human	hsa-miR-361-5p	miRNA	dexmedetomidine (DEX)	osteoporosis	human umbilical vein endothelial cells (HUVECs)	dexamethasone (DEX) treatment	"After Dex treatment, the expressions of miR-361-5p, VEGFA, BMD related indexes were increased in OP rats."	33631172
7638	Human	hsa-miR-361-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	Human pulmonary artery smooth muscle cells (hPASMCs)	hypoxia induce	upregulated	29339076
7639	Human	hsa-miR-3619-5p	miRNA	platelet-derived growth factor (PDGF)	asthma	Human fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	downregulated	31014672
7640	Human	hsa-miR-3619-5p	miRNA	5-fluorouracil (5-FU)	gastric cancer (GC)	AGS cell; MKN45 cells	5-fluorouracil (5-FU) treatment	downregulated	32300102
7641	Human	hsa-miR-3619-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS/DPP; NUGC-3/DPP cells	cisplatin treatment	PVT1 silencing attenuated the DPP resistance in GC by downregulating TBL1XR1 via sponging miR-3619-5p.	32407172
7642	Human	hsa-miR-3619-5p	miRNA	oxaliplatin	gastric cancer (GC)	AGS cell; MKN45 cells	oxaliplatin (OXA) treatment	downregulated	32300102
7643	Human	hsa-miR-3619-5p	miRNA	heat stress	hepatocellular carcinoma (HCC)	Huh7 cells; MHCC97 cells	heating treatment	downregulated	32799553
7644	Human	hsa-miR-3619-5p	miRNA	naringenin	lung cancer	A549 cells; PC9 cells	naringenin treatment	Naringenin hindered cell metastasis in vitro and tumor growth in vivo by reducing circFOXM1 and SPAG5 expression and inducing the expression of miR-3619-5p in lung cancer.	32598178
7645	Human	hsa-miR-3619-5p	miRNA	isoimperatorin (ISO)	melanin metabolism disorders	HaCaT cells	Isoimperatorin (ISO) treatment	downregulated	32299303
7646	Human	hsa-miR-362	miRNA	erythropoietin (EPO)	erythroid cell differentiation	The original UT-7 cell line	erythropoietin treatment	upregulated	18492109
7647	Human	hsa-miR-3620-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
7648	Human	hsa-miR-362-3p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	downregulated	30131392
7649	Human	hsa-miR-362-3p	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
7650	Human	hsa-miR-362-3p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
7651	Human	hsa-miR-362-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-362-3p expression increased while methylation of its promoter significantly decreased in human HCC cells and tissues compared with normal cells and adjacent noncancerous tissues.	25649327
7652	Human	hsa-miR-362-5p	miRNA	"chlorpromazine, haloperidol and clozapine"	psychosis	JM-Jurkat T-lymphocytes	"chlorpromazine, haloperidol and clozapine treatment"	dysregulated	24480591
7653	Human	hsa-miR-362-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	downregulated	31790802
7654	Human	hsa-miR-362-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	GC cell line SGC7901	cisplatin treatment	downregulated	31423228
7655	Human	hsa-miR-362-5p	miRNA	crizotinib	non-small cell lung cancer (NSCLC)	ALK-positive NSCLC patients plasma	crizotinib treatment	upregulated	28514730
7656	Human	hsa-miR-363	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
7657	Human	hsa-miR-363	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 14¡ã HDT bed rest experiment	downregulated	28261104
7658	Human	hsa-miR-363	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	downregulated	26143754
7659	Human	hsa-miR-363	miRNA	oxaliplatin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	oxaliplatin (OXA) treatment	miR-363 expression levels were downregulated in oxaliplatin-resis- tant HCC cell lines compared with parental cell lines	29602203
7660	Human	hsa-miR-363	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
7661	Human	hsa-miR-363-3p	miRNA	dual MEK/Aurora kinase inhibitor BI-847325	anaplastic thyroid carcinoma (ATC)	ATC cell lines (C643 and SW1736)	dual MEK/Aurora kinase inhibitor BI-847325 treatment	upregulated	31077090
7662	Human	hsa-miR-363-3p	miRNA	clopidogrel	gastric mucosal injury	GES-1 cells	clopidogrel treatment	The expression of miR-363-3p in gastric mucosal injury caused by clopidogrel was higher than that in normal samples.	33208005
7663	Human	hsa-miR-363-3p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	The level of miR-363-3p was significantly decreased in TGF-¦Â1-treated HK-2 cells	33630202
7664	Human	hsa-miR-363-3p	miRNA	cadmium (Cd)	renal injury	serum	cadmium (Cd) treatment	We tested five dysregulated miRNAs and determined a significant increase of sera miR-363-3p.	33857584
7665	Human	hsa-miR-3648	miRNA	thapsigargin (TG) and tunicamycin (TM)	cell proliferation	HeLa and HEK293T cells	Thapsigargin (TG) and Tunicamycin (TM)s treatment	upregulated	28661420
7666	Human	hsa-miR-365	miRNA	intermittent cyclic mechanical tension (ICMT)	intervertebral disc degeneration (IDD)	primary human end plate chondrocytes	intermittent cyclic mechanical tension (ICMT) treatment	downregulated	31472300
7667	Human	hsa-miR-365	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
7668	Human	hsa-miR-365	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
7669	Human	hsa-miR-365	miRNA	crocin	cervical cancer (CC)	sensitive human cervical cancer cell line (OV2008) and resistant one (C13)	crocin treatment	downregulated	28763753
7670	Human	hsa-miR-365	miRNA	chondrogenic medium	chondrogenesis	"articular cartilage-derived mesenchymal stem cells from osteoarthritis patients (OA-MSC), bone marrow-derived mesenchymal stem cells (BMSC)"	chondrogenic medium cultures	upregulated	31287025
7671	Human	hsa-miR-365	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose treatment	"High glucose treatment led to downregulated RPSAP52 and Timp3, but upregulated miR-365 in RPE cells."	33178344
7672	Human	hsa-miR-365	miRNA	hydatid cyst fluid (HCF)	melanoma	human melanoma cell A375	Hydatid cyst fluid (HCF) treatment	"The fold change of Bax/Bcl-2 ratio, Caspase-9, miR-365 and Caspase-3 activity was higher in the fertile HCF-treated melanoma cells compared to infertile fluid treated A375 cells and human normal epithelial cell (as control cell)."	33609644
7673	Human	hsa-miR-365	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
7674	Human	hsa-miR-365	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	30233734
7675	Human	hsa-miR-365	miRNA	oxidized low density lipoprotein (ox-LDL)	focal cerebral ischemia	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	21640710
7676	Human	hsa-miR-3651	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
7677	Human	hsa-miR-3651	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
7678	Human	hsa-miR-3652	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
7679	Human	hsa-miR-3653-3p	miRNA	melatonin	osteoporosis	human bone marrow mesenchymal stem cell (hBMSC)	melatonin (MEL) treatment	Circ_0003865 expression in BMSCs was significantly decreased by MEL treatment.	33632317
7680	Human	hsa-miR-3656	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
7681	Human	hsa-miR-3659	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
7682	Human	hsa-miR-3659	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
7683	Human	hsa-miR-365a-3p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	upregulated	32582989
7684	Human	hsa-miR-365a-3p	miRNA	sulforaphane (SFN)	pancreatic ductal adenocarcinoma (PDAC)	AsPC-1 cells	sulforaphane treatment	upregulated	30910589
7685	Human	hsa-miR-365a-5p	miRNA	excessive mechanical tension	intervertebral disc degeneration (IDD)	primary human endplate chondrocytes culture	Excessive mechanical tension induce	"circRNA_0058097 can upregulate the expression of downstream target gene histone deacetylase 4 by sponge adsorption of miR-365a-5p, which promoted morphological changes of endplate chondrocytes, and increased extracellular matrix degradation and degeneration of endplate cartilage."	31222836
7686	Human	hsa-miR-365b-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	coronary atherosclerosis (CAS)	human coronary artery smooth muscle cells (HCASMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	30402161
7687	Human	hsa-miR-3663	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
7688	Human	hsa-miR-3663-3p	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
7689	Human	hsa-miR-3666	miRNA	all-trans retinoic acid (ATRA)	colorectal cancer (CRC)	Human CRC HCT116 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29772445
7690	Human	hsa-miR-3666	miRNA	palmitic acid (PA)	hepatic steatosis	HepG2 cells	palmitic acid (PA) treatment	In PA treated HepG2 cells during development of hepatic steatosis PPAR¦Ã was significantly upregulated concomitant with downregulated of miR-3666	32755726
7691	Human	hsa-miR-367	miRNA	c-reactive protein (CRP)	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	CRP treatment	upregulated	31646586
7692	Human	hsa-miR-367	miRNA	hypoxia	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	hypoxia induce	upregulated	31646586
7693	Human	hsa-miR-367	miRNA	paclitaxel (PTX)	tumorigenesis	NCI60 cancer cell line£¬Ovarian cancer (OVCA) cell lines and Human stem cell lines (H9)	paclitaxel treatment	miR-367 upregulated and miR-30a-5p downregulated	24220856
7694	Human	hsa-miR-367	miRNA	sodium butyrate (NaB)	somatic cell reprogramming	human foreskin fibroblasts (HFFs)	NaB treatment	upregulated	24568633
7695	Human	hsa-miR-3675-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
7696	Human	hsa-miR-3676	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	downregulated	25722110
7697	Human	hsa-miR-3676-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
7698	Human	hsa-miR-3679-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
7699	Human	hsa-miR-3682-3p	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
7700	Human	hsa-miR-3687	miRNA	lucidum	breast cancer	MCF-7 breast cancer cells	lucidum treatment	upregulated	25954907
7701	Human	hsa-miR-369	miRNA	azacitidine (AZA)	gastric cancer (GC)	"HGC27, SGC7091, MGC803, and MKN45 cell lines"	azacitidine (AZA) treatment	upregulated	31162777
7702	Human	hsa-miR-369-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
7703	Human	hsa-miR-369-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
7704	Human	hsa-miR-369-3p	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	A549 cells	bleomycin (BLM) treatment	TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells. DLEU2 directly targeted miR-369-3p.	33760118
7705	Human	hsa-miR-369-3p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â1 treatment	TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells DLEU2 directly targeted miR-369-3p	33760118
7706	Human	hsa-miR-37	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	acute myeloid leukemia (AML)	THP-1 line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26191124
7707	Human	hsa-miR-370	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31900142
7708	Human	hsa-miR-370	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33298736
7709	Human	hsa-miR-370	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen glucose deprivation (OGD) treatment	miR-370 expression was significantly promoted in SH-SY5Y cells after OGD treated.	32311231
7710	Human	hsa-miR-370	miRNA	homoharringtonine (HHT)	chronic myeloid leukemia (CML)	chronic myeloid leukemia K562 cells	Homoharringtonine (HHT) treatment	upregulated	24148180
7711	Human	hsa-miR-370	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
7712	Human	hsa-miR-370	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells; LN229 cells;glioma tissues	temozolomide (TMZ) treatment	miR-370 expression was significantly downregulated in TMZ-resistant glioma tissues and glioma cells	33188501
7713	Human	hsa-miR-370	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	Glioblastoma cells	Japanese encephalitis virus (JEV) infection	downregulated	27703358
7714	Human	hsa-miR-370	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteosarcoma (OS)	human osteosarcoma cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28539830
7715	Human	hsa-miR-370-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ_0010283 mediated cell viability and migration via a miR-370-3p/HMGB1 axis in ox-LDL-induced VSMCs.	32945389
7716	Human	hsa-miR-370-3p	miRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	downregulated	33376537
7717	Human	hsa-miR-370-3p	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	SKOV-3 cells; OVCAR3 cells	TGF-¦Â treatment	TGF-¦Â treatment upregulated H19 and downregulated miR-370-3p	29403287
7718	Human	hsa-miR-370-3p	miRNA	baohuoside-I	nasopharyngeal carcinoma (NPC)	CNE1 cells; CNE2 cells	baohuoside-I treatment	upregulated	32945196
7719	Human	hsa-miR-370-3p	miRNA	osteogenic differentiation medium	osteogenesis	human bone marrow-derived mesenchymal stem cells (HBMSCs)	"osteogenic differentiation medium with 100 mmol/L dexamethasone, 0.05 mmol/L ascorbic acid, and 10 mmol/L ¦Â-glycerophosphate treatment"	downregulated	30795799
7720	Human	hsa-miR-370-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 human lung fibroblasts cells	lipopolysaccharide (LPS) treatment	downregulated	31066476
7721	Human	hsa-miR-370-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	LPS treatment	"SNHG16 impeded cell viability and promoted apoptosis, inflammatory injury by targeting IGF2 mediated by miR-370-3p in LPS-induced A549 cells."	31841752
7722	Human	hsa-miR-370-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	lipopolysaccharides (LPS) treatment	downregulated	31841752
7723	Human	hsa-miR-370-3p	miRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	Exosomes were isolated from MDA-MB-231 cells	cisplatin treatment	upregulated	31424364
7724	Human	hsa-miR-371a-3p	miRNA	orchiectomy	germ cell tumour (GCT)	serum	orchiectomy treatment	downregulated in serum	25187505
7725	Human	hsa-miR-371a-5p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	tumor tissue and serum from HCC patients	hepatitis B virus (HBV) infection	upregulated	29928866
7726	Human	hsa-miR-371a-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
7727	Human	hsa-miR-371b-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	SH-SY5Y human neuroblastoma cells	GDNF	downregulated	28829278
7728	Human	hsa-miR-372	miRNA	cadmium (Cd)	cell cycle and proliferation	hepatoma cell line (HepG2)	cadmium (Cd) treatment	upregulated	25101185
7729	Human	hsa-miR-372	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
7730	Human	hsa-miR-372	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	Huh7 or HCCLM3 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-372 expression was restored upon 5-aza-dCyd treatment	25880458
7731	Human	hsa-miR-372	miRNA	propofol (PPF)	lung cancer	A549 cells	propofol treatment	downregulated	30547768
7732	Human	hsa-miR-372	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	"Two NPC cell lines, 5©\8F and C666©\1"	ionization radiation treatment	upregulated	30656832
7733	Human	hsa-miR-372	miRNA	caudatin	oxidative stress	human gastric carcinoma cell lines	caudatin? treatment	downregulated	23708208
7734	Human	hsa-miR-372	miRNA	IL-1¦Â	spinal cord injury (SCI)	human neural stem cells (hNSC)	IL-3¦Â treatment	upregulated	28298306
7735	Human	hsa-miR-372-3p	miRNA	rapamycin	dyslipidemia	serum	rapamycin treatment	hsa-miR-372-3p was filtered using RNA sequencing and identified as a key regulator in rapamycin-induced TGs accumulation	33705959
7736	Human	hsa-miR-372-3p	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	serum	Dox treatment	We found a significantly higher level of miR-372-3p in the blood of the responder group of HCC patients who received TACE with Dox than of non-responders	32416702
7737	Human	hsa-miR-372-3p	miRNA	fructose	liver fibrosis	primary human hepatocytes	fructose treatment	downregulated	31299062
7738	Human	hsa-miR-372-3p	miRNA	high glucose (HG)	liver fibrosis	LX-2 and HepG2 cells	high glucose treatment	downregulated	31299062
7739	Human	hsa-miR-372-3p	miRNA	palmitate	liver fibrosis	primary human hepatocytes	palmitate treatment	downregulated	31299062
7740	Human	hsa-miR-372-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
7741	Human	hsa-miR-372-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oral squamous cell carcinoma (OSCC)	SCC-4 cells	Mono-2-ethyhexyl phthalate (MEHP) treatment	downregulated	30858031
7742	Human	hsa-miR-373	miRNA	berberine (BBR)	abnormal lipid accumulation	MIHA cells; HepG2 cells	berberine (BBR) treatment	MicroRNA-373 (MiR-373) was consistently upregulated in both cell lines upon berberine treatments.	29477657
7743	Human	hsa-miR-373	miRNA	trastuzumab or lapatinib	breast cancer	patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer	chemotherapy combin either trastuzumab or lapatinib treatment	upregulated	25086636
7744	Human	hsa-miR-373	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
7745	Human	hsa-miR-373	miRNA	pomegranate juice (PJ)	colorectal cancer (CRC)	?prostate cancer cells	Pomegranate juice (PJ) treatment	downregulated	21594291
7746	Human	hsa-miR-373	miRNA	suberoylanilide hydroxamic acid (SAHA)	non-small cell lung cancer (NSCLC)	Calu-6 non-small cell lung cancer (NSCLC) cell line	SAHA treatment	upregulated	25063738
7747	Human	hsa-miR-373	miRNA	trichostatin A (TSA)	non-small cell lung cancer (NSCLC)	A549 and Calu-6 cells	trichostatin A treatment	downregulated	25063738
7748	Human	hsa-miR-373	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	circRNA-UBE2G1 facilitates the progression in the LPS-induced OA cell model via regulating the miR-373/HIF-1a axis.	32476580
7749	Human	hsa-miR-373	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
7750	Human	hsa-miR-373	miRNA	TGF-¦Â1	renal fibrosis	human kidney-2 cells	TGF-¦Â1 treatment	upregulated	29723660
7751	Human	hsa-miR-373	miRNA	TGF-¦Â1	renal fibrosis	human kidney-2 cells	TGF-¦Â1 treatment	upregulated	29723660
7752	Human	hsa-miR-373	miRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	Exosomes were isolated from MDA-MB-231 cells	cisplatin treatment	upregulated	31424364
7753	Human	hsa-miR-373-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	lncRNA SNHG16 knockdown significantly limited the progression of OA by sponging miR-373-3p in vitro	33300061
7754	Human	hsa-miR-373-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
7755	Human	hsa-miR-373-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute hepatic injury	THLE-3 cells	Lipopolysaccharide (LPS) treatment	downregulated of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis.	33129786
7756	Human	hsa-miR-374a	miRNA	isoliquiritigenin	breast cancer	"MDA-MB-231, MCF-7, BT474, 4T1, MCF-10A and 293 T"	isoliquiritigenin treatment	downregulated	28827662
7757	Human	hsa-miR-374a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 human renal tubular epithelial cells	high glucose (HG) treatment	downregulated	30147653
7758	Human	hsa-miR-374a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	"Serum miR-374a was progressively accelerated in patients with NDR, NPDR and PDR than in healthy controls."	33941051
7759	Human	hsa-miR-374a	miRNA	etoposide (VP-16)	glioblastoma multiforme (GBM)	"Human glioma cell lines A172, U118-MG and LN-18"	Etoposide (VP-16) treatment	knockdown of miR-374a was able to enhance the etoposide-induced cytotoxicity against glioma cells.	30841958
7760	Human	hsa-miR-374a	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	downregulated	21274007
7761	Human	hsa-miR-374a	miRNA	ferric ammonium citrate (FAC)	liver fibrosis	LO-2 cells	ferric ammonium citrate (FAC) treatment	downregulated	31171361
7762	Human	hsa-miR-374a	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	HepG2 and SMMC-7721 cells	Propofol treatment	downregulated	30257238
7763	Human	hsa-miR-374a	miRNA	¦Ã-rays	irradiation-induced ischemic stroke	HA-1800 cells	¦Ã-radiation treatment	downregulated	29984671
7764	Human	hsa-miR-374a	miRNA	propofol (PPF)	ovarian cancer (OC)	A2780 cells	propofol treatment	Propofol decreased miR-374a expression levels in A2780 cells	32016462
7765	Human	hsa-miR-374a-5p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
7766	Human	hsa-miR-374b	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
7767	Human	hsa-miR-374b	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"human HCC cell lines (Hep3B, HepG2, and HCCLM3)"	sorafenib treatment	The suppression of PKM2 by miR-374b re-sensitizes sorafenib-resistant HCC cells and mouse xenografts to sorafenib treatment by antagonizing glycolysis pathway.	31106002
7768	Human	hsa-miR-374b	miRNA	melatonin	prostate cancer	hypoxic PC-3 cells	melatonin treatment	upregulated	25553085
7769	Human	hsa-miR-374b	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
7770	Human	hsa-miR-374b-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35."	33279663
7771	Human	hsa-miR-374b-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y	amyloid-¦Â (A¦Â) 25-35 treatment	MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells.	33279663
7772	Human	hsa-miR-374c-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	cervical squamous cell	TGF¦Â1 treatment	downregulated	28810526
7773	Human	hsa-miR-375	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	allergic rhinitis (AR)	Human nasal mucosa cells HNEpC	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29677549
7774	Human	hsa-miR-375	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"Overexpression of WT1-AS can inhibit the miR-375/SIX4 axis, OSI and neuronal apoptosis in AD by inhibiting WT1 expression."	33234729
7775	Human	hsa-miR-375	miRNA	PAX8/PPAR¦Ã fusion protein (PPFP)	anaplastic thyroid carcinoma (ATC)	"ATC cell lines: BHT-101; FRO, C-643; KTC-2;KTC-3"	PAX8/PPAR¦Ã fusion protein (PPFP) treatment	upregulated	23598436
7776	Human	hsa-miR-375	miRNA	ketamine	anesthesia-induced neural cytotoxicity	human embryonic stem cell (hESC)-derived neuron	Ketamine treatment	upregulated	30500346
7777	Human	hsa-miR-375	miRNA	phytoestrogens	anti-cancer therapy	"human osteosarcoma cell line, U2OS"	Phytoestrogens treatment	upregulated	26381132
7778	Human	hsa-miR-375	miRNA	platelet-derived growth factor (PDGF)	asthma	airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	miR-375 expression was significantly decreased in fetal ASM cells that were treated with PDGF	29245068
7779	Human	hsa-miR-375	miRNA	biochanin A	breast cancer	breast cancer cells	biochanin A treatment	upregulated	25613180
7780	Human	hsa-miR-375	miRNA	biochanin A	breast cancer	"ER¦Á-positive breast cancer cells (T47D, MCF-7)"	biochanin A treatment	upregulated	25613180
7781	Human	hsa-miR-375	miRNA	formononetin	breast cancer	"HUVEC cells, MCF-7 cells"	Formononetin treatment	upregulated	25663261
7782	Human	hsa-miR-375	miRNA	tamoxifen (TAM)	breast cancer	"The human breast cancer cell lines, MCF-7 and MDA-MB-231, and lung cancer cell lines, H1703 and H1299 ;HEK-293FT cells and The human ovarian cancer cell line, Ovcar-5"	tamoxifen treatment	downregulated	22508479
7783	Human	hsa-miR-375	miRNA	formononetin	cell proliferation	"HUVEC, MCF-7"	Formononetin treatment	upregulated	25663261
7784	Human	hsa-miR-375	miRNA	doxorubicin (DOX)	cell senescence	K562 cells	Doxorubicin (DOX) treatment	upregulated	22606351
7785	Human	hsa-miR-375	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cervical cancer (CC)	"cervical cell lines SiHa, CaSki and HeLa"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31326568
7786	Human	hsa-miR-375	miRNA	folic acid	cervical cancer (CC)	CaSki cells	folic acid treatment	upregulated	27313708
7787	Human	hsa-miR-375	miRNA	paclitaxel (PTX)	cervical cancer (CC)	SiHa and Caski cells	paclitaxel treatment	upregulated	23778521
7788	Human	hsa-miR-375	miRNA	paclitaxel (PTX)	cervical cancer (CC)	"two human cervical cancer cell lines, SiHa and CaSki"	paclitaxel treatment	upregulated	25330011
7789	Human	hsa-miR-375	miRNA	high-risk human papillomavirus (hrHPV)	cervical cancer (CC)	The HPV16-immortalized keratinocyte cellline FK16A	high-risk human papillomavirus (hrHPV)infection	downregulated	22987659
7790	Human	hsa-miR-375	miRNA	formaldehyde	chronic respiratory disease (CRD)	human bronchial epithelial cells 16HBE	formaldehyde treatment	downregulated	31172816
7791	Human	hsa-miR-375	miRNA	high glucose (HG)	diabetic nephropathy (DN)	enteric glia cell (EGC)	high glucose treatment	upregulated	30140011
7792	Human	hsa-miR-375	miRNA	cyclic hydroxamic acid-containing peptide 31 (CHAP31)	esophageal squamous cell carcinoma (ESCC)	The human ESCC cell lines ( T.Tn cells; TE2 cells; CHAP31 )	cyclic hydroxamic acid-containing peptide 31 (CHAP31) treatment	upregulated	22752059
7793	Human	hsa-miR-375	miRNA	imatinib and lapatinib	fulvestrant-resistant breast cancer	fulvestrant-resistant breast cancer (FRBC) MCF-7 cells	imatinib+lapatinib dual treatment	upregulated	29522716
7794	Human	hsa-miR-375	miRNA	cisplatin (DDP)	gastric cancer (GC)	human gastric cancer cells	cisplatin treatment	downregulated	26893657
7795	Human	hsa-miR-375	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	gastric epithelial cells	lipopolysaccharide (LPS) treatment	downregulated	25307786
7796	Human	hsa-miR-375	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	"human gastric epithelial cell lines, AGS and MKN45"	LPS from H. pylori 26695 treatment	downregulated	25307786
7797	Human	hsa-miR-375	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
7798	Human	hsa-miR-375	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
7799	Human	hsa-miR-375	miRNA	everolimus	hepatocellular carcinoma (HCC)	"Human HCC cell lines PLC/PRF/5, and JHH-6"	everolimus (EVE) treatment	downregulated	31406139
7800	Human	hsa-miR-375	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCCs	hypoxia treatment	"MiR-375 presented an obviously differential expression in human HCCs versus background livers (BLs) and HCCs versus normal liver tissues (NLTs). In rat models, miR-375 was gradually declined during hepatocarcinogenesis."	32215815
7801	Human	hsa-miR-375	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells	Sorafenib treatment	downregulated	32431510
7802	Human	hsa-miR-375	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Hep3B cells; HepG2 cells	sorafenib treatment	downregulated	32616906
7803	Human	hsa-miR-375	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	human papillomaviruses (HPV) infection	Ca Ski and SiHa cell	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28521287
7804	Human	hsa-miR-375	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	human foreskin keratinocytes	Using CD4+ T-cells expressing only Human immunodeficiency virus (HIV)-1 envelope inoculated on human adult foreskin tissues	upregulated	28443609
7805	Human	hsa-miR-375	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	downregulated	29516639
7806	Human	hsa-miR-375	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	upregulated	29516639
7807	Human	hsa-miR-375	miRNA	helicobacter pylori (H. pylori)	helicobacter pylori (H. pylori) infection	GES-1 and BGC-823 cells	H. pylori infection treatment	downregulated	24718681
7808	Human	hsa-miR-375	miRNA	ketamine	ketamine-induced neurotoxicity	human embryonic stem cell (hESC)	ketamine treatment	upregulated	30500346
7809	Human	hsa-miR-375	miRNA	ASH1	lung cancer	CLC cell line; ACC-LC-172; A549 cells	The transcription factor ASH1 treatment	upregulated	21856745
7810	Human	hsa-miR-375	miRNA	SGI-110 and/or trichostatin A	multiple myeloma (MM)	human myeloma cell lines (HMCLs)	SGI-110 and/or trichostatin A treatment	upregulated	28439875
7811	Human	hsa-miR-375	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
7812	Human	hsa-miR-375	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmiticacid (PA) treatment	upregulated	29569260
7813	Human	hsa-miR-375	miRNA	radiation	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) tissues	radiation treatment	downregulated	32940043
7814	Human	hsa-miR-375	miRNA	teriparatide (TP)	osteoporosis	human marrow mesenchymal cells (hMSCs)	teriparatide (TP) treatment	downregulated	31858576
7815	Human	hsa-miR-375	miRNA	platelet-derived growth factor (PDGF)	pediatric asthma	human fetal airway smooth muscle cells	PDGF treatment	downregulated	29245068
7816	Human	hsa-miR-375	miRNA	docetaxel (DTX)	prostate cancer	DU145 and PC-3 cells	docetaxel (DTX) treatment	upregulated	27832783
7817	Human	hsa-miR-375	miRNA	TGF-¦Â	lung fibrosis	human lung fibroblasts	TGF-¦Â treatment	miR-375 was markedly upregulated in human lung fibroblasts after TGF-¦Â stimulation	32582987
7818	Human	hsa-miR-375	miRNA	trichostatin A (TSA)	tongue squamous cell carcinoma (TSCC)	human tongue cancer cell lines SCC-15 and CAL27	human tongue cancer cell lines SCC-15 and CAL27 treatment	upregulated	27878285
7819	Human	hsa-miR-375	miRNA	trichostatin A (TSA)	tongue squamous cell carcinoma (TSCC)	human tongue cancer cell lines SCC-15 and CAL27	TSA treatment	upregulated	27878285
7820	Human	hsa-miR-375	miRNA	"polycistronic viral vector expressing Sox2, Klf4, c-Myc, and Oct4"	type 1 diabetes mellitus (T1DM)	hiPSCs from human foreskin fibroblasts	polycistronic viral vector treatment	upregulated	24469711
7821	Human	hsa-miR-375	miRNA	formononetin	vascular endothelial cells (ECs) proliferation	human umbilical vein endothelial cells (HUVECs)	Formononetin (Form) treatment	upregulated	29722068
7822	Human	hsa-miR-375	miRNA	androgen	adipogenic differentiation	mature adipocytes	androgen treatment	downregulated	26219823
7823	Human	hsa-miR-375	miRNA	particulate matter (PM) and diesel exhaust particles (DEP)	asthma	?human bronchial epithelial cells	particulate matter (PM) and diesel exhaust particles (DEP) treatment	upregulated	23455502
7824	Human	hsa-miR-375	miRNA	radiation and etoposide	gastric cancer (GC)	gastric cancer cell lines(BGC823; MGC803; SGC7901;AGS; N87;MKN45)	radiation and etoposide treatment	upregulated	23835407
7825	Human	hsa-miR-375-3p	miRNA	hypoxia	congenital heart disease (CHD)	serum	hypoxia induce	miR-375-3p was upregulated and FOXP1/Bcl2l2 was downregulated in maternal serum of women with fetal CHD and hypoxia-induced rat cardiomyocyte h9c2 cells.	33128129
7826	Human	hsa-miR-375-3p	miRNA	solasonine (SS)	hepatocellular carcinoma (HCC)	"HepG2 cells, QGY-7703 cells"	Solasonine (SS) treatment	upregulated	31681610
7827	Human	hsa-miR-376	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	hepatocellular carcinoma (HCC)	"everolimus (EVE) resistant PLC/PRF/5, and JHH-6 cells"	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	31406139
7828	Human	hsa-miR-376	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	HFF cells	infect with HCMV	upregulated	24586166
7829	Human	hsa-miR-376a	miRNA	esomeprazole	adeno and squamous-cell-carcinoma	human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines	esomeprazole treatment	downregulated	25175076
7830	Human	hsa-miR-376a	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HCMEC/D3 cells	Oxygen-glucose deprivation (OGD) treatment	LncRNA SNHG1 depressed apoptosis and inflammation of IS cell model via inhibiting miR-376a and upregulating CBS/H2S signal	32532171
7831	Human	hsa-miR-376a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
7832	Human	hsa-miR-376a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
7833	Human	hsa-miR-376a	miRNA	arsenic trioxide (ATO)	retinoblastoma (RB)	retinoblastoma cells	arsenic trioxide?treatment	downregulated	23373993
7834	Human	hsa-miR-376b-3p	miRNA	matrine	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	matrine treatment	downregulated	29045804
7835	Human	hsa-miR-376c	miRNA	IL-1¦Â	osteosarcoma (OS)	hFOB;Saos2;MG63;U2OS;SW1353	IL-1¦Â?treatmrnt	upregulated	29441940
7836	Human	hsa-miR-376c	miRNA	Thrombospondin-1 (TSP-1)	prostate cancer	human PCa cells	TSP-1 treatment	downregulated	28122633
7837	Human	hsa-miR-376c	miRNA	bacillus calmette-guerin (BCG)	tuberculosis (TB)	TB patients	bacillus calmette-guerin (BCG) treatment	upregulated	24586438
7838	Human	hsa-miR-376c-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
7839	Human	hsa-miR-376c-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
7840	Human	hsa-miR-376c-3p	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	31844418
7841	Human	hsa-miR-376C-3p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
7842	Human	hsa-miR-377	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	downregulated	27158236
7843	Human	hsa-miR-377	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
7844	Human	hsa-miR-377	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	downregulated	27158236
7845	Human	hsa-miR-377	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
7846	Human	hsa-miR-377	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Primary cultures of normal human mesangial cells (NHMCs)	high glucose treatment	upregulated	18716028
7847	Human	hsa-miR-377	miRNA	TGF-¦Â	diabetic nephropathy (DN)	Primary cultures of normal human mesangial cells (NHMCs)	transforming growth factor-¦Â treatment	?upregulated	18716028
7848	Human	hsa-miR-377	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose treatment	upregulated	30706373
7849	Human	hsa-miR-377	miRNA	hypoxia	diabetic retinopathy (DR)	human retinal endothelial cells	hypoxia induce	upregulated	30706373
7850	Human	hsa-miR-377	miRNA	hypoxia	ischemic heart disease (IHD)	Hypoxic MSCs	"cultured in DMEM without glucose and with 1% FBS under hypoxic conditions of 1% O2, 5% CO2 treatment"	downregulated	25251394
7851	Human	hsa-miR-377	miRNA	gefitinib	lung adenocarcinoma (LUAD)	PC9 cells; A549 cells	gefitinib treatment	upregulated	29592872
7852	Human	hsa-miR-377	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
7853	Human	hsa-miR-377	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischaemic injury	human neonatal cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	miR-377 expression was downregulated in cardiomyocyte exposed to H/R.	32647500
7854	Human	hsa-miR-377	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
7855	Human	hsa-miR-377	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
7856	Human	hsa-miR-377	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
7857	Human	hsa-miR-377	miRNA	titanium (Ti) particle	wear particle-induced osteolysis (PIO)	Bone marrow macrophages (BMMs)	titanium (Ti) particle treatment	downregulated	30958621
7858	Human	hsa-miR-377-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-377-3p inhibits atherosclerosis-associated vascular smooth muscle cell proliferation and migration via targeting neuropilin2.	32373927
7859	Human	hsa-miR-377-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Normal human articular chondrocytes	IL-1¦Â treatment	downregulated	31831175
7860	Human	hsa-miR-377-3p	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	downregulated	32028542
7861	Human	hsa-miR-377-3p	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells; Saos-2 cells	cisplatin treatment	OIP5-AS1 positively modulated FOSL2 expression to decrease CDDP sensitivity in OS by sponging miR-377-3p.	32440152
7862	Human	hsa-miR-377-3p	miRNA	tuberculosis (MTB)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (MTB) infection treatment	downregulated	33271233
7863	Human	hsa-miR-378	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
7864	Human	hsa-miR-378	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) exposure	downregulated	31696490
7865	Human	hsa-miR-378	miRNA	acute exercise	congestive heart failure (CHF)	CHF patients	acute exercise treatment	upregulated	26799589
7866	Human	hsa-miR-378	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
7867	Human	hsa-miR-378	miRNA	Fatty acid	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	Fatty acid treatment	miR-378 was significantly increased in Fatty acid treated human hepatoma HepG2 cells.	29625129
7868	Human	hsa-miR-378	miRNA	oleacein (OA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	oleate treatment	upregulated	30281809
7869	Human	hsa-miR-378	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
7870	Human	hsa-miR-378	miRNA	IL-6	obesity	matured human adipocytes	"TNF-¦Á, IL-6, leptin, or resistin treatment"	upregulated	24771406
7871	Human	hsa-miR-378	miRNA	leptin	obesity	matured human adipocytes	"TNF-¦Á, IL-6, leptin, or resistin treatment"	upregulated	24771406
7872	Human	hsa-miR-378	miRNA	resistin	obesity	matured human adipocytes	"TNF-¦Á, IL-6, leptin, or resistin treatment"	upregulated	24771406
7873	Human	hsa-miR-378	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	matured human adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	24771406
7874	Human	hsa-miR-378	miRNA	high-intensity interval training (HIIT)	skeletal muscle adaptation	human	human treatment	downregulated	27101297
7875	Human	hsa-miR-378	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	downregulated	21030674
7876	Human	hsa-miR-378	miRNA	adipokines	systemic adipose tissue inflammation	human visceral preadipocytes	adipokines and inflammatory cytokines on treatment	upregulated	24923530
7877	Human	hsa-miR-378-3p	miRNA	morphine	morphine tolerance	Be(2)C cells	morphine treatment	Chronic morphine treatment significantly increased the miR-378-3p level in Be(2)C cells.	31999011
7878	Human	hsa-miR-378a-3p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
7879	Human	hsa-miR-378a-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7; HCCLM3; SK-HEP-1	sorafenib treatment	downregulated	32754282
7880	Human	hsa-miR-378a-3p	miRNA	radiation	tumor radiotherapy	U87 cells-derived exosome	radiation treatment	upregulated	32267172
7881	Human	hsa-miR-378a-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
7882	Human	hsa-miR-378a-5p	miRNA	forskolin (FSK)	choriocarcinoma	human choriocarcinoma cell line BeWo	forskolin treatment	downregulated	25122062
7883	Human	hsa-miR-378a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
7884	Human	hsa-miR-378b	miRNA	arctiin	antiviral immune response	normal human dermal fibroblasts (nHDFs)	arctiin treatment	downregulated	28990056
7885	Human	hsa-miR-378b	miRNA	ultraviolet (UV) irradiation	dermal fibroblasts aging	human dermal fibroblasts (HDFs)	UVB-exposed treatment	upregulated	28983623
7886	Human	hsa-miR-378b	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
7887	Human	hsa-miR-378b	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	TiO2-NPs-mediated colonic cytotoxicity	NCM460 cells; HCT116 cells	Titanium dioxide nanoparticles (TiO2-NPs) treatment	upregulated	32423014
7888	Human	hsa-miR-378c	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
7889	Human	hsa-miR-378c	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
7890	Human	hsa-miR-378d	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
7891	Human	hsa-miR-378d	miRNA	sodium fluoride (NaF)	female reproductive dysfunction	KGN cells	sodium fluoride (NaF) treatment	The miR-378d was the most significantly upregulated one dose dependently by NaF	33405077
7892	Human	hsa-miR-378f	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
7893	Human	hsa-miR-378g	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
7894	Human	hsa-miR-378g	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-378g was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
7895	Human	hsa-miR-378g	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-miR-378g was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
7896	Human	hsa-miR-378g	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	TiO2-NPs-mediated colonic cytotoxicity	HCT116 cells	Titanium dioxide nanoparticles (TiO2-NPs) treatment	upregulated	32423014
7897	Human	hsa-miR-378g	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	TiO2-NPs-mediated colonic cytotoxicity	NCM460 cells	Titanium dioxide nanoparticles (TiO2-NPs) treatment	downregulated	32423014
7898	Human	hsa-miR-378h	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
7899	Human	hsa-miR-378h	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	downregulated	29510375
7900	Human	hsa-miR-378h	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
7901	Human	hsa-miR-378i	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
7902	Human	hsa-miR-379	miRNA	coenzyme Q10 (CoQ10)	atherosclerosis (AS)	human THP-1 macrophages	CoQ10 treatment	downregulated	24675663
7903	Human	hsa-miR-379	miRNA	genistein	hepatocellular carcinoma (HCC)	HepG2 cells	Genistein (GNT) treatment	downregulated	25781341
7904	Human	hsa-miR-379	miRNA	rifampicin	hepatocellular carcinoma (HCC)	HepG2 cells	rifampicin treatment	a miRNA negatively regulating ABCC2 on the post-transcriptional level and provide evidence that this miRNA impedes overexpression of ABCC2 protein after a PXR-mediated external transcriptional stimulus	21540293
7905	Human	hsa-miR-379-5p	miRNA	arsenite	arsenite-induced liver damage	L-02 cells	arsenite exposure	downregulated	30643918
7906	Human	hsa-miR-380	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human Bronchial Epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	miR-380 showed a tendency of high expression in COPD patients and CSE models.	31821848
7907	Human	hsa-miR-380	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human Bronchial Epithelial cells	cigarette smoke extract (CSE) exposure	upregulated	31821848
7908	Human	hsa-miR-380-3p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissue	cigarette smoke (CS) exposure	upregulated	31819170
7909	Human	hsa-miR-381	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
7910	Human	hsa-miR-381	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary heart disease (CHD)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Protective effect of microRNA-381 against inflammatory damage of endothelial cells during coronary heart disease by targeting CXCR4.	32016478
7911	Human	hsa-miR-381	miRNA	periostin	epithelial-mesenchymal transition (EMT)	human lung adenocarcinoma cell line A549	periostin treatment	downregulated	28977942
7912	Human	hsa-miR-381	miRNA	radiotherapy	esophageal cancer (EC)	tissues from primary ESCC and recurrent ESCC in situ after radiotherapy	radiotherapy treatment	downregulated	25628936
7913	Human	hsa-miR-381	miRNA	metformin (Met)	non-small cell lung cancer (NSCLC)	A549 cells	metformin treatment	Metformin dose- and time- dependently increased the RNA level of miR-381.	31906986
7914	Human	hsa-miR-381	miRNA	lipopolysaccharide (LPS)	respiratory infections	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	26688820
7915	Human	hsa-miR-381	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
7916	Human	hsa-miR-381-3p	miRNA	kartogenin	chondrogenesis	Small extracellular vesicles (sEVs) derived from human umbilical cord mesenchymal stem cells (hUCMSCs)	kartogenin preconditioned	upregulated	31864017
7917	Human	hsa-miR-381-3p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
7918	Human	hsa-miR-381-3p	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	Caco-2 cells	hypoxia induce	upregulated	29706629
7919	Human	hsa-miR-381-3p	miRNA	Hypoxia	nasopharyngeal carcinoma (NPC)	HK-1 and C666-1	hypoxia treatment	"XIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis, providing new insights into the pathogenesis of NPC."	32196601
7920	Human	hsa-miR-381-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	THP-1 cells	"4,4'-methylene diphenyl diisocyanate (MDI) treatment"	Both in vivo murine MDI aerosol exposure and in vitro MDI-GSH exposures in THP-1 macrophages result in downregulated of endogenous miR-206-3p and miR-381-3p and upregulation of PPP3CA and iNOS expression.	31609387
7921	Human	hsa-miR-381-3p	miRNA	fingolimod	relapsing-remitting multiple sclerosis (RRMS)	peripheral blood	Fingolimod treatment	upregulated	32215780
7922	Human	hsa-miR-382	miRNA	hypoxia	gastric cancer (GC)	MKN1 human gastric cancer cells	hypoxia treatment	upregulated	24914051
7923	Human	hsa-miR-382	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
7924	Human	hsa-miR-382	miRNA	polydatin (PD)	colorectal cancer (CRC)	The CRC cell lines (Caco-2 and HCT 116)	Polydatin treatment	upregulated	31755739
7925	Human	hsa-miR-382	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human kidney epithelial cell HK-2	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	"Knockdown of miR-382, which was upregulated by TGF-¦Â1,attenuated TGF-¦Â1-induced loss of the epithelial marker E-cadherin"	20716515
7926	Human	hsa-miR-382	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
7927	Human	hsa-miR-382	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
7928	Human	hsa-miR-382	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	downregulated	29172709
7929	Human	hsa-miR-382	miRNA	propranolol (PRO)	infantile hemangioma (IH)	XPTS-1 cells	propranolol treatment	downregulated	28112362
7930	Human	hsa-miR-382	miRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells	high levels of phosphate treatment	downregulated	28522697
7931	Human	hsa-miR-382-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human OA chondrocytes	IL-1¦Â treatment	downregulated	31144313
7932	Human	hsa-miR-382-5p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	upregulated	30453015
7933	Human	hsa-miR-382-5p	miRNA	TGF-¦Â	epidural fibrosis	Primary human fibroblasts	TGF-¦Â treatment	upregulated	29949138
7934	Human	hsa-miR-382-5p	miRNA	diesel exhaust particle (DEP)	PM 2.5 or DEPs-induced inflammatory response	HBE cells	diesel exhaust particle (DEP) exposure	The expression level of miR-382-5p was downregulated after exposure to DEPs.	32146367
7935	Human	hsa-miR-382-5p	miRNA	particulate matter (PM2.5)	PM 2.5 or DEPs-induced inflammatory response	HBE cells	fine particulate matter (PM 2.5) exposure treatment	The expression level of miR-382-5p was downregulated in HBE cells after exposure to PM 25	32146367
7936	Human	hsa-miR-382-5p	miRNA	TGF-¦Â1	primary myelofibrosis (PMF)	PMF CD34+ cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30259659
7937	Human	hsa-miR-383	miRNA	high glucose (HG)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31994599
7938	Human	hsa-miR-383	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 human RPE cell lines	high glucose	upregulated	28559987
7939	Human	hsa-miR-383	miRNA	high glucose (HG)	diabetic retinopathy (DR)		high glucose treatment	AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of ARPE-19 cells by downregulating miR-383.	31391356
7940	Human	hsa-miR-383	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	downregulated	24589211
7941	Human	hsa-miR-383-5p	miRNA	resveratrol	diabetic nephropathy (DN)	human podocytes	resveratrol (RS) treatment	downregulated	28374806
7942	Human	hsa-miR-384	miRNA	luteolin	colorectal cancer (CRC)	HT-29 cells	"Luteolin (3,4,5,7-tetrahydroxyflavone) treatment"	upregulated	31059061
7943	Human	hsa-miR-384	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	CircBPTF knockdown protected against HG-induced inflammatory injuries and oxidative stress by mediating the miR-384/LIN28B axis in HUVECs.	32524321
7944	Human	hsa-miR-384	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	"NSCLC cells (H1650, H1299, H460, A549)"	curcumin treatment	"After curcumin treatment, the expression tendency of circ-PRKCA, miR-384, and ITGB1 in NSCLC cells was overturned."	33684690
7945	Human	hsa-miR-3907	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
7946	Human	hsa-miR-3911	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
7947	Human	hsa-miR-3923	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	downregulated	30100735
7948	Human	hsa-miR-3928	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
7949	Human	hsa-miR-3928-5p	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-3928-5p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
7950	Human	hsa-miR-3928-5p	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-3928-5p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
7951	Human	hsa-miR-3928v	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HBV (+) HCC tissues	hepatitis B virus (HBV) infection	upregulated	29378599
7952	Human	hsa-miR-3929	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
7953	Human	hsa-miR-3935	miRNA	sodium butyrate (NaB)	lung cancer	A549 cells	sodium butyrate(NaB) treatment	upregulated	29231270
7954	Human	hsa-miR-3940-5p	miRNA	thymosin ¦Á1 (T¦Á1)	non-segmental vitiligo (NSV)	peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV)	thymosin ¦Á1 (T¦Á1) treatment	downregulated	25495156
7955	Human	hsa-miR-3941	miRNA	lipopolysaccharide (LPS)	acute pancreatitis (AP)	A549 cells	lipopolysaccharides (LPS) treatment	downregulated	29328418
7956	Human	hsa-miR-3941	miRNA	lipopolysaccharide (LPS)	acute pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	LPS treatment also resulted in a significantly decreased expression of miR-3941 in A549 cells.	29328418
7957	Human	hsa-miR-399-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta vascular smooth muscle cells (HA-VSMCs); human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ANRIL promoted AS progression by sponging miR-399-5p and regulating RAS/RAF/ERK signal pathway.	32141564
7958	Human	hsa-miR-409-3p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
7959	Human	hsa-miR-409-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
7960	Human	hsa-miR-410	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29518604
7961	Human	hsa-miR-410	miRNA	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P)	early non-genotoxic events	HepaRG cells	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) treatment	upregulated	26609139
7962	Human	hsa-miR-410	miRNA	aflatoxin B1 (AFB1)	genotoxicity	HepaRG cells	aflatoxin B1 (AFB1) treatment	upregulated	26609139
7963	Human	hsa-miR-410	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
7964	Human	hsa-miR-410	miRNA	andes hantavirus (ANDV)	liver damage	human endothelial cells (ECs)	andes hantavirus (ANDV) infection	downregulated	20844033
7965	Human	hsa-miR-410	miRNA	TGF-¦Â3	osteoarthritis (OA)	human bone marrow mesenchymal stem cells	TGF-¦Â3 treatment	upregulated	28123640
7966	Human	hsa-miR-410	miRNA	"rapamycin, doxorubicin , cisplatin"	osteosarcoma (OS)	U2OS and MG-63 human osteosarcoma cell lines	"rapamycin, doxorubicin , cisplatin treatment"	upregulated	28138700
7967	Human	hsa-miR-410	miRNA	vascular endothelial growth factor (VEGF)	osteosarcoma (OS)	OS cell lines	VEGF treatment	"restoration of VEGF reversed the effect of miR-410 on OS cells, and upregulated the expression of phosphorylated AKT"	25385479
7968	Human	hsa-miR-410	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	31067440
7969	Human	hsa-miR-410	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
7970	Human	hsa-miR-410	miRNA	vascular endothelial growth factor (VEGF)	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (hPAECs)	vascular endothelial growth factor (VEGF) treatment	downregulated	31289307
7971	Human	hsa-miR-410-3p	miRNA	vemurafenib	melanoma	A375 cells; G361 cells; SKMEL1 cells	vemurafenib treatment	miR-410-3p is induced by vemurafenib.	32555626
7972	Human	hsa-miR-410-3p	miRNA	calcium chloride or osteogenic medium	osteogenic-like differentiation	human renal interstitial fibroblasts (hRIFs)	calcium chloride or osteogenic medium treatment	Suppression of osteogenic-like differentiation in human renal interstitial fibroblasts by miRNA-410-3p through MSX2	33209671
7973	Human	hsa-miR-410-3p	miRNA	magnoflorine	osteosarcoma (OS)	MG-63 cells; U-2 OS cells	Magnoflorine treatment	"Magnoflorine significantly suppressed HMGB1 expression and NF-¦ÊB activation, but upregulated miR-410-3p level."	32553931
7974	Human	hsa-miR-410-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	human pancreatic cancer xenograft (HPCx) in mouse	gemcitabine treatment	downregulated	29296182
7975	Human	hsa-miR-411	miRNA	curcumin (Cur)	prostate cancer	22Rv1 cells	curcumin treatment	upregulated	29172709
7976	Human	hsa-miR-411	miRNA	IL-1¦Â	osteoarthritis (OA)	C28/I2 cells	IL-1¦Â treatment	miRNA-411 Regulates Chondrocyte Autophagy in Osteoarthritis by Targeting Hypoxia-Inducible Factor 1 alpha (HIF-1¦Á)	32072994
7977	Human	hsa-miR-411	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
7978	Human	hsa-miR-421	miRNA	"chlorpromazine, haloperidol and clozapine"	psychosis	JM-Jurkat T-lymphocytes	"chlorpromazine, haloperidol and clozapine treatment"	dysregulated	24480591
7979	Human	hsa-miR-421	miRNA	lidocaine	cervical cancer (CC)	HeLa cells	lidocaine treatment	lidocaine inhibited the growth of cervical cancer cells by modulating the lncRNA-MEG3/miR-421/BTG1 signaling pathway	31632519
7980	Human	hsa-miR-421	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	human GC MGC-803 cells	5-fluorouracil (5-FU) treatment	upregulated	31115533
7981	Human	hsa-miR-421	miRNA	Helicobacter pylori (H. pylori) extract (HPE)	gastric cancer (GC)	HGC-27 cells	Helicobacter pylori (H. pylori) infection	upregulated	33065487
7982	Human	hsa-miR-421	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	A172 cells; U251 cells	temozolomide (TMZ) treatment	"Circ-HIPK3 was obviously increased in TMZ-resistant glioma cells and their exosomes, miR-421, was downregulated in TMZ-resistant glioma"	32644821
7983	Human	hsa-miR-421	miRNA	lidocaine	hepatocellular carcinoma (HCC)	HCC cells	?lidocaine treatment	"circ_ITCH and CPEB3 levels were decreased in hepatocellular carcinoma tissues and cells, and were restored in cells via lidocaine treatment"	33433806
7984	Human	hsa-miR-421	miRNA	bitter melon seed water extract (BMSW)	hepatocellular carcinoma (HCC)	HepG2 cells	Bitter melon seed water extract (BMSW) treatment	The expression level of miR-421 in HepG2 was distinctly downregulated by 13.74 fold with 600 ?g/ml of BMSW.	33844303
7985	Human	hsa-miR-421	miRNA	tunicamycin (TM)	vitiligo	human melanocytes	tunicamycin (TM) treatment	upregulated	31974624
7986	Human	hsa-miR-422a	miRNA	"chenodeoxycholic acid, GW4064"	bile acid synthesis	human primary hepatocytes	"chenodeoxycholic acid, GW4064 treatment"	upregulated	20351063
7987	Human	hsa-miR-422a	miRNA	fibroblast growth factor 19 ( FGF19)	bile acid synthesis	human primary hepatocytes	fibroblast growth factor ( FGF)19 treatment	upregulated	20351063
7988	Human	hsa-miR-422a	miRNA	doxorubicin (DOX)	gastric cancer (GC)	BGC823 cells	doxorubicin (DOX) treatment	The results showed that the miR-422a level was markedly elevated 6 hr after DOX stimulation.	30195778
7989	Human	hsa-miR-422a	miRNA	IFN-¦Á	human immunodeficiency virus (HIV)-1 infection	PBMC	TNF-¦Á treatment	downregulated	25275557
7990	Human	hsa-miR-422a	miRNA	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	NCI cells; FaDu cells	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment	downregulated	32326378
7991	Human	hsa-miR-422a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuron apoptosis	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32999283
7992	Human	hsa-miR-422a	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
7993	Human	hsa-miR-422a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	palmitic acid (PA) treatment	downregulated	32143184
7994	Human	hsa-miR-422a	miRNA	TGF-¦Â1	oral squamous cell carcinoma (OSCC)	"human OSCC cell lines (Te13, Te1 , Eca109)"	TGF-¦Â1 treatment	Microarray analysis revealed that miR-422a exhibited the greatest downregulated (fold change: 022) in the presence of TGF-¦Â1	33107637
7995	Human	hsa-miR-422a	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-422a was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
7996	Human	hsa-miR-422a	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-422a was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
7997	Human	hsa-miR-422a	miRNA	high iodine	thyroid cancer (TC)	"TPC-1cells, K1 cells and Nthy-3 cells"	high iodine	downregulated	28992617
7998	Human	hsa-miR-423	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
7999	Human	hsa-miR-423	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
8000	Human	hsa-miR-423	miRNA	lanthionine	lanthionine toxicity	EA.hy926 cell cultures	lanthionine treatment	downregulated	31071929
8001	Human	hsa-miR-423	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
8002	Human	hsa-miR-423	miRNA	low fat diet (LFD)	overweight and obese	plasma	low fat diet (LFD) treatment	downregulated in plasma	29233590
8003	Human	hsa-miR-423	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
8004	Human	hsa-miR-423	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	upregulated	28534445
8005	Human	hsa-miR-423-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
8006	Human	hsa-miR-423-5	miRNA	IL-1¦Â	disc degeneration	NP cells	IL-1¦Â treatment	upregulated	32467560
8007	Human	hsa-miR-423-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	human kidney (HK-2) cells	hypoxia/reoxygenation (H/R) treatment	upregulated	29137244
8008	Human	hsa-miR-423-5p	miRNA	T-helper type 2 (Th2)-biased cytokine environment 	allergic asthma (AA)	Bronchial epithelial cells	T-helper type 2 (Th2)-biased cytokine environment treatment	downregulated	26289417
8009	Human	hsa-miR-423-5p	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
8010	Human	hsa-miR-423-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	upregulated	31455213
8011	Human	hsa-miR-423-5p	miRNA	chaenomeles speciosa (CSTT)	gastric injury	GES-1 cells	Chaenomeles speciosa (CSTT) treatment	CSTT obviously downregulated miR-423-5p mRNA.	31895380
8012	Human	hsa-miR-423-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Hepatocellular carcinoma (HCC) cells	sorafenib treatment	upregulated	25782064
8013	Human	hsa-miR-423-5p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
8014	Human	hsa-miR-423-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
8015	Human	hsa-miR-423-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	Our data showed that MPP+?induced UCA1 expression in SK-N-SH cells.	33464446
8016	Human	hsa-miR-423-5p	miRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	Exosomes were isolated from MDA-MB-231 cells	cisplatin treatment	upregulated	31424364
8017	Human	hsa-miR-424	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
8018	Human	hsa-miR-424	miRNA	CoCl2	acute mountain sickness (AMS)	Human pulmonary microvascular ECs (HPMECs) and HUVECs	CoCl2 treatment	upregulated	31461385
8019	Human	hsa-miR-424	miRNA	hypoxia	acute mountain sickness (AMS)	Human pulmonary microvascular ECs (HPMECs) and HUVECs	hypoxia induce	upregulated	31461385
8020	Human	hsa-miR-424	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human alveolar epithelial cells A549 and BEAS-2B	lipopolysaccharide (LPS) treatment	downregulated	31881228
8021	Human	hsa-miR-424	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells; BEAS-2B cells	lipopolysaccharide (LPS) treatment	downregulated	31881228
8022	Human	hsa-miR-424	miRNA	hypoxia	apoptosis	A375;U251;HCT116;HEK293T cells	hypoxia treatment	upregulated	24967963
8023	Human	hsa-miR-424	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
8024	Human	hsa-miR-424	miRNA	VEGF or basic fibroblast growth factor (bFGF)	tumorigenesis	endothelial vascellum	VEGF or basic fibroblast growth factor (bFGF) treatment	upregulated	21885851
8025	Human	hsa-miR-424	miRNA	TGF-¦Â	cell cycle arrest	MCF-10A and MCF-12 cells	TGF-¦Â treatment	upregulated	25266660
8026	Human	hsa-miR-424	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA SNHG1 regulates OGD/R-induced cell death through serving as a ceRNA for miR-424 in SH-SY5Y cells	31900069
8027	Human	hsa-miR-424	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
8028	Human	hsa-miR-424	miRNA	TGF-¦Â1	lung fibrosis	human lung fibroblasts (HLFs)	TGF-¦Â1 treatment	miR-424 expression was increased by 26-fold in HLFs in response to TGF-¦Â1	32712053
8029	Human	hsa-miR-424	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
8030	Human	hsa-miR-424	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
8031	Human	hsa-miR-424	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	human visceral preadipocytes (HPA©\V cells)	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á treatment significantly downregulated the expression levels of miR-424 via binding to its promoter region and reducing its transcriptional activity	33179089
8032	Human	hsa-miR-424	miRNA	recombinant lentivirus	cell differentiation	hDPCs	recombinant lentivirus?infection treatment	downregulated	24331995
8033	Human	hsa-miR-424	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells	cisplatin treatment	"Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma."	31642110
8034	Human	hsa-miR-424	miRNA	cisplatin and doxorubicin	osteosarcoma (OS)	MG63 cells	cisplatin and doxorubicin treatment	"Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma."	31642110
8035	Human	hsa-miR-424	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells	doxorubicin treatment	"Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma."	31642110
8036	Human	hsa-miR-424	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
8037	Human	hsa-miR-424	miRNA	H2O2	oxidative stress	hTERT-transduced human adipose derived mesenchymal stem cells (hASCs)	H2O2 treatment	downregulated	28186136
8038	Human	hsa-miR-424	miRNA	IL-13	pulmonary arterial hypertension (PAH)	primary human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
8039	Human	hsa-miR-424	miRNA	IL-13	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
8040	Human	hsa-miR-424	miRNA	hypoxia	wilson's disease	human endothelial cells	Hypoxia treatment	downregulated	20972335
8041	Human	hsa-miR-424-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
8042	Human	hsa-miR-424-3p	miRNA	baicalin (BAI)	non-small cell lung cancer (NSCLC)	A549 and H460 cells	baicalin (BAI) treatment	downregulated	29392841
8043	Human	hsa-miR-424-5p	miRNA	ginsenoside Rg3	breast cancer	MCF-7 breast cancer cells	ginsenoside Rg3 treatment	upregulated	33477683
8044	Human	hsa-miR-424-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	Human cerebral microvascular endothelia cells (hCMEC/D3)	amyloid-¦Â (A¦Â) treatment	upregulated	31375213
8045	Human	hsa-miR-424-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circ_0029589 silence might inhibit the progression of AS by regulating miR-424-5p/IGF2 axis	32860985
8046	Human	hsa-miR-424-5p	miRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	downregulated	33376537
8047	Human	hsa-miR-424-5p	miRNA	quinidine	cell proliferation and apoptosis	human glioma U87-MG cells	quinidine treatment	the upregulation of miR-149-3p and downregulated of miR-424-5p	25420507
8048	Human	hsa-miR-424-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	"Knockdown of CDKN2B-AS1 suppressed proliferation, ECM accumulation and PI3K/AKT signaling by increasing miR-424-5p and decreasing HMGA2 in high glucose-treated HMGC cells."	31707340
8049	Human	hsa-miR-424-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	downregulated	31707340
8050	Human	hsa-miR-424-5p	miRNA	ropivacaine	glioblastoma multiforme (GBM)	T98G cells; LN229 cells	ropivacaine treatment	upregulated	33817285
8051	Human	hsa-miR-424-5p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Huh7-HBV;Hep3B-HBV cells	hepatitis B virus (HBV) infection	"Circ-RNF13 was upregulated in HBV-infected human HCC tissues and HBV-expressing cells (Huh7-HBV and Hep3B-HBV), accompanied with TGIF2 upregulation and miR-424-5p downregulated."	33714261
8052	Human	hsa-miR-424-5p	miRNA	saturated fatty acids (SFA) palmitate (PA)	obesity-induced hepatic insulin resistance	HepG2 cells	saturated fatty acids (SFA) palmitate (PA) treatment	miR-424-5p was upregulated in PA-treated HepG2 cells	30033101
8053	Human	hsa-miR-424-5p	miRNA	silver nanoparticles (AgNPs)	silver nanoparticles (SNPs) induced cytotoxicity	human dermal fibroblasts (HDFs)	silver nanoparticles (SNPs) treatment	upregulated	30305212
8054	Human	hsa-miR-424-5p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
8055	Human	hsa-miR-425	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	acute respiratory distress syndrome (ARDS)	A549 and HFL-1 cells	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	downregulated	31934088
8056	Human	hsa-miR-425	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8057	Human	hsa-miR-425	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8058	Human	hsa-miR-425	miRNA	IL-1¦Â	gastric cancer (GC)	AGS cells	IL-1¦Â treatment	upregulated	24571667
8059	Human	hsa-miR-425	miRNA	angiotensin II (Ang II)	heart failure (HF)	Human adult atrial fibroblast primary cultures (NHCF-A)	angiotensin II (Ang II) treatment	downregulated	30392569
8060	Human	hsa-miR-425	miRNA	glucose	obesity and diabetes	Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and HepG2 cells	glucose treatment	upregulated	26892417
8061	Human	hsa-miR-425	miRNA	CuO nanowire fabricated with folic acid (CuO-Nw-FA)	triple negative breast cancer (TNBC)	MDAMB-231 cells	MDAMB-231 cells treatment	downregulated	26520043
8062	Human	hsa-miR-425-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCC cell lines	sorafenib treatment	upregulation	25040368
8063	Human	hsa-miR-425-3p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells secreted exosomes	cisplatin (DPP) treatment	upregulated	31632022
8064	Human	hsa-miR-425-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
8065	Human	hsa-miR-425-5p	miRNA	sodium arsenite (NaAsO2)	cardiovascular disease (CVD)	HUVECs	sodium arsenite (NaAsO2) treatment	downregulated	27132035
8066	Human	hsa-miR-425-5p	miRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31711985
8067	Human	hsa-miR-425-5p	miRNA	high glucose (HG) and IL-1¦Â	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) and interleukin-1¦Â (IL-1¦Â) treatment	miR-425-5p was significantly upregulated in diabetic patients and human umbilical vein endothelial cells (HUVECs) treated with high glucose (HG) and interleukin-1¦Â (IL-1¦Â).	31711985
8068	Human	hsa-miR-425-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
8069	Human	hsa-miR-425-5p	miRNA	TGF-¦Â1	liver fibrosis	LX©\2 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31148365
8070	Human	hsa-miR-4257	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
8071	Human	hsa-miR-4262	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human lung fibroblast WI-38 cells and human PMVECs	lipopolysaccharide (LPS) treatment	MEG3 was downregulated by LPS and its knockdown aggravated LPS-induced injury of human lung cells through miR-4262-mediated downregulated of KLF4.	31184231
8072	Human	hsa-miR-4262	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Caco-2 cells	dextran sulfate sodium (DSS) treatment	miR-4262 is upregulated in 2% DSS©\stimulated Caco-2 cells.	32765699
8073	Human	hsa-miR-4267	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
8074	Human	hsa-miR-4269	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
8075	Human	hsa-miR-4271	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8076	Human	hsa-miR-4274	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
8077	Human	hsa-miR-4274	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
8078	Human	hsa-miR-4275	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
8079	Human	hsa-miR-4281	miRNA	IL-2	immunological self-tolerance and suppress	human PBMCs	IL-2 treatment	upregulated	29282311
8080	Human	hsa-miR-4284	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
8081	Human	hsa-miR-4286	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32141990
8082	Human	hsa-miR-4287	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	downregulated	29806389
8083	Human	hsa-miR-4288	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
8084	Human	hsa-miR-4289	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
8085	Human	hsa-miR-4289	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
8086	Human	hsa-miR-4289	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
8087	Human	hsa-miR-429	miRNA	Vitamin E ¦Ä-tocotrienol	breast cancer	TNBC cell lines (MDA-MB-231 and MDA-MB-468)	Vitamin E ¦Ä-tocotrienol treatment	upregulated	26629059
8088	Human	hsa-miR-429	miRNA	epstein-barr virus (EBV)	tumorigenesis	EBV-positive B-lymphocytic cell lines;Epithelial gastric carcinoma AGSB95.8 cells;MCF-7 cells (ATCC)	Epstein-Barr Virus (EBV) infection	downregulated	20668090
8089	Human	hsa-miR-429	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-429 expression levels were upregulated in cultured neurons with OGD/R treatment	29624520
8090	Human	hsa-miR-429	miRNA	hypoxia	chronic hypoxia	human endothelial cells	binder CO2/O2 incubator treatment	upregulated	25550463
8091	Human	hsa-miR-429	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	chronic hypoxia	endothelial cells	HIF1A treatment	"miR-429 attenuates HIF-1 activity by decreasing HIF1A message during the early stages of hypoxia before HIF-2 is activated, and this regulatory network helps explain the HIF-1 transition to HIF-2 during chronic hypoxia in endothelial cells."	25550463
8092	Human	hsa-miR-429	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
8093	Human	hsa-miR-429	miRNA	tacrolimus (FK506)	epidural fibrosis	human fibroblasts	FK506 treatment	downregulated	28669722
8094	Human	hsa-miR-429	miRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	SW480 cells; HCT116 cells	metformin treatment	upregulated	30017802
8095	Human	hsa-miR-429	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
8096	Human	hsa-miR-429	miRNA	hypoxia	hypoxic-related diseases	primary human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	miR-200b and miR-429 are upregulated in response to hypoxia.	29737439
8097	Human	hsa-miR-429	miRNA	hypoxia	myocardial ischaemic injury	human cardiomyocytes	hypoxia treatment	upregulated	27082497
8098	Human	hsa-miR-429	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	MiR-429 expression level was increased in LPS-stimulated WI-38 cells.	32003671
8099	Human	hsa-miR-429	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-20B cells	human papillomaviruses (HPVs) 20 treatment	downregulated	31911577
8100	Human	hsa-miR-429	miRNA	H2O2	osteogenesis	human adipose-derived mesenchymal stem cells	hydrogen peroxid (H2O2) treatment	upregulated	31885708
8101	Human	hsa-miR-429	miRNA	H2O2	osteogenesis	hADMSCs	H2O2 treatment	upregulated	31885708
8102	Human	hsa-miR-429	miRNA	H2O2	renal cell carcinoma (RCC)	ACHN and Caki-1 cells	H2O2 treatment	downregulated	31550675
8103	Human	hsa-miR-429	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
8104	Human	hsa-miR-429	miRNA	Schizandrin A (SchA)	thyroid cancer (TC)	TC cell line TPC-1	Schizandrin A (SchA) treatment	downregulated	30909188
8105	Human	hsa-miR-429	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	hepatoma cells	Hepatitis B virus X protein (HBx)? treatment	downregulated	23471881
8106	Human	hsa-miR-429	miRNA	hypoxia	hypoxia-induced injury	primary human umbilical vein endothelial cells	hypoxia treatment	downregulated	26954587
8107	Human	hsa-miR-4291	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
8108	Human	hsa-miR-4295	miRNA	H2O2	glaucoma	human trabecular meshwork (HTM) cells	H2O2 treatment	downregulated	30594603
8109	Human	hsa-miR-4295	miRNA	H2O2 and Lycium barbarum polysaccharides (LBPs)	glaucoma	human trabecular meshwork (HTM) cells	H2O2 and Lycium barbarum polysaccharides (LBPs)  treatment	MiR-4295 expression was upregulated in H 2O 2 and LBPs treated cells.	30594603
8110	Human	hsa-miR-4295	miRNA	lycium barbarum polysaccharide (LBP)	glaucoma	H2O2 treated human trabecular meshwork (HTM) cells	Lycium barbarum polysaccharides (LBPs) treatment	upregulated	30594603
8111	Human	hsa-miR-4295	miRNA	propranolol (PRO)	infantile hemangioma (IH)	Human umbilical vein endothelial cells (HUVECs)	propranolol treatment	downregulated	30368887
8112	Human	hsa-miR-4295	miRNA	propranolol (PRO)	infantile hemangioma (IH)	human umbilical vein endothelial cells (HUVECs)	propranolol treatment	Propranolol treatment downregulated miR-4295 expression in HUVECs.	30368887
8113	Human	hsa-miR-4295	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
8114	Human	hsa-miR-4298	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
8115	Human	hsa-miR-4298	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	downregulated	28534445
8116	Human	hsa-miR-4299	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
8117	Human	hsa-miR-4306	miRNA	MnCl2	neurodegeneration (ND)	SH-SY5Y cells	MnCl2 treatment	upregulated	28302480
8118	Human	hsa-miR-431	miRNA	IFN-¦Â	cell proliferation	human embryo-derived fibroblasts	IFN-¦Â? treatment	downregulated	22293894
8119	Human	hsa-miR-431	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
8120	Human	hsa-miR-431	miRNA	hypoxia	hepatocellular carcinoma (HCC)	SNU-387 cells; Huh7 cells	hypoxia treatment	miR-431 expression was reduced in SNU-387 and Huh7 cells under hypoxia treatment.	33193848
8121	Human	hsa-miR-431	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	downregulated	32807750
8122	Human	hsa-miR-431	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
8123	Human	hsa-miR-4310	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
8124	Human	hsa-miR-4313	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
8125	Human	hsa-miR-431-5p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
8126	Human	hsa-miR-4317	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
8127	Human	hsa-miR-4319	miRNA	IL-4	macrophage polarization	peripheral blood mononuclear cells (PBMCs)	IL-4 treatment	downregulated	31267263
8128	Human	hsa-miR-432	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
8129	Human	hsa-miR-432	miRNA	thermal stress	heat shock	HeLa cells	were subjected to heat shock at 42C for 60 min and kept at 37C for 4 h treatment	upregulated	25280995
8130	Human	hsa-miR-432	miRNA	dopamine cocktail and retinoic acid	neuronal differentiation	SH-SY5Y and IMR-32 cells	were dopamine cocktail and retinoic acid treatment	dysregulated	24657437
8131	Human	hsa-miR-432	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
8132	Human	hsa-miR-432	miRNA	low fat diet (LFD)	overweight and obese	plasma	low fat diet (LFD) treatment	downregulated in plasma	29233590
8133	Human	hsa-miR-432	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
8134	Human	hsa-miR-4320	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
8135	Human	hsa-miR-4324	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
8136	Human	hsa-miR-4327	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
8137	Human	hsa-miR-4328	miRNA	everolimus	lung cancer	A549 cells	everolimus (EVE) treatment	downregulated	31612036
8138	Human	hsa-miR-433	miRNA	hypoxia	cerebral infarction (CI)	HUVECs	hypoxia treatment	downregulated	27815672
8139	Human	hsa-miR-433	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
8140	Human	hsa-miR-433	miRNA	manganese (Mn)	idiopathic Parkinson's disease	human neuroblastoma SH-SY5Y cells	manganese (100¦ÌM) treatment	downregulated	28986288
8141	Human	hsa-miR-433	miRNA	manganese (Mn)	manganese induced neurotoxic	SH-SY5Y cells	manganese treatment	The expressions of miR-7 and miR-433 significantly reduced upon manganese exposure.	28986288
8142	Human	hsa-miR-433	miRNA	hypoxia	neuron proliferation and migration	human umbilical vein vascular endothelial cells (HUVECs)	hypoxia treatment	downregulated	27815672
8143	Human	hsa-miR-433	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
8144	Human	hsa-miR-433	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
8145	Human	hsa-miR-4417	miRNA	nickel	epithelial-mesenchymal transition (EMT)	BEAS-2B and A549	nickel	upregulated	29127306
8146	Human	hsa-miR-4417	miRNA	TGF-¦Â inhibitor SB525334	epithelial-mesenchymal transition (EMT)	TGF-¦Â-treated BEAS-2B and A549	SB525334 treatment	downregulated	29127306
8147	Human	hsa-miR-4421	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
8148	Human	hsa-miR-4422	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"miR-4422 was downregulated in CNE-2 cells after treatment by radiation, while curcumin treatment upregulated the expression."	32127962
8149	Human	hsa-miR-4423-3p	miRNA	doxorubicin (DOX)	cardiotoxicity	human-induced pluripotent stem cell (hiPSC)	doxorubicin treatment	upregulated	26842497
8150	Human	hsa-miR-4425	miRNA	ginsenoside 20(S)-Rg3	ovarian cancer (OC)	SKOV3 cells; 3AO cells	ginsenoside 20(S)-Rg3 treatment	20(S)-Rg3 reduced miR-4425 to alleviate the malignant phenotypes of ovarian cancer cells.	32877662
8151	Human	hsa-miR-4428	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	downegulated	32323778
8152	Human	hsa-miR-4428	miRNA	hyperbaric oxygen (HBO)	hepatocellular carcinoma (HCC)	Hepatoma cell lines (BEL-7402 and SK-Hep1)	HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment	upregulated	24956259
8153	Human	hsa-miR-4430	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	upregulated	31549595
8154	Human	hsa-miR-4433	miRNA	suberoylanilide hydroxamic acid (SAHA)	chronic lymphocytic leukemia (CLL)	CML cells K562	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	31737104
8155	Human	hsa-miR-4433	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
8156	Human	hsa-miR-4433-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8157	Human	hsa-miR-4434	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
8158	Human	hsa-miR-4442	miRNA	prednisolone	polymyositis (PM)	plasma	prednisolone treatment	downregulated	29321815
8159	Human	hsa-miR-4446-3p	miRNA	mechanical compression	breast cancer	MDA-MB-231 cells and CAFs	mechanical compression treatment	upregulated	27027350
8160	Human	hsa-miR-4448	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
8161	Human	hsa-miR-4448	miRNA	IFN-¦Ã	corneal allograft rejection	human corneal epithelial cells (HCECs)	IFN-¦Ã treatment	downregulated	30013574
8162	Human	hsa-miR-4448	miRNA	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep)	gastric cancer (GC)	gastric and liver cancer cells	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) treatment	upregulated	24861464
8163	Human	hsa-miR-4448	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
8164	Human	hsa-miR-4448	miRNA	respiratory syncytial virus (RSV)	innate immune response	human dendritic cells	respiratory syncytial virus (RSV) infection treatment	upregulated	29970194
8165	Human	hsa-miR-4448	miRNA	titanium (Ti)	osteoblastic differentiation	human bone marrow mesenchymal stem cells (hMSCs)	Ti treatment	downregulated	24619927
8166	Human	hsa-miR-4455	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
8167	Human	hsa-miR-4455	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
8168	Human	hsa-miR-4455	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	downregulated	25722110
8169	Human	hsa-miR-4458	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B cells	propofol treatment	miR-4458 was significantly increased by propofol	32705160
8170	Human	hsa-miR-4458	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H460 cells	cisplatin treatment	Circ-PRMT5 promoted DDP resistance via REV3L by sponging miR-4458 in NSCLC	32808744
8171	Human	hsa-miR-4459	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
8172	Human	hsa-miR-446	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
8173	Human	hsa-miR-4463	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33245416
8174	Human	hsa-miR-4463	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2	upregulated	28713907
8175	Human	hsa-miR-4463	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	30244253
8176	Human	hsa-miR-4463	miRNA	hypoxia	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	30244253
8177	Human	hsa-miR-4463	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular smooth muscle cell (VSMC) phenotypic switching	human aortic smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	Ox-LDL decreased the level of miR-4463.	33245416
8178	Human	hsa-miR-4465	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 and Hey-8	Paclitaxel (PTX) treatment	SDHAP1 was upregulated in PTX-resistant SKOV3 and Hey-8 ovarian cancer cell lines while the level of miR-4465 was downregulated	32211849
8179	Human	hsa-miR-4468	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
8180	Human	hsa-miR-4474	miRNA	fusobacterium nucleatum (F. nucleatum)	colorectal cancer (CRC)	The human epithelial colorectal cell line Caco-2	Fusobacterium nucleatum (F. nucleatum) infection	upregulated	30951563
8181	Human	hsa-miR-4478	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
8182	Human	hsa-miR-4478	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
8183	Human	hsa-miR-448	miRNA	hypoxia	antiarrhythmic	RL14 cells	hypoxia treatment	upregulated	33108349
8184	Human	hsa-miR-448	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
8185	Human	hsa-miR-448	miRNA	platelet derived growth factor-BB (PDGF-BB)	coronary artery disease (CAD)	human VSMCs	PDGF-bb (20 ng/ml) treatment	upregulated	28799067
8186	Human	hsa-miR-448	miRNA	IL-1¦Â	osteoarthritis (OA)	Chondrocytes	IL-1¦Â treatment	The level of miR-448 was significantly higher in IL-1¦Â-induced chondrocytes.	29483929
8187	Human	hsa-miR-448	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN cells	hypoxia induce	upregulated	29561961
8188	Human	hsa-miR-448	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (MTB) treatment	downregulated	32048448
8189	Human	hsa-miR-4484	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	downregulated	30100735
8190	Human	hsa-miR-4485-3p	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	upregulated	33197057
8191	Human	hsa-miR-4485-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
8192	Human	hsa-miR-4485-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
8193	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	allergic asthma (AA)	16HBE cells	TGF-¦Â1 treatment	miR-448-5p was dramatically decreased in TGF-¦Â1-stimulated bronchial epithelial cells	30362537
8194	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	asthma	"Human bronchial epithelial cells, 16HBE"	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30362537
8195	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human bronchial epithelial cells, 16HBE"	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30362537
8196	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	lung fibrosis	"Human bronchial epithelial cells, 16HBE"	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30362537
8197	Human	hsa-miR-4487	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH5Y-SY cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â 25-35 downregulated hsa-miR-4487 in SH-SY5Y cell lines associated with A¦Â-mediated pathophysiology.	30547775
8198	Human	hsa-miR-4488	miRNA	adeno-associated virus (AAV)	cellular physiology	Huh-7 cells; ARPE-19 cells	adeno-associated virus (AAV) serotypes 2 and 3 infection	downregulated	31629820
8199	Human	hsa-miR-4488	miRNA	adeno-associated virus (AAV)	adeno-associated virus (AAV) infection	ARPE-19 cells	adeno-associated virus (AAV) treatment	downregulated	31629820
8200	Human	hsa-miR-4488	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	Exosomes derived from human primary melanocytes	ultraviolet B (UVB) irradiation treatment	upregulated	32785244
8201	Human	hsa-miR-449	miRNA	IL-13	autophagy	BEAS-2B cells	IL-13 treatment	upregulated	28796252
8202	Human	hsa-miR-449	miRNA	corticosteroid	erythroid cell differentiation	bronchial epithelial? cells	corticosteroids treatment	downregulated	22955319
8203	Human	hsa-miR-449	miRNA	doxorubicin (DOX)	triple negative breast cancer (TNBC)	"The MDA-MB-231, MDA-MB-468, and MCF-7 breast cancer cell lines"	doxorubicin treatment	upregulated	30926829
8204	Human	hsa-miR-4496	miRNA	rebamipide	gastric cancer (GC)	cancer-initiating cells (C-IC)	Rebamipide treatment	upregulated	27265143
8205	Human	hsa-miR-4499	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
8206	Human	hsa-miR-449a	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
8207	Human	hsa-miR-449a	miRNA	IL-1¦Â	cartilage destruction	chondrocytes	IL-1¦Â treatment	upregulated	27421775
8208	Human	hsa-miR-449a	miRNA	E2F transcription factor 1 (E2F1)	cell proliferation and apoptosis	HCT116 cells;H1299;U2OS;GH;833KE ;Saos-2 cells	E2F1 treatment	upregulated	19960022
8209	Human	hsa-miR-449a	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	human air-liquid-interface (ALI) airway cultures	cigarette smoke (CS)?exposure	"In particular, a time-dependent decrease in the expression of miR-449a, a conserved miRNA highly enriched in ciliated airway epithelia and implicated in motile ciliogenesis, was observed in CS-exposed cultures. Similar alterations in miR-449a have been reported in smokers with COPD."	33704509
8210	Human	hsa-miR-449a	miRNA	melatonin	colorectal cancer (CRC)	HCT116 cells	melatonin treatment	"Compared with the control group, melatonin significantly enhanced the expression levels of the miR-34a/449a cluster"	33398374
8211	Human	hsa-miR-449a	miRNA	neferine (NEF)	gastrointestinal stromal tumor (GIST)	GIST cell line GIST-T1	Neferin (Nef) treatment	upregulated	30551450
8212	Human	hsa-miR-449a	miRNA	bromopyruvate (3-BrPA)	glioblastoma multiforme (GBM)	Malignantly transformed macrophages (tM?); dendritic cells (tDC)	bromopyruvate (3-BrPA) treatment	upregulated	31710894
8213	Human	hsa-miR-449a	miRNA	bromopyruvate (3-BrPA)	glioblastoma multiforme (GBM)	Malignantly transformed macrophages (tM?) and dendritic cells (tDC) induced by glioma stem cells in the glioma microenvironment	bromopyruvate (3-BrPA) treatment	upregulated	31710894
8214	Human	hsa-miR-449a	miRNA	hepatitis C virus (HCV)	liver fibrosis	human Primary Hepatocytes£» HEPG2 Cell Line	hepatitis C virus (HCV) infection	downregulated	23226395
8215	Human	hsa-miR-449a	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	downregulated	31824817
8216	Human	hsa-miR-449a	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	A549 cells	at doses ranging from 4 to 8 Gy at 24 h	upregulated	28800787
8217	Human	hsa-miR-449a	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	A549 cells	ionizing radiation (IR) treatment	upregulated	28800787
8218	Human	hsa-miR-449a	miRNA	hypoxia	organs hypoxia	Primary human fibroblasts	hypoxia treatment	downregulated	20356416
8219	Human	hsa-miR-449a	miRNA	hypoxia	pressure ulcer (PU)	HaCaT cells	hypoxia treatment	circ-Ttc3 alleviated hypoxic injury and activated NF-¦ÊB and PI3K/AKT pathways by downregulating miR-449a in HaCaT cells.	32043754
8220	Human	hsa-miR-449a	miRNA	S-adenosyl-L-methionine (AdoMet)	triple negative breast cancer (TNBC)	MDA-MB-231; MDA-MB-468 cells	S-adenosyl-L-methionine (AdoMet) treatment	AdoMet exerts its antitumor effects in TNBC cells through upregulating the expression of miR-34c and miR-449a	33396625
8221	Human	hsa-miR-449b	miRNA	E2F transcription factor 1 (E2F1)	cell proliferation and apoptosis	HCT116 cells;H1299;U2OS;GH;833KE ;Saos-2 cells	E2F1 treatment	upregulated	19960022
8222	Human	hsa-miR-449b	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
8223	Human	hsa-miR-449b	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	NP69 cells	cisplatin (DPP) treatment	downregulated	29795279
8224	Human	hsa-miR-449b	miRNA	hypoxia	organs hypoxia	Primary human fibroblasts	hypoxia treatment	downregulated	20356416
8225	Human	hsa-miR-449b-3p	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	downregulated	31824817
8226	Human	hsa-miR-449b-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	LN229 cells	hypoxia treatment	downregulated	32849915
8227	Human	hsa-miR-449b-5p	miRNA	radiation	radiation resistance of breast cancer (BRCA)	MCF©\7; T47D; LM©\MCF©\7; BT©\474;SKBR©\3; MDA©\MB©\231	radiation treatment	LncRNA HOTAIR facilitates the expression of HSPA1A by sequestering miR-449b-5p post-transcriptionally and thereby endows BRCA with radiation resistance	32374522
8228	Human	hsa-miR-449c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteosarcoma tumorigenesis	human osteosarcoma cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28924385
8229	Human	hsa-miR-4500	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HT29 colorectal cancer cells	ursolic acid (UA) treatment	upregulated	30597956
8230	Human	hsa-miR-4505	miRNA	lipopolysaccharide (LPS)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	miR-4505 was highly expressed in HUVECs stimulated by LPS.	29115487
8231	Human	hsa-miR-4505	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8232	Human	hsa-miR-4505	miRNA	lipopolysaccharide (LPS)	vascular endothelial cell injury	HUVECs	lipopolysaccharide (LPS) treatment	upregulated	29115487
8233	Human	hsa-miR-4508	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8234	Human	hsa-miR-4508	miRNA	MnCl2	neurodegeneration (ND)	SH-SY5Y cells	MnCl2 treatment	upregulated	28302480
8235	Human	hsa-miR-450a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
8236	Human	hsa-miR-450a	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
8237	Human	hsa-miR-450a	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
8238	Human	hsa-miR-450b-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
8239	Human	hsa-miR-450b-5p	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
8240	Human	hsa-miR-450b-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
8241	Human	hsa-miR-450b-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT-29 cells and HCT-116 cells	5-fluorouracil (5-FU) treatment	downregulated	26845645
8242	Human	hsa-miR-450b-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"miR-450b-5p was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression."	32127962
8243	Human	hsa-miR-451	miRNA	erythropoietin (EPO)	apoptosis	SH-SY5Y neuronal-like cells	EPO treatment	downregulated	25324845
8244	Human	hsa-miR-451	miRNA	tamoxifen (TAM)	breast cancer	breast cancer cell	Tamoxifen treatment	downregulated	21666713
8245	Human	hsa-miR-451	miRNA	hypoxia	cerebral ischemia injury (CII)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	31173234
8246	Human	hsa-miR-451	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN-45 cells	docetaxel (DTX) treatment	downregulated	33416185
8247	Human	hsa-miR-451	miRNA	propofol (PPF)	gastric cancer (GC)	SGC-7901 cell	Propofol treatment	upregulated	27173190
8248	Human	hsa-miR-451	miRNA	erythropoietin (EPO)	glioblastoma multiforme (GBM)	U87 human glioblastoma cell line	EPO treatment	downregulated	28629521
8249	Human	hsa-miR-451	miRNA	¦Â2 adrenergic agonist	glioblastoma multiforme (GBM)	1321N1 astrocytoma cells	a selective ¦Â2 adrenergic agonist treatment	upregulated	24714982
8250	Human	hsa-miR-451	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
8251	Human	hsa-miR-451	miRNA	microcystin-leucine arginine (MC-LR)	liver damage	HL7702 cells	Microcystin-LR treatment	downregulated	30875960
8252	Human	hsa-miR-451	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	upregulated	28347920
8253	Human	hsa-miR-451	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC tissues and cell lines	cisplatin treatment	"?TATDN1 and TRIM66 was significantly upregulated while miR-451 was downregulated in NSCLC tissues and cell lines, especially in DDP-resistant tumor tissues and cells."	30481109
8254	Human	hsa-miR-451	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H157 cells	cisplatin treatment	downregulated	30481109
8255	Human	hsa-miR-451	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	upregulated	20110569
8256	Human	hsa-miR-451	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	upregulated	21030674
8257	Human	hsa-miR-451	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
8258	Human	hsa-miR-451-1	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
8259	Human	hsa-miR-4516	miRNA	BET inhibitors (JQ1)	anaplastic thyroid carcinoma (ATC)	ATC-derived cell lines (SW1736 and 8505c)	treat with either 5 ?M JQ1	downregulated	29251329
8260	Human	hsa-miR-4516	miRNA	BET inhibitors (JQ1)	anaplastic thyroid carcinoma (ATC)	SW1736 cells; 8505c cells	BET inhibitors (JQ1) treatment	upregulated	29251329
8261	Human	hsa-miR-4516	miRNA	melatonin	chronic kidney disease (CKD)	mesenchymal stem/stromal cell (MSC)	melatonin treatment	upregulated	31989677
8262	Human	hsa-miR-4516	miRNA	coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	16HBE cells	coxsackievirus A16 (CV-A16) treatment	upregulated	29686973
8263	Human	hsa-miR-4516	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	16HBE cells	Enterovirus 71 (EV71) infection	downregulated	29686973
8264	Human	hsa-miR-4516	miRNA	cyclosporine A (CsA)	nephrotoxicity	human proximal tubule cells	cyclosporine A treatment	dysregulated	28925592
8265	Human	hsa-miR-4516	miRNA	particulate matter (PM2.5)	non-small cell lung cancer (NSCLC)	A549 cells	particulate matter (PM2.5) treatment	upregulated	27329587
8266	Human	hsa-miR-4516	miRNA	photochemotherapy with psoralens and ultraviolet A (PUVA)	psoriasis	human keratinocytes (HaCaT cells)	PUVA treatment	upregulated	24610393
8267	Human	hsa-miR-4516	miRNA	house dust mite (HDM)	lung fibrosis	serum	dust exposure	upregulated	30090591
8268	Human	hsa-miR-451a	miRNA	common aeroallergens	asthma	peripheral blood lymphocytes	common aeroallergens treatment	downregulated of miRNA-451a Promotes the Differentiation of CD4+ T Cells towards Th2 Cells by Upregulating ETS1 in Childhood Asthma	33271553
8269	Human	hsa-miR-451a	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 15¡ã HDT bed rest experiment	downregulated	28261104
8270	Human	hsa-miR-451a	miRNA	microcystin-leucine arginine (MC-LR)	cytoskeletal reorganization	HL7702 liver cells	microcystin (MC)-LR treatment	downregulated	30422063
8271	Human	hsa-miR-451a	miRNA	paroxetine	depression	serum	paroxetine treatment	upregulated	29791588
8272	Human	hsa-miR-451a	miRNA	4-hydroxynonenal (4-HNE)	diabetic retinopathy (DR)	RPE cells	4-hydroxynonenal (4-HNE) treatment	The expression of miR-451a was downregulated both in the retina of Akita mice and 4-hydroxynonenal (4-HNE)-treated RPE cells.	30576241
8273	Human	hsa-miR-451a	miRNA	simvastatin	endometriosis	Serum	simvastatin treatment	downregulated	29587611
8274	Human	hsa-miR-451a	miRNA	hydroquinone (HQ)	erythroid cell differentiation	CD34 + hematopoietic progenitor cells	hydroquinone (HQ) treatment	downregulated	28733890
8275	Human	hsa-miR-451a	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
8276	Human	hsa-miR-451a	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
8277	Human	hsa-miR-451a	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
8278	Human	hsa-miR-451a	miRNA	hydroquinone (HQ)	hematotoxicity	CD34 hematopoietic progenitor cells	treat with HQ	downregulated	28733890
8279	Human	hsa-miR-451a	miRNA	endothelin-1 (ET-1)	cardiac dysfunction	Cor.4U human inducible pluripotent stem cell-derived cardiomyocytes (hiPS-CMs)	endothelin-1 (ET-1) treatment	downregulated	31618079
8280	Human	hsa-miR-451a	miRNA	hypoxia	cardiac dysfunction	Cor.4U human inducible pluripotent stem cell-derived cardiomyocytes (hiPS-CMs)	hypoxia induce	downregulated	31618079
8281	Human	hsa-miR-451a	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	downregulated	29516639
8282	Human	hsa-miR-451a	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	upregulated	29516639
8283	Human	hsa-miR-451a	miRNA	doxorubicin (DOX)	lung cancer	A549 cells; PC9 cells	doxorubicin (Dox) treatment	upregulated	32106373
8284	Human	hsa-miR-451a	miRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	human normal liver cell line HL7702	icrocystin-LR (MC-LR) treatment	downregulated	29265921
8285	Human	hsa-miR-451a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
8286	Human	hsa-miR-451a	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
8287	Human	hsa-miR-451a	miRNA	noise	noise-induced hearing loss (NIHL)	plasma	noise treatment	downregulated	26278637
8288	Human	hsa-miR-451a	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	"free fatty acids (FFAs; oleate/palmitate, 2:1 ratio) treatment"	downregulated	29604329
8289	Human	hsa-miR-451a	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
8290	Human	hsa-miR-451a	miRNA	radiation	oesophageal adenocarcinoma (OAC)	OE19 cells	radiation treatment	Inhibition of miR-451a in the radiation resistant OAC cell line OE19 increased radiosensitivity	33255413
8291	Human	hsa-miR-451a	miRNA	4-hydroxynonenal (4-HNE)	proliferative diabetic retinopathy (PDR)	ARPE-19 cells and primary human RPE cells	4-hydroxynonenal (4-HNE) treatment	downregulated	30576241
8292	Human	hsa-miR-451a	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
8293	Human	hsa-miR-452	miRNA	adriamycin (ADR)	breast cancer	adriamycin-resistant MCF-7 cells (MCF-7/ADR)	adriamycin (ADR) treatment	downregulated	25040964
8294	Human	hsa-miR-452	miRNA	hypoxia	sleep apnea syndrome (SAS)	human SW872 adipocytes	hypoxia treatment	downregulated	31013606
8295	Human	hsa-miR-4521	miRNA	hypoxia	gastric cancer (GC)	GC cells	hypoxia treatment	Further studies showed that hypoxia repressed miR-4521 expression via inducing ETS1 and miR-4521 mitigated hypoxia-mediated metastasis	33407516
8296	Human	hsa-miR-4521	miRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line HL7702	"treatment with MC-LR at concentrations of 1, 2.5, 5 or 10 ¦ÌM"	downregulated	29265921
8297	Human	hsa-miR-4521	miRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	human normal liver cell line HL7702	icrocystin-LR (MC-LR) treatment	downregulated	29265921
8298	Human	hsa-miR-452-3p	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
8299	Human	hsa-miR-4525	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8300	Human	hsa-miR-452-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose treatment	upregulated	31849505
8301	Human	hsa-miR-452-5p	miRNA	sunitinib (SU)	metastatic renal cell carcinoma (mRCC)	OSRC-2 and SW839 cells	sunitinib treatment	downregulated	30419914
8302	Human	hsa-miR-453	miRNA	cisplatin (DDP)	cell death	A549 cell	cisplatin (DPP) treatment	downregulated	21880462
8303	Human	hsa-miR-4530	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	downregulated	31359311
8304	Human	hsa-miR-4532	miRNA	ultraviolet (UV) irradiation	cataract	human lens epithelial cells (HLECs)	Ultra-violet radiation (UVR) exposure treatment	"Functional studies show that UVR-induced cytotoxicity and apoptosis in HLECs were potentiated by miR-4532 overexpression, Nrf2 depletion or SIRT6 shRNA"	31079921
8305	Human	hsa-miR-454	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	A2780; SKOV3	cisplatin treatment	CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.	32124583
8306	Human	hsa-miR-454	miRNA	advanced glycation end product (AGE)	epithelial-mesenchymal transition (EMT)	primary human peritoneal mesothelial cells (HPMCs)	advanced glycation end products (AGEs) treatment	"iRNA-454, potentially targeting STAT3, was downregulated in AGEs-treated HPMCs. Overexpression of miRNA-454 prevented AGEs- induced EMT in HPMCs."	30820783
8307	Human	hsa-miR-454	miRNA	placenta growth factor (PlGF)	lung fibrosis	endothelial cells	placenta growth factor (PlGF) treatment	downregulated	26460070
8308	Human	hsa-miR-454	miRNA	TGF-¦Â1	schistosomiasis	LX-2 cells	TGF-¦Â1 treatment	downregulated	24685242
8309	Human	hsa-miR-454-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	?human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"In the present study, the results revealed that miR-454-3p expression was substantially downregulated in human aortic endothelial cells (HAECs) following oxidized low-density lipoprotein (ox-LDL) treatment."	33732296
8310	Human	hsa-miR-454-3p	miRNA	X-rays	laryngeal cancer	"Laryngeal cancer cell lines TU212, LLN and TU686"	X-ray radiation treatment	HOTAIR knockdown reduced laryngeal cancer cell radiosensitivity by sponging miR-454-3p to silence E2F2	31849488
8311	Human	hsa-miR-454-3p	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
8312	Human	hsa-miR-454-3p	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; H157 cells	cisplatin treatment	miR-454-3p was expressed lower in cisplatin-resistant LUAD cells than that in the parental LUAD cells.	30099826
8313	Human	hsa-miR-454-3p	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	C666-1 cells; HNE1 cells	cisplatin treatment	elevated HOXA11-AS and reduced miR-454-3p were found in NPC tissue and cisplatin-resistant NPC cells.	33115978
8314	Human	hsa-miR-455	miRNA	arsenite	arsenite-induced carcinogenesis	human keratinocyte (HaCaT) cells	arsenite exposure	downregulated	29216394
8315	Human	hsa-miR-455	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â1 treatment	UCA1 exerted its role via regulating the UCA1/miR-455/ZEB1 regulatory axis in HUVECs treated with TGF-¦Â1	32584608
8316	Human	hsa-miR-455	miRNA	CoCl2	hypoxia-induced injury	Human lung epithelial cells BEAS-2B	CoCl2 treatment	downregulated	30193773
8317	Human	hsa-miR-455	miRNA	hydrogen sulfide (H2S)	hypoxia-induced injury	CoCl2-induced human lung epithelial cells BEAS-2B	hydrogen sulfide (H2S) treatment	upregulated	30193773
8318	Human	hsa-miR-455	miRNA	H2O2	oxidative stress	human endometrial stromal cells (HESCs)	hydrogen peroxide (H2O2) treatment	downregulated	31638263
8319	Human	hsa-miR-455-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	human neuroblastoma cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	28934394
8320	Human	hsa-miR-455-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
8321	Human	hsa-miR-455-3p	miRNA	TGF-¦Â	chronic obstructive pulmonary disease (COPD)	primary parenchymal lung fibroblasts	TGF-¦Â treatment	upregulated	28910321
8322	Human	hsa-miR-455-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMC) and human proximal tubule epithelial cells (HK-2)	high glucose (HG) treatment	downregulated	29932921
8323	Human	hsa-miR-455-3p	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	human mesangial cells (HMC) and human proximal tubule epithelial cells (HK-2)	transforming growth factor beta 1 (TGF-¦Â1) treatment	downregulated	29932921
8324	Human	hsa-miR-455-3p	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
8325	Human	hsa-miR-455-3p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
8326	Human	hsa-miR-455-3p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8327	Human	hsa-miR-455-3p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8328	Human	hsa-miR-455-3p	miRNA	bicyclol	idiopathic pulmonary fibrosis (IPF)	human lung epithelial cells HPAEpiC	bicyclol treatment	upregulated	31407409
8329	Human	hsa-miR-455-3p	miRNA	vehicle and bicyclol	idiopathic pulmonary fibrosis (IPF)	human pulmonary alveolar epithelial cells (HPAEpiCs)	vehicle and bicyclol treatment	upregulated	31407409
8330	Human	hsa-miR-455-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
8331	Human	hsa-miR-455-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	transforming growth factor ¦Â1 (TGF-¦Â1) treatment	downregulated	31150929
8332	Human	hsa-miR-455-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	cultured chondrocytes	interleukin-1¦Â (IL-1¦Â) treatment	downregulated	31508417
8333	Human	hsa-miR-455-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocyte cell line CHON-001	IL-1¦Â treatment	upregulated	31809639
8334	Human	hsa-miR-455-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	"miR-455-3p continued to increase in the first 21 days during chondrogenesis, peaked at day 21, and then declined."	32343998
8335	Human	hsa-miR-455-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32982172
8336	Human	hsa-miR-455-5p	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-455-5p was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
8337	Human	hsa-miR-455-5p	miRNA	intermittent cyclic mechanical tension (ICMT)	degeneration of endplate chondrocytes	human endplate cartilage tissues	Intermittent cyclic mechanical tension (ICMT)	downregulated	30132981
8338	Human	hsa-miR-455-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	human brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	CircPHC3 was highly expressed in human BMECs after OGD	33519202
8339	Human	hsa-miR-455-5p	miRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte	hypoxia induce	Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p.	30898696
8340	Human	hsa-miR-455-5p	miRNA	total flavonoids (TFs)	oxLDL-induced vascular smooth muscle cell inflammation	vascular smooth muscle cells	total flavones of Clematis filamentosa Dunn treatment	The total flavones of Clematis filamentosa Dunn promoted the expression of miR-455-5p.	33040830
8341	Human	hsa-miR-4634	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
8342	Human	hsa-miR-4634	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
8343	Human	hsa-miR-4634	miRNA	Human metapneumovirus (HMPV)	innate immune response	human dendritic cells	Human metapneumovirus (HMPV) infection	upregulated	29970194
8344	Human	hsa-miR-4634	miRNA	respiratory syncytial virus (RSV)	innate immune response	human dendritic cells	respiratory syncytial virus (RSV) infection treatment	upregulated	29970194
8345	Human	hsa-miR-4650	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	downregulated	25722110
8346	Human	hsa-miR-4651	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
8347	Human	hsa-miR-4653-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8348	Human	hsa-miR-4654	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
8349	Human	hsa-miR-4654	miRNA	alternariol (AOH)	cytotoxicity	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
8350	Human	hsa-miR-4654	miRNA	resveratrol	hypertrophic scars (HS)	HS-derived fibroblasts (HSFBs)	resveratrol (RS) treatment	microRNA-4654 (miR-4654) was significantly decreased in the HSFBs and re-upregulated by resveratrol treatment dose-dependently	32945452
8351	Human	hsa-miR-4656	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
8352	Human	hsa-miR-466	miRNA	p53	esophageal squamous cell carcinoma (ESCC)	ESCC cell lines	?p53 overexpression treatment	downregulated	31185143
8353	Human	hsa-miR-4665-3p	miRNA	arsenic sulfide	gastric cancer (GC)	AGS cells	arsenic sulfide treatment	upregulated	31692505
8354	Human	hsa-miR-4665-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8355	Human	hsa-miR-4667-5p	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
8356	Human	hsa-miR-4668	miRNA	fluticasone	eosinophilic esophagitis (EoE)	salivary	fluticasone treatment	downregulated	32923026
8357	Human	hsa-miR-4669	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
8358	Human	hsa-miR-467	miRNA	high glucose (HG)	angiogenesis	HUVECs;HDMECs;HAECs	?high glucose treatment	upregulated	23316333
8359	Human	hsa-miR-4680-3p	miRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	human embryonic palatal mesenchymal (HEPM) cells	all-trans retinoic acid (ATRA) treatment	We found that?all-trans?retinoic acid (atRA) specifically induces?miR-4680-3p?in cultured human embryonic palatal mesenchymal (HEPM) cells.	33585479
8360	Human	hsa-miR-4689	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
8361	Human	hsa-miR-4701-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8362	Human	hsa-miR-4708	miRNA	titanium (Ti)	osteoblastic differentiation	human bone marrow mesenchymal stem cells (hMSCs)	Ti treatment	downregulated	24619927
8363	Human	hsa-miR-4709-3p	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular cells (HK-2)	TGF-¦Â1 treatment	upregulated	31455266
8364	Human	hsa-miR-4710	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
8365	Human	hsa-miR-4712-3p	miRNA	thymosin ¦Á1 (T¦Á1)	non-segmental vitiligo (NSV)	peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV)	thymosin ¦Á1 (T¦Á1) treatment	upregulated	25495156
8366	Human	hsa-miR-4715-3p	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
8367	Human	hsa-miR-4715-3p	miRNA	alternariol (AOH)	cytotoxicity	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
8368	Human	hsa-miR-4716-5p	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
8369	Human	hsa-miR-4717	miRNA	fusobacterium nucleatum (F. nucleatum)	colorectal cancer (CRC)	The human epithelial colorectal cell line Caco-2	Fusobacterium nucleatum (F. nucleatum) infection	upregulated	30951563
8370	Human	hsa-miR-4717-3p	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
8371	Human	hsa-miR-4726-5p	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
8372	Human	hsa-miR-4728-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8373	Human	hsa-miR-4734	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
8374	Human	hsa-miR-4739	miRNA	bleomycin (BLM)	pleural fibrosis	The human pleural mesothelial cells (PMCs)	bleomycin (BLM) treatment	upregulated	30850350
8375	Human	hsa-miR-4739	miRNA	TGF-¦Â1	pleural fibrosis	The human pleural mesothelial cells (PMCs)	TGF-¦Â1 treatment	upregulated	30850350
8376	Human	hsa-miR-4741	miRNA	herapy with transarterial chemoembolisation (TACE)	hepatocellular carcinoma (HCC)	HCC patients	TACE treatment	dysregulated	25230788
8377	Human	hsa-miR-4747-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
8378	Human	hsa-miR-4749-5p	miRNA	xanthohumol (XN)	glioblastoma multiforme (GBM)	A172 cells; U87-MG cells	xanthohumol (XN) treatment	upregulated	32422304
8379	Human	hsa-miR-4750	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
8380	Human	hsa-miR-4756	miRNA	albumin	diabetic nephropathy (DN)	HK-2 cells	albumin treatment	upregulated	30145827
8381	Human	hsa-miR-4756	miRNA	albumin	diabetic nephropathy (DN)	HK-2 cells	albumin treatment	Albumin stimulation significantly increased miR-4756 levels in HK-2 cells.	30145827
8382	Human	hsa-miR-4763-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8383	Human	hsa-miR-4769-5p	miRNA	mechanical compression	breast cancer	MDA-MB-231 cells and CAFs	mechanical compression treatment	upregulated	27027350
8384	Human	hsa-miR-4773	miRNA	titanium (Ti)	osteoblastic differentiation	human bone marrow mesenchymal stem cells (hMSCs)	Ti treatment	downregulated	24619927
8385	Human	hsa-miR-4784	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
8386	Human	hsa-miR-4785	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	downregulated	25959385
8387	Human	hsa-miR-4788	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
8388	Human	hsa-miR-4792	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	upregulated	30100735
8389	Human	hsa-miR-4795-5p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
8390	Human	hsa-miR-483	miRNA	sera from acute KD patients	acute Kawasaki disease (KD)	human umbilical vein endothelial cell	sera from acute KD patients treatment	downregulated	27923814
8391	Human	hsa-miR-483	miRNA	TGF-¦Â1	anaplastic thyroid carcinoma (ATC)	8505C cells; FRO cells	TGF-¦Â1 treatment	TGF-¦Â1 increases miR-483 expression and decreases Pard3 expression	30171257
8392	Human	hsa-miR-483	miRNA	tunicamycin (TM)	apoptosis	HEK293 cells	tunicamycin treatment	upregulated	31792031
8393	Human	hsa-miR-483	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
8394	Human	hsa-miR-483	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
8395	Human	hsa-miR-483-3p	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
8396	Human	hsa-miR-483-3p	miRNA	black raspberry (BRB) anthocyanins	colorectal cancer (CRC)	LoVo cells; SW480 cells; HCT116 cells	black raspberry (BRB) anthocyanins treatment	downregulated	31763724
8397	Human	hsa-miR-483-3p	miRNA	black raspberry (BRB) anthocyanins	colorectal cancer (CRC)	"Human HCT116 and HT29 CRC cell lines, LoVo cells and SW480 cells"	black raspberry (BRB) anthocyanins treatment	downregulated	31763724
8398	Human	hsa-miR-483-3p	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
8399	Human	hsa-miR-483-3p	miRNA	heartmate II left ventricular assist device (LVAD) implantation	heartmate II left ventricular assist device (LVAD) implantation therapy effect	plasma and myocardial samples	LVAD treatment	upregulated	24961598
8400	Human	hsa-miR-483-3p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
8401	Human	hsa-miR-483-5p	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
8402	Human	hsa-miR-483-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	AC16 cells	hypoxia treatment	miR-483-5p were also upregulated in hypoxia-induced AC16 cell injury.	32206064
8403	Human	hsa-miR-483-5p	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
8404	Human	hsa-miR-483-5p	miRNA	retinoic acid (RA)	breast cancer	Human embryonic kidney cells (HEK293T) ;HepG2 cells; Huh7  cells; adjacent non-tumor tissues	retinoic acid treatment	downregulated	22971576
8405	Human	hsa-miR-483-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
8406	Human	hsa-miR-483-5p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
8407	Human	hsa-miR-483-5p	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
8408	Human	hsa-miR-483-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
8409	Human	hsa-miR-483-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
8410	Human	hsa-miR-483-5p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
8411	Human	hsa-miR-484	miRNA	forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	forskolin (Fsk) treatment	upregulated	33508847
8412	Human	hsa-miR-484	miRNA	polyalthia longifolia leaf extract	cell death	HeLa cells	Polyalthia longifolia leaf extract treatment	downregulated	31383043
8413	Human	hsa-miR-484	miRNA	5-fluorouracil (5-Fu)	diabetic nephropathy (DN)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
8414	Human	hsa-miR-484	miRNA	5-fluorouracil (5-Fu)	metastatic colorectal cancer (mCRC)	mCRC patients	5-fluorouracil (5-FU) treatment	upregulated	24119443
8415	Human	hsa-miR-484	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
8416	Human	hsa-miR-484	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	downregulated	26298803
8417	Human	hsa-miR-484	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
8418	Human	hsa-miR-485	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SK-N-SH; SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Long Noncoding RNA MIR210HG Promotes the Warburg Effect and Tumor Growth by Enhancing HIF-1¦Á Translation in Triple-Negative Breast Cancer	31794744
8419	Human	hsa-miR-485	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	downregulated	31727371
8420	Human	hsa-miR-485	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	miR-485 expression is significantly decreased in HG-stimulated HMCs.	31727371
8421	Human	hsa-miR-485	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	human neuroblastoma cell lines SK-N-SH and SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31794744
8422	Human	hsa-miR-485	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	downregulated	30182373
8423	Human	hsa-miR-485	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	A549/cisplatin (A549/CDDP) cells	epigallocatechin-3-gallate (EGCG) treatment	upregulated	30182373
8424	Human	hsa-miR-485-3p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid-¦Â (A¦Â) treatment	upregulated	33220166
8425	Human	hsa-miR-485-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	33220166
8426	Human	hsa-miR-485-3p	miRNA	hypoxia	angiogenesis	Human Brain Microvascular Endothelial Cells (HBMEC)	hypoxia induce	downregulated	31737200
8427	Human	hsa-miR-485-3p	miRNA	paclitaxel (PTX)	breast cancer	SK-BR-3 cells	paclitaxel (PTX) treatment	downregulated	32897218
8428	Human	hsa-miR-485-3p	miRNA	IL-1¦Á	cutaneous lupus erythematosus	primary PBMCs isolated from discoid lupus erythematosus (DLE) patients	IL-1¦Á treatment	upregulated	30130620
8429	Human	hsa-miR-485-3p	miRNA	TGF-¦Â1	cutaneous lupus erythematosus	primary PBMCs isolated from discoid lupus erythematosus (DLE) patients	TGF-¦Â1 treatment	upregulated	30130620
8430	Human	hsa-miR-485-3p	miRNA	IL-1¦Á	discoid lupus erythematosus (DLE)	peripheral mononuclear blood cells from DLE patients	IL-1¦Á treatment	upregulated	30130620
8431	Human	hsa-miR-485-3p	miRNA	TGF-¦Â1	discoid lupus erythematosus (DLE)	peripheral mononuclear blood cells from DLE patients	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30130620
8432	Human	hsa-miR-485-3p	miRNA	ovalbumin (OVA)	pediatric asthma	Lymphocytes	ovalbumin (OVA) treatment	Upregulated	22895815
8433	Human	hsa-miR-485-3p	miRNA	fludarabine	prostate cancer	DU-145 cells	Fludarabine treatment	"?in fludarabine treated cells the release of miR-485-3p, as well as its association with exosomes, was reduced suggesting that miR-485-3p was retained by surviving cells"	23734815
8434	Human	hsa-miR-485-5p	miRNA	resveratrol	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	resveratrol (RS) treatment	upregulated	33718067
8435	Human	hsa-miR-485-5p	miRNA	TGF-¦Â1	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	TGF-¦Â1 treatment	downregulated	33718067
8436	Human	hsa-miR-485-5p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	upregulated	24927770
8437	Human	hsa-miR-485-5p	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	"A549, H1299, H460 cells"	epigallocatechin-3-gallate (EGCG) treatment	upregulated	30058740
8438	Human	hsa-miR-485-5p	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
8439	Human	hsa-miR-486	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
8440	Human	hsa-miR-486	miRNA	TGF-¦Â1 or bone morphogenetic protein 2 (BMP-2)	calcific aortic valve disease (CAVD)	human aortic valve interstitial cells (AVICs)	"TGF-¦Â1,BMP-2 treatment"	dysregulated	28377507
8441	Human	hsa-miR-486	miRNA	tocotrienol-rich fraction (TRF)	cell differentiation	senescent human skeletal muscle myoblasts (HSMM)	senescent human skeletal muscle myoblasts (HSMM) were treated with 50 ¦Ìg/mL TRF for 24 h treatment	upregulated	30519366
8442	Human	hsa-miR-486	miRNA	hypoxia	erythroid cell differentiation	TF-1 cells	hypoxia treatment	upregulated	28043832
8443	Human	hsa-miR-486	miRNA	hypoxia	erythroid cell differentiation	erythroleukemia TF-1 cells	hypoxia treatment	upregulated	28043832
8444	Human	hsa-miR-486	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	upregulated	28797462
8445	Human	hsa-miR-486	miRNA	hypoxia	hypoxic/ischemic injury	bone marrow-derived mesnechymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	26801559
8446	Human	hsa-miR-486	miRNA	propofol (PPF)	lung cancer	lung cancer cell lines H1299 and H1792	propofol treatment	upregulated	28076456
8447	Human	hsa-miR-486	miRNA	high-intensity interval training (HIIT)	skeletal muscle adaptation	human	human treatment	downregulated	27101297
8448	Human	hsa-miR-486	miRNA	lidocaine	skin healing process	denatured skin tissues	Lidocaine treatment	"lidocaine treatment promoted the skin healing after thermal injury through up-regulating miR-486 and miR-663 expression, and partially explained how lidocaine modulates wound healing processes."	31815358
8449	Human	hsa-miR-486	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
8450	Human	hsa-miR-486-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
8451	Human	hsa-miR-486-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
8452	Human	hsa-miR-486-3p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8453	Human	hsa-miR-486-3p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8454	Human	hsa-miR-486-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8455	Human	hsa-miR-486-3p	miRNA	nintedanib	idiopathic pulmonary fibrosis (IPF)	Human IPF lung fibroblasts	nintedanib treatment	downregulated	30841487
8456	Human	hsa-miR-486-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
8457	Human	hsa-miR-486-5p	miRNA	hesperetin	breast cancer	MDA-MB-231 and MCF-7 cells	hesperetin treatment	"?Hesperetin restored the expression of miR-486-5p, inhibited H19 lncRNA and ICAM-1 expression and selectively regressed mBC cell aggressiveness."	33882812
8458	Human	hsa-miR-486-5p	miRNA	cisplatin (DDP)	bladder cancer	5637 cells; EJ138 cancer cells	cisplatin treatment	MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and downregulated of metastatic genes.	32527702
8459	Human	hsa-miR-486-5p	miRNA	adoMet	breast cancer	MCF-7 cells	adoMet treatment	downregulated	30533999
8460	Human	hsa-miR-486-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"XIST and GAB2 were significantly highly expressed, while miR-486-5p was low expressed in SH-SY5Y cells under I/R"	33660813
8461	Human	hsa-miR-486-5p	miRNA	hydroquinone (HQ)	erythroid cell differentiation	CD34 + hematopoietic progenitor cells	hydroquinone (HQ) treatment	downregulated	28733890
8462	Human	hsa-miR-486-5p	miRNA	solasonine (SS)	gastric cancer (GC)	SNU1 cells; SNU5 cells	solasonine treatment	Solasonine increased the expression of miR-486-5p significantly.	32774717
8463	Human	hsa-miR-486-5p	miRNA	hydroquinone (HQ)	hematotoxicity	CD34 hematopoietic progenitor cells	treat with HQ	downregulated	28733890
8464	Human	hsa-miR-486-5p	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh-7 cells	hepatitis C virus (HCV) infection	downregulated	27698829
8465	Human	hsa-miR-486-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	lipopolysaccharides (LPS) treatment	downregulated	30790508
8466	Human	hsa-miR-486-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
8467	Human	hsa-miR-486-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	non-small cell lung cancer (NSCLC)	human NSCLC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28965852
8468	Human	hsa-miR-486-5p	miRNA	estrogen (ES)	ovarian cancer (OC)	SKOV3 cells	SKOV3 cells treatment	downregulated	26871282
8469	Human	hsa-miR-486-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
8470	Human	hsa-miR-486-5p	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	upregulated	32587527
8471	Human	hsa-miR-486-5p	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	SRA01/04 cells	TGF-¦Â2 treatment	downregulated	29229876
8472	Human	hsa-miR-487a	miRNA	TGF-¦Â1	breast cancer	MCF-7 and MDA-MB-231	MCF-7 and MDA-MB-231 treatment	upregulation	27019625
8473	Human	hsa-miR-487a-3p	miRNA	5-fluorouracil (5-FU)	locally advanced rectal cancer (LARC)	tumor tissues	5-fluorouracil (5-FU) treatment	upregulated	32345666
8474	Human	hsa-miR-487a-3p	miRNA	capecitabine	locally advanced rectal cancer (LARC)	tumor tissues	capecitabine treatment	upregulated	32345666
8475	Human	hsa-miR-487a-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	Expression level of circHIPK3 in HK-2 cells was remarkably decreased after the treatment of HG.	33628038
8476	Human	hsa-miR-487a-5p	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
8477	Human	hsa-miR-487b	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
8478	Human	hsa-miR-487b	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
8479	Human	hsa-miR-487b	miRNA	cigarette smoke condensate (CSC)	breast cancer	Primary lung cancer specimens and adjacent histologically normal lung parenchyma	cigarette smoke condensate (CSC) treatment	downregulated	23426183
8480	Human	hsa-miR-487b	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells	TGF-¦Â1 treatment	"the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2,"	24258346
8481	Human	hsa-miR-487b	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
8482	Human	hsa-miR-487b	miRNA	TGF-¦Â1	lung adenocarcinoma (LUAD)	human adenocarcinoma cell lines	transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment	upregulated	24258346
8483	Human	hsa-miR-487b	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
8484	Human	hsa-miR-487b-3p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
8485	Human	hsa-miR-487b-5p	miRNA	temozolomide (TMZ)	lung cancer	A549 and H1299 cells	Temozolomide (TMZ) treatment	downregulated	27097129
8486	Human	hsa-miR-488	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells (HMCs)	high glucose (HG) treatment	upregulated	31173306
8487	Human	hsa-miR-488	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
8488	Human	hsa-miR-488	miRNA	18¦Â-glycyrrhetinic acid (GA)	prostate cancer	LNCaP cells	18¦Â-glycyrrhetinic acid (GA) treatment	miR-488 was markedly induced by GA treatment.	32219716
8489	Human	hsa-miR-488-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
8490	Human	hsa-miR-489	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	downregulated	27158236
8491	Human	hsa-miR-489	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	downregulated	27158236
8492	Human	hsa-miR-489	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SK-N-SH cell lines	fluoxetine treatment	upregulated	27716787
8493	Human	hsa-miR-489	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
8494	Human	hsa-miR-489	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
8495	Human	hsa-miR-489	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
8496	Human	hsa-miR-489-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells; HSC-T6 cells	TGF-¦Â1 treatment	downregulated	32144602
8497	Human	hsa-miR-489-3p	miRNA	bupivacaine	spinal cord injury (SCI)	"human neural cell lines, AGE1.HN and SY-SH-5Y"	bupivacaine treatment	upregulated	29441872
8498	Human	hsa-miR-490	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	human HCC cell lines HepG2 and Hep3B	hepatitis C virus (HCV) infection	upregulated	28781655
8499	Human	hsa-miR-490	miRNA	hepatitis C virus E2 envelope glycoprotein (HCV-E2)	hepatocellular carcinoma (HCC)	mast cells (MCs) line HMC-1	HCV-E2	upregulated	28781655
8500	Human	hsa-miR-490	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	downregulated	31435813
8501	Human	hsa-miR-490-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	HPAEpiC (human type II alveolar epithelial cell)	lipopolysaccharide (LPS) treatment	downregulated	33456519
8502	Human	hsa-miR-490-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells; HPAEpiC (human type II alveolar epithelial cell)	lipopolysaccharide (LPS) treatment	downregulated	33456519
8503	Human	hsa-miR-490-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	"The HepG2 cell, hCASMC, and human coronary artery endothelial cell (hCAEC)"	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	23821525
8504	Human	hsa-miR-490-3p	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
8505	Human	hsa-miR-490-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	AGS cells	Helicobacter pylori (H. pylori) infection	downregulated	32735911
8506	Human	hsa-miR-490-3p	miRNA	TGF-¦Â	invasive ductal carcinoma (IDC)	MCF10A cells	TGF-¦Â treatment	The expression of miR-490-3p was induced following transforming growth factor (TGF)-¦Â-induced epithelial-to-mesenchymal transition (EMT) in MCF10A cells	33416185
8507	Human	hsa-miR-490-3p	miRNA	TGF-¦Â1	silicosis	MRC-5 cells	TGF-¦Â1treatment treatment	MiR-490-3p was significantly downregulated in silica-induced fibrotic mouse lung tissues and TGF-¦Â1 treated fibroblasts	33482250
8508	Human	hsa-miR-490-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
8509	Human	hsa-miR-491	miRNA	curcumin (Cur)	colorectal cancer (CRC)	human HCT-116 cells	curcumin treatment	upregulated	29058812
8510	Human	hsa-miR-491	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	human hepatocellular carcinoma (HCC)	arsenic trioxide (As2O3) treatment	upregulated	25304214
8511	Human	hsa-miR-491	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	SMMC-7721 cells	Ginsenoside Rh2 treatment	upregulated	25561284
8512	Human	hsa-miR-491	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	human liver cancer cells	arsenic trioxide (As2O3) treatment	upregulated	24680928
8513	Human	hsa-miR-491	miRNA	ginsenoside Rh2	lung adenocarcinoma (LUAD)	hypoxia-induced A549 and H1299 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	31272362
8514	Human	hsa-miR-491	miRNA	hypoxia	lung adenocarcinoma (LUAD)	A549 and H1299 cells	hypoxia induce	downregulated	31272362
8515	Human	hsa-miR-491	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	The hepatoma-derived cell line Huh7	hepatitis C virus (HCV) infection	suppression of HCV replication by miR-491 was dependent on the PI3 kinase/Akt pathway. miRNAs altered by HCV infection would then affect HCV replication	21802413
8516	Human	hsa-miR-491-3p	miRNA	atorvastatin	hypercholesterolemia	HepG2 cells	atorvastatin treatment	downregulated	27575876
8517	Human	hsa-miR-491-3p	miRNA	metformin (Met)	polycystic ovarian syndrome (PCOS)	human Ishikawa cells	metformin treatment	downregulated	30599813
8518	Human	hsa-miR-492	miRNA	glucose	atherosclerosis (AS)	HUVEC CRL-1730 cells	high glucose stress treatment	downregulated	24526524
8519	Human	hsa-miR-492	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	upregulated	32362797
8520	Human	hsa-miR-492	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	clear cell renal cell carcinoma (ccRCC)	ccRCC tissues and matched adjacent normal tissues	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25815441
8521	Human	hsa-miR-492	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	miR-492 was upregulated in SGC7901-CDDP Cells.	32065219
8522	Human	hsa-miR-493	miRNA	lidocaine	melanoma	melanoma cell line SK-MEL-2	(0-100 uM) lidocaine	upregulated	29442040
8523	Human	hsa-miR-493	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
8524	Human	hsa-miR-493	miRNA	hypoxia	renal fibrosis	HK2 cells	hypoxia induce	upregulated	30183377
8525	Human	hsa-miR-493	miRNA	Shear stress	ruptured intracranial aneurysm (IA)	human umbilical vein endothelial cells (HUVECs)	Shear stress treatment	miR-493 was significantly downregulated in HUVECs exposed to shear stress	33332775
8526	Human	hsa-miR-493	miRNA	nicotine	head and neck squamous cell carcinoma (HNSCC)	head and neck cancer cell lines UPCI:SCC131 and SCC172	Nicotine treatment	downregulated	27956702
8527	Human	hsa-miR-493-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
8528	Human	hsa-miR-493-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
8529	Human	hsa-miR-493-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	CML cell line (K562)	imatinib in a CML cell line (K562) treatment	upregulated	25506832
8530	Human	hsa-miR-493-5p	miRNA	acrolein	environmental pollutants	human umbilical vein endothelial cells	acrolein treatment	upregulated	24812010
8531	Human	hsa-miR-494	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK-2 cells	cisplatin treatment	downregulated	31930399
8532	Human	hsa-miR-494	miRNA	bone morphogenetic protein 4 (BMP4)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	bone morphogenetic protein 4 (BMP4) treatment	upregulated(miR-126-5p) ;downregulated (miR-494 )	28124060
8533	Human	hsa-miR-494	miRNA	ionizing radiation (IR)	apoptosis	medulloblastoma (MB) cells	ionizing radiation (IR) treatment	upregulated	23728345
8534	Human	hsa-miR-494	miRNA	"N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99)"	arthritis	Human mononuclear suspension cells THP-1	"N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99) treatment"	upregulated	31881378
8535	Human	hsa-miR-494	miRNA	C8 fluoride derivative of cheliensisin A (ChlA-F)	bladder cancer	"Human BC cell lines (UMUC3, T24T and HT1197)"	ChlA-F treatment	upregulated	31167152
8536	Human	hsa-miR-494	miRNA	diesel exhaust particle (DEP)	bronchial epithelial cell cancer	Primary human bronchial epithelial cells	diesel exhaust particle (DEP) exposure	upregulated	20049127
8537	Human	hsa-miR-494	miRNA	ethanol extract of spica prunellae (EESP)	colorectal cancer (CRC)	HCT-8/5-FU cells	ethanol extract of Spica Prunellae (EESP) treatment with 48h	upregulated	31662984
8538	Human	hsa-miR-494	miRNA	nerve growth factor (NGF)	cornea epithelial diseases	hCECs	NGF	downregulated	28765880
8539	Human	hsa-miR-494	miRNA	cinobufacini	gastric cancer (GC)	BGC-823 cells; SGC-7901	cinobufacini treatment	"miR-494 and BAG-1 exhibited opposing trends of in cinobufacini-treated cells, with miR-494 was upregulated and BAG-1 downregu- lated by cinobufacini."	29568970
8540	Human	hsa-miR-494	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	plasma	enterovirus 71 treatment	Circulating miR-494 was abnormally upregulated in plasma of the children with EV71-induced HFMD.	32985212
8541	Human	hsa-miR-494	miRNA	estrogen (ES)	hepatocellular carcinoma (HCC)	HuH-7 cells	Estrogen treatment	miR-494 levels are upregulated following estrogen treatment in HuH-7 liver cells in association with downregulated PROS1 mRNA and PS levels.	23789915
8542	Human	hsa-miR-494	miRNA	hepatitis C virus (HCV)	liver fibrosis	Huh 7.5.1 cells	hepatitis C virus (HCV) infection	downregulated	26157120
8543	Human	hsa-miR-494	miRNA	hexavalent chromium [Cr(VI)]	lung cancer	human bronchial epithelial cells BEAS-2B	Hexavalent chromium [Cr(VI)] exposure	downregulated	31504995
8544	Human	hsa-miR-494	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
8545	Human	hsa-miR-494	miRNA	compound 331	malignant glioma	glioma cells	compound 331 treatment	upregulated	26153143
8546	Human	hsa-miR-494	miRNA	silibinin (SB)	neck squamous cell carcinomas (HNC)	neck squamous cell carcinomas (HNC)	silibinin (SB) treatment	upregulated	26090866
8547	Human	hsa-miR-494	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
8548	Human	hsa-miR-494	miRNA	silybin	osteosarcoma (OS)	Saos-2 cells	silybin treatment	upregulated	29068478
8549	Human	hsa-miR-494	miRNA	TGF-¦Â3	preeclampsia (PE)	Decidual mesenchymal stem cells (dMSCs)	TGF-¦Â3 treatment	upregulated	27149081
8550	Human	hsa-miR-494	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
8551	Human	hsa-miR-494	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	downregulated	28534445
8552	Human	hsa-miR-494	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
8553	Human	hsa-miR-494	miRNA	TGF-¦Â	tumor immune evasion in gastric cancer (GC)	T cells	TGF-¦Â treatment	upregulated	33247701
8554	Human	hsa-miR-494-3p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	lncRNA TUG1 was decreased while miR-494-3p was elevated in vivo and in vitro.	33663500
8555	Human	hsa-miR-494-3p	miRNA	hypoxia/reoxygenation (H/R)	cardiac surgery-associated acute kidney injury (CSA-AKI)	human kidney tubular epithelial (HK2) cells	hypoxia/reoxygenation (H/R) treatment	"Our result showed that Hsa-miR-494-3p was elevated in the serum of patients with CSA-AKI, and also induced in hypoxic reoxygenated HK2 cells."	33462352
8556	Human	hsa-miR-494-3p	miRNA	enterovirus 71 (EV71)	endometrial cancer (EC)	Rhabdomyosarcoma (RD) and human embryonic kidney (HEK) 293 cells	Enterovirus 71 (EV71) infection	upregulated	30234021
8557	Human	hsa-miR-494-3p	miRNA	sodium butyrate (NaB)	lung cancer	A549 cells	sodium butyrate(NaB) treatment	upregulated	29231270
8558	Human	hsa-miR-494-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	29567426
8559	Human	hsa-miR-494-3p	miRNA	pramipexole (PPX)	parkinson's disease (PD)	SK-N-SH cells; CHP 212 cells	Pramipexole (PPX) treatment	PPX inhibited MPP+-induced neurotoxicity in SK-N-SH and CHP 212 cells by decreasing miR-494-3p and increasing BDNF	31811458
8560	Human	hsa-miR-494-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH and CHP 212 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31811458
8561	Human	hsa-miR-494-3p	miRNA	pramipexole (PPX)	parkinson's disease (PD)	1-Methyl-4-phenylpyridinium (MPP+) treated SK-N-SH and CHP 212 cells	Pramipexole (PPX) treatment	downregulated	31811458
8562	Human	hsa-miR-494-3p	miRNA	rotenone (ROT)	RPE mitochondrial dysfunction	ARPE-19 cells	rotenone treatment	Elevated levels of miR-494-3p in EVs released by ARPE-19 cells indicate diminished capacity of the mitochondria within these cells	32240720
8563	Human	hsa-miR-495	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	"human BC cell lines MCF-7 , HCC1973, the immortalized breast epithelial MCF10A,human embryonic kidney 293T"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28498478
8564	Human	hsa-miR-495	miRNA	high glucose (HG)	cardiac fibrosis	human cardiac fibroblasts (CFs)	high glucose treatment	downregulated	29760746
8565	Human	hsa-miR-495	miRNA	propofol (PPF)	chondrosarcoma	JEG-3 cells	propofol treatment	upregulated	31046467
8566	Human	hsa-miR-495	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	upregulated	31226416
8567	Human	hsa-miR-495	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	downregulated	31226416
8568	Human	hsa-miR-495	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
8569	Human	hsa-miR-495	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	"human colonic epithelial cell lines (HT-29, LOVO, and Caco-2)"	dextran sulfate sodium (DSS) treatment	miR-495 was lowly expressed in the colonic epithelial cell lines.	31251902
8570	Human	hsa-miR-495	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	The cisplatin-R group exhibited lower levels of UCA1 and NRF2 expression but a higher level of miR-495 expression than the cisplatin-S group	31583720
8571	Human	hsa-miR-495	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	CircSERPINE2 could mediate TGFBR2 expression by binding with miR-495.	33094798
8572	Human	hsa-miR-495-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33856026
8573	Human	hsa-miR-495-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33830389
8574	Human	hsa-miR-495-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	AGS cells; SNU484 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28991363
8575	Human	hsa-miR-495-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"AGS, MKN28, MKN45 , SNU216, SNU484 cancer cell lines"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	restore miR-495-3p expression	28991363
8576	Human	hsa-miR-495-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human Nucleus Pulposus Cells	tumor necrosis factor alpha (TNF-¦Á) treatment	MiRNA-495-3p Attenuates TNF-¦Á Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Targeting IL5RA	32445070
8577	Human	hsa-miR-495-3p	miRNA	hypoxia/reoxygenation (H/R)	intestinal hypoxia/reoxygenation injury	caco-2 cells	hypoxia-reoxygeneration (H/R) treatment	upregulated	26935288
8578	Human	hsa-miR-495-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
8579	Human	hsa-miR-496	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30597231
8580	Human	hsa-miR-496	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30597231
8581	Human	hsa-miR-496	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	human cardiomyocyte (HCM)	hypoxia/reoxygenation (H/R) treatment	miR-496 was lowly expressed in H/R-treated human cardiomyocyte (HCM).	31436348
8582	Human	hsa-miR-496	miRNA	IL-1¦Â	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMMSC)	IL-1¦Â treatment	upregulated	28509407
8583	Human	hsa-miR-496	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
8584	Human	hsa-miR-496	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular endothelial dysfunction	human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30811087
8585	Human	hsa-miR-497	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	27918592
8586	Human	hsa-miR-497	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28653788
8587	Human	hsa-miR-497	miRNA	cisplatin (DDP)	tumorigenesis	A549 cells	cisplatin treatment	downregulated	21258880
8588	Human	hsa-miR-497	miRNA	hypoxia	cell proliferation	human primary pulmonary artery smooth muscle cells	hypoxia induce	upregulated	31370272
8589	Human	hsa-miR-497	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	downregulated	31696986
8590	Human	hsa-miR-497	miRNA	bufalin	colorectal cancer (CRC)	human colorectal cancer HCT116 cells	bufalin treatment	upregulated	24375248
8591	Human	hsa-miR-497	miRNA	probucol	coronary artery disease (CAD)	HUVECs	probucol treatment	upregulated	26897284
8592	Human	hsa-miR-497	miRNA	high glucose (HG)	diabetic foot ulcer (DFU)	human dermal fibroblasts cells	high glucose treatment	downregulated	31707336
8593	Human	hsa-miR-497	miRNA	lipopolysaccharide (LPS)	diabetic foot ulcer (DFU)	human dermal fibroblasts cells	lipopolysaccharide (LPS) treatment	downregulated	31707336
8594	Human	hsa-miR-497	miRNA	high glucose (HG)	diabetic nephropathy (DN)	kidney tissues	high glucose (HG) treatment	ANRIL and TXNIP were elevated in DN kidney tissues and HG-treated HK-2 cells while miR-497 was reduced.?miR-497 mimics inhibited caspase-1-dependent pyroptosis while co-overexpression of TXNIP blocked its effects in HG-treated HK-2 cells.	33160992
8595	Human	hsa-miR-497	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial cell cells (HK-2)	high glucose (HG) treatment	ANRIL promotes pyroptosis and kidney injury in DN via acting as miR-497 sponge to disinhibit TXNIP expression.	33160992
8596	Human	hsa-miR-497	miRNA	melatonin	diabetic nephropathy (DN)	glomerular endothelial cells (GEnCs)	melatonin (MT) treatment	MiR-497 expression was increased in melatonin-treated glomerular endothelial cells (GEnCs).	30212830
8597	Human	hsa-miR-497	miRNA	high glucose (HG) and lipopolysaccharide (LPS)	diabetic retinopathy (DR)	HDF; WI38 cells	high glucose (HG) and LPS treatment	downregulated	31707336
8598	Human	hsa-miR-497	miRNA	metformin (Met)	esophageal squamous cell carcinoma (ESCC)	KYSE510 cells	metformin treatment	upregulated	30771436
8599	Human	hsa-miR-497	miRNA	hypoxia	glioblastoma multiforme (GBM)	Glioma cells U87 and U251 and HEK293T cells	1% oxygen for 12 h treatment	upregulated	25080009
8600	Human	hsa-miR-497	miRNA	cigarette smoke extract (CSE)	human bronchial epithelial (HBE) cells injury	HBE cells	cigarette smoke extract (CSE) exposure	CSE treatment decreased miR-497 level in HBE cells.	31696986
8601	Human	hsa-miR-497	miRNA	vincristine (VCR)	lung cancer	human gastric cancer cell line SGC7901	vincristine (VCR) treatment	downregulated	21258880
8602	Human	hsa-miR-497	miRNA	ethanol (EtOH)	neuronal cell death	SH-SY5Y cells	ethanol treatment	upregulated	21878650
8603	Human	hsa-miR-497	miRNA	amikacin	neuronal cell death	SH-SY5Y cells	treat with amikacin	downregulated	27209189
8604	Human	hsa-miR-497	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
8605	Human	hsa-miR-497	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-497 in CMS-treated PLL cells was restored by a demethylation reagent 5-aza-2'-deoxycytidine (AZA).	32432317
8606	Human	hsa-miR-497	miRNA	cyclic mechanical stretch (CMS)	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	cyclic mechanical stress (CMS) treatment	miR-497 was downregulated in treated PLL cells.	32432317
8607	Human	hsa-miR-497-5p	miRNA	mitogen activated-protein kinase pathway inhibitors (MAPKis)	cutaneous malignant melanoma (CMM)	extracellular microvesicle in matched plasma	Mitogen activated-protein kinase pathway inhibitors (MAPKis) treatment	upregulated	30399176
8608	Human	hsa-miR-497-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901	cisplatin treatment	downregulated	33149605
8609	Human	hsa-miR-497-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
8610	Human	hsa-miR-497-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Chondrocytes	IL-1¦Â treatment	downregulated	31934153
8611	Human	hsa-miR-497-5p	miRNA	X-rays	radiosensitivity	"KYSE-30, KYSE-180, KYSE-150 and TE-5"	X-ray radiation treatment	LINC00473 reduces the radiosensitivity of ESCC cells by modulating the miR-497-5p/CDC25A axis	32468021
8612	Human	hsa-miR-498	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	upregulated	31315126
8613	Human	hsa-miR-498	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	"Linc00632 inhibited IL-13-induced GM-CSF, eotaxin, and MUAC5AC production in IL-13-treated NECs by targeting miR-498"	31315126
8614	Human	hsa-miR-498	miRNA	propofol (PPF)	esophageal cancer (EC)	EC109; KYSE70 cells	Propofol treatment	"Propofol suppresses hypoxia-induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO-AS1/miR-498 axis"	32643321
8615	Human	hsa-miR-498	miRNA	hypoxia	myocardial infarction (MI)	human induced pluripotent stem-derived cardiomyocytes (HCMs)	hypoxia treatment	Circ_0068655 Promotes Cardiomyocyte Apoptosis via miR-498/PAWR Axis	32767028
8616	Human	hsa-miR-498	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
8617	Human	hsa-miR-498	miRNA	"trans-3,5,4-trimethoxystilbene (TMS)"	non-small cell lung cancer (NSCLC)	H1299 and PC©\9/GR cells	"trans-3,5,4-trimethoxystilbene (TMS) treatment"	upregulated	30701693
8618	Human	hsa-miR-498	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
8619	Human	hsa-miR-498	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	upregulated	26987780
8620	Human	hsa-miR-498	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide (LPS) treatment	?TUG1 was downregulated upon LPS stimulation in hPDLCs.	32762066
8621	Human	hsa-miR-498	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	tissue injury	OVCAR3 cells; A2780 cells;A2780-CP cells; C13 cells;OV2008 cells; CAOV3 cells; MCF-7 cells; Ishikawa cells;HeLa cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	"miR-498 induced by 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3)) decreases the mRNA expression of the human telomerase reverse transcriptase"	23055531
8622	Human	hsa-miR-498-5p	miRNA	neodymium oxide (Nd2O3)	inflammation	human bronchial epithelial (16HBE) cells	neodymium oxide treatment	upregulated	32199215
8623	Human	hsa-miR-499	miRNA	hemodialysis	cardiac hypertrophy	cardiac patients on hemodialysis plasma	treat with high-flux or low-flux dialysis	downregulated	29064177
8624	Human	hsa-miR-499	miRNA	anthracycline (AC)	cardiotoxicity	children plasma	anthracycline (AC) treatment	upregulated	28377429
8625	Human	hsa-miR-499	miRNA	caffeine	cardiovascular disease (CVD)	HL-1 and primary embryonic cardiomyocytes	exposure to physiologically relevant doses of caffeine treatment	upregulated	25354728
8626	Human	hsa-miR-499	miRNA	cyclic mechanical stretch (CMS)	cardiovascular disease (CVD)	human cardiac fibroblasts-adult atrial (HCF-aa)	cyclic stretching treatment	"MiR208a was upregulated early by stretching and returned to normal levels with longer stretching cycles, whereas the expression of miR499 and Bcl-2 was upregulated by longer stretching times."	33605072
8627	Human	hsa-miR-499	miRNA	homocysteine (Hcy)	hyperhomocysteinemia (HHcy)	HL-1 cardiomyocytes	100 ¦ÌM homocysteine treatment	downregulated	24495916
8628	Human	hsa-miR-499-5p	miRNA	exercise (Ex)	muscle injury	muscle	exercise treatment	upregulated	26472872
8629	Human	hsa-miR-499-5p	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
8630	Human	hsa-miR-499a-5p	miRNA	ursolic acid (UA)	breast cancer	"breast CSCs enriched from breast cancer cell lines, MCF7, MDA-MB-231 and T47D"	ursolic acid (UA) treatment	"UA can target breast CSCs via Wnt by suppressing miR-499a-5p and upregulating the Wnt antagonist, sFRP4"	33278391
8631	Human	hsa-miR-499a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (NPC)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30856535
8632	Human	hsa-miR-499a-5p	miRNA	forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	forskolin (Fsk) treatment	upregulated	33508847
8633	Human	hsa-miR-499a-5p	miRNA	IL-1¦Â and forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	IL-1¦Â and forskolin (Fsk) treatment	downregulated	33508847
8634	Human	hsa-miR-499a-5p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7 cells	hepatitis C virus (HCV) infection	upregulated	24241692
8635	Human	hsa-miR-499b-5p	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	UCA1 inhibition protected WI-38 cells against LPS-managed inflammatory injury and apoptosis process via miR-499b-5p/TLR4 crosstalk.	33368965
8636	Human	hsa-miR-499b-5p	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	?We displayed that UCA1 was elevated in LPS-injured WI-38 cells.	33368965
8637	Human	hsa-miR-4a-5p	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
8638	Human	hsa-miR-500	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
8639	Human	hsa-miR-5001-5p	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
8640	Human	hsa-miR-5006-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
8641	Human	hsa-miR-5006-5p	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	upregulated	31549595
8642	Human	hsa-miR-500a-3p	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK2 cell	cisplatin treatment	downregulated	30365367
8643	Human	hsa-miR-500a-3P	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK-2 cells	cisplatin treatment	hsa-miR-500a-3P was significantly suppressed in cisplatin-treated human tubular epithelial (HK2) cells.	30365367
8644	Human	hsa-miR-500a-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	MGC803 cells; MKN45 cells	cisplatin treatment	Exosomal miR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer	32588541
8645	Human	hsa-miR-500a-5p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
8646	Human	hsa-miR-500a-5p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
8647	Human	hsa-miR-500a-5p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
8648	Human	hsa-miR-500a-5p	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	AB8/13 podocytes	angiotensin II (Ang II) treatment	"AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p."	32974919
8649	Human	hsa-miR-500a-5p	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	human podocyte cell line AB8/13 podocytes	angiotensin II (Ang II) treatment	"AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p, and induced cell apoptosis in podocytes."	32974919
8650	Human	hsa-miR-501	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
8651	Human	hsa-miR-501	miRNA	doxorubicin (DOX)	gastric cancer (GC)	SGC7901 cells	doxorubicin treatment	"Endogenous miR-501 was higher, whereas BLID was lower, in doxorubicin-resistant gastric cancer SGC7901/ADR cells compared with their parental SGC7901 cells."	30195794
8652	Human	hsa-miR-501	miRNA	doxorubicin (DOX)	gastric cancer (GC)	doxorubicin-resistant gastric cancer (GC) SGC7901/ADR cell-secreted exosomes (ADR Exo)	doxorubicin treatment	upregulated	31173853
8653	Human	hsa-miR-501-3p	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
8654	Human	hsa-miR-501-3p	miRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	U251 cells	cisplatin treatment	Cisplatin treatment inhibited the level of miR-501-3p in a time-dependent way.	30221699
8655	Human	hsa-miR-501-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
8656	Human	hsa-miR-501-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV)-induced liver disease and hepatocarcinogenesis	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
8657	Human	hsa-miR-501-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
8658	Human	hsa-miR-501-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
8659	Human	hsa-miR-502	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma extracellular vesicle (EV)	doxorubicin (Dox) treatment	upregulated	32255536
8660	Human	hsa-miR-502	miRNA	BAY11-7082	intervertebral disc degeneration (IDD)	TNF-¦Á treated human nucleus pulposus (NP) cell	BAY 11-7082 treatment	"Moreover, both TNF-¦Á?and BAY 11-7082 treatments were associated with marked miRNA dysregulation, with miR-502 being upregulated by TNF-¦Á?treatment and downregulated by BAY 11-7082 treatment, respectively."	33869626
8661	Human	hsa-miR-502	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cell	tumor necrosis factor alpha (TNF-¦Á) treatment	"Moreover, both TNF-¦Á?and BAY 11-7082 treatments were associated with marked miRNA dysregulation, with miR-502 being upregulated by TNF-¦Á?treatment and downregulated by BAY 11-7082 treatment, respectively"	33869626
8662	Human	hsa-miR-502-3p	miRNA	niacin	insulin resistance (IR)	hMADS adipocytes	niacin treatment	upregulated	30482933
8663	Human	hsa-miR-502-3p	miRNA	niacin	insulin resistance (IR)	human adipocytes	niacin treatment	upregulated	30482933
8664	Human	hsa-miR-502-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human primary chondrocytes	IL-1¦Â treatment	downregulated	26861148
8665	Human	hsa-miR-502c	miRNA	co-nanoencapsulated curcumin (Cur) and chrysin (Chr)	breast cancer	MDA-MB-231 breast cancer cells	co-nanoencapsulated Curcumin (Cur) and Chrysin (Chr) treatment	upregulated	30955355
8666	Human	hsa-miR-503	miRNA	hypoxia	tumor angiogenesis and growth	Cell lines HepG2 and LO2	?hypoxia treatment	downregulated	23352645
8667	Human	hsa-miR-503	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
8668	Human	hsa-miR-503	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
8669	Human	hsa-miR-503	miRNA	TGF-¦Â	cell cycle arrest	MCF-10A and MCF-12 cells	TGF-¦Â treatment	upregulated	25266660
8670	Human	hsa-miR-503	miRNA	TGF-¦Â	liver fibrosis	LX-2 cells	TGF-¦Â treatment	upregulated	32648079
8671	Human	hsa-miR-503	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	hepatocellular apoptosis	Hep-nonstructural protein 5A (Hep-NS5A) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28343379
8672	Human	hsa-miR-503	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	downregulated	32807750
8673	Human	hsa-miR-503	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
8674	Human	hsa-miR-503	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	non-small cell lung cancer (NSCLC)	NSCLC cell lines from patients with NSCLC	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24486548
8675	Human	hsa-miR-503	miRNA	high glucose (HG)	proximal tubular cell apoptosis	Human proximal tubular (HK-2) cells	high glucose (HG) treatment	MIR503HG indirectly regulates Bcl-2 by promoting the co-transcription of miRNA-503 to participate high-glucose-induced proximal tubular cell apoptosis.	33262626
8676	Human	hsa-miR-503	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (hPASMCs)	hypoxia treatment	lncRNA MALAT1 promotes the proliferation and migration of hPASMCs and inhibits their apoptosis by inhibiting the miR-503/TLR4 signal axis.	32712618
8677	Human	hsa-miR-503	miRNA	IL-13	pulmonary arterial hypertension (PAH)	primary human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
8678	Human	hsa-miR-503	miRNA	IL-13	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
8679	Human	hsa-miR-503-5p	miRNA	microgravity	apoptosis	human pulmonary microvascular endothelial cells (HPMECs)	microgravity treatment	upregulated	30216505
8680	Human	hsa-miR-503-5p	miRNA	microgravity	endothelial dysfunction	human pulmonary microvascular endothelial cells (HPMECs)	microgravity treatment	miR-503-5p is dramatically upregulated in HPMECs in simulated microgravity.	30216505
8681	Human	hsa-miR-503-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	downegulated	32323778
8682	Human	hsa-miR-504	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
8683	Human	hsa-miR-504	miRNA	IFN-¦Â	multiple sclerosis (MS)	whole blood	IFN-¦Â treatment	"The expression level of miR-504 was significantly higher in patients who respond to IFN-¦Â therapy, compared with non-responders."	32199199
8684	Human	hsa-miR-505	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
8685	Human	hsa-miR-505	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	exosomes from human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31768526
8686	Human	hsa-miR-505	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
8687	Human	hsa-miR-505	miRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901 cells	cisplatin treatment	upregulated	31885317
8688	Human	hsa-miR-505	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
8689	Human	hsa-miR-505	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30025813
8690	Human	hsa-miR-505	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
8691	Human	hsa-miR-506	miRNA	TGF-¦Â1	lung fibrosis	MRC-5 cells	TGF-¦Â1 treatment	downregulated	31214773
8692	Human	hsa-miR-506	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
8693	Human	hsa-miR-506	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells and the control untransformed cell line 16HBE-N cells	"anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide (anti-BPDE) treatment"	expression of miR-506 was reduced in 16HBE-T transformed malignant human bronchial epithelial cells compared with 16HBE normal human bronchial epithelial cells	21726609
8694	Human	hsa-miR-506	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	SK-HEP-1 cells; Huh-7 cells; HCC tissues	sorafenib treatment	miR-506 was downregulated in sorafenib-resistant HCC tissues and cells	33000204
8695	Human	hsa-miR-506	miRNA	H2O2	cardiac dysfunction	human cardiomyocyte (HCM)	H2O2 treatment	downregulated	28849090
8696	Human	hsa-miR-506	miRNA	¦Ã-rays	laryngeal cancer	human larynx squamous carcinoma cell line Hep-2	637 cGy 60Co rays radiation	downregulated	30980388
8697	Human	hsa-miR-506	miRNA	IL-1¦Â	osteosarcoma (OS)	"human OS cell line(Saos2, MG63, U2OS, and SW1353)"	IL-6¦Â treatment	downregulated	28926924
8698	Human	hsa-miR-506	miRNA	rosmarinic acid (RA)	pancreatic cancer (PC)	Pancreatic cancer cell lines (Panc-1 and SW1990)	rosmarinic acid treatment	upregulated	31060006
8699	Human	hsa-miR-506-3p	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	HCC4006 cells	erlotinib treatment	miR-506-3p expression was markedly reduced in erlotinib-resistant (ER) cells.	33291316
8700	Human	hsa-miR-506-3p	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	PC-9 cells	gefitinib treatment	downregulated	30535506
8701	Human	hsa-miR-506-3p	miRNA	high glucose (HG)	oxidative stress	HK-2 cells	high glucose (HG) treatment	"downregulated of KCNQ1OT1 inhibited the inflammation, oxidative stress and pyroptosis of HG-induced HK-2 cells by up-regulating the expression of miR-506-3p."	32104033
8702	Human	hsa-miR-506-5p	miRNA	estradiol-17¦Â (E2)	endometriosis	ectopic endometrial tissue	estradiol-17¦Â (E2) treatment	LINC01541 functions as a ceRNA that modulates the Wnt/¦Â-catenin pathway by decoying miR-506-5p.	32833189
8703	Human	hsa-miR-508-3p	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
8704	Human	hsa-miR-508-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ZNF295-AS1 inhibits autophagy via the ZNF295-AS1/miR-508-5p/ATG7 axis in AS	32633396
8705	Human	hsa-miR-508-5p	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
8706	Human	hsa-miR-509-3p	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
8707	Human	hsa-miR-509-3p	miRNA	respiratory syncytial virus (RSV)	respiratory syndrome virus (PRRSV) infection	sputum specimens; A549 cells; BEAS-2B cells	respiratory syncytial virus (RSV) infection treatment	upregulated	32102886
8708	Human	hsa-miR-5094	miRNA	X-rays	cellular radiation response	HeLa cells	X-ray irradiation treatment	"upregulated of miR-5094 downregulated the expression of STAT5b, thereby suppressing cell proliferation after X-ray irradiation"	32127949
8709	Human	hsa-miR-5095	miRNA	X-rays	cervical cancer (CC)	Hela cells	irradiated with 6?Gy of X-ray treatment	downregulated	31169309
8710	Human	hsa-miR-5096	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8711	Human	hsa-miR-512	miRNA	prostaglandin E1 (PGE1)	contrast-induced nephropathy (CIN)	THP-1 cells; peripheral blood samples	PGE1 treatment	MiR-512 could directly bind to and negatively regulate the expression of PTGS1 and HULC	32678165
8712	Human	hsa-miR-512	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
8713	Human	hsa-miR-512-3p	miRNA	thrombospondin-1 (TSP-1)	angiogenesis	vascular smooth muscle cell (VSMC)	Thrombospondin-1 (TSP-1) treatment	upregulated	26728995
8714	Human	hsa-miR-512-3p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia treatment	Hypoxia could elevate miR-512-3p levels in HCC cells.	32612368
8715	Human	hsa-miR-512-5p	miRNA	radiation	cervical cancer (CC)	cervical cancer tissues	radiation treatment	miR-512-5p expression was dramatically downregulated in the radiotherapy resistant group	32126879
8716	Human	hsa-miR-512-5p	miRNA	retinoic acid (RA)	non-small cell lung cancer (NSCLC)	NSCLC cell lines A549 and H1299	retinoic acid treatment	downregulated	26648284
8717	Human	hsa-miR-512-5p	miRNA	retinoic acid (RA)	non-small cell lung cancer (NSCLC)	A549 and H1299 cell lines	retinoic acid treatment	upregulated	26648284
8718	Human	hsa-miR-513	miRNA	cryptosporidium parvum	human biliary cryptosporidiosis	cholangiocytes H69 cells	cryptosporidium parvum? infection	downregulated	19916867
8719	Human	hsa-miR-513	miRNA	IFN-¦Ã	immune response	H69 cells	IFN-¦Ã treatment	downregulated	19155478
8720	Human	hsa-miR-513a-5p	miRNA	5-fluorouracil (5-Fu)	retinoblastoma (RB)	retinoblastoma cells	5-fluorouracil (5-Fu) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
8721	Human	hsa-miR-513a-5p	miRNA	carboplatin (CBP)	retinoblastoma (RB)	retinoblastoma cells	carboplatin (CBP) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
8722	Human	hsa-miR-513a-5p	miRNA	cisplatin (DDP)	retinoblastoma (RB)	retinoblastoma cells	cisplatin treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
8723	Human	hsa-miR-513a-5p	miRNA	vincristine (VCR)	retinoblastoma (RB)	retinoblastoma cells	vincristine (VCR) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
8724	Human	hsa-miR-513a-5p	miRNA	etoposide (VP-16)	retinoblastoma (RB)	retinoblastoma cells	Etoposide (VP-16) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells	31264280
8725	Human	hsa-miR-513a-5p	miRNA	dichlorvos (DDVP)	apoptosis	human kidney cell line HK-2	dichlorvos treatment	upregulated	30372899
8726	Human	hsa-miR-513a-5p	miRNA	TNF-¦Á and lipopolysaccharide (LPS)	apoptosis	human umbilical vein endothelial cells (HUVECs)	?tumour necrosis factor-¦Á (TNF-¦Á) and lipopolysaccharide (LPS) treatment	upregulated	22504158
8727	Human	hsa-miR-513a-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	downregulated	33592319
8728	Human	hsa-miR-513a-5p	miRNA	diesel exhaust particle (DEP)	bronchial epithelial cell cancer	Primary human bronchial epithelial cells	diesel exhaust particle (DEP) exposure	upregulated	20049127
8729	Human	hsa-miR-513a-5p	miRNA	etoposide (VP-16)	cardioprotective therapy	retinoblastoma cells	etoposide treatment	downregulated	22886978
8730	Human	hsa-miR-513a-5p	miRNA	4-aminobiphenyl (4-ABP)	DNA damage	HepG2 cells	4-Aminobiphenyl (4-ABP) treatment	upregulation	24857880
8731	Human	hsa-miR-513a-5p	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	?Insulin-like growth factor (IGF)-1 treatment	upregulated	31805126
8732	Human	hsa-miR-513a-5p	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?7 cells	heme treatment	downregulated	23538684
8733	Human	hsa-miR-513a-5p	miRNA	carboplatin (CBP)	retinoblastoma (RB)	SO-RB50 cells	carboplatin (CBP) treatment	downregulated	31702387
8734	Human	hsa-miR-513a-5p	miRNA	vincristine (VCR)	retinoblastoma (RB)	SO-RB50 cells	vincristine (VCR) treatment	downregulated	31702387
8735	Human	hsa-miR-513b	miRNA	lipopolysaccharide (LPS)	procalcitonin (PCT) production	HepG2 cells	lipopolysaccharide (LPS) treatment	downregulated	29891911
8736	Human	hsa-miR-515-3p	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
8737	Human	hsa-miR-515-5p	miRNA	estrogen receptor	breast cancer	Human breast cancer cell lines (MCF7; ZR-75-1; MDA-MB-231)	estrogen receptor treatment	downregulated	23928990
8738	Human	hsa-miR-515-5p	miRNA	cigarette smoke (CS)	epithelial-mesenchymal transition (EMT)	human bronchial epithelial (HBE) cells	Cigarette smoke (CS) exposure	downregulated	32768781
8739	Human	hsa-miR-515-5p	miRNA	oxaliplatin	gastric cancer (GC)	HGC-27 cells; AGS cells	oxaliplatin (OXA) treatment	"A marked upregulation of miR- 515-5p was viewed in HGC-27 and AGS cells compared with HGC-27/OXA, and AGS/OXA cells"	33123829
8740	Human	hsa-miR-515-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	Circ_0134111 was overexpressed in OA cartilage tissues and IL-1¦Â-induced chondrocytes.	33684877
8741	Human	hsa-miR-515-5p	miRNA	radiation	radioresistance	C666-1; 5¨C8F cells	radiation exposure treatment	"PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis"	33116864
8742	Human	hsa-miR-516	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
8743	Human	hsa-miR-516b	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	upregulated	22366961
8744	Human	hsa-miR-516b-5p	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
8745	Human	hsa-miR-517c	miRNA	human immunodeficiency virus (HIV)-1	pregnancy	peripheral plasmas	human immunodeficiency virus (HIV)-1 infection	upregulated	26757431
8746	Human	hsa-miR-517c	miRNA	plasmodium falciparum	pregnancy	peripheral plasmas	Plasmodium falciparum infection treatment	upregulated	26757431
8747	Human	hsa-miR-518a-5p	miRNA	dasatinib	chronic myeloid leukemia (CML)	CML cell line K562	dasatinib treatment	upregulated	30814857
8748	Human	hsa-miR-518a-5p	miRNA	hypoxia	periodontitis	human periodontal ligament cells (hPDLCs)	hypoxia treatment	"We selected LINC01126, which was the most highly expressed lncRNA, to further verify its functions in periodontitis-induced hypoxia."	33231338
8749	Human	hsa-miR-518a-5p	miRNA	cysteine-rich 61 (CCN1)	rheumatoid arthritis (RA)	"human osteoblast-like cell line MG63, human fetal osteoblastic cell line hFOB"	cysteine-rich 61 (CCN1) treatment	downregulated	28341837
8750	Human	hsa-miR-518b	miRNA	gambogic acid (GA)	apoptosis	SW1353 cells	GA treatment	upregulated	24173143
8751	Human	hsa-miR-518b	miRNA	bone morphogenetic protein 2 (BMP2)	tumorigenesis	NT2/D1 cells	"BMP-2 at 6, 12, and 24 h, and on days 6 and 10 treatment"	upregulated	24383669
8752	Human	hsa-miR-518b	miRNA	gambogic acid (GA)	chondrosarcoma	SW1353 human chondrosarcoma cells	Gallic acid (GA) treatment	upregulated	24173143
8753	Human	hsa-miR-518b	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
8754	Human	hsa-miR-518d-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
8755	Human	hsa-miR-519	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 and SW1990 cell	hypoxia induce	downregulated	31966071
8756	Human	hsa-miR-519	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells; SW1990 cells	hypoxia treatment	downregulated	31966071
8757	Human	hsa-miR-5194	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	downregulated	31549595
8758	Human	hsa-miR-5194	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
8759	Human	hsa-miR-5195	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
8760	Human	hsa-miR-5195-3p	miRNA	paclitaxel (PTX)	triple negative breast cancer (TNBC)	BT549 and MDA-MB-231 cells	paclitaxel (PTX) treatment	downregulated	31308851
8761	Human	hsa-miR-519a	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	downregulated	21274007
8762	Human	hsa-miR-519a-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	A172 ; LN229	temozolomide (TMZ) treatment	Exosomal lncRNA HOTAIR mediated TMZ resistance through miR-519a-3p/RRM1 axis in GB	32721218
8763	Human	hsa-miR-519b	miRNA	TGF-¦Â1	osteoarthritis (OA)	human osteoarthritic synovial fibroblasts (OASFs)	TGF-¦Â1 treatment	downregulated	28423042
8764	Human	hsa-miR-519c-5p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8765	Human	hsa-miR-519c-5p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8766	Human	hsa-miR-519d	miRNA	resistin	chondrosarcoma	human chondrosarcoma cells	resistin treatment	downregulated	25404641
8767	Human	hsa-miR-519d	miRNA	connective tissue growth factor (CTGF)	osteosarcoma (OS)	human osteosarcoma	CTGF/CCN2 treatment	downregulated	25003330
8768	Human	hsa-miR-519d-3p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
8769	Human	hsa-miR-519e-5p	miRNA	human papilloma viruses 16 (HPV16) E6	cervical cancer (CC)	C33A cells; SiHa cells; CaSki cells	human papillomaviruses 16 (HPV16) E6 infection	downregulated	32844486
8770	Human	hsa-miR-520	miRNA	oxymatrine	lung cancer	A549 cells	Oxymatrine (OMT) treatment	upregulated	31091971
8771	Human	hsa-miR-520-3p	miRNA	CH12	hepatocellular carcinoma (HCC)	HCC cells	CH12 treatment	upregulated	24007863
8772	Human	hsa-miR-520a-3p	miRNA	lidocaine	colorectal cancer (CRC)	SW480 cells; HCT116 cells	Lidocaine treatment	upregulated	30262429
8773	Human	hsa-miR-520a-3p	miRNA	lidocaine	retinoblastoma (RB)	"The RB cell line, Y79"	Lidocaine treatment	upregulated	31173241
8774	Human	hsa-miR-520b	miRNA	apigenin	hepatocellular carcinoma (HCC)	doxorubicin-resistant hepatocellular carcinoma cell line BEL-7402/ADM	apigenin treatment	upregulated	29191453
8775	Human	hsa-miR-520b	miRNA	apigenin	hepatocellular carcinoma (HCC)	hepatocellular carcinoma cell line BEL-7402/ADM	apicidin treatment	upregulated	29191453
8776	Human	hsa-miR-520b	miRNA	bufalin	prostate cancer	prostate cancer DU145 and PC3 cells	bufalin treatment	upregulated	31028291
8777	Human	hsa-miR-520b-3p	miRNA	thapsigargin (Tg)	cellular stress response	HeLa cells	thapsigargin (Tg) treatment	Diverse stress conditions trigger a rapid and dramatic decrease in miR-520b-3p and a corresponding increase in ATF5 mRNA over time in HeLa cells.	32603335
8778	Human	hsa-miR-520c	miRNA	glucocorticoid (GC)	myeloma	sensitive RPMI-8226 cell line	chronic glucocorticoid exposure	upregulated	28035377
8779	Human	hsa-miR-520c	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	lung fibrosis	Kasumi-1 cells; K562 cells;MCF7 cells; MDA-MB-231 cells?	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	23820258
8780	Human	hsa-miR-520c-3p	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	downregulated	30466095
8781	Human	hsa-miR-520c-3p	miRNA	hypoxia	preeclampsia (PE)	HTR8/SVneo cells	hypoxia induce	downregulated	31143973
8782	Human	hsa-miR-520d-3p	miRNA	monoclonal antibody CH12	inflammatory breast cancer (IBC)	HCC cells	The monoclonal antibody CH12 treatment	CH12 treatment upregulated miR-520-3p and downregulated E2F-1 and TS at the mRNA and protein levels	24007863
8783	Human	hsa-miR-520d-3p	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
8784	Human	hsa-miR-520d-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial hypoxia/reoxygenation (H/R) injury	human myocardial cell (HCM)	Hypoxia/reoxygenation (H/R)? treatment	"Hypoxia/reoxygenation (H/R) injury could inhibit cell viability, apoptosis and inhibited microRNA-520d-3p expression in HCM."	33389611
8785	Human	hsa-miR-520d-5p	miRNA	midazolam (MDZ)	non-small cell lung cancer (NSCLC)	A549 cells	midazolam treatment	upregulated	31938232
8786	Human	hsa-miR-520e	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	A549 cells	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	30475986
8787	Human	hsa-miR-520g	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell lines RPMI-8266 and H929	bortezomib? treatment	miR-520g were significantly downregulated in bortezomib-resistant MM cell lines	31204563
8788	Human	hsa-miR-520g	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
8789	Human	hsa-miR-520h	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
8790	Human	hsa-miR-520h	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
8791	Human	hsa-miR-520h	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	downregulated	27081844
8792	Human	hsa-miR-520h	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell lines RPMI-8266 and H929	bortezomib? treatment	miR-520h were significantly downregulated in bortezomib-resistant MM cell lines	31204563
8793	Human	hsa-miR-521	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
8794	Human	hsa-miR-521	miRNA	hypoxia	prostate cancer	LNCaP cells; LNCaP cells exosomes	hypoxia treatment	upregulated	29568403
8795	Human	hsa-miR-521	miRNA	radiation	prostate cancer	LNCaP cells;C4-2 cells	radiation treatment	upregulated	18668526
8796	Human	hsa-miR-522	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	hepatitis B virus (HBV) infection	upregulated	32128112
8797	Human	hsa-miR-522-3p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3ip1 cells; HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
8798	Human	hsa-miR-523	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	hepatitis B virus (HBV) infection	upregulated	32128112
8799	Human	hsa-miR-524*	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
8800	Human	hsa-miR-524*	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
8801	Human	hsa-miR-524-5p	miRNA	nifedipine	angina and hypertension	MDA-MB-231 cells	nifedipine treatment	downregulated	25436889
8802	Human	hsa-miR-524-5p	miRNA	PLX4032 (vemurafenib)	melanoma	SK-Mel-19 cells	PLX4032 (vemurafenib) treatment	downregulated	33142243
8803	Human	hsa-miR-525-3p	miRNA	ionizing radiation (IR)	tumorigenesis	RPE£» HUVEC£»tumor-derived cell lines (HeLa;U2-Os;EA.hy926) cell lines	Ionizing radiation (IR)?treatment	upregulated	24147004
8804	Human	hsa-miR-525-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
8805	Human	hsa-miR-525-3p	miRNA	RV (human Wa RV or Rhesus RV) strains	rotavirus (RV) infection	"human colon cancer Caco-2, HT-29, and HEK293 cells"	infect with RV treatment	downregulated	28890396
8806	Human	hsa-miR-525-5p	miRNA	lipopolysaccharide (LPS)	inflammation	monocytes£» U937 cells	liposaccharide (LPS) treatment	upregulated	20706588
8807	Human	hsa-miR-526b	miRNA	CoCl2	breast cancer	MCF-7 cells	CoCl2 treatment	upregulated	32707933
8808	Human	hsa-miR-526b	miRNA	platelet derived growth factor-BB (PDGF-BB) and insulin-like growth factor (IGF)-1	idiopathic pulmonary fibrosis (IPF)	human fibroblastic cell line (LL-24)	PDGF-BB and IGF-1 treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2	32694556
8809	Human	hsa-miR-527	miRNA	dasatinib	chronic myeloid leukemia (CML)	CML cell line K562	dasatinib treatment	upregulated	30814857
8810	Human	hsa-miR-532	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8811	Human	hsa-miR-532-3p	miRNA	rituximab (RTX)	chronic lymphocytic leukemia (CLL)	CD19 cells of CML patients	rituximab treatment	downregulated	28126961
8812	Human	hsa-miR-532-3p	miRNA	proanthocyanidin extract (GSPE)	hepatocellular carcinoma (HCC)	HepG2 cells	proanthocyanidin extract (GSPE) treatment	upregulated	21998738
8813	Human	hsa-miR-532-3p	miRNA	ginsenoside 20(S)-Rg3	ovarian cancer (OC)	SKOV3 ovarian cancer cells	Ginsenoside 20(S)-Rg3 treatment	upregulated	29558748
8814	Human	hsa-miR-532-3p	miRNA	estrogen (ES)	postmenopausal osteoporosis (PMOP)	human bone marrow mesenchymal stem cells (BMSCs)	estrogen treatment	downregulated	33577975
8815	Human	hsa-miR-532-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33867350
8816	Human	hsa-miR-532-5p	miRNA	tripterine	hepatocellular carcinoma (HCC)	HCCLM3 celsl; MHCC97H cells	tripterine treatment	"Under tripterine treatment, the level of miR-532-5p was strikingly raised"	32308429
8817	Human	hsa-miR-532-5p	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	downregulated	28347920
8818	Human	hsa-miR-539	miRNA	lidocaine	lung cancer	A549 and NCI-H1299 cells	Lidocaine treatment	upregulated	31299862
8819	Human	hsa-miR-539-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	HCN-2 cells	oxygen glucose deprivation (OGD) treatment	downregulated	32491927
8820	Human	hsa-miR-539-5p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
8821	Human	hsa-miR-541-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
8822	Human	hsa-miR-541-3p	miRNA	staphylococcal protein A (SpA)	osteomyelitis	Human bone mesenchymal stem cells (hBMSCs)	staphylococcal protein A (SpA) treatment	FAM83H-AS1/miR-541-3p/WNT3A ameliorated SpA-mediated inhibition of the osteogenic differentiation of hBMSCs	31871129
8823	Human	hsa-miR-541-6p	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	Human normal pulmonary fibroblasts MRC-5 and hFL1 and HEK-293 cells	treat with TGF-¦Â treatment	downregulated	28816543
8824	Human	hsa-miR-542-3p	miRNA	T-helper type 2 (Th2)-biased cytokine environment 	allergic asthma (AA)	Bronchial epithelial cells	T-helper type 2 (Th2)-biased cytokine environment treatment	downregulated	26289417
8825	Human	hsa-miR-542-3p	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
8826	Human	hsa-miR-542-3p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
8827	Human	hsa-miR-542-3p	miRNA	angiopoietin-1 (Ang-1)	breast cancer	HUVECs	angiopoietin-1 (Ang-1) treatment	downregulated	26272182
8828	Human	hsa-miR-542-3p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	upregulated	30245930
8829	Human	hsa-miR-542-3p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
8830	Human	hsa-miR-542-3p	miRNA	trastuzumab	breast cancer	SKBR3 and MCF7/Her2 breast cancer cell lines	Trastuzumab treatment	Trastuzumab induced miRNA-542-3p expression in SKBR3 and MCF7/Her2 cells	25586125
8831	Human	hsa-miR-542-3p	miRNA	TGF-¦Â1	liver fibrosis	LX©\2 cells	transforming growth factor ¦Â1 (TGF¦Â1) treatment	upregulated	30368874
8832	Human	hsa-miR-542-3p	miRNA	8-bromo-cyclic adenosine monophosphate (8-bromo-cAMP) and medroxyprogesterone acetate (MPA)	migration and invasion of endometriotic cells	human ectopic endometrial stromal cells (HEcESCs)	8-Br-cAMP and MPA treatment	downregulated	29259466
8833	Human	hsa-miR-542-3p	miRNA	resveratrol	recanalization of thrombi	Endothelial progenitor cells (EPCs)	resveratrol (RSV) treatment	downregulated	31606730
8834	Human	hsa-miR-542-3p	miRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	upregulated	32470449
8835	Human	hsa-miR-542-5p	miRNA	pristimerin	breast cancer	MCF-7 cells; MDA-MB-231 cells	pristimerin treatment	upregulated	32753899
8836	Human	hsa-miR-542-5p	miRNA	pristimerin	ectopic pregnancy (EP)	HTR-8/SVneo cells	pristimerin treatment	downregulated	33173276
8837	Human	hsa-miR-542-5p	miRNA	pristimerin	glioblastoma multiforme (GBM)	Human U373 glioma cells	Pristimerin treatment	downregulated	31015365
8838	Human	hsa-miR-542-5p	miRNA	forskolin and dexamethasone (FSK/DEX)	hyperglycemia and hyperlipoidemia	HepG2 cells	forskolin/dexamethasone (FSK/DEX) treatment	downregulated	32882762
8839	Human	hsa-miR-542-5p	miRNA	oleic acid (OA)	hyperglycemia and hyperlipoidemia	HepG2 cells	oleate treatment	downregulated	32882762
8840	Human	hsa-miR-542-5p	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
8841	Human	hsa-miR-542¨C5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
8842	Human	hsa-miR-543	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
8843	Human	hsa-miR-543	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT8 cells	5-fluorouracil (5-FU) treatment	upregulated	30842340
8844	Human	hsa-miR-543	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	The L-OHP-resistant cell line HCT-8/L and its parental cell line HCT-8	dichloroacetate (DCA) treatment	downregulated	31762813
8845	Human	hsa-miR-543	miRNA	oxaliplatin	colorectal cancer (CRC)	The L-OHP-resistant cell line HCT-8/L and its parental cell line HCT-8	oxaliplatin (L-OHP) treatment	upregulated	31762813
8846	Human	hsa-miR-543	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high glucose (HG) treatment	upregulated	31056258
8847	Human	hsa-miR-543	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
8848	Human	hsa-miR-543	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
8849	Human	hsa-miR-543	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"human gastric cancer tissue, the human gastric cancer cell lines SNU1, AGS, MGC803, and MKN1"	Helicobacter pylori (H. pylori) infection	upregulated	31423013
8850	Human	hsa-miR-543	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	hypertension	insulin-resistant HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26562529
8851	Human	hsa-miR-543	miRNA	suberoylanilide hydroxamic acid (SAHA)	neuroblastoma (NB)	SH-SY5Y cells	suberoylanilide hydroxamic acid (SAHA) treatment	downregulated	30091530
8852	Human	hsa-miR-543	miRNA	TGF-¦Â2	cell proliferation	ARPE-19 cells	TGF-¦Â2 treatment	"miR-543 was found in exosomes from EMTed RPE cells, and miR-543-enriched exosomes significantly induced the EMT of recipient RPE cells"	33047885
8853	Human	hsa-miR-543	miRNA	H2O2	cell senescence	hMSCs	400 ¦ÌM hydrogen peroxide solution treatment	downregulated	25465621
8854	Human	hsa-miR-543	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
8855	Human	hsa-miR-543*	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	upregulated	25552929
8856	Human	hsa-miR-544	miRNA	cisplatin (DDP)	esophageal squamous cell carcinoma (ESCC)	"The EC9706, KYSE450 and TE-1 human ESCC cell lines and the human immortalized normal esophageal epithelial cell line HET-1A"	cisplatin treatment	"overexpression of miR-544 led to increased sensitivity of ESCC cells to cisplatin, an anticancer drug."	31579422
8857	Human	hsa-miR-544a-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
8858	Human	hsa-miR-545	miRNA	lipopolysaccharide (LPS)	HK-2 cells injury	HK-2 cells	Lipopolysaccharide (LPS) treatment	highly expressed circPRKCI relieved inflammatory injury induced by LPS in HK2 cells by suppressing miR-545/ZEBs and depressing the briskness of NF-kB pathway.	32104945
8859	Human	hsa-miR-545	miRNA	H2O2	oxidative stress	SH-SY5Y neuronal cells	H2O2 treatment	upregulated	31053300
8860	Human	hsa-miR-545-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
8861	Human	hsa-miR-548a-3p	miRNA	IL-22	psoriasis	human keratinocytes (HaCaT)	Interleukin-22 (IL-22) treatment	upregulated	29181737
8862	Human	hsa-miR-548a-5p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	upregulated	26987780
8863	Human	hsa-miR-548aa	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
8864	Human	hsa-miR-548ah-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	downregulated	25526515
8865	Human	hsa-miR-548an	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
8866	Human	hsa-miR-548as-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	non-small cell lung cancer (NSCLC)	H1299 NSCLC cell line	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30727918
8867	Human	hsa-miR-548c-3p	miRNA	doxorubicin (DOX)	breast cancer	MDA-MB-231;MDA-MB-468;MCF-10A;MCF-7 cell lines	doxorubicin treatment	miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability	25802200
8868	Human	hsa-miR-548d-3p	miRNA	BET inhibitors (JQ1)	breast cancer	MDA-MB-231 cells; BT549 cells	BET bromodomain inhibitors (BETi)-JQ1 treatment	"JQ1 treatment evicts BRD4 from the FOXD3-localized MIR548D1 gene promoter, leading to repression of miR-548d-3p."	31937753
8869	Human	hsa-miR-548d-5p	miRNA	dexamethasone (DEX)	corticosteroid-induced osteonecrosis	hBMSCs	dexamethasone (DEX) treatment	downregulated	24929254
8870	Human	hsa-miR-548d-5p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8871	Human	hsa-miR-548d-5p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8872	Human	hsa-miR-548j	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
8873	Human	hsa-miR-548z	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
8874	Human	hsa-miR-549	miRNA	neoadjuvant multimodality ment	adenocarcinomas	serum	received neoadjuvant therapy and subsequently underwent surgical resection treatment	upregulation	25429911
8875	Human	hsa-miR-550	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
8876	Human	hsa-miR-550	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
8877	Human	hsa-miR-550	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	upregulated	22366961
8878	Human	hsa-miR-550a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetes mellitus (DM)	B cells of diabetic patients	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulation	27935135
8879	Human	hsa-miR-550a	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
8880	Human	hsa-miR-550a	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
8881	Human	hsa-miR-550a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
8882	Human	hsa-miR-550a-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
8883	Human	hsa-miR-551a	miRNA	5-fluorouracil (5-Fu)	drug resistance	Hep3B cells	5-fluorouracil (5-FU) treatment	"miR-551a-expressing cells (Hep3B-lenti-miR-551a) were resistant to 5-FU-induced cell death, and after 5-FU treatment, and showed significant increases in cell viability, cell survival, and sphere formation."	30703870
8884	Human	hsa-miR-551a	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
8885	Human	hsa-miR-551a	miRNA	demethoxycurcumin	ovarian cancer (OC)	human epithelia ovarian cancer cells	demethoxycurcumin treatment	upregulated	28345465
8886	Human	hsa-miR-551b-5p	miRNA	mechanical stretch	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	"mechanical stretch for 3 h (60 cycles/min, 15% elongation)"	upregulated	28639574
8887	Human	hsa-miR-552-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
8888	Human	hsa-miR-552-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
8889	Human	hsa-miR-556-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32536864
8890	Human	hsa-miR-557	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
8891	Human	hsa-miR-557	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
8892	Human	hsa-miR-557	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
8893	Human	hsa-miR-557	miRNA	fibroblast growth factor 2 (FGF2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fibroblast growth factor 2 (FGF2) treatment	downregulated	30414893
8894	Human	hsa-miR-558	miRNA	IL-1¦Â	osteoarthritis (OA)	human articular chondrocytes and OA chondrocytes	IL-1¦Â treatment	downregulated	23611898
8895	Human	hsa-miR-558	miRNA	CoCl2	spinal cord injury (SCI)	AGE1.HN	CoCl2 treatment	circ-HIPK3 relieves the neuronal cell apoptosis through regulating miR-588/DPYSL5 axis in SCI.	32247616
8896	Human	hsa-miR-5583-5p	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	downregulated	28007639
8897	Human	hsa-miR-5583-5p	miRNA	altertoxin II (ATX II)	cytotoxicity	HepG2	altertoxin II (ATX II) treatment	downregulated	28007639
8898	Human	hsa-miR-561	miRNA	acetaminophen (APAP)	hepatotoxicity	HepG2 cells	acetaminophen (APAP) treatment	upregulated	24104199
8899	Human	hsa-miR-561	miRNA	retinoic acid (RA)	human neuronal differentiation	SH-SY5Y cells	retinoic acid (RA) treatment	downregulated	30951518
8900	Human	hsa-miR-561	miRNA	acetaminophen (APAP)	macular degeneration	HepG2 cells and primary human hepatocytes	acetaminophen (APAP) treatment	upregulated	24104199
8901	Human	hsa-miR-564	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	hPC and HEK 293	TGF-¦Â treatment	TMEM63C Is Regulated by MicroRNA-564 and Transforming Growth Factor beta in Human Renal Cells	33080601
8902	Human	hsa-miR-564	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
8903	Human	hsa-miR-565	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
8904	Human	hsa-miR-5680	miRNA	high glucose (HG)	autophagy	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680.	30957640
8905	Human	hsa-miR-5680	miRNA	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO)	vascular endothelial cells (VECs) autophagy and apoptosis	human vascular endothelial cells (VECs)	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment	3BDO promoted the expression of miR-5680 in VECs under high glucose conditions.	30957640
8906	Human	hsa-miR-569	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	upregulated	30100735
8907	Human	hsa-miR-5701	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	The level of miR-5701 was significantly downregulated in the presence of 6-OHDA.	28710704
8908	Human	hsa-miR-5701	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y Cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28710704
8909	Human	hsa-miR-5703	miRNA	luteolin and gefitinib	prostate cancer	PC-3 cells	luteolin and/or gefitinib treatment	upregulated	24971999
8910	Human	hsa-miR-570-3p	miRNA	metformin (Met)	osteosarcoma (OS)	143B and U2OS cells	Metformin treatment	upregulated	29795113
8911	Human	hsa-miR-571	miRNA	alcohol	liver cirrhosis	blood	alcohol exposure	upregulated	22412969
8912	Human	hsa-miR-572	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SK-N-SH cell lines	fluoxetine treatment	upregulated	27716787
8913	Human	hsa-miR-572	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
8914	Human	hsa-miR-572	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
8915	Human	hsa-miR-573	miRNA	hyperbaric oxygen (HBO)	intervertebral disc degeneration (IDD)	human degenerative nucleus pulposus (NP) cells	hyperbaric oxygen (HBO)?induce	MiR-573 was induced by HBO and simultaneous suppression of Bax was observed in NP cells.	33413477
8916	Human	hsa-miR-574	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
8917	Human	hsa-miR-574-3p	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
8918	Human	hsa-miR-574-3p	miRNA	remnant-like lipoproteins (RLPs)	ePCs senescence	Total peripheral mononuclear cells (PB-MNCs)	Remnant-like lipoproteins (RLPs) treatment	miR-148b and miR-155 were upregulated while miR-574-3p was downregulated	23044309
8919	Human	hsa-miR-574-3p	miRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	SKOV3 and CAOV3 cells	cisplatin treatment	downregulated	31396325
8920	Human	hsa-miR-574-3p	miRNA	paclitaxel (PTX)	epithelial ovarian cancer (EOC)	SKOV3 and CAOV3 cells	paclitaxel treatment	downregulated	31396325
8921	Human	hsa-miR-574-3p	miRNA	TGF-¦Â1	gastric cancer (GC)	AGS cells	TGF-¦Â1 treatment	upregulated	28042090
8922	Human	hsa-miR-574-3p	miRNA	X-rays	genotoxicity	the lung cancer cell line A549	X-ray irradiation treatment	upregulated	24566139
8923	Human	hsa-miR-574-3p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
8924	Human	hsa-miR-574-3p	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
8925	Human	hsa-miR-574-3p	miRNA	sodium butyrate (NaB)	lung cancer	A549 cells	sodium butyrate(NaB) treatment	upregulated	29231270
8926	Human	hsa-miR-574-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
8927	Human	hsa-miR-574-3p	miRNA	TGF-¦Â1	gastric cancer (GC)	AGS cells	induced upregulation in treatment	upregulated	28042090
8928	Human	hsa-miR-574-3p	miRNA	genistein	prostate cancer	"Human PCa cell lines, PC3£» DU145£»non-malignant epithelial prostate cell line, RWPE-1"	Genistein? treatment	upregulated	23554959
8929	Human	hsa-miR-574-3p	miRNA	lectin	prostate cancer	Prostate cancer (PC) cell lines	lectin treatment	upregulated	26417675
8930	Human	hsa-miR-574-5p	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
8931	Human	hsa-miR-574-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	"In ARDS models, microRNA-574-5p (miR-574-5p) expression could be induced by the TLR4/NF-¦ÊB pathway upon LPS stimulation."	33202146
8932	Human	hsa-miR-574-5p	miRNA	TGF-¦Â	cardiac fibrosis	human cardiac fibroblasts (HCFs)	TGF-¦Â treatment	upregulated	31672272
8933	Human	hsa-miR-574-5p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
8934	Human	hsa-miR-575	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
8935	Human	hsa-miR-575	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
8936	Human	hsa-miR-575	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
8937	Human	hsa-miR-575	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
8938	Human	hsa-miR-575	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
8939	Human	hsa-miR-576-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87 and U251 cells	hypoxia induce	downregulated	31017266
8940	Human	hsa-miR-576-3p	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
8941	Human	hsa-miR-577	miRNA	TGF-¦Â	gastric cancer (GC)	human GC cell lines (MKN45 and MGC803)	Transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	30879950
8942	Human	hsa-miR-579	miRNA	mycobacterium tuberculosis (Mtb)	apoptosis	primary human monocyte-derived macrophages	Mycobacterium tuberculosis (MTB) infection	upregulated	31434611
8943	Human	hsa-miR-579	miRNA	dexamethasone (DEX)	cytotoxicity	DEX-treated human OB-6 osteoblastic cells	dexamethasone (Dex) treatment	miR-579 is upregulated in the necrotic femoral head tissues of DEX-taking human patients as well as in DEX-treated human osteoblasts. Forced miR-579 overexpression induced significant cytotoxicity in human osteoblasts.	31376935
8944	Human	hsa-miR-580-3p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
8945	Human	hsa-miR-582-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
8946	Human	hsa-miR-582-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	NNT-AS1 played a promoting role in smoking-induced COPD via modulating miR-582-5p/FBXO11 signaling.	32768929
8947	Human	hsa-miR-582-5p	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
8948	Human	hsa-miR-582-5p	miRNA	heroin	immunosuppression	monocytes	heroin treatment	downregulated	26978739
8949	Human	hsa-miR-582-5p	miRNA	particulate matter (PM2.5)	lung cancer	BEAS-2B and HBE cells	particulate matter (PM2.5) treatment	Loss of NEAT1 represses the malignant transformation of BEAS-2B and HBE cells induced by PM25	33829382
8950	Human	hsa-miR-582-5p	miRNA	berberine (BBR)	melanoma	A375 cells	berberine (BBR) treatment	The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression.	32915362
8951	Human	hsa-miR-584	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	downregulated	28886127
8952	Human	hsa-miR-584	miRNA	porphyromonas gingivalis	anti-inflammatory responses	OBA-9(immortalized HGECs)	Pg treatment	upregulated	24228808
8953	Human	hsa-miR-584	miRNA	TGF-¦Â	breast cancer	breast cancer cells	?TGF-¦Â treatment	downegulated	23479725
8954	Human	hsa-miR-584	miRNA	porphyromonas gingivalis	destructive periodontitis	Human Gingival Epithelial Cells(HGECs)	Porphyromonas gingivalis treatment	upregulated	24228808
8955	Human	hsa-miR-584	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neuroblastoma (NB)	neuroblastoma cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
8956	Human	hsa-miR-584	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neurological disorders	SK-N-SH cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
8957	Human	hsa-miR-584-3p	miRNA	metformin (Met)	melanoma	"The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951"	Metformin treatment	upregulated	30754729
8958	Human	hsa-miR-584-5p	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	downregulated	30100735
8959	Human	hsa-miR-585-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y Cells	1-methyl-4-phenylpyridinium (MPP+) treatment	H19 knockdown markedly increased miR-585-3p expression.	32356199
8960	Human	hsa-miR-589	miRNA	antrodia cinnamomea	cancer treatment	"THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68"	antrodia cinnamomea treatment	downregulated	28602756
8961	Human	hsa-miR-589	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
8962	Human	hsa-miR-589	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	HMrSV5 cells	TGF-¦Â1 treatment	The changes were accompanied with notably decreased level of miRNA589 in HMrSV5 cells treated with TGF¦Â1	23118514
8963	Human	hsa-miR-589	miRNA	H2O2	oxidative stress	SH-SY5Y neuronal cells	H2O2 treatment	upregulated	31053300
8964	Human	hsa-miR-589-3p	miRNA	lipopolysaccharide (LPS)	lumbar disc degeneration (LDD)	human NP cell line	lipopolysaccharide (LPS) treatment	upregulated	29434746
8965	Human	hsa-miR-589-3p	miRNA	lipopolysaccharide (LPS)	lumbar disc degeneration (LDD)	Nucleus pulposus (NP) cells	Lipopolysaccharide (LPS) treatment	upregulated	29434746
8966	Human	hsa-miR-590	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
8967	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	26648441
8968	Human	hsa-miR-590	miRNA	nobiletin	atherosclerosis (AS)	human THP-1 macrophages	Nobiletin treatment	upregulated	30471854
8969	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	The human umbilical vascular endothelial cell (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	26648441
8970	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30799593
8971	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein ECs (HUVECs); human coronary artery ECs (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33022677
8972	Human	hsa-miR-590	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
8973	Human	hsa-miR-590	miRNA	hydroxychloroquine plus prednisone	systemic lupus erythematosus (SLE)	Th17 cells	Hydroxychloroquine (HCQ) plus prednisone treatment	upregulated	29545450
8974	Human	hsa-miR-590-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29436491
8975	Human	hsa-miR-590-3p	miRNA	melatonin	apoptosis	human fetal osteoblastic cell line hFOB 1.19	Melatonin treatment	downregulated	29568931
8976	Human	hsa-miR-590-3p	miRNA	radiation	colorectal cancer (CRC)	HCT116 cells	radiation treatment	upregulated	33738143
8977	Human	hsa-miR-590-3p	miRNA	hypoxia	coronary artery disease (CAD)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	Long non-coding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR-590-3p under hypoxic conditions.	32323787
8978	Human	hsa-miR-590-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31618425
8979	Human	hsa-miR-590-3p	miRNA	hypoxia	angiogenesis 	Primary human ADSCs (ADSCs)	hypoxia treatment	downregulated	32277427
8980	Human	hsa-miR-590-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	The immortalized human chondrocytes cell lines C20/A4	IL-1¦Â treatment	upregulated	31571401
8981	Human	hsa-miR-590-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	MES23.5 and SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	27064872
8982	Human	hsa-miR-590-3p	miRNA	YKL-40	rheumatoid arthritis (RA)	human osteoblast-like cell line MG-63	stimulated with YKL-40 for 24 h treatment	downregulated	28448439
8983	Human	hsa-miR-590-3p	miRNA	H2O2	cell senescence	hMSCs	400 ¦ÌM hydrogen peroxide solution treatment	downregulated	25465621
8984	Human	hsa-miR-590-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	human airway smooth muscle cells (ASMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	downregulated	33825599
8985	Human	hsa-miR-590-5p	miRNA	platelet-derived growth factor (PDGF)	asthma	fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	downregulated	30154893
8986	Human	hsa-miR-590-5p	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HUVEC	angiotensin II (Ang II) treatment	downregulated	26906623
8987	Human	hsa-miR-590-5p	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	upregulated	31226416
8988	Human	hsa-miR-590-5p	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	downregulated	31226416
8989	Human	hsa-miR-590-5p	miRNA	hypoxia	colorectal cancer (CRC)	human colorectal cancer cell lines RKO and HCT116	hypoxia treatment	upregulated	29247825
8990	Human	hsa-miR-590-5p	miRNA	hypoxia	colorectal cancer (CRC)	"colorectal cancer (CRC) cell lines RKO, HCT116, SW480, HT29, SW620, LS174T, LoVo, SW403, Colo205, DLD-1, HCT15"	hypoxia induce	upregulated	29247825
8991	Human	hsa-miR-590-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
8992	Human	hsa-miR-590-5p	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
8993	Human	hsa-miR-590-5p	miRNA	heroin	immunosuppression	monocytes	heroin treatment	downregulated	26978739
8994	Human	hsa-miR-590-5p	miRNA	TGF-¦Â1	intrauterine adhesion (IUA)	human embryonic stem cells (hESCs)	TGF-¦Â1 treatment	lncRNA TUG1 promotes endometrial fibrosis and inflammation by sponging miR-590-5p to regulate Fasl in intrauterine adhesions	32599321
8995	Human	hsa-miR-590-5p	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	MRC-5 cells	IAV/Hong Kong/498/97 (H3N2) treatment	Viral infection up-regulates miR-590-5p expression.	30291142
8996	Human	hsa-miR-592	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
8997	Human	hsa-miR-593	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	NPC cells	curcumin treatment	upregulated	27313684
8998	Human	hsa-miR-593-3p	miRNA	insulin	hepatocellular carcinoma (HCC)	hepatocellular carcinoma HepG2 and Bel7402 cells	Insulin treatment	upregulated	27613819
8999	Human	hsa-miR-593-5p	miRNA	cisplatin (DDP)	rectal cancer	SW837 cells; HR8348 cells	cisplatin treatment	"LINC00461 mediates cisplatin resistance of rectal cancer by targeting miR-593-5p/CCND1 axis, shedding new light on the treatment of rectal cancer."	31972361
9000	Human	hsa-miR-593-5p	miRNA	cisplatin (DDP)	tongue squamous cell carcinoma (TSCC)	tongue squamous cell carcinoma (TSCC) cells	cisplatin treatment	downregulated	25912308
9001	Human	hsa-miR-596	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
9002	Human	hsa-miR-596	miRNA	steroids	non-traumatic osteonecrosis of femoral head (ONFH)	bone marrow	steroid treatment	upregulated	32410637
9003	Human	hsa-miR-598	miRNA	alpha-1 antitrypsin (AAT)	anti-inflammatory responses	monocytes of AAT deficient (ZZ) individuals	alpha-1 antitrypsin (AAT) treatment	downregulated	29062067
9004	Human	hsa-miR-599	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	32248560
9005	Human	hsa-miR-599	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33235026
9006	Human	hsa-miR-599	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33566259
9007	Human	hsa-miR-599	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	circANKRD36 sponge miR-599 to up-regulate the expression of Casz1 and thus prevent apoptosis and inflammation in OA.	33205602
9008	Human	hsa-miR-599	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	30720180
9009	Human	hsa-miR-601	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
9010	Human	hsa-miR-601	miRNA	H2O2	oxidative stress	ARPE-19?cells and primary human RPE cells	H2O2 treatment	upregulated	31178131
9011	Human	hsa-miR-601	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
9012	Human	hsa-miR-602	miRNA	troxerutin	alopecia	HDP cells	troxerutin treatment	has-miR-602 was the most markedly upregulated by troxerutin in the H2O2-treated HDP cells	25955790
9013	Human	hsa-miR-605	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
9014	Human	hsa-miR-608	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	neuroblastoma (NB)	SK-N-SH neuroblastoma cells	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	28860601
9015	Human	hsa-miR-608	miRNA	doxorubicin (DOX)	non-small cell lung cancer (NSCLC)	NSCLC cell lines A549 and HCC4006	doxorubicin treatment	"overexpression of miR-608 promoted doxorubicin-induced apoptosis in NSCLC cell lines A549 and HCC4006 by inhibiting the expression of transcription factor activating enhancer-binding protein 4 (TFAP4), and high expression levels of TFAP4 were observed in NSCLC tissues."	31552102
9016	Human	hsa-miR-608	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	ovarian cancer (OC)	SKOV3 cells	physcion 8-O-¦Â-glucopyranoside (PG) treatment	downregulated	31299866
9017	Human	hsa-miR-6086	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	TNF¦Á-induced endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29605606
9018	Human	hsa-miR-6088	miRNA	steviol	gastrointestinal cancer	HCT-116 cells	steviol treatment	downregulated	29899860
9019	Human	hsa-miR-6088	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9020	Human	hsa-miR-612	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
9021	Human	hsa-miR-612	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
9022	Human	hsa-miR-6126	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	upregulated	29337256
9023	Human	hsa-miR-6127	miRNA	cyclosporine A (CsA)	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	cyclosporine A (CsA) treatment	downregulated	31371743
9024	Human	hsa-miR-6127	miRNA	rapamycin	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	rapamycin (RAPA) treatment	upregulated	31371743
9025	Human	hsa-miR-613	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	paclitaxel (PTX) treatment	Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis	32425595
9026	Human	hsa-miR-613	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	L02 cells	oleic acid (OA) treatment	"CCAT1 increases LXR¦Á transcription by serving as a competing endogenous RNA for miR-613 in an LXRE-dependent manner, thereby promoting lipid droplet formation and NAFLD."	32413192
9027	Human	hsa-miR-613	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	MiRNA-613 alleviates IL-1¦Â-induced injury in chondrogenic CHON-001 cells by targeting fibronectin 1.	33042421
9028	Human	hsa-miR-6132	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
9029	Human	hsa-miR-615	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
9030	Human	hsa-miR-615-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	myocardial infarction (MI)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31355606
9031	Human	hsa-miR-615-3p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
9032	Human	hsa-miR-615-3p	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	two NSCLC cell lines (A549 and H1299)	hypoxia induce	downregulated	31422060
9033	Human	hsa-miR-615-5p	miRNA	bovine serum albumin (BSA)	focal segmental glomerulosclerosis (FSGS)	HK-2 cells	bovine serum albumin (BSA) treatment	downregulated	32800553
9034	Human	hsa-miR-615-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
9035	Human	hsa-miR-616	miRNA	tissue factor pathway inhibitor TFPI-2	metabolic syndrome	prostate cancer cells	tissue factor pathway inhibitor TFPI-2 treatment	"reexpression of TFPI-2 in LNCaP cells with stable miR-616 overexpression rescued the AD phenotype, TFPI-2 expression to be inversely correlated to miR-616 in a series of prostate cell lines"	21224345
9036	Human	hsa-miR-616-5p	miRNA	sulforaphane (SFN)	lung cancer	"human NSCLC cell lines H1299, 95C and 95D"	sulforaphane treatment	upregulated	27890917
9037	Human	hsa-miR-616-5p	miRNA	sulforaphane (SFN)	non-small cell lung cancer (NSCLC)	"human H1299, 95C, and 95D NSCLC cell lines"	100 ¦Ìg/mL streptomycin treatment	downregulated	27890917
9038	Human	hsa-miR-616¨C5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	SH-SY5Y human neuroblastoma cells	GDNF	downregulated	28829278
9039	Human	hsa-miR-617	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
9040	Human	hsa-miR-617	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
9041	Human	hsa-miR-619	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
9042	Human	hsa-miR-619-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
9043	Human	hsa-miR-619-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV)-induced liver disease and hepatocarcinogenesis	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
9044	Human	hsa-miR-620	miRNA	TGF-¦Â1	asthma	human airway smooth muscle cells (ASMCs)	TGF-¦Â1 treatment	upregulated	32583575
9045	Human	hsa-miR-622	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"The expression of circ_ANRIL in OGD/R-induced human brain microvascular endothelial cells (HBMECs) was significantly upregulated, while that of miR-622 was significantly downregulated"	32616043
9046	Human	hsa-miR-622	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
9047	Human	hsa-miR-622	miRNA	5-fluorouracil (5-Fu)	locally advanced rectal cancer (LARC)	Tumor tissues	5-fluorouracil (5-FU) treatment	upregulated	25961730
9048	Human	hsa-miR-622	miRNA	FOXO3a	lung cancer	U0126-treated A549 cells	FOXO3a treatment	upregulated	26528854
9049	Human	hsa-miR-622	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
9050	Human	hsa-miR-622	miRNA	high glucose (HG)	vascular smooth muscle aging	human umbilical vein endothelial cell (HUVEC)	high glucose (HG) treatment	HG-HUVECs derived exosomes induced the VSMCs senescence by circRNA0077930-miR622-Kras CeRNA network.	32307741
9051	Human	hsa-miR-623	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
9052	Human	hsa-miR-623	miRNA	hypoxia	myocardial infarction (MI)	human cardiomyocytes (HMCs)	hypoxia treatment	downregulated	32222118
9053	Human	hsa-miR-625	miRNA	1-methyl-4-phenylpyridinium (MPP+)	neuronal cell injury	human neuroblastoma SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	lnc-p21 regulated MPP + -induced neuronal injury by sponging miR-625 and upregulating TRPM2 in SH-SY5Y cells	31004593
9054	Human	hsa-miR-625	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human neuroblastoma SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	lnc-p21 regulated MPP + -induced neuronal injury by sponging miR-625 and upregulating TRPM2 in SH-SY5Y cells	31004593
9055	Human	hsa-miR-625*	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec1A cells	Progesterone treatment	upregulated	22543862
9056	Human	hsa-miR-625-3p	miRNA	oxaliplatin	metastatic colorectal cancer (mCRC)	HCT116 cells; LoVo cells	oxaliplatin? treatment	High expression of microRNA-625-3p	23506979
9057	Human	hsa-miR-625-3p	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC-9 cells	Gefitinib treatment	miR-625-3p expression was downregulated in the HCC827GR cells.	32319651
9058	Human	hsa-miR-625-3p	miRNA	icariin (ICA)	thyroid cancer (TC)	SW579 cells;TPC1 cells	icariin (ICA) treatment	downregulated	30551506
9059	Human	hsa-miR-625-3p	miRNA	icariin (ICA)	thyroid cancer (TC)	SW579 and TPC1 cells	icariin (ICA) treatment	downregulated	30551506
9060	Human	hsa-miR-625-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (hNPC) and annulus fibrosus cells (hAFC)	lipopolysaccharide (LPS) treatment	upregulated	30972168
9061	Human	hsa-miR-625-5p	miRNA	lipopolysaccharide (LPS)	asthma	human bronchial epithelial cells (HBECs) 16HBEC	lipopolysaccharide (LPS) treatment	upregulated	30628701
9062	Human	hsa-miR-625-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	"The normal human astrocyte line SVGp12 and two human glioma cell lines, U87MG and A172"	hypoxia induce	downregulated	30988674
9063	Human	hsa-miR-625-5p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	downregulated	24927770
9064	Human	hsa-miR-626	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19?cells and primary human RPE cells	H2O2 treatment	downregulated	31446056
9065	Human	hsa-miR-627	miRNA	TGF-¦Â1	lung fibrosis	normal human lung fibroblast	TGF-¦Â1 treatment	downregulated	30536600
9066	Human	hsa-miR-627	miRNA	TGF-¦Â1	lung fibrosis	normal human lung fibroblast (NHLF)	TGF-¦Â1 treatment	downregulated	30536600
9067	Human	hsa-miR-627	miRNA	TGF-¦Â1	lung fibrosis	normal human primary lung fibroblasts (NHLFs)	TGF-¦Â1 treatment	downregulated	33482190
9068	Human	hsa-miR-627-5p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
9069	Human	hsa-miR-627-5p	miRNA	palbociclib	glioblastoma multiforme (GBM)	"HMC3 cells, temozolomide-resistant (TMZ-R) cells"	palbociclib treatment	"SNHG15 to promote GBM tumorigenesis was by inhibiting tumor suppressor, miR-627-5p which leads to activation of CDK6"	31462285
9070	Human	hsa-miR-628-5p	miRNA	acute bout of resistance exercise	"ageing, activation of Rho signalling"	older (60-75 years) people	acute bout of resistance exercise	upregulated	27739650
9071	Human	hsa-miR-628-5p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	A-172; SHG-44	Sevoflurane (Sev) treatment	Sev mediated glioma progression via circ_0002755/miR-628-5p/MAGT1 axis	32669871
9072	Human	hsa-miR-629	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	31240850
9073	Human	hsa-miR-629-3p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
9074	Human	hsa-miR-629-3p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
9075	Human	hsa-miR-629-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
9076	Human	hsa-miR-630	miRNA	4-aminobiphenyl (4-ABP)	4-Aminobiphenyl (4-ABP)-induced liver injury	Hep3B cells; L-02 cells	4-Aminobiphenyl (4-ABP) treatment	4-ABP induced miR-630 expression in Hep3B and L-02 cells.	32433928
9077	Human	hsa-miR-630	miRNA	H2O2	age-related nuclear cataract	human lens epithelial B3 (HLE-B3) cell	H2O2 treatment	upregulated	29653565
9078	Human	hsa-miR-630	miRNA	H2O2	cataract	HLE-B3 cells	H2O2 treatment	miR-630 was significantly upregulated in HLE-B3 after H2O2 treatment.	31869263
9079	Human	hsa-miR-630	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
9080	Human	hsa-miR-630	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	"Human colorectal cancer cell lines Ls174T, SW480, HCT116, SW837, HR8348, and HT29"	ionic radiation (IR) treatment	"After IR treatment, miR-630 induced apoptosis in cells"	26263387
9081	Human	hsa-miR-630	miRNA	4-aminobiphenyl (4-ABP)	DNA damage	HepG2 cells	4-Aminobiphenyl (4-ABP) treatment	upregulation	24857880
9082	Human	hsa-mir-630	miRNA	cisplatin (DDP)	DNA damage	human lung cancer A549 cells	cisplatin treatment	upregulated	24909689
9083	Human	hsa-miR-630	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	upregulated	21274007
9084	Human	hsa-miR-630	miRNA	bone morphogenetic protein 4 (BMP4) and TGF-¦Â2	heterotopic ossification (HO)	HD-MVECs	bone morphogenetic protein 4 (BMP4) and TGF-¦Â2 treatment	downregulated	26940839
9085	Human	hsa-miR-630	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
9086	Human	hsa-miR-630	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) A549 cells	cisplatin treatment	upregulated	20145152
9087	Human	hsa-miR-630	miRNA	H2O2	oxidative stress	human lens epithelium cell line HLE-B3	H2O2 treatment	upregulated	31869263
9088	Human	hsa-miR-630	miRNA	luteolin and gefitinib	prostate cancer	PC-3 cells	luteolin and/or gefitinib treatment	upregulated	24971999
9089	Human	hsa-miR-630	miRNA	radiation	radioresistance	"human glioma cell lines BT325, U373, U87 and U251"	radiation treatment	downregulated	28386351
9090	Human	hsa-miR-630	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9091	Human	hsa-miR-630	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
9092	Human	hsa-miR-633	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec5A cells	Progesterone treatment	upregulated	22543862
9093	Human	hsa-miR-633	miRNA	anacardic acid (AnAc)	rheumatoid arthritis (RA)	RA fibroblast-like synoviocytes (RA-FLSs)	anacardic acid (AnAc) treatment	upregulated	30273785
9094	Human	hsa-miR-634	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
9095	Human	hsa-miR-636	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
9096	Human	hsa-miR-636	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	upregulated	32438192
9097	Human	hsa-miR-636	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
9098	Human	hsa-miR-636	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9099	Human	hsa-miR-637	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cell line (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-637 expression was decreased in a dose- and time-dependent manner in animal models with ox-LDL-induced atherosclerosis.	32399056
9100	Human	hsa-miR-637	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	U251 cell	Sevoflurane treatment	upregulated	27840895
9101	Human	hsa-miR-637	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?10 cells	heme treatment	upregulated	23538684
9102	Human	hsa-miR-638	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 adjusted the AKT/mTOR signaling pathway via miR-638 in ox-LDL-induced HAECs to accelerate their proliferation and impede their apoptosis.	32377692
9103	Human	hsa-miR-638	miRNA	PhIP and 17-¦Â-estradiol	breast cancer	MCF-7 human breast adenocarcinoma cell line	PhIP and 17-¦Â-estradiol (E2) treatment	dysregulated	24877718
9104	Human	hsa-miR-638	miRNA	inorganic arsenic (iAs)	tumorigenesis	human Jurkat leukemic T cell	"Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment"	upregulated	24317173
9105	Human	hsa-miR-638	miRNA	platelet-derived growth factor (PDGF)	cell proliferation and migration	human vascular smooth muscle cells(SMCs)	platelet-derived growth factor (PDGF) treatment	downregulated	23554459
9106	Human	hsa-miR-638	miRNA	extract of Stellerachamaejasme L(ESC)	hepatocellular carcinoma (HCC)	HepG2 and MHCC97H cells	extract of Stellerachamaejasme L(ESC) treatment	upregulated	29554896
9107	Human	hsa-miR-638	miRNA	benzo(a)pyrene (BaP)	leukemia	peripheral lymphocytes	benzo(a)pyrene (BaP) exposure	miR-638 is involved in the BaP-induced carcinogenesis by targeting BRCA1	22048643
9108	Human	hsa-miR-638	miRNA	bostrycin	lung cancer	human lung carcinoma A549 cells	bostrycin treatment	upregulated	21303527
9109	Human	hsa-miR-638	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human cardiomyocytes (HCMs)	hypoxia/reoxygenation (H/R) treatment	"Hypoxia/reoxygenation (H/R) treatment suppressed cell viability, increased cell apoptotic rate and suppressed miR-638 expression in the HCMs."	30556888
9110	Human	hsa-miR-638	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
9111	Human	hsa-miR-638	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC cell line SPC-A1	cisplatin treatment	upregulated	25952770
9112	Human	hsa-miR-638	miRNA	SMPD3 inhibitor GW4869	release of microRNAs into extracellular spaces	SW480 and HuH-7 cells	the SMPD3 inhibitor GW4869 treatment	extracellular and intracellular miR-638 were dose-dependently downregulated and upregulated	25394686
9113	Human	hsa-miR-638	miRNA	ginsenoside Rh2	retinoblastoma (RB)	Human RB Y79 and RBL-13 cells	Ginsenoside Rh2 (GRh2) treatment	downregulated	30853612
9114	Human	hsa-miR-638	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
9115	Human	hsa-miR-638	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
9116	Human	hsa-miR-639	miRNA	TGF-¦Â	tongue cancer	TSCC cell lines SCC9 and CAL27	human recombinant TGF¦Â1 for 48 h treatment	?downregulated	25130698
9117	Human	hsa-miR-640	miRNA	hydrogen sulfide (H2S)	angiogenesis	vascular endothelial cells (ECs)	hydrogen sulfide (H2S) treatment	downregulated	26879375
9118	Human	hsa-miR-640	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	Nucleus pulposus (NP) cells	IL©\1¦Â treatment	upregulated	31343104
9119	Human	hsa-miR-640	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	Nucleus pulposus (NP) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31343104
9120	Human	hsa-miR-640	miRNA	angiopoietin-1 (Ang-1)	Ang-1-induced endothelial cell migration and differentiation	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	Exposure to Ang-1 (300 ng/mL) from 6 to 72 h significantly decreased expression of mature miR-640.	32630670
9121	Human	hsa-miR-640	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammatory injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miRNA-640 expression was gradually increased in HUVECs treatment with OX-LDL.	33300444
9122	Human	hsa-miR-640	miRNA	hydrogen sulfide (H2S)	proangiogenic function	vascular endothelial cells (ECs)	hydrogen sulfide (H2S) treatment	downregulated	26879375
9123	Human	hsa-miR-641	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
9124	Human	hsa-miR-642	miRNA	X-rays	gastric cancer (GC)	human gastric cancer tissue samples	"4 Gy of X-rays (6 MV, 0.8 Gy/min) treatment"	downregulated	24919435
9125	Human	hsa-miR-642	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
9126	Human	hsa-miR-642-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
9127	Human	hsa-miR-642a	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
9128	Human	hsa-miR-642a-3p	miRNA	vorinostat (SAHA)	breast cancer	BT474 cells	vorinostat (SAHA) treatment	upregulated	29620153
9129	Human	hsa-miR-642a-3p	miRNA	rosmarinic acid (RA)	gastric cancer (GC)	SGC7901 cells	rosmarinic acid (RA) treatment	RA treated SGC7901/5-Fu cells showed reduced expression levels of miR-642a-3p and miR-6785-5p compared to untreated SGC7901/5-Fu cells	30551491
9130	Human	hsa-miR-642a-5p	miRNA	lipopolysaccharide (LPS)	acute Lung Injury (ALI)/acute respiratory distress syndrome (ARDS)	pulmonary microvascular endothelial cells (PMVECs)	lipopolysaccharide (LPS) treatment	miR-642a-5p levels are significantly upregulated in LPS-stimulated PMVECs.	32881411
9131	Human	hsa-miR-642a-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
9132	Human	hsa-miR-643	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine treatment	upregulated	25722110
9133	Human	hsa-miR-643	miRNA	entamoeba histolytica	parasites infection	SW-480 colon cells	Entamoeba histolytica infection	upregulated	30671387
9134	Human	hsa-miR-646	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	hsa_circ_0041795 contributes to human retinal pigment epithelial cells (ARPE 19) injury induced by high glucose via sponging miR-646 and activating VEGFC	32259632
9135	Human	hsa-miR-646	miRNA	TGF-¦Â1	gastric cancer (GC)	human GC cell lines	TGF-¦Â1 treatment	upregulated	28632723
9136	Human	hsa-miR-646	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells	hypoxia treatment	MiR-646 is critical for downregulated of MIIP under hypoxia.	29343850
9137	Human	hsa-miR-646	miRNA	ischemia	preeclampsia (PE)	endothelial progenitor cells	ischemia treatment	microRNA-646 inhibits angiogenesis of endothelial progenitor cells in pre-eclamptic pregnancy by targeting the VEGF-A/HIF-1¦Á axis	32782496
9138	Human	hsa-miR-646	miRNA	R-2-hydroxyglutarate (R-2HG)	prostate cancer	"C4-2, PC3, DU145, LNCaP cells"	R-2-hydroxyglutarate (R-2HG) treatment	downregulated	31846689
9139	Human	hsa-miR-647	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31486513
9140	Human	hsa-miR-647	miRNA	argon-helium cryoablation treatment	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	argon-helium cryoablation treatment	miR-647 was high expression in tumor that under argon-helium cryoablation treatment in contrast to the tumor under non argon-helium cryoablation treatment and inhibited cell proliferation of A549 and H1299 cells by inducing G1-S transition.	30349310
9141	Human	hsa-miR-647	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
9142	Human	hsa-miR-648	miRNA	placenta growth factor (PlGF)	sickle cell anemia (SCA)	human umbilical vein endothelial cells (HUVEC)	placenta growth factor (PlGF) treatment	downregulated	25403488
9143	Human	hsa-miR-649	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	HeLa cells	infect with HSV-1	downregulated	27813118
9144	Human	hsa-miR-649	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	HeLa cells	infect wirh HSV-1	downregulated	27813118
9145	Human	hsa-miR-650	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer (GC) tissues; HGC-27 cells; MKN-45 cells	helicobacter pylori (HP) treatment	upregulated	33147052
9146	Human	hsa-miR-650	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GC cells	Helicobacter pylori (HP) treatment	miR-650 was upregulated in HP+ tissues and cells	33147052
9147	Human	hsa-miR-651-3p	miRNA	atropine	myopia	Human corneal epithelial cells	0.003% atropine treatment	dysregulated	31540331
9148	Human	hsa-miR-652	miRNA	acidity	pancreatic cancer (PC)	"human pancreatic cancer cell lines AsPC-1, BxPC-3, PANC-1, SW1990 and MIAPaCa-2"	acidity treatment	downregulated	26498682
9149	Human	hsa-miR-652-3p	miRNA	simvastatin	aberrant endothelial function	human umbilical vein endothelial cells (HUVECs)	Simvastatin treatment	Simvastatin blocked oxidized LDL (ox-LDL)-induced increases in miR-652-3p and ox-LDL-induced decreases in ISL1 protein expression.	32277945
9150	Human	hsa-miR-652-3p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
9151	Human	hsa-miR-653-5p	miRNA	IL-1¦Â	chondrocyte apoptosis	CHON-001 cells	IL-1¦Â treatment	upregulated	32517436
9152	Human	hsa-miR-654-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32349937
9153	Human	hsa-miR-654-3p	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	downregulated	29172709
9154	Human	hsa-miR-654-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
9155	Human	hsa-miR-654-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9156	Human	hsa-miR-654-3p	miRNA	silver ions Ag+	toxicity of silver (Ag)	Jurkat T cells	Ag ions treatment	downregulated	24974768
9157	Human	hsa-miR-654-5p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells; HeyA8 cells	paclitaxel (PTX) treatment	downregulated	32016960
9158	Human	hsa-miR-655	miRNA	CoCl2	breast cancer	MCF-7 cells	CoCl2 treatment	upregulated	32707933
9159	Human	hsa-miR-655	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells	TGF-¦Â1 treatment	"the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2,"	24258346
9160	Human	hsa-miR-655	miRNA	benzyl butyl phthalate (BBP)	hemangioma (HA)	The human HA HDEC and CRL-2586 EOMA cells	benzyl butyl phthalate (BBP) treatment	downregulated	31212022
9161	Human	hsa-miR-655	miRNA	TGF-¦Â1	lung adenocarcinoma (LUAD)	human adenocarcinoma cell lines	transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment	upregulated	24258346
9162	Human	hsa-miR-655-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
9163	Human	hsa-miR-655-3p	miRNA	echinacea purpurea (EP)	hepatoblastoma	human hepatoblastoma HepG2 cells	50 ?g/mL methanolic extract of commercial EP capsules	downregulated	28990842
9164	Human	hsa-miR-656-3p	miRNA	resveratrol	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	resveratrol (RS) treatment	upregulated	33718067
9165	Human	hsa-miR-656-3p	miRNA	TGF-¦Â1	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	TGF-¦Â1 treatment	downregulated	33718067
9166	Human	hsa-miR-657	miRNA	Spatholobus suberectus Dunn (SSD)	apoptosis	U266 and U937 cells	Spatholobus suberectus Dunn (SSD) treatment	downregulated	30696076
9167	Human	hsa-miR-657	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	gestational diabetes mellitus (GDM)	THP-1 cells	LPS and IFN-¦Ã treatment	upregulated	31915414
9168	Human	hsa-miR-658	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
9169	Human	hsa-miR-658	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
9170	Human	hsa-miR-660	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
9171	Human	hsa-miR-660	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9172	Human	hsa-miR-660-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SKhep1 cells; Huh7 cells; LM3 cells	sorafenib treatment	downregulated	33222692
9173	Human	hsa-miR-660-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	primary hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	upregulated	32584784
9174	Human	hsa-miR-660-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29505299
9175	Human	hsa-miR-663	miRNA	waltonitone	apoptosis	H460 and H3255 lung cancer cells	waltonitone treatment	upregulated	25301444
9176	Human	hsa-miR-663	miRNA	oscillatory shear stress (OS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oscillatory shear stress (OS) treatment	miR-663 plays a key role in OS-induced inflammatory responses by mediating the expression of inflammatory gene network in HUVECs	21378144
9177	Human	hsa-miR-663	miRNA	vascular endothelial growth factor (VEGF)	atherosclerosis (AS)	Human umbilical vein ECs (HUVECs) and human coronary artery ECs (HCAECs)	VEGF treatment	"miR-663 is critically important for 2 key events induced in ECs by stress agents and oxidized lipids, namely induction of transcription factor ATF4 and its downstream gene VEGF"	22776647
9178	Human	hsa-miR-663	miRNA	PhIP and 17-¦Â-estradiol	breast cancer	MCF-7 human breast adenocarcinoma cell line	PhIP and 17-¦Â-estradiol (E2) treatment	dysregulated	24877718
9179	Human	hsa-miR-663	miRNA	inorganic arsenic (iAs)	tumorigenesis	human Jurkat leukemic T cell	"Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment"	upregulated	24317173
9180	Human	hsa-miR-663	miRNA	arsenite	chronic arsenic toxicity	skin cancer tissues	arsenic (As) exposure	miR-663 was significantly reduced in arsenic induced skin cancer tissues compared to control tissue.	32563914
9181	Human	hsa-miR-663	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
9182	Human	hsa-miR-663	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
9183	Human	hsa-miR-663	miRNA	rotenone (ROT)	oxidative stress	human fibroblasts of different age	0.6 ¦ÌM rotenone in stressed conditions treatment	upregulated	24664125
9184	Human	hsa-miR-663	miRNA	metformin (Met)	pancreatic cancer (PC)	BxPC-3 cells; MIAPaCa-2 cells	metformin treatment	miR-663 was upregulated after treatment of metformin.	33116621
9185	Human	hsa-miR-663	miRNA	lidocaine	skin healing process	denatured skin tissues	Lidocaine treatment	"lidocaine treatment promoted the skin healing after thermal injury through up-regulating miR-486 and miR-663 expression, and partially explained how lidocaine modulates wound healing processes."	31815358
9186	Human	hsa-miR-663a	miRNA	ultraviolet (UV) irradiation	cell senescence	primary human dermal fibroblasts	UVB-irradiated treatment	"RP11-670E136/miR-663a/CDK4?and?RP11-670E136/miR-663a/CDK6?axis, which may function as competitive endogenous RNA networks, played important roles in UVB-induced cellular senescence"	31444317
9187	Human	hsa-miR-663a	miRNA	antimicrobial peptides (AMPs)	colorectal cancer (CRC)	HCT116 cells	administration of the human cathelicidin AMP	upregulated	28061765
9188	Human	hsa-miR-663a	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
9189	Human	hsa-miR-663a	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	thapsigargin (Tg) treatment	upregulated	30753838
9190	Human	hsa-miR-663a	miRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	tunicamycin (TM)? treatment	upregulated	30753838
9191	Human	hsa-miR-663a	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
9192	Human	hsa-miR-663a	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
9193	Human	hsa-miR-663a	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SK-N-SH cell lines	fluoxetine treatment	upregulated	27716787
9194	Human	hsa-miR-663a	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
9195	Human	hsa-miR-663a	miRNA	IL-1¦Â	osteoarthritis (OA)	OA cartilage tissues	IL-1¦Â treatment	"The expression of HOTTIP and FRK were upregulated, while miR-663a was downregulated in OA cartilage tissues."	33435956
9196	Human	hsa-miR-663a	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"Human PDAC cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2)"	Gemcitabine (GEM) treatment	upregulated	30788003
9197	Human	hsa-miR-663a	miRNA	OSI-027	pancreatic ductal adenocarcinoma (PDAC)	"Human PDAC cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2)"	OSI-027 treatment	downregulated	30788003
9198	Human	hsa-miR-663b	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	downregulated	33197057
9199	Human	hsa-miR-663b	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
9200	Human	hsa-miR-663b	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells	tamoxifen (TAM) treatment	miRNA-663b was upregulated in breast cancer with TAM resistance	29845295
9201	Human	hsa-miR-663b	miRNA	pterostilbene	endometrial cancer (EC)	HTB-111 and Ishikawa cells	PT (25-100 ¦Ìmol/L) treatment	downregulated	28552912
9202	Human	hsa-miR-664	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
9203	Human	hsa-miR-664-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9204	Human	hsa-miR-664a-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Beas-2B cells	cigarette smoke extract (CSE) exposure	upregulated	31632001
9205	Human	hsa-miR-664a-5p	miRNA	all-trans retinoic acid (ATRA)	neuronal differentiation	SH-SY5Y cells	all-trans retinoic acid (ATRA) treatment	upregulated	29341475
9206	Human	hsa-miR-665	miRNA	hypoxia	cell proliferation	human primary pulmonary artery smooth muscle cells	hypoxia induce	upregulated	31370272
9207	Human	hsa-miR-665	miRNA	propofol (PPF)	neurotoxicity	human stem cell-derived neurons	Propofol treatment	upregulated	31656124
9208	Human	hsa-miR-665	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
9209	Human	hsa-miR-665	miRNA	olmesartan (OMST)	vascular senescence	vascular smooth muscle cells (VSMCs)	Olmesartan (OMST) treatment	downregulated	33042414
9210	Human	hsa-miR-665-3p	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	Caco-2 cells	hypoxia induce	upregulated	29706629
9211	Human	hsa-miR-671	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
9212	Human	hsa-miR-671	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes CHON-001	IL-1¦Â treatment	downregulated	31085006
9213	Human	hsa-miR-671	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	The expression of circ_0114876 was increased in OA tissues and inhibition of circ_0114876 could induce cell viability and suppress inflammation as well as inhibit cell apoptosis in IL-1¦Â induced CHON-001 cells.	33404903
9214	Human	hsa-miR-671-3p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
9215	Human	hsa-miR-671-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
9216	Human	hsa-miR-671-5p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia induce	downregulated	30250300
9217	Human	hsa-miR-671-5p	miRNA	lipopolysaccharide (LPS)	inflammation	OFSCs (OFSCs-CM)	upon co-culture with activated macrophages treatment	downregulated	25124290
9218	Human	hsa-miR-671-5p	miRNA	3-methyladenine (3-MA)	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	3-Methyladenine (3-MA) treatment	downregulated	31582727
9219	Human	hsa-miR-671-5p	miRNA	hypoxia	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	hypoxia induce	downregulated	31582727
9220	Human	hsa-miR-671-5p	miRNA	rapamycin	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	rapamycin treatment	downregulated	31582727
9221	Human	hsa-miR-671-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	"Circ-IQGAP1 abundance was enhanced in the cartilage tissues from OA patients compared with normal subjects (n = 32), and its expression was increased in CHON-001 cells after treatment of IL-1¦Â in a dose-dependent pattern."	33675175
9222	Human	hsa-miR-671-5p	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	downregulated	22366961
9223	Human	hsa-miR-6720-3p	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
9224	Human	hsa-miR-6720-3p	miRNA	alternariol (AOH)	cytotoxicity	HepG2	alternariol (AOH) treatment	upregulated	28007639
9225	Human	hsa-miR-6731-5p	miRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	downregulated	29339075
9226	Human	hsa-miR-6732-3p	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
9227	Human	hsa-miR-6732-3p	miRNA	radiation	nasopharyngeal carcinoma (NPC)	serum	radiation treatment	downregulated	32198434
9228	Human	hsa-miR-6734-3p	miRNA	arsenic resistance protein 2 (Ars2)	acute myeloid leukemia (AML)	U937 cells	Ars2 deficiency	downregulated	30518811
9229	Human	hsa-miR-6734-5p	miRNA	arsenic trioxide (ATO)	bladder cancer	T24 cells	arsenic trioxide (As2O3) treatment	lncRNA OTUD6B-AS1 Exacerbates As 2 O 3-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2	32952848
9230	Human	hsa-miR-6740	miRNA	stiff (50 kPa) hydrogel substrates	cardiovascular disease (CVD)	human umbilical vein endothelial cells	stiff (50 kPa) hydrogel substrates cultures treatment	downregulated	31606530
9231	Human	hsa-miR-6746-5p	miRNA	cyclosporine A (CsA)	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	cyclosporine A (CsA) treatment	downregulated	31371743
9232	Human	hsa-miR-6746-5p	miRNA	rapamycin	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	rapamycin (RAPA) treatment	upregulated	31371743
9233	Human	hsa-miR-675	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	30815865
9234	Human	hsa-miR-675	miRNA	early growth response protein 1 (EGR1)	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	early growth response protein 1 (EGR1) treatment	upregulated	30815865
9235	Human	hsa-miR-675	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	upregulated	30692507
9236	Human	hsa-miR-675	miRNA	lipopolysaccharide (LPS)	gestational diabetes mellitus (GDM)	Human leukemia cell line THP©\1 cells	lipopolysaccharide (LPS) treatment	upregulated	30362558
9237	Human	hsa-miR-675	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	31468534
9238	Human	hsa-miR-675	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	curcumin (CUR) treatment	downregulated	31468534
9239	Human	hsa-miR-675	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	curcumin (CUR) treatment	CUR downregulated the expression of miR-675.	31468534
9240	Human	hsa-miR-675	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	curcumin (CUR) treatment	"1,25(OH) 2 D3 downregulated the expression of H19 and miR-675."	31468534
9241	Human	hsa-miR-675	miRNA	hepatitis B virus (HBV)	hepatoblastoma	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	30367502
9242	Human	hsa-miR-675	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU©\449; SNU©\387	sorafenib treatment	Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675	32627034
9243	Human	hsa-miR-675	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	Hep3B cells	2 ng/ml TGF-¦Â for 48 h treatment	upregulation	24703882
9244	Human	hsa-miR-675	miRNA	hepatitis B virus X protein (HBx)	liver damage	L02 cells	hepatitis B X protein (HBx) treatment	"the expression of lncRNA H19 and miR-675 was upregulated in patients with chronic hepatitis B. Inhibition of lncRNA H19 or miR-675 in L02 cells increased cell viability, suppressed hepatitis B X protein (HBx)-induced cell apoptosis, inflammatory cytokine production, and oxidative stress, and remodelled energy metabolism."	31574452
9245	Human	hsa-miR-675	miRNA	angelica polysaccharide (AP)	neuroblastoma (NB)	SH-SY5Y cells	angelica polysaccharide (AP) treatment	downregulated	29465760
9246	Human	hsa-miR-675	miRNA	hypoxia	osteoarthritis (OA)	human cartilage cells	Hypoxia treatment	upregulated	22527881
9247	Human	hsa-miR-675	miRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	human cartilage cells	IL-1¦Â and TNF-¦Á?treatment	downregulated	22527881
9248	Human	hsa-miR-675	miRNA	H2O2	premature senescence	C-kit(+) cardiac progenitor cells (CPCs)	H2 O2 treatment	downregulated	27062045
9249	Human	hsa-miR-675	miRNA	melatonin	subarachnoid hemorrhage (SAH)	U87 cells; U251 cells	melatonin (MT) treatment	upregulated	29367587
9250	Human	hsa-miR-6751	miRNA	triptolide (TPL)	ovarian cancer (OC)	cisplatin-resistant ovarian cancer cell line A2780/CP70	triptolide (TPL) treatment	upregulated	29966441
9251	Human	hsa-miR-6752-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
9252	Human	hsa-miR-675-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocytes	IL-1¦Â treatment	The overexpression of miR-675-3p inhibited apoptosis and cartilage matrix degradation and promoted cell proliferation in human chondrocytes.	32336544
9253	Human	hsa-miR-675-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
9254	Human	hsa-miR-675-5p	miRNA	hypoxia	bone ossification	hMSCs	hypoxia treatment	upregulated	29111380
9255	Human	hsa-miR-675-5p	miRNA	huaier extract	breast cancer	"breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF8"		downregulated	29145193
9256	Human	hsa-miR-675-5p	miRNA	hypoxia	colorectal cancer (CRC)	SW620 cells; HCT116 cells	hypoxia treatment	Hypoxia-Induced miR-675-5p Supports ¦Â-Catenin Nuclear Localization by Regulating GSK3-¦Â Activity in Colorectal Cancer Cell Lines	32481626
9257	Human	hsa-miR-675-5p	miRNA	Prostaglandin E2 (PGE2)	colorectal cancer (CRC)	LS174T colorectal cancer cells	Prostaglandin E2 (PGE2) treatment	upregulated	31734182
9258	Human	hsa-miR-675-5p	miRNA	prostaglandin E2 (PGE2)	colorectal cancer (CRC)	LS174T cells	Prostaglandin E2 (PGE2) treatment	Prostaglandin E 2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression	31734182
9259	Human	hsa-miR-6776-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
9260	Human	hsa-miR-6779-5p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
9261	Human	hsa-miR-6785-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC7901 cells	5-fluorouracil (5-FU) treatment	upregulated	30551491
9262	Human	hsa-miR-6785-5p	miRNA	rosmarinic acid (RA)	gastric cancer (GC)	SGC7901/5-Fu cells	Rosmarinic acid (RA) treatment	downregulated	30551491
9263	Human	hsa-miR-6785-5p	miRNA	rosmarinic acid (RA)	gastric cancer (GC)	SGC7901 cells	rosmarinic acid (RA) treatment	RA treated SGC7901/5-Fu cells showed reduced expression levels of miR-642a-3p and miR-6785-5p compared to untreated SGC7901/5-Fu cells	30551491
9264	Human	hsa-miR-6787-5p	miRNA	cyclosporine A (CsA)	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	cyclosporine A (CsA) treatment	downregulated	31371743
9265	Human	hsa-miR-6787-5p	miRNA	rapamycin	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	rapamycin (RAPA) treatment	upregulated	31371743
9266	Human	hsa-miR-6794-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
9267	Human	hsa-miR-6797-5p	miRNA	parathyroid hormone (PTH)	cell differentiation	human bone marrow stromal cells (hBMSCs)	Parathyroid hormone (PTH) treatment	upregulated	30562548
9268	Human	hsa-miR-6797-5p	miRNA	parathyroid hormone (PTH)	osteoblastic differentiation	human bone marrow stromal cells (hBMSCs)	parathyroid hormone (PTH) treatment	PTH-treatment increased the expression of miR-6797-5p in hBMSCs	30562548
9269	Human	hsa-miR-6808-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
9270	Human	hsa-miR-6808-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
9271	Human	hsa-miR-6809-5p	miRNA	luteolin	hepatocellular carcinoma (HCC)	"Huh7 cells, HepG2 cells"	"Luteolin (3,4,5,7-tetrahydroxy flavone) treatment"	upregulated	30668319
9272	Human	hsa-miR-6809-5p	miRNA	luteolin	hepatocellular carcinoma (HCC)	"Huh7 cells, HepG2 cells"	"Luteolin (3,4,5,7-tetrahydroxy flavone) treatment"	upregulated	30668319
9273	Human	hsa-miR-6810-5p	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
9274	Human	hsa-miR-6813-5p	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
9275	Human	hsa-miR-6816	miRNA	suberoylanilide hydroxamic acid (SAHA)	chronic myeloid leukemia (CML)	K562 cells	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	29343029
9276	Human	hsa-miR-6817-5p	miRNA	Nel-like molecule type 1 (NELL-1)	osteogenesis	human adipose-derived stem cells (hASCs)	"recombinant nel-like molecule, type 1 (NELL-1) treatment"	downregulated	31633307
9277	Human	hsa-miR-682	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	human colonic epithelial cells	hypoxia treatment	upregulated	27124584
9278	Human	hsa-miR-6825-5p	miRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	downregulated	28166203
9279	Human	hsa-miR-6832-5p	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
9280	Human	hsa-miR-6839-5p	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	upregulated	32362797
9281	Human	hsa-miR-684	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	upregulated	25552929
9282	Human	hsa-miR-6842-5p	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
9283	Human	hsa-miR-6845-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH5Y-SY cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â 25-35 upregulated hsa-miR-6845-3p in SH-SY5Y cell lines associated with A¦Â-mediated pathophysiology.	30547775
9284	Human	hsa-miR-6845-5p	miRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	downregulated	28166203
9285	Human	hsa-miR-6873-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial inflammation	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ-RELL1 modulate inflammatory response by miR-6873-3p/MyD88/NF-¦ÊB axis in ox-LDL induced endothelial cells.	33008595
9286	Human	hsa-miR-6886-3p	miRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	downregulated	28166203
9287	Human	hsa-miR-6889-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
9288	Human	hsa-miR-7	miRNA	hepatocyte growth factor (HGF)	breast cancer	MCF-10A cells	HGF	upregulated	29133945
9289	Human	hsa-miR-7	miRNA	trichostatin A (TSA)	breast cancer	lapatinib-ed triple-negative breast cancer cells	TSA treatment	upregulated	24707474
9290	Human	hsa-miR-7	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-7 cells	estradiol-17¦Â (E2) treatment	upregulated	23227519
9291	Human	hsa-miR-7	miRNA	estrogen (ES)	breast cancer	MCF-7 cells; SK-BR-3 cells	estrogen treatment	miRNAs were significantly induced by E2 treatment in the MCF-7 cell line.miR-7 suppress epidermal growth factor receptor (EGFR) expression in several human malignancies.	23227519
9292	Human	hsa-miR-7	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
9293	Human	hsa-miR-7	miRNA	oleic acid (OA)	cervical cancer (CC)	HeLa cells	OA induces production in	upregulated	28483648
9294	Human	hsa-miR-7	miRNA	gefitinib	drug resistance	A549 sub-clone	gefitinib-resistant was established by exposure to escalating gefitinib concentrations over a period of 16-24 months treatment	downregulated	25339453
9295	Human	hsa-miR-7	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
9296	Human	hsa-miR-7	miRNA	IL-1¦Â and TNF-¦Á	gastric cancer (GC)	gastric tumor cells	IL-1¦Â and TNF-¦Á treatment	downregulated	22139078
9297	Human	hsa-miR-7	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
9298	Human	hsa-miR-7	miRNA	yangzheng sanjie decoction (YZSJD)	gastric cancer (GC)	GC MKN-45 cell line	yangzheng Sanjie Decoction (YZSJD) treatment	upregulated	29467883
9299	Human	hsa-miR-7	miRNA	H2O2	glaucoma	human trabecular meshwork (TM) cells	"For the stimulation with H2 O2 , the cells were cultured in Trabecular Meshwork Cell Medium (TMCM) containing 50-400 ¦ÌM H2O2 (Sigma-Aldrich, St. Louis, MO, USA) for 24 h after they reached 80-85% confluence."	miR-7 overexpression abrogated the effects of lncRNA ANRIL on H2O2-treated TM cells. Phosphorylation levels of the key kinases in the mTOR and MEK/ERK pathways were enhanced by lncRNA ANRIL via down-regulating miR-7 in H2O2-treated TM cells.	31081068
9300	Human	hsa-miR-7	miRNA	lapatinib	HER2-positive breast cancer	primary human breast cancer cells	lapatinib treatment	"microRNA-7 directly binds and inhibits Raf-1 3'UTR activity, and that downregulated of miR-7 by lapatinib contributes to the activation of Raf-1 signaling pathway and the induction of IL-6 expression"	26513016
9301	Human	hsa-miR-7	miRNA	manganese (Mn)	idiopathic Parkinson's disease	human neuroblastoma SH-SY5Y cells	manganese (100¦ÌM) treatment	downregulated	28986288
9302	Human	hsa-miR-7	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	The human lung fibroblasts (WI-38 cells)	TGF-¦Â1 treatment	downregulated	31786325
9303	Human	hsa-miR-7	miRNA	single-walled carbon nanotubes (SWCNTs)	immune response	normal human astrocytes (line NHA/TS)	single-walled carbon nanotubes (SWCNTs) treatment	upregulated	29906516
9304	Human	hsa-miR-7	miRNA	docetaxel (DTX)	lung cancer	NSCLC cell lines A549 and H460	docetaxel (DTX) treatment	upregulated	26464649
9305	Human	hsa-miR-7	miRNA	gefitinib	lung cancer	A549 human lung cancer cell	gefitinib treatment	downregulated	25339453
9306	Human	hsa-miR-7	miRNA	manganese (Mn)	manganese induced neurotoxic	SH-SY5Y cells	manganese treatment	The expressions of miR-7 and miR-433 significantly reduced upon manganese exposure.	28986288
9307	Human	hsa-miR-7	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
9308	Human	hsa-miR-7	miRNA	metformin (Met)	non-small cell lung cancer (NSCLC)	A549 cells	metformin (Met) treatment	"Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells."	31789625
9309	Human	hsa-miR-7	miRNA	IL-1¦Â	osteoarthritis (OA)	Human OA chondrocytes (C28/12 cell line)	IL-1¦Â treatment	upregulated	30925324
9310	Human	hsa-miR-7	miRNA	curcumin (Cur)	pancreatic cancer (PC)	pancreatic carcinoma PANC-1 cells	curcumin treatment	upregulated	28259961
9311	Human	hsa-miR-7	miRNA	curcumin (Cur)	pancreatic cancer (PC)	human AsPC-1 and BxPC-3 PC cells	curcumin treatment	upregulated	25256401
9312	Human	hsa-miR-7	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells	gemcitabine treatment	miR-7 expression was decreased in gemcitabine-resistant pancreatic cancer cells.	33552258
9313	Human	hsa-miR-7	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	29953413
9314	Human	hsa-miR-7	miRNA	pramipexole (PPX)	parkinson's disease (PD)	1-methyl-4-phenylpyridinium (MMP+) treated SH-SY5Y cells	pramipexole (PPX) treatment	upregulated	29953413
9315	Human	hsa-miR-7	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
9316	Human	hsa-miR-7	miRNA	astaxanthin	parkinson's disease (PD)	SH-SY5Y Cells	astaxanthin (AST) treatment	AST reverses the dysregulation of miR-7 and SNCA in SH-SY5Y cells induced by MPP+.	32333925
9317	Human	hsa-miR-7	miRNA	lipopolysaccharide (LPS)	periodontitis	Human periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	"CDR1as was significantly downregulated in LPS-treated PDLSCs compared to untreated cells, as well as in normal periodontal ligament tissues compared to periodontitis tissues."	31582895
9318	Human	hsa-miR-7	miRNA	ultraviolet (UV) irradiation	pigmented skin diseases	HaCaT cells; FB cells	Ultraviolet B (UVB)? treatment	downregulated	33687273
9319	Human	hsa-miR-7	miRNA	docetaxel (DTX)	prostate cancer	PC-3 cells; DU145 cells	docetaxel (DTX) treatment	miR-7 was downregulated in DTX-resistant PCa tissues and cells.	32714093
9320	Human	hsa-miR-7	miRNA	lapatinib	triple negative breast cancer (TNBC)	triple-negative MDA-MB-231 breast cancer cells	Lapatinib treatment	downregulated	23355539
9321	Human	hsa-miR-7	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
9322	Human	hsa-miR-7	miRNA	silica	silicosis	HBE cells; A549 cells	silica treatment	miR-7 was downregulated in HBE and A549 cells treated with silica	30202956
9323	Human	hsa-miR-7	miRNA	IL-21	systemic lupus erythematosus (SLE)	normal and SLE B cells	IL-21 treatment	upregulated	25101889
9324	Human	hsa-miR-7	miRNA	vitamin D	type 2 diabetes mellitus (T2DM)	type 2 diabetes patients	vitamin D treatment	dysregulated	28945992
9325	Human	hsa-miR-7	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
9326	Human	hsa-miR-7	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
9327	Human	hsa-miR-7013-3p	miRNA	hydroxyurea	melanoma	B16 melanoma cells	Hydroxyurea (HU) treatment	We found that miR-7013-3p exhibited increased expression after HU treatment and could bind to MITF.	33746605
9328	Human	hsa-miR-706	miRNA	H2O2	hepatitis	L02 cells	H2O2 treatment	miR-706 mimic partly abolished the influence of H2O2-resulted damage on L02 cells.	31479678
9329	Human	hsa-miR-706	miRNA	H2O2	hepatitis	L02 cells	H2O2 treatment	downregulated	31479678
9330	Human	hsa-miR-708	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	L0-2 cells	ethanol treatment	downregulated	32721464
9331	Human	hsa-miR-708	miRNA	maritoclax	apoptosis	"renal carcinoma (Caki, ACHN and A498), lung cancer (A549) and hepatocellular carcinoma (SK-Hep1) cells"	Maritoclax treatment	upregulated	30463333
9332	Human	hsa-miR-708	miRNA	antcin A (ATA)	breast cancer	human breast cancer cells MCF-7 and MDA-MB-231	antcin A (ATA) treatment	upregulated	30726934
9333	Human	hsa-miR-708	miRNA	dexamethasone (DEX)	breast cancer	human breast cancer cells MCF-7 and MDA-MB-231	dexamethasone (DEX) treatment	upregulated	30726934
9334	Human	hsa-miR-708	miRNA	dexamethasone (DEX)	breast cancer	MDA-MB-231 cells	dexamethasone (DEX) treatment	The dose dependent induction of miR-708 by DEX was observed in the MDA-MB-231 cells from 1 nM to 100 nM.	33065150
9335	Human	hsa-miR-708	miRNA	carnosic acid (CA)	chronic lymphocytic leukemia (CLL)	CML KBM-7 cell line	Carnosic acid (CA) treatment	downregulated	30003745
9336	Human	hsa-miR-708	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	human neuroblastoma cells (SH-SY5Y)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29128627
9337	Human	hsa-miR-708	miRNA	glucocorticoid (GC)	osteonecrosis of femoral head (ONFH)	mesenchymal stem cells (MSCs)	glucocorticoid (GC) treatment	upregulated	26932538
9338	Human	hsa-miR-708	miRNA	deubiquitinases inhibitor (WP1130)	renal cell carcinoma (RCC)	Caki cells	WP1130 treatment	upregulated	30862047
9339	Human	hsa-miR-708-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human macrophages (HTP-1 and U937 cells)	Mycobacterium tuberculosis (M.tb) infection	upregulated	31599428
9340	Human	hsa-miR-709	miRNA	cyclosporine A (CsA)	nephrotoxicity	HEK293	cyclosporine A treatment	upregulated	28414804
9341	Human	hsa-miR-710	miRNA	carbon monoxide (CO)	colonic inflammation	The YAMC (Young Adult Mouse Colon) cell	carbon monoxide (CO) treatment	downregulated	20005208
9342	Human	hsa-miR-7109-5p	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
9343	Human	hsa-miR-711	miRNA	dexamethasone (DEX)	ischemic liver injury	L-02 cells	dexamethasone (DEX) treatment	"Dexmedetomidine attenuated OGD-induced apoptosis and inflammation, and dexmedetomidine downregulated the expression of miR-711."	30338821
9344	Human	hsa-miR-7-1-3p	miRNA	rapamycin	glioblastoma multiforme (GBM)	U87MG and T98G	rapamycin (RAPA) treatment	upregulated	26573275
9345	Human	hsa-miR-718	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
9346	Human	hsa-miR-720	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
9347	Human	hsa-miR-744	miRNA	lactic acid (LA)	cervical cancer (CC)	HPV16 positive SiHa cells	lactic acid treatment	upregulated	30423314
9348	Human	hsa-miR-744	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells	oxaliplatin treatment	upregulated	31884801
9349	Human	hsa-miR-744	miRNA	oxaliplatin	colorectal cancer (CRC)	colorectal cancer tissues; HCT116 cells	oxaliplatin (OXA) treatment	upregulated	31884801
9350	Human	hsa-miR-744	miRNA	angiotensin II (Ang II)	heart failure (HF)	Human adult atrial fibroblast primary cultures (NHCF-A)	angiotensin II (Ang II) treatment	downregulated	30392569
9351	Human	hsa-miR-744	miRNA	CCAAT/enhancer binding protein delta (CEBPD)	leukemia	human monocytic leukemic cell line THP-1 and the human myeloid cell line U937	CEBPD treatment	upregulated	29120412
9352	Human	hsa-miR-744	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9353	Human	hsa-miR-744-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9354	Human	hsa-miR-758	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs or HAECs (human artery cells)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29660520
9355	Human	hsa-miR-758	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	CircRSF1 could protect against ox-LDL-induced endothelial cell injury in vitro via miR-758/CCND2 axis	32791147
9356	Human	hsa-miR-758	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
9357	Human	hsa-miR-758	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
9358	Human	hsa-miR-7-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human alveolar epithelial cell line A549	lipopolysaccharide (LPS) treatment	upregulated	27331901
9359	Human	hsa-miR-7-5p	miRNA	ccrriizottiiniib	anaplastic lymphoma kinase positive anaplastic large cell lymphomas	Karpas-299 cells; SU-DHL-1 cells	ccrriizottiiniib treatment	downregulated	31626878
9360	Human	hsa-miR-7-5p	miRNA	hydroquinone (HQ)	cell proliferation and apoptosis	TK6 cells	Hydroquinone (HQ) treatment	downregulated	29421518
9361	Human	hsa-miR-7-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-7-5p expression was upregulated in OGD/R-treated SH-SY5Y cells.	32453073
9362	Human	hsa-miR-7-5p	miRNA	hyperoxia	experimental retinopathy	human umbilical vein endothelial cells	incubated at 2% oxygen	upregulated	28353063
9363	Human	hsa-miR-7-5p	miRNA	2-deoxy-d-glucose (2-DG)	glioblastoma multiforme (GBM)	U87MG cells; LN229 cells; A172 cells; T98G cells	2-Deoxy-d-glucose (2-DG) treatment	2-DG treatment downregulates the tumor suppressive miR-7-5p in GBM cell lines in vitro.	29621542
9364	Human	hsa-miR-7-5p	miRNA	verbascoside (VB)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	Verbascoside (VB) treatment	VB promoted the expression of miR-7-5p in GBM	33768139
9365	Human	hsa-miR-7-5p	miRNA	aspirin	hepatocellular carcinoma (HCC)	Huh-7 cells	Aspirin treatment	downregulated	32627038
9366	Human	hsa-miR-7-5p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	downregulated	31176168
9367	Human	hsa-miR-7-5p	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	32018039
9368	Human	hsa-miR-7-5p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	downregulated	27018851
9369	Human	hsa-miR-7-5p	miRNA	hypoxia	pulmonary hypertension (PH)	Human pulmonary artery smooth muscle cell (HPASMC)	hypoxia treatment	CDR1as/miR-7-5p/CNN3 and CAMK2D regulatory axis mediates HPASMC osteoblastic differentiation and calcification induced by hypoxia.	33230455
9370	Human	hsa-miR-760	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells; Caco2 cells	5-fluorouracil (5-FU) treatment	miR-760 expression was markedly increased in CRC resistant cells.	32982440
9371	Human	hsa-miR-760	miRNA	methotrexate (MTX)	colorectal cancer (CRC)	The human CRC cell line HT29 and Caco2 cells	methotrexate (MTX) treatment	KCNQ1OT1 enhanced the MTX resistance of CRC cells by regulating miR-760-mediated PPP1R1B expression via the cAMP signalling pathway	30997746
9372	Human	hsa-miR-760	miRNA	peiminine	colorectal cancer (CRC)	SW620 and HT29 cells	peiminine treatment	"Peiminine notably downregulated the expression of LINC00659, while the expression of miR-760 was upregulated by peiminine treatment"	32740014
9373	Human	hsa-miR-760	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
9374	Human	hsa-miR-760	miRNA	X-rays	non-small cell lung cancer (NSCLC)	Human NSCLC A549 and H460 cells	"cells were irradiated using experimental X-ray irradiator (Gulmay Medical Inc., Atlanta, GA, xstrahl.com) at a rate of 2.4 Gy/min for the time required treatment"	upregulated	30901121
9375	Human	hsa-miR-760	miRNA	insulin	polycystic ovarian syndrome (PCOS)	KGN cells; SVOG cells	insulin treatment	"miR-760 expression was decreased in PCOS tissues insulin treated GCs, KGN and SVOG cells."	32540374
9376	Human	hsa-miR-760	miRNA	repeatedly passed	premature senescence	lung fibroblast IMR-90 cells	repeatedly passed until a senescence-like state was observed treatment	upregulated	25139266
9377	Human	hsa-miR-760	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cell (hPASMC)	hypoxia induce	downregulated	30226538
9378	Human	hsa-miR-761	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32772311
9379	Human	hsa-miR-761	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	T98G cell; LN229 cells	sevoflurane (Sev) treatment	miR-761 was upregulated in sevoflurane-treated glioma cells	32495888
9380	Human	hsa-miR-761	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
9381	Human	hsa-miR-762	miRNA	vorinostat (SAHA)	breast cancer	BT474 cells	vorinostat (SAHA) treatment	upregulated	29620153
9382	Human	hsa-miR-762	miRNA	pseudomonas aeruginosa (PA)	infection and excessive inflammation	human corneal epithelial cells	Pseudomonas aeruginosa treatment	upregulated	23469087
9383	Human	hsa-miR-762	miRNA	tear fluid	infection and excessive inflammation	human corneal epithelial cells	tear fluid treatment	upregulated	23469087
9384	Human	hsa-miR-762	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9385	Human	hsa-miR-762	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	"Human NSCLC cell lines, including A549, NCI-H820, NCI-H2170, NCI-H1650, NCI-H1993, NCI-H2126, NCI-H1975, NCIH1299, NCI-H1648, NCI-H1703, NCI-H2347, PC-9 and a normal human lung epithelial cell line NuLi-1 ATCC-CRL-4011)"	gefitinib treatment	upregulated	31823748
9386	Human	hsa-miR-7641	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
9387	Human	hsa-miR-765	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
9388	Human	hsa-miR-765	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9389	Human	hsa-miR-765	miRNA	hyperbaric oxygen (HBO)	hepatocellular carcinoma (HCC)	Hepatoma cell lines (BEL-7402 and SK-Hep1)	HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment	upregulated	24956259
9390	Human	hsa-miR-765	miRNA	vincristine (VCR)	multidrug resistance (MDR)	SGC7901 cells	vincristine (VCR) treatment	upregulated	32166887
9391	Human	hsa-miR-765	miRNA	cisplatin (DDP)	osteosarcoma (OS)	9901 cells	cisplatin treatment	upregulated	28775773
9392	Human	hsa-miR-765	miRNA	fulvestrant	prostate cancer	DU145 cells; PC-3 cells	Fulvestrant treatment	upregulated	24837491
9393	Human	hsa-miR-765	miRNA	fulvestrant	prostate cancer	prostate cancer patients	a single dose (250 mg) of fulvestrant 28 days before prostatectomy treatment	downregulated	24837491
9394	Human	hsa-miR-766	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
9395	Human	hsa-miR-766	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
9396	Human	hsa-miR-766	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
9397	Human	hsa-miR-766	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9398	Human	hsa-miR-766-3p	miRNA	baicalin (BAI)	osteoarthritis (OA)	primary chondrocytes	baicalin (BAI) treatment	Baicalin protects human OA chondrocytes against IL-1¦Â-induced apoptosis and the degradation of ECM through activating autophagy via miR-766-3p/AIFM1 axis.	32753846
9399	Human	hsa-miR-766-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9400	Human	hsa-miR-766-3p	miRNA	abatacept	rheumatoid arthritis (RA)	plasma	abatacept treatment	downregulated	30769772
9401	Human	hsa-miR-769-5p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
9402	Human	hsa-miR-769-5p	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation-induced bystander effects (UV-RIBEs)	Human skin fibroblasts	ultraviolet radiation treatment	Exosomal MiR-769-5p Exacerbates Ultraviolet-Induced Bystander Effect by Targeting TGFBR1	33329055
9403	Human	hsa-miR-770	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human gastric cancer cell lines MKN45, SGC7901, BGC823, and AGS"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28345805
9404	Human	hsa-miR-7704	miRNA	MnCl2	neurodegeneration (ND)	SH-SY5Y cells	MnCl2 treatment	upregulated	28302480
9405	Human	hsa-miR-7704	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	Exosomes derived from human primary melanocytes	ultraviolet B (UVB) irradiation treatment	upregulated	32785244
9406	Human	hsa-miR-770-5p	miRNA	X-rays	breast cancer	MCF7 cells	"2, 8, and 24 h post irradiation"	upregulated	28333152
9407	Human	hsa-miR-770-5p	miRNA	methotrexate (MTX)	colorectal cancer (CRC)	HT-29 cells	Methotrexate (MTX) treatment	Upregulation of miR-770-5p significantly decreased the sensitivity of HT-29 cells to MTX.	31853309
9408	Human	hsa-miR-770-5p	miRNA	dexamethasone (DEX)	cytotoxicity	primary human osteoblasts	dexamethasone (DEX) treatment	upregulated	31313024
9409	Human	hsa-miR-770-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes	high glucose (HG) treatment	upregulated	32696822
9410	Human	hsa-miR-770-5p	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	upregulated	29172709
9411	Human	hsa-miR-770-5p	miRNA	methotrexate (MTX)	methotrexate (MTX) resistance	HT-29 cells	Methotrexate (MTX) treatment	miR-770-5p modulates resistance to methotrexate in human colorectal adenocarcinoma cells by downregulating HIPK1.	31853309
9412	Human	hsa-miR-770-5p	miRNA	curcumin (Cur)	prostate cancer	HuPCaSC lines DU145 and 22Rv1	curcumin treatment	dysregulated	29172709
9413	Human	hsa-miR-7845-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
9414	Human	hsa-miR-7a-2-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
9415	Human	hsa-miR-801	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
9416	Human	hsa-miR-802	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A547 cells	lipopolysaccharide (LPS) treatment	downregulated	31696241
9417	Human	hsa-miR-802	miRNA	arsenite	arsenic carcinogenesis	HK-2 human renal epithelial cells	arsenic exposure	downregulated	30334557
9418	Human	hsa-miR-802	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC cells	cisplatin treatment	circDONSON promoted cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis.	32581651
9419	Human	hsa-miR-802	miRNA	hepatitis B virus (HBV)	HBV-associated hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV) infection	upregulated	31611549
9420	Human	hsa-miR-802	miRNA	high fat diet (HFD)	insulin resistance (IR)	human liver tissues	high fat diet (HFD) treatment	upregulated	23389544
9421	Human	hsa-miR-802	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	human oral keratinocytes	lipopolysaccharide (LPS) treatment	upregulated	30074824
9422	Human	hsa-miR-802	miRNA	vitamin D	oral lichen planus (OLP)	LPS-treated human oral keratinocytes	Vitamin D treatment	downregulated	30074824
9423	Human	hsa-miR-8055	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-8055 was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
9424	Human	hsa-miR-8055	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-8055 was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
9425	Human	hsa-miR-8056	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
9426	Human	hsa-miR-8485	miRNA	bone marrow mesenchymal stem cells (BMSCs)	chondrogenesis	chondrocytes	bone marrow mesenchymal stem cells (BMSCs) treatment	chondrocytes-derived exosomal miR-8485 regulated the Wnt/¦Â-catenin pathways to promote chondrogenic differentiation of BMSCs	31898972
9427	Human	hsa-miR-873	miRNA	norcantharidin (NCTD)	breast cancer	MCF-7 and ZR75-1 cells	Norcantharidin (NCTD) treatment	upregulated	31120927
9428	Human	hsa-miR-873-5p	miRNA	genistein	non-small cell lung cancer (NSCLC)	human NSCLC cell lines (H292 and A549)	genistein treatment	"circ_0031250 abundance was elevated in NSCLC samples and cell lines, and it was reduced via genistein exposure."	33159503
9429	Human	hsa-miR-874	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	asthma	human fetal airway smooth muscle (fASM) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á treatment significantly downregulated the expression of miR-874 in fASM cells	29448029
9430	Human	hsa-miR-874	miRNA	psoralen	diabetic nephropathy (DN)	HK-2 cells	psoralen treatment	Psoralen could significantly alleviate HG-induced HK-2 cell injury via upregulation of miR-874	32698907
9431	Human	hsa-miR-874	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
9432	Human	hsa-miR-874	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	Jurkat cells	Enterovirus 71 (EV71) infection	EV71 infection significantly decreased the expression of miR-874 in Jurkat cells.	32851429
9433	Human	hsa-miR-874	miRNA	¦Ä-opioid receptor (DOR)	hepatocellular carcinoma (HCC)	Bel-7402 cells; SK-hep-1 cells; HepG2 cells; Huh7 cells; Li-7 cells; LO2 cells	¦Ä-opioid receptor (DOR) treatment	upregulated	29374140
9434	Human	hsa-miR-874-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced renal podocyte injury	human podocytes	doxorubicin (DOX) treatment	upregulated	32908641
9435	Human	hsa-miR-874-3p	miRNA	high glucose (HG)	diabetic vasculopathy	human aortic endothelial cells (HAECs)	high glucose (HG)	downregulated	28824448
9436	Human	hsa-miR-874-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31200256
9437	Human	hsa-miR-874-5p	miRNA	atropine	myopia	Human corneal epithelial cells	0.003% atropine treatment	dysregulated	31540331
9438	Human	hsa-miR-874-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	HOTAIR promoted MPP+-induced neuronal injury via modulating the miR-874-5p/ATG10 axis in SK-N-SH cells.	33013268
9439	Human	hsa-miR-876	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28723693
9440	Human	hsa-miR-876-3p	miRNA	rosiglitazone	insulin resistance (IR)	adipocytes	rosiglitazone treatment	Rosiglitazone treatment in CI-induced IR adipocytes drastically reduced miR-876-3p expression	30307150
9441	Human	hsa-miR-877	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
9442	Human	hsa-miR-877	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
9443	Human	hsa-miR-877-3p	miRNA	high glucose (HG)	autophagy	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680.	30957640
9444	Human	hsa-miR-877-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	human aortic vascular smooth muscle cells (HA-VSMCs) injury	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31957850
9445	Human	hsa-miR-877-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9446	Human	hsa-miR-877-3P	miRNA	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO)	vascular endothelial cells (VECs) autophagy and apoptosis	human vascular endothelial cells (VECs)	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment	3BDO promoted the expression of miR-877-3P in VECs under high glucose conditions.	30957640
9447	Human	hsa-miR-877-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	children serum samples	acetaminophen(APAP) treatment	upregulated in serum samples	29067470
9448	Human	hsa-miR-877-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
9449	Human	hsa-miR-877-5p	miRNA	acetaminophen (APAP)	acute liver failure (ALF)	serum	acetaminophen (APAP) treatment	hsa-miR-320a and hsa-miR-877-5p levels were significantly elevated in serum samples obtained from children with APAP overdose compared to health controls.	29067470
9450	Human	hsa-miR-885	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	human cardiomyocytes (HCMs)	hypoxia/reoxygenation (H/R) treatment	miR-885 in HCMs was markedly repressed after H/R stimulation.	31960416
9451	Human	hsa-miR-885	miRNA	hypoxia	prostate cancer	LNCaP cells; LNCaP cells exosomes	hypoxia treatment	upregulated	29568403
9452	Human	hsa-miR-885-3p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
9453	Human	hsa-miR-885-5p	miRNA	erythropoietin (EPO)	apoptosis	SH-SY5Y neuronal-like cells	EPO treatment	downregulated	25324845
9454	Human	hsa-miR-885-5p	miRNA	hepatitis C virus (HCV)	liver fibrosis	hepatoma cells	hepatitis C virus (HCV) infection	upregulated	26157120
9455	Human	hsa-miR-886	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
9456	Human	hsa-miR-886-3p	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
9457	Human	hsa-miR-886-5p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
9458	Human	hsa-miR-888-5p	miRNA	methyl donor S-Adenosylmethionine (AdoMet)	laryngeal squamous cell carcinoma (LSCC)	JHU-SCC-011 cells; HNO210 LSCC cells	methyl donor S-Adenosylmethionine (AdoMet) treatment	miR-888-5p Is Involved in S-Adenosylmethionine Antitumor Effects in Laryngeal Squamous Cancer Cells	33297397
9459	Human	hsa-miR-889	miRNA	arsenite	arsenite-induced carcinogenesis	HaCaT cells	arsenite exposure	upregulated	30167605
9460	Human	hsa-miR-889	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
9461	Human	hsa-miR-891a	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
9462	Human	hsa-miR-891a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
9463	Human	hsa-miR-891b	miRNA	enterovirus 71 (EV71)	apoptosis	Human rhabdomyosarcoma cells (RD)	EV71 infection	"host cells suppress lnc-IRAK3-3 to relieve lnc-IRAK3-3-sequestered miR-891b, restrain GADD45¦Â, and attenuate apoptosis in EV71 infection that prevent host cells from severe damages."	31099182
9464	Human	hsa-miR-892a	miRNA	melatonin	oral cancer	SAS cells; SCC9 cells	Melatonin treatment	Melatonin reduced the drug resistance and promoted the apoptosis of VCR-resistant oral cancer cells through the upregulation of microRNA-892a (miR-892a) and miR-34b-5p expressions.	31982774
9465	Human	hsa-miR-892a	miRNA	melatonin	vincristine (VCR) resistance	SAS cells; SCC9 cells	Melatonin treatment	upregulated	31982774
9466	Human	hsa-miR-892c-3p	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	upregulated	31549595
9467	Human	hsa-miR-9	miRNA	tetramethylpyrazine (TMP)	activation of hepatic stellate cells (HSCs)	hepatic stellate cells (HSCs)	were transfect TMP treatment	upregulated	25560232
9468	Human	hsa-miR-9	miRNA	daunorubicin	acute myeloid leukemia (AML)	"The AML cell lines HL-60, KG-1, THP-1 and Kasumi-1"	Daunorubicin (Dnr) treatment	downregulated	30745844
9469	Human	hsa-miR-9	miRNA	arsenite	angiogenesis	EA.hy926 cells	arsenic (As) exposure	downregulated	21503876
9470	Human	hsa-miR-9	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
9471	Human	hsa-miR-9	miRNA	N-(4-hydoxyphenyl)-retinamide (4HPR)	apoptosis	human retinal pigment epithelial (HRPE) cell	N-(4-hydoxyphenyl)-retinamide (4HPR) treatment	upregulated	20806079
9472	Human	hsa-miR-9	miRNA	proanthocyanidin	atherosclerosis (AS)	THP-1 cells	proanthocyanidins treatment	"proanthocyanidins suppressed the expression of ACAT1 via up-regulating the expression of miR-9, thus lessening the intracellular lipid accumulation and eventually inhibiting macrophage foam cell formation"	31967154
9473	Human	hsa-miR-9	miRNA	P. aeruginosa GroEL	bacterial infection	"A549 cells (human alveolar epithelial cells), THP-1 cells (human monocytes), and U937 cells (human monocytes)"	infect with P. aeruginosa GroEL treatment	downregulated	28031262
9474	Human	hsa-miR-9	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
9475	Human	hsa-miR-9	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
9476	Human	hsa-miR-9	miRNA	mechanical compression	breast cancer	MDA-MB-231 and BT-474 breast cancer cell lines	mechanical compression	downregulated	28252641
9477	Human	hsa-miR-9	miRNA	cigarette smoke (CS)	cell proliferation	na?ve and desialylated human alveolar epithelial cells (A549 cells)	cigarette smoke (CS) treatment	downregulated	29492899
9478	Human	hsa-miR-9	miRNA	dexamethasone (DEX)	cell proliferation	cigarette smoke-induced na?ve and desialylated human alveolar epithelial cells (A549 cells)	dexamethasone (DEX) treatment	upregulated	29492899
9479	Human	hsa-miR-9	miRNA	lipopolysaccharide (LPS)	cell proliferation	cigarette smoke-induced na?ve and desialylated human alveolar epithelial cells (A549 cells)	lipopolysaccharide (LPS) treatment	upregulated	29492899
9480	Human	hsa-miR-9	miRNA	staurosporine	cervical cancer (CC)	iPSCs	staurosporine treatment	downregulated	24143176
9481	Human	hsa-miR-9	miRNA	lipopolysaccharide (LPS)	cervical cancer (CC)	HeLa cells	lipopolysaccharide (LPS) treatment	upregulated	31450920
9482	Human	hsa-miR-9	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	hearts	high glucose treatment	downregulated	26898797
9483	Human	hsa-miR-9	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes cells (HPCs)	high glucose (HG) treatment	SOX2OT overexpression alleviates the HG-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis.	31301307
9484	Human	hsa-miR-9	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	miR-9 expression remarkably decreased	33721156
9485	Human	hsa-miR-9	miRNA	dopaminergic (DA) neuron differentiation medium	dopaminergic (DA) neuron differentiation	human trabecular meshwork mesenchymal stem cells	"the induction medium was prepared by adding 10 ¦ÌM retinoic acid (RA) (Sigma, USA), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma, USA) and 0.5 mM N6,2¡ä-O-Dibutyryladenosine 3¡ä,5¡ä-cyclic monophosphate (dbcAMP) (Sigma, USA) to 10% FBS supplemented DMEM."	upregulated	31173848
9486	Human	hsa-miR-9	miRNA	enterovirus 71 (EV71)	endometrial cancer (EC)	"293T, Vero, RD, HT-29, HeLa, and THP-1 cells"	Enterovirus 71 (EV71) infection	downregulated	30186747
9487	Human	hsa-miR-9	miRNA	nicotine	epithelial-mesenchymal transition (EMT)	"head and neck squamous cell carcinoma cell lines, UMSCC-10B ;HN-1"	nicotine treatment	upregulated	23300583
9488	Human	hsa-miR-9	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, YES2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	28539329
9489	Human	hsa-miR-9	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
9490	Human	hsa-miR-9	miRNA	GSK1059615	gastric cancer (GC)	AGS cells and primary human GC cells	GSK1059615 treatment	downregulated	30765226
9491	Human	hsa-miR-9	miRNA	sulforaphane (SFN)	gastric cancer (GC)	MKN45 cells	sulforaphane treatment	upregulated	30096452
9492	Human	hsa-miR-9	miRNA	sulforaphane (SFN)	gastric cancer (GC)	HF2FF cells	sulforaphane treatment	upregulated	30096452
9493	Human	hsa-miR-9	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 glioma cells	temozolomide (TMZ) treatment	upregulated	31186688
9494	Human	hsa-miR-9	miRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	SCC90 cells; SCC47 cells; SCC104 cells	human papillomavirus (HPV) treatment	miR-9 was upregulated in HPV + HNSCC cells.	32120025
9495	Human	hsa-miR-9	miRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	"exosome of SCC90 cells, SCC47 cells and SCC104 cells"	human papillomavirus (HPV) treatment	miR-9 was upregulated in HPV + HNSCC exosomes.	32120025
9496	Human	hsa-miR-9	miRNA	angiotensin II (Ang II)	hypertension	human umbilical vein endothelial cells	angiotensin II (Ang II) treatment	microRNA-9 (miR-9) suppressed angiotensin II-induced apoptosis and enhanced proliferation in human umbilical vein endothelial cells.	31345003
9497	Human	hsa-miR-9	miRNA	high glucose (HG)	inflammation	smooth muscle cell line C-12511	high glucose treatment	downregulated	31122000
9498	Human	hsa-miR-9	miRNA	lipopolysaccharide (LPS)	inflammation	HK-2 cells	lipopolysaccharides (LPS) treatment	downregulated	31432701
9499	Human	hsa-miR-9	miRNA	molecular hydrogen	inflammatory injury	Retinal Microglia cells	Molecular hydrogen?treatment	downregulated	23826519
9500	Human	hsa-miR-9	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	infect with IAV	upregulated	27322373
9501	Human	hsa-miR-9	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	The oxygen-glucose deprivation (OGD) in SH-SY5Y cells significantly reduced miR-9 expression	30539420
9502	Human	hsa-miR-9	miRNA	glucosamine	ischemic stroke (IS)	OGD-treated SH-SY5Y cells	Glucosamine treatment	upregulated	30539420
9503	Human	hsa-miR-9	miRNA	hypoxia	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	30539420
9504	Human	hsa-miR-9	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	leukemia	UoCM1 and K562 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31054042
9505	Human	hsa-miR-9	miRNA	VitB12	methylmalonic acidemia (MMA)	MMA patient	VitB12 treatment	upregulated	24798023
9506	Human	hsa-miR-9	miRNA	ultraviolet (UV) irradiation	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	UV light treatment	upregulated	25891118
9507	Human	hsa-miR-9	miRNA	retinoic acid (RA)	nervous system cancers	SK-N-BE(2)-C £»SH SY5Y??cells?;SH-EP cells£» HEK 293T cells	retinoic acid treatment	upregulated	22848373
9508	Human	hsa-miR-9	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	A549 cells	ionizing radiation (IR) treatment	"microRNA-9 overexpression increased the radiosensitivity of A549 cells by inhibiting cell activity and migration, and by increasing apoptosis."	31158449
9509	Human	hsa-miR-9	miRNA	prophylactic cranial irradiation (PCI)	non-small cell lung cancer (NSCLC)	A549 cells	prophylactic cranial irradiation (PCI)? treatment	levels of miR-9 secreted by irradiated M1 microglia significantly increased	33758511
9510	Human	hsa-miR-9	miRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	A549 and HCC827 cells	TGF-¦Â1 treatment	upregulated	28266181
9511	Human	hsa-miR-9	miRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	"cell lines A549, NCI-H1299 and HCC827"	5 ng/ml TGF-¦Â1 for 24 h treatment	upregulated	29118814
9512	Human	hsa-miR-9	miRNA	alkannin	oral squamous cell carcinoma (OSCC)	CAL-27 and SCC-9 cells	alkannin (ALK) treatment	downregulated	31349748
9513	Human	hsa-miR-9	miRNA	hydroxytyrosol (HT)	osteoarthritis (OA)	human primary and C-28/I2 chondrocytes	were pre-treated with 100 ¦ÌM HT 30 min before 100 ¦ÌM H2O2	upregulated	27914878
9514	Human	hsa-miR-9	miRNA	IL-1¦Â	osteoarthritis (OA)	OA chondrocytes	IL-1¦Â treatment	upregulated	25917063
9515	Human	hsa-miR-9	miRNA	TNF-a and MMP13	osteoarthritis (OA)	human OA cartilage and bone	TNF-a and MMP13 treatment	upregulated	19008124
9516	Human	hsa-miR-9	miRNA	vorinostat (SAHA)	osteoarthritis (OA)	human OA chondrocytes	SAHA treatment	downregulated	27404795
9517	Human	hsa-miR-9	miRNA	estradiol-17¦Â (E2)	osteosarcoma (OS)	Human OS cell line MG-63	estradiol-17¦Â (E2) treatment	upregulated	25592968
9518	Human	hsa-miR-9	miRNA	curcumin (Cur)	ovarian cancer (OC)	SKOV3 cells	curcumin treatment	upregulated	24870723
9519	Human	hsa-miR-9	miRNA	propofol (PPF)	ovarian cancer (OC)	ES-2 cells	propofol treatment	upregulated	27982283
9520	Human	hsa-miR-9	miRNA	platelet derived growth factor-BB (PDGF-BB)	prion infection	U87 glioblastoma cells and neonatal cardiomyocytes	PDGFR-beta treatment	upregulated	21684288
9521	Human	hsa-miR-9	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
9522	Human	hsa-miR-9	miRNA	platelet derived growth factor-BB (PDGF-BB)	prostate cancer	neuronal progenitor cells	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	24336080
9523	Human	hsa-miR-9	miRNA	tumor resection	squamous cell carcinoma (SQCC) and adenocarcinoma (ADC£©	SQCC and ADC patients	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28634901
9524	Human	hsa-miR-9	miRNA	butyrate and inulin	type 2 diabetes mellitus (T2DM)	peripheral blood mononuclear cells (PBMCs)	butyrate and inulin treatment	butyrate and concomitant use of butyrate and inulin caused a significant increase in the fold change of miR-146a and miR-9 compared with the placebo group.	32315958
9525	Human	hsa-miR-9	miRNA	human immunodeficiency virus (HIV)-1 and methamphetamine	uveal melanoma	human frontal cortex	human immunodeficiency virus (HIV) and methamphetamine treatment	significantly increased expression of the neuron-specific miR-9	23508624
9526	Human	hsa-miR-9	miRNA	ultraviolet (UV) irradiation	vitiligo repigmentation	HaCaT keratinocytes	UVB irradiation treatment	downregulated	31499059
9527	Human	hsa-miR-9*	miRNA	hydroxychloroquine	apoptosis	cervical cancer SiHa cells	HCQ treatment	downregulated	24944668
9528	Human	hsa-miR-9*	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
9529	Human	hsa-miR-9-1	miRNA	decitabine	acute myeloid leukemia (AML)	RUNX1-RUNX1T1 (+) AML cell lines	decitabine£¬trichostatin A	upregulated	27770540
9530	Human	hsa-mir-92	miRNA	estrogen receptor-¦Á	breast cancer	breast cancer cells	The estrogen receptor-¦Á treatment	upregulated	19706389
9531	Human	hsa-mir-92	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
9532	Human	hsa-miR-92	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
9533	Human	hsa-miR-92	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	upregulated	17653614
9534	Human	hsa-miR-92	miRNA	platelet derived growth factor-BB (PDGF-BB)	vascular restenosis	human vascular smooth muscle cells (VSMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	31933825
9535	Human	hsa-miR-923	miRNA	diesel exhaust particle (DEP)	bronchial epithelial cell cancer	Primary human bronchial epithelial cells	diesel exhaust particle (DEP) exposure	upregulated	20049127
9536	Human	hsa-miR-923	miRNA	bostrycin	lung cancer	human lung carcinoma A549 cells	bostrycin treatment	upregulated	21303527
9537	Human	hsa-miR-923	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
9538	Human	hsa-miR-92-3p	miRNA	silybin	hepatoprotective	HepG2 cells	Silybin treatment	downregulated	31058823
9539	Human	hsa-miR-92a	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
9540	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	33015189
9541	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	31841757
9542	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	pulmonary microvascular endothelial cells (HPMEC); A549 cells	lipopolysaccharide (LPS) treatment	upregulated	32534035
9543	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	Inhibition of microRNA-92a ameliorates lipopolysaccharide-induced endothelial barrier dysfunction by targeting ITGA5 through the PI3K/Akt signaling pathway in human pulmonary microvascular endothelial cells	31841757
9544	Human	hsa-miR-92a	miRNA	hyperbaric oxygen (HBO)	angiogenesis	human coronary artery endothelial cells (HCAECs)	Hyperbaric oxygen (HBO) treatment	downregulated	30301563
9545	Human	hsa-miR-92a	miRNA	triptolide (TPL)	angiogenesis	human dermal microvascular endothelial cells (HMEC-1)	triptolide (TPL) treatment	upregulated	31691162
9546	Human	hsa-miR-92a	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
9547	Human	hsa-miR-92a	miRNA	serum	apoptosis	vascular smooth muscle cell (VSMC)	serum treatment	upregulated	24705900
9548	Human	hsa-miR-92a	miRNA	ML-7 (an inhibitor of myosin light chain kinase)	atherosclerosis (AS)	Human aortic smooth muscle cells (HASMCs)	ML-7 (an inhibitor of myosin light chain kinase) treatment	downregulated	30907506
9549	Human	hsa-miR-92a	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
9550	Human	hsa-miR-92a	miRNA	butyrate	colorectal cancer (CRC)	human colon cancer cells	butyrate treatment	downregulated	26463716
9551	Human	hsa-miR-92a	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	RKO cells	kaempferol-3- O-glycoside treatment	downregulated	31441682
9552	Human	hsa-miR-92a	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	colon cancer cell line (RKO)	kaempferol-3-O-glycoside treatment	downregulated	31441682
9553	Human	hsa-miR-92a	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-92a was downregulated in resistant patients when compared with sensitive patients	33072545
9554	Human	hsa-miR-92a	miRNA	advanced glycation end products (AGEs) and oxidized low-density lipoprotein (ox-LDL)	diabetes mellitus (DM)	human umbilical vein endothelial Cells (HUVEC£©	AGEs and oxidized low-density lipoprotein	upregulated	28683566
9555	Human	hsa-miR-92a	miRNA	"H2O2, angiotensin II (AngII) and oxidized low-density lipoprotein (ox-LDL)"	endothelial dysfunction	HUVECs	"with H2O2, Ang II, and oxidized LDL (ox-LDL) treatment"	upregulated	25550450
9556	Human	hsa-miR-92a	miRNA	swainsonine (SW)	glioblastoma multiforme (GBM)	U251 and LN444 cells	swainsonine (SW) treatment	downregulated	30890138
9557	Human	hsa-miR-92a	miRNA	alkannin	hepatocellular carcinoma (HCC)	Huh7 and Hep3B2.1-7 cells	alkannin (ALK) treatment	downregulated	30909147
9558	Human	hsa-miR-92a	miRNA	human cytomegalovirus (HCMV; human herpesvirus 5)	human cytomegalovirus (HCMV) infection	HFFF cells	human cytomegalovirus (HCMV; human herpesvirus 5) treatment	hsa-miR-92a downregulated	21471310
9559	Human	hsa-miR-92a	miRNA	sulfur mustard (SM)	lung diseases	plasma and serum	Sulfur mustard (SM) treatment	downregulated	26525353
9560	Human	hsa-miR-92a	miRNA	AZD6244	lymphoma	"Raji, MOLT4 and 293T cells w"	AZD6244 treatment	downregulated	24375836
9561	Human	hsa-miR-92a	miRNA	berberine (BBR)	multiple myeloma (MM)	RPMI-8266 cells; U266 cells	berberine (BBR) treatment	Berberine downregulated miR-92a cluster expression in multiple myeloma (MM) cells.	29687521
9562	Human	hsa-miR-92a	miRNA	TGF-¦Â1	neointimal hyperplasia	human umbilical vein endothelial cells (HUVEC)	TGF-¦Â1 treatment	TGF-¦Â1 treatment of HUVECs significantly increased miR-92a expression and induced EndMT	33253710
9563	Human	hsa-miR-92a	miRNA	hyperbaric oxygen (HBO)	neovascularization	human coronary artery endothelial cells (HCAECs)	hyperbaric oxygen (HBO) treatment	downregulated	30301563
9564	Human	hsa-miR-92a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
9565	Human	hsa-miR-92a	miRNA	TGF-¦Â1	osteoarthritis (OA)	human osteoarthritis synovial fibroblasts (OASFs)	TGF-¦Â1 treatment	downregulated	31232696
9566	Human	hsa-miR-92a	miRNA	integrin ¦Á5	ovarian cancer (OC)	"The ovarian cancer cell lines, A2780£» CaOV3 cells£» RMUG-S£» OVISE£»and RMG-1 cell lines£»SKOV3ip1 cells £»HeyA-8 cell"	integrin ¦Á5 treatment	miR-92a overexpression	23499550
9567	Human	hsa-miR-92a	miRNA	advanced glycation end product (AGE)	oxidative stress	human umbilical vein endothelial cells (HUVECs)	advanced glycation end products (AGEs) treatment	upregulated	28683566
9568	Human	hsa-miR-92a	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28683566
9569	Human	hsa-miR-92a	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
9570	Human	hsa-miR-92a	miRNA	TGF-¦Â1	vein grafts	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â1 treatment	we show that TGF-¦Â1 treatment of HUVECs significantly increased miR-92a expression and induced EndMT	33253710
9571	Human	hsa-miR-92a-1-5p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
9572	Human	hsa-miR-92a-1-5p	miRNA	bile acids	gastric intestinal metaplasia (IM)	"BGC823, GES-1, SGC7901, MKN28, MKN45 and AGS cells"	bile acids treatment	upregulated	30635407
9573	Human	hsa-miR-92a-1-5p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
9574	Human	hsa-miR-92a-3p	miRNA	H2O2	angiogenesis	human umbilical vein endothelial cells (HUVECs) exosomes	H2O2 treatment	Primary miR-92a (pri-miR-92a-1) was decreased in Exo-H2O2-treated HUVECs.	32901851
9575	Human	hsa-miR-92a-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
9576	Human	hsa-miR-92a-3p	miRNA	hypoxia	cell differentiation	human (P3 and U87) glioma cell lines	hypoxia induce	upregulated	30536597
9577	Human	hsa-miR-92a-3p	miRNA	¦Ã-rays	ionizing radiation (IR) injury	whole blood samples from healthy donors extracellular vesicles (ELVs)	irradiate with 2 Gy gamma rays treatment	upregulated	28264626
9578	Human	hsa-miR-92a-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
9579	Human	hsa-miR-92a-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	cardiomyocytes	Doxorubicin (Dox) treatment	Dox-treated cardiomyocytes expressed a higher level of miR-92a-3p.	32384281
9580	Human	hsa-miR-92a-3p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
9581	Human	hsa-miR-92a-3p	miRNA	"MS-275, a histone deacetylase inhibitor"	melanoma	TRAIL-resistant or TRAIL-sensitive cutaneous and uveal melanoma cells	MS-275 treatment	downregulated	27620505
9582	Human	hsa-miR-92a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes (PHCs)	IL-1¦Â	downregulated	29241192
9583	Human	hsa-miR-92a-3p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-92a-3p was downregulated in treated patients when compared with untreated patients.	29523324
9584	Human	hsa-miR-92b	miRNA	IL-13	asthma	human bronchial epithelial cells (NHBE)	IL-13 treatment	upregulated	31386204
9585	Human	hsa-miR-92b	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
9586	Human	hsa-miR-92b-3p	miRNA	hypoxia	cell proliferation	Human primary pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	upregulated	30518907
9587	Human	hsa-miR-92b-3p	miRNA	deoxycholic acid (DCA)	gallbladder cancer (GBC)	NOZ cells; GBC-SD cells	deoxycholic acid (DCA) treatment	DCA treatment decreased miR-92b-3p expression.	32514152
9588	Human	hsa-miR-92b-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
9589	Human	hsa-miR-92b-3p	miRNA	dipogenic differentiation mixture (MDI)	liver fibrosis	LX-2 cells	dipogenic differentiation mixture (MDI) treatment	"We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1. However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)."	33618248
9590	Human	hsa-miR-92b-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	"We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1 However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)"	33618248
9591	Human	hsa-miR-92b-3p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
9592	Human	hsa-miR-92b-3p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
9593	Human	hsa-miR-93	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33505213
9594	Human	hsa-miR-93	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-10A cells;T47D cells	estradiol-17¦Â (E2) treatment	upregulated	23492819
9595	Human	hsa-miR-93	miRNA	vitamin C	breast cancer	MCF-10A cells;T47D cells	vitamin C treatment	downregulated	23492819
9596	Human	hsa-miR-93	miRNA	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC)	chronic inflammatory diseases	human umbilical vein endothelial cells (HUVECs) exosomes	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment	upregulated	29161413
9597	Human	hsa-miR-93	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
9598	Human	hsa-miR-93	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells; HCT116 cells	ionizing radiation (IR) treatment	HOTAIR knockdown enhances radiosensitivity through regulating microRNA-93/ATG12 axis in colorectal cancer.	32144238
9599	Human	hsa-miR-93	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	miR-93 was dramatically decreased in TGF-¦Â1-stimulated HK2 cells	29551286
9600	Human	hsa-miR-93	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	H19 played an important role in regulating inflammatory processes in retinal endothelial cells under high-glucose condition through modulating miR-93/XBP1s axis.	31953562
9601	Human	hsa-miR-93	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Primary human retinal pigment epithelium (RPE) cells and ARPE-19 cells	high glucose (HG) treatment	"lncRNA MEG3 depresses HG-induced apoptosis and inflammation of RPE via miR-93/Nrf2 axis, providing a novel perspective on the genesis and development of DR."	32473920
9602	Human	hsa-miR-93	miRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	downregulated	30544204
9603	Human	hsa-miR-93	miRNA	cigarette smoke (CS)	emphysema	HBE cells	Cigarette smoke (CS) exposure	upregulated	33660100
9604	Human	hsa-miR-93	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 and T98G cells	temozolomide (TMZ) treatment	miR-93 and -193 decreased cell cycling quiescence and induced resistance to TMZ.	30853911
9605	Human	hsa-miR-93	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	human primary hepatocytes isolated from humanized chimeric uPA/SCID mice as efficient sources	hepatitis B virus (HBV) infection	downregulated	25026299
9606	Human	hsa-miR-93	miRNA	radiotherapy	head and neck squamous cell carcinoma (HNSCC)	neck squamous cell carcinoma patients saliva samples	radiotherapy treatment	upregulated in saliva samples	28677748
9607	Human	hsa-miR-93	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
9608	Human	hsa-miR-93	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	influenza A virus (IAV) infection significantly inhibited miR-93 expression in alveolar epithelial type II cells through RIG-I/JNK pathway.	32652502
9609	Human	hsa-miR-93	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	31432162
9610	Human	hsa-miR-93	miRNA	H2O2	mitophagy	HeLa and HEK 293T cells	H2O2 treatment	"We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions."	33627622
9611	Human	hsa-miR-93	miRNA	diet	obesity	Plasma	diet treatment	"Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss."	32439373
9612	Human	hsa-miR-93	miRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin (DPP) treatment	upregulated	31128026
9613	Human	hsa-miR-93	miRNA	berberine (BBR)	ovarian cancer (OC)	cisplatin resistant A2780 cell lines	berberine (BBR) treatment	upregulated	26087719
9614	Human	hsa-miR-93	miRNA	L-tetrahydropalmatine (L-THP)	ovarian cancer (OC)	A2780 cells	L-Tetrahydropalmatine (L-THP) treatment	downregulated	31128026
9615	Human	hsa-miR-93	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
9616	Human	hsa-miR-93	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
9617	Human	hsa-miR-93	miRNA	curcumin (Cur)	peripheral arterial disease (PAD)	Human umbilical vein endothelial cells (HUVECs)	curcumin treatment	upregulated	30651865
9618	Human	hsa-miR-93	miRNA	hypoxia	peripheral arterial disease (PAD)	EA.hy926 endothelial cells	hypoxia induce	upregulated	31059098
9619	Human	hsa-miR-93	miRNA	green tea polysaccharide (GTP)	prostate cancer	PC-3 cells	green tea (Camellia sinensis) polysaccharide (GTP) treatment	downregulated	30342140
9620	Human	hsa-miR-93	miRNA	green tea polysaccharide (GTP)	prostate cancer	PC-3 cells	green tea polysaccharide (GTP) treatment	downregulated	30342140
9621	Human	hsa-miR-93	miRNA	hypoxia	prostate cancer	LNCaP cells	5% O2 treatment	upregulated	24135225
9622	Human	hsa-miR-93	miRNA	TGF-¦Â	renal cell carcinoma (RCC)	renal cancer cells	TGF-¦Â treatment	downregulated	25183046
9623	Human	hsa-miR-93	miRNA	salvianolic acid B (Sal B)	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	Sal B treatment	upregulated	25094038
9624	Human	hsa-miR-93	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	TGF-¦Â1 treatment	downregulated	25094038
9625	Human	hsa-miR-93	miRNA	leptin	rheumatoid arthritis (RA)	human osteoblasts	leptin treatment	downregulated	25198901
9626	Human	hsa-miR-9-3	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
9627	Human	hsa-miR-9-3	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	lung cancer	NSCLC A549 cells	5-aza-20-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A treatment	upregulated	22282464
9628	Human	hsa-miR-9-3	miRNA	sulforaphane (SFN)	lung cancer	lung cancer A549 cells	Sulforaphane (SFN) treatment	upregulated	29525530
9629	Human	hsa-miR-933	miRNA	27-hydroxycholesterol (27-OHC)	Alzheimer's disease (AD)	microvascular endothelial cell (HMVEC)	27 hydroxycholesterol (27-OHC) treatment	upregulated	29966198
9630	Human	hsa-miR-933	miRNA	ursolic acid (UA)	breast cancer	MCF-7 cells	usnic acid treatment	downregulated	31549595
9631	Human	hsa-miR-933	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
9632	Human	hsa-miR-933	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9633	Human	hsa-miR-93-3p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
9634	Human	hsa-miR-934	miRNA	alcohol	head and neck squamous cell carcinoma (HNSCC)	normal oral keratinocytes	alcohol exposure	upregulated	26472042
9635	Human	hsa-miR-935	miRNA	intermediate-sized hyaluronan (INT-HA)	macrophage polarization	Primary human macrophages derived from peripheral blood monocytes	Intermediate-sized hyaluronan (INT-HA) treatment	downregulated	30341559
9636	Human	hsa-miR-935	miRNA	intermediate-sized hyaluronan (INT-HA)	macrophage polarization	Primary human macrophages	Intermediate-sized hyaluronan (INT-HA) treatment	downregulated	30341559
9637	Human	hsa-miR-93-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	Endothelial progenitor cells-secreted extracellular vesicles containing microRNA-93-5p confer protection against sepsis-induced acute kidney injury via the KDM6B/H3K27me3/TNF-¦Á axis	32679234
9638	Human	hsa-miR-93-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	?human renal tubular epithelial HK-2 cells	?high glucose (HG) induce	silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN	31545928
9639	Human	hsa-miR-93-5p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	"serum of patients with HCV-1b infection, Huh7 cells"	hepatitis C virus (HCV) infection	upregulated	29375208
9640	Human	hsa-miR-93-5p	miRNA	neodymium oxide (Nd2O3)	inflammation	human bronchial epithelial cells (16HBE)	neodymium oxide (Nd2O3) treatment	upregulation of circ_0039411 mediated Nd2O3-induced inflammation and dysfunction by sponging miR-93-5p.	30903189
9641	Human	hsa-miR-93-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	cultured primary chondrocyte	IL-1¦Â treatment	downregulated	30930294
9642	Human	hsa-miR-93-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
9643	Human	hsa-miR-939	miRNA	monocyte chemoattractant protein-1 (MCP-1)	complex regional pain syndrome (CRPS)	THP-1 monocytes secreted small extracellular vesicles (sEVs)	monocyte chemoattractant protein-1 (MCP-1) treatment	upregulated	31489147
9644	Human	hsa-miR-939	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	downregulated	27709720
9645	Human	hsa-miR-939	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9646	Human	hsa-miR-93a	miRNA	H2O2	apoptosis	vascular smooth muscle cell (VSMC)	H2O2 treatment	downregulated	24705900
9647	Human	hsa-miR-9-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary artery disease (CAD)	endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	miR-9-3p was downregulated by oxLDL treatment in endothelial cell.	30485507
9648	Human	hsa-miR-9-3p	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
9649	Human	hsa-miR-9-3p	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
9650	Human	hsa-miR-940	miRNA	dasatinib	chronic myeloid leukemia (CML)	CML cell line K562	dasatinib treatment	downregulated	30814857
9651	Human	hsa-miR-940	miRNA	acute exercise	congestive heart failure (CHF)	CHF patients	acute exercise treatment	upregulated	26799589
9652	Human	hsa-miR-940	miRNA	hypoxia	epithelial ovarian cancer (EOC)	macrophages of human epithelial ovarian cancer (EOC) exosomes	hypoxia treatment	upregulated	28586039
9653	Human	hsa-miR-940	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
9654	Human	hsa-miR-941	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	T-HESC; primary human endometrial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-941 activates Nrf2 cascade to protect human endometrial cells from OGDR-induced oxidative stress and programmed necrosis	32102665
9655	Human	hsa-miR-941	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	upregulated	32587527
9656	Human	hsa-miR-942	miRNA	"chlorpromazine, haloperidol and clozapine"	psychosis	JM-Jurkat T-lymphocytes	"chlorpromazine, haloperidol and clozapine treatment"	dysregulated	24480591
9657	Human	hsa-miR-942	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
9658	Human	hsa-miR-942	miRNA	oxidized low density lipoprotein (ox-LDL)	carotid artery atherosclerosis	HCtAEC | Human Carotid Artery Endothelial Cells; THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LncRNA ZEB1-AS1 contributed to ox-LDL-mediated injury and apoptosis of HCtAEC cells and the oxidative stress and inflammation of THP-1 cells through up-regulating HMGB1 via sponging miR-942.	31962131
9659	Human	hsa-miR-942	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	human hepatoma cell line HLCZ01	infectious HCV isolate JFH1 treatment	downregulated	24727952
9660	Human	hsa-miR-942	miRNA	lipopolysaccharide (LPS)	liver fibrosis	human primary hepatic stellate cells; LX-2 cells	lipopolysaccharide (LPS) treatment	upregulated	30097701
9661	Human	hsa-miR-942	miRNA	TGF-¦Â1	liver fibrosis	human primary hepatic stellate cells; LX-2 cells	TGF-¦Â1 treatment	upregulated	30097701
9662	Human	hsa-miR-942-5p	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	MiR-942-5p expression was reduced in lipopolysaccharide (LPS)-treated HK-2 cells.	32572890
9663	Human	hsa-miR-944	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
9664	Human	hsa-miR-95	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
9665	Human	hsa-miR-95	miRNA	glargine	pancreatic cancer (PC)	pancreatic cancer cells	glargine treatment	upregulated	22690071
9666	Human	hsa-miR-95	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
9667	Human	hsa-miR-9500	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
9668	Human	hsa-miR-95-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
9669	Human	hsa-miR-9-5p	miRNA	traffic-originated PM2.5 organic component (tPo)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	Traffic-related air pollution particulate matter 2.5 (TRAPM2.5) treatment	LncRNA RP11-86H71 promotes airway inflammation induced by TRAPM25 by acting as a ceRNA of miRNA-9-5p to regulate NFKB1 in HBECS	32665564
9670	Human	hsa-miR-9-5p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
9671	Human	hsa-miR-9-5p	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
9672	Human	hsa-miR-9-5p	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
9673	Human	hsa-miR-9-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	31500865
9674	Human	hsa-miR-9-5p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
9675	Human	hsa-miR-9-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	29073595
9676	Human	hsa-miR-9-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30826419
9677	Human	hsa-miR-9-5p	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
9678	Human	hsa-miR-9-5p	miRNA	lithium (Li)	spinal cord injury (SCI)	SH-SY5Y cells	lithium treatment	Lithium treatment rescued the upregulation of BDNF-AS expression and downregulated of miR-9-5p expression induced by H2O2 in SH-SY5Y cells.	33464390
9679	Human	hsa-miR-9-5p	miRNA	high glucose (HG)	vascular endothelial cell injury	human umbilical vascular endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	30716366
9680	Human	hsa-miR-96	miRNA	curcumin (Cur)	breast cancer	T47D breast cancer cells	curcumin treatment	48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells.	30467667
9681	Human	hsa-miR-96	miRNA	coffee	colorectal cancer (CRC)	Caco-2 human colon carcinoma cells	coffee treatment	upregulated	28693281
9682	Human	hsa-miR-96	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1	32765688
9683	Human	hsa-miR-96	miRNA	cisplatin and doxorubicin	gastric cancer (GC)	SGC7901 cells	cisplatin and doxorubicin treatment	treatment with a low dose of either chemotherapeutic agent induced miR-96 expression.	30128023
9684	Human	hsa-miR-96	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	293A and 293T cells	infect with HSV-1	upregulated	28783105
9685	Human	hsa-miR-96	miRNA	mitochondrial dysfunction	insulin resistance (IR)	SK-Hep1 cells (ATCC HTB-52)	mitochondrial dysfunction treatment	upregulated	23583389
9686	Human	hsa-miR-96	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
9687	Human	hsa-miR-96	miRNA	hyperoxia	oxygen-induced retinopathy (OIR)	human retinal microvascular endothelial cells (HRMEC)	hyperoxia treatment	MicroRNA-96 Promotes Vascular Repair in Oxygen-Induced Retinopathy-A Novel Uncovered Vasoprotective Function.	32116694
9688	Human	hsa-miR-96	miRNA	hypoxia	prostate cancer	prostate cancer cell lines LNCaP;22Rv1 cells	hypoxia treatment	upregulated	25333253
9689	Human	hsa-miR-96	miRNA	carbon black nanoparticle (CBNP)	lung fibrosis	human bronchial epithelial (16HBE) cells	carbon black nanoparticle (CBNP) treatment	downregulated	31683435
9690	Human	hsa-miR-96	miRNA	light	retinal injury	retinal pigment epithelial (RPE) cells	light treatment	upregulated	25955435
9691	Human	hsa-miR-96	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
9692	Human	hsa-miR-96-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32342116
9693	Human	hsa-miR-96-5p	miRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	human AML cell lines HL60 and THP-1	cytarabine (Ara-C) treatment	"miR-96 downregulated abolished the effects of MALAT1 knockdown on the proliferation, apoptosis, Ara-C sensitivity in AML cells."	30970520
9694	Human	hsa-miR-96-5p	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	autophagy	human HTR-8/SVneo (HTR) cells	Titanium dioxide nanoparticles (TiO2 NPs) treatment	upregulated	30345998
9695	Human	hsa-miR-96-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
9696	Human	hsa-miR-96-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
9697	Human	hsa-miR-96-5p	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	The expression of miR-96-5p were significantly increased in the GAS5 knockdown group The level of miR-96-5p was downregulated in the renal tissues of DM mice miR-96- 5p mimic downregulated GAS5 expression	31810140
9698	Human	hsa-miR-96-5p	miRNA	sanguinarine	gastric cancer (GC)	BGC-823 cells	sanguinarine treatment	downregulated	31243669
9699	Human	hsa-miR-96-5p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
9700	Human	hsa-miR-96-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
9701	Human	hsa-miR-96-5p	miRNA	malathion	organophosphate-induced cytotoxicity	HK-2 cells	Malathion treatment	Malathion decreased HK-2 cell viability and the expression of miR-96-5p in a dose- and time-dependent manner.	32897819
9702	Human	hsa-miR-96-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
9703	Human	hsa-miR-96-5p	miRNA	hypoxia	pancreatic cancer (PC)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	hypoxic exosomal UCA1 could promote angiogenesis and tumor growth through the miR-96-5p/AMOTL2/ERK1/2 axis	32942233
9704	Human	hsa-miR-96-5p	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	placental development	"human trophoblast-derived cell, HTR8-Svneo"	Titanium dioxide nanoparticles (TiO2 NPs) treatment	upregulated	31226636
9705	Human	hsa-miR-96-5p	miRNA	angiotensin II (Ang II)	"proliferation, migration, and apoptosis of VSMCs"	vascular smooth muscle cell (VSMC)	angiotensin II (Ang II) treatment	miR-96-5p was downregulated in Ang II-induced VSMCs.	32045906
9706	Human	hsa-miR-96-5p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	miR-96-5p targets FN1 and alleviates TGF-¦Â1-induced fibrosis in HK-2 cells	31810140
9707	Human	hsa-miR-98	miRNA	cisplatin (DDP)	cell death	A549 cell	cisplatin (DPP) treatment	downregulated	21880462
9708	Human	hsa-miR-98	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	human umbilical vein ECs (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28565756
9709	Human	hsa-miR-98	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
9710	Human	hsa-miR-98	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
9711	Human	hsa-miR-98	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
9712	Human	hsa-miR-98	miRNA	TGF-¦Â1	cardiac fibrosis	human cardiac fibroblasts (HCFs)	TGF-¦Â1 treatment	downregulated in a time- and concentration-dependent manner	28251559
9713	Human	hsa-miR-98	miRNA	cryptosporidium parvum	cryptosporidium parvum infection	"C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)"	cryptosporidium parvum? infection	downregulated	20486857
9714	Human	hsa-miR-98	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	"glioma cell lines (U87, U251, U373 and SHG44)"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29436585
9715	Human	hsa-miR-98	miRNA	hypoxia	inflammation	human Aortic Smooth Muscle Cells (hASMCs)	Hypoxia treatment	downregulated	26045772
9716	Human	hsa-miR-98	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cells (BMVEC)	oxygen-glucose deprivation (OGD) treatment	downregulated	31601141
9717	Human	hsa-miR-98	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
9718	Human	hsa-miR-98	miRNA	curcumin (Cur)	lung cancer	lung cancer cell line A549	curcumin treatment	upregulated	28587210
9719	Human	hsa-miR-98	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	ANRIL knockdown inhibited the development of DDP resistance by upregulating miR-98.	32705261
9720	Human	hsa-miR-98	miRNA	TNF-a and MMP13	osteoarthritis (OA)	human OA cartilage and bone	TNF-a and MMP13 treatment	upregulated	19008124
9721	Human	hsa-miR-98	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	human synoviocytes (HS) cell line	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31077735
9722	Human	hsa-miR-98-5p	miRNA	H2O2	acute myocardial infarction (AMI)	Human myocardial cell line (AC16)	H2O2 treatment	downregulated	32888161
9723	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33542956
9724	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33249762
9725	Human	hsa-miR-98-5p	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	NCI-H460 cells and another kind of NSCLC cells	EGCG treatment	upregulated	24712372
9726	Human	hsa-miR-98-5p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
9727	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"The expression of OIP5-AS1 was upregulated, while miR-98-5p was downregulated in ox-LDL-induced human umbilical vein endothelial cells (HUVECs)."	32990894
9728	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33249762
9729	Human	hsa-miR-98-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"human glioma cell lines (U87, U251, LN229, A172)"	temozolomide (TMZ) treatment	"downregulated FOXD2-AS1 repressed invasion, proliferation, migration and drug resistance of drug-resistant glioma cells while stimulating their apoptosis via increasing miR-98-5p and inhibiting CPEB4 expression."	31770107
9730	Human	hsa-miR-98-5p	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
9731	Human	hsa-miR-98-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells	sorafenib treatment	downregulated	32821157
9732	Human	hsa-miR-98-5p	miRNA	¦Ã- Mangostin (¦Ã-MS)	osteoarthritis (OA)	SW983 cells	¦Ã- Mangostin (¦Ã-MS) treatment	upregulated	32302289
9733	Human	hsa-miR-98-5p	miRNA	osteogenic differentiation medium	osteogenesis	bone marrow-derived mesenchymal stem cells (BMMSCs)	osteogenic-inducing medium [10% FBS; 5 mM L-glycerophosphate; 100 nM dexamethasone (Sigma-Aldrich; Merck KGaA) and 50 mg/ml ascorbic acid (Sigma-Aldrich; Merck KGaA)] treatment	downregulated	31555368
9734	Human	hsa-miR-98-5p	miRNA	osteogenic differentiation medium	osteogenesis	bone marrow-derived mesenchymal stem cells (BMMSCs) and MC3T3-E1 cells	osteogenic-inducing medium [10% FBS; 5 mM L-glycerophosphate; 100 nM dexamethasone (Sigma-Aldrich; Merck KGaA) and 50 mg/ml ascorbic acid (Sigma-Aldrich; Merck KGaA)] treatment	downregulated	31555368
9735	Human	hsa-miR-98-5p	miRNA	H2O2	ulcerative colitis (UC)	Caco-2 cells	H2O2 treatment	upregulated	33394187
9736	Human	hsa-miR-98a-5p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
9737	Human	hsa-miR-99a	miRNA	benzyl isothiocyanate (BITC)	bladder cancer	Human bladder cancer cell lines derived from patients (5637 and T24)	benzyl isothiocyanate (BITC) treatment	upregulated	31587482
9738	Human	hsa-miR-99a	miRNA	advanced glycation end product (AGE)	colorectal cancer (CRC)	HCT-116 cells	advanced glycation end products (AGEs) treatment	downregulated	31819515
9739	Human	hsa-miR-99a	miRNA	salidroside (SAL)	gastric cancer (GC)	GC cell lines (SNU-216 and MGC803) and gastric epithelial cell line GES-1	Salidroside (SAL) treatment	upregulated	31432697
9740	Human	hsa-miR-99a	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh-7 cells	hepatitis C virus (HCV) infection	Cell-culture-derived HCV (HCVcc) infection caused downregulated of miR-99a in Huh-7 cells.	32605105
9741	Human	hsa-miR-99a	miRNA	lipopolysaccharide (LPS)	inflammation	HUVECs cells	lipopolysaccharide (LPS) treatment	downregulated	27403035
9742	Human	hsa-miR-99a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9743	Human	hsa-miR-99a	miRNA	radiation	non-small cell lung cancer (NSCLC)	A549 cells	radiation treatment	miR-99a was significantly upregulated in radiation-sensitive A549 cells compared with radiation-resistant A549 cells	29614485
9744	Human	hsa-miR-99a	miRNA	insulin	polycystic ovarian syndrome (PCOS)	Granulosa cells (GCs)	insulin treatment	downregulated	30374732
9745	Human	hsa-miR-99a	miRNA	insulin	premature senescence	HepG2 cells; HL7702 cells	insulin treatment	downregulated	23762265
9746	Human	hsa-miR-99a	miRNA	androgen	prostate cancer	prostate cancer cells	androgen treatment	downregulated	23503464
9747	Human	hsa-miR-99a	miRNA	mifepristone (MIF)	prostate cancer	prostate cells	Mifepristone treatment	upregulated	27340920
9748	Human	hsa-miR-99a	miRNA	curcumin (Cur)	retinoblastoma (RB)	?Two Rb cell lines SO-Rb50 and Y79	curcumin treatment	upregulated	30526546
9749	Human	hsa-miR-99a	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	downregulated	26640557
9750	Human	hsa-miR-99a*	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
9751	Human	hsa-miR-99a*	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
9752	Human	hsa-miR-99a-5p	miRNA	benzyl isothiocyanate (BITC)	bladder cancer	"Human BC cell lines RT4, 5637, HT1376, HT1197, T24 and humanureter-sumian-virus-40 transformed immortalized epithelial cell line SV-HUC-1"	benzyl isothiocyanate (BITC) treatment	upregulated	30942430
9753	Human	hsa-miR-99a-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823	cisplatin (DPP) treatment	CircMCTP2 sensitizes GC to CDDP through the upregulation of MTMR3 by sponging miR-99a-5p.	33198772
9754	Human	hsa-miR-99a-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	downregulated	26298803
9755	Human	hsa-miR-99b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The expression of miR-99b was increased in the OGD/R model.	32343508
9756	Human	hsa-miR-99b	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer tissues; BGC-823 cells	Helicobacter pylori treatment	microRNA (miR)-99b levels increased in H. pylori-infected gastric cancer tissues and the BGC-823 gastric cancer cell line.	30250606
9757	Human	hsa-miR-99b	miRNA	IL-1¦Â	inflammatory response	monocytes	IL-1¦Â treatment	upregulated	30245693
9758	Human	hsa-miR-99b	miRNA	lipopolysaccharide (LPS)	inflammatory response	monocytes	lipopolysaccharide (LPS) treatment	upregulated	30245693
9759	Human	hsa-miR-99b	miRNA	TLR2 agonist pam3CSK4	inflammatory response	monocytes	TLR2 agonist pam3CSK4 treatment	upregulated	30245693
9760	Human	hsa-miR-99b	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	upregulated	32807750
9761	Human	hsa-miR-99b	miRNA	nicotine	non-small cell lung cancer (NSCLC)	A549 and NCI-H460 cells	nicotine treatment	downregulated	29518612
9762	Human	hsa-miR-99b	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
9763	Human	hsa-miR-99b-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
9764	Human	hsa-miR-99b-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
9765	Human	hsa-miR-99b-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
9766	Human	hsa-miR-99b-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
9767	Human	hsa-miR-99b-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	neutrophil	M.tb infection	downregulated	29477867
9768	Human	hsa-miR-99b-5p	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
9769	Human	hsa-miR-9a-3p	miRNA	methylglyoxal (MGO)	ascular tone regulation	HEK293 cells	methylglyoxal (MGO) treatment	upregulated	25354529
9770	Human	hsa-miR-AB40	miRNA	IL-27	human immunodeficiency virus (HIV)-1 infection	macrophages;monocytes	IL-27 treatment	Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis confirmed that IL-27 dysregulatedthe expression of 16 of the 38 miRNAs.	33525571
9771	Human	hsa-miR-B1-3p	miRNA	polyomavirus BK (BKV)	polyomavirus BK (BKV) infection	HK-2 cells	BKV infection treatment	upregulated	24735545
9772	Human	hsa-miR-B1-5p	miRNA	polyomavirus BK (BKV)	polyomavirus BK (BKV) infection	HK-2 cells	BKV infection treatment	upregulated	24735545
9773	Human	hsa-miR-hz02	miRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	miscarriage	trophoblast Swan 71 and HTR-8/SVneo cells	"BPDE (benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide) treatment"	"If trophoblast cells are exposed to BPDE, both miR-hz02 and lnc-HZ02 are upregulated"	33851497
9774	Human	hsa-miR-K12-11	miRNA	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV)	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	BCBL1cells; JSC-1cells; BJAB cells; Ramous; Loukes ; DG75 cells	Kaposi's sarcoma-associated herpesvirus (KSHV) infection	upregulated	21221132
9775	Human	hsa-miR-SX1	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
9776	Human	hsa-miR-SX2	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
9777	Human	hsa-miR-SX3	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
9778	Human	hsa-miR-SX6	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
9779	Human	hsa-miR-U86	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	Jjhan and HSB2 cells	totransform HHV-6A-BAC-containing SW102 cells for insertion by homologous recombination treatment	upregulated	25520507
9780	Human	hsa-miR-UL22A	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	"THP-1 , differentiated THP-1 , human embryo lung fibroblasts"	HCMV infection treatment	dysregulated	32275696
9781	Human	hsa-miR-UL70	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	"THP-1 , differentiated THP-1 , human embryo lung fibroblasts"	HCMV infection treatment	dysregulated	32275696
9782	Human	hsa-miR-US33	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	"THP-1 , differentiated THP-1 , human embryo lung fibroblasts"	HCMV infection treatment	dysregulated	32275696
9783	Human	hsa-miR-5703	miRNA	TGF-¦Â1	breast cancer	MDA-MB231 cells	TGF-¦Â1 treatment	miR-5703 expression was significantly downregulated at both precursor and mature levels upon TGF-¦Â1-treatment in human breast cancer cells.	34492519
9784	Human	hsa-miR-16-2-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	peripheral blood	SARS-CoV-2 infection	"A miRNA¡¯s high-throughput sequencing analysis in peripheral blood of 10 COVID-19 patients and 4 control donors indicated 35 upregulated and 38 downregulated miRNAs, in which changes of miR-16-2-3p is most remarkable in the upregulated list."	33675361
9785	Human	hsa-miR-183-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	peripheral blood	SARS-CoV-2 infection	"A miRNA¡¯s high-throughput sequencing analysis in peripheral blood of 10 COVID-19 patients and 4 control donors indicated 35 upregulated and 38 downregulated miRNAs, in which changes of miR-183-5p is the most remarkable in the downregulated list."	33675361
9786	Human	hsa-miR-146a-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-146a-5p was consistently downregulated."	33675361
9787	Human	hsa-miR-21-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-21-5p was consistently downregulated."	33675361
9788	Human	hsa-miR-142-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-142-3p was consistently downregulated."	33675361
9789	Human	hsa-miR-3605-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-3605-3p was consistently upregulated."	33675361
9790	Human	hsa-miR-15b-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-15b-5p was upregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
9791	Human	hsa-miR-486-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-486-3p was upregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
9792	Human	hsa-miR-486-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-486-5p was upregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
9793	Human	hsa-miR-181a-2-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-181a-2-3p was downregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
9794	Human	hsa-miR-31-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-31-5p was downregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
9795	Human	hsa-miR-99a-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-99a-5p was downregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
